<SEC-DOCUMENT>0001731122-20-001338.txt : 20201228
<SEC-HEADER>0001731122-20-001338.hdr.sgml : 20201228
<ACCEPTANCE-DATETIME>20201228172732
ACCESSION NUMBER:		0001731122-20-001338
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		48
CONFORMED PERIOD OF REPORT:	20200930
FILED AS OF DATE:		20201228
DATE AS OF CHANGE:		20201228

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ANAVEX LIFE SCIENCES CORP.
		CENTRAL INDEX KEY:			0001314052
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
		IRS NUMBER:				208365999
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37606
		FILM NUMBER:		201419254

	BUSINESS ADDRESS:	
		STREET 1:		51 W 52ND STREET,
		STREET 2:		7TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10019-6163
		BUSINESS PHONE:		800-689-3939

	MAIL ADDRESS:	
		STREET 1:		51 W 52ND STREET,
		STREET 2:		7TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10019-6163

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Thrifty Printing Inc.
		DATE OF NAME CHANGE:	20050111
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>e2298_10k.htm
<DESCRIPTION>FORM 10-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:us-roles="http://fasb.org/us-roles/2020-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2020-01-31" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:avxl="http://anavex.com/20200930">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02B_US%2DGAAP%2D2020_currency -->
<!-- Field: Set; Name: xdx; ID: xdx_038_avxl_anavex.com_20200930 -->
<!-- Field: Set; Name: xdx; ID: xdx_040_20191001_20200930 -->
<!-- Field: Set; Name: xdx; ID: xdx_05A_edei%2D%2DEntityCentralIndexKey_0001314052 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_056_edei%2D%2DDocumentFiscalYearFocus_2020 -->
<!-- Field: Set; Name: xdx; ID: xdx_05A_edei%2D%2DDocumentFiscalPeriodFocus_FY -->
<!-- Field: Set; Name: xdx; ID: xdx_05E_edei%2D%2DCurrentFiscalYearEndDate_%2D%2DLS0wOS0zMA== -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_069_Pure_4_xbrli%2D%2Dpure -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
  <ix:hidden>
    <ix:nonNumeric contextRef="From2019-10-01to2020-09-30" name="dei:EntityCentralIndexKey">0001314052</ix:nonNumeric>
    <ix:nonNumeric contextRef="From2019-10-01to2020-09-30" format="ixt:booleanfalse" name="dei:AmendmentFlag">false</ix:nonNumeric>
    <ix:nonNumeric contextRef="From2019-10-01to2020-09-30" name="dei:DocumentFiscalYearFocus">2020</ix:nonNumeric>
    <ix:nonNumeric contextRef="From2019-10-01to2020-09-30" name="dei:DocumentFiscalPeriodFocus">FY</ix:nonNumeric>
    <ix:nonNumeric contextRef="From2019-10-01to2020-09-30" name="dei:CurrentFiscalYearEndDate">--09-30</ix:nonNumeric>
    <ix:nonFraction name="avxl:StockIssuedDuringPeriodValueAcquisitions2" contextRef="From2018-10-012019-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0249" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2" contextRef="From2018-10-012019-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0256" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2" contextRef="From2018-10-012019-09-30" id="xdx2ixbrl0257" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" contextRef="From2018-10-012019-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0263" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="avxl:SharesIssuedPursuantToCashlessExerciseOfWarrants" contextRef="From2018-10-012019-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0277" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="avxl:SharesIssuedPursuantToCashlessExerciseOfWarrants" contextRef="From2018-10-012019-09-30" id="xdx2ixbrl0278" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2018-10-012019-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0282" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2018-10-012019-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0284" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2018-10-012019-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0287" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2018-10-012019-09-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0288" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" contextRef="From2019-10-012020-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0301" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1" contextRef="From2019-10-012020-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0308" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1" contextRef="From2019-10-01to2020-09-30" id="xdx2ixbrl0309" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="avxl:SharesIssuedPursuantToCashlessExerciseOfOptions" contextRef="From2019-10-012020-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0315" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="avxl:SharesIssuedPursuantToCashlessExerciseOfOptions" contextRef="From2019-10-01to2020-09-30" id="xdx2ixbrl0316" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2019-10-012020-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0327" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2019-10-012020-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0329" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2019-10-012020-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0332" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2019-10-012020-09-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0333" unitRef="USD" xs:nil="true"></ix:nonFraction>
    </ix:hidden>
  <ix:references>
    <link:schemaRef xlink:href="avxl-20200930.xsd" xlink:type="simple" />
    </ix:references>
  <ix:resources>
    <xbrli:context id="From2019-10-01to2020-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-10-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-28">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-28</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-10-012019-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-10-01</xbrli:startDate>
        <xbrli:endDate>2019-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-10-012019-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-10-01</xbrli:startDate>
        <xbrli:endDate>2019-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-10-012019-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-10-01</xbrli:startDate>
        <xbrli:endDate>2019-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-10-012019-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-10-01</xbrli:startDate>
        <xbrli:endDate>2019-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-012020-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-10-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-012020-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-10-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-012020-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-10-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-10-012017-09-30_custom_ClinicalStudyGrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">avxl:ClinicalStudyGrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-10-01</xbrli:startDate>
        <xbrli:endDate>2017-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-012020-09-30_currency_AUD">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:AUD</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-10-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-10-012019-09-30_currency_AUD">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:AUD</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-10-01</xbrli:startDate>
        <xbrli:endDate>2019-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-10-012019-09-30_custom_NYCBiotechCreditMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">avxl:NYCBiotechCreditMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-10-01</xbrli:startDate>
        <xbrli:endDate>2019-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-10-012019-09-30_custom_PurchaseAgreementMember_custom_LincolnParkCapitalFundLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:PurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-10-01</xbrli:startDate>
        <xbrli:endDate>2019-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-06-062019-06-07_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:PurchaseAgreement1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-06-06</xbrli:startDate>
        <xbrli:endDate>2019-06-07</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-012020-09-30_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:PurchaseAgreement1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-10-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-012020-09-30_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:PurchaseAgreement1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-10-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-10-012019-09-30_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:PurchaseAgreement1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-10-01</xbrli:startDate>
        <xbrli:endDate>2019-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-292020-05-01_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:EquityOfferingSalesAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:CantorFitzgeraldAndCoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-29</xbrli:startDate>
        <xbrli:endDate>2020-05-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-012020-09-30_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:EquityOfferingSalesAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:CantorFitzgeraldAndCoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-10-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-30_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:EquityOfferingSalesAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:CantorFitzgeraldAndCoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-09-30_custom_PurchaseWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:PurchaseWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-10-012019-09-30_custom_PurchaseWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:PurchaseWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-10-01</xbrli:startDate>
        <xbrli:endDate>2019-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-09-30_custom_PurchaseWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:PurchaseWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-012020-09-30_custom_PurchaseWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:PurchaseWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-10-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-30_custom_PurchaseWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:PurchaseWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-30_custom_PurchaseWarrants1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:PurchaseWarrants1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-30_custom_PurchaseWarrants2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:PurchaseWarrants2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-30_custom_StockOptionPlan2015Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2015Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-09-30_custom_StockOptionPlan2015Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2015Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-012020-09-30_custom_StockOptionPlan2019Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2019Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-10-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-30_custom_StockOptionPlan2019Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2019Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-09-30_custom_StockOptionPlan2019Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2019Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-09-30_custom_StockOptionPlan2015Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2015Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-10-012019-09-30_custom_StockOptionPlan2015Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2015Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-10-01</xbrli:startDate>
        <xbrli:endDate>2019-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-012020-09-30_custom_StockOptionPlan2015Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2015Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-10-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-012020-09-30_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-10-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-10-012019-09-30_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-10-01</xbrli:startDate>
        <xbrli:endDate>2019-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-012020-09-30_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-10-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-10-012019-09-30_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-10-01</xbrli:startDate>
        <xbrli:endDate>2019-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-30_us-gaap_ForeignCountryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-30_us-gaap_ForeignCountryMember_currency_AUD">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:AUD</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-09-30_us-gaap_ForeignCountryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
    </ix:resources>
  </ix:header>
</div>


<p style="margin: 0"></p>




<p style="font: 10.5pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>UNITED
STATES</b></span></p>

<p style="font: 10.5pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>SECURITIES
AND EXCHANGE COMMISSION</b></span></p>

<p style="font: 10.5pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Washington,
D.C. 20549</span></p>

<p style="font: 10.5pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10.5pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>FORM
<span id="xdx_909_edei--DocumentType_c20191001__20200930_zuSBOzW2Wwge"><ix:nonNumeric contextRef="From2019-10-01to2020-09-30" name="dei:DocumentType">10-K</ix:nonNumeric></span></b></span></p>

<p style="font: 10.5pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10.5pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">(Mark
One)</span></p>

<p style="font: 10.5pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10.5pt Courier New, Courier, Monospace; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90F_edei--DocumentAnnualReport_c20191001__20200930_z2xRUtcVjcsi"><ix:nonNumeric contextRef="From2019-10-01to2020-09-30" format="ixt:booleantrue" name="dei:DocumentAnnualReport">&#9746;</ix:nonNumeric></span>&#160;ANNUAL
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></p>

<p style="font: 10.5pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">For
the fiscal year ended <b><span style="text-decoration: underline"><span id="xdx_90F_edei--DocumentPeriodEndDate_c20191001__20200930_zVtAgGdHKlv"><ix:nonNumeric contextRef="From2019-10-01to2020-09-30" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">September 30, 2020</ix:nonNumeric></span></span></b></span></p>

<p style="font: 10.5pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10.5pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90F_edei--DocumentTransitionReport_c20191001__20200930_z8tQOWQdZYcb"><ix:nonNumeric contextRef="From2019-10-01to2020-09-30" format="ixt:booleanfalse" name="dei:DocumentTransitionReport">&#9744;</ix:nonNumeric></span>&#160;TRANSITION
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></p>

<p style="font: 10.5pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">For
the transition period from ______________ to________________</span></p>

<p style="font: 10.5pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10.5pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Commission
file number<b>: <span style="text-decoration: underline"><span id="xdx_907_edei--EntityFileNumber_c20191001__20200930_z9HGd0KQbu6e"><ix:nonNumeric contextRef="From2019-10-01to2020-09-30" name="dei:EntityFileNumber">001-37606</ix:nonNumeric></span></span></b></span></p>

<p style="font: 10.5pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10.5pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span style="text-decoration: underline"><span id="xdx_90D_edei--EntityRegistrantName_c20191001__20200930_zf3dC6Z5o8S1"><ix:nonNumeric contextRef="From2019-10-01to2020-09-30" name="dei:EntityRegistrantName">ANAVEX LIFE SCIENCES CORP.</ix:nonNumeric></span></span></b></span></p>

<p style="font: 10.5pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(Exact
name of registrant as specified in its charter)</span></p>

<p style="font: 10.5pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Courier New, Courier, Monospace; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="border-bottom: Black 1pt solid; width: 57%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_907_edei--EntityIncorporationStateCountryCode_c20191001__20200930_zK73GikQMwSa"><ix:nonNumeric contextRef="From2019-10-01to2020-09-30" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Nevada</ix:nonNumeric></span></span></td>
    <td style="width: 7%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; width: 36%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90F_edei--EntityTaxIdentificationNumber_c20191001__20200930_zvdMYouBs5n"><ix:nonNumeric contextRef="From2019-10-01to2020-09-30" name="dei:EntityTaxIdentificationNumber">98-0608404</ix:nonNumeric></span></span></td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(State
    or other jurisdiction of incorporation or organization)</span></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(I.R.S.
    Employer Identification No.)</span></td></tr>
<tr style="vertical-align: top">
    <td style="border-top: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-top: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: top">
    <td style="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_900_edei--EntityAddressAddressLine1_c20191001__20200930_zhtOmhMq4KW1"><ix:nonNumeric contextRef="From2019-10-01to2020-09-30" name="dei:EntityAddressAddressLine1">51 W 52nd Street</ix:nonNumeric></span>, <span id="xdx_905_edei--EntityAddressAddressLine2_c20191001__20200930_zSXwAAqOmqxj"><ix:nonNumeric contextRef="From2019-10-01to2020-09-30" name="dei:EntityAddressAddressLine2">7th Floor</ix:nonNumeric></span>, <span id="xdx_90A_edei--EntityAddressCityOrTown_c20191001__20200930_zKkZlw35Jo5j"><ix:nonNumeric contextRef="From2019-10-01to2020-09-30" name="dei:EntityAddressCityOrTown">New York</ix:nonNumeric></span></span><span style="font: 10pt Times New Roman, Times, Serif">,
    <span id="xdx_909_edei--EntityAddressStateOrProvince_c20191001__20200930_z5HKuQZVFU36"><ix:nonNumeric contextRef="From2019-10-01to2020-09-30" name="dei:EntityAddressStateOrProvince">NY</ix:nonNumeric></span> <span id="xdx_90D_edei--EntityAddressCountry_c20191001__20200930_z8HhnJVFVvVi"><ix:nonNumeric contextRef="From2019-10-01to2020-09-30" name="dei:EntityAddressCountry">US</ix:nonNumeric></span>A</span></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_905_edei--EntityAddressPostalZipCode_c20191001__20200930_z3Yuic1VzUg5"><ix:nonNumeric contextRef="From2019-10-01to2020-09-30" name="dei:EntityAddressPostalZipCode">10019</ix:nonNumeric></span></span></td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(Address
    of principal executive offices)</span></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(Zip
    Code)</span></td></tr>
</table>
<p style="font: 10.5pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10.5pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Registrant&#8217;s
telephone number, including area code <span style="text-decoration: underline">1-<span id="xdx_903_edei--CityAreaCode_c20191001__20200930_zPeixBmQnddi"><ix:nonNumeric contextRef="From2019-10-01to2020-09-30" name="dei:CityAreaCode">844</ix:nonNumeric></span>-<span id="xdx_90C_edei--LocalPhoneNumber_c20191001__20200930_zFJYHcY6RwK2"><ix:nonNumeric contextRef="From2019-10-01to2020-09-30" name="dei:LocalPhoneNumber">689-3939</ix:nonNumeric></span></span></span></p>

<p style="font: 10.5pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10.5pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Securities
registered under Section 12(b) of the Act:</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Courier New, Courier, Monospace; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_901_edei--Security12bTitle_c20191001__20200930_zh0bn4Ybj6Tl"><ix:nonNumeric contextRef="From2019-10-01to2020-09-30" name="dei:Security12bTitle">Common
    Stock, $0.001 par value</ix:nonNumeric></span></span></td>
    <td style="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90A_edei--TradingSymbol_c20191001__20200930_ztTXh9pJYUp5"><ix:nonNumeric contextRef="From2019-10-01to2020-09-30" name="dei:TradingSymbol">AVXL</ix:nonNumeric></span></span></td>
    <td style="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90E_edei--SecurityExchangeName_c20191001__20200930_zQuaKsI2xxhi"><ix:nonNumeric contextRef="From2019-10-01to2020-09-30" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">NASDAQ Stock Market LLC</ix:nonNumeric></span></span></td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Title
    of each class</span></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Trading
    Symbol</span></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Name
    of each exchange on which registered</span></td></tr>
</table>
<p style="font: 10.5pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10.5pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Securities
registered pursuant to Section 12(g) of the Act:</span></p>

<p style="font: 10.5pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span style="text-decoration: underline">Common
Stock, $0.001 par value</span></b></span></p>

<p style="font: 10.5pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(Title
of class)</span></p>

<p style="font: 10.5pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Indicate
by checkmark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.</span></p>

<p style="font: 10.5pt Times New Roman, Times, Serif; margin: 0; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">Yes&#160;&#9744;
<span id="xdx_902_edei--EntityWellKnownSeasonedIssuer_c20191001__20200930_z4t6hvk3qawk"><ix:nonNumeric contextRef="From2019-10-01to2020-09-30" name="dei:EntityWellKnownSeasonedIssuer">No</ix:nonNumeric></span>&#160;&#9746;</span></p>

<p style="font: 10.5pt Times New Roman, Times, Serif; margin: 0; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10.5pt Times New Roman, Times, Serif; margin: 0; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Indicate
by checkmark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act.</span></p>

<p style="font: 10.5pt Times New Roman, Times, Serif; margin: 0; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">Yes&#160;&#9744;
<span id="xdx_900_edei--EntityVoluntaryFilers_c20191001__20200930_zqBPjaprO5ff"><ix:nonNumeric contextRef="From2019-10-01to2020-09-30" name="dei:EntityVoluntaryFilers">No</ix:nonNumeric></span> &#9746;</span></p>

<p style="font: 10.5pt Times New Roman, Times, Serif; margin: 0; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Indicate
by checkmark whether the registrant has (1) filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports),
and (2) has been subject to such filing requirements for the past 90 days.</span></p>

<p style="font: 10.5pt Times New Roman, Times, Serif; margin: 0; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90F_edei--EntityCurrentReportingStatus_c20191001__20200930_zp7pTfpnPBMk"><ix:nonNumeric contextRef="From2019-10-01to2020-09-30" name="dei:EntityCurrentReportingStatus">Yes</ix:nonNumeric></span>&#160;&#9746;
No&#160;&#9744;</span></p>

<p style="font: 10.5pt Times New Roman, Times, Serif; margin: 0; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Indicate
by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant
to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that
the registrant was required to submit and post such files).</span></p>

<p style="font: 10.5pt Times New Roman, Times, Serif; margin: 0; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90C_edei--EntityInteractiveDataCurrent_c20191001__20200930_zb8tHcjAboHg"><ix:nonNumeric contextRef="From2019-10-01to2020-09-30" name="dei:EntityInteractiveDataCurrent">Yes</ix:nonNumeric></span>&#160;&#9746;
No&#160;&#9744;</span></p>

<p style="font: 10.5pt Times New Roman, Times, Serif; margin: 0; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Indicate
by checkmark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer&#8221;,
&#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></p>

<p style="font: 10.5pt Times New Roman, Times, Serif; margin: 0; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10.5pt Times New Roman, Times, Serif; margin: 0; text-align: left"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Courier New, Courier, Monospace; width: 100%; border-collapse: collapse">
<tr>
    <td style="width: 23%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Large
    accelerated filer</span></td>
    <td style="width: 8%"><span style="font: 10pt Times New Roman, Times, Serif">&#9744;</span></td>
    <td style="vertical-align: top; width: 23%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; width: 37%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Accelerated
    filer&#160;</span></td>
    <td style="width: 9%"><span style="font: 10pt Times New Roman, Times, Serif">&#9744;</span></td></tr>
<tr>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90B_edei--EntityFilerCategory_c20191001__20200930_z7cvws9ygoj4"><ix:nonNumeric contextRef="From2019-10-01to2020-09-30" name="dei:EntityFilerCategory">Non-accelerated Filer</ix:nonNumeric></span></span></td>
    <td><span style="font: 10pt Times New Roman, Times, Serif">&#9746;</span></td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Smaller
    reporting company&#160;&#160;</span></td>
    <td><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_905_edei--EntitySmallBusiness_c20191001__20200930_zAXWoHv5tvXi"><ix:nonNumeric contextRef="From2019-10-01to2020-09-30" format="ixt:booleantrue" name="dei:EntitySmallBusiness">&#9746;</ix:nonNumeric></span></span></td></tr>
<tr>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Emerging
    growth company</span></td>
    <td><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90E_edei--EntityEmergingGrowthCompany_c20191001__20200930_zN47ej8MnRl4"><ix:nonNumeric contextRef="From2019-10-01to2020-09-30" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span></td></tr>
</table>


<p style="font: 10.5pt Times New Roman, Times, Serif; margin: 0; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;&#160;</span></p>

<p style="font: 10.5pt Times New Roman, Times, Serif; margin: 0; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act</span></p>

<p style="font: 10.5pt Times New Roman, Times, Serif; margin: 0; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#9744;</span></p>

<p style="font: 10.5pt Times New Roman, Times, Serif; margin: 0; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).</span></p>

<p style="font: 10.5pt Times New Roman, Times, Serif; margin: 0; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">Yes&#160;&#9744;
<span id="xdx_90A_edei--EntityShellCompany_c20191001__20200930_zWsReevyabtc"><ix:nonNumeric contextRef="From2019-10-01to2020-09-30" format="ixt:booleanfalse" name="dei:EntityShellCompany">No</ix:nonNumeric></span>&#160;&#9746;</span></p>

<p style="font: 10.5pt Times New Roman, Times, Serif; margin: 0; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10.5pt Times New Roman, Times, Serif; margin: 0; text-align: left"></p>

<p style="font: 10.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">State
the aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price
at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day
of the registrant&#8217;s most recently completed second fiscal quarter: $<span id="xdx_900_edei--EntityPublicFloat_iI_c20200331_znTWhv7yL0Oi"><ix:nonFraction name="dei:EntityPublicFloat" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">177,399,544</ix:nonFraction></span> based on a price of $3.15 per share, being
the closing price of the registrant&#8217;s common stock on March 31, 2020.</span></p>

<p style="font: 10.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif; background-color: White">Indicate
the number of shares outstanding of each of the registrant&#8217;s classes of common stock, as of the latest practicable date
<span id="xdx_90E_edei--EntityCommonStockSharesOutstanding_iI_c20201228_zqxm1VfpCOqi"><ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" contextRef="AsOf2020-12-28" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">66,962,957</ix:nonFraction></span></span> <span style="font: 10pt Times New Roman, Times, Serif; background-color: White">issued
and outstanding as of December 28, 2020.</span></p>

<p style="font: 10.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10.5pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">DOCUMENTS
INCORPORATED BY REFERENCE</span></p>

<p style="font: 10.5pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">None.</span></p>


<!-- Field: Page; Sequence: 24 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo --><!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10.5pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span style="text-decoration: underline">TABLE
OF CONTENTS</span></b></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 24pt 0 0; color: #365F91"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>



<table cellpadding="0" cellspacing="0" style="width: 100%">
<tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom">
    <td style="width: 90%; text-align: left; padding-top: 0in; padding-bottom: 5pt; padding-left: 0in"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#part1">PART I</a></span></td>
    <td style="width: 10%; text-align: right; padding-top: 0in; padding-bottom: 5pt"><span style="font: 10pt Times New Roman, Times, Serif">1</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 5pt; padding-left: 11pt"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#item1">ITEM 1. BUSINESS</a></span></td>
    <td style="text-align: right; padding-top: 0in; padding-bottom: 5pt"><span style="font: 10pt Times New Roman, Times, Serif">1</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 5pt; padding-left: 11pt"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#item1a">ITEM 1A. RISK FACTORS</a></span></td>
    <td style="text-align: right; padding-top: 0in; padding-bottom: 5pt"><span style="font: 10pt Times New Roman, Times, Serif">22</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 5pt; padding-left: 11pt"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#item1b">ITEM 1B. UNRESOLVED STAFF COMMENTS</a></span></td>
    <td style="text-align: right; padding-top: 0in; padding-bottom: 5pt"><span style="font: 10pt Times New Roman, Times, Serif">36</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 5pt; padding-left: 11pt"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#item2">ITEM 2. PROPERTIES</a></span></td>
    <td style="text-align: right; padding-top: 0in; padding-bottom: 5pt"><span style="font: 10pt Times New Roman, Times, Serif">36</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 5pt; padding-left: 11pt"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#item3">ITEM 3. LEGAL PROCEEDINGS</a></span></td>
    <td style="text-align: right; padding-top: 0in; padding-bottom: 5pt"><span style="font: 10pt Times New Roman, Times, Serif">36</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 5pt; padding-left: 11pt"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#item4">ITEM 4. MINE SAFETY DISCLOSURES</a></span></td>
    <td style="text-align: right; padding-top: 0in; padding-bottom: 5pt"><span style="font: 10pt Times New Roman, Times, Serif">36</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 5pt; padding-left: 0in"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#part2">PART II</a></span></td>
    <td style="text-align: right; padding-top: 0in; padding-bottom: 5pt"><span style="font: 10pt Times New Roman, Times, Serif">37</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 5pt; padding-left: 11pt"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#item5">ITEM 5. MARKET FOR REGISTRANT&#8217;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</a></span></td>
    <td style="text-align: right; padding-top: 0in; padding-bottom: 5pt"><span style="font: 10pt Times New Roman, Times, Serif">37</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 5pt; padding-left: 11pt"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#item6">ITEM 6 SELECTED FINANCIAL DATA</a></span></td>
    <td style="text-align: right; padding-top: 0in; padding-bottom: 5pt"><span style="font: 10pt Times New Roman, Times, Serif">37</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 5pt; padding-left: 11pt"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#item7">ITEM 7 MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATION</a></span></td>
    <td style="text-align: right; padding-top: 0in; padding-bottom: 5pt"><span style="font: 10pt Times New Roman, Times, Serif">37</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 5pt; padding-left: 11pt"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#item7a">ITEM 7A QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</a></span></td>
    <td style="text-align: right; padding-top: 0in; padding-bottom: 5pt"><span style="font: 10pt Times New Roman, Times, Serif">42</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 5pt; padding-left: 11pt"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#item8">ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</a></span></td>
    <td style="text-align: right; padding-top: 0in; padding-bottom: 5pt"><span style="font: 10pt Times New Roman, Times, Serif">42</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 5pt; padding-left: 11pt"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#item9">ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL MATTERS</a></span></td>
    <td style="text-align: right; padding-top: 0in; padding-bottom: 5pt"><span style="font: 10pt Times New Roman, Times, Serif">43</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 5pt; padding-left: 11pt"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#item9a">ITEM 9A. CONTROLS AND PROCEDURES</a></span></td>
    <td style="text-align: right; padding-top: 0in; padding-bottom: 5pt"><span style="font: 10pt Times New Roman, Times, Serif">43</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 5pt; padding-left: 11pt"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#item9b">ITEM 9B OTHER INFORMATION</a></span></td>
    <td style="text-align: right; padding-top: 0in; padding-bottom: 5pt"><span style="font: 10pt Times New Roman, Times, Serif">43</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 5pt; padding-left: 0in"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#part3">PART III</a></span></td>
    <td style="text-align: right; padding-top: 0in; padding-bottom: 5pt"><span style="font: 10pt Times New Roman, Times, Serif">44</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 5pt; padding-left: 11pt"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#item10">ITEM 10 DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</a></span></td>
    <td style="text-align: right; padding-top: 0in; padding-bottom: 5pt"><span style="font: 10pt Times New Roman, Times, Serif">44</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 5pt; padding-left: 11pt"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#item11">ITEM 11. EXECUTIVE COMPENSATION</a></span></td>
    <td style="text-align: right; padding-top: 0in; padding-bottom: 5pt"><span style="font: 10pt Times New Roman, Times, Serif">47</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 5pt; padding-left: 11pt"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#item12">ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS.</a></span></td>
    <td style="text-align: right; padding-top: 0in; padding-bottom: 5pt"><span style="font: 10pt Times New Roman, Times, Serif">50</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 5pt; padding-left: 11pt"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#item13">ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</a></span></td>
    <td style="text-align: right; padding-top: 0in; padding-bottom: 5pt"><span style="font: 10pt Times New Roman, Times, Serif">53</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 5pt; padding-left: 11pt"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#item14">ITEM 14. PRINCIPAL ACCOUNTING FEES AND SERVICES</a></span></td>
    <td style="text-align: right; padding-top: 0in; padding-bottom: 5pt"><span style="font: 10pt Times New Roman, Times, Serif">53</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 5pt; padding-left: 0in"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#part4">PART IV</a></span></td>
    <td style="text-align: right; padding-top: 0in; padding-bottom: 5pt"><span style="font: 10pt Times New Roman, Times, Serif">55</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 5pt; padding-left: 11pt"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#item15">ITEM 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES</a></span></td>
    <td style="text-align: right; padding-top: 0in; padding-bottom: 5pt"><span style="font: 10pt Times New Roman, Times, Serif">55</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom">
    <td style="text-align: left; padding-top: 0in; padding-bottom: 5pt; padding-left: 11pt"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#item16">ITEM 16. FORM 10-K SUMMARY</a></span></td>
    <td style="text-align: right; padding-top: 0in; padding-bottom: 5pt"><span style="font: 10pt Times New Roman, Times, Serif">56</span></td></tr>
</table>

<p style="margin-top: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<!-- Field: Page; Sequence: 24 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->ii<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Forward
Looking Statements.</i></span></p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">This
Annual Report on Form 10-K includes forward-looking statements. All statements other than statements of historical facts contained
in this Annual Report on Form 10-K, including statements regarding our anticipated future clinical and regulatory milestone events,
future financial position, business strategy and plans and objectives of management for future operations, are forward-looking
statements. The words &#8220;believe,&#8221; &#8220;may,&#8221; &#8220;estimate,&#8221; &#8220;continue,&#8221; &#8220;anticipate,&#8221;
&#8220;intend,&#8221; &#8220;expect&#8221; &#8220;should,&#8221; &#8220;forecast,&#8221; &#8220;could,&#8221; &#8220;suggest,&#8221;
&#8220;plan&#8221; and similar expressions, as they relate to us, are intended to identify forward-looking statements. Such forward-looking
statements include, without limitation, statements regarding:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 20.65pt"></td><td style="width: 18pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#8226;</b></span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">our
                                         ability to successfully conduct clinical and preclinical trials for our product candidates;</span></td></tr>
<tr style="vertical-align: top">
<td style="width: 20.65pt"></td><td style="width: 18pt"><span style="font: 10pt Times New Roman, Times, Serif">&#8226;</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">our
                                         ability to raise additional capital on favorable terms and the impact of such activities
                                         on our stockholders and stock price;</span></td></tr>
<tr style="vertical-align: top">
<td style="width: 20.65pt"></td><td style="width: 18pt"><span style="font: 10pt Times New Roman, Times, Serif">&#8226;</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">the
                                         impact of the COVID-19 outbreak and its effect on us;</span></td></tr>
<tr style="vertical-align: top">
<td style="width: 20.65pt"></td><td style="width: 18pt"><span style="font: 10pt Times New Roman, Times, Serif">&#8226;</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">our
                                         ability to generate any revenue or to continue as a going concern;</span></td></tr>
<tr style="vertical-align: top">
<td style="width: 20.65pt"></td><td style="width: 18pt"><span style="font: 10pt Times New Roman, Times, Serif">&#8226;</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">our
                                         ability to execute our research and development plan on time and on budget;</span></td></tr>
<tr style="vertical-align: top">
<td style="width: 20.65pt"></td><td style="width: 18pt"><span style="font: 10pt Times New Roman, Times, Serif">&#8226;</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">our
                                         products ability to demonstrate efficacy or an acceptable safety profile of our product
                                         candidates;</span></td></tr>
<tr style="vertical-align: top">
<td style="width: 20.65pt"></td><td style="width: 18pt"><span style="font: 10pt Times New Roman, Times, Serif">&#8226;</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">our
                                         ability to obtain the support of qualified scientific collaborators;</span></td></tr>
<tr style="vertical-align: top">
<td style="width: 20.65pt"></td><td style="width: 18pt"><span style="font: 10pt Times New Roman, Times, Serif">&#8226;</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">our
                                         ability, whether alone or with commercial partners, to successfully commercialize any
                                         of our product candidates that may be approved for sale;</span></td></tr>
<tr style="vertical-align: top">
<td style="width: 20.65pt"></td><td style="width: 18pt"><span style="font: 10pt Times New Roman, Times, Serif">&#8226;</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">our
                                         ability to identify and obtain additional product candidates;</span></td></tr>
<tr style="vertical-align: top">
<td style="width: 20.65pt"></td><td style="width: 18pt"><span style="font: 10pt Times New Roman, Times, Serif">&#8226;</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">our
                                         reliance on third parties in non-clinical and clinical studies;</span></td></tr>
<tr style="vertical-align: top">
<td style="width: 20.65pt"></td><td style="width: 18pt"><span style="font: 10pt Times New Roman, Times, Serif">&#8226;</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">our
                                         ability to defend against product liability claims;</span></td></tr>
<tr style="vertical-align: top">
<td style="width: 20.65pt"></td><td style="width: 18pt"><span style="font: 10pt Times New Roman, Times, Serif">&#8226;</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">our
                                         ability to safeguard against security breaches;</span></td></tr>
<tr style="vertical-align: top">
<td style="width: 20.65pt"></td><td style="width: 18pt"><span style="font: 10pt Times New Roman, Times, Serif">&#8226;</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">our
                                         ability to obtain and maintain sufficient intellectual property protection for our product
                                         candidates;</span></td></tr>
<tr style="vertical-align: top">
<td style="width: 20.65pt"></td><td style="width: 18pt"><span style="font: 10pt Times New Roman, Times, Serif">&#8226;</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">our
                                         ability to comply with our intellectual property licensing agreements;</span></td></tr>
<tr style="vertical-align: top">
<td style="width: 20.65pt"></td><td style="width: 18pt"><span style="font: 10pt Times New Roman, Times, Serif">&#8226;</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">our
                                         ability to defend against claims of intellectual property infringement;</span></td></tr>
<tr style="vertical-align: top">
<td style="width: 20.65pt"></td><td style="width: 18pt"><span style="font: 10pt Times New Roman, Times, Serif">&#8226;</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">our
                                         ability to comply with the maintenance requirements of the government patent agencies;</span></td></tr>
<tr style="vertical-align: top">
<td style="width: 20.65pt"></td><td style="width: 18pt"><span style="font: 10pt Times New Roman, Times, Serif">&#8226;</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">our
                                         ability to protect our intellectual property rights throughout the world;</span></td></tr>
<tr style="vertical-align: top">
<td style="width: 20.65pt"></td><td style="width: 18pt"><span style="font: 10pt Times New Roman, Times, Serif">&#8226;</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">competition;</span></td></tr>
<tr style="vertical-align: top">
<td style="width: 20.65pt"></td><td style="width: 18pt"><span style="font: 10pt Times New Roman, Times, Serif">&#8226;</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">the
                                         anticipated start dates, durations and completion dates of our ongoing and future clinical
                                         studies;</span></td></tr>
<tr style="vertical-align: top">
<td style="width: 20.65pt"></td><td style="width: 18pt"><span style="font: 10pt Times New Roman, Times, Serif">&#8226;</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">the
                                         anticipated designs of our future clinical studies;</span></td></tr>
<tr style="vertical-align: top">
<td style="width: 20.65pt"></td><td style="width: 18pt"><span style="font: 10pt Times New Roman, Times, Serif">&#8226;</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">our
                                         anticipated future regulatory submissions and our ability to receive regulatory approvals
                                         to develop and market our product candidates, including any orphan drug or fast track
                                         designations; and </span></td></tr>
<tr style="vertical-align: top">
<td style="width: 20.65pt"></td><td style="width: 18pt"><span style="font: 10pt Times New Roman, Times, Serif">&#8226;</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">our
                                         anticipated future cash position. </span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
have based these forward-looking statements largely on our current expectations and projections about future events, including
the responses we expect from the U.S. Food and Drug Administration, (&#8220;FDA&#8221;), and other regulatory authorities and
financial trends that we believe may affect our financial condition, results of operations, business strategy, preclinical and
clinical trials, and financial needs. These forward-looking statements are subject to a number of risks, uncertainties and assumptions
including without limitation the risks described in &#8220;Risk Factors&#8221; in Part I, Item 1A of this Annual Report on Form
10-K. These risks are not exhaustive. Other sections of this Annual Report on Form 10-K include additional factors which could
adversely impact our business and financial performance. Moreover, we operate in a very competitive and rapidly changing environment.
New risk factors emerge from time to time and it is not possible for our management to predict all risk factors, nor can we assess
the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results
to differ materially from those contained in any forward-looking statements. You should not rely upon forward-looking statements
as predictions of future events. We cannot assure you that the events and circumstances reflected in the forward-looking statements
will be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Except
as required by applicable laws including the securities laws of the United States, we assume no obligation to update or supplement
forward-looking statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">As
used in this Annual Report on Form 10-K, the terms &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221;, &#8220;Company&#8221;
and &#8220;Anavex&#8221; mean Anavex Life Sciences Corp., unless the context clearly requires otherwise.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 24 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->iii<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: bold 10.5pt Times New Roman, Times, Serif; margin: 12pt 0 0"><span style="font: 10pt Times New Roman, Times, Serif"><span id="part1"></span>PART
I</span></p>

<p style="font: italic bold 10.5pt Times New Roman, Times, Serif; margin: 12pt 0 3pt"><span style="font: normal 10pt Times New Roman, Times, Serif"><span id="item1"></span><b><i>ITEM
1. BUSINESS</i></b></span></p>

<p style="font: 10.5pt Times New Roman, Times, Serif; margin: 5pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Overview
and Strategy</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Anavex
Life Sciences Corp. is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by
applying precision medicine to central nervous system (&#8220;CNS&#8221;) diseases with high unmet need. We analyze genomic data
from clinical studies to identify biomarkers, which we use to select patients that will receive the therapeutic benefit for the
treatment of neurodegenerative and neurodevelopmental diseases.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Our
lead compound, ANAVEX<sup>&#174;</sup>2-73, is being developed to treat Alzheimer&#8217;s disease, Parkinson&#8217;s disease and
potentially other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological
monogenic disorder caused by mutations in the X-linked gene, methyl-CpG-binding protein 2 (&#8220;MECP2&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We currently have two core programs and two
seed programs. Our core programs are at various stages of clinical and preclinical development, in neurodegenerative and neurodevelopmental
diseases.</p>

<p style="font: 10.5pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">The
following table summarizes key information about our programs:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;&#160;</b></span></p>

<p style="font: 10.5pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<img src="image_001.jpg" alt="" /></span></p>
<!-- Field: Page; Sequence: 24 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Anavex
has a portfolio of compounds varying in sigma-1 receptor (S1R) binding activities. The SIGMAR1 gene encodes the S1R protein, which
is an intracellular chaperone protein with important roles in cellular communication. S1R is also involved in transcriptional
regulation at the nuclear envelope and restores homeostasis and stimulates recovery of cell function when activated. In order
to validate the ability of our compounds to activate quantitatively the S1R, we performed, in collaboration with Stanford University,
a quantitative Positron Emission Tomography (PET) imaging scan in mice, which demonstrated a dose-dependent ANAVEX<sup>&#174;</sup>2-73
target engagement or receptor occupancy (RO) with S1R in the brain.</span></p>

<p style="font: 10.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 5pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><img src="img_002.jpg" alt="" style="height: 329.25pt; width: 468pt" /></span></p>

<p style="font: 10.5pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 5pt 0 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Cellular
Homeostasis</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Many
diseases are possibly directly caused by chronic homeostatic imbalances or cellular stress of brain cells. In pediatric diseases
like Rett syndrome or infantile spasms, the chronic cellular stress is possibly caused by the presence of a constant genetic mutation.
In neurodegenerative diseases, such as Alzheimer&#8217;s and Parkinson&#8217;s diseases, chronic cellular stress is possibly caused
by age-correlated buildup of cellular insult and hence chronic cellular stress. Specifically, defects in homeostasis of protein
or ribonucleic acid (&#8220;RNA&#8221;) lead to the death of neurons and dysfunction of the nervous system. The spreading of protein
aggregates resulting in a proteinopathy, a characteristic finding in Alzheimer&#8217;s and Parkinson&#8217;s diseases that results
from disorders of protein synthesis, trafficking, folding, processing or degradation in cells. The clearance of macromolecules
in the brain is particularly susceptible to imbalances that result in aggregation and degeneration in nerve cells. For example,
Alzheimer&#8217;s disease pathology is characterized by the presence of amyloid plaques, neurofibrillary tangles, which are aggregates
of hyperphosphorylated Tau protein that are a marker of other diseases known as tauopathies as well as inflammation of microglia.
With the SIGMAR1 activation through SIGMAR1 agonists like ANAVEX<sup>&#174;</sup>2-73, our approach is to restore cellular balance,
i.e. homeostasis. Therapies that correct defects in cellular homeostasis might have the potential to halt or delay neurodevelopmental
and neurodegenerative disease progression.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>
<!-- Field: Page; Sequence: 24 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>ANAVEX</i></b><sup>&#174;</sup><b><i>2-73-specific
Biomarkers</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">A
full genomic analysis of Alzheimer&#8217;s disease (AD) patients treated with ANAVEX<sup>&#174;</sup>2-73 resulted in the identification
of actionable genetic variants. A significant impact of the genomic biomarkers SIGMAR1, the direct target of ANAVEX<sup>&#174;</sup>2-73
and COMT, a gene involved in memory function, on the drug response level was identified, leading to an early ANAVEX<sup>&#174;</sup>2-73-specific
biomarker hypothesis. It is expected that <i>excluding</i> patients with these two identified biomarker variants (approximately
10%-20% of the population) in prospective studies would identify approximately 80%-90% patients that would display clinically
significant improved functional and cognitive scores. The consistency between the identified DNA and RNA data related to ANAVEX<sup>&#174;</sup>2-73,
which are considered independent of AD pathology, as well as multiple endpoints and time-points, provides support for precision
medicine clinical development of ANAVEX<sup>&#174;</sup>2-73 by using genetic biomarkers identified within the study population
itself to target patients who are most likely to respond to ANAVEX<sup>&#174;</sup>2-73 treatment in AD as well as indications
like Parkinson&#8217;s disease dementia (PDD) or Rett syndrome (RTT) in which ANAVEX<sup>&#174;</sup>2-73 is currently studied.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Clinical
Studies Overview</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Alzheimer&#8217;s
Disease</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
November 2016, we completed a Phase 2a clinical trial, consisting of PART A and PART B, which lasted a total of 57 weeks, for
ANAVEX<sup>&#174;</sup>2-73 in mild-to-moderate Alzheimer&#8217;s patients. This open-label randomized trial met both primary and
secondary endpoints and was designed to assess the safety and exploratory efficacy of ANAVEX<sup>&#174;</sup>2-73 in 32 patients.
ANAVEX<sup>&#174;</sup>2-73 targets sigma-1 and muscarinic receptors, which have been shown in preclinical studies to reduce stress
levels in the brain believed to restore cellular homeostasis and to reverse the pathological hallmarks observed in Alzheimer&#8217;s
disease. The Phase 2a trial demonstrated positive pharmacokinetic (PK) and pharmacodynamic (PD) data, which established a concentration-effect
relationship between ANAVEX<sup>&#174;</sup>2-73 and study measurements. These measures obtained from all patients who participated
in the entire 57 weeks include exploratory cognitive and functional scores as well as biomarker signals of brain activity. Additionally,
the study appears to show that ANAVEX<sup>&#174;</sup>2-73 activity is enhanced by its active metabolite (ANAVEX19-144), which
also targets the sigma-1 receptor and has a half-life approximately twice as long as the parent molecule.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Two
consecutive trial extensions for the Phase 2a trial have allowed participants who completed the 52-week PART B of the study to
continue taking ANAVEX<sup>&#174;</sup>2-73, providing an opportunity to gather extended safety data for a cumulative time period
of five years. In August 2020, patients completing these Phase 2a trial extensions were granted continued access to treatment
with ANAVEX<sup>&#174;</sup>2-73 through the Australian Government Department of Health &#8211; Therapeutic Goods Administration
(TGA) compassionate use Special Access Scheme.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">A
larger Phase 2b/3 double-blind, placebo-controlled study of ANAVEX<sup>&#174;</sup>2-73 in Alzheimer&#8217;s disease
commenced in August 2018. The Phase 2b/3 study will enroll approximately 450 patients for 48 weeks, randomized 1:1:1 to two
different ANAVEX<sup>&#174;</sup>2-73 doses or placebo. The trial commenced in Australia; and during fiscal 2020 additional
regions were added in the United Kingdom, The Netherlands, Germany and Canada. The ANAVEX<sup>&#174;</sup>2-73 Phase 2b/3
study design incorporates genomic precision medicine biomarkers identified in the ANAVEX<sup>&#174;</sup>2-73 Phase 2a study.
Primary and secondary endpoints will assess safety and both cognitive and functional efficacy, measured through
Alzheimer&#8217;s Disease Assessment Scale &#8211; Cognition (ADAS-Cog), ADCS-ADL and Clinical Dementia Rating &#8211; Sum of
Boxes for cognition and function (CDR-SB).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>
<!-- Field: Page; Sequence: 24 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
October 2019, we initiated a long-term open label extension study of ANAVEX<sup>&#174;</sup>2-73, entitled the ATTENTION-AD study,
for patients who have completed the 48-week Phase 2b/3 placebo-controlled trial referenced above. This study is expected to last
two years and will give patients the opportunity to continue their treatment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Rett
Syndrome </i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
February 2016, we presented positive preclinical data for ANAVEX<sup>&#174;</sup>2-73 in Rett syndrome, a rare neurodevelopmental
disease. The study was funded by the International Rett Syndrome Foundation (&#8220;Rettsyndrome.org&#8221;). In January 2017,
we were awarded a financial grant from Rettsyndrome.org of a minimum of $0.6 million to cover some of the costs of a multicenter
Phase 2 clinical trial of ANAVEX<sup>&#174;</sup>2-73 for the treatment of Rett syndrome. This award was received in quarterly
instalments which commenced during fiscal 2018.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
March 2019, we commenced the first Phase 2 clinical trial in a planned Rett syndrome program of ANAVEX<sup>&#174;</sup>2-73 for
the treatment of Rett syndrome. The studies will be conducted in a range of patient age demographics and geographic regions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The first Phase 2 study, which took place
in the United States, was completed in December 2020. This trial was a randomized double-blind, placebo-controlled safety, tolerability,
pharmacokinetic and efficacy study of oral liquid ANAVEX<sup>&#174;</sup>2-73formulation in 25 adult female patients with Rett
syndrome over a 7-week treatment period including ANAVEX<sup>&#174;</sup>2-73-specific genomic precision medicine biomarkers.
The primary endpoint of the trial was safety. The convenient oral liquid once-daily dosing of 5 mg ANAVEX<sup>&#174;</sup>2-73
was well-tolerated and demonstrated dose-proportional PK (pharmacokinetics). All secondary efficacy endpoints of the trial showed
statistically significant and clinically meaningful, drug exposure-dependent response in the Rett Syndrome Behaviour Questionnaire
(RSBQ) Total scores, when compared to placebo, in the ITT cohort (all participants, p = 0.048). 66.7% of ANAVEX<sup>&#174;</sup>2-73
treated subjects showed a statistically significant improvement in drug exposure-dependent RSBQ response as compared to 10% of
the subjects on placebo in the ITT cohort (all participants, p = 0.011). ANAVEX<sup>&#174;</sup>2-73 treatment resulted in a sustained
improvement in Clinical Global Impression Improvement (CGI-I) scores throughout the 7-week study, when compared to placebo in
the ITT cohort (all participants, p = 0.014). 86.7% of ANAVEX<sup>&#174;</sup>2-73 treated subjects showed a statistically significant
CGI-I response, defined as sustained improvement to treatment, as compared to 40% of the subjects on placebo in the ITT cohort
(all participants, p = 0.014). Consistent with previous ANAVEX<sup>&#174;</sup>2-73 clinical trials, patients carrying the common
form of the SIGMAR1 gene treated with ANAVEX<sup>&#174;</sup>2-73 experienced stronger improvements in the prespecified efficacy
endpoints.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-align: justify">The second Phase 2 study of ANAVEX<sup>&#174;</sup>2-73
for the treatment of Rett syndrome, called the AVATAR study, commenced in June 2019. This study is taking place in Australia and
the United Kingdom using a convenient once-daily oral liquid ANAVEX<sup>&#174;</sup>2-73 formulation at a higher dose than the
U.S. based Phase 2 study for Rett syndrome. The study will evaluate the safety and efficacy of ANAVEX<sup>&#174;</sup>2-73 in approximately
33 patients over a 7-week treatment period including ANAVEX<sup>&#174;</sup>2-73 specific precision medicine biomarkers. All patients
who participate in the study will be eligible to receive ANAVEX<sup>&#174;</sup>2-73 under a voluntary open label extension protocol.<span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
July 2020, we commenced the third study of ANAVEX<sup>&#174;</sup>2-73 for the treatment of Rett syndrome, called the EXCELLENCE
study. This Phase 2/3 study in pediatric patients with Rett syndrome is using a convenient once-daily oral liquid ANAVEX<sup>&#174;</sup>2-73
formulation. The study will evaluate the safety and efficacy of ANAVEX<sup>&#174;</sup>2-73 in at least 69 pediatric patients,
aged 5 to 18, over a 12-week treatment period incorporating ANAVEX<sup>&#174;</sup>2-73 specific precision medicine biomarkers.
All patients who participate in the study will be eligible to receive ANAVEX<sup>&#174;</sup>2-73 under a voluntary open label
extension protocol.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>
<!-- Field: Page; Sequence: 24 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Parkinson&#8217;s
Disease</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
September 2016, we presented positive preclinical data for ANAVEX<sup>&#174;</sup>2-73 in Parkinson&#8217;s disease, which demonstrated
significant improvements on all measures: behavioral, histopathological, and neuroinflammatory endpoints. The study was funded
by the Michael J. Fox Foundation. Additional data was announced in October 2017 from the model for experimental parkinsonism.
The data presented indicates that ANAVEX<sup>&#174;</sup>2-73 induces robust neurorestoration in experimental parkinsonism. The
encouraging results we have gathered in this model, coupled with the favorable profile of this compound in the Alzheimer&#8217;s
disease trial, support the notion that ANAVEX<sup>&#174;</sup>2-73 is a promising clinical candidate drug for Parkinson&#8217;s
disease dementia.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
October 2020, we completed a double-blind, randomized, placebo-controlled proof-of-concept Phase 2 trial with ANAVEX<sup>&#174;</sup>2-73
in Parkinson&#8217;s Disease Dementia (PDD), to study the effect of the compound on both the cognitive and motor impairment of
Parkinson&#8217;s disease. The Phase 2 study enrolled approximately 132 patients for 14 weeks, randomized 1:1:1 to two different
ANAVEX<sup>&#174;</sup>2-73 doses, 30mg and 50mg, or placebo. The ANAVEX<sup>&#174;</sup>2-73 Phase 2 PDD study design incorporated
genomic precision medicine biomarkers identified in the ANAVEX<sup>&#174;</sup>2-73 Phase 2a study.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
study found that ANAVEX<sup>&#174;</sup>2-73 was safe and well tolerated in oral doses up to 50mg once daily. The results show
clinically meaningful, dose-dependent, and statistically significant improvements in the Cognitive Drug Research (CDR) computerized
assessment system analysis. The study confirmed the precision medicine approach of targeting SIGMAR1 as a genetic biomarker in
response to ANAVEX<sup>&#174;</sup>2-73.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
August 2020, we announced a financial commitment by Shake It Up Australia Foundation for Parkinson&#8217;s Research to fund up
to 50% of the costs of an Australian clinical study to develop ANAVEX<sup>&#174;</sup>2-73 for the disease modifying treatment
of Parkinson&#8217;s disease. The financial commitment would be made through private placement purchases of our common stock at
200% of the fair market value on the purchase date and will be contingent upon the completion of certain clinical trial milestones
relating to the proposed clinical trial. The proposed clinical trial will use a convenient, once-daily oral ANAVEX<sup>&#174;</sup>2-73
formulation to confirm the previously established potential disease modifying features of ANAVEX<sup>&#174;</sup>2-73 in an animal
model of Parkinson&#8217;s disease. Safety and efficacy will be investigated in an appropriately powered placebo-controlled clinical
study of Parkinson&#8217;s disease patients over at least 48-weeks including ANAVEX<sup>&#174;</sup>2-73-specific precision medicine
biomarkers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Frontotemporal
Dementia</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
July 2020, we commenced the First-in-Human Phase 1 clinical trial of ANAVEX<sup>&#174;</sup>3-71, which was previously granted
orphan drug designation for the treatment of Frontotemporal Dementia (FTD) by the FDA. ANAVEX<sup>&#174;</sup>3-71 is an orally
administered small molecule targeting sigma-1 and M1 muscarinic receptors that is designed to be beneficial for neurodegenerative
diseases. In preclinical studies, <span style="background-color: white">ANAVEX<sup>&#174;</sup>3-71 demonstrated disease-modifying
activity against the major hallmarks of Alzheimer&#8217;s disease in transgenic (3xTg-AD) mice, including cognitive deficits,
amyloid and tau pathologies, as well as beneficial effects on mitochondrial dysfunction and neuroinflammation.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">The
Phase 1 clinical trial will be a prospective double-blind, randomized, placebo-controlled study. A total of at least 36 healthy
male and female subjects will be included. Single escalating doses of ANAVEX<sup>&#174;</sup>3-71 will be administered in order
to evaluate the safety, tolerability, and pharmacokinetics (PK) of ANAVEX<sup>&#174;</sup>3-71 and the effects of food and gender
on its PK in healthy volunteers. This study is expected to be followed by longer duration dosing including patients with FTD or
other dementia indications with unmet medical need, incorporating exploratory efficacy and disease biomarker measures<span style="color: #1F1F1F">.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Our
Pipeline</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Our
research and development pipeline includes ANAVEX<sup>&#174;</sup>2-73 currently in three different clinical study indications,
and several other compounds in different stages of clinical and pre-clinical study.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Our
proprietary SIGMACEPTOR&#8482; Discovery Platform produced small molecule drug candidates with unique modes of action, based on
our understanding of sigma receptors. Sigma receptors may be targets for therapeutics to combat many human diseases, both of neurodegenerative
nature, including Alzheimer&#8217;s disease, as well as of neurodevelopmental nature, like Rett syndrome. When bound by the appropriate
ligands, sigma receptors influence the functioning of multiple biochemical signals that are involved in the pathogenesis (origin
or development) of disease. Multiple viruses including SARS-CoV-2 (COVID-19) induce cellular stress by intrinsic mitochondrial
apoptosis and other related cellular processes, in order to ensure survival and replication. Hence, it is possible that S1R could
play a role in modulating the cellular response to viral infection and ameliorate pathogenesis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Compounds
that have been subjects of our research include the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">ANAVEX<sup>&#174;</sup>2-73
<i>(blarcamesine)</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">ANAVEX<sup>&#174;</sup>2-73
may offer a disease-modifying approach in neurodegenerative and neurodevelopmental diseases by activation of sigma-1 receptors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
Rett syndrome, administration of ANAVEX<sup>&#174;</sup>2-73 resulted in both significant and dose related improvements in an array
of behavioral paradigms in the MECP2 HET Rett syndrome disease model. In addition, in a further experiment sponsored by Rettsyndrome.org,
ANAVEX<sup>&#174;</sup>2-73 was evaluated in automatic visual response and respiration tests in 7-month old mice, an age at which
advanced pathology is evident. Vehicle-treated MECP2 mice demonstrated fewer automatic visual responses than wild-type mice. Treatment
with ANAVEX<sup>&#174;</sup>2-73 for four weeks significantly increased the automatic visual response in the MECP2 Rett syndrome
disease mouse. Additionally, chronic oral dosing daily for 6.5 weeks of ANAVEX<sup>&#174;</sup>2-73 starting at ~5.5 weeks of age
was conducted in the MECP2 HET Rett syndrome disease mouse model assessed the different aspects of muscular coordination, balance,
motor learning and muscular strengths, some of the core deficits observed in Rett syndrome. Administration of ANAVEX<sup>&#174;</sup>2-73
resulted in both significant and dose related improvements in an array of these behavioral paradigms in the MECP2 HET Rett syndrome
disease model.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
March 2019, we commenced the first Phase 2 clinical trial in a planned Rett syndrome program of ANAVEX<sup>&#174;</sup>2-73 for
the treatment of Rett syndrome. This study, which took place in the United States, was completed in December 2020, however two
other clinical trials in Rett syndrome, the AVATAR study and the EXCELLENCE study, are still underway. The studies are being conducted
in a range of patient age demographics and geographic regions, as more fully described above under <i>Clinical Studies Overview
&#8211; Rett Syndrome</i>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>
<!-- Field: Page; Sequence: 24 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
May 2016 and June 2016, the FDA granted Orphan Drug Designation to ANAVEX<sup>&#174;</sup>2-73 for the treatment of Rett syndrome
and infantile spasms, respectively. In November 2019, the FDA granted to ANAVEX<sup>&#174;</sup>2-73 the Rare Pediatric Disease
(RPD) designation for the treatment of Rett syndrome. The RPD designation provides priority review by the FDA to encourage the
development of treatments for rare pediatric diseases.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Further,
in February 2020, the FDA granted Fast Track designation for the ANAVEX<sup>&#174;</sup>2-73 clinical development program for the
treatment of Rett syndrome. The FDA Fast Track program is designed to facilitate and expedite the development and review of new
drugs to address unmet medical needs in the treatment of serious and life-threatening conditions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">For
Parkinson&#8217;s disease, data demonstrates significant improvements and restoration of function in a disease modifying animal
model of Parkinson&#8217;s disease. Significant improvements were seen on all measures tested: behavioral, histopathological,
and neuroinflammatory endpoints. In October 2020, we completed a double-blind, randomized, placebo-controlled proof-of-concept
Phase 2 trial with ANAVEX<sup>&#174;</sup>2-73 in Parkinson&#8217;s Disease Dementia (PDD), to study the effect of the compound
on both the cognitive and motor impairment of Parkinson&#8217;s disease. The Phase 2 study enrolled approximately 132 patients
for 14 weeks, randomized 1:1:1 to two different ANAVEX<sup>&#174;</sup>2-73 doses, 30mg and 50mg, or placebo. The ANAVEX<sup>&#174;</sup>2-73
Phase 2 PDD study design incorporated genomic precision medicine biomarkers identified in the ANAVEX<sup>&#174;</sup>2-73 Phase
2a study.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
study found that ANAVEX<sup>&#174;</sup>2-73 was safe and well tolerated in oral doses up to 50mg once daily. The results show
clinically meaningful, dose-dependent, and statistically significant improvements in the Cognitive Drug Research (CDR) computerized
assessment system analysis. We anticipate conducting further clinical trials of ANAVEX<sup>&#174;</sup>2-73 in Parkinson&#8217;s
disease dementia after submitting the results of the study to the FDA to obtain regulatory guidance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
Alzheimer&#8217;s disease (AD) animal models, ANAVEX<sup>&#174;</sup>2-73 has shown pharmacological, histological and behavioral
evidence as a potential neuroprotective, anti-amnesic, anti-convulsive and anti-depressive therapeutic agent, due to its potent
affinity to sigma-1 receptors and moderate affinities to M1-4 type muscarinic receptors. In addition, ANAVEX<sup>&#174;</sup>2-73
has shown a potential dual mechanism which may impact both amyloid and tau pathology. In a transgenic AD animal model Tg2576,
ANAVEX<sup>&#174;</sup>2-73 induced a statistically significant neuroprotective effect against the development of oxidative stress
in the mouse brain, as well as significantly increased the expression of functional and synaptic plasticity markers that is apparently
amyloid-beta independent. It also statistically alleviated the learning and memory deficits developed over time in the animals,
regardless of sex, both in terms of spatial working memory and long-term spatial reference memory.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Based
on the results of pre-clinical testing, we initiated and completed a Phase 1 single ascending dose (SAD) clinical trial of ANAVEX<sup>&#174;</sup>2-73.
In this Phase 1 SAD trial, the maximum tolerated single dose was defined per protocol as 55-60 mg. This dose is above the equivalent
dose shown to have positive effects in mouse models of AD. There were no significant changes in laboratory or electrocardiogram
(ECG) parameters. ANAVEX<sup>&#174;</sup>2-73 was well tolerated below the 55-60 mg dose with only mild adverse events in some
subjects. Observed adverse events at doses above the maximum tolerated single dose included headache and dizziness, which were
moderate in severity and reversible. These side effects are often seen with drugs that target CNS conditions, including AD.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>
<!-- Field: Page; Sequence: 24 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
December 2014, a Phase 2a clinical trial was initiated for ANAVEX<sup>&#174;</sup>2-73, for the treatment of Alzheimer&#8217;s
disease. The open-label randomized trial was designed to assess the safety and exploratory efficacy of ANAVEX<sup>&#174;</sup>2-73
in 32 patients with mild-to-moderate Alzheimer&#8217;s disease. ANAVEX<sup>&#174;</sup>2-73 targets sigma-1 and muscarinic receptors,
which have been shown in preclinical studies to reduce stress levels in the brain believed to restore cellular homeostasis and
to reverse the pathological hallmarks observed in Alzheimer&#8217;s disease. The Phase 2a study met both primary and secondary
objectives of the study.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">In
July 2018, we presented the results of a genomic DNA and RNA evaluation of the participants in the Phase 2a study. More than 33,000
genes were analyzed using unbiased, data driven, machine learning, artificial intelligence (AI) system for analyzing DNA &amp;
RNA data in patients exposed to ANAVEX<sup>&#174;</sup>2-73. The analysis identified genetic variants that impacted response to
ANAVEX<sup>&#174;</sup>2-73, among them variants related to the Sigma-1 receptor (SIGMAR1), the target for ANAVEX<sup>&#174;</sup>2-73.
Results showed that study participants with the common SIGMAR1 wild type gene variant, which is about 80 percent of the population
worldwide, demonstrated improved cognitive (MMSE) and the functional (ADCS-ADL) scores. The results from this evaluation have
been used to establish a precision medicine approach in subsequent clinical trials, since these signatures can now be applied
to neurological indications tested in clinical studies with ANAVEX<sup>&#174;</sup>2-73 including Alzheimer&#8217;s disease, Parkinson&#8217;s
disease dementia and Rett syndrome.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">ANAVEX<sup>&#174;</sup>2-73
data presented met prerequisite information in order to progress into a Phase 2b/3 placebo-controlled study. On July 2, 2018,
the Human Research Ethics Committee in Australia approved the initiation of our Phase 2b/3, double-blind, randomized, placebo-controlled
48-week safety and efficacy trial of ANAVEX<sup>&#174;</sup>2-73 for the treatment of early Alzheimer&#8217;s disease. Clinical
trial sites in Canada, the United Kingdom, the Netherlands and Germany were also added. This Phase 2b/3 study design incorporates inclusion of
genomic precision medicine biomarkers identified in the ANAVEX<sup>&#174;</sup>2-73 Phase 2a study. The Phase 2b/3 study, which
is expected to enroll approximately 450 patients, randomized 1:1:1 to either two different ANAVEX<sup>&#174;</sup>2-73 doses or
placebo, commenced in October 2018.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Preclinical
data also validates ANAVEX<sup>&#174;</sup>2-73 as a prospective platform drug for other neurodegenerative diseases beyond Alzheimer&#8217;s
disease, Parkinson&#8217;s disease or Rett syndrome, more specifically, epilepsy, infantile spasms, Fragile X syndrome, Angelman
syndrome, multiple sclerosis and, more recently, tuberous sclerosis complex (TSC). ANAVEX<sup>&#174;</sup>2-73 demonstrated significant
improvements in all of these indications in the respective preclinical animal models.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
a study sponsored by the Foundation for Angelman Syndrome, ANAVEX<sup>&#174;</sup>2-73 was assessed in a mouse model for the development
of audiogenic seizures. &#160;The results indicated that ANAVEX<sup>&#174;</sup>2-73 administration significantly reduced audiogenic-induced
seizures. In a study sponsored by FRAXA Research Foundation regarding Fragile X syndrome, data demonstrated that ANAVEX<sup>&#174;</sup>2-73
restored hippocampal brain-derived neurotrophic factor (BDNF) expression to normal levels. BDNF under-expression has been observed
in many neurodevelopmental and neurodegenerative pathologies. BDNF signaling promotes maturation of both excitatory and inhibitory
synapses. ANAVEX<sup>&#174;</sup>2-73 normalization of BDNF expression could be a contributing factor for the positive data observed
in both neurodevelopmental and neurodegenerative disorders like Angelman and Fragile X syndromes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Preclinical
data presented also indicates that ANAVEX<sup>&#174;</sup>2-73 demonstrates protective effects of mitochondrial enzyme complexes
during pathological conditions, which, if impaired, are believed to play a role in the pathogenesis of neurodegenerative and neurodevelopmental
diseases.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Preclinical
data on ANAVEX<sup>&#174;</sup>2-73 related to multiple sclerosis indicates that ANAVEX<sup>&#174;</sup>2-73 may promote remyelination
in multiple sclerosis disease. Further, data also demonstrates that ANAVEX<sup>&#174;</sup>2-73 provides protection for oligodendrocytes
(&#8220;OL&#8217;s&#8221;) and oligodendrocyte precursor cells (&#8220;OPC&#8217;s&#8221;), as well as central nervous system
neurons in addition to helping repair by increasing OPC proliferation and maturation in tissue culture.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
March 2018, we presented preclinical data of ANAVEX<sup>&#174;</sup>2-73 in a genetic mouse model of tuberous sclerosis complex
(&#8220;TSC&#8221;). TSC is a rare genetic disorder characterized by the growth of numerous benign tumors in many parts of the
body with a high incidence of seizures. The new preclinical data demonstrates that treatment with ANAVEX<sup>&#174;</sup>2-73 significantly
increases survival and reduces seizures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>
<!-- Field: Page; Sequence: 24 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>ANAVEX<sup>&#174;</sup>3-71</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">ANAVEX<sup>&#174;</sup>3-71
is a clinical drug candidate with a novel mechanism of action via sigma-1 receptor activation and M1 muscarinic allosteric modulation,
which has been shown to enhance neuroprotection and cognition in Alzheimer&#8217;s disease models. ANAVEX<sup>&#174;</sup>3-71
is a CNS-penetrable potential disease modifying treatment for cognitive impairments. It is highly effective in very small doses
against the major Alzheimer&#8217;s hallmarks in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid and tau pathologies,
and also has beneficial effects on inflammation and mitochondrial dysfunctions. ANAVEX<sup>&#174;</sup>3-71 indicates extensive
therapeutic advantages in Alzheimer&#8217;s and other protein-aggregation-related diseases given its ability to enhance neuroprotection
and cognition via sigma-1 receptor activation and M1 muscarinic allosteric modulation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">A
preclinical study examined the response of ANAVEX<sup>&#174;</sup>3-71 in aged transgenic animal models and showed a significant
reduction in the rate of cognitive deficit, amyloid beta pathology and inflammation with the administration of ANAVEX 3-71. In
April 2016, the FDA granted Orphan Drug Designation to ANAVEX<sup>&#174;</sup>3-71 for the treatment of Frontotemporal dementia
(FTD).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">During
pathological conditions ANAVEX<sup>&#174;</sup>3-71 demonstrated the formation of new synapses between neurons (synaptogenesis)
without causing an abnormal increase in the number of astrocytes. In neurodegenerative diseases such as Alzheimer&#8217;s and
Parkinson&#8217;s disease, synaptogenesis is believed to be impaired. Additional preclinical data presented also indicates that
in addition to reducing oxidative stress, ANAVEX<sup>&#174;</sup>3-71 demonstrates protective effects of mitochondrial enzyme complexes
during pathological conditions, which, if impaired, are believed to play a role in the pathogenesis of neurodegenerative and neurodevelopmental
diseases.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
July 2020, we commenced the first Phase 1 clinical trial of ANAVEX<sup>&#174;</sup>3-71, with focus on the treatment of Frontotemporal
Dementia (FTD) and <span style="background-color: white">other dementia indications with unmet medical need</span>. The study
is more fully described above under <i>Clinical Studies Overview &#8211; Frontotemporal Dementia</i>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>ANAVEX<sup>&#174;</sup>1-41</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">ANAVEX<sup>&#174;</sup>1-41
is a sigma-1 receptor agonist. Pre-clinical tests revealed significant neuroprotective benefits (i.e., protects nerve cells from
degeneration or death) through the modulation of endoplasmic reticulum, mitochondrial and oxidative stress, which damages and
impairs cell viability. In addition, in animal models, ANAVEX<sup>&#174;</sup>1-41 prevented the expression of caspase-3, an enzyme
that plays a key role in apoptosis (programmed cell death) and loss of cells in the hippocampus, the part of the brain that regulates
learning, emotion and memory. These activities involve both muscarinic and sigma-1 receptor systems through a novel mechanism
of action.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Preclinical
data presented also indicates that ANAVEX<sup>&#174;</sup>1-41 demonstrates protective effects of mitochondrial enzyme complexes
during pathological conditions, which, if impaired, are believed to play a role in the pathogenesis of neurodegenerative and neurodevelopmental
diseases.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>ANAVEX<sup>&#174;</sup>1066</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">ANAVEX<sup>&#174;</sup>1066,
a mixed sigma-1/sigma-2 ligand is designed for the potential treatment of neuropathic and visceral pain. ANAVEX<sup>&#174;</sup>1066
was tested in two preclinical models of neuropathic and visceral pain that have been extensively validated in rats. In the chronic
constriction injury model of neuropathic pain, a single oral administration of ANAVEX<sup>&#174;</sup>1066 dose-dependently restored
the nociceptive threshold in the affected paw to normal levels while leaving the contralateral healthy paw unchanged. Efficacy
was rapid and remained significant for two hours. In a model of visceral pain, chronic colonic hypersensitivity was induced by
injection of an inflammatory agent directly into the colon and a single oral administration of ANAVEX<sup>&#174;</sup>1066 returned
the nociceptive threshold to control levels in a dose-dependent manner. Companion studies in rats demonstrated the lack of any
effects on normal gastrointestinal transit with ANAVEX<sup>&#174;</sup>1066 and a favorable safety profile in a battery of behavioral
measures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>
<!-- Field: Page; Sequence: 24 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>ANAVEX<sup>&#174;</sup>1037
</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">ANAVEX<sup>&#174;</sup>1037
is designed for the treatment of prostate and pancreatic cancer. It is a low molecular weight, synthetic compound exhibiting high
affinity for sigma-1 receptors at nanomolar levels and moderate affinity for sigma-2 receptors and sodium channels at micromolar
levels. In advanced pre-clinical studies, this compound revealed antitumor potential. It has also been shown to selectively kill
human cancer cells without affecting normal/healthy cells and also to significantly suppress tumor growth in immune-deficient
mice models. Scientific publications highlight the possibility that these ligands may stop tumor growth and induce selective cell
death in various tumor cell lines. Sigma receptors are highly expressed in different tumor cell types. Binding by appropriate
sigma-1 and/or sigma-2 ligands can induce selective apoptosis. In addition, through tumor cell membrane reorganization and interactions
with ion channels, our drug candidates may play an important role in inhibiting the processes of metastasis (spreading of cancer
cells from the original site to other parts of the body), angiogenesis (the formation of new blood vessels) and tumor cell proliferation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Our
compounds are in the pre-clinical and clinical testing stages of development, and there is no guarantee that the activity demonstrated
in pre-clinical models will be shown in human testing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
continue to identify and initiate discussions with potential strategic and commercial partners to most effectively advance our
programs and realize maximum shareholder value. Further, we may acquire or develop new intellectual property and assign, license,
or otherwise transfer our intellectual property to further our goals.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Our
Target Indications</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
have developed compounds with potential application to two broad categories and several specific indications. including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Central
Nervous System Diseases</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ul style="margin-top: 0in; list-style-type: disc">

<li style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif; color: windowtext">Alzheimer&#8217;s
disease &#8211; In 2020, an estimated 5.8 million Americans were suffering from Alzheimer&#8217;s disease. The Alzheimer&#8217;s
Association<sup>&#174;</sup> estimates that by 2050, this number will rise to nearly 14 million Americans. Medications on the market
today treat only the symptoms of Alzheimer&#8217;s disease and do not have the ability to stop its onset or its progression. There
is an urgent and unmet need for both a disease modifying cure for Alzheimer&#8217;s disease as well as for better symptomatic
treatments</span><span style="font: 10pt Times New Roman, Times, Serif">.</span></li>

</ul>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ul style="margin-top: 0in; list-style-type: disc">

<li style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Parkinson&#8217;s
disease &#8211; Parkinson&#8217;s disease is a progressive disease of the nervous system marked by tremors, muscular rigidity,
and slow, imprecise movement. It is associated with degeneration of the basal ganglia of the brain and a deficiency of the neurotransmitter
dopamine. Parkinson&#8217;s disease afflicts more than 10 million people worldwide, typically middle-aged and elderly people.
The Parkinson&#8217;s disease market is expected to expand to $3.2 billion by 2021, according to business intelligence provider
GBI Research.</span></li>

</ul>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ul style="margin-top: 0in; list-style-type: disc">

<li style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif; color: windowtext">Rett
syndrome - Rett syndrome is a rare X-linked genetic neurological and developmental disorder that affects the way the brain develops,
including protein transcription, which is altered and as a result leads to severe disruptions in neuronal homeostasis. It is considered
a rare, progressive neurodevelopmental disorder and is caused by a single mutation in the MECP2 gene. Because males have a different
chromosome combination from females, boys who have the genetic MECP2 mutation are affected in devastating ways. Most of them die
before birth or in early infancy. For females who survive infancy, Rett syndrome leads to severe impairments, affecting nearly
every aspect of the child&#8217;s life; severe mental retardation, their ability to speak, walk and eat, sleeping problems, seizures
and even the ability to breathe easily. Rett syndrome affects approximately 1 in every 10,000-15,000 females</span><span style="font: 10pt Times New Roman, Times, Serif">.</span></li>

</ul>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ul style="margin-top: 0in; list-style-type: disc">

<li style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif; color: windowtext">Depression
- Depression is a major cause of morbidity worldwide according to the World Health Organization. Pharmaceutical treatment for
depression is dominated by blockbuster brands, with the leading nine brands historically accounting for approximately 75% of total
sales. However, the dominance of the leading brands is waning, largely due to the effects of patent expiration and generic competition</span><span style="font: 10pt Times New Roman, Times, Serif">.</span></li>

</ul>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ul style="margin-top: 0in; list-style-type: disc">

<li style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif; color: windowtext">Epilepsy
- Epilepsy is a common chronic neurological disorder characterized by recurrent unprovoked seizures. These seizures are transient
signs and/or symptoms of abnormal, excessive or synchronous neuronal activity in the brain. According to the Centers for Disease
Control and Prevention, in 2015 epilepsy affected 3.4 million Americans. Today, epilepsy is often controlled, but not cured, with
medication that is categorized as older traditional anti-epileptic drugs and second generation anti-epileptic drugs. Because epilepsy
afflicts sufferers in different ways, there is a need for drugs used in combination with both traditional anti-epileptic drugs
and second generation anti-epileptic drugs</span><span style="font: 10pt Times New Roman, Times, Serif">.</span></li>

</ul>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>
<!-- Field: Page; Sequence: 24 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->
<ul style="margin-top: 0in; list-style-type: disc">

<li style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif; color: windowtext">Neuropathic
Pain &#8211; We define neuralgia, or neuropathic pain, as pain that is not related to activation of pain receptor cells in any
part of the body. Neuralgia is more difficult to treat than some other types of pain because it does not respond well to normal
pain medications. Special medications have become more specific to neuralgia and typically fall under the category of membrane
stabilizing drugs or antidepressants</span><span style="font: 10pt Times New Roman, Times, Serif">.</span></li>

</ul>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Cancer</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ul style="margin-top: 0in; list-style-type: disc">

<li style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Malignant
Melanoma - Predominantly a skin cancer, malignant melanoma can also occur in melanocytes found in the bowel and the eye. Malignant
melanoma accounts for 75% of all deaths associated with skin cancer. The treatment includes surgical removal of the tumor, adjuvant
treatment, chemo and immunotherapy, or radiation therapy. According to IMS Health the worldwide malignant melanoma market is expected
to grow to $4.4 billion by 2022.</span></li>

</ul>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ul style="margin-top: 0in; list-style-type: disc">

<li style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Prostate
Cancer &#8211; Specific to men, prostate cancer is a form of cancer that develops in the prostate, a gland in the male reproductive
system. The cancer cells may metastasize from the prostate to other parts of the body, particularly the bones and lymph nodes.
Drug therapeutics for prostate cancer are expected to increase to nearly $13.5 billion in 2024 according to Datamonitor Healthcare.</span></li>

</ul>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ul style="margin-top: 0in; list-style-type: disc">

<li style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Pancreatic
Cancer - Pancreatic cancer is a malignant neoplasm of the pancreas. In the United States, approximately 55,000 new cases of pancreatic
cancer will be diagnosed this year and approximately 44,000 patients will die as a result of their cancer, according to the American
Cancer Society. Sales predictions by GBI Research forecast that the market for the pharmaceutical treatment of pancreatic cancer
in the United States and five largest European countries will increase to $2.9 billion by 2021<span style="color: windowtext">.</span></span></li>

</ul>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-bottom: 12pt; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Competition</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
pharmaceutical industry is intensely competitive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">At
this time, our competitors are other biomedical development companies that are trying to discover and develop compounds to be
used in the treatment of Alzheimer&#8217;s disease and other CNS diseases, and those companies already doing so. Those companies
include Biogen (NASDAQ:BIIB), Pfizer Inc. (NYSE:PFE), Abbvie Plc (NYSE:ABBV), Novartis AG (NYSE:NVS), GlaxoSmithKline Plc (NYSE:GSK),
Merck &amp; Co. Inc. (NYSE:MRK), Eli Lilly &amp; Co. (NYSE: LLY), Johnson &amp; Johnson (NYSE:JNJ) and Roche Holding AG (VTX:ROG).
For additional discussion of the risks related to competition, see Item 1A &#8220;Risk Factors.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Patents,
Trademarks and Intellectual Property </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
hold ownership or exclusive rights to nine U.S. patents, ten U.S. patent applications, and various PCT or ex-U.S. patent applications
relating to our drug candidates, methods associated therewith, and to our research programs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
own one issued U.S. patent entitled &#8220;ANAVEX<sup>&#174;</sup>2-73 and certain anticholinesterase inhibitors composition and
method for neuroprotection&#8221; claims a composition of matter of ANAVEX<sup>&#174;</sup>2-73 directed to a novel and synergistic
neuroprotective compound combined with donepezil and other cholinesterase inhibitors.&#160; This patent is expected to expire
in June 2034, absent any patent term extension for regulatory delays. We own two issued U.S. patents each with claims directed
to crystalline forms of ANAVEX<sup>&#174;</sup>2-73. The first of these two patents claims crystalline forms of ANAVEX<sup>&#174;</sup>2-73,
dosage forms and compositions containing crystalline ANAVEX<sup>&#174;</sup>2-73, and methods of treatment for Alzheimer&#8217;s
disease using them. This patent is expected to expire in July 2036, absent any patent term extension for regulatory delays. The
second of these two patents claims pharmaceutical compositions containing a crystalline form of ANAVEX<sup>&#174;</sup>2-73, and
methods of treatment for Alzheimer&#8217;s disease using the compositions. This patent is expected to expire in June 2037, absent
any patent term extension for regulatory delays. We also own an issued U.S. patent that claims methods and dosage forms for treating
seizures, the dosage forms containing a low-dose anti-epilepsy drug combined with either: (i) ANAVEX<sup>&#174;</sup>2-73 and its
active metabolite ANAVEX<sup>&#174;</sup>19-144; or (ii) ANAVEX<sup>&#174;</sup>19-144. This patent is expected to expire in October
2035, absent any patent term extension for regulatory delays. We also own an issued U.S. patent that claims methods for treating
a neurodevelopmental disorder or multiple sclerosis by administering ANAVEX<sup>&#174;</sup>2-73, ANAVEX<sup>&#174;</sup>19-144,
and/or ANAVEX<sup>&#174;</sup>1-41, another sigma receptor ligand similar to ANAVEX<sup>&#174;</sup>2-73. This patent is expected
to expire in January 2037, absent any patent term extension for regulatory delays. In addition, we own one issued U.S. Patent
with claims directed to methods of treating melanoma with a compound related to ANAVEX<sup>&#174;</sup>2-73. This patent is expected
to expire in February 2030, absent any patent term extension for regulatory delays.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<!-- Field: Page; Sequence: 24 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
also own one issued patent with claims directed to methods for treating or preventing pain with ANAVEX<sup>&#174;</sup>1066. This
patent is expected to expire in November 2036, absent any patent term extension for regulatory delays.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">For
ANAVEX<sup>&#174;</sup>2-73, ANAVEX<sup>&#174;</sup>19-144, ANAVEX<sup>&#174;</sup>1-41, and ANAVEX<sup>&#174;</sup>1066, we also
have granted or pending applications in Australia, Canada, China, Europe, Japan, and Hong Kong, and are expected to expire after
2035.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">With
regard to ANAVEX<sup>&#174;</sup>3-71, we own exclusive rights to two issued U.S. patents with claims respectively directed to
the ANAVEX<sup>&#174;</sup>3-71 compound and methods of treating various diseases including Alzheimer&#8217;s with the same. These
patents are expected to expire in April 2030, and January 2030, respectively, absent any patent term extension for regulatory
delays. We also own exclusive rights to related patents or applications that are granted or pending in Australia, Canada, China,
Europe, Japan, Korea, New Zealand, Russia, and South Africa, and are expected to expire in January 2030.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
also own other patent applications directed to enantiomers, formulations and uses that may provide additional protection for one
or more of our product candidates.&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
regard patents and other intellectual property rights as corporate assets. Accordingly, we attempt to optimize the value of intellectual
property in developing our business strategy including the selective development, protection, and exploitation of our intellectual
property rights. In addition to filings made with intellectual property authorities, we protect our intellectual property and
confidential information by means of carefully considered processes of communication and the sharing of information, and by the
use of confidentiality and non-disclosure agreements and provisions for the same in contractor&#8217;s agreements. While no agreement
offers absolute protection, such agreements provide some form of recourse in the event of disclosure, or anticipated disclosure.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Our
intellectual property position, like that of many biomedical companies, is uncertain and involves complex legal and technical
questions for which important legal principles are unresolved. For more information regarding challenges to our existing or future
patents, see Item 1A &#8220;Risk Factors.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Government
regulation </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Government
authorities in the United States, at the federal, state and local level, and other countries extensively regulate, among other
things, the research, development, testing, manufacture, quality control, approval, labeling, packaging, storage, record-keeping,
promotion, advertising, distribution, marketing and export and import of products such as those we are developing. A new drug
must be approved by the FDA through the NDA process before it may be legally marketed in the United States. We are subject to
various government regulations in connection with the development of our pipeline.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-bottom: 12pt; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif"><i>U.S.
Drug Development and Regulation </i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-bottom: 12pt; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif">In
the United States, the FDA regulates drugs under the federal Food, Drug, and Cosmetic Act and its implementing regulations (&#8220;FDCA&#8221;).
The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local and foreign
statutes and regulations require the expenditure of substantial time and financial resources. Failure to comply with the applicable
U.S. requirements at any time during the product development process, approval process or after approval may subject an applicant
to administrative or judicial sanctions. These sanctions could include the FDA&#8217;s refusal to approve pending applications,
withdrawal of an approval, a clinical hold, warning letters, product recalls, product seizures, total or partial suspension of
production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement or civil or criminal
penalties. Any agency or judicial enforcement action could have a material adverse effect on us.</span></p>

<!-- Field: Page; Sequence: 24 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

    <p style="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Once
a drug candidate is identified for development, it enters the preclinical testing stage. Preclinical tests include laboratory
evaluations of product chemistry, toxicity and formulation, as well as animal studies. An Investigational New Drug application
(&#8220;IND&#8221;) sponsor must submit the results of the preclinical tests, together with manufacturing information and analytical
data, to FDA as part of the IND. The sponsor must also include a protocol detailing, among other things, the objectives of the
first phase of clinical trials, the parameters to be used in monitoring the safety of the trial, and the effectiveness criteria
to be evaluated should the first phase lend itself to an efficacy evaluation. Some preclinical testing may continue even after
the IND is submitted. The IND automatically becomes effective thirty (30) days after receipt by FDA, unless FDA, within the 30-day
time period, places the clinical trial on a clinical hold. Clinical holds also may be imposed by the FDA at any time before or
during clinical trials due to safety concerns about on-going or proposed clinical trials or non-compliance with specific FDA requirements,
and the trials may not begin or continue until the FDA notifies the sponsor that the hold has been lifted.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-bottom: 12pt; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif">All
clinical trials must be conducted under the supervision of one or more qualified investigators in accordance with FDA good clinical
practice (&#8220;GCP&#8221;) requirements, which include a requirement that all research subjects provide their informed consent
in writing for their participation in any clinical trial. Clinical trials must be conducted under protocols detailing the objectives
of the trial, dosing procedures, subject selection and exclusion criteria and the safety and/or effectiveness criteria to be evaluated.
Each protocol must be submitted to FDA as part of the IND, and timely safety reports must be submitted to FDA and the investigators
for serious and unexpected adverse events. An Institutional Review Board (&#8220;IRB&#8221;) at each institution participating
in the clinical trial must review and approve each protocol before a clinical trial may commence at the institution and must also
approve the information regarding the trial as well as the consent form that must be provided to each trial subject or his or
her legal representative, monitor the study until completed and otherwise comply with all applicable IRB regulations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-bottom: 12pt; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif">Human
clinical trials are typically conducted in three sequential phases that may overlap or be combined in certain cases:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-bottom: 12pt; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif">Phase
1: The compound is initially introduced into healthy human subjects and tested for safety, dosage tolerance, absorption, metabolism,
distribution and excretion and, if possible, to gain an early indication of its effectiveness. In most cases, initial Phase 1
clinical trials are conducted with healthy volunteers. However, where the compound being evaluated is for the treatment of severe
or life-threatening diseases, such as cancer, and especially when the product may be too toxic to ethically administer to healthy
volunteers, the initial human testing may be conducted on patients with the target disease or condition. Sponsors sometimes subdivide
their Phase 1 clinical trials into Phase 1a and Phase 1b clinical trials. Phase 1b clinical trials are typically aimed at confirming
dosage, pharmacokinetics and safety in a larger number of patients. Some Phase 1b studies evaluate biomarkers or surrogate markers
that may be associated with efficacy in patients with specific types of diseases or conditions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-bottom: 12pt; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif">Phase
2: This phase involves clinical trials in a limited patient population to identify possible adverse effects and safety risks,
to preliminarily evaluate the efficacy of the product for specific targeted diseases or conditions and to confirm dosage tolerance
and appropriate dosage.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-bottom: 12pt; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif">Phase
3: Phase 3 clinical trials are undertaken to further evaluate dosage, clinical efficacy and safety in an expanded patient population,
generally at geographically dispersed clinical study sites. These clinical trials, often referred to as &#8220;pivotal&#8221;
clinical trials, are intended to establish the overall risk-benefit ratio of the compound and provide, if appropriate, an adequate
basis for product labeling.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-bottom: 12pt; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif">FDA
or the sponsor may suspend a clinical trial at any time on various grounds, including any finding that the research subjects or
patients are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial
at its institution if the clinical trial is not being conducted in accordance with the IRB&#8217;s requirements or if the drug
has been associated with unexpected, serious harm to study subjects. In addition, clinical trials may be overseen by an independent
group of qualified experts organized by the sponsor, known as a data safety monitoring board or committee. Depending on its charter,
this committee may determine whether a trial may move forward at designated check points based on access to certain data from
the trial.</span></p>

<!-- Field: Page; Sequence: 24 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Post-approval
trials may also be conducted after a drug receives initial marketing approval. These trials, often referred to as &#8220;Phase
4&#8221; trials, are used to gain additional experience from the treatment of patients in the intended therapeutic indication.
In certain instances, FDA may mandate the performance of such clinical trials as a condition of approval of an NDA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-bottom: 12pt; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-bottom: 12pt; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif">During
the development of a new drug, sponsors are given several opportunities to meet with FDA. These meetings can provide an opportunity
for the sponsor to share information about the progress of the application or clinical trials, for the FDA to provide advice,
and for the sponsor and the FDA to reach agreement on the next phase of development. These meetings may occur prior to the submission
of an IND, at the end of Phase 2 clinical trials, or before an NDA is ultimately submitted. Sponsors typically use the meetings
at the end of the Phase 2 trials to discuss Phase 2 clinical results and present plans for the pivotal Phase 3 clinical trials
that they believe will support approval of the new drug. Meetings at other times may be made upon request.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-bottom: 12pt; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif">Concurrent
with clinical trials, companies typically complete additional, animal or other non-clinical studies, develop additional information
about the chemistry and physical characteristics of the drug, and finalize a process for manufacturing the product in commercial
quantities in accordance with FDA&#8217;s current Good Manufacturing Practices (&#8220;cGMP&#8221;) requirements. The manufacturing
process must consistently produce quality batches of the drug and, among other things, the manufacturer must develop methods for
testing the identity, strength, quality and purity of the final drug. In addition, appropriate packaging must be selected and
tested, and stability studies must be conducted to demonstrate the effectiveness of the packaging and that the compound does not
undergo unacceptable deterioration over its shelf life.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-bottom: 12pt; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif">While
the IND is active, progress reports summarizing the results of ongoing clinical trials and nonclinical studies performed since
the last progress report must be submitted on at least an annual basis to FDA, and written IND safety reports must be submitted
to FDA and investigators for serious and unexpected adverse events, findings from other studies suggesting a significant risk
to humans exposed to the same or similar drugs, findings from animal or in vitro testing suggesting a significant risk to humans,
and any clinically important, increased incidence of a serious adverse reaction compared to that listed in the protocol or investigator
brochure.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-bottom: 12pt; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif">There
are also requirements governing the submission of certain clinical trials and completed trial results to public registries. Sponsors
of certain clinical trials of FDA-regulated products are required to register and disclose specified clinical trial registration
and results information, which is made publicly available at www.clinicaltrials.gov. Failure to properly report clinical trial
results can result in civil monetary penalties. Disclosure of clinical trial results can often be delayed until the new product
or new indication being studied has been approved.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-bottom: 12pt; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif"><i>U.S.
review and approval process </i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-bottom: 12pt; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif">The
results of product development, preclinical and other non-clinical studies and clinical trials, along with descriptions of the
manufacturing process, analytical tests conducted on the chemistry of the drug, proposed labeling and other relevant information
are submitted to FDA as part of a New Drug Application (&#8220;NDA&#8221;). The submission of an NDA is subject to the payment
of substantial user fees; a waiver of which may be obtained under certain limited circumstances.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-bottom: 12pt; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif">FDA
reviews NDAs to determine, among other things, whether the product is safe and effective for its intended use and whether it is
manufactured in a cGMP-compliant manner, which will assure and preserve the product&#8217;s identity, strength, quality and purity.
Under the Prescription Drug User Fee Act (&#8220;PDUFA&#8221;), FDA has a goal of ten months from the date of &#8220;filing&#8221;
of a standard, completed NDA for a new molecular entity to review and act on the submission. This review typically takes twelve
months from the date the NDA is submitted to FDA because FDA has approximately two months to make a &#8220;filing&#8221; decision
after the application is submitted. FDA conducts a preliminary review of all NDAs within the first sixty days after submission,
before accepting them for filing, to determine whether they are sufficiently complete to permit substantive review. FDA may request
additional information rather than accept an NDA for filing. In this event, the NDA must be resubmitted with the additional information.
The resubmitted application also is subject to review before the FDA accepts it for filing.</span></p>

<!-- Field: Page; Sequence: 24 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-bottom: 12pt; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-bottom: 12pt; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif">FDA
may refer an application for a new drug to an advisory committee within FDA. An advisory committee is a panel of independent experts,
including clinicians and other scientific experts, that reviews, evaluates and provides a recommendation as to whether and under
what conditions the application should be approved. FDA is not bound by the recommendations of such an advisory committee, but
it considers advisory committee recommendations carefully when making decisions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-bottom: 12pt; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif">Before
approving an NDA, FDA will also inspect the facility where the product is manufactured. FDA will not approve an application unless
it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and are adequate to assure
consistent production of the product within required specifications. Before approving an NDA, FDA may also inspect one or more
clinical trial sites to assure compliance with GCP requirements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-bottom: 12pt; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif">After
the FDA evaluates an NDA, it will issue an approval letter or a Complete Response Letter. A Complete Response Letter indicates
that the review cycle of the application is complete, and the application will not be approved in its present form. A Complete
Response Letter usually describes the specific deficiencies in the NDA identified by FDA and may require additional clinical data,
such as an additional pivotal Phase 3 trial or other significant and time-consuming requirements related to clinical trials, nonclinical
studies or manufacturing. If a Complete Response Letter is issued, the sponsor must resubmit the NDA, addressing all of the deficiencies
identified in the letter, or withdraw the application. Even if such data and information are submitted, FDA may decide that the
NDA does not satisfy the criteria for approval. An approval letter authorizes commercial marketing of the drug with prescribing
information for specific indications.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-bottom: 12pt; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif">The
Pediatric Research Equity Act (&#8220;PREA&#8221;), requires IND sponsors to conduct pediatric clinical trials for most drugs,
for a new active ingredient, new indication, new dosage form, new dosing regimen or new route of administration. Under PREA, original
NDAs and supplements must contain a pediatric assessment unless the sponsor has received a deferral or waiver. The required assessment
must evaluate the safety and effectiveness of the product for the claimed indications in all relevant pediatric subpopulations
and support dosing and administration for each pediatric subpopulation for which the product is safe and effective. The sponsor
or FDA may request a deferral of pediatric clinical trials for some or all of the pediatric subpopulations. A deferral may be
granted for several reasons, including a finding that the drug is ready for approval for use in adults before pediatric clinical
trials are complete or that additional safety or effectiveness data needs to be collected before the pediatric clinical trials
begin. FDA must send a non-compliance letter to any sponsor that fails to submit the required assessment, keep a deferral current
or fails to submit a request for approval of a pediatric formulation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-bottom: 12pt; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif">If
a drug receives FDA approval, the approval may be limited to specific diseases and dosages, which could restrict the commercial
value of the product. In addition, FDA may require testing and surveillance programs to monitor the safety of approved products
which have been commercialized, and may require a sponsor to conduct post-marketing clinical trials, which are designed to further
assess a drug&#8217;s safety and effectiveness after NDA approval. FDA may also place other conditions on approval, including
a requirement for a risk evaluation and mitigation strategy (&#8220;REMS&#8221;) to assure the safe use of the drug. If FDA concludes
a REMS is needed, the sponsor of the NDA must submit a proposed REMS. FDA will not approve the NDA without an approved REMS, if
required. A REMS could include medication guides, physician communication plans or elements to assure safe use, such as restricted
distribution methods, patient registries and other risk minimization tools. Any of these limitations on approval or marketing
could restrict the commercial promotion, distribution, prescribing or dispensing of products. Marketing approval may be withdrawn
for non-compliance with REMS or other regulatory requirements, or if problems occur following initial marketing.</span></p>

<!-- Field: Page; Sequence: 24 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-bottom: 12pt; margin-left: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-bottom: 12pt; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif"><i>Post-approval
requirements </i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-bottom: 12pt; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif">Once
an approval is granted, FDA may withdraw the approval if compliance with regulatory standards is not maintained or if problems
occur after the drug reaches the market. Later discovery of previously unknown problems with a drug may result in restrictions
on the drug or even complete withdrawal of the drug from the market. After approval, some types of changes to the approved drug,
such as adding new indications, certain manufacturing changes and additional labeling claims, are subject to further FDA review
and approval. Manufacturers and other entities involved in the manufacture and distribution of approved drugs are required to
register their establishments with FDA and certain state agencies and are subject to periodic unannounced inspections by FDA and
certain state agencies for compliance with cGMP regulations and other laws and regulations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-bottom: 12pt; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif">Any
drug product manufactured or distributed by us pursuant to FDA approval will be subject to continuing regulation by FDA, including,
among other things, record-keeping requirements, reporting of adverse experiences with the drug, providing FDA with updated safety
and efficacy information, drug sampling and distribution requirements, complying with certain electronic records and signature
requirements, and complying with FDA promotion and advertising requirements. FDA strictly regulates labeling, advertising, promotion
and other types of information regarding approved drugs that are placed on the market, and imposes requirements and restrictions
on drug manufacturers, such as those related to direct-to-consumer advertising, the prohibition on promoting products for uses
or in patient populations that are not described in the product&#8217;s approved labeling (known as &#8220;off-label use&#8221;),
industry-sponsored scientific and educational activities, and promotional activities involving the internet. Discovery of previously
unknown problems or the failure to comply with the applicable regulatory requirements may result in restrictions on the marketing
of a product for a certain indication or withdrawal of the product from the market as well as possible civil or criminal sanctions.
Failure to comply with the applicable governmental requirements at any time during the product development process, approval process
or after approval, may subject an applicant or manufacturer to administrative or judicial civil or criminal sanctions and adverse
publicity. FDA sanctions could include refusal to approve pending applications, withdrawal of an approval, clinical holds on post-marketing
clinical trials, enforcement letters, product recalls, product seizures, total or partial suspension of production or distribution,
injunctions, fines, refusals of government contracts, mandated corrective advertising or communications with doctors, debarment,
restitution, disgorgement of profits, or civil or criminal penalties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-bottom: 12pt; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif"><i>Expedited
development and review programs </i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-bottom: 12pt; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif">The
FDA has a fast track designation program that is intended to expedite or facilitate the process for reviewing new drug products
that meet certain criteria. Specifically, new drugs are eligible for fast track designation if they are intended to treat a serious
or life-threatening disease or condition and demonstrate the potential to address unmet medical needs for the disease or condition.
With regard to a fast track product, FDA may consider for review sections of the NDA on a rolling basis before the complete application
is submitted, if the sponsor provides a schedule for the submission of the sections of the NDA, FDA agrees to accept sections
of the NDA and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the
first section of the NDA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-bottom: 12pt; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif">Any
product submitted to FDA for approval, including a product with a fast track designation, may also be eligible for other types
of FDA programs intended to expedite development and review, such as priority review and accelerated approval.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-bottom: 12pt; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif">A
product is eligible for priority review if it is intended to treat a serious condition, and if approved, would provide a significant
improvement in safety or efficacy compared to currently marketed products. FDA will attempt to direct additional resources to
the evaluation of an application for a new drug designated for priority review in an effort to facilitate the review. FDA endeavors
to review applications with priority review designations within six months of the filing date, as compared to ten months for review
of NDAs under its current PDUFA review goals.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-bottom: 12pt; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif">In
addition, a product may be eligible for accelerated approval. Drugs intended to treat serious or life-threatening diseases or
conditions may be eligible for accelerated approval upon a determination that the product has an effect on a surrogate endpoint
that is reasonably likely to predict a clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible
morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical
benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative
treatments. As a condition of approval, the FDA may require that a sponsor of a drug receiving accelerated approval perform adequate
and well-controlled post-marketing clinical trials. Drugs receiving accelerated approval may be subject to expedited withdrawal
procedures if the sponsor fails to conduct the required post-marketing trials or if such trials fail to verify the predicted clinical
benefit. In addition, the FDA currently requires as a condition for accelerated approval pre-approval of promotional materials,
which could adversely impact the timing of the commercial launch of the product.</span></p>

<!-- Field: Page; Sequence: 24 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-bottom: 12pt; margin-left: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-bottom: 12pt; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif">The
Food and Drug Administration Safety and Innovation Act (&#8220;FDASIA&#8221;) established a category of drugs referred to as &#8220;breakthrough
therapies&#8221; that may be eligible to receive breakthrough therapy designation. A sponsor may seek FDA designation of a compound
as a &#8220;breakthrough therapy&#8221; if the product is intended, alone or in combination with one or more other products, to
treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the product may demonstrate
substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment
effects observed early in clinical development. The designation includes all of the fast track program features, as well as more
intensive FDA interaction and guidance. The breakthrough therapy designation is a distinct status from both accelerated approval
and priority review, which can also be granted to the same drug if relevant criteria are met. If a product is designated as breakthrough
therapy, FDA will work to expedite the development and review of such drug.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-bottom: 12pt; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif">Fast
track designation, priority review and breakthrough therapy designation do not change the standards for approval but may expedite
the development or approval process. However, even if a product qualifies for one or more of these programs, FDA may later decide
that the product no longer meets the conditions for qualification or decide that the time period for FDA review or approval will
not be shortened.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-bottom: 12pt; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif"><i>Orphan
drug designation </i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-bottom: 12pt; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif">Under
the Orphan Drug Act, FDA may grant orphan designation to a drug intended to treat a rare disease or condition, which is a disease
or condition that affects fewer than 200,000 individuals in the United States or, if it affects more than 200,000 individuals
in the United States, there is no reasonable expectation that the cost of developing and making a drug product available in the
United States for this type of disease or condition will be recovered from sales of the product. Orphan designation must be requested
before an NDA is submitted. After FDA grants orphan designation, the identity of the therapeutic agent and its potential orphan
use are publicly disclosed by FDA. Orphan designation does not convey any advantage in or shorten the duration of the regulatory
review and approval process.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-bottom: 12pt; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif">If
a product that has orphan designation subsequently receives the first FDA approval for the disease or condition for which it has
such designation, the product is entitled to orphan product exclusivity, which means that FDA may not approve any other applications
to market the same drug for the same indication for seven years, except in limited circumstances, such as a showing of clinical
superiority to the product with orphan exclusivity or inability to manufacture the product in sufficient quantities. The designation
of such drug also entitles a party to financial incentives such as opportunities for grant funding towards clinical trial costs,
tax advantages and user-fee waivers. However, competitors, may receive approval of different products for the indication for which
the orphan product has exclusivity or obtain approval for the same product but for a different indication for which the orphan
product has exclusivity. Orphan exclusivity also could block the approval of one of our compounds for seven years if our compound
is determined to be contained within the competitor&#8217;s product for the same indication or disease, or if a competitor obtains
approval of the same drug as defined by the FDA. In addition, if an orphan designated product receives marketing approval for
an indication broader than what is designated, it may not be entitled to orphan exclusivity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-bottom: 12pt; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif"><i>Marketing
exclusivity </i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-bottom: 12pt; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif">Market
exclusivity provisions under the FDCA can delay the submission or approval of certain marketing applications. The FDCA provides
a five-year period of non-patent marketing exclusivity within the United States to the first applicant to obtain approval of an
NDA for a new chemical entity. A drug is a new chemical entity if FDA has not previously approved any other new drug containing
the same active moiety, which is the molecule or ion responsible for the action of the drug substance. During the exclusivity
period, the FDA may not approve or even accept for review an abbreviated new drug application (&#8220;ANDA&#8221;), or an NDA
submitted under Section 505(b)(2) (a &#8220;505(b)(2) NDA&#8221;), submitted by another company for another drug based on the
same active moiety, regardless of whether the drug is intended for the same indication as the original innovative drug or for
another indication, where the applicant does not own or have a legal right of reference to all the data required for approval.
However, an application may be submitted after four years if it contains a certification of patent invalidity or non-infringement
to one of the patents listed with the FDA by the innovator NDA holder.</span></p>

<!-- Field: Page; Sequence: 24 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-bottom: 12pt; margin-left: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-bottom: 12pt; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif">The
FDCA alternatively provides three years of marketing exclusivity for an NDA, or supplement to an existing NDA, if new clinical
investigations, other than bioavailability studies, that were conducted or sponsored by the applicant are deemed by the FDA to
be essential to the approval of the application, for example new indications, dosages or strengths of an existing drug. This three-year
exclusivity covers only the modification for which the drug received approval on the basis of the new clinical investigations
and does not prohibit the FDA from approving ANDAs or 505(b)(2) NDAs for drugs containing the active ingredient for the original
indication or condition of use. Five-year and three-year exclusivity will not delay the submission or approval of a full NDA.
However, an applicant submitting a full NDA would be required to conduct or obtain a right of reference to all of the preclinical
studies and adequate and well-controlled clinical trials necessary to demonstrate safety and effectiveness.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-bottom: 12pt; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif">Pediatric
exclusivity is another type of marketing exclusivity available in the United States. Pediatric exclusivity provides for an additional
six months of marketing exclusivity attached to another period of exclusivity if a sponsor conducts clinical trials in children
in response to a written request from the FDA. The issuance of a written request does not require the sponsor to undertake the
described clinical trials. In addition, orphan drug exclusivity, as described above, may offer a seven-year period of marketing
exclusivity, except in certain circumstances.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Foreign
Sales</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Sales
outside the United States of potential drug compounds we develop will also be subject to foreign regulatory requirements governing
human clinical trials and marketing for drugs. The requirements vary widely from country to country, but typically the registration
and approval process takes several years and requires significant resources. In most cases, if the FDA has not approved a potential
drug compound for sale in the United States, the potential drug compound may be exported for sale outside of the United States,
only if it has been approved in any one of the following: the European Union, Canada, Australia, New Zealand, Japan, Israel, Switzerland
and South Africa. There are specific FDA regulations that govern this process.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>U.S.
coverage and reimbursement </i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Significant
uncertainty exists as to the coverage and reimbursement status of any compound for which we may seek regulatory approval. Sales
in the United States will depend in part on the availability of sufficient coverage and adequate reimbursement from third-party
payors, which include government health programs such as Medicare, Medicaid, CHIP, TRICARE and the Veterans Administration, as
well as managed care organizations and private health insurers. Prices at which we or our customers seek reimbursement for our
therapeutic compounds can be subject to challenge, reduction or denial by payors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
process for determining whether a payor will provide coverage for a product is typically separate from the process for setting
the reimbursement rate that the payor will pay for the product. A payor&#8217;s decision to provide coverage for a product does
not imply that an adequate reimbursement rate will be available. Additionally, in the United States there is no uniform policy
among payors for coverage or reimbursement. Third-party payors often rely upon Medicare coverage policy and payment limitations
in setting their own coverage and reimbursement policies, but also have their own methods and approval processes. Therefore, coverage
and reimbursement for products can differ significantly from payor to payor. If coverage and adequate reimbursement are not available,
or are available only at limited levels, successful commercialization of, and obtaining a satisfactory financial return on, any
product we develop may not be possible.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Third-party
payors are increasingly challenging the price and examining the medical necessity and cost-effectiveness of medical products and
services, in addition to their safety and efficacy. In order to obtain coverage and reimbursement for any product that might be
approved for marketing, we may need to conduct expensive studies in order to demonstrate the medical necessity and cost-effectiveness
of any products, which would be in addition to the costs expended to obtain regulatory approvals. Third-party payors may not consider
our compounds to be medically necessary or cost-effective compared to other available therapies, or the rebate percentages required
to secure favorable coverage may not yield an adequate margin over cost or may not enable us to maintain price levels sufficient
to realize an appropriate return on our investment in drug development.</span></p>

<!-- Field: Page; Sequence: 24 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Fraud
and Abuse Laws </i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Federal
and state health care laws and regulations restrict business practices in the biopharmaceutical industry. In the biopharmaceutical
industry, there are a number of federal and state health care regulatory requirements that apply to entities, including, but not
limited to, the federal and state fraud and abuse laws. These laws include, but are not limited to, anti-kickback and self-referral
law, civil false claims act law, criminal false statement law, civil monetary penalty laws, exclusion law, and other civil, criminal,
and administrative laws. Health care laws, regulations, and guidance continuously evolve and are thereby subject to constant change.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Federal Anti-Kickback Statute, 42 U.S.C. &#167; 1320a-7b(b), among other things, prohibits the knowing and willful offer, payment,
solicitation or receipt of any form of remuneration, whether directly or indirectly and overtly or covertly in cash or in kind,
in return for, or to induce the referral of an individual for the:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#8226;
&#9;furnishing or arranging for the furnishing of items or services reimbursable in whole or in part under Medicare, Medicaid
or other federal healthcare programs; or</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#8226;
&#9;purchase, lease, or order of, or the arrangement or recommendation of the purchasing, leasing, or ordering of any item or
service reimbursable in whole or in part under Medicare, Medicaid or other federal healthcare programs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">There
are a number of narrow safe harbors to the Federal Anti-Kickback Statute. Such safe harbors permit certain payments and business
practices that, although they would otherwise potentially implicate the Federal Anti-Kickback Statute, are not treated as an offense
under the same if all of the requirements of the specific applicable safe harbor are met. Actual knowledge of the statute or specific
intent to violate it is not required in order for a person or entity to have committed a violation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Federal Anti-Kickback Statute applies to certain arrangements with healthcare providers, product end users and other parties,
including marketing arrangements and discounts and other financial incentives offered in connection with the sales of our products.
Regulatory authorities may determine that certain marketing, pricing, or other activities violate the Federal Anti-Kickback Statute
or other applicable laws. Noncompliance with the Federal Anti-Kickback Statute can result in civil, administrative and/or criminal
penalties, restrictions on the ability to operate in certain jurisdictions, and exclusion from participation in Medicare, Medicaid
or other federal healthcare programs. In addition, non-compliance can result in the need to curtail and/or restructure operations.
Any penalties, damages, fines, exclusions, curtailment or restructuring of operations could adversely affect the ability to operate
a business, financial condition, and results of operations. A violation of the Federal Anti-Kickback Statute can serve as a false
or fraudulent claim for purposes of the civil False Claims Act and the civil monetary penalties statute.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Ethics in Patient Referrals Act, commonly known as the &#8220;Stark Law,&#8221; 42 U.S.C. &#167; 1395nn, prohibits a physician
from making referrals for certain &#8220;designated health services&#8221; payable by Medicare to an entity in which the physician
or an immediate family member of such physician has an ownership or investment interest or with which the physician has entered
into a compensation arrangement, unless a statutory exception applies. There are a number of exceptions to the Stark Law. Such
exceptions permit certain payments and arrangements that, although they would otherwise potentially implicate the Stark Law, are
not treated as a violation under the same if the requirements of the specific exceptions are met. Violation of the Stark Law could
result in denial of payment, disgorgement of reimbursements received under a noncompliance arrangement, civil penalties, damages
and exclusion from Medicare or other governmental programs. These requirements are highly technical and there can be no guarantee
that regulatory authorities will not determine or assert that arrangements are in violation of the Stark Law and do not otherwise
meet applicable Stark Law exceptions.</span></p>

<!-- Field: Page; Sequence: 24 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
federal false statements statute, 42 U.S.C. &#167; 1320a-7b(a), prohibits knowingly and willfully falsifying, concealing, or omitting
a material fact or making any materially false statement in connection with the delivery of health care benefits, items, or services.
Similarly, 18 U.S.C. &#167; 1035 prohibits a person or entity, in any matter involving a health care benefit program, from knowingly
or willfully falsifying, concealing, or covering up by any trick, scheme, or device a material fact; making any materially false,
fictitious, or fraudulent statements or representations; or making or using any materially false writing or document knowing the
same to contain any materially false, fictitious, or fraudulent statement or entry. In addition to criminal penalties, violation
of these statutes may result in collateral administrative sanctions, including exclusion from participation in Medicare, Medicaid
and other federal health care programs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">18
U.S.C. &#167; 669 prohibits knowingly and willfully embezzling, stealing, or otherwise without authority converting to the use
of any person or entity other than the rightful owner, or intentionally misapplying any of the moneys, funds, securities, premiums,
credits, property, or other assets of a health care benefit program. In addition to criminal penalties, violation of this statute
may result in collateral administrative sanctions, including exclusion from participation in Medicare, Medicaid and other federal
health care programs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
criminal health care fraud statute, 18 U.S.C. &#167; 1347, establishes criminal liability for whoever knowingly and willfully
executes, or attempts to execute, a scheme or artifice to defraud any health care benefit program, or to obtain, by means of false
or fraudulent pretenses, representations, or promises, any of the money or property owned by, or under the custody or control
of, any health care benefit program, in connection with the delivery of or payment for health care benefits, items, or services.
In addition to criminal penalties, violation of this statute may result in collateral administrative sanctions, including exclusion
from participation in Medicare, Medicaid and other federal health care programs. A person or entity need not have actual knowledge
of this law or specific intent to commit a violation of this law.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">18
U.S.C. &#167; 1518 establishes criminal liability for whoever willfully prevents, obstructs, misleads, delays or attempts to prevent,
obstruct, mislead, or delay the communication of information or records relating to a violation of a Federal health care offense
to a criminal investigator. In addition to criminal penalties, violation of this statute may result in collateral administrative
sanctions, including exclusion from participation in Medicare, Medicaid and other federal health care programs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">18
U.S.C. &#167; 286 establishes criminal liability for whoever enters into any agreement, combination, or conspiracy to defraud
the United States, or any department or agency thereof, by obtaining or aiding to obtain the payment or allowance of any false,
fictitious or fraudulent claim. In addition to criminal penalties, violation of this statute may result in collateral administrative
sanctions, including exclusion from participation in Medicare, Medicaid and other federal health care programs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">18
U.S.C. &#167; 287 establishes criminal liability for whoever knowingly makes or presents a false, fictitious or fraudulent claim
to the United States Government, including any department or agency thereof. In addition to criminal penalties, violation of this
statute may result in collateral administrative sanctions, including exclusion from participation in Medicare, Medicaid and other
federal health care programs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Federal False Claims Act, 31 U.S.C. &#167; 3729, et seq., provides, in part, that the federal government&#8212;or a private party
on behalf of the government&#8212;may bring a lawsuit against any person whom it believes has knowingly presented, or caused to
be presented, a false or fraudulent claim for payment, or who has made a false statement or used a false record to get a claim
paid or to avoid, decrease or conceal an obligation to pay money to the federal government or who has knowingly retained an overpayment.
Knowledge under the Federal False Claims Act means actual knowledge, deliberate indifference, or reckless disregard. In addition,
amendments in 1986 to the Federal False Claims Act have made it easier for private parties to bring whistleblower lawsuits against
companies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
civil monetary penalties law, 42 U.S.C. &#167; 1320a-7a, provides, in part, that the federal government may seek civil monetary
penalties against any person who presents or causes to be presented claims to a Federal health care program that the person knows
or should know is for an item or services that was not provided as claimed or is false or fraudulent, or the person has made a
false statement or used a false record to get a claim paid. The federal government may also seek civil monetary penalties for
a wide variety of other conduct, including offering remuneration to influence a Medicare or Medicaid beneficiary&#8217;s selection
of providers and violations of the Federal Anti-Kickback Statute.</span></p>

<!-- Field: Page; Sequence: 24 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Violations
of the Federal False Claims Act and/or the Civil Monetary Penalties Law can result in penalties ranging from $11,665 to $23,331
for each false claim violation of the Federal False Claims Act and varying amounts based on the type of violation of the Civil
Monetary Penalties Law, plus up to three times the amount of damages that the federal government sustained. In addition, the federal
government may also seek exclusion from participation in all federal health care programs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">42
U.S.C. Section 1320a-7 provides that individuals and entities can be mandatorily or permissively excluded from participation in
federal health care programs. The grounds for mandatory exclusion include, but are not limited to, conviction for a criminal offense
related to the delivery of an item or service reimbursed under a federal or state health care program, and a conviction related
to health care fraud. The grounds for permissive exclusion include, but are not limited to, criminal offenses relating to fraud
inside and outside of health care, convictions related to obstruction of an investigation or audit, and/or failure to disclose
certain required information. Exclusion from federal health care programs&#8212;whether mandatory or permissive&#8212;may mean
that we would not be entitled to participation in federal and/or state health care programs for services rendered.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>State
Fraud and Abuse Provisions</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Many
states have also adopted some form of anti-kickback and anti-referral laws and false claims acts and civil monetary penalties
and other fraud and abuse provisions that apply regardless of payer, in addition to items and services reimbursed under Medicaid
and other state programs. A determination of liability under such laws could result in fines, penalties, and exclusion, as well
as restrictions on the ability to operate in these jurisdictions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Corporate
liability can be present as a result of the illegal activities of employees, representatives, contractors, collaborators, agents,
subsidiaries, or affiliates, even if they were not explicitly authorized. There can be no assurance that all employees, representatives,
contractors, collaborators, agents, subsidiaries or affiliates will comply with the foregoing laws at all times. Violation of
the aforementioned and other laws could result in whistleblower complaints, investigations, sanctions, settlements, prosecution,
government oversight and reporting, other enforcement actions, disgorgement of profits, significant fines, damages, other civil
and criminal penalties or injunctions or other administrative remedies, suspension and/or debarment from contracting with certain
governments or other persons, the loss of privileges, reputational harm, contract damages, adverse media coverage and other collateral
consequences. In addition, corporate directors, officers, employees, and other representatives who engage in violations of these
and other laws may face imprisonment, fines, and penalties. If any subpoenas or investigations are launched, or governmental or
other sanctions are imposed, or if a company does not prevail in any possible civil or criminal litigation, business, financial
condition, and results of operations could be materially harmed. In addition, responding to any action will likely result in a
materially significant diversion of management&#8217;s attention and resources and significant defense costs and other professional
fees. Enforcement actions and sanctions could further harm business, financial condition, and results of operations. Any of the
consequences contained in this paragraph and section could adversely affect the ability to operate the business, financial condition,
and the results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Health
Insurance Portability and Accountability Act </i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Health Insurance Portability and Accountability Act, as amended by the Health Information Technology for Economic and Clinical
Health Act (&#8220;HITECH&#8221;), and implementing regulations thereunder (collectively, &#8220;HIPAA&#8221;) requires certain
healthcare providers, health plans and healthcare clearinghouses who conduct specified electronic healthcare transactions (&#8220;covered
entities&#8221;), as well as their independent contractors and agents who conduct certain activities involving protected health
information on their behalf (&#8220;business associates&#8221;) to comply with enumerated requirements relating to the privacy,
security and transmission of protected health information. Failure to comply with HIPAA can result in corrective action, as well
as civil fines and penalties and government oversight. Among other changes, HITECH made HIPAA security standards directly applicable
to business associates, increased the tiered civil and criminal fines and penalties that may be imposed against covered entities,
business associates and possibly other persons, and gave state attorneys general new authority to file actions to enforce HIPAA.
Further, the breach notification rule implemented under HITECH requires covered entities to notify affected individuals, the U.S.
Department of Health and Human Services Office of Civil Rights (&#8220;OCR&#8221;), the agency that enforces HIPAA, and for breaches
affecting more than 500 individuals, the media, of any breaches of unsecured protected health information. HIPAA does not create
a private right of action for individuals, though individuals may submit complaints related to HIPAA to OCR.</span></p>

<!-- Field: Page; Sequence: 24 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Patient
Protection and Affordable Care Act </i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
the United States, there have been, and continue to be multiple legislative and regulatory changes and proposed changes regarding
the healthcare system that could impact our business. Policymakers and third party reimbursement programs (i.e. payors) have articulated
the goals of controlling healthcare costs, improving quality and/or expanding access in connection with these healthcare reform
efforts. As a leading example, in March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and
Education Reconciliation Act (collectively, the &#8220;ACA&#8221;), was passed, ushering in significant changes to the way healthcare
is financed in the United States. With respect to impacts specific to the U.S. pharmaceutical industry, among other things, the
ACA:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#8226;&#9;increased
the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program and extended the rebate program to
include Medicaid managed care organizations as well as Medicaid fee-for-service programs;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#8226;&#9;expanded
eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to additional individuals,
correspondingly increasing manufacturers&#8217; Medicaid rebate liability;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#8226;&#9;created
a new methodology by which average manufacturing price is calculated for drugs that are inhaled, infused, instilled, implanted
or injected and not generally dispensed through retail community pharmacies;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#8226;&#9;established
an annual, nondeductible fee on any entity that manufactures or imports certain specified branded prescription drugs and biologic
products;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#8226;&#9;expanded
the availability of lower drug pricing under the 340B drug pricing program to additional types of covered entities;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#8226;&#9;created
a new partial prescription drug benefit for Medicare recipients under the Medicare Part D coverage gap discount program, in which
manufacturers must agree to offer point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries
during their coverage gap period, as a condition for the manufacturer&#8217;s outpatient drugs to be covered under Medicare Part
D;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#8226;&#9;amended
the Public Health Service Act to create an abbreviated approval pathway for biological products that are demonstrated to be biosimilar
to or interchangeable with an FDA-approved biological product;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#8226;&#9;added
a requirement to annually report product samples that manufacturers and distributors provide to physicians;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#8226;&#9;established
new requirements, known as &#8220;Sunshine Act&#8221; requirements for manufacturers of products reimbursed by Medicare, Medicaid
or the Children&#8217;s Health Insurance Program (&#8220;CHIP&#8221;) to collect and annually report detailed data to the Centers
for Medicare and Medicaid Services (&#8220;CMS&#8221;) regarding payments or other transfers of value to physicians and teaching
hospitals (&#8220;covered recipients&#8221;), as well as any ownership or investment interest held by physicians and their immediate
family members. The reporting data must be accompanied by an attestation as to the accuracy of the data and failure to timely
and accurately submit required information may result in civil monetary penalties;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#8226;&#9;established
a Center for Medicare &amp; Medicaid Innovation at CMS, to test innovative payment and service delivery models to lower Medicare
and Medicaid spending, potentially including prescription drugs;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#8226;&#9;created
a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness
research, along with funding for such research; and</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#8226;&#9;expanded
healthcare fraud and abuse laws, including the civil False Claims Act and the federal Anti-Kickback Statute, and enhanced penalties
for noncompliance, which are applicable beyond the U.S. pharmaceutical industry (e.g. to other types of healthcare entities) but
also are of specific relevance to the U.S. pharmaceutical industry.</span></p>

<!-- Field: Page; Sequence: 24 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Bipartisan Budget Act of 2018 amended the ACA, effective January 1, 2019, to close the coverage gap in most Medicare drug plans,
commonly referred to as the &#8220;donut hole.&#8221; Further, the Substance-Use Disorder Prevention that Promotes Opioid Recovery
and Treatment for Patients and Communities Act (&#8220;SUPPORT Act&#8221;) amended the Sunshine Act to expand the definition of
covered recipient for whom applicable manufacturers must collect ad report data to include physician assistants, nurse practitioners,
clinical nurse specialists, certified nurse anesthetists and certified nurse mid-wives for data reported on or after January 1,
2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">There
have been multiple judicial challenges to certain aspects of the ACA, as well as Congressional efforts to repeal or replace the
ACA, and efforts by the Trump administration to delay or circumvent the implementation of certain ACA requirements. For example,
the Tax Cuts and Jobs Act of 2017 repealed, effective January 1, 2019, the tax-based shared responsibility payment imposed by
the ACA on certain individuals who fail to maintain minimum essential health care insurance, commonly known as the &#8220;individual
mandate.&#8221; On December 14, 2018, a U.S. District Court in the Northern District of Texas ruled that the individual mandate
is a critical and inseverable feature of the ACA, and therefore, because it was repealed as part of the Tax Cuts and Jobs Act,
the remaining provisions of the ACA are invalid as well. On December 18, 2019, the U.S. Court of Appeals for the 5th Circuit affirmed
the District Court&#8217;s decision that the individual mandate was unconstitutional but remanded the case back to the District
Court to determine whether the remaining provisions of the ACA are invalid as well. The U.S. Supreme Court has agreed to review
the case and oral arguments heard oral arguments in November 2020. Therefore, ongoing force and effect of certain or all of the
provisions of the ACA remain in a state of uncertainty at this current time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Research
and Development Expenses</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Historically,
a significant portion of our operating expenses has related to research and development. See our Consolidated Financial Statements
contained elsewhere in this Annual Report for costs and expenses related to research and development, and other financial information
for fiscal years 2020 and 2019.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Scientific
Advisors </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
are advised by scientists and physicians with experience relevant to our Company and our product candidates. Our scientific advisors
include clinicians and scientists who are affiliated with a number of highly regarded medical institutions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Employees</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
currently have twenty full-time employees, and we retain several independent contractors on a regular or as-needed basis. We believe
that we have good relations with our employees.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Available
Information</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Our
internet website address is www.anavex.com. Our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on
Form 8-K and amendments to those reports filed or furnished pursuant to section 13(a) or 15(d) of the Exchange Act are available
free of charge through our website. We include our website address in this report only as an inactive textual reference and do
not intend it to be an active link to our website. The contents of our website are not incorporated into this report.</span></p>

<!-- Field: Page; Sequence: 24 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

    <p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 12pt 0 3pt"><span style="font: normal 10pt Times New Roman, Times, Serif"><span id="item1a"></span><b><i>ITEM
1A. RISK FACTORS</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
addition to other information in this Annual Report on Form 10-K, the following risk factors should be carefully considered in
evaluating our business because such factors may have a significant impact on our business, operating results, liquidity and financial
condition. As a result of the risk factors set forth below, actual results could differ materially from those projected in any
forward-looking statements. Additional risks and uncertainties not presently known to us, or that we currently consider to be
immaterial, may also impact our business, operating results, liquidity and financial condition. If any such risks occur, our business,
operating results, liquidity and financial condition could be materially affected in an adverse manner. Under such circumstances,
the trading price of our securities could decline, and you may lose all or part of your investment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Risks
Related to our Company</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>We
have had a history of losses and no revenue, which raises a risk regarding our ability to continue as a going concern in the future.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Since
inception through September 30, 2020, we have accumulated a deficit of approximately $160 million. We can offer no assurance that
we will ever operate profitably or that we will generate positive cash flow in the future. To date, we have not generated any
revenues from our operations. Our history of losses and no revenues creates a greater risk of our continued ability to continue
as a going concern in the future. As a result, our management expects the business to continue to experience negative cash flows
for the foreseeable future and cannot predict when, if ever, our business might become profitable. We will need to raise additional
funds, and such funds may not be available on commercially acceptable terms, if at all. If we are unable to raise funds on acceptable
terms, we may not be able to execute our business plan, take advantage of future opportunities, or respond to competitive pressures
or unanticipated requirements. This may seriously harm our business, financial condition and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>We
are an early stage pharmaceutical research and development company and may never be able to successfully develop marketable products
or generate any revenue. We have a very limited relevant operating history upon which an evaluation of our performance and prospects
can be made. There is no assurance that our future operations will result in profits. If we cannot generate sufficient revenues,
we may suspend or cease operations.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
are an early stage company and have not generated any revenues to date and have no operating history. All of our potential drug
compounds are in the concept stage or early clinical development stage. Moreover, we cannot be certain that our research and development
efforts will be successful or, if successful, that our potential drug compounds will ever be approved for sales to pharmaceutical
companies or generate commercial revenues. We have no relevant operating history upon which an evaluation of our performance and
prospects can be made. We are subject to all of the business risks associated with a new enterprise, including, but not limited
to, risks of unforeseen capital requirements, failure of potential drug compounds either in non-clinical testing or in clinical
trials, failure to establish business relationships and competitive disadvantages against larger and more established companies.
If we fail to become profitable, we may suspend or cease operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>We
will need additional funding and may be unable to raise additional capital when needed, which would force us to delay, reduce
or eliminate our research and development activities.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
will need to raise additional funding and the current economic conditions may have a negative impact on our ability to raise additional
needed capital on terms that are favorable to our Company or at all. We may not be able to generate significant revenues for several
years, if at all. Until we can generate significant revenues, if ever, we expect to satisfy our future cash needs through equity
or debt financing. We cannot be certain that additional funding will be available on acceptable terms, or at all. If adequate
funds are not available, we may be required to delay, reduce the scope of, or eliminate one or more of our research and development
activities.</span></p>

<!-- Field: Page; Sequence: 24 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Risks
Related to our Business</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Even
if we are able to develop our potential drug compounds, we may not be able to receive regulatory approval, or if approved, we
may not be able to generate significant revenues or successfully commercialize our products, which will adversely affect our financial
results and financial condition and we will have to delay or terminate some or all of our research and development plans which
may force us to cease operations.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">All
of our potential drug compounds will require extensive additional research and development, including non-clinical testing and
clinical trials, as well as regulatory approvals, before we can market them. In particular, human therapeutic products are subject
to rigorous non-clinical and clinical testing and other approval procedures of the FDA and similar regulatory authorities in other
countries. Various federal statutes and regulations also govern or influence testing, manufacturing, safety, labeling, storage,
and record-keeping related to such products and their marketing. We cannot predict if or when any of the potential drug compounds
we intend to develop will be approved for marketing. There are many reasons that we may fail in our efforts to develop our potential
drug compounds. These include:</span></p>

<ul style="list-style-type: disc">

<li style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">the
possibility that non-clinical testing or clinical trials may show that our potential drug compounds are ineffective and/or cause
harmful side effects;</span></li>

<li style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">regulators
may not authorize us to commence or continue a clinical trial or may impose a clinical hold or may limit the conduct of a clinical
trial through the imposition of a partial clinical hold;</span></li>

<li style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">the
number of patients required for clinical trials for our drug candidates may be larger than we anticipate, enrollment in these
clinical trials may be slower than we anticipate, participants may drop out of these clinical trials at a higher rate than we
anticipate or the duration of these clinical trials may be longer than we anticipate;</span></li>

<li style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">our
third-party contractors, including investigators, may fail to meet their contractual obligations to us in a timely manner, or
at all, or may fail to comply with regulatory requirements;</span></li>

<li style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">our
potential drug compounds may prove to be too expensive to manufacture or administer to patients;</span></li>

<li style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">our
potential drug compounds may fail to receive necessary regulatory approvals from the United States Food and Drug Administration
or foreign regulatory authorities in a timely manner, or at all;</span></li>

<li style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">even
if our potential drug compounds are approved, we may not be able to produce them in commercial quantities or at reasonable costs;</span></li>

<li style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">even
if our potential drug compounds are approved, they may not achieve commercial acceptance;</span></li>

<li style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">regulatory
or governmental authorities may apply restrictions to any of our potential drug compounds, which could adversely affect their
commercial success; and</span></li>

<li style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">the
proprietary rights of other parties may prevent us or our potential collaborative partners from marketing our potential drug compounds.</span></li>

</ul>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">If
we fail to develop our potential drug compounds, our financial results and financial condition will be adversely affected, we
will have to delay or terminate some or all of our research and development plans and may be forced to cease operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Our
research and development plans will require substantial additional future funding which could impact our operations and financial
condition. Without the required additional funds, we will likely cease operations.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">It
will take several years before we can develop potentially marketable products, if at all. Our research and development plans will
require substantial additional capital, arising from costs to:</span></p>

<ul style="list-style-type: disc">

<li style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">conduct
research, non-clinical testing and human studies;</span></li>

<li style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">establish
pilot scale and commercial scale manufacturing processes and facilities; and</span></li>

<li style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">establish
and develop quality control, regulatory, marketing, sales, finance and administrative capabilities to support these programs.</span></li>

</ul>

<!-- Field: Page; Sequence: 24 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Our
future operating and capital needs will depend on many factors, including:</span></p>

<ul style="list-style-type: disc">

<li style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">the
pace of scientific progress in our research and development programs and the magnitude of these programs;</span></li>

<li style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">the
scope and results of pre-clinical testing and human studies;</span></li>

<li style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">the
time and costs involved in obtaining regulatory approvals;</span></li>

<li style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">the
time and costs involved in preparing, filing, prosecuting, securing, maintaining and enforcing patents;</span></li>

<li style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">competing
technological and market developments;</span></li>

<li style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">our
ability to establish additional collaborations;</span></li>

<li style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">changes
in our existing collaborations;</span></li>

<li style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">the
cost of manufacturing scale-up; and</span></li>

<li style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">the
effectiveness of our commercialization activities.</span></li>

</ul>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
base our outlook regarding the need for funds on many uncertain variables. Such uncertainties include the success of our research
initiatives, regulatory approvals, the timing of events outside our direct control such as negotiations with potential strategic
partners and other factors. Any of these uncertain events can significantly change our cash requirements as they determine such
one-time events as the receipt or payment of major milestones and other payments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Additional
funds will be required to support our operations and if we are unable to obtain them on favorable terms, we may be required to
cease or reduce further research and development of our drug product programs, sell some or all our intellectual property, merge
with another entity or cease operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>We
have received fast track designation for one of our compounds and may seek such designation or breakthrough therapy and priority
review for other compounds in the future. Fast track designation or breakthrough therapy designation may not actually lead to
a faster FDA review and approval process.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">For
some of our compounds, including ANAVEX<sup>&#174;</sup>2-73, we hope to benefit from FDA&#8217;s fast track and priority review
programs. In February 2020, the FDA granted Fast Track designation for the ANAVEX<sup>&#174;</sup>2-73 clinical development program
for the treatment of Rett syndrome. However, the fast-track designation may be withdrawn by FDA if FDA believes that the designation
is no longer supported by data emerging in the clinical trial process.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;Under
FDA policies, a compound is eligible for priority review, or review within a six-month time frame from the time a complete NDA
is accepted for filing, if the compound provides a significant improvement compared to marketed drugs in the treatment, diagnosis
or prevention of a disease. A fast-track designated compound would ordinarily meet the FDA&#8217;s criteria for priority review.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;Fast
track or breakthrough therapy designation for our compounds may not actually lead to a faster review process, and a delay in the
review process or in the approval of our compounds will delay revenue from their potential sales and will increase the capital
necessary to fund these compound development programs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>We
have received orphan drug designation for several of our compounds, but we may be unable to maintain any benefits associated with
orphan drug designation, including market exclusivity.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Under
the Orphan Drug Act, FDA may grant orphan designation to a drug intended to treat a rare disease or condition or for which there
is no reasonable expectation that the cost of developing and making available in the United States a drug for a disease or condition
will be recovered from sales in the United States for that drug. If a product that has orphan drug designation subsequently receives
the first FDA approval for the indication for which it has such designation, the product is entitled to orphan product exclusivity,
which means that the FDA may not approve any other applications, including a full NDA, to market the same drug or biologic for
the same indication for seven years, except in limited circumstances, such as a showing of clinical superiority to the product
with orphan drug exclusivity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;We
have received orphan drug designation for several of our compounds, but exclusive marketing rights in the United States may be
limited if we seek FDA marketing approval for an indication broader than the orphan designated indication. Additionally, any compound
with orphan drug designation may lose such designation if the FDA later determines that the request for designation was materially
defective or if the manufacturer is unable to assure sufficient quantities of the product to meet the needs of patients with the
rare disease or condition. In addition, others may obtain orphan drug exclusivity for products addressing the same diseases or
conditions as products we are developing, thus limiting our ability to compete in the markets addressing such diseases or conditions
for a significant period of time.<b>&#160;</b></span></p>

<!-- Field: Page; Sequence: 24 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>If
we fail to demonstrate efficacy in our non-clinical studies and clinical trials our future business prospects, financial condition
and operating results will be materially adversely affected.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
success of our research and development efforts will be greatly dependent upon our ability to demonstrate potential drug compound
efficacy in non-clinical studies, as well as in clinical trials. Non-clinical studies involve testing potential drug compounds
in appropriate non-human disease models to demonstrate efficacy and safety. Regulatory agencies evaluate these data carefully
before they will approve clinical testing in humans. If certain non-clinical data reveals potential safety issues or the results
are inconsistent with an expectation of the potential drug compound&#8217;s efficacy in humans, the regulatory agencies may require
additional more rigorous testing before allowing human clinical trials. This additional testing will increase program expenses
and extend timelines. We may decide to suspend further testing on our potential drug compounds if, in the judgment of our management
and advisors, the non-clinical test results do not support further development.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Moreover,
success in non-clinical testing and early clinical trials does not ensure that later clinical trials will be successful, and we
cannot be sure that the results of later clinical trials will replicate the results of prior clinical trials and non-clinical
testing. The clinical trial process may fail to demonstrate that our potential drug compounds are safe for humans and effective
for indicated uses. This failure would cause us to abandon a drug candidate and may delay development of other potential drug
compounds. Any delay in, or termination of, our non-clinical testing or clinical trials will delay the filing of an IND and NDA
with the Food and Drug Administration or the equivalent applications with pharmaceutical regulatory authorities outside the United
States and, ultimately, our ability to commercialize our potential drug compounds and generate product revenues. In addition,
we expect that our early clinical trials will involve small patient populations. Because of the small sample size, the results
of these early clinical trials may not be indicative of future results. Also, the IND process may be extremely costly and may
substantially delay the development of our potential drug compounds. Moreover, positive results of non-clinical tests will not
necessarily indicate positive results in subsequent clinical trials.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Following
successful non-clinical testing, potential drug compounds will need to be tested in a clinical development program to provide
data on safety and efficacy prior to becoming eligible for product approval and licensure by regulatory agencies. From the first
human trial through to regulatory approval can take many years and 10-12 years is not unusual for certain compounds.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">If
any of our future clinical development potential drug compounds become the subject of problems, our ability to sustain our development
programs will become critically compromised. For example, efficacy or safety concerns may arise, whether or not justified, that
could lead to the suspension or termination of our clinical programs. Examples of problems that could arise include, among others:</span></p>

<ul style="list-style-type: disc">

<li style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">efficacy
or safety concerns with the potential drug compounds, even if not justified;</span></li>

<li style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">manufacturing
difficulties or concerns;</span></li>

</ul>

<ul style="margin-top: 0in; list-style-type: disc">

<li style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">regulatory
proceedings subjecting the potential drug compounds to potential recall;</span></li>

<li style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">publicity
affecting doctor prescription or patient use of the potential drug compounds;</span></li>

<li style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">pressure
from competitive products; or</span></li>

<li style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">introduction
of more effective treatments.</span></li>

</ul>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Each
clinical phase is designed to test attributes of the drug and problems that might result in the termination of the entire clinical
plan can be revealed at any time throughout the overall clinical program. The failure to demonstrate efficacy in our clinical
trials would have a material adverse effect on our future business prospects, financial condition and operating results.</span></p>

<!-- Field: Page; Sequence: 24 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>If
we do not obtain the support of qualified scientific collaborators, our revenue, growth and profitability will likely be limited,
which would have a material adverse effect on our business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
will need to establish relationships with leading scientists and research institutions. We believe that such relationships are
pivotal to establishing products using our technologies as a standard of care for various indications. Additionally, although
in discussion, there is no assurance that our current research partners will continue to work with us or that we will be able
to attract additional research partners. If we are not able to establish scientific relationships to assist in our research and
development, we may not be able to successfully develop our potential drug compounds. If this happens, our business will be adversely
affected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>We
may not be able to develop, market or generate sales of our products to the extent anticipated. Our business may fail and investors
could lose all their investment in our Company.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Assuming
that we are successful in developing our potential drug compounds and receiving regulatory clearances to market our products,
our ability to successfully penetrate the market and generate sales of those products may be limited by a number of factors, including
the following:</span></p>

<ul style="list-style-type: disc">

<li style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">If
our competitors receive regulatory approvals for and begin marketing similar products in the United States, the European Union,
Japan and other territories before we do, greater awareness of their products as compared to ours will cause our competitive position
to suffer;</span></li>

<li style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Information
from our competitors or the academic community indicating that current products or new products are more effective or offer compelling
other benefits than our future products could impede our market penetration or decrease our future market share; and</span></li>

<li style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
pricing and reimbursement environment for our future products, as well as pricing and reimbursement decisions by our competitors
and by payers, may have an effect on our revenues.</span></li>

</ul>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">If
this happens, our business will be adversely affected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>None
of our potential drug compounds may reach the commercial market for a number of reasons and our business may fail.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Successful
research and development of pharmaceutical products is high risk. Most products and development candidates fail to reach the market.
Our success depends on the discovery of new drug compounds that we can commercialize. It is possible that our products may never
reach the market for a number of reasons. They may be found ineffective or may cause harmful side-effects during non-clinical
testing or clinical trials or fail to receive necessary regulatory approvals. We may find that certain products cannot be manufactured
at a commercial scale and, therefore, they may not be economical to produce. Our potential products could also fail to achieve
market acceptance or be precluded from commercialization by proprietary rights of third parties. Our patents, patent applications,
trademarks and other intellectual property may be challenged, and this may delay or prohibit us from effectively commercializing
our products. Furthermore, we do not expect our potential drug compounds to be commercially available for a number of years, if
at all. If none of our potential drug compounds reach the commercial market, our business will likely fail and investors will
lose all of their investment in our Company. If this happens, our business will be adversely affected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>If
our competitors succeed in developing products and technologies faster or that are more effective or with a better profile than
our own, or if scientific developments change our understanding of the potential scope and utility of our potential products,
then our technologies and future products may be rendered undesirable or obsolete.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
face significant competition from industry participants that are pursuing technologies in similar disease states to those that
we are pursuing and are developing pharmaceutical products that are competitive with our products. Nearly all of our industry
competitors have greater capital resources, larger overall research and development staffs and facilities, and a longer history
in drug discovery and development, obtaining regulatory approval and pharmaceutical product manufacturing and marketing than we
do. With these additional resources, our competitors may be able to respond to the rapid and significant technological changes
in the biotechnology and pharmaceutical industries faster than we can. Our future success will depend in large part on our ability
to maintain a competitive position with respect to these technologies. Rapid technological development, as well as new scientific
developments, may result in our products becoming obsolete before we can recover any of the expenses incurred to develop them.
For example, changes in our understanding of the appropriate population of patients who should be treated with a targeted therapy
like we are developing may limit the drug&#8217;s market potential if it is subsequently demonstrated that only certain subsets
of patients should be treated with the targeted therapy.</span></p>

<!-- Field: Page; Sequence: 24 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Our
reliance on third parties, such as university laboratories, contract manufacturing organizations and contract or clinical research
organizations, may result in delays in completing, or a failure to complete, non-clinical testing or clinical trials if they fail
to perform under our agreements with them.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
the course of product development, we may engage university laboratories, other biotechnology companies or contract or clinical
manufacturing organizations to manufacture drug material for us to be used in non-clinical and clinical testing and contract research
organizations to conduct and manage non-clinical and clinical studies. If we engage these organizations to help us with our non-clinical
and clinical programs, many important aspects of this process have been and will be out of our direct control. If any of these
organizations we may engage in the future fail to perform their obligations under our agreements with them or fail to perform
non-clinical testing and/or clinical trials in a satisfactory manner, we may face delays in completing our clinical trials, as
well as commercialization of any of our potential drug compounds. Furthermore, any loss or delay in obtaining contracts with such
entities may also delay the completion of our clinical trials, regulatory filings and the potential market approval of our potential
drug compounds.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>If
we fail to compete successfully with respect to partnering, licensing, mergers, acquisitions, joint venture and other collaboration
opportunities, we may be limited in our ability to research and develop our potential drug compounds.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Our
competitors compete with us to attract established biotechnology and pharmaceutical companies or organizations for partnering,
licensing, mergers, acquisitions, joint ventures or other collaborations. Collaborations include contracting with academic research
institutions for the performance of specific scientific testing. If our competitors successfully enter into partnering arrangements
or license agreements with academic research institutions, we will then be precluded from pursuing those specific opportunities.
Since each of these opportunities is unique, we may not be able to find a substitute. Other companies have already begun many
drug development programs, which may target diseases that we are also targeting, and have already entered into partnering and
licensing arrangements with academic research institutions, reducing the pool of available opportunities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Universities
and public and private research institutions also compete with us. While these organizations primarily have educational or basic
research objectives, they may develop proprietary technology and acquire patent applications and patents that we may need for
the development of our potential drug compounds. In some instances, we will attempt to license this proprietary technology, if
available. These licenses may not be available to us on acceptable terms, if at all. If we are unable to compete successfully
with respect to acquisitions, joint venture and other collaboration opportunities, we may be limited in our ability to develop
new products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>The
use of any of our products in clinical trials may expose us to liability claims, which may cost us significant amounts of money
to defend against or pay out, causing our business to suffer.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
nature of our business exposes us to potential liability risks inherent in the testing, manufacturing and marketing of our products.
We currently have one drug compound in clinical trials, however, when any of our products enter clinical trials or become marketed
products, they could potentially harm people or allegedly harm people possibly subjecting us to costly and damaging product liability
claims. Some of the patients who participate in clinical trials are already ill when they enter a trial or may intentionally or
unintentionally fail to meet the exclusion criteria. The waivers we obtain may not be enforceable and may not protect us from
liability or the costs of product liability litigation. Although we intend to obtain product liability insurance, which we believe
is adequate, we are subject to the risk that our insurance will not be sufficient to cover claims. The insurance costs along with
the defense or payment of liabilities above the amount of coverage could cost us significant amounts of money and management distraction
from other elements of the business, causing our business to suffer.</span></p>

<!-- Field: Page; Sequence: 24 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>If
we are unable to safeguard against security breaches with respect to our information systems, our business may be adversely affected.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
the course of our business, we gather, transmit and retain confidential information through our information systems. Although
we endeavor to protect confidential information through the implementation of security technologies, processes and procedures,
it is possible that an individual or group could defeat security measures and access sensitive information about our business
and employees. Any misappropriation, loss or other unauthorized disclosure of confidential information gathered, stored or used
by us could have a material impact on the operation of our business, including damaging our reputation with our employees, third
parties and investors. We could also incur significant costs implementing additional security measures and organizational changes,
implementing additional protection technologies, training employees or engaging consultants. In addition, we could incur increased
litigation as a result of any potential cyber-security breach. We are not aware that we have experienced any material misappropriation,
loss or other unauthorized disclosure of confidential or personally identifiable information as a result of a cyber-security breach
or other act, however, a cyber-security breach or other act and/or disruption to our information technology systems could have
a material adverse effect on our business, prospects, financial condition or results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Even
if we receive regulatory approval for one or more compounds, we will be subject to continuing regulatory obligations and ongoing
regulatory review, which may result in significant additional expense. Additionally, our compounds, if approved, could be subject
to labeling and other restrictions on marketing or withdrawal from the market, and we may be subject to penalties, if we fail
to comply with regulatory requirements or if we experience unanticipated problems with our compounds, when and if any of them
are approved. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Following
potential approval of any our compounds, FDA may impose significant restrictions on a drug&#8217;s indicated uses or marketing
or require potentially costly and time-consuming post-approval studies, post-market surveillance or clinical trials to monitor
the safety and efficacy of the drug. FDA may also require a Risk Evaluation and Mitigation Strategy (&#8220;REMS&#8221;) as a
condition of approval of one or more of our compounds, which could include requirements for a medication guide, physician communication
plans or additional elements to ensure safe use of the drug. Additional REMS elements may include restricted distribution methods,
patient registries and other risk minimization tools.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
addition, if FDA or a comparable foreign regulatory authority approves one or more of our compounds, the manufacturing processes,
labeling, packaging, distribution, adverse event reporting, storage, advertising, promotion, import, export and recordkeeping
for the approved drug will be subject to additional and potentially extensive ongoing regulatory requirements. These requirements
include submissions of safety and other post-marketing information and reports, establishment registration, as well as continued
compliance with cGMPs and GCP requirements for any clinical trials that we conduct post-approval. Later discovery of previously
unknown problems with our products, including adverse events of unanticipated severity or frequency, or with our third-party manufacturers
or manufacturing processes, or failure to comply with regulatory requirements, may result in, among other things:</span></p>

<table cellpadding="0" cellspacing="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; margin-top: 0; margin-bottom: 10pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#8226;</b></span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">restrictions
                                         on the marketing or manufacturing of our products, withdrawal of the product from the
                                         market or voluntary or mandatory product recalls; </span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; margin-top: 0; margin-bottom: 10pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#8226;</b></span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">fines,
                                         restitutions, disgorgement of profits or revenues, warning letters, untitled letters
                                         or holds on clinical trials; </span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; margin-top: 0; margin-bottom: 10pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#8226;</b></span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">restrictions
                                         on product distribution or use, or requirements to conduct post-marketing studies or
                                         clinical trials; </span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; margin-top: 0; margin-bottom: 10pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#8226;</b></span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">product
                                         seizure or detention, or refusal to permit the import or export of our products;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; margin-top: 0; margin-bottom: 10pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#8226;</b></span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">injunctions
                                         or the imposition of civil or criminal penalties; and</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; margin-top: 0; margin-bottom: 10pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#8226;</b></span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">refusal
                                         by the FDA to approve pending applications or supplements to approved applications filed
                                         by us or suspension or revocation of approvals.</span></td></tr></table>

<!-- Field: Page; Sequence: 24 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
occurrence of any event or penalty described above may limit our ability to commercialize our compounds and generate revenue,
and could require us to expend significant time and resources in response or generate negative publicity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">If
any of our compounds are approved, our product labeling, advertising and promotion will also be subject to regulatory requirements
and ongoing regulatory review. FDA strictly regulates the promotional claims that may be made about drug products. In particular,
a drug may not be promoted for uses that are not approved by FDA as reflected in the drug&#8217;s approved labeling. If we receive
marketing approval for a compound, physicians may nevertheless lawfully prescribe it to their patients in a manner that is inconsistent
with the approved label. While FDA recently clarified that mere knowledge that a physician is prescribing a drug for off label
use is not sufficient to constitute unlawful off-label promotion, if we are found to have actively promoted such off label uses,
we may become subject to significant liability under the FDCA. The federal government has levied large civil and criminal fines
against companies for alleged improper promotion and has enjoined several companies from engaging in off-label promotion. FDA
has also requested that companies enter into consent decrees or permanent injunctions under which specified promotional conduct
is changed or curtailed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0 10pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">FDA&#8217;s
and other regulatory authorities&#8217; policies are subject to change at any time, and additional government regulations may
be enacted that could prevent, limit or delay regulatory approval of our compounds. If we are unable to timely adapt to changes
in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance
post-marketing, we may lose any marketing approval that we may have obtained, and we may not achieve or sustain profitability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Finally,
we cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative
or executive action, either in the United States or abroad. It is difficult to predict how any such legislative, administrative
or executive actions will be implemented, and the extent to which they will impact the FDA&#8217;s ability to exercise its regulatory
authority. If these legislative or executive actions impose constraints on FDA&#8217;s ability to engage in oversight and implementation
activities in the normal course, our business may be negatively impacted.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>The
COVID-19 coronavirus could adversely impact our business, including our clinical trials, and financial condition.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
December 2019, a novel strain of coronavirus, COVID-19, was reported to have surfaced in Wuhan, China. Since then, the COVID-19
coronavirus has spread to multiple countries, including the United States, Australia and European and Asia-Pacific countries,
including countries in which we have planned or active clinical trial sites. As the COVID-19 coronavirus continues to spread around
the globe, we may experience disruptions that could potentially impact our business and clinical trials.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
addition, the spread of COVID-19 coronavirus has had and may continue to severely impact the trading price of shares of our common
stock and could further severely impact our ability to raise additional capital on a timely basis or at all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
global outbreak of the COVID-19 coronavirus continues to rapidly evolve. The extent to which the COVID-19 coronavirus may impact
our future business operations, including our clinical trials, and financial condition will depend on future developments, which
are highly uncertain and cannot be predicted with confidence, such as the ultimate geographic spread of the disease, the duration
of the outbreak, travel restrictions and social distancing in the United States and other countries, business closures or business
disruptions and the effectiveness of actions taken in the United States and other countries to contain and treat the disease.</span></p>

<!-- Field: Page; Sequence: 24 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Risks
Related to our Common Stock</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>A
decline in the price of our common stock could affect our ability to raise further working capital and adversely impact our operations
and would severely dilute existing or future investors if we were to raise funds at lower prices.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">A
prolonged decline in the price of our common stock could result in a reduction in our ability to raise capital. Because our operations
have been financed through the sale of equity securities, a decline in the price of our common stock could be especially detrimental
to our continued operations. Any reduction in our ability to raise equity capital in the future would force us to reallocate funds
from other planned uses and would have a significant negative effect on our business plans and operations, including our ability
to develop new products and continue our current operations. If our stock price declines, there can be no assurance that we can
raise additional capital or generate funds from operations sufficient to meet our obligations. We believe the following factors
could cause the market price of our common stock to continue to fluctuate widely and could cause our common stock to trade at
a price below the price at which you purchase your shares of common stock:</span></p>

<ul style="list-style-type: disc">

<li style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">actual
or anticipated variations in our quarterly operating results;</span></li>

<li style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">announcements
of new services, products, acquisitions or strategic relationships by us or our competitors;</span></li>

<li style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">changes
in accounting treatments or principles;</span></li>

<li style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">changes
in earnings estimates by securities analysts and in analyst recommendations; and</span></li>

<li style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">general
political, economic, regulatory and market conditions.</span></li>

</ul>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
market price for our common stock may also be affected by our ability to meet or exceed expectations of analysts or investors.
Any failure to meet these expectations, even if minor, could materially adversely affect the market price of our common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>If
we issue additional shares of common stock in the future, it will result in the dilution of our existing stockholders and may
cause the share price of our common stock to fall.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Our
articles of incorporation authorize the issuance of 10,000,000 shares of preferred stock and 100,000,000 shares of common stock.
Our board of directors has the authority to issue additional shares of preferred and common stock up to the authorized capital
stated in the articles of incorporation. Our board of directors may choose to issue some or all such shares of common stock to
acquire one or more businesses or to provide additional financing in the future. The issuance of any such shares of common stock
will result in a reduction of the book value or market price of the outstanding shares of our common stock. If we do issue any
such additional shares of common stock, such issuance also will cause a reduction in the proportionate ownership and voting power
of all other stockholders. Further, any such issuance may result in a change of control of our corporation. In the event we do
issue or sell additional shares of common or preferred stock, it may result in shareholder dilution and may cause our share price
to fall.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Trading
of our common stock may be volatile and sporadic, which could depress the market price of our common stock and make it difficult
for our stockholders to resell their shares.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">There
is currently a limited market for our common stock and the volume of our common stock traded on any day may vary significantly
from one period to another. Trading in our stock is often thin and characterized by wide fluctuations in trading prices, due to
many factors that may have little to do with our operations or business prospects. The availability of buyers and sellers represented
by this volatility could lead to a market price for our common stock that is unrelated to operating performance. There is no assurance
that a sufficient market will develop in the stock, in which case it could be difficult for our stockholders to resell their stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>The
sale or issuance of our common stock to Lincoln Park may cause dilution and the sale of the shares of common stock acquired by
Lincoln Park, or the perception that such sales may occur, could cause the price of our common stock to fall.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">On
June 7, 2019, we entered into a Purchase Agreement (the &#8220;2019 Purchase Agreement&#8221;) with Lincoln Park Capital Fund,
LLC (&#8220;Lincoln Park&#8221;), as amended on July 1, 2020, pursuant to which Lincoln Park committed to purchase up to $50 million
of our common stock. The purchase price for shares that we may sell to Lincoln Park under the 2019 Purchase Agreement will fluctuate
based on the price of our common stock. Depending on market liquidity at the time, sales of such shares may cause the trading
price of our common stock to fall.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
have the right to control the timing and amount of any sales of our shares to Lincoln Park in our sole discretion, subject to
certain limits on the amount of shares that can be sold on a given date. Sales of shares of our common stock, if any, to Lincoln
Park will depend upon market conditions and other factors to be determined by us. Therefore, Lincoln Park may ultimately purchase
all, some or none of the shares of our common stock that may be sold pursuant to the 2019 Purchase Agreement and, after it has
acquired shares, Lincoln Park may sell all, some or none of those shares. Sales to Lincoln Park by us could result in substantial
dilution to the interests of other holders of our common stock. Additionally, the sale of a substantial number of shares of our
common stock to Lincoln Park, or the anticipation of such sales, could make it more difficult for us to sell equity or equity-related
securities in the future at a time and at a price that we might otherwise wish to effect sales, which could have a materially
adverse effect on our business and operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<!-- Field: Page; Sequence: 24 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>We
may not be able to access sufficient funds under the 2019 Purchase Agreement or the Sales Agreement when needed.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Our
ability to sell shares to Lincoln Park and obtain funds under the 2019 Purchase Agreement is limited by the terms and conditions
in the 2019 Purchase Agreement, including restrictions on the amounts we may sell to Lincoln Park at any one time, and a limitation
on our ability to sell shares to Lincoln Park to the extent that it would cause Lincoln Park to beneficially own more than 4.99%
of our outstanding shares of common stock. Additionally, the sale of common shares to Lincoln Park may be limited to a number
of shares equal to 19.99% of the shares of common stock outstanding on the date of the amendment to the 2019 Purchase Agreement
unless we obtain shareholder approval or the average price of such sales exceeds the price of our common stock on the amendment
date of July 1, 2020 as determined under NASDAQ rules. <span style="background-color: white">At September 30, 2020, approximately
$24.1 million in shares of our common stock remained available for purchase by Lincoln Park under the 2019 Purchase Agreement</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
addition, on May 1, 2020, we entered into an Amended and Restated Sales Agreement (the &#8220;Sales Agreement&#8221;) with Cantor
Fitzgerald &amp; Co. and SVB Leerink LLC (the &#8220;Sales Agents&#8221;) to offer shares of our common stock from time to time
through &#8220;at-the-market&#8221; offerings, pursuant to which we may offer and sell shares of our common stock for an aggregate
offering price of up to $50 million. While we have offered 1,760,429 shares of common stock through the Sales Agents pursuant
to the Sales Agreement for gross proceeds of $7,499,900 through September 30, 2020 under the Sales Agreement, the Sales Agents
are only obligated to act as our agent in the sale of shares pursuant to the Sales Agreement on a commercially reasonable efforts
basis and subject to certain conditions set forth in the Sales Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Therefore,
we may not in the future, have access to the full amount available to us under the Purchase Agreement or the Sales Agreement.
In addition, any amounts we sell under the 2019 Purchase Agreement or the Sales Agreement may not satisfy all of our funding needs,
even if we are able and choose to sell and issue all of our common stock currently registered.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Risks
Related to our Intellectual Property </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>If
we are unable to obtain and maintain sufficient intellectual property protection for our product candidates, or if the scope of
the intellectual property protection obtained is not sufficiently broad, our competitors could develop and commercialize product
candidates similar or identical to ours, and our ability to successfully commercialize our product candidates that we may pursue
may be impaired. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Our
success depends in large part on our ability to obtain and maintain protection of our intellectual property, particularly patents,
in the United States and other countries with respect to our product candidates and technology. We seek to protect our proprietary
position by filing patent applications in the United States and abroad related to our product candidates or by in-licensing intellectual
property. U.S. patents related to ANAVEX<sup>&#174;</sup>2-73 are directed to a dosage form comprising certain doses of ANAVEX<sup>&#174;</sup>2-73
and donepezil, and the coverage is limited to the United States only. We may not be able to obtain patent protection for ANAVEX<sup>&#174;</sup>2-73
as a single drug or in other jurisdictions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Moreover,
we may be subject to a third-party preissuance submission of prior art to the United States Patent and Trademark Office, or the
USPTO, or become involved in opposition, derivation, reexamination, inter partes review, post-grant review or interference proceedings
challenging our patent rights or the patent rights of others. An adverse determination in any such submission, proceeding or litigation
could reduce the scope of, or invalidate, our patent rights, allow third parties to commercialize our product candidates and compete
directly with us, without payment to us, or result in our inability to manufacture or commercialize drugs without infringing on
third-party patent rights. In addition, if the breadth or strength of protection provided by our patents and patent applications
is threatened, regardless of the outcome, it could dissuade companies from collaborating with us to license, develop or commercialize
current or future product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<!-- Field: Page; Sequence: 24 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
addition, the issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our patents
may be challenged in the courts or patent offices in the United States and abroad. Such challenges may result in loss of exclusivity
or freedom to operate or in patent claims being narrowed, invalidated or held unenforceable, in whole or in part, which could
limit our ability to stop others from using or commercializing similar or identical product candidates, or limit the duration
of the patent protection of our product candidates. Given the amount of time required for the development, testing and regulatory
review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are
commercialized. As a result, our patent portfolio may not provide us with sufficient rights to exclude others from commercializing
drugs similar or identical to ours.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
hold ownership or exclusive rights to nine issued U.S. patent, ten U.S. patent applications, and various PCT or ex-U.S. patent
applications relating to our drug candidates, methods associated therewith, and to our research programs. Neither patents nor
patent applications ensure the protection of our intellectual property for a number of reasons, including the following:</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Courier New, Courier, Monospace; width: 100%; border-collapse: collapse">
<tr>
    <td style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 5%; padding-bottom: 10pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 11pt Calibri, Helvetica, Sans-Serif; vertical-align: top; width: 5%; padding-bottom: 10pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">1.</span></td>
    <td style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-bottom: 10pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Competitors
    may interfere with our patenting process in a variety of ways. Competitors may claim that Anavex is not entitled to an issued
    patent for a variety of legal reasons. Competitors may also claim that we are infringing their patents and restrict our freedom
    to operate. If a court or, in some circumstances, a board of a national patent authority, agrees, we would lose some or all
    of our patent protection. As a company, we have no meaningful experience with competitors interfering with our patents or
    patent applications.</span></td></tr>
<tr>
    <td style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-bottom: 10pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 11pt Calibri, Helvetica, Sans-Serif; vertical-align: top; padding-bottom: 10pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">2.</span></td>
    <td style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-bottom: 10pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Because
    of the time, money and effort involved in obtaining and enforcing patents, our management may spend less time and resources
    on developing potential drug compounds than they otherwise would, which could increase our operating expenses and delay product
    programs.</span></td></tr>
<tr>
    <td style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-bottom: 10pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 11pt Calibri, Helvetica, Sans-Serif; vertical-align: top; padding-bottom: 10pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">3.</span></td>
    <td style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-bottom: 10pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Issuance
    of a patent may not provide significant practical protection. If we receive a patent of narrow scope, then it may be possible
    for competitors to design products that do not infringe our patent(s).</span></td></tr>
<tr>
    <td style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-bottom: 10pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 11pt Calibri, Helvetica, Sans-Serif; vertical-align: top; padding-bottom: 10pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">4.</span></td>
    <td style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-bottom: 10pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Anavex
    is seeking patent protection for a number of indications, combination products and drug regimens. The lack of patent protection
    in global markets for a specific end product or indication may inhibit our ability to advance our compounds and may make Anavex
    less attractive to potential partners.</span></td></tr>
<tr>
    <td style="font: 11pt Calibri, Helvetica, Sans-Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 11pt Calibri, Helvetica, Sans-Serif; vertical-align: top; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">5.</span></td>
    <td style="font: 11pt Calibri, Helvetica, Sans-Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Defending
    a patent lawsuit takes significant time and can be very expensive.</span></td></tr>
<tr>
    <td style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-bottom: 10pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 11pt Calibri, Helvetica, Sans-Serif; vertical-align: top; padding-bottom: 10pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">6.</span></td>
    <td style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-bottom: 10pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">If
    a court decides that an Anavex compound, its method of manufacture or use, infringes on the competitor&#8217;s patent, we
    may have to pay substantial damages for infringement.</span></td></tr>
<tr>
    <td style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-bottom: 10pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 11pt Calibri, Helvetica, Sans-Serif; vertical-align: top; padding-bottom: 10pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">7.</span></td>
    <td style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-bottom: 10pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">A
    court may prohibit us from making, selling or licensing the potential drug compound unless the patent holder grants a license.
    A patent holder is not required to grant a license. If a license is available, we may have to pay substantial royalties or
    grant cross licenses to our patents, and the license terms may be unacceptable.</span></td></tr>
<tr>
    <td style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-bottom: 10pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 11pt Calibri, Helvetica, Sans-Serif; vertical-align: top; padding-bottom: 10pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">8.</span></td>
    <td style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-bottom: 10pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Redesigning
    our potential drug compounds so that they do not infringe on other patents may not be possible or could require substantial
    funds and time.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">It
is also unclear whether our trade secrets are adequately protected. While we use reasonable efforts to protect our trade secrets,
our employees or consultants may unintentionally or willfully disclose our information to competitors. Enforcing a claim that
someone illegally obtained and is using our trade secrets, like patent litigation, is expensive and time consuming, and the outcome
is unpredictable. In addition, courts outside the United States are sometimes less willing to protect trade secrets. Our competitors
may independently develop equivalent knowledge, methods and know-how.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
may also support and collaborate in research conducted by government organizations, hospitals, universities or other educational
institutions. These research partners may be unable or unwilling to grant us exclusive rights to technology or products derived
from these collaborations.</span></p>

<!-- Field: Page; Sequence: 24 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">If
we do not obtain required intellectual property licenses or rights, we could encounter delays in our product development efforts
while we attempt to design around other patents or even be prohibited from developing, manufacturing or selling potential drug
compounds requiring these rights or licenses. There is also a risk that legal disputes may arise as to the rights to technology
or potential drug compounds developed in collaboration with other parties, all with attendant risk, distraction, expense, and
lack of predictability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>If
we fail to comply with our obligations in the agreements under which we license intellectual property rights from third parties
or otherwise experience disruptions to our business relationships with our licensors, we could lose intellectual property rights
that are important to our business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
are party to an exclusive license agreement with Life Science Research Israel Ltd., with respect to certain in-licensed intellectual
property related to our ANAVEX&#174;3-71 product candidate, and we may need to obtain additional licenses from others in the future.
Our license agreement with Life Science Research Israel Ltd. imposes, and we expect that future license agreements will impose,
various development, diligence, commercialization, and other obligations on us. In spite of our efforts, our licensors might conclude
that we have materially breached our obligations under such license agreements and might therefore terminate the license agreements,
thereby removing or limiting our ability to develop and commercialize products and technology covered by these license agreements.
If these in-licenses are terminated, or if the underlying patents fail to provide the intended exclusivity, competitors or other
third parties would have the freedom to seek regulatory approval of, and to market, products identical to ours and we may be required
to cease our development and commercialization of ANAVEX<sup>&#174;</sup>3-71 or other product candidates covered by any such future
licenses. Any of the foregoing could have a material adverse effect on our competitive position, business, financial conditions,
results of operations, and prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Moreover,
disputes may arise regarding intellectual property subject to a licensing agreement, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Courier New, Courier, Monospace; width: 100%; border-collapse: collapse">
<tr>
    <td style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 5%; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 11pt Calibri, Helvetica, Sans-Serif; vertical-align: top; width: 2%; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#8226;</span></td>
    <td style="font: 11pt Calibri, Helvetica, Sans-Serif; vertical-align: top; width: 1%; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 11pt Calibri, Helvetica, Sans-Serif; vertical-align: top; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">the
    scope of rights granted under the license agreement and other interpretation-related issues;</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Courier New, Courier, Monospace; width: 100%; border-collapse: collapse">
<tr>
    <td style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 5%; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 11pt Calibri, Helvetica, Sans-Serif; vertical-align: top; width: 2%; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#8226;</span></td>
    <td style="font: 11pt Calibri, Helvetica, Sans-Serif; vertical-align: top; width: 1%; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 11pt Calibri, Helvetica, Sans-Serif; vertical-align: top; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">the
    extent to which our product candidates, technology and processes infringe on intellectual property of the licensor that is
    not subject to the licensing agreement;</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Courier New, Courier, Monospace; width: 100%; border-collapse: collapse">
<tr>
    <td style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 5%; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 11pt Calibri, Helvetica, Sans-Serif; vertical-align: top; width: 2%; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#8226;</span></td>
    <td style="font: 11pt Calibri, Helvetica, Sans-Serif; vertical-align: top; width: 1%; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 11pt Calibri, Helvetica, Sans-Serif; vertical-align: top; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">the
    sublicensing of patent and other rights under our collaborative development relationships;</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
<tr>
    <td style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 5%; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 11pt Calibri, Helvetica, Sans-Serif; vertical-align: top; width: 2%; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#8226;</span></td>
    <td style="font: 11pt Calibri, Helvetica, Sans-Serif; vertical-align: top; width: 1%; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 11pt Calibri, Helvetica, Sans-Serif; vertical-align: top; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">our
    diligence obligations under the license agreement and what activities satisfy those diligence obligations; </span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
<tr>
    <td style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 5%; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 11pt Calibri, Helvetica, Sans-Serif; vertical-align: top; width: 2%; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#8226;</span></td>
    <td style="font: 11pt Calibri, Helvetica, Sans-Serif; vertical-align: top; width: 1%; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 11pt Calibri, Helvetica, Sans-Serif; vertical-align: top; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">the
    inventorship and ownership of inventions and know-how resulting from the joint creation or use of intellectual property by
    our licensors and us and our partners; and</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
<tr>
    <td style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 5%; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 11pt Calibri, Helvetica, Sans-Serif; vertical-align: top; width: 2%; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#8226;</span></td>
    <td style="font: 11pt Calibri, Helvetica, Sans-Serif; vertical-align: top; width: 1%; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">the
                                    priority of invention of patented technology.</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
addition, the agreements under which we currently license intellectual property or technology from third parties are complex,
and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation
disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or
technology, or increase what we believe to be our financial or other obligations under the relevant agreement, either of which
could have a material adverse effect on our business, financial condition, results of operations, and prospects. Moreover, if
disputes over intellectual property that we have licensed prevent or impair our ability to maintain our licensing arrangements
on commercially acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates,
which could have a material adverse effect on our business, financial conditions, results of operations, and prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">If
we do not obtain required intellectual property licenses or rights, we could encounter delays in our product development efforts
while we attempt to design around other patents or even be prohibited from developing, manufacturing or selling potential drug
compounds requiring these rights or licenses. There is also a risk that legal disputes may arise as to the rights to technology
or potential drug compounds developed in collaboration with other parties, all with attendant risk, distraction, expense, and
lack of predictability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<!-- Field: Page; Sequence: 24 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Third-party
claims of intellectual property infringement may prevent or delay our development and commercialization efforts.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Our
success will also depend in part on our ability to commercialize our compounds without infringing the proprietary rights of others.
We have not conducted extensive freedom of use patent searches and no assurance can be given that patents do not exist or could
be issued which would have an adverse effect on our ability to market our technology or maintain our competitive position with
respect to our technology. If our compounds or other subject matter are claimed under other United States patents or other international
patents or are otherwise protected by third party proprietary rights, we may be subject to infringement actions. In such event,
we may challenge the validity of such patents or other proprietary rights or we may be required to obtain licenses from such companies
in order to develop, manufacture or market our technology. There can be no assurances that we would be successful in a challenge
or be able to obtain such licenses or that such licenses, if available, could be obtained on commercially reasonable terms. Furthermore,
the failure to succeed in a challenge, develop a commercially viable alternative or obtain needed licenses could be materially
adverse. Adverse consequences include delays in marketing some or all of our potential drug compounds based on our drug technology
or the inability to proceed with the development, manufacture or sale of potential drug compounds requiring such licenses. If
we defend ourselves against charges of patent infringement or to protect our proprietary rights against third parties, substantial
costs will be incurred regardless of whether we are successful. Such proceedings are typically protracted with no certainty of
success. An adverse outcome could subject us to significant liabilities to third parties and force us to curtail or cease the
research and development of our technology.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Parties
making claims against us may obtain injunctive or other equitable relief, which could effectively block our ability to further
develop and commercialize ANAVEX<sup>&#174;</sup>2-73 or our other product candidates. Defense of these claims, regardless of their
merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business.
In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages
and attorneys&#8217; fees for willful infringement, pay royalties, redesign our infringing products or obtain one or more licenses
from third parties, which may be impossible or require substantial time and monetary expenditure. Additionally, parties making
claims against us may be able to sustain the costs of complex patent litigation more effectively than we can because they have
substantially greater resources. Furthermore, because of the substantial amount of discovery required in connection with intellectual
property litigation or administrative proceedings, there is a risk that some of our confidential information could be compromised
by disclosure. In addition, any uncertainties resulting from the initiation and continuation of any litigation could have material
adverse effect on our ability to raise additional funds or otherwise have a material adverse effect on our business, results of
operations, financial condition and prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>If
we are unable to protect the confidentiality of our trade secrets, the value of our technology could be materially adversely affected
and our business would be harmed.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">While
we use reasonable efforts to protect our trade secrets, our employees or consultants may unintentionally or willfully disclose
our information to competitors. Enforcing a claim that someone illegally obtained and is using our trade secrets, like patent
litigation, is expensive and time consuming, and the outcome is unpredictable. In addition, courts outside the United States are
sometimes less willing to protect trade secrets. Our competitors may independently develop equivalent knowledge, methods and know-how.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
seek to protect our confidential proprietary information, in part, by confidentiality agreements and invention assignment agreements
with our employees, consultants, scientific advisors, contractors and collaborators. These agreements are designed to protect
our proprietary information. However, we cannot be certain that such agreements have been entered into with all relevant parties,
and we cannot be certain that our trade secrets and other confidential proprietary information will not be disclosed or that competitors
will not otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques.
For example, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets,
and we may not be able to obtain adequate remedies for such breaches. We also seek to preserve the integrity and confidentiality
of our confidential proprietary information by maintaining physical security of our premises and physical and electronic security
of our information technology systems, but it is possible that these security measures could be breached. If any of our confidential
proprietary information were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent
such competitor from using that technology or information to compete with us, which could harm our competitive position.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<!-- Field: Page; Sequence: 24 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Although
we are not currently involved in any litigation, we may become involved in lawsuits to protect or enforce our patents or other
intellectual property, which could be expensive, time consuming and unsuccessful.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Competitors
may infringe our patents or other intellectual property. Although we are not currently involved in any litigation, if we were
to initiate legal proceedings against a third party to enforce a patent covering ANAVEX<sup>&#174;</sup>2-73 or our other product
candidates, the defendant could counterclaim that the patent covering our product candidate is invalid and/or unenforceable. In
patent litigation in the United States, defendant counterclaims alleging invalidity and/or unenforceability are commonplace. Grounds
for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty,
obviousness, written description or non-enablement. Grounds for an unenforceability assertion could be an allegation that someone
connected with prosecution of the patent withheld relevant information from the USPTO, or made a misleading statement, during
prosecution. The outcome following legal assertions of invalidity and unenforceability is unpredictable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Interference
or derivation proceedings provoked by third parties or brought by us or declared by the USPTO may be necessary to determine the
priority of inventions with respect to our patents or patent applications. An unfavorable outcome could require us to cease using
the related technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing
party does not offer us a license on commercially reasonable terms or at all, or if a non-exclusive license is offered and our
competitors gain access to the same technology. Our defense of litigation or interference or derivation proceedings may fail and,
even if successful, may result in substantial costs and distract our management and other employees. In addition, the uncertainties
associated with litigation could have a material adverse effect on our ability to raise the funds necessary to continue our clinical
trials, continue our research programs, license necessary technology from third parties, or enter into development partnerships
that would help us bring ANAVEX<sup>&#174;</sup>2-73 or our other product candidates to market.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>We
may be subject to claims challenging the inventorship of our patents and other intellectual property.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
or our licensors may be subject to claims that former employees, collaborators or other third parties have an interest in our
owned or in-licensed patents, trade secrets, or other intellectual property as an inventor or co-inventor. For example, we or
our licensors may have inventorship disputes arise from conflicting obligations of employees, consultants or others who are involved
in developing our product candidates. Litigation may be necessary to defend against these and other claims challenging inventorship
or our or our licensors&#8217; ownership of our owned or in-licensed patents, trade secrets or other intellectual property. If
we or our licensors fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual
property rights, such as exclusive ownership of, or right to use, intellectual property that is important to our product candidates.
Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction
to management and other employees. Any of the foregoing could have a material adverse effect on our business, financial condition,
results of operations and prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Obtaining
and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other
requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance
with these requirements.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Periodic
maintenance fees, renewal fees, annuity fees and various other governmental fees on patents and/or applications will be due to
be paid to the USPTO and various governmental patent agencies outside of the United States in several stages over the lifetime
of the patents and/or applications. We have systems in place to remind us to pay these fees, and we employ an outside firm and
rely on our outside counsel to pay these fees due to non-U.S. patent agencies. The USPTO and various non-U.S. governmental patent
agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent
application process. We employ reputable law firms and other professionals to help us comply, and in many cases, an inadvertent
lapse can be cured by payment of a late fee or by other means in accordance with the applicable rules. However, there are situations
in which non-compliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete
loss of patent rights in the relevant jurisdiction. In such an event, our competitors might be able to enter the market and this
circumstance would have a material adverse effect on our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<!-- Field: Page; Sequence: 24 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>We
may not be able to protect our intellectual property rights throughout the world.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Filing,
prosecuting and defending patents on our product candidates in all countries throughout the world would be prohibitively expensive,
and our intellectual property rights in some countries outside the United States can be less extensive than those in the United
States. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal
and state laws in the United States. Consequently, we may not be able to prevent third parties from practicing our inventions
in all countries outside the United States, or from selling or importing products made using our inventions in and into the United
States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection
to develop their own products and may also export infringing products to territories where we have patent protection, but enforcement
is not as strong as that in the United States. These products may compete with our products and our patents or other intellectual
property rights may not be effective or sufficient to prevent them from competing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 12pt 0 3pt"><span style="font: normal 10pt Times New Roman, Times, Serif"><span id="item1b"></span><b><i>ITEM
1B. UNRESOLVED STAFF COMMENTS</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><span style="font: 10pt Times New Roman, Times, Serif">None.</span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 12pt 0 3pt"><span style="font: normal 10pt Times New Roman, Times, Serif"><span id="item2"></span><b><i>ITEM
2. PROPERTIES</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
do not own any real property. We maintain several offices of which the office at 7th Floor, 51 West 52nd Street, New York, NY,
USA is our main office. Our lease costs are approximately $20,000 per month. We believe our offices are suitable and adequate
to operate our business now as they provide us with sufficient space to conduct our operations. We fully utilize our current premises.</span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 12pt 0 3pt"><span style="font: normal 10pt Times New Roman, Times, Serif"><span id="item3"></span><b><i>ITEM
3. LEGAL PROCEEDINGS</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">We
know of no material pending legal proceedings, other than ordinary routine litigation incidental to our business, to which our
Company or our subsidiary is a party or of which any of their property is subject. There are no proceedings in which any of our
directors, officers or affiliates, or any registered or beneficial stockholder holding more than 5% of our shares, is an adverse
party or has a material interest adverse to our or our subsidiary&#8217;s interest.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 12pt 0 3pt"><span style="font: normal 10pt Times New Roman, Times, Serif"><span id="item4"></span><b><i>
ITEM 4. MINE SAFETY DISCLOSURES</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><span style="font: 10pt Times New Roman, Times, Serif">Not
applicable.</span></p>

<!-- Field: Page; Sequence: 24 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

    <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"><span id="part2"></span>PART
II</span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 12pt 0 3pt; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"><span id="item5"></span><b><i>
ITEM 5. MARKET FOR REGISTRANT&#8217;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-bottom: 12pt; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Market
information</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Our
common stock is quoted on the NASDAQ Stock Market LLC (&#8220;NASDAQ&#8221;) under the symbol &#8220;AVXL.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-bottom: 12pt; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Holders
of Common Stock </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">As
of December 28, 2020, there were approximately 53 holders of record and <span style="background-color: White">66,962,957</span>
shares of our common stock were issued and outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-bottom: 12pt; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Dividends
</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><span style="font: 10pt Times New Roman, Times, Serif">We
have not paid any cash dividends on our common stock and have no intention of paying any dividends on the shares of our common
stock. Our current policy is to retain earnings, if any, for use in our operations and in the development of our business. Our
future dividend policy will be determined from time to time by our board of directors.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-bottom: 12pt; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Recent
Sales of Unregistered Securities </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Since
the beginning of our fiscal year ended September 30, 2020, we have not sold any equity securities that were not registered under
the Securities Act of 1933 that were not previously reported in a quarterly report on Form 10-Q or in a current report on Form
8-K.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-bottom: 12pt; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Repurchases
of Equity Securities by Our Company and Affiliated Purchasers</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><span style="font: 10pt Times New Roman, Times, Serif">None.</span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 12pt 0 3pt"><span style="font: normal 10pt Times New Roman, Times, Serif"><span id="item6"></span><b><i>ITEM
6 SELECTED FINANCIAL DATA</i></b></span></p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 10pt"><span style="font: 10pt Times New Roman, Times, Serif">Not
applicable.</span></p>

<!-- Field: Page; Sequence: 24 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

    <p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 12pt 0 3pt"><span style="font: normal 10pt Times New Roman, Times, Serif"><span id="item7"></span><b><i>ITEM
7 MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATION</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">The
following discussion should be read in conjunction with our audited consolidated financial statements and notes thereto for the
fiscal year ended September 30, 2020, included elsewhere in this Annual Report on Form 10-K.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-bottom: 12pt; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Financial
Highlights</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">During
fiscal 2020, we made significant progress in the advancement of clinical studies for ANAVEX<sup>&#174;</sup>2-73, including continued
enrollment of our Phase 2b/3 Alzheimer&#8217;s disease trial and expansion of this trial internationally, completion of our proof-of-concept
Phase 2 Parkinson&#8217;s disease dementia trial, continued advancement of a multi-regional Phase 2/3 clinical program for the
treatment of Rett syndrome, including completion of the Phase 2 U.S. trial and expansion of the AVATAR Phase 2 study internationally
and the commencement of the EXCELLENCE Phase 2/3 pediatric Rett syndrome study. While fiscal 2020 was marked by the outbreak of
COVID-19, which temporarily slowed down activities in many of the countries in which these trials are taking place, our clinical
trials were able to continue largely uninterrupted in compliance with local regulations and policies, and we were able to continue
to recruit and screen new patients as much as possible to advance these studies. Additionally, we commenced the first in human
Phase 1 clinical trial of ANAVEX<sup>&#174;</sup>3-71 during fiscal 2020 with focus on the treatment of Frontotemporal Dementia
(FTD) and other dementia indications with unmet medical need.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">As
a result, our operating expenses for fiscal 2020 increased to $31.1 million, from $29.1 million in fiscal 2019, an increase of
approximately 6.9%. The increase is attributable to an increase in research and development expenses of $2.9 million in 2020 to
$25.2 million, or approximately 13.3%.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">During
fiscal 2020, we utilized $21.3 million to fund our operations, compared to $18.5 million during fiscal 2019. Our cash position
increased to $29.2 million at September 30, 2020. Our operations were financed through the issuance of shares of common stock
under the 2019 Purchase Agreement, and the Sales Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
continue to see an increase in our research and development expenditures as we advance our ANAVEX<sup>&#174;</sup>2-73 clinical
studies, including adding extension studies to allow us to continue to gather longer term data, and adding additional staffing
to manage the clinical studies currently underway. We also continue to receive support from the Australian government for various
clinical trials being conducted within Australia. We will continue to target potential research partners to further advance our
pipeline compounds.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
August 2020, we announced a financial commitment by Shake It Up Australia Foundation (SIUAF) for Parkinson&#8217;s Research to
fund up to 50% of the costs of an Australian clinical study to develop ANAVEX<sup>&#174;</sup>2-73 for the disease modifying treatment
of Parkinson&#8217;s disease. The financial commitment would be made through private placement purchases of our common stock at
200% of the fair market value on the purchase date and will be contingent upon the completion of certain clinical trial milestones
relating to the proposed clinical trial. There was no impact on our consolidated financial statements for the year ended September
30, 2020 as a result of the commitment from SIUAF.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Net
loss for fiscal 2020 was $26.3 million, or $0.45 per share, as compared to $26.3 million, or $0.54 per share in fiscal 2019.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<!-- Field: Page; Sequence: 24 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

    <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Results
of Operations</span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Revenue</i></span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">We
are in the development stage and have not earned any revenues since our inception. We do not anticipate earning any revenues
until we can establish an alliance with other companies to develop, co-develop, license, acquire or market our products.</span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"><b>Year
ended September 30, 2020 compared to year ended September 30, 2019</b></span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Operating
Expenses</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Total
operating expenses for the year ended September 30, 2020 were $31.1 million, compared to $29.1 million in fiscal 2019, which was
an increase of approximately $2.0 million from fiscal 2019, or 6.9%.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Research
and development expenses for fiscal 2020 were $25.2 million, as compared to $22.3 million fiscal 2019, an increase of $2.9 million,
or approximately 13.3%. The largest reason for this increase is due to continued advancement, enrollment and expansion of the
company&#8217;s clinical trials with ANAVEX<sup>&#174;</sup>2-73, the commencement of clinical trials for ANAVEX<sup>&#174;</sup>3-71
and expanded clinical development staffing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">During
fiscal 2020 our general and administrative expenses were $5.9 million as compared to $6.8 million in fiscal 2019, a decrease of
$0.9 million, primarily related to decreased stock-option compensation charges of $1.0 million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Other
income </i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
net amount of other income for the year ended September 30, 2020 was $4.8 million as compared to $2.9 million for fiscal 2019.
During fiscal 2020, we recorded $4.4 million in research and development incentive income, including the Australian research and
development incentive credit administered through the Australian Tax Office, in connection with fiscal 2020 eligible expenditures
and fiscal 2019 expenditures for which an overseas finding ruling was obtained during the current year. In comparison, research
and development incentive income for fiscal 2019 was $2.5 million in connection with fiscal 2019 eligible expenditures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Net
loss for fiscal 2020 was $26.3 million, or $0.45 per share, compared to a net loss of approximately $26.3 million, or $0.54 per
share for fiscal 2019.</span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-bottom: 12pt; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>Liquidity
and Capital Resources </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-bottom: 0; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>Working
Capital</b></span></p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 90%; margin-left: 30pt; margin-right: 30pt; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 61%; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; width: 1%; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; white-space: nowrap; width: 18%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>2020</b></span></td>
    <td style="border-bottom: black 1pt solid; width: 1%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; width: 1%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; width: 18%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>2019</b></span></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Current Assets </span></td>
    <td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">$&#160;</span></td>
    <td style="padding-right: 12.8pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">34,542,197</span></td>
    <td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td>
    <td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-right: 8.95pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">25,329,373</span></td></tr>
<tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Current Liabilities
    </span></td>
    <td style="border-bottom: black 1pt solid; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; padding-right: 12.8pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">7,305,628</span></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; padding-right: 8.95pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">5,039,674</span></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Working Capital
    </span></td>
    <td style="border-bottom: black 1pt solid; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td>
    <td style="border-bottom: black 1pt solid; padding-right: 12.8pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">27,236,569</span></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; padding-right: 8.95pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">20,289,699</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">At
September 30, 2020, we had $29.2 million in cash and cash equivalents, an increase of $7.0 million, from $22.2 million at
September 30, 2019. The principal reason for this increase is due to net cash received from financing activities of $28.4
million from the issuance of common shares, offset by cash utilized in operations of $21.3 million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
intend to continue to use our capital resources to advance our clinical trials for ANAVEX<sup>&#174;</sup>2-73, and to perform
work necessary to prepare for future development of our pipeline compounds.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<!-- Field: Page; Sequence: 24 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

    <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Cash
Flows</span></p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 57%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 19%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><b>2020</b></span></td>
    <td style="width: 3%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 18%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><b>2019</b></span></td>
    <td style="width: 3%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Cash
    flows used in operating activities</span></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">$
    (21,287,046)</span></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">$
    (18,527,117)</span></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: top; background-color: White">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Cash
    flows provided by financing activities</span></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">28,350,434</span></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">17,782,109</span></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Increase
    (decrease) in cash</span></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">$&#160;&#160;&#160;&#160;&#160;7,063,388</span></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">$&#160;&#160;(745,008)</span></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>
<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Cash
flow used in operating activities</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">There
was an increase in cash used in operating activities of $2.8 million during fiscal 2020 due to an increase in clinical trial activities,
as more fully described above.</span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Cash
flow provided by financing activities</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Cash
provided by financing activities for fiscal 2020 was related to cash received from the issuance of shares under the 2019
Purchase Agreement and the Sales Agreement, as more fully described below. During fiscal 2020, we issued an aggregate of 9.4
million shares for gross proceeds of $28.8 million. During fiscal 2019, we issued an aggregate of 6.7 million shares for
gross proceeds of $17.8 million.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Other
Financings</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Purchase
Agreement</b></span></p>

<p style="font: 10.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">On
June 7, 2019, we entered into a Purchase Agreement (the &#8220;2019 Purchase Agreement&#8221;) with Lincoln Park Capital Fund,
LLC (&#8220;Lincoln Park&#8221;), as amended on July 1, 2020, pursuant to which Lincoln Park committed to purchase up to $50,000,000
of our common stock. Concurrently with the execution of the 2019 Purchase Agreement in 2019, we issued 324,383 shares of our common
stock to Lincoln Park as a fee for its commitment to purchase shares of our common stock under the 2019 Purchase Agreement and
shall issue up to 162,191 shares pro rata, when and if Lincoln Park purchases, at our discretion, the $50,000,000 aggregate commitment.
The purchase shares that may be sold pursuant to the 2019 Purchase Agreement may be sold by us to Lincoln Park at our discretion
from time to time until July 1, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
may direct Lincoln Park, at our sole discretion, and subject to certain conditions, to purchase up to 200,000 shares of common
stock on any business day (a &#8220;Regular Purchase&#8221;). The amount of a Regular Purchase may be increased under certain
circumstances up to 250,000 shares provided that Lincoln Park&#8217;s committed obligation for Regular Purchases on any business
day shall not exceed $2,000,000. In the event we purchase the full amount allowed for a Regular Purchase on any given business
day, we may also direct Lincoln Park to purchase additional amounts as accelerated and additional purchases. The purchase price
of shares of common stock related to the future funding will be based on the then prevailing market prices of such shares at the
time of sales as described in the 2019 Purchase Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">At
September 30, 2020, approximately $24.1 million in shares of our common stock remained available for purchase by Lincoln Park
under the 2019 Purchase Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<!-- Field: Page; Sequence: 24 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

    <p style="font: 10.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Controlled
Equity Offering Sales Agreement</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">On
May 1, 2020, we entered into an Amended and Restated&#160;Sales Agreement (the &#8220;Sales Agreement&#8221;) with Cantor
Fitzgerald &amp; Co. and SVB Leerink LLC (the &#8220;Sales Agents&#8221;), pursuant to which we may offer and sell shares of
common stock, for aggregate gross sale proceeds of up to $50,000,000 from time to time through the Sales Agents (the
&#8220;At-the-Market Offering&#8221;).&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Upon
delivery of a placement notice based on our instructions and subject to the terms and conditions of the Sales Agreement, the Sales
Agents may sell shares of common stock by methods deemed to be an &#8220;at the market offering&#8221;, in negotiated transactions
at market prices prevailing at the time of sale or at prices related to such prevailing market prices, or by any other method
permitted by law, including negotiated transactions, subject to our prior written consent. We are not obligated to make any sales
of shares under the Sales Agreement. We or the Sales Agents may suspend or terminate the At-the-Market Offering upon notice to
the other party, subject to certain conditions.&#160; The Sales Agents will act as agents on a commercially reasonable efforts
basis consistent with their normal trading and sales practices and applicable state and federal law, rules&#160;and regulations
and the rules&#160;of Nasdaq.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
have agreed to pay the Sales Agents commissions for their services of 3.0% of the gross proceeds from the sale of the Shares pursuant
to the Sales Agreement.&#160; We have also agreed to provide the Sales Agents with customary indemnification and contribution
rights. At September 30, 2020, an amount of $42.5 million remained available under the Sales Agreement.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<p style="font: 10.5pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-bottom: 12pt; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><i></i></b></span></p>

<p style="font: 10.5pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-bottom: 12pt; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Off-Balance
Sheet Arrangements</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
have no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial
condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital
resources that are material to our stockholders.</span></p>

<!-- Field: Page; Sequence: 24 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

    <p style="font: 10.5pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif; text-transform: uppercase"><b>Application
of Critical Accounting Policies</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Our
financial statements and accompanying notes are prepared in accordance with generally accepted accounting principles in the United
States. Preparing financial statements requires management to make estimates and assumptions that affect the reported amounts
of assets, liabilities, revenue and expenses. These estimates and assumptions are affected by management&#8217;s application of
accounting policies. We believe that understanding the basis and nature of the estimates and assumptions involved with the following
aspects of our financial statements is critical to an understanding of our financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
base our assumptions and estimates on historical experience and other sources that we believe to be reasonable at the time. Actual
results may vary from our estimates due to changes in circumstances, politics, global economics, general business conditions and
other factors. Our significant estimates are related to the valuation of warrants and options.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">There
are accounting policies that we believe are significant to the presentation of our financial statements. The most significant
of these accounting policies relates to the accounting for our research and development expenses and stock-based compensation
expense.</span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Research
and Development Expenses</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Research
and development costs are expensed as incurred. These expenses are comprised of the costs of the Company&#8217;s proprietary research
and development efforts, including preclinical studies, clinical trials, manufacturing costs, employee salaries and benefits and
stock based compensation expense, contract services including external research and development expenses incurred under arrangements
with third parties such as contract research organizations (&#8220;CROs&#8221;), facilities costs, overhead costs and other related
expenses. Milestone payments made by the Company to third parties are expensed when the specific milestone has been achieved.
Manufacturing costs are expensed as incurred in accordance with Accounting Standard Codification (&#8220;ASC&#8221;) 730, Research
and Development, as these materials have no alternative future use outside of their intended use.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Nonrefundable
advance payments for goods or services that will be used or rendered for future research and development activities are deferred
and amortized over the period that the goods are delivered, or the related services are performed, subject to an assessment of
recoverability. The Company makes estimates of costs incurred in relation to external CROs, and clinical site costs. The Company
analyzes the progress of clinical trials, including levels of patient enrollment, invoices received and contracted costs when
evaluating the adequacy of the amount expensed and the related prepaid asset and accrued liability. Significant judgments and
estimates must be made and used in determining the accrued balance and expense in any accounting period. The Company reviews and
accrues CRO expenses and clinical trial study expenses based on work performed and relies upon estimates of those costs applicable
to the stage of completion of a study. Accrued CRO costs are subject to revisions as such trials progress to completion. Revisions
are charged to expense in the period in which the facts that give rise to the revision become known. With respect to clinical
site costs, the financial terms of these agreements are subject to negotiation and vary from contract to contract. Payments under
these contracts may be uneven and depend on factors such as the achievement of certain events, the successful recruitment of patients,
the completion of portions of the clinical trial or similar conditions. The objective of our policy is to record expenses in our
financial statements based on actual services received and efforts expended. As such, expense accruals related to clinical site
costs are recognized based on our estimate of the degree of completion of the event or events specified in the specific clinical
study or trial contract.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify">In addition, we incur expenses in respect
of patents and trademarks. The probability of success and length of time to develop
commercial applications of the compounds subject to the underlying patents and trademarks is difficult to determine and numerous risks
and uncertainties exist with respect to the timely completion of the development projects. There is no assurance the compounds
subject to the underlying patents and trademarks will ever be successfully commercialized. Due to these risks and uncertainties,
we expense the patent and trademark costs within general and administrative expenses in our financial statements.</p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Stock-based
Compensation</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
account for all stock-based payments and awards under the fair value-based method.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
account for the granting of share purchase options and warrants to employees using the fair value method whereby all awards to
employees will be recorded at fair value on the date of the grant. The fair value of all share purchase options and warrants are
expensed over their contractual vesting period, or over the expected performance period for only the portion of awards expected
to vest, in the case of milestone-based vesting, with a corresponding increase to additional paid-in capital.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Share
purchase options and warrants issued to non-employees are measured at the fair value of the equity instruments issued. Compensation
expense for share purchase options and warrants issued to non-employees is recorded over the service performance period. Prior
to our adoption of ASU No. 2018-07, Compensation-Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment
Accounting on October 1, 2019, options and warrants subject to vesting were periodically re-measured until the counterparty performance
was complete, and any change therein was recognized over the vesting period of the award and in the same manner as if we had paid
cash instead of paying with or using equity based instruments. After the adoption of ASU No. 2018-07, we measure equity-classified
share-based payment awards issued to nonemployees on the grant date, rather than remeasuring the awards through the performance
completion date as previously required.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Compensation
costs for stock-based payments with graded vesting are recognized on a straight-line basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
use the Black-Scholes option valuation model to calculate the fair value of share purchase options and warrants at the date of
the grant. Option pricing models require the input of highly subjective assumptions, including the expected price volatility.
Changes in these assumptions can materially affect the fair value estimates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">For
a discussion of recent accounting pronouncements and their possible effect on our results, see Note 2(n) to our Consolidated Financial
Statements found elsewhere in this Annual Report.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<!-- Field: Page; Sequence: 24 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

    <p style="font: italic bold 10.5pt Times New Roman, Times, Serif; margin: 12pt 0 3pt"><span style="font: normal 10pt Times New Roman, Times, Serif"><span id="item7a"></span><b><i>
ITEM
7A QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 10pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Not
Applicable.</span></p>

<p style="font: italic bold 10.5pt Times New Roman, Times, Serif; margin: 12pt 0 3pt"><span style="font: normal 10pt Times New Roman, Times, Serif"><span id="item8"></span><b><i>
ITEM
8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</i></b></span></p>

<p style="font: 10.5pt/115% Times New Roman, Times, Serif; margin: 0 0 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<!-- Field: Page; Sequence: 24 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --><p style="font: 10.5pt/115% Times New Roman, Times, Serif; margin: 0 0 10pt; text-indent: 20pt"></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>ANAVEX
LIFE SCIENCES CORP.</b></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 12pt 0 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">CONSOLIDATED
FINANCIAL STATEMENTS</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 12pt 0 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">September
30, 2020</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 12pt 0 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 12pt 0 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 12pt 0 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<!-- Field: Page; Sequence: 24 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10.5pt/115% Times New Roman, Times, Serif; margin: 0 0 10pt; text-indent: 20pt"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; color: Black"><b>Report of Independent
Registered Public Accounting Firm</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; color: Black; text-align: justify">Shareholders and Board
of Directors</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; color: Black; text-align: justify">Anavex Life Sciences Corp.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; color: Black; text-align: justify">New York, New York</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 0cm; color: Black"><b style="color: Black">Opinion
on the Consolidated Financial Statements </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 0cm; color: Black">We
have audited the accompanying consolidated balance sheets of Anavex Life Sciences Corp. and subsidiaries (the &#8220;Company&#8221;)
as of September 30, 2020 and 2019, the related consolidated statements of operations, changes in stockholders&#8217; equity, and
cash flows for the years in the period ended September 30, 2020, and the related notes (collectively referred to as the &#8220;consolidated
financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects,
the financial position of the Company at September 30, 2020 and 2019, and the results of its operations and its cash flows for
the years then ended, in conformity with accounting principles generally accepted in the United States of America.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; color: Black"><b style="color: Black">Basis for Opinion</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 0cm; color: Black">These
consolidated financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an
opinion on the Company&#8217;s consolidated financial statements based on our audits. We are a public accounting firm registered
with the Public Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;) and are required to be independent with
respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities
and Exchange Commission and the PCAOB.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; color: Black">We conducted our audits
in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable
assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud.
The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting.
As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the
purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly,
we express no such opinion.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; color: Black; text-align: justify">Our audits included performing procedures
to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing
procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and
disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant
estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. <span style="color: Black">We
believe that our audits provide a reasonable basis for our opinion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: Black">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: Black">/s/ BDO USA, LLP</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; color: Black; text-align: justify">We have served as the Company's auditor
since 2013.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: Black">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: Black">New York, New York</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 4.7pt; text-align: justify; color: Black">December 28, 2020<span style="font: 10pt Times New Roman, Times, Serif; color: Black">&#160;</span></p>

<p style="font: 10.5pt/115% Times New Roman, Times, Serif; margin: 0 0 10pt; text-indent: 20pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<!-- Field: Page; Sequence: 24 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->&#160;<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

    <p style="font: 10.5pt/115% Times New Roman, Times, Serif; margin: 0 0 10pt; text-indent: 20pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>ANAVEX
LIFE SCIENCES CORP.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">CONSOLIDATED
BALANCE SHEETS</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">As
at September 30, 2020 and 2019</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30D_111_zOMxP5NoP5i4" summary="xdx: Statement - CONSOLIDATED BALANCE SHEETS" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_491_20200930_zG3k5KH1HJT2" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_495_20190930_zEfDTEpphOWd" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; white-space: nowrap"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="border-bottom: Black 1pt solid; font-weight: bold; white-space: nowrap"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>2020</b></span></td><td style="border-bottom: Black 1pt solid; font-weight: bold; white-space: nowrap"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">2019</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="white-space: nowrap; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="white-space: nowrap; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40E_eus-gaap--AssetsAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font: 10pt Times New Roman, Times, Serif">Assets</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_402_eus-gaap--AssetsCurrentAbstract_i01B" style="vertical-align: bottom; background-color: White">
    <td><span style="font: 10pt Times New Roman, Times, Serif">Current</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40F_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i02I_pp0p0_maAzsjZ_zo0zAPejS2l5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 70%; text-align: left; padding-left: 9pt"><span style="font: 10pt Times New Roman, Times, Serif">Cash
    and cash equivalents</span></td><td style="width: 1%; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="width: 12%; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">29,249,018</ix:nonFraction></span></td><td style="width: 1%; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="width: 12%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">22,185,630</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40C_eus-gaap--IncomeTaxesReceivable_i02I_pp0p0_maAzsjZ_znIMTSTH6nHh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 9pt"><span style="font: 10pt Times New Roman, Times, Serif">Incentive
    and tax receivables</span></td><td style="font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:IncomeTaxesReceivable" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,849,340</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:IncomeTaxesReceivable" contextRef="AsOf2019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,642,745</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_405_eus-gaap--PrepaidExpenseCurrent_i02I_pp0p0_maAzsjZ_zKeXiZvJVeHa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 1pt solid; text-align: left; padding-left: 9pt"><span style="font: 10pt Times New Roman, Times, Serif">Prepaid
    expenses and deposits</span></td><td style="border-bottom: Black 1pt solid; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:PrepaidExpenseCurrent" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">443,839</ix:nonFraction></span></td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:PrepaidExpenseCurrent" contextRef="AsOf2019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">500,998</ix:nonFraction></span></td><td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>

<tr id="xdx_406_eus-gaap--Assets_i01TI_pp0p0_mtAzsjZ_zb4rUw0qab3l" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Total
    Assets</span></td><td style="border-bottom: Black 2.5pt double; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">34,542,197</ix:nonFraction></span></td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">25,329,373</ix:nonFraction></span></td><td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40C_eus-gaap--LiabilitiesAndStockholdersEquityAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Liabilities and Stockholders'
    Equity</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_409_eus-gaap--LiabilitiesCurrentAbstract_i01B" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Current Liabilities</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40E_eus-gaap--AccountsPayableCurrent_i02I_pp0p0_maLCzRCI_zpFem7BscbBa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt"><span style="font: 10pt Times New Roman, Times, Serif">Accounts
    payable</span></td><td style="font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,989,054</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,523,332</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40F_eus-gaap--AccruedLiabilitiesCurrent_i02I_pp0p0_maLCzRCI_zSPfO03uTv99" style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 1pt solid; text-align: left; padding-left: 9pt"><span style="font: 10pt Times New Roman, Times, Serif">Accrued
    liabilities</span></td><td style="border-bottom: Black 1pt solid; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,316,574</ix:nonFraction></span></td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,516,342</ix:nonFraction></span></td><td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40E_eus-gaap--Liabilities_i02TI_pp0p0_mtLCzRCI_maLASEzOUW_z5klftKrijke" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Total
    Liabilities</span></td><td style="border-bottom: Black 1pt solid; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">7,305,628</ix:nonFraction></span></td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,039,674</ix:nonFraction></span></td><td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_407_eus-gaap--CommitmentsAndContingencies_i01I_pp0p0_d0_zvPWFfgctS9h" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Commitments and Contingencies
    - Note 5</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Capital stock</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in"><span style="font: 10pt Times New Roman, Times, Serif">Authorized:</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90E_eus-gaap--PreferredStockSharesAuthorized_c20200930_pii" title="Preferred stock, authorized"><span id="xdx_906_eus-gaap--PreferredStockSharesAuthorized_c20190930_pii" title="Preferred stock, authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2019-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,000,000</ix:nonFraction></ix:nonFraction></span></span> preferred
    stock, par value $<span id="xdx_901_eus-gaap--PreferredStockParOrStatedValuePerShare_c20200930_pii" title="Preferred stock, par value (in dollars per share)"><span id="xdx_90A_eus-gaap--PreferredStockParOrStatedValuePerShare_c20190930_pii" title="Preferred stock, par value (in dollars per share)"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2019-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></ix:nonFraction></span></span> per share</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_eus-gaap--PreferredStockValue_i01I_pp0p0_d0_maSEzBZb_c20200930_zy2kFu3LKV2c" title="Capital stock Authorized: 10,000,000 preferred stock, par value $0.001 per share" style="display: none; text-align: right"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2020-09-30" format="ixt:zerodash" decimals="0" scale="0" sign="-" unitRef="USD">-</ix:nonFraction><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_eus-gaap--PreferredStockValue_i01I_pp0p0_d0_maSEzBZb_c20190930_z5cJw9krNcRh" title="Capital stock Authorized: 10,000,000 preferred stock, par value $0.001 per share" style="display: none; text-align: right"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2019-09-30" format="ixt:zerodash" decimals="0" scale="0" sign="-" unitRef="USD">-</ix:nonFraction><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90B_eus-gaap--CommonStockSharesAuthorized_c20200930_pii" title="Common shares, authorized"><span id="xdx_902_eus-gaap--CommonStockSharesAuthorized_c20190930_pii" title="Common shares, authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2019-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">100,000,000</ix:nonFraction></ix:nonFraction></span></span> common
    stock, par value $<span id="xdx_90D_eus-gaap--CommonStockParOrStatedValuePerShare_c20200930_pii" title="Common shares, par value (in dollars per share)"><span id="xdx_905_eus-gaap--CommonStockParOrStatedValuePerShare_c20190930_pii" title="Common shares, par value (in dollars per share)"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2019-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></ix:nonFraction></span></span> per share</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in"><span style="font: 10pt Times New Roman, Times, Serif">Issued
    and outstanding:</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_902_eus-gaap--CommonStockSharesIssued_c20200930_pii" title="Common shares, issued"><span id="xdx_903_eus-gaap--CommonStockSharesOutstanding_c20200930_pii" title="Common shares, outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">62,045,198</ix:nonFraction></ix:nonFraction></span></span> common
    shares (2019 - <span id="xdx_909_eus-gaap--CommonStockSharesIssued_c20190930_pii" title="Common shares, issued"><span id="xdx_90C_eus-gaap--CommonStockSharesOutstanding_c20190930_pii" title="Common shares, outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2019-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2019-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">52,650,521</ix:nonFraction></ix:nonFraction></span></span>)</span></td><td style="font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_eus-gaap--CommonStockValue_i01I_pp0p0_maSEzBZb_c20200930_zu39l7HYqm0k" title="Capital stock Authorized: 100,000,000 common shares, par value $0.001 per share Issued and outstanding: 62,045,198 common shares (2019 - 52,650,521)" style="font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">62,047</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_eus-gaap--CommonStockValue_i01I_pp0p0_maSEzBZb_c20190930_z1gFSjST5Pq5" title="Capital stock Authorized: 100,000,000 common shares, par value $0.001 per share Issued and outstanding: 62,045,198 common shares (2019 - 52,650,521)" style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">52,652</ix:nonFraction>&#160;</span></td></tr>
<tr id="xdx_404_eus-gaap--AdditionalPaidInCapitalCommonStock_i01I_pp0p0_maSEzBZb_zLHmstOa5Bq9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Additional paid-in
    capital</span></td><td style="font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">186,851,752</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="AsOf2019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">153,633,807</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_406_eus-gaap--RetainedEarningsAccumulatedDeficit_i01I_pp0p0_maSEzBZb_z6qntnoUO8Zi" style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Accumulated
    deficit</span></td><td style="border-bottom: Black 1pt solid; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">159,677,230</ix:nonFraction></span></td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="border-bottom: Black 1pt solid"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">133,396,760</ix:nonFraction></span></td><td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td></tr>
<tr id="xdx_403_eus-gaap--StockholdersEquity_i01TI_pp0p0_mtSEzBZb_maLASEzOUW_zlXZ3dWNGTc9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Total
    Stockholders' Equity</span></td><td style="border-bottom: Black 1pt solid; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">27,236,569</ix:nonFraction></span></td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">20,289,699</ix:nonFraction></span></td><td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_404_eus-gaap--LiabilitiesAndStockholdersEquity_iTI_pp0p0_mtLASEzOUW_zyjFQV94fE21" style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 2.5pt double; text-align: left; padding-left: 0.125in"><span style="font: 10pt Times New Roman, Times, Serif">Total
    Liabilities and Stockholders' Equity</span></td><td style="border-bottom: Black 2.5pt double; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">34,542,197</ix:nonFraction></span></td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">25,329,373</ix:nonFraction></span></td><td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">See
Accompanying Notes to Consolidated Financial Statements</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 40; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>ANAVEX
LIFE SCIENCES CORP.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">CONSOLIDATED
STATEMENTS OF OPERATIONS</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">For
the years ended September 30, 2020 and 2019</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>




<table border="0" cellpadding="0" cellspacing="0" id="xdx_305_113_zLjEpzyWvMH7" summary="xdx: Statement - CONSOLIDATED STATEMENTS OF OPERATIONS" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: middle; background-color: white">
    <td style="text-align: left">&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td>
    <td id="xdx_49B_20191001__20200930_z9fTdFoxXLhh" style="font-weight: bold; text-align: right">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td id="xdx_49E_20181001__20190930_zz7fwe8vxMq9" style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: middle">
    <td style="border-bottom: black 1pt solid"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td style="border-bottom: black 1pt solid; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: black 1pt solid; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>2020</b></span></td>
    <td style="border-bottom: black 1pt solid; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td style="border-bottom: black 1pt solid"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">2019</span></td>
    <td style="border-bottom: black 1pt solid"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td></tr>
<tr id="xdx_40A_eus-gaap--OperatingExpensesAbstract_iB" style="vertical-align: middle; background-color: #CCEEFF">
    <td style="text-align: left; width: 64%"><span style="font: 10pt Times New Roman, Times, Serif">Operating
    expenses</span></td>
    <td style="width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right; width: 15%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right; width: 15%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_407_eus-gaap--GeneralAndAdministrativeExpense_i01_pp0p0_maOEzlOO_ze6ZVVDrk8nh" style="vertical-align: middle; background-color: white">
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">General and administrative</span></td>
    <td style="font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td>
    <td style="font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2019-10-01to2020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,856,609</ix:nonFraction></span></td>
    <td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td>
    <td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2018-10-012019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">6,846,599</ix:nonFraction></span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_404_eus-gaap--ResearchAndDevelopmentExpense_i01_pp0p0_maOEzlOO_zsbJX9uQB0fh" style="vertical-align: middle; background-color: #CCEEFF">
    <td style="border-bottom: black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Research
    and development</span></td>
    <td style="border-bottom: black 1pt solid; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2019-10-01to2020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">25,231,623</ix:nonFraction></span></td>
    <td style="border-bottom: black 1pt solid; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1pt solid"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2018-10-012019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">22,260,349</ix:nonFraction></span></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40E_eus-gaap--OperatingExpenses_i01NT_pp0p0_di_mtOEzlOO_msILFCOzgOk_zqGtt6QDxpv1" style="vertical-align: middle; background-color: white">
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Total operating expenses</span></td>
    <td style="font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2019-10-01to2020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">31,088,232</ix:nonFraction></span></td>
    <td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td>
    <td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2018-10-012019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">29,106,948</ix:nonFraction></span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td></tr>
<tr style="vertical-align: middle; background-color: #CCEEFF">
    <td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40F_eus-gaap--NonoperatingIncomeExpenseAbstract_iB" style="vertical-align: middle; background-color: white">
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Other income (expenses)</span></td>
    <td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40E_ecustom--NonOperatingIncomeFromGrant_i01_pp0p0_maNIEz8G1_zXWlzk6ATBOe" style="vertical-align: middle; background-color: #CCEEFF">
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Grant income</span></td>
    <td style="font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="avxl:NonOperatingIncomeFromGrant" contextRef="From2019-10-01to2020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">149,888</ix:nonFraction></span></td>
    <td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="avxl:NonOperatingIncomeFromGrant" contextRef="From2018-10-012019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">298,943</ix:nonFraction></span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40C_ecustom--ResearchAndDevelopmentIncentiveIncome_i01_pp0p0_maNIEz8G1_zZddv1GGpfQj" style="vertical-align: middle; background-color: white">
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Research and development
    incentive income</span></td>
    <td style="font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="avxl:ResearchAndDevelopmentIncentiveIncome" contextRef="From2019-10-01to2020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,375,025</ix:nonFraction></span></td>
    <td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="avxl:ResearchAndDevelopmentIncentiveIncome" contextRef="From2018-10-012019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,465,691</ix:nonFraction></span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_402_eus-gaap--InterestIncomeExpenseNet_i01_pp0p0_maNIEz8G1_zueOlWyFUE7a" style="vertical-align: middle; background-color: #CCEEFF">
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Interest income, net</span></td>
    <td style="font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:InterestIncomeExpenseNet" contextRef="From2019-10-01to2020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">179,973</ix:nonFraction></span></td>
    <td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:InterestIncomeExpenseNet" contextRef="From2018-10-012019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">207,280</ix:nonFraction></span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40F_eus-gaap--GainsLossesOnExtinguishmentOfDebt_i01_pp0p0_d0_maNIEz8G1_zaA319vYdNpg" style="vertical-align: middle; background-color: white">
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Gain on settlement
    of accounts payable</span></td>
    <td style="font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2019-10-01to2020-09-30" format="ixt:zerodash" decimals="0" scale="0" unitRef="USD">&#8212;</ix:nonFraction>&#160;&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2018-10-012019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">115,758</ix:nonFraction></span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40E_eus-gaap--DebtRelatedCommitmentFeesAndDebtIssuanceCosts_i01N_pp0p0_di0_msNIEz8G1_zTgj5Rbk81ml" style="vertical-align: middle; background-color: #CCEEFF">
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Financing related charges</span></td>
    <td style="font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:DebtRelatedCommitmentFeesAndDebtIssuanceCosts" contextRef="From2019-10-01to2020-09-30" format="ixt:zerodash" decimals="0" scale="0" sign="-" unitRef="USD">&#8212;</ix:nonFraction>&#160;&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:DebtRelatedCommitmentFeesAndDebtIssuanceCosts" contextRef="From2018-10-012019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">151,133</ix:nonFraction></span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td></tr>
<tr id="xdx_405_eus-gaap--ForeignCurrencyTransactionGainLossBeforeTax_i01_pp0p0_maNIEz8G1_zGQetwhF4u6i" style="vertical-align: middle; background-color: white">
    <td style="border-bottom: black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Foreign
    exchange gain (loss), net</span></td>
    <td style="border-bottom: black 1pt solid; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="From2019-10-01to2020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">125,540</ix:nonFraction></span></td>
    <td style="border-bottom: black 1pt solid; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1pt solid"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="From2018-10-012019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">42,389</ix:nonFraction></span></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td></tr>
<tr style="vertical-align: middle; background-color: #CCEEFF">
    <td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40F_eus-gaap--NonoperatingIncomeExpense_i01T_pp0p0_mtNIEz8G1_maILFCOzgOk_zukKWDoUfnbl" style="vertical-align: middle; background-color: white">
    <td style="border-bottom: black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Total
    other income, net</span></td>
    <td style="border-bottom: black 1pt solid; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2019-10-01to2020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,830,426</ix:nonFraction></span></td>
    <td style="border-bottom: black 1pt solid; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1pt solid"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2018-10-012019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,894,150</ix:nonFraction></span></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_404_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_i01T_pp0p0_mtILFCOzgOk_maNILzVJy_zei3MT62VkKa" style="vertical-align: middle; background-color: #CCEEFF">
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Net loss before provision
    for income taxes</span></td>
    <td style="font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2019-10-01to2020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">26,257,806</ix:nonFraction></span></td>
    <td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td>
    <td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2018-10-012019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">26,212,798</ix:nonFraction></span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td></tr>
<tr style="vertical-align: middle; background-color: white">
    <td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_408_eus-gaap--CurrentIncomeTaxExpenseBenefit_iN_pp0p0_di_msNILzVJy_zVJXmbidKks8" style="vertical-align: middle; background-color: #CCEEFF">
    <td style="border-bottom: black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Income
    tax expense, current</span></td>
    <td style="border-bottom: black 1pt solid; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:CurrentIncomeTaxExpenseBenefit" contextRef="From2019-10-01to2020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">22,664</ix:nonFraction></span></td>
    <td style="border-bottom: black 1pt solid; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td>
    <td style="border-bottom: black 1pt solid"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:CurrentIncomeTaxExpenseBenefit" contextRef="From2018-10-012019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">82,181</ix:nonFraction></span></td>
    <td style="border-bottom: black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td></tr>
<tr style="vertical-align: middle; background-color: white">
    <td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40A_eus-gaap--NetIncomeLoss_iT_pp0p0_mtNILzVJy_zfR8yG8ot5M6" style="vertical-align: middle; background-color: #CCEEFF">
    <td style="border-bottom: black 2pt double; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Net
    loss and comprehensive loss</span></td>
    <td style="border-bottom: black 2pt double; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 2pt double; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td>
    <td style="border-bottom: black 2pt double; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2019-10-01to2020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">26,280,470</ix:nonFraction></span></td>
    <td style="border-bottom: black 2pt double; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td>
    <td style="border-bottom: black 2pt double"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 2pt double; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td>
    <td style="border-bottom: black 2pt double; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2018-10-012019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">26,294,979</ix:nonFraction></span></td>
    <td style="border-bottom: black 2pt double; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td></tr>
<tr style="vertical-align: middle; background-color: white">
    <td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40C_eus-gaap--EarningsPerShareBasicAndDilutedAbstract_iB" style="vertical-align: middle; background-color: #CCEEFF">
    <td><span style="font: 10pt Times New Roman, Times, Serif">Net Loss per share</span></td>
    <td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40B_eus-gaap--EarningsPerShareBasicAndDiluted_i01_pii" style="vertical-align: middle; background-color: white">
    <td style="border-bottom: black 2pt double; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Basic
    and diluted</span></td>
    <td style="border-bottom: black 2pt double; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 2pt double; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td>
    <td style="border-bottom: black 2pt double; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="From2019-10-01to2020-09-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.45</ix:nonFraction></span></td>
    <td style="border-bottom: black 2pt double; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td>
    <td style="border-bottom: black 2pt double"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 2pt double; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td>
    <td style="border-bottom: black 2pt double; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="From2018-10-012019-09-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.54</ix:nonFraction></span></td>
    <td style="border-bottom: black 2pt double; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td></tr>
<tr style="vertical-align: middle; background-color: #CCEEFF">
    <td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40A_eus-gaap--EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_iB" style="vertical-align: middle; background-color: white">
    <td colspan="2"><span style="font: 10pt Times New Roman, Times, Serif">Weighted average number of shares
    outstanding</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_400_eus-gaap--WeightedAverageNumberOfShareOutstandingBasicAndDiluted_i01_pii">
    <td style="border-bottom: black 2pt double; vertical-align: middle; text-align: left; background-color: #CCEEFF"><span style="font: 10pt Times New Roman, Times, Serif">Basic
    and diluted</span></td>
    <td style="border-bottom: black 2pt double; vertical-align: middle; background-color: #CCEEFF"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 2pt double; vertical-align: middle; text-align: left; background-color: #CCEEFF"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 2pt double; vertical-align: middle; text-align: right; background-color: #CCEEFF"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="From2019-10-01to2020-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">58,194,894</ix:nonFraction></span></td>
    <td style="border-bottom: black 2pt double; vertical-align: middle; text-align: left; background-color: #CCEEFF"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 2pt double; vertical-align: middle; background-color: #CCEEFF"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 2pt double; vertical-align: middle; text-align: left; background-color: #CCEEFF"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 2pt double; vertical-align: middle; text-align: right; background-color: #CCEEFF"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="From2018-10-012019-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">48,906,470</ix:nonFraction></span></td>
    <td style="vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;&#160;</span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">See
Accompanying Notes to Consolidated Financial Statements&#160;</span></p>


<!-- Field: Page; Sequence: 41; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>ANAVEX
LIFE SCIENCES CORP.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>CONSOLIDATED
STATEMENTS OF CASH FLOWS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">For
the years ended September 30, 2020 and 2019</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>




<table cellpadding="0" cellspacing="0" id="xdx_30C_112_znIr0hv0RYZ8" summary="xdx: Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_498_20191001__20200930_z1FYoCod0Qbl" style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_49D_20181001__20190930_zw46PxgZCn7f" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">2020</span></td><td style="border-bottom: Black 1pt solid; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">2019</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40B_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_iB_zlgFNZWPinU1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Cash Flows used in
    Operating Activities</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40B_eus-gaap--NetIncomeLoss_i01_maCz5k9_zWCY6z5IE6Tj" style="vertical-align: bottom; background-color: White">
    <td style="width: 56%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Net loss</span></td><td style="width: 8%; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="width: 12%; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2019-10-01to2020-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">26,280,470</ix:nonFraction></span></td><td style="width: 1%; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="width: 8%; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="width: 12%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2018-10-012019-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">26,294,979</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td></tr>
<tr id="xdx_40D_eus-gaap--AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_i01B_zZlD67SJM1P9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Adjustments to reconcile
    net loss to net cash used in operations:</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40F_eus-gaap--ShareBasedCompensation_i02_maCz5k9_z8MbAenUtrga" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Stock-based compensation</span></td><td style="font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2019-10-01to2020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,876,906</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2018-10-012019-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,430,873</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40D_ecustom--DeferredCharges_i02_d0_maCz5k9_z1UFWU4Rz6L9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Deferred costs</span></td><td style="font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="avxl:DeferredCharges" contextRef="From2019-10-01to2020-09-30" format="ixt:zerodash" decimals="0" unitRef="USD">&#8212;</ix:nonFraction>&#160;&#160;</span></td><td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="avxl:DeferredCharges" contextRef="From2018-10-012019-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">151,133</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_406_eus-gaap--GainsLossesOnRestructuringOfDebt_i02N_di0_msCz5k9_zE8WAJGfhWY7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Gain on settlement
    of accounts payable</span></td><td style="font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:GainsLossesOnRestructuringOfDebt" contextRef="From2019-10-01to2020-09-30" format="ixt:zerodash" decimals="0" sign="-" unitRef="USD">&#8212;</ix:nonFraction>&#160;&#160;</span></td><td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:GainsLossesOnRestructuringOfDebt" contextRef="From2018-10-012019-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">115,758</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td></tr>
<tr id="xdx_408_eus-gaap--IncreaseDecreaseInOperatingCapitalAbstract_i01B_zpiHVVYoKmmk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Changes in non-cash
    working capital balances related to operations:</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40F_eus-gaap--IncreaseDecreaseInIncomeTaxesReceivable_i02N_di_msCz5k9_zmXEImDZWme1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Incentive and tax receivables</span></td><td style="font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInIncomeTaxesReceivable" contextRef="From2019-10-01to2020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,206,595</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInIncomeTaxesReceivable" contextRef="From2018-10-012019-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">772,388</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td></tr>
<tr id="xdx_40F_eus-gaap--IncreaseDecreaseInPrepaidExpense_i02N_di_msCz5k9_zYziux4EB24l" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Prepaid expenses and
    deposits</span></td><td style="font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidExpense" contextRef="From2019-10-01to2020-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">57,159</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidExpense" contextRef="From2018-10-012019-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">803,196</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"></span></td></tr>
<tr id="xdx_40D_eus-gaap--IncreaseDecreaseInAccountsPayable_i02_maCz5k9_zITFuV3du1Kd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Accounts payable</span></td><td style="font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="From2019-10-01to2020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">465,722</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="From2018-10-012019-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">683,797</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40B_eus-gaap--IncreaseDecreaseInAccruedLiabilities_i02_maCz5k9_z1xeLIehA3mb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 1pt solid; text-align: left; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">Accrued
    liabilities</span></td><td style="border-bottom: Black 1pt solid; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="From2019-10-01to2020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,800,232</ix:nonFraction></span></td><td style="border-bottom: Black 1pt solid; padding-bottom: 1pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="From2018-10-012019-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">587,009</ix:nonFraction></span></td><td style="border-bottom: Black 1pt solid; padding-bottom: 1pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40E_eus-gaap--NetCashProvidedByUsedInOperatingActivities_i02T_mtCz5k9_maCzD5i_zNaXV6Zlx7w8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Net cash used in operating
    activities</span></td><td style="font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2019-10-01to2020-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">21,287,046</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2018-10-012019-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">18,527,117</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_407_eus-gaap--NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_iB_zgBr0mPXYZxb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Cash Flows provided
    by Financing Activities</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_401_eus-gaap--ProceedsFromIssuanceOfCommonStock_i01_maCzP8B_ztlCK71JTIrj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font: 10pt Times New Roman, Times, Serif">Issuance of common shares</span></td><td style="font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2019-10-01to2020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">28,754,198</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2018-10-012019-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,832,109</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40D_eus-gaap--PaymentsOfStockIssuanceCosts_i01N_di0_msCzP8B_z7d6gMaGGFC1" style="vertical-align: bottom; background-color: White">
    <td><span style="font: 10pt Times New Roman, Times, Serif">Share issue costs</span></td><td style="font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="From2019-10-01to2020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">403,764</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="From2018-10-012019-09-30" format="ixt:zerodash" decimals="0" sign="-" unitRef="USD">&#8212;</ix:nonFraction>&#160;&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_404_eus-gaap--PaymentsOfDebtIssuanceCosts_i01N_di0_msCzP8B_z0Xwl76t3LR4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 1pt solid; text-align: left; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">Deferred
    financing charges</span></td><td style="border-bottom: Black 1pt solid; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:PaymentsOfDebtIssuanceCosts" contextRef="From2019-10-01to2020-09-30" format="ixt:zerodash" decimals="0" sign="-" unitRef="USD">&#8212;</ix:nonFraction>&#160;&#160;</span></td><td style="border-bottom: Black 1pt solid; padding-bottom: 1pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:PaymentsOfDebtIssuanceCosts" contextRef="From2018-10-012019-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,000</ix:nonFraction></span></td><td style="border-bottom: Black 1pt solid; padding-bottom: 1pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td></tr>
<tr id="xdx_40B_eus-gaap--NetCashProvidedByUsedInFinancingActivities_i01T_mtCzP8B_maCzD5i_zE4Z94DlEA2l" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Net cash provided by
    financing activities</span></td><td style="font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2019-10-01to2020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">28,350,434</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2018-10-012019-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,782,109</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40B_eus-gaap--CashAndCashEquivalentsPeriodIncreaseDecrease_iT_mtCzD5i_zZopCLnM4F1j" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Increase (decrease)
    in cash and cash equivalents during the period</span></td><td style="font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease" contextRef="From2019-10-01to2020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,063,388</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease" contextRef="From2018-10-012019-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">745,008</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td></tr>
<tr id="xdx_404_eus-gaap--Cash_iS_pp0p0_zsV2oJwDUDKk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">Cash
    and cash equivalents, beginning of year</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:Cash" contextRef="AsOf2019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">22,185,630</ix:nonFraction></span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:Cash" contextRef="AsOf2018-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">22,930,638</ix:nonFraction></span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_405_eus-gaap--Cash_iE_pp0p0_zJHOSuiiiuKk" style="vertical-align: bottom; background-color: White">
    <td style="border-top: Black 1pt solid; border-bottom: Black 2.5pt double; text-align: left; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">Cash
    and cash equivalents, end of year</span></td><td style="border-top: Black 1pt solid; border-bottom: Black 2.5pt double; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-top: Black 1pt solid; border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="border-top: Black 1pt solid; border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:Cash" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">29,249,018</ix:nonFraction></span></td><td style="border-top: Black 1pt solid; border-bottom: Black 2.5pt double; padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-top: Black 1pt solid; border-bottom: Black 2.5pt double; font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-top: Black 1pt solid; border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="border-top: Black 1pt solid; border-bottom: Black 2.5pt double; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:Cash" contextRef="AsOf2019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">22,185,630</ix:nonFraction></span></td><td style="border-top: Black 1pt solid; border-bottom: Black 2.5pt double; padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">See
Accompanying Notes to Consolidated Financial Statements</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 42; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>ANAVEX
LIFE SCIENCES CORP.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">CONSOLIDATED
STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">For
the years ended September 30, 2020 and 2019</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"></p>




<table cellpadding="0" cellspacing="0" id="xdx_301_114_zdocmruSg7N" summary="xdx: Statement - CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS&apos; EQUITY" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_4B2_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_znydQpNW0rAi" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_4BD_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_ziY2pjgO0AFj" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_4BA_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_zuoQlKaZwGRi" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_4B0_zxHlu8jDI6b" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="text-align: center"></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="7" style="border-bottom: Black 1pt solid; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Common
    Stock</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Additional
    Paid-in</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Accumulated</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Shares</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Par
    Value</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Capital</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Deficit</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Total</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_43A_c20181001__20190930_eus-gaap--StockholdersEquity_iS_zRadklKX9ZH3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 35%"><span style="font: 10pt Times New Roman, Times, Serif">Balance, September 30, 2018</span></td><td style="width: 2%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_eus-gaap--SharesOutstanding_iS_pii_c20181001__20190930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zci5fv3bn6U1" title="Balance Beginning (in shares)" style="width: 9%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2018-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">45,933,472</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2018-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">45,935</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2018-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">129,377,542</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 2%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2018-09-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">107,101,781</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="width: 2%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2018-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">22,321,696</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Shares issued under
    2015 Purchase Agreement</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_406_ecustom--StockIssuedDuringPeriodValueAcquisitions2_zc8krNGb25Q" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Purchase shares</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_988_ecustom--StockIssuedDuringPeriodSharesAcquisitions2_pii_c20181001__20190930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z3tZ57Py1One" title="Shares issued under 2015 Purchase Agreement - Purchase shares (in shares)" style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="avxl:StockIssuedDuringPeriodSharesAcquisitions2" contextRef="From2018-10-012019-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,848,995</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="avxl:StockIssuedDuringPeriodValueAcquisitions2" contextRef="From2018-10-012019-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,849</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="avxl:StockIssuedDuringPeriodValueAcquisitions2" contextRef="From2018-10-012019-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,192,755</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0249">&#8212;</span>&#160;&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="avxl:StockIssuedDuringPeriodValueAcquisitions2" contextRef="From2018-10-012019-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,197,604</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40E_ecustom--CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2_zMZbUF01vtuh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Commitment shares</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98F_ecustom--CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2_pii_c20181001__20190930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zVFD7tOAE87k" title="Shares issued under 2015 Purchase Agreement - Commitment shares (in shares)" style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="avxl:CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2" contextRef="From2018-10-012019-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">23,701</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2" contextRef="From2018-10-012019-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">24</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2" contextRef="From2018-10-012019-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">24</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0256">&#8212;</span>&#160;&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0257">&#8212;</span>&#160;&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Shares issued under
    2019 Purchase Agreement</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40C_eus-gaap--StockIssuedDuringPeriodValueAcquisitions_zBruQAkPqwpa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Purchase shares</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_pii_c20181001__20190930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zBbeqed9g6x2" title="Shares issued under 2019 Purchase Agreement - Purchase shares (in shares)" style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" contextRef="From2018-10-012019-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,500,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" contextRef="From2018-10-012019-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,500</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" contextRef="From2018-10-012019-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,633,005</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0263">&#8212;</span>&#160;&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" contextRef="From2018-10-012019-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,634,505</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40A_ecustom--CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Commitment shares</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_987_ecustom--CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement1_pii_c20181001__20190930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z4513ATrsj8k" title="Shares issued under 2019 Purchase Agreement - Commitment shares (in shares)" style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="avxl:CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement1" contextRef="From2018-10-012019-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">339,415</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1" contextRef="From2018-10-012019-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">339</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1" contextRef="From2018-10-012019-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">339</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_406_ecustom--SharesIssuedPursuantToCashlessExerciseOfWarrants_i_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Shares issued pursuant
    to cashless exercise of warrants</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_ecustom--SharesIssuedPursuantToCashlessExerciseOfWarrantsInShares_pii_c20181001__20190930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_za7PzHgecY1b" title="Shares issued pursuant to cashless exercise of warrants (in shares)" style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="avxl:SharesIssuedPursuantToCashlessExerciseOfWarrantsInShares" contextRef="From2018-10-012019-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,938</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="avxl:SharesIssuedPursuantToCashlessExerciseOfWarrants" contextRef="From2018-10-012019-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="avxl:SharesIssuedPursuantToCashlessExerciseOfWarrants" contextRef="From2018-10-012019-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5</ix:nonFraction>)</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0277">&#8212;</span>&#160;&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0278">&#8212;</span>&#160;&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40D_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_zrDM9htMHJpe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font: 10pt Times New Roman, Times, Serif">Share based compensation</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#8212;&#160;&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0282">&#8212;</span>&#160;&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2018-10-012019-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,430,873</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0284">&#8212;</span>&#160;&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2018-10-012019-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,430,873</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40D_eus-gaap--NetIncomeLoss_zwKz7q3oBJi4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">Net
    loss</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#8212;&#160;&#160;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0287">&#8212;</span>&#160;&#160;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0288">&#8212;</span>&#160;&#160;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2018-10-012019-09-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">26,294,979</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2018-10-012019-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">26,294,979</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td></tr>
<tr id="xdx_43F_c20191001__20200930_eus-gaap--StockholdersEquity_iS_zv6zJolSC8Hh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font: 10pt Times New Roman, Times, Serif">Balance, September 30, 2019</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_eus-gaap--SharesOutstanding_iS_pii_c20191001__20200930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zNSRttGaeGXb" title="Balance Beginning (in shares)" style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2019-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">52,650,521</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2019-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">52,652</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2019-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">153,633,807</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2019-09-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">133,396,760</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2019-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,289,699</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Shares issued under
    2019 Purchase Agreement</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40E_eus-gaap--StockIssuedDuringPeriodValueAcquisitions_zJCcYeNfgBsc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Purchase shares</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_pii_c20191001__20200930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zwTqyzuUTGDj" title="Shares issued under 2019 Purchase Agreement - Purchase shares (in shares)" style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" contextRef="From2019-10-012020-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,564,584</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" contextRef="From2019-10-012020-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,565</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" contextRef="From2019-10-012020-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">21,246,733</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0301">&#8212;</span>&#160;&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" contextRef="From2019-10-01to2020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">21,254,298</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40D_ecustom--CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1_zKVTrM3pAMnj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Commitment shares</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_ecustom--CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement1_pii_c20191001__20200930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zF7IAYh1ZgQg" title="Shares issued under 2019 Purchase Agreement - Commitment shares (in shares)" style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="avxl:CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement1" contextRef="From2019-10-012020-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">68,943</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1" contextRef="From2019-10-012020-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">69</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1" contextRef="From2019-10-012020-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">69</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0308">&#8212;</span>&#160;&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0309">&#8212;</span>&#160;&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_409_ecustom--SharesIssuedPursuantToCashlessExerciseOfOptions_iP3custom--SharesIssuedPursuantToCashlessExerciseOfWarrants_zeMuJ7sTz0El" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Shares issued pursuant
    to cashless exercise of options</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_980_ecustom--SharesIssuedPursuantToCashlessExerciseOfOptionsInShares_iP3custom--SharesIssuedPursuantToCashlessExerciseOfOptions_pii_c20191001__20200930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zmKYqoqqJyBa" title="Shares issued pursuant to cashless exercise of options (in shares)" style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="avxl:SharesIssuedPursuantToCashlessExerciseOfOptionsInShares" contextRef="From2019-10-012020-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">721</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="avxl:SharesIssuedPursuantToCashlessExerciseOfOptions" contextRef="From2019-10-012020-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="avxl:SharesIssuedPursuantToCashlessExerciseOfOptions" contextRef="From2019-10-012020-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0315">&#8212;</span>&#160;&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0316">&#8212;</span>&#160;&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_407_ecustom--SharesIssuedDuringPeriodValueUnderSalesAgreement_iP3custom--SharesIssuedPursuantToCashlessExerciseOfOptionsInShares_zFbLs0iRgWoa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Shares issued under
    Sales Agreement, net of shares issue costs</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_984_ecustom--SharesIssuedDuringPeriodSharesUnderSalesAgreement_iP3custom--SharesIssuedDuringPeriodValueUnderSalesAgreement_pii_c20191001__20200930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zsOlaLoJ5Uo1" title="Shares issued under Sales Agreement, net of shares issue costs (in shares)" style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="avxl:SharesIssuedDuringPeriodSharesUnderSalesAgreement" contextRef="From2019-10-012020-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,760,429</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="avxl:SharesIssuedDuringPeriodValueUnderSalesAgreement" contextRef="From2019-10-012020-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,760</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="avxl:SharesIssuedDuringPeriodValueUnderSalesAgreement" contextRef="From2019-10-012020-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,094,376</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="avxl:SharesIssuedDuringPeriodValueUnderSalesAgreement" contextRef="From2019-10-01to2020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,096,136</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40D_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_zZKSPc7qIrI9" style="vertical-align: bottom; background-color: White">
    <td><span style="font: 10pt Times New Roman, Times, Serif">Share based compensation</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#8212;&#160;&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0327">&#8212;</span>&#160;&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2019-10-012020-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,876,906</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0329">&#8212;</span>&#160;&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2019-10-01to2020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,876,906</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40B_eus-gaap--NetIncomeLoss_zXNuw85mokok" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">Net
    loss</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#8212;&#160;&#160;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0332">&#8212;</span>&#160;&#160;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0333">&#8212;</span>&#160;&#160;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2019-10-012020-09-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">26,280,470</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2019-10-01to2020-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">26,280,470</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td></tr>
<tr id="xdx_434_c20191001__20200930_eus-gaap--StockholdersEquity_iE_zjSd5zWXKpD1" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">Balance, September
    30, 2020</span></td><td style="padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_987_eus-gaap--SharesOutstanding_iE_pii_c20191001__20200930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zKcaX9K7B9pk" title="Balance Ending (in shares)" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2020-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">62,045,198</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">62,047</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">186,851,752</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-09-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">159,677,230</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">27,236,569</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">See
Accompanying Notes to Consolidated Financial Statements</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<!-- Field: Page; Sequence: 24 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->F-4<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

    <ix:nonNumeric contextRef="From2019-10-01to2020-09-30" escape="true" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"><p id="xdx_808_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_z75PDRB2VO23" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: top; text-align: left">
    <td style="width: 7%"><span style="font: 10pt Times New Roman, Times, Serif">Note 1</span></td>
    <td style="width: 93%"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline"><span id="xdx_824_zUqaA1Rg7Ipk">Business Description
    and Basis of Presentation</span></span></span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Business</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Anavex
Life Sciences Corp. (&#8220;Anavex&#8221; or the &#8220;Company&#8221;) is a clinical stage biopharmaceutical company engaged
in the development of differentiated therapeutics by applying precision medicine to central nervous system (&#8220;CNS&#8221;)
diseases with high unmet need. Anavex analyzes genomic data from clinical studies to identify biomarkers, which are used to select
patients that will receive the therapeutic benefit for the treatment of neurodegenerative and neurodevelopmental diseases. The
Company&#8217;s lead compound ANAVEX<sup>&#174;</sup>2-73 is being developed to treat Alzheimer&#8217;s disease, Parkinson&#8217;s
disease and potentially other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological
monogenic disorder caused by mutations in the X-linked gene, methyl-CpG-binding protein 2 (&#8220;MECP2&#8221;).</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 12pt 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Basis
of Presentation</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">These
consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission
(&#8220;SEC&#8221;) and the instructions to Form 10-K and have been prepared under the accounting principles generally accepted
in the United States of America (&#8220;U.S. GAAP&#8221;).</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Liquidity</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">All
of the Company&#8217;s potential drug compounds are in the clinical development stage and the Company cannot be certain that its
research and development efforts will be successful or, if successful, that its potential drug compounds will ever be approved
for sales to pharmaceutical companies or generate commercial revenues. To date, we have not generated any revenues from our operations.
The Company expects the business to continue to experience negative cash flows for the foreseeable future and cannot predict when,
if ever, our business might become profitable.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company believes that its existing cash and cash equivalents, along with existing financial commitments from third parties, will
be sufficient to meet its cash commitments for in excess of two years after the date that these consolidated financial statements
are issued. The process of drug development can be costly, and the timing and outcomes of clinical trials is uncertain.&#160;The
assumptions upon which the Company has based its estimates are routinely evaluated and may be subject to change.&#160;The actual
amount of the Company&#8217;s expenditures will vary depending upon a number of factors including but not limited to the design,
timing and duration of future clinical trials, the progress of the Company&#8217;s research and development programs and the level
of financial resources available. The Company has the ability to adjust its operating plan spending levels based on the timing
of future clinical trials.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 12pt 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Other
than our rights related to the 2019 Purchase Agreement and the Sales Agreement (each as defined below in Note 4), there can be
no assurance that additional financing will be available to us when needed or, if available, that it can be obtained on commercially
reasonable terms. If the Company is not able to obtain the additional financing on a timely basis, if and when it is needed, it
will be forced to delay or scale down some or all of its research and development activities.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
December 2019, a novel strain of coronavirus, COVID-19, was reported to have surfaced in Wuhan, China. In March 2020, the World
Health Organization (&#8220;WHO&#8221;) declared COVID-19 to be a global pandemic as a result of the rapid spread of the virus
beyond its point of origin.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:exclude><!-- Field: Page; Sequence: 42; Value: 1 -->
    <div id="xdx_234_zQBf0b4YFlb3" style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" id="xdx_23F_zaZ4XCeXmCZj" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td><td id="xdx_236_zVTGKHKGvVxi" style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_23B_zdnPynoIoHjf" style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p id="xdx_23A_zqDxNX26aMQd" style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

    <ix:exclude><p id="xdx_23A_zPfIPDSA7Ce1" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p></ix:exclude>

<ix:exclude><table cellpadding="0" cellspacing="0" id="xdx_232_zUBTyQJy6Yt" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: top; text-align: left"><td style="width: 7%"><span style="font: 10pt Times New Roman, Times, Serif">Note
                                         1</span></td>
    <td style="width: 93%"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Business Description and
    Basis of Presentation </span>- (continued)</span></td></tr>
</table></ix:exclude>

<ix:exclude><p id="xdx_238_zTFlsxlWaLNi" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p></ix:exclude>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
global outbreak of COVID-19 continues to rapidly evolve as of the date these consolidated financial statements are issued. As
such, it is uncertain as to the full magnitude that the outbreak will have on the Company&#8217;s financial condition and future
results of operations. Management is actively monitoring the global situation on its business, including on its clinical trials
and operations and financial condition. The effects of COVID-19 did not have a material impact on the Company&#8217;s result of
operations or financial condition for the year ended September 30, 2020. However, given the daily evolution of the COVID-19 situation,
and the global responses to curb its spread, the Company is not able to estimate the effects COVID-19 may have on its future results
of operations or financial condition.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 12pt 42.6pt; text-align: justify; text-indent: -0.05pt"><span style="font: 10pt Times New Roman, Times, Serif">On
March 27, 2020, the President of the United States signed into law the &#8220;Coronavirus Aid, Relief, and Economic Security (CARES)
Act.&#8221; The CARES Act, among other things, includes provisions relating to refundable payroll tax credits, deferment of employer
side social security payments, net operating loss carryback periods, alternative minimum tax credit refunds, modifications to
the net interest deduction limitations, increased limitations on qualified charitable contributions, and technical corrections
to tax depreciation methods for qualified improvement property. The enactment of the CARES Act did not have any material impact
on the Company&#8217;s consolidated financial statements or deferred tax assets or liabilities.</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2019-10-01to2020-09-30" escape="true" name="us-gaap:SignificantAccountingPoliciesTextBlock"><p id="xdx_801_eus-gaap--SignificantAccountingPoliciesTextBlock_zPAEJlyL59U1" style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: top; text-align: left"><td style="width: 7%"><span style="font: 10pt Times New Roman, Times, Serif">Note
                                         2</span></td>
    <td style="width: 93%"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline"><span id="xdx_82A_znJJvmOlL31k">Summary of Significant
    Accounting Policies</span></span></span></td></tr>
</table>

<ix:nonNumeric contextRef="From2019-10-01to2020-09-30" escape="true" name="us-gaap:UseOfEstimates"><p id="xdx_84D_eus-gaap--UseOfEstimates_zqf4ghFK9O8l" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 42.55pt"></td><td style="width: 18pt"><span style="font: 10pt Times New Roman, Times, Serif">a)</span></td><td style="text-align: justify"><span id="xdx_869_zEAgumzB06sa" style="font: 10pt Times New Roman, Times, Serif">Use
                                         of Estimates</span></td></tr></table>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify; margin-left: 42.55pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect
the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenue and
expenses in the reporting period. The Company regularly evaluates estimates and assumptions related to accounting for research
and development costs, incentive income receivable, valuation and recoverability of deferred tax assets, asset impairment, stock-based
compensation and loss contingencies. The Company bases its estimates and assumptions on current facts, historical experience and
various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making
judgments about the book values of assets and liabilities and the accrual of costs and expenses that are not readily apparent
from other sources. The actual results experienced by the Company may differ materially and adversely from the Company&#8217;s
estimates. To the extent there are material differences between the estimates and the actual results, future results of operations
will be affected.</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2019-10-01to2020-09-30" escape="true" name="us-gaap:ConsolidationPolicyTextBlock"><p id="xdx_84E_eus-gaap--ConsolidationPolicyTextBlock_zhaxDESkVTBc" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>



<table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 42.5pt"></td><td style="width: 18pt"><span style="font: 10pt Times New Roman, Times, Serif">b)</span></td><td id="xdx_86C_zg9HiwiTiKfl" style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Principles
                                         of Consolidation</span></td></tr></table>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify; margin-left: 42.55pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">These
consolidated financial statements include the accounts of Anavex Life Sciences Corp. and its wholly-owned subsidiaries, Anavex
Australia Pty Limited. (&#8220;Anavex Australia&#8221;), a company incorporated under the laws of Australia, Anavex Germany GmbH,
a company incorporated under the laws of Germany, and Anavex Canada Ltd., a company incorporated under the laws of the Province
of Ontario, Canada. All inter-company transactions and balances have been eliminated.</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2019-10-01to2020-09-30" escape="true" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock"><p id="xdx_84B_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zPqyXkDd3gml" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 42.55pt"></td><td style="width: 18pt"><span style="font: 10pt Times New Roman, Times, Serif">c)</span></td><td id="xdx_861_zvIIr6UoDIAj" style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Cash
                                         and equivalents</span></td></tr></table>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify; margin-left: 42.55pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company considers only those investments which are highly liquid, readily convertible to cash and that mature within three months
from the date of purchase to be cash equivalents.</span></p>


<ix:exclude><!-- Field: Page; Sequence: 42; Value: 1 -->
    <div id="xdx_23D_zP3x55qazyqb" style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" id="xdx_234_zzuNwuNhFyuk" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td><td id="xdx_23C_z91H4KNBF6J" style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_234_znSiM1UPBDl1" style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p id="xdx_239_zScwBLrKUrd8" style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_231_zvQnDwupE53b" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p></ix:exclude>

<ix:exclude><table cellpadding="0" cellspacing="0" id="xdx_233_zbwADB2pZ05h" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: top; text-align: left"><td style="width: 7%"><span style="font: 10pt Times New Roman, Times, Serif">Note
                                         2</span></td>
    <td style="width: 93%"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Summary of Significant
    Accounting Policies </span>- (continued)</span></td></tr>
</table></ix:exclude>

</ix:nonNumeric><ix:nonNumeric contextRef="From2019-10-01to2020-09-30" escape="true" name="us-gaap:ResearchAndDevelopmentExpensePolicy"><p id="xdx_847_eus-gaap--ResearchAndDevelopmentExpensePolicy_zYhMikPyjcA6" style="font: 10pt Arial, Helvetica, Sans-Serif; text-indent: 40pt; text-align: left; margin-top: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 42.55pt"></td><td style="width: 18pt"><span style="font: 10pt Times New Roman, Times, Serif">d)</span></td><td id="xdx_86F_zXm5kmXnzwQa" style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Research
                                         and Development Expenses</span></td></tr></table>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i></i></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Research
and development costs are expensed as incurred. These expenses are comprised of the costs of the Company&#8217;s proprietary research
and development efforts, including preclinical studies, clinical trials, manufacturing costs, employee salaries and benefits and
stock based compensation expense, contract services including external research and development expenses incurred under arrangements
with third parties such as contract research organizations (&#8220;CROs&#8221;), facilities costs, overhead costs and other related
expenses. Milestone payments made by the Company to third parties are expensed when the specific milestone has been achieved.
Manufacturing costs are expensed as incurred in accordance with Accounting Standard Codification (&#8220;ASC&#8221;) 730, Research
and Development, as these materials have no alternative future use outside of their intended use.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Nonrefundable
advance payments for goods or services that will be used or rendered for future research and development activities are deferred
and amortized over the period that the goods are delivered, or the related services are performed, subject to an assessment of
recoverability. The Company makes estimates of costs incurred in relation to external CROs, and clinical site costs. The Company
analyzes the progress of clinical trials, including levels of patient enrollment, invoices received and contracted costs when
evaluating the adequacy of the amount expensed and the related prepaid asset and accrued liability. Significant judgments and
estimates must be made and used in determining the accrued balance and expense in any accounting period. The Company reviews and
accrues CRO expenses and clinical trial study expenses based on work performed and relies upon estimates of those costs applicable
to the stage of completion of a study. Accrued CRO costs are subject to revisions as such trials progress to completion. Revisions
are charged to expense in the period in which the facts that give rise to the revision become known. With respect to clinical
site costs, the financial terms of these agreements are subject to negotiation and vary from contract to contract. Payments under
these contracts may be uneven and depend on factors such as the achievement of certain events, the successful recruitment of patients,
the completion of portions of the clinical trial or similar conditions. The objective of our policy is to record expenses in our
financial statements based on the actual services received and efforts expended. As such, expense accruals related to clinical
site costs are recognized based on our estimate of the degree of completion of the event or events specified in the specific clinical
study or trial contract.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
addition, the Company incurs expenses in respect of intellectual property costs relating to patents and trademarks. The probability
of success and length of time to develop commercial applications of the compounds subject to the underlying patent and trademark costs
is difficult to determine and numerous risks and uncertainties exist with respect to the timely completion of the development
projects. There is no assurance the compounds subject to the underlying patents and trademarks will ever be successfully commercialized.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Due
to these risks and uncertainties, the patent and trademark costs do not meet the definition of an asset and thus are expensed
as incurred within general and administrative expenses.</span></p>

<ix:exclude><p id="xdx_231_zy9SxVtbCfZ8" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p></ix:exclude>


<ix:exclude><!-- Field: Page; Sequence: 42; Value: 1 -->
    <div id="xdx_23D_z8IEIEeQv0pe" style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" id="xdx_23D_zADcSQkGr9Oc" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td><td id="xdx_237_zUfhbitxSmn3" style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_234_zgUW3fveEW6h" style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p id="xdx_237_zAiXZAXMFIC7" style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_238_zHuJcABZ1Vnd" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p></ix:exclude>

<ix:exclude><table cellpadding="0" cellspacing="0" id="xdx_239_z6hHOnv6sVnf" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: top; text-align: left"><td style="width: 7%"><span style="font: 10pt Times New Roman, Times, Serif">Note
                                         2</span></td>
    <td style="width: 93%"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Summary of Significant
    Accounting Policies </span>- (continued)</span></td></tr>
</table></ix:exclude>

</ix:nonNumeric><ix:nonNumeric contextRef="From2019-10-01to2020-09-30" escape="true" name="us-gaap:RevenueRecognitionIncentives"><p id="xdx_84E_eus-gaap--RevenueRecognitionIncentives_zuSeUQhdS7m6" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-indent: 40pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 42.55pt"></td><td style="width: 18pt"><span style="font: 10pt Times New Roman, Times, Serif">e)</span></td><td id="xdx_861_zyUp2pHZqMX2" style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Research
                                         and Development Incentive Income</span></td></tr></table>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i></i></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company is eligible to obtain certain research and development tax credits, including the New York City Biotechnology Tax Credit
(&#8220;NYC Biotech credit&#8221;), and the Australian research and development tax incentive credit (the &#8220;Australia R&amp;D
credit&#8221;) through a program administered through the Australian Tax Office (the &#8220;ATO&#8221;), which provides for a
cash refund based on a percentage of certain research and development activities undertaken in Australia by the Company&#8217;s
wholly owned subsidiary, Anavex Australia Pty Ltd. (&#8220;Anavex Australia&#8221;). <span id="xdx_90F_ecustom--CashRefundAvailableDescription_c20191001__20200930_zYDIUwSyjgIe" title="Cash Refund Available description"><ix:nonNumeric contextRef="From2019-10-01to2020-09-30" name="avxl:CashRefundAvailableDescription">The cash refund is available to eligible
companies with an annual aggregate revenue of less than $20.0 million Australian during the reimbursable period.</ix:nonNumeric></span></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
tax incentives are available on the basis of specific criteria with which the Company must comply. Although the tax incentive
may be administered through the local tax authority, the Company has accounted for the incentives outside of the scope of ASC
Topic 740, Income Taxes (&#8220;ASC 740&#8221;), since the incentives are not linked to the Company&#8217;s taxable income and
can be realized regardless of whether the Company has generated taxable income in the respective jurisdictions.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">With
respect to the Australia R&amp;D credit, Anavex Australia may be eligible to receive the cash refund for certain research and
development expenses incurred by Anavex Australia outside of Australia, to the extent such expenses are pre-approved by the Australian
authority pursuant to an advanced overseas finding application. The Company accrues for the amount of cash refund it expects to
receive in relation to research and development expenses outside of Australia only to the extent it has received advanced approval
from the Department of Industry, Innovation and Science in Australia, pursuant to an approved advanced overseas finding application.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company recognizes the amount of cash refund it expects to receive related to the NYC Biotech credit and Australian research and
development tax incentive program when there is reasonable assurance that the cash refund will be received, when the relevant
expenditures have been incurred, and when the amount can be reliably measured. This amount is included in Incentive and tax receivables
in the accompanying consolidated balance sheets.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
addition, Anavex Australia and Anavex Canada incur Goods and Services Tax (GST) on certain services provided by local vendors.
As a domestic entity in those jurisdictions, Anavex Australia and Anavex Canada are entitled to a refund of the GST paid. Similarly,
Anavex Germany incurs Value Added Tax (VAT) on certain services provided by local vendors, to which it is entitled to a refund
of such VAT paid. The Company&#8217;s estimate of the amount of cash refund it expects to receive related to GST and VAT incurred
is included in Incentive and tax receivables in the accompanying consolidated balance sheets.</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2019-10-01to2020-09-30" escape="true" name="us-gaap:EarningsPerSharePolicyTextBlock"><p id="xdx_847_eus-gaap--EarningsPerSharePolicyTextBlock_z9bhd4heuAOg" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 42.55pt"></td><td style="width: 18pt"><span style="font: 10pt Times New Roman, Times, Serif">f)</span></td><td id="xdx_863_z5HZwLOz94rl" style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Basic
                                         and Diluted Loss per Share</span></td></tr></table>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify; margin-left: 42.55pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Basic
income/(loss) per common share is computed by dividing net income/(loss) available to common stockholders by the weighted average
number of common shares outstanding during the period. Diluted income/(loss) per common share is computed by dividing net income/(loss)
available to common stockholders by the sum of (1) the weighted-average number of common shares outstanding during the period,
(2) the dilutive effect of the assumed exercise of options and warrants using the treasury stock method and (3) the dilutive effect
of other potentially dilutive securities. For purposes of the diluted net loss per share calculation, options and warrants are
potentially dilutive securities and are excluded from the calculation of diluted net loss per share because their effect would
be anti-dilutive.</span></p>


<ix:exclude><!-- Field: Page; Sequence: 42; Value: 1 -->
    <div id="xdx_234_zRBXKPS6TYre" style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" id="xdx_238_ztnODtepOjM6" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td><td id="xdx_237_zcIcW2oUO1tc" style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_233_zWsLTDlvHjD1" style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p id="xdx_235_zmjTHxBNTsK5" style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_234_zhCN7OqQhc22" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p></ix:exclude>

<ix:exclude><table cellpadding="0" cellspacing="0" id="xdx_230_zTTq7tnzEr8f" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: top; text-align: left"><td style="width: 7%"><span style="font: 10pt Times New Roman, Times, Serif">Note
                                         2</span></td>
    <td style="width: 93%"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Summary of Significant
    Accounting Policies </span>- (continued)</span></td></tr>
</table></ix:exclude>

<ix:exclude><p id="xdx_23A_zBK2Mc90gSa3" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;&#160;</span></p></ix:exclude>

<ix:exclude><table cellpadding="0" cellspacing="0" id="xdx_23D_zy4Mh8QZWWva" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 42.55pt"></td><td style="width: 18pt"><span style="font: 10pt Times New Roman, Times, Serif">f)</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Basic
                                         and Diluted Loss per Share &#8211; (continued)</span></td></tr></table></ix:exclude>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">As
of September 30, 2020, diluted loss per share excludes <span id="xdx_90A_eus-gaap--IncrementalCommonSharesAttributableToCallOptionsAndWarrants_c20191001__20200930_pii" title="Loss per share for potentially dilutive common shares"><ix:nonFraction name="us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants" contextRef="From2019-10-01to2020-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,576,266</ix:nonFraction></span> (2019 &#8211; <span id="xdx_900_eus-gaap--IncrementalCommonSharesAttributableToCallOptionsAndWarrants_c20181001__20190930_pii" title="Loss per share for potentially dilutive common shares"><ix:nonFraction name="us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants" contextRef="From2018-10-012019-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,812,933</ix:nonFraction></span>) potentially dilutive common shares
related to outstanding options and warrants, as their effect was anti-dilutive.</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2019-10-01to2020-09-30" escape="true" name="us-gaap:FairValueOfFinancialInstrumentsPolicy"><p id="xdx_849_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zHovEUI4h1bd" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 42.55pt"></td><td style="width: 18pt"><span style="font: 10pt Times New Roman, Times, Serif">g)</span></td><td id="xdx_86D_zNfEIBZhcqt3" style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Financial
                                         Instruments</span></td></tr></table>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify; margin-left: 42.55pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
book value of the Company&#8217;s financial instruments, consisting of cash and equivalents, incentive and tax receivables, and
accounts payable and accrued liabilities approximate their fair value due to the short-term maturity of such instruments. Unless
otherwise noted, it is management&#8217;s opinion that the Company is not exposed to significant interest, currency or credit
risks arising from these financial instruments.</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2019-10-01to2020-09-30" escape="true" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"><p id="xdx_845_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zCbIp40N19gf" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 42.55pt"></td><td style="width: 18pt"><span style="font: 10pt Times New Roman, Times, Serif">h)</span></td><td id="xdx_863_zVPPTBc3bS78" style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Foreign
                                         Currency Translation</span></td></tr></table>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify; margin-left: 42.55pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
functional currency of the Company is the US dollar. Monetary items denominated in a foreign currency are translated into US dollars
at exchange rates prevailing at the balance sheet date and non-monetary items are translated at exchange rates prevailing when
the assets were acquired, or obligations incurred. Foreign currency denominated expense items are translated at exchange rates
prevailing on the transaction date. Unrealized gains or losses arising from the translations are credited or charged to income
in the period in which they occur.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify; margin-left: 42.55pt"><span style="font: 10pt Times New Roman, Times, Serif">The
Company has determined that the functional currency of Anavex Australia Pty Limited, Anavex Germany GmbH, and Anavex Canada Ltd.
is the US dollar.</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2019-10-01to2020-09-30" escape="true" name="us-gaap:SegmentReportingPolicyPolicyTextBlock"><p id="xdx_84C_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zTUojE9iNMp7" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 42.55pt"></td><td style="width: 18pt"><span style="font: 10pt Times New Roman, Times, Serif">i)</span></td><td id="xdx_86C_znNVXLYjswP3"><span style="font: 10pt Times New Roman, Times, Serif">Segment
                                         and Geographic Reporting</span></td></tr></table>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify; margin-left: 42.55pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Operating
segments are defined as components of an enterprise for which separate discrete information is available for evaluation by the
chief operating decision maker or decision-making group, in deciding how to allocate resources and in assessing performance. The
Company views its operations and manages its business as one operating segment, which is the business of developing novel therapies
for the management of CNS diseases.</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2019-10-01to2020-09-30" escape="true" name="avxl:GrantIncomePolicyTextBlock"><p id="xdx_849_ecustom--GrantIncomePolicyTextBlock_zbwzoBiBjCk8" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top">
<td style="width: 42.55pt"></td><td style="width: 18pt"><span style="font: 10pt Times New Roman, Times, Serif">j)</span></td><td id="xdx_86C_zsAUiTgEYkNb" style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Grant
                                         Income</span></td></tr></table>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Grant
income is recognized at the fair value of the grant when it is received, and all substantive conditions have been satisfied. Grants
received from government and other agencies in advance of the specific research and development costs to which they relate are
deferred and recognized in the consolidated statement of operations in the period they are earned and when the related research
and development costs are incurred.</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2019-10-01to2020-09-30" escape="true" name="us-gaap:IncomeTaxPolicyTextBlock"><p id="xdx_84A_eus-gaap--IncomeTaxPolicyTextBlock_zy1jE2n57rK2" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 42.55pt"></td><td style="width: 18pt"><span style="font: 10pt Times New Roman, Times, Serif">k)</span></td><td id="xdx_869_zPTgLOqDBPqg" style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Income
                                         Taxes</span></td></tr></table>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify; margin-left: 42.55pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company follows the provisions of ASC 740, which requires the asset and liability method of accounting for income taxes. Under
the asset and liability method, deferred tax assets and liabilities are recognized for the future tax consequences attributable
to temporary differences between the financial statements carrying amounts of existing assets and liabilities and their respective
tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the
years in which those temporary differences are expected to be recovered or settled.</span></p>

<ix:exclude><!-- Field: Page; Sequence: 42; Value: 1 -->
    <div id="xdx_23C_zkII2JSttjAj" style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" id="xdx_231_z6Jytcf8QJ5j" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td><td id="xdx_23B_zCUlErTZToAc" style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_23D_zN6AEkdOtK8f" style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p id="xdx_238_zH78UZW6uFA9" style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

    <ix:exclude><table cellpadding="0" cellspacing="0" id="xdx_237_zbeak0Zbg4a8" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: top; text-align: left">
    <td style="width: 7%"><span style="font: 10pt Times New Roman, Times, Serif">Note 2</span></td>
    <td style="width: 93%"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Summary of Significant
    Accounting Policies </span>- (continued)</span></td></tr>
</table></ix:exclude>

<ix:exclude><p id="xdx_236_zGCYaUqZZv94" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p></ix:exclude>

<ix:exclude><p id="xdx_239_zqRy4myL4d41" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"></span></p></ix:exclude>

<ix:exclude><table cellpadding="0" cellspacing="0" id="xdx_23C_zjO0MyOxa1Ab" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 42.55pt"></td><td style="width: 18pt"><span style="font: 10pt Times New Roman, Times, Serif">k)</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Income
                                         Taxes &#8211; (continued) </span></td></tr></table></ix:exclude>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify; margin-left: 42.55pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: justify; margin-right: 0; margin-left: 42.55pt"><span style="font: 10pt Times New Roman, Times, Serif">The
Company follows the provisions of ASC 740 regarding accounting for uncertainty in income taxes. The Company initially recognizes
tax positions in the financial statements when it is more likely than not the position will be sustained upon examination by the
tax authorities. Such tax positions are initially and subsequently measured as the largest amount of tax benefit that is greater
than 50% likely of being realized upon ultimate settlement with the tax authority assuming full knowledge of the position and
all relevant facts. Application requires numerous estimates based on available information. The Company considers many factors
when evaluating and estimating its tax positions and tax benefits, and its recognized tax positions and tax benefits may not accurately
anticipate actual outcomes. As additional information is obtained, there may be a need to periodically adjust the recognized tax
positions and tax benefits. These periodic adjustments may have a material impact on the consolidated statements of operations.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify; margin-left: 42.55pt"><span style="font: 10pt Times New Roman, Times, Serif">The
Company recognizes interest and penalties related to current income tax expense on the interest income, net line, in the accompanying
consolidated statement of operations. Accrued interest and penalties, if any, are included in accrued liabilities on the consolidated
balance sheets.</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2019-10-01to2020-09-30" escape="true" name="us-gaap:ShareBasedCompensationForfeituresPolicyTextBlock"><p id="xdx_844_eus-gaap--ShareBasedCompensationForfeituresPolicyTextBlock_z4JyiDfbV3kl" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 42.55pt"></td><td style="width: 18pt"><span style="font: 10pt Times New Roman, Times, Serif">l)</span></td><td id="xdx_861_zrffvkOwY1mi" style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Stock-based
                                         Compensation</span></td></tr></table>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify; margin-left: 42.55pt">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company accounts for all stock-based payments and awards under the fair value method.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify; margin-left: 42.55pt"><span style="font: 10pt Times New Roman, Times, Serif">The
Company accounts for the granting of share purchase options and warrants to employees using the fair value method whereby all
awards to employees will be recorded at fair value on the date of the grant. The fair value of all share purchase options and
warrants are expensed over their contractual vesting period, or over the expected performance period for only the portion of awards
expected to vest, in the case of milestone-based vesting, with a corresponding increase to additional paid-in capital.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: justify"></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: justify; margin-right: 0; margin-left: 42.55pt"><span style="font: 10pt Times New Roman, Times, Serif">Share
purchase options and warrants issued to non-employees are measured at the fair value of the equity instruments issued. Compensation
expense for share purchase options and warrants issued to non-employees is recorded over the service performance period. Prior
to the Company&#8217;s adoption of ASU No. 2018-07, Compensation-Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based
Payment Accounting on October 1, 2019, options and warrants subject to vesting were periodically re-measured until the counterparty
performance was complete, and any change therein was recognized over the vesting period of the award and in the same manner as
if the Company had paid cash instead of paying with or using equity based instruments. After the adoption of ASU No. 2018-07,
the Company measures equity-classified share-based payment awards issued to nonemployees on the grant date, rather than remeasuring
the awards through the performance completion date as previously required (see Note 2 n)).</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: justify; margin-right: 0; margin-left: 42.55pt"><span style="font: 10pt Times New Roman, Times, Serif">Compensation
costs for stock-based payments with graded vesting are recognized on a straight-line basis.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: justify; margin-right: 0; margin-left: 42.55pt"><span style="font: 10pt Times New Roman, Times, Serif">The
Company uses the Black-Scholes option valuation model to calculate the fair value of share purchase options and warrants at the
date of the grant. Option pricing models require the input of highly subjective assumptions, including the expected price volatility.
Changes in these assumptions can materially affect the fair value estimates.</span></p>

<ix:exclude><!-- Field: Page; Sequence: 42; Value: 1 -->
    <div id="xdx_239_zgWJgbBAeAU2" style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" id="xdx_234_zhRiAr8DsQg5" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td><td id="xdx_23A_zkVsJ2lokjJl" style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_231_zdWCZptUtwUl" style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p id="xdx_23D_zDUBBfhywDH" style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

    <ix:exclude><table cellpadding="0" cellspacing="0" id="xdx_23B_zOEAFlnnirie" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; margin-bottom: 5pt; width: 100%">
<tr style="vertical-align: top; text-align: left">
    <td style="width: 7%"><span style="font: 10pt Times New Roman, Times, Serif">Note 2</span></td>
    <td style="width: 93%"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Summary of Significant Accounting Policies </span>- (continued)</span></td></tr>
</table></ix:exclude>

</ix:nonNumeric><ix:nonNumeric contextRef="From2019-10-01to2020-09-30" escape="true" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock"><p id="xdx_84F_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zrtONMDFaYfk" style="font: 10pt Arial, Helvetica, Sans-Serif; text-indent: 40pt; text-align: left; margin-top: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 42.55pt"></td><td style="width: 18pt"><span style="font: 10pt Times New Roman, Times, Serif">m)</span></td><td id="xdx_86A_zvoqyRoz7lO3" style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Fair
                                         Value Measurements</span></td></tr></table>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Fair
value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in
the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at
the measurement date. Assets and liabilities that are measured at fair value are reported using a three-level fair value hierarchy
that prioritizes the inputs used to measure fair value. This hierarchy maximizes the use of observable inputs and minimizes the
use of unobservable inputs. The three levels of inputs used to measure fair value are as follows:</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt"><span style="font: 10pt Times New Roman, Times, Serif">Level
1 - &#9;quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access
at the measurement date;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Level
2 - observable inputs other than Level 1, quoted prices for similar assets or liabilities in active &#9;&#9;markets, quoted prices
for identical or similar assets and liabilities in markets that are not active, and model-derived prices whose inputs are observable
or whose significant value drivers are observable; and</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 60.55pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Level
3 - &#9;assets and liabilities whose significant value drivers are unobservable by little or no market activity and that are significant
to the fair value of the assets or liabilities.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">At
September 30, 2020 and 2019, the Company did not have any Level 3 assets or liabilities.</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2019-10-01to2020-09-30" escape="true" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock"><p id="xdx_847_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_ztjvIPjOXAKb" style="font: 10pt Arial, Helvetica, Sans-Serif; text-indent: 40pt; text-align: left; margin-top: 0; margin-right: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 42.55pt"></td><td style="width: 18pt"><span style="font: 10pt Times New Roman, Times, Serif">n)</span></td><td id="xdx_86D_zQI1JnzoS1gj" style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Recent
                                         Accounting Pronouncements</span></td></tr></table>


<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Recently
Adopted Accounting Pronouncements</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
February 2016, Topic 842, Leases was issued to replace the leases requirements in Topic 840, Leases. The main difference
between previous U.S. GAAP and Topic 842 is the recognition of lease assets and lease liabilities by lessees for those leases
classified as operating leases under previous U.S. GAAP. A lessee should recognize in the balance sheet a liability to make
lease payments (the lease liability) and a right-of-use asset representing its right to use the underlying asset for the
lease term. For leases with a term of 12 months or less, a lessee is permitted to make an accounting policy election by class
of underlying asset not to recognize lease assets and lease liabilities. If a lessee makes this election, it should recognize
lease expense for such leases generally on a straight-line basis over the lease term. The accounting applied by a lessor is
largely unchanged from that applied under previous U.S. GAAP. The Company elected the package of practical expedients
permitted under the transition guidance that allowed, among other things, the historical lease classifications to be carried
forward without reassessment. Further, the Company elected to not recognize lease assets and lease liabilities for leases
with a term of 12 months or less. The adoption of this standard on October 1, 2019 did not have any impact on the Company's
consolidated results of operations, financial condition, cash flows, and financial statement disclosures.</span></p>

<ix:exclude><p id="xdx_235_zQsEI72GR9ne" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p></ix:exclude>


<ix:exclude><!-- Field: Page; Sequence: 42; Value: 1 -->
    <div id="xdx_23B_zDrn3Sap9pW3" style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" id="xdx_23E_zBRixZtCcQl8" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td><td id="xdx_237_zt51jncrovu8" style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_23E_zH1zPh9fVLmc" style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p id="xdx_23A_zDpSZajrX7w6" style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_232_zZMYyc8oLPng" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p></ix:exclude>

<ix:exclude><table cellpadding="0" cellspacing="0" id="xdx_232_zwYEaXZTjkm6" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: top; text-align: left"><td style="width: 7%"><span style="font: 10pt Times New Roman, Times, Serif">Note
                                         2</span></td>
    <td style="width: 93%"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Summary of Significant
    Accounting Policies </span>- (continued)</span></td></tr>
</table></ix:exclude>

<ix:exclude><p id="xdx_233_zmt3oDzPtlK7" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;&#160;</span></p></ix:exclude>

<ix:exclude><table cellpadding="0" cellspacing="0" border="0" id="xdx_23D_zfWCpvS1VWxa" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 42.55pt"></td>
    <td style="text-align: justify; padding-left: 10pt; text-indent: -10pt; width: 18pt"><span style="font: 10pt Times New Roman, Times, Serif">n)</span></td>
    <td style="text-align: justify; padding-left: 10pt; text-indent: -10pt"><span style="font: 10pt Times New Roman, Times, Serif">Recently Adopted Accounting Pronouncements &#8211; (continued)</span></td></tr>
</table></ix:exclude>


<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
June 2018, the FASB issued ASU No. 2018-07, Compensation-Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based
Payment Accounting, which simplifies the accounting for share-based payments to nonemployees for goods and services by aligning
it with the accounting for share-based payments to employees, with certain exceptions. The new guidance was effective for the
Company beginning on October 1, 2019 and was required to be applied retrospectively with the cumulative effect recognized at the
date of initial application. The adoption of this standard on October 1, 2019 did not have any material impact on the Company's
consolidated results of operations, financial condition, cash flows, and financial statement disclosures.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Recent
Accounting Pronouncements Not Yet Adopted</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
December 2019, the FASB issued ASU 2019-12, &#34;Simplifying the Accounting for Income Taxes (ASC 740)&#34;, which is intended
to simplify various aspects related to accounting for income taxes by removing certain exceptions to the general principles in
Topic 740 and clarifying and amending existing guidance to improve consistent application. ASU 2019-12 is effective for the Company
on October 1, 2021. Early adoption is permitted. The Company is currently evaluating the impact of this guidance on its consolidated
financial statements but does not expect such guidance to have a material impact.</span></p>

</ix:nonNumeric></ix:nonNumeric><ix:nonNumeric contextRef="From2019-10-01to2020-09-30" escape="true" name="avxl:OtherIncomeDisclosureTextBlock"><p id="xdx_80C_ecustom--OtherIncomeDisclosureTextBlock_zz32Y6XIRnG8" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: top; text-align: left"><td style="width: 7%"><span style="font: 10pt Times New Roman, Times, Serif">Note
                                         3</span></td>
    <td style="width: 93%"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline"><span id="xdx_821_zKYw3RGdgpj5">Other Income</span></span></span></td></tr>
</table>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Grant
income</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">During
the year ended September 30, 2017, the Company was awarded grant funding in the amount of $<span id="xdx_90C_ecustom--FundingOfDeferredIncomeAwardedGrant_c20161001__20170930__srt--ProductOrServiceAxis__custom--ClinicalStudyGrantMember_pp0p0" title="Awarded grant funding amount"><ix:nonFraction name="avxl:FundingOfDeferredIncomeAwardedGrant" contextRef="From2016-10-012017-09-30_custom_ClinicalStudyGrantMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">597,886</ix:nonFraction></span>. The grant was received in
equal quarterly installments over a period of two years ending during the year ended September 30, 2020, in exchange for a commitment
to complete clinical testing for a therapeutic drug candidate for the treatment of Rett syndrome.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">The
grant income was deferred when received and amortized to other income as the related research and development expenditures were
incurred. During the year ended September 30, 2020, the Company recognized $<span id="xdx_902_ecustom--NonOperatingIncomeFromGrant_c20191001__20200930_pp0p0" title="Grant income"><span id="xdx_901_ecustom--NonOperatingIncomeFromGrant_pp0p0_c20191001__20200930_zv7vl8S7LZyb" title="Grant income"><ix:nonFraction name="avxl:NonOperatingIncomeFromGrant" contextRef="From2019-10-01to2020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD"><ix:nonFraction name="avxl:NonOperatingIncomeFromGrant" contextRef="From2019-10-01to2020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">149,888</ix:nonFraction></ix:nonFraction></span></span> (2019: $<span id="xdx_902_ecustom--NonOperatingIncomeFromGrant_pp0p0_c20181001__20190930_zbzFY1ZJTIl5" title="Grant income"><ix:nonFraction name="avxl:NonOperatingIncomeFromGrant" contextRef="From2018-10-012019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">298,943</ix:nonFraction></span>) of this grant on its statement
of operations as a component of other income. At September 30, 2020, the Company had recognized the full amount of grant funding.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 42; Value: 1 -->
    <div id="xdx_239_z0egn6y7hAli" style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" id="xdx_23B_zW5R7RYkreZc" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td><td id="xdx_23B_z62wADROG5p4" style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_235_zGSbfYTJGlAd" style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p id="xdx_238_zfDaSGMskZc1" style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23E_zfnWnql2VZVa" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p></ix:exclude>

<ix:exclude><table cellpadding="0" cellspacing="0" id="xdx_236_zwm8pyPJZRUg" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: top; text-align: left">
    <td style="width: 7%"><span style="font: 10pt Times New Roman, Times, Serif">Note 3</span></td>
    <td style="width: 93%"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Other Income </span>&#8211;
    (continued)</span></td></tr>
</table></ix:exclude>

<ix:exclude><p id="xdx_23E_zjegva04tBn6" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p></ix:exclude>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Research
and development incentive income</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Research
and development incentive income during the years ended September 30, 2020 and 2019 represents the receipt by Anavex Australia,
of the Australia R&amp;D Credit, as well as receipt by the Company of the New York City Biotechnology Credit (&#8220;NYC Biotech
credit&#8221;).</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">During
the year ended September 30, 2020, the Company recorded research and development incentive income of $<span id="xdx_908_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pp0p0_c20191001__20200930_zKLsquhZRyJ" title="Research and development incentive income"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" contextRef="From2019-10-01to2020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,375,025</ix:nonFraction></span> (AUD <span id="xdx_900_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pp0p0_uUSD_c20191001__20200930__srt--CurrencyAxis__currency--AUD_zIbRUdKipgo6" title="Research and development incentive income"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" contextRef="From2019-10-012020-09-30_currency_AUD" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">6,392,266</ix:nonFraction></span>)
(2019: $<span id="xdx_905_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pp0p0_c20181001__20190930_zrSpdSG54Xoh" title="Research and development incentive income"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" contextRef="From2018-10-012019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,215,691</ix:nonFraction></span> (AUD <span id="xdx_900_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pp0p0_uUSD_c20181001__20190930__srt--CurrencyAxis__currency--AUD_zjdwEUNoiJr8" title="Research and development incentive income"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" contextRef="From2018-10-012019-09-30_currency_AUD" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,281,300</ix:nonFraction></span>)) in respect of the Australia R&amp;D Credit for eligible research and development expenses incurred
during the year, or expenditures to which the Company became eligible during the year.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">During
the year ended September 30, 2019, the Company recorded research and development incentive income of $<span id="xdx_904_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pp0p0_c20181001__20190930__srt--ProductOrServiceAxis__custom--NYCBiotechCreditMember_zo7NuVdY2sah" title="Research and development incentive income"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" contextRef="From2018-10-012019-09-30_custom_NYCBiotechCreditMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">250,000</ix:nonFraction></span> in respect of the
NYC Biotech Credit. The Company was no longer eligible for the NYC Biotech Credit for the fiscal year ended September 30, 2020.</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2019-10-01to2020-09-30" escape="true" name="avxl:EquityOfferingAgreementsTextBlock"><p id="xdx_809_ecustom--EquityOfferingAgreementsTextBlock_ziXhn4RIZmh8" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: top; text-align: left"><td style="width: 7%"><span style="font: 10pt Times New Roman, Times, Serif">Note
                                         4</span></td>
    <td style="width: 93%"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline"><span id="xdx_820_zwBBPE1lB1T7">Equity Offering Agreements</span></span></span></td></tr>
</table>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">2015
Purchase Agreement</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">On
October 21, 2015, the Company entered into a $50,000,000 purchase agreement (the &#8220;2015 Purchase Agreement&#8221;) with Lincoln
Park Capital Fund, LLC (&#8220;Lincoln Park&#8221;), pursuant to which the Company could sell and issue to Lincoln Park, and Lincoln
Park was obligated to purchase, up to $50,000,000 in value of its shares of common stock from time to time over a 36-month period.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">During
the year ended September 30, 2019, the Company issued to Lincoln Park an aggregate of <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pii_c20181001__20190930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zBSOc3VRAqDg"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2018-10-012019-09-30_custom_PurchaseAgreementMember_custom_LincolnParkCapitalFundLLCMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,872,696</ix:nonFraction></span> shares of common stock under the
2015 Purchase Agreement, including <span id="xdx_900_ecustom--StockIssuedDuringPeriodSharesNewIssues4_pii_c20181001__20190930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zbGbfUNv9rEa"><ix:nonFraction name="avxl:StockIssuedDuringPeriodSharesNewIssues4" contextRef="From2018-10-012019-09-30_custom_PurchaseAgreementMember_custom_LincolnParkCapitalFundLLCMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,848,995</ix:nonFraction></span> shares of common stock for an aggregate purchase price of $<span id="xdx_905_ecustom--StockIssuedDuringPeriodValueNewIssues3_pp0p0_c20181001__20190930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zakyZTGUPy7e"><ix:nonFraction name="avxl:StockIssuedDuringPeriodValueNewIssues3" contextRef="From2018-10-012019-09-30_custom_PurchaseAgreementMember_custom_LincolnParkCapitalFundLLCMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">13,197,604</ix:nonFraction></span> and <span id="xdx_906_ecustom--StockIssuedDuringPeriodSharesNewIssues3_pii_c20181001__20190930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_z3OHjx3k46g7"><ix:nonFraction name="avxl:StockIssuedDuringPeriodSharesNewIssues3" contextRef="From2018-10-012019-09-30_custom_PurchaseAgreementMember_custom_LincolnParkCapitalFundLLCMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">23,701</ix:nonFraction></span>
as commitment shares. At September 30, 2019, all remaining purchase amounts available for issuance under the 2015 Purchase Agreement
had been utilized and the 2015 Purchase Agreement has expired pursuant to its terms. As such, no further shares will be sold under
the 2015 Purchase Agreement.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 42; Value: 1 -->
    <div id="xdx_237_z5iq8e9UwF61" style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" id="xdx_233_zht8NHkCWd54" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td><td id="xdx_230_zEPRWZSdt9mk" style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_238_zetQKP13FH98" style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p id="xdx_238_zBrafNZFj54d" style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23D_zUGKfxsrSu0l" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p></ix:exclude>

<ix:exclude><table cellpadding="0" cellspacing="0" id="xdx_233_zLvflf0Puxwa" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: top; text-align: left"><td style="width: 7%"><span style="font: 10pt Times New Roman, Times, Serif">Note
                                         4</span></td>
    <td style="width: 93%"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Equity Offering Agreements
    </span>- (continued)</span></td></tr>
</table></ix:exclude>

<ix:exclude><p id="xdx_238_zArzJjjvKHB7" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p></ix:exclude>

<ix:exclude><p id="xdx_23D_zAhqMTJcQRA9" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"></span></p></ix:exclude>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">2019
Purchase Agreement</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">On
June 7, 2019, the Company entered into a $<span id="xdx_90D_ecustom--ValueOfSharesObligatedToPurchase_c20190606__20190607__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pp0p0" title="Total number of shares obligated to purchase"><ix:nonFraction name="avxl:ValueOfSharesObligatedToPurchase" contextRef="From2019-06-062019-06-07_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">50,000,000</ix:nonFraction></span> purchase agreement (the &#8220;2019 Purchase Agreement&#8221;) with Lincoln
Park, as amended on July 1, 2020 (the &#8220;Amendment Date&#8221;), pursuant to which the Company may sell and issue to Lincoln
Park, and Lincoln Park is obligated to purchase, up to $50,000,000 in value of its shares of common stock from time to time from
June 12, 2019, the date a prospectus supplement under which shares of common stock issuable under the 2019 Purchase Agreement
was filed with the SEC, until July 1, 2022, which is the first day of the next month following the <span id="xdx_90A_ecustom--AgreementTerm_dtM_c20190606__20190607__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zswYi1t0JfHa" title="Agreement term"><ix:nonNumeric contextRef="From2019-06-062019-06-07_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember" format="ixt-sec:durmonth" name="avxl:AgreementTerm">36</ix:nonNumeric></span>-month anniversary of June
12, 2019.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_904_eus-gaap--UnrecordedUnconditionalPurchaseObligationDescription_c20190606__20190607__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember" title="Description of purchases price"><ix:nonNumeric contextRef="From2019-06-062019-06-07_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember" name="us-gaap:UnrecordedUnconditionalPurchaseObligationDescription">The
Company may direct Lincoln Park, at its sole discretion, and subject to certain conditions, to purchase up to 200,000 shares of
common stock on any business day (a &#8220;Regular Purchase&#8221;). The amount of a Regular Purchase may be increased under certain
circumstances up to 250,000 shares, provided that Lincoln Park&#8217;s committed obligation for Regular Purchases on any business
day shall not exceed $2,000,000. In the event the Company purchases the full amount allowed for a Regular Purchase on any given
business day, the Company may also direct Lincoln Park to purchase additional amounts as accelerated and additional accelerated
purchases. The purchase price of shares of common stock related to the future funding will be based on the then prevailing market
prices of such shares at the time of sales as described in the 2019 Purchase Agreement.</ix:nonNumeric></span></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company&#8217;s sale of shares of Common Stock to Lincoln Park subsequent to the Amendment Date is limited to <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pii_c20191001__20200930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zPOm8p4VLhr9"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2019-10-012020-09-30_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">12,016,457</ix:nonFraction></span> shares
of Common Stock, representing <span id="xdx_909_ecustom--PercentageOfGrossProceedsFromSales_pii_dp_c20191001__20200930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zRBtmNmXF893"><ix:nonFraction name="avxl:PercentageOfGrossProceedsFromSales" contextRef="From2019-10-012020-09-30_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">19.99</ix:nonFraction>%</span> of the shares of the Common Stock outstanding on the Amendment Date unless (i) shareholder
approval is obtained to issue more than such amount or (ii) the average price of all applicable sales of Common Stock to Lincoln
Park under the 2019 Purchase Agreement after the Amendment Date equals or exceeds the lower of (A) the closing price of the Common
Stock on the Nasdaq Capital Market immediately preceding the Amendment Date or (B) the average of the closing prices of the Common
Stock on the Nasdaq Capital Market for the five Business Days immediately preceding the Amendment Date, and it also limits the
Company&#8217;s sale of shares to Lincoln Park to the extent it would cause Lincoln Park to beneficially own more than 4.99% of
the Company&#8217;s outstanding shares of Common Stock at any given time.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 12pt 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
consideration for entering into the 2019 Purchase Agreement, the Company issued to Lincoln Park <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20190606__20190607__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pii" title="Number of share issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2019-06-062019-06-07_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">324,383</ix:nonFraction></span> shares of common stock
as a commitment fee and agreed to issue up to <span id="xdx_90D_ecustom--NumberOfSharesObligatedToPurchaseProrataBasic_c20190606__20190607__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pii" title="Pro rata basic number of shares obligated to purchase"><ix:nonFraction name="avxl:NumberOfSharesObligatedToPurchaseProrataBasic" contextRef="From2019-06-062019-06-07_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">162,191</ix:nonFraction></span> shares pro rata, when and if, Lincoln Park purchases at the Company&#8217;s
discretion the $50,000,000 aggregate commitment.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 12pt 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">During
the year ended September 30, 2020, the Company issued to Lincoln Park an aggregate of <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pii_c20191001__20200930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zvwjbRADkBf8"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2019-10-012020-09-30_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,633,527</ix:nonFraction></span> (2019 -<span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pii_c20181001__20190930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zPc8aJO5yWMc"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2018-10-012019-09-30_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,839,415</ix:nonFraction></span>) shares of common
stock under the 2019 Purchase Agreement, including <span id="xdx_903_ecustom--StockIssuedDuringPeriodSharesNewIssues4_pii_c20191001__20200930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zLfnMaZbIml3"><ix:nonFraction name="avxl:StockIssuedDuringPeriodSharesNewIssues4" contextRef="From2019-10-012020-09-30_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,564,584</ix:nonFraction></span> (2019: <span id="xdx_90B_ecustom--StockIssuedDuringPeriodSharesNewIssues4_pii_c20181001__20190930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zawTt1F3bA38"><ix:nonFraction name="avxl:StockIssuedDuringPeriodSharesNewIssues4" contextRef="From2018-10-012019-09-30_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,500,000</ix:nonFraction></span>) shares of common stock for an aggregate purchase
price of $<span id="xdx_90D_ecustom--StockIssuedDuringPeriodValueNewIssues3_pp0p0_c20191001__20200930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zfCGnkrPJQT9"><ix:nonFraction name="avxl:StockIssuedDuringPeriodValueNewIssues3" contextRef="From2019-10-012020-09-30_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">21,254,298</ix:nonFraction></span> (2019: $<span id="xdx_90F_ecustom--StockIssuedDuringPeriodValueNewIssues3_pp0p0_c20181001__20190930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zCy4fdXcsxGj"><ix:nonFraction name="avxl:StockIssuedDuringPeriodValueNewIssues3" contextRef="From2018-10-012019-09-30_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,634,505</ix:nonFraction></span>) and <span id="xdx_90E_ecustom--StockIssuedDuringPeriodSharesNewIssues3_pii_c20191001__20200930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zopjK80y29bf"><ix:nonFraction name="avxl:StockIssuedDuringPeriodSharesNewIssues3" contextRef="From2019-10-012020-09-30_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">68,943</ix:nonFraction></span> (2019: <span id="xdx_904_ecustom--StockIssuedDuringPeriodSharesNewIssues3_pii_c20181001__20190930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zq4SbVkWgwld"><ix:nonFraction name="avxl:StockIssuedDuringPeriodSharesNewIssues3" contextRef="From2018-10-012019-09-30_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">339,415</ix:nonFraction></span>) commitment shares. At September 30, 2020, an amount of $<span id="xdx_901_ecustom--StockIssuedDuringPeriodValueNewIssues4_pp0p0_c20191001__20200930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zVupzoNiHA3c"><ix:nonFraction name="avxl:StockIssuedDuringPeriodValueNewIssues4" contextRef="From2019-10-012020-09-30_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">24,111,197</ix:nonFraction></span>
(2019: $<span id="xdx_906_ecustom--StockIssuedDuringPeriodValueNewIssues4_pp0p0_c20181001__20190930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zwZUOHdnEb8h"><ix:nonFraction name="avxl:StockIssuedDuringPeriodValueNewIssues4" contextRef="From2018-10-012019-09-30_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">45,365,495</ix:nonFraction></span>) remained available under the 2019 Purchase Agreement.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 42; Value: 1 -->
    <div id="xdx_237_zB6YJLQxrib5" style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" id="xdx_238_zzZ4sNTNAnn6" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td><td id="xdx_230_zJRM3nd8DY5c" style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_235_zGJyceu8ElO2" style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p id="xdx_23E_zhj3tf62tER6" style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_234_zR8E76Q0e7ji" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p></ix:exclude>

<ix:exclude><table cellpadding="0" cellspacing="0" id="xdx_23F_z8M20aaCZOS9" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: top; text-align: left"><td style="width: 7%"><span style="font: 10pt Times New Roman, Times, Serif">Note
                                         4</span></td>
    <td style="width: 93%"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Equity Offering Agreements
    </span>- (continued)</span></td></tr>
</table></ix:exclude>

<ix:exclude><p id="xdx_23A_zwDFzHN1uQSe" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;&#160;</span></p></ix:exclude>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Sales
Agreement</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company entered into a Controlled Equity Offering Sales Agreement on July 6, 2018, which was amended and restated on May 1, 2020
(the &#8220;Sales Agreement&#8221;) with Cantor Fitzgerald&#160;&amp; Co. and SVB Leerink LLC (together the &#8220;Sales Agents&#8221;),
pursuant to which the Company may offer and sell shares of common stock, for aggregate gross sale proceeds of up to $<span id="xdx_906_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20200429__20200501__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_pp0p0" title="Gross sale proceeds"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2020-04-292020-05-01_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">50,000,000</ix:nonFraction></span>
from time to time through the Sales Agents (the &#8220;Offering&#8221;).&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Upon
delivery of a placement notice based on the Company&#8217;s instructions and subject to the terms and conditions of the Sales
Agreement, the Sales Agents may sell the Shares by methods deemed to be an &#8220;at the market offering&#8221; offering, in negotiated
transactions at market prices prevailing at the time of sale or at prices related to such prevailing market prices, or by any
other method permitted by law, including negotiated transactions, subject to the prior written consent of the Company. The Company
is not obligated to make any sales of Shares under the Sales Agreement. The Company or Sales Agents may suspend or terminate the
offering of Shares upon notice to the other party, subject to certain conditions.&#160; The Sales Agents will act as agent on
a commercially reasonable efforts basis consistent with their normal trading and sales practices and applicable state and federal
law, rules&#160;and regulations and the rules&#160;of Nasdaq.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company has agreed to pay the Sales Agents commissions for their services of up to <span id="xdx_900_ecustom--PercentageOfGrossProceedsFromSales_c20191001__20200930__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_pii" title="Percentage of gross proceeds from sales"><ix:nonFraction name="avxl:PercentageOfGrossProceedsFromSales" contextRef="From2019-10-012020-09-30_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3.0</ix:nonFraction>%</span> of the gross proceeds from the sale of
the Shares pursuant to the Sales Agreement.&#160; The Company also agreed to provide the Sales Agents with customary indemnification
and contribution rights. During the year ended September 30, 2020, <span id="xdx_90A_ecustom--NumberOfStockSold_c20191001__20200930__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_zv0uaeXjvJ81" title="Number of stock sold"><ix:nonFraction name="avxl:NumberOfStockSold" contextRef="From2019-10-012020-09-30_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,760,429</ix:nonFraction></span> shares were sold pursuant to the Offering for gross
proceeds of $<span id="xdx_902_ecustom--GrossProceedsFromSaleOfCommonStock_c20191001__20200930__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_zAjwJC284hj2" title="Gross proceeds from sale of common stock"><ix:nonFraction name="avxl:GrossProceedsFromSaleOfCommonStock" contextRef="From2019-10-012020-09-30_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,499,900</ix:nonFraction></span> (net proceeds of $<span id="xdx_902_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20191001__20200930__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_zCdrqBUHX8K3" title="Proceeds from sale of common stock"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2019-10-012020-09-30_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,096,136</ix:nonFraction></span> after deducting offering expenses). At September 30, 2020, an amount of $<span id="xdx_90D_ecustom--NumberOfSharesAvailable_iI_c20200930__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_zAAUcfZJULHi" title="Number of shares available"><ix:nonFraction name="avxl:NumberOfSharesAvailable" contextRef="AsOf2020-09-30_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">42,500,100</ix:nonFraction></span>
remained available under the Sales Agreement.</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2019-10-01to2020-09-30" escape="true" name="us-gaap:CommitmentsDisclosureTextBlock"><p id="xdx_80D_eus-gaap--CommitmentsDisclosureTextBlock_zhdF2fjEldOk" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: top; text-align: left"><td style="width: 7%"><span style="font: 10pt Times New Roman, Times, Serif">Note
                                         5</span></td>
    <td style="width: 93%"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline"><span id="xdx_821_zDBqjo45kMGk">Commitments</span></span></span></td></tr>
</table>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 42.75pt"></td><td style="width: 18pt"><span style="font: 10pt Times New Roman, Times, Serif">a)</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">Lease</span></td></tr></table>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; color: gray"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">During
the year ended September 30, 2020 the Company incurred office lease expense of $<span id="xdx_90E_eus-gaap--LeaseAndRentalExpense_c20191001__20200930_pp0p0"><ix:nonFraction name="us-gaap:LeaseAndRentalExpense" contextRef="From2019-10-01to2020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">233,423</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">(2019: $<span id="xdx_904_eus-gaap--LeaseAndRentalExpense_c20181001__20190930_pp0p0"><ix:nonFraction name="us-gaap:LeaseAndRentalExpense" contextRef="From2018-10-012019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">190,416</ix:nonFraction></span></span><span style="font: 10pt Times New Roman, Times, Serif">).</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; color: gray"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 42.75pt"></td><td style="width: 18pt"><span style="font: 10pt Times New Roman, Times, Serif">b)</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">Litigation</span></td></tr></table>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 60.75pt"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">The
Company is subject to claims and legal proceedings that arise in the ordinary course of business. Such matters are inherently
uncertain, and there can be no guarantee that the outcome of any such matter will be decided favorably to the Company or that
the resolution of any such matter will not have a material adverse effect upon the Company's consolidated financial statements.
The Company does not believe that any of such pending claims and legal proceedings will have a material adverse effect on its
consolidated financial statements.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 60.75pt; color: gray"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:exclude><p id="xdx_233_zCZFVXmmAwVi" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p></ix:exclude>


<ix:exclude><!-- Field: Page; Sequence: 42; Value: 1 -->
    <div id="xdx_238_zhva7ZLWalde" style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" id="xdx_23E_zc0UFpNoVdMi" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td><td id="xdx_238_zss66ivuLapd" style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_233_z0Pt8BK8V5e" style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p id="xdx_237_zwXyccOi7gq3" style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_231_zqHzsc0lAEY1" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p></ix:exclude>

<ix:exclude><table cellpadding="0" cellspacing="0" id="xdx_238_zSEw50I51lof" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: top; text-align: left"><td style="width: 7%"><span style="font: 10pt Times New Roman, Times, Serif">Note
                                         5</span></td>
    <td style="width: 93%"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Commitments </span>- (continued)</span></td></tr>
</table></ix:exclude>

<ix:exclude><p id="xdx_23A_zDCP1C4QJsng" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p></ix:exclude>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 42.75pt"></td><td style="width: 18pt"><span style="font: 10pt Times New Roman, Times, Serif">c)</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">Share
                                         Purchase Warrants</span></td></tr></table>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 58.5pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
following table summarizes the warrant activity during the years ended September 30, 2020 and 2019:</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"></p>

<ix:nonNumeric contextRef="From2019-10-01to2020-09-30" escape="true" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_892_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zCeX6ZSscUs4" summary="xdx: Disclosure - Commitments (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%; margin-left: 50pt">
<tr style="vertical-align: bottom">
    <td colspan="3" style="text-align: left">&#160;<span id="xdx_8B7_zpVFSbMks2pe" style="display: none">Schedule of exercisable share purchase warrants outstanding</span></td><td>&#160;</td>
    <td colspan="3">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Weighted Average Exercise</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Number of Shares</td><td style="border-bottom: Black 1pt solid">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Exercise Price ($)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 60%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Balance , September 30 , 2018</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pii_c20181001__20190930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zmTtd7r9uibd" title="Share Purchase Warrants Balance, at beginning" style="width: 15%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2018-09-30_custom_PurchaseWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">678,379</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_iS_pii_c20181001__20190930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zfsfjDTFyuCc" title="Weighted Average Exercise Price Balance, at beginning" style="width: 15%; text-align: right"><ix:nonFraction name="avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2018-09-30_custom_PurchaseWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.87</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Exercised</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pii_di_c20181001__20190930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zz1loBMAaAkh" title="Share Purchase Warrants Exercised" style="text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" contextRef="From2018-10-012019-09-30_custom_PurchaseWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,750</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExercised_c20181001__20190930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_pii" title="Weighted Average Exercise Price, Exercised" style="text-align: right"><ix:nonFraction name="avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExercised" contextRef="From2018-10-012019-09-30_custom_PurchaseWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.13</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Expired</span></td><td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_pii_di_c20181001__20190930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zonaDXZ9QF17" title="Share Purchase Warrants Expired" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" contextRef="From2018-10-012019-09-30_custom_PurchaseWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">319,629</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; text-align: left">)</td><td style="border-bottom: Black 1pt solid">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExpired_c20181001__20190930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_pii" title="Weighted Average Exercise Price, Expired" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExpired" contextRef="From2018-10-012019-09-30_custom_PurchaseWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.46</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Balance , September 30 , 2019</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pii_c20191001__20200930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zYN80Ghjgly9" title="Share Purchase Warrants Balance, at beginning" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2019-09-30_custom_PurchaseWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">350,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_iS_pii_c20191001__20200930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zQxXXV1tAT3c" title="Weighted Average Exercise Price Balance, at beginning" style="text-align: right"><ix:nonFraction name="avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2019-09-30_custom_PurchaseWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.19</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Granted</span></td><td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod_c20191001__20200930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_pii" title="Share Purchase Warrants Granted" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod" contextRef="From2019-10-012020-09-30_custom_PurchaseWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">150,000</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice_c20191001__20200930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_pii" title="Weighted Average Exercise Price, Granted" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="avxl:ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice" contextRef="From2019-10-012020-09-30_custom_PurchaseWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.17</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Balance,
                                                                            September 30, 2020</span></td><td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pii_c20191001__20200930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_z8toB2rDxIb" title="Share Purchase Warrants Balance, at ending" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2020-09-30_custom_PurchaseWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">500,000</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_iE_pii_c20191001__20200930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zPE1MCG6ernb" title="Weighted Average Exercise Price Balance, at ending" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2020-09-30_custom_PurchaseWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.88</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td></tr>
</table>



</ix:nonNumeric><p id="xdx_8AF_zscZ3vRd44Dl" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 6pt 42.55pt; text-align: justify; text-indent: -0.8pt"><span style="font: 10pt Times New Roman, Times, Serif">During
the year ended September 30, 2019, the Company issued <span id="xdx_902_ecustom--SharesIssuedPursuantToCashlessExerciseOfWarrantInShares_pii_c20191001__20200930_zMG6cZW4sGOj" title="Shares issued pursuant to cashless exercise of warrants"><ix:nonFraction name="avxl:SharesIssuedPursuantToCashlessExerciseOfWarrantInShares" contextRef="From2019-10-01to2020-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,938</ix:nonFraction></span> shares in connection with the exercise of <span id="xdx_90A_ecustom--StockIssuedPursuantToCashlessExerciseOfWarrants_c20191001__20200930_pii" title="Stock issued pursuant to cashless exercise of warrants"><ix:nonFraction name="avxl:StockIssuedPursuantToCashlessExerciseOfWarrants" contextRef="From2019-10-01to2020-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,750</ix:nonFraction></span> warrants on a cashless
basis.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 6pt 42.55pt; text-align: justify; text-indent: -0.8pt"><span style="font: 10pt Times New Roman, Times, Serif">At
September 30, 2020 the Company had share purchase warrants outstanding as follows:</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 6pt 42.55pt; text-align: justify; text-indent: -0.8pt"></p>

<ix:nonNumeric contextRef="From2019-10-01to2020-09-30" escape="true" name="avxl:ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_89F_ecustom--ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock_zNtmAaOFD1Mh" summary="xdx: Disclosure - Commitments (Details 1)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 50%; margin-left: 50pt">
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_8BC_zFut8NusmD2i" style="display: none">Schedule of share purchase warrants outstanding</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="3" style="text-align: center">Number</td><td style="text-align: center">&#160;</td>
    <td colspan="3" style="text-align: center">Exercise Price</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">Expiry Date</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_c20200930__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_pii" title="Number" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" contextRef="AsOf2020-09-30_custom_PurchaseWarrants1Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">350,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_c20200930__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_pii" title="Exercise Price" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" contextRef="AsOf2020-09-30_custom_PurchaseWarrants1Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.19</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td id="xdx_98F_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_c20200930__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member" title="Expiry Date" style="width: 56%; text-align: right"><ix:nonNumeric contextRef="AsOf2020-09-30_custom_PurchaseWarrants1Member" format="ixt:datemonthdayyearen" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate">June 30, 2021</ix:nonNumeric></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_c20200930__us-gaap--AwardTypeAxis__custom--PurchaseWarrants2Member_pii" title="Number" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" contextRef="AsOf2020-09-30_custom_PurchaseWarrants2Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">150,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_c20200930__us-gaap--AwardTypeAxis__custom--PurchaseWarrants2Member_pii" title="Exercise Price" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" contextRef="AsOf2020-09-30_custom_PurchaseWarrants2Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.17</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td id="xdx_98E_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_c20200930__us-gaap--AwardTypeAxis__custom--PurchaseWarrants2Member" title="Expiry Date" style="text-align: right"><ix:nonNumeric contextRef="AsOf2020-09-30_custom_PurchaseWarrants2Member" format="ixt:datemonthdayyearen" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate">May 6, 2024</ix:nonNumeric></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_c20200930_pii" title="Number" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">500,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">&#160;</td></tr>
</table>



</ix:nonNumeric><p id="xdx_8A7_zpbNf3kB7Fx3" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 6pt 42.55pt; text-align: justify; text-indent: -0.8pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 42; Value: 1 -->
    <div id="xdx_232_zh70BhuMK0Rb" style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" id="xdx_23B_zQDKfCu6PCYc" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-1<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td><td id="xdx_23F_zE8xeWp8yya1" style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_231_zzwD8Bz0FMV8" style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p id="xdx_236_zdSUaovLDJB3" style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23D_zBBW4mkIyTG2" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p></ix:exclude>

<ix:exclude><table cellpadding="0" cellspacing="0" id="xdx_23F_zLnTDtSCwJ9" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: top; text-align: left"><td style="width: 7%"><span style="font: 10pt Times New Roman, Times, Serif">Note
                                         5</span></td>
    <td style="width: 93%"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Commitments </span>- (continued)</span></td></tr>
</table></ix:exclude>

<ix:exclude><p id="xdx_239_zcibkC6wXkgd" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p></ix:exclude>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 42.75pt"></td><td style="width: 18pt"><span style="font: 10pt Times New Roman, Times, Serif">d)</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Stock&#8211;based
                                         Compensation Plan</span></td></tr></table>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">2015
Stock Option Plan</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify; text-indent: -1in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">On
September 18, 2015, the Company&#8217;s board of directors approved a 2015 Omnibus Incentive Plan (the &#8220;2015 Plan&#8221;),
which provided for the grant of stock options and restricted stock awards to directors, officers, employees and consultants of
the Company.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
maximum number of our common shares reserved for issue under the plan was <span id="xdx_90D_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_c20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pii" title="Maximum number of common shares reserved for future issuance"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="AsOf2020-09-30_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,050,553</ix:nonFraction></span> shares, subject to adjustment in the event
of a change of the Company&#8217;s capitalization. At September 30, 2020, <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zu0sesh6W6Ia"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="AsOf2020-09-30_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">146,371</ix:nonFraction></span> (2019: <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20190930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zMoDUtlMbv3k"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="AsOf2019-09-30_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">146,371</ix:nonFraction></span>) options remain available for
issue under the 2015 Plan.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">2019
Stock Option Plan</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">On
January 15, 2019, the Board approved the 2019 Omnibus Incentive Plan (the &#8220;2019 Plan&#8221;), which provides for the grant
of stock options and restricted stock awards to directors, officers, employees, consultants and advisors of the Company. Under
the terms of the 2019 Plan, <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2019Member_pii" title="Additional shares of common stock available for issuance"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" contextRef="From2019-10-012020-09-30_custom_StockOptionPlan2019Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,000,000</ix:nonFraction></span> additional shares of Common Stock are available for issuance under the 2019 Plan, in addition
to the shares available under the 2015 Plan. Any awards outstanding under the 2015 Plan or the Company&#8217;s 2007 Stock Option
Plan (the &#8220;2007 Plan&#8221;) will remain subject to and be paid under the 2015 Plan or the 2007 Plan, respectively, and
any shares subject to outstanding awards under the 2015 Plan or the 2007 Plan that subsequently cease to be subject to such awards
(other than by reason of settlement of the awards in shares) will automatically become available for issuance under the 2019 Plan.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
2019 Plan provides that it may be administered by the Board, or the Board may delegate such responsibility to a committee. The
exercise price will be determined by the board of directors at the time of grant shall be at least equal to the fair market value
on such date. If the grantee is a 10% stockholder on the grant date, then the exercise price shall not be less than 110% of fair
market value of the Company&#8217;s shares of common stock on the grant date. Stock options may be granted under the 2019 Plan
for an exercise period of up to ten years from the date of grant of the option or such lesser periods as may be determined by
the board, subject to earlier termination in accordance with the terms of the 2019 Plan. At September 30, 2020, <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2019Member_zTfo6dJQhPY6"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="AsOf2020-09-30_custom_StockOptionPlan2019Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,161,665</ix:nonFraction></span> (2019:
<span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20190930__us-gaap--PlanNameAxis__custom--StockOptionPlan2019Member_zYBl353Lyqr6"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="AsOf2019-09-30_custom_StockOptionPlan2019Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,788,333</ix:nonFraction></span>) options remain available for issue under the 2019 Plan.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">A
summary of the status of Company&#8217;s outstanding stock purchase options is presented below:</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"></p>

<ix:nonNumeric contextRef="From2019-10-01to2020-09-30" escape="true" name="us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_896_eus-gaap--ScheduleOfStockOptionsRollForwardTableTextBlock_zm10SLpqS2u6" summary="xdx: Disclosure - Commitments (Details 2)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 50pt; margin-right: 30pt">
<tr style="vertical-align: bottom">
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: left"><span id="xdx_8BE_zhSeLDdBnF7f" style="display: none">Schedule of outstanding stock purchase options&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: center">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Number of Shares</td><td style="border-bottom: Black 1pt solid; text-align: center">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Weighted Average Exercise Price</td><td style="border-bottom: Black 1pt solid; text-align: center">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Weighted Average Grant Date Fair Value ($)</td><td style="border-bottom: Black 1pt solid; text-align: center">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Aggregate intrinsic value ($)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 26%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Outstanding, September 30, 2018</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pii_c20181001__20190930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zh9Gqg9kHKJf" title="Options Outstanding at beginning" style="width: 15%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2018-09-30_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,506,917</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pii_c20181001__20190930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zba4eDIJnP5e" title="Weighted Average Exercise Price Outstanding at beginning" style="width: 15%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2018-09-30_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.83</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 15%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20181001__20190930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zEKezIwO51H3" title="Aggregate intrinsic value Outstanding at beginning" style="width: 15%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2018-09-30_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,353,088</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Granted</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20181001__20190930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pii" title="Options Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2018-10-012019-09-30_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,265,399</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20181001__20190930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pii" title="Weighted Average Exercise Price Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2018-10-012019-09-30_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.79</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20181001__20190930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pii" title="Weighted Average Grant Date Fair Value Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2018-10-012019-09-30_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.27</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Forfeited</span></td><td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pii_di_c20181001__20190930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zJKYxHhyezg5" title="Options Forfeited" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="From2018-10-012019-09-30_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">309,383</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; text-align: left">)</td><td style="border-bottom: Black 1pt solid">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20181001__20190930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pii" title="Weighted Average Exercise Price Forfeited" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="From2018-10-012019-09-30_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.25</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Outstanding, September 30, 2019</span></td><td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pii_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zQTunKIezEq2" title="Options Outstanding at beginning" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2019-09-30_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,462,933</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pii_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_z8T1R15cmUx3" title="Weighted Average Exercise Price Outstanding at beginning" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2019-09-30_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.58</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zKBvON9vvBTe" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2019-09-30_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,115,032</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Granted</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pii" title="Options Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2019-10-012020-09-30_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,695,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pii" title="Weighted Average Exercise Price Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2019-10-012020-09-30_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.96</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pii" title="Weighted Average Grant Date Fair Value Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2019-10-012020-09-30_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.27</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td title="Aggregate intrinsic value Outstanding at ending" style="text-align: right"></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Forfeited</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pii_di_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zC4oNndN1Jgc" title="Options Forfeited" style="text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="From2019-10-012020-09-30_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">68,332</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pii" title="Weighted Average Exercise Price Forfeited" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="From2019-10-012020-09-30_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.01</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Exercised</span></td><td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pii_di_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zgKsNRQ2uz4f" title="Options Exercised" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2019-10-012020-09-30_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">13,335</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; text-align: left">)</td><td style="border-bottom: Black 1pt solid">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pii" title="Weighted Average Exercise Price Exercised" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="From2019-10-012020-09-30_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.15</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Outstanding, September 30, 2020</span></td><td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pii_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_z71n7ruaXmj2" title="Options Outstanding at ending" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2020-09-30_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,076,266</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pii_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zAOoelwUl4pf" title="Weighted Average Exercise Price Outstanding at ending" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2020-09-30_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.48</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zBdK6aD3ajf2" title="Aggregate intrinsic value Outstanding at ending" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2020-09-30_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">14,982,581</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Exercisable, September 30, 2020</span></td><td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zCSeOZ8OIdRg" title="Options Exercisable at ending" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2020-09-30_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,412,100</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pii_c20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zQ46uv7GgYnj" title="Weighted Average Exercise Price Exercisable at ending" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2020-09-30_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.66</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_c20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pp0p0" title="Aggregate intrinsic value Exercisable at ending" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="AsOf2020-09-30_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">10,763,906</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td></tr>
</table>



</ix:nonNumeric><p id="xdx_8A7_z0jlJsnN3pI4" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 6pt 42.55pt; text-align: justify; text-indent: -0.8pt"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 6pt 42.55pt; text-align: justify; text-indent: -0.8pt"><span style="font: 10pt Times New Roman, Times, Serif">During
the year ended September 30, 2020, the Company issued <span id="xdx_90C_ecustom--SharesIssuedPursuantToCashlessExercisesOfOption_c20191001__20200930_zXcjR5fThcF3" title="Shares issued pursuant to cashless exercises of option"><ix:nonFraction name="avxl:SharesIssuedPursuantToCashlessExercisesOfOption" contextRef="From2019-10-01to2020-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">721</ix:nonFraction></span> shares in connection with the exercise of <span id="xdx_904_ecustom--NumberOfCashlessExerciseOption_c20191001__20200930_zROVJdJcKIm9" title="Number of cashless exercise option"><ix:nonFraction name="avxl:NumberOfCashlessExerciseOption" contextRef="From2019-10-01to2020-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">13,335</ix:nonFraction></span> options on a cashless
basis.</span></p>

<ix:exclude><!-- Field: Page; Sequence: 42; Value: 1 -->
    <div id="xdx_231_zdUHraPAgVz7" style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" id="xdx_23C_z2WTizEEbvhe" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td><td id="xdx_238_zZ7MtysIXZuj" style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_234_z56ASNq7P667" style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p id="xdx_231_zZ5hQ5I5u8Jj" style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

    <ix:exclude><table cellpadding="0" cellspacing="0" id="xdx_238_zAelnTuccaVa" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: top; text-align: left"><td style="width: 7%"><span style="font: 10pt Times New Roman, Times, Serif">Note
                                         5</span></td>
    <td style="width: 93%"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Commitments </span>- (continued)</span></td></tr>
</table></ix:exclude>

<ix:exclude><p id="xdx_239_zpJ01bTgXnG" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span style="font-style: normal">&#160;</span></span></p></ix:exclude>

<ix:exclude><table cellpadding="0" cellspacing="0" id="xdx_23E_zznMb3SjiNk" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 45pt"></td><td style="width: 18pt"><span style="font: 10pt Times New Roman, Times, Serif">d)</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Stock&#8211;based
                                         Compensation Plan &#8211; (continued)</span></td></tr></table></ix:exclude>

<ix:exclude><p id="xdx_237_z7EsyyOYzezj" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p></ix:exclude>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
aggregate intrinsic value is calculated as the difference between the exercise price of the underlying awards and the quoted market
price of the Company&#8217;s stock for the options that were in-the-money on the applicable date.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company recognized stock-based compensation expense of $<span id="xdx_908_eus-gaap--AllocatedShareBasedCompensationExpense_c20191001__20200930_pp0p0" title="Share based compensation"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2019-10-01to2020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,876,906</ix:nonFraction></span> during the year ended September 30, 2020 (2019: $<span id="xdx_903_eus-gaap--AllocatedShareBasedCompensationExpense_c20181001__20190930_pp0p0" title="Share based compensation"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2018-10-012019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">6,430,873</ix:nonFraction></span>)
in connection with the issuance and vesting &#9;of stock options and warrants in exchange for services. These amounts have been
included in general and &#9;administrative expenses and research and development expenses on the Company&#8217;s consolidated
statements of &#9;operations as follows:</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"></p>

<ix:nonNumeric contextRef="From2019-10-01to2020-09-30" escape="true" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_895_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_z10fcU3yhNC" summary="xdx: Disclosure - Commitments (Details 3)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%; margin-left: 50pt; margin-right: 30pt">
<tr style="vertical-align: bottom">
    <td style="text-align: left"><span id="xdx_8B3_zLXz9RQiDpaf" style="display: none">Schedule of general and administrative expenses and research and development expenses</span></td><td style="text-align: center">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">2020</td><td style="border-bottom: Black 1pt solid; text-align: center">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">2019</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: left">General and administrative</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--AllocatedShareBasedCompensationExpense_c20191001__20200930__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pp0p0" title="Total share based compensation" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2019-10-012020-09-30_us-gaap_GeneralAndAdministrativeExpenseMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,210,789</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--AllocatedShareBasedCompensationExpense_c20181001__20190930__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pp0p0" title="Total share based compensation" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2018-10-012019-09-30_us-gaap_GeneralAndAdministrativeExpenseMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,203,165</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Research and development</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--AllocatedShareBasedCompensationExpense_c20191001__20200930__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pp0p0" title="Total share based compensation" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2019-10-012020-09-30_us-gaap_ResearchAndDevelopmentExpenseMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,666,117</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--AllocatedShareBasedCompensationExpense_c20181001__20190930__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pp0p0" title="Total share based compensation" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2018-10-012019-09-30_us-gaap_ResearchAndDevelopmentExpenseMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,227,708</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total share based compensation</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--AllocatedShareBasedCompensationExpense_c20191001__20200930_pp0p0" title="Total share based compensation" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2019-10-01to2020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,876,906</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--AllocatedShareBasedCompensationExpense_c20181001__20190930_pp0p0" title="Total share based compensation" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2018-10-012019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">6,430,873</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
</table>



</ix:nonNumeric><p id="xdx_8A6_zzfKjvViDfk6" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 6pt 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">An
amount of approximately $<span id="xdx_900_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_pp0p0_c20200930_zOWoVSb0HVs4" title="Remaining stock based compensation"><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,040,812</ix:nonFraction></span> in stock-based compensation is expected to be recorded over the remaining term &#9;of such
options and warrants through 2023.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
fair value of each option and warrant award is estimated on the date of grant using the Black Scholes option pricing model based
on the following weighted average assumptions:</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify; text-indent: 1in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify; text-indent: 1in"></p>

<ix:nonNumeric contextRef="From2019-10-01to2020-09-30" escape="true" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_887_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zIt31fNFgdO6" summary="xdx: Disclosure - Commitments (Details 4)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; margin-left: 50pt; margin-right: 30pt; width: 80%">
<tr style="vertical-align: bottom">
    <td style="text-align: left"><span id="xdx_8B3_z2ukEIarV4Xg" style="display: none">Schedule of weighted average assumptions for fair value of each option award&#160;</span></td><td style="text-align: center">&#160;</td>
    <td colspan="3" style="text-align: center">2020</td><td style="text-align: center">&#160;</td>
    <td colspan="3" style="text-align: center">2019</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: left">Risk-free interest rate</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pii_dp_c20191001__20200930_zi7JAzbq67Lc" title="Risk-free interest rate" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2019-10-01to2020-09-30" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1.57</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pii_dp_c20181001__20190930_zLa7ChuAS8b7" title="Risk-free interest rate" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2018-10-012019-09-30" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">2.50</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected life of option (years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20191001__20200930_zmlZr7zJWeca" title="Expected life of options (years)" style="text-align: right"><ix:nonNumeric contextRef="From2019-10-01to2020-09-30" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">5.53</ix:nonNumeric></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20181001__20190930_zUSNWh7Xc5vc" title="Expected life of options (years)" style="text-align: right"><ix:nonNumeric contextRef="From2018-10-012019-09-30" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">6.05</ix:nonNumeric></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Annualized volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pii_dp_c20191001__20200930_zL7d4I6ZUXZh" title="Annualized volatility" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2019-10-01to2020-09-30" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">95.99</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pii_dp_c20181001__20190930_zL6bXerDkGPa" title="Annualized volatility" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2018-10-012019-09-30" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">104.45</ix:nonFraction></td><td style="text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Dividend rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c20191001__20200930_pii" title="Dividend rate" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2019-10-01to2020-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">0.00</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c20181001__20190930_pii" title="Dividend rate" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2018-10-012019-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">0.00</ix:nonFraction></td><td style="text-align: left">%</td></tr>
</table></ix:nonNumeric>



<p id="xdx_8A2_zVuVHQXNSVHb" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: left; text-indent: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
fair value of stock compensation charges recognized during the years ended September 30, 2020 and 2019 was determined with reference
to the quoted market price of the Company&#8217;s shares on the grant date.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 42; Value: 1 -->
    <div id="xdx_237_z909qylMFLEd" style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" id="xdx_233_zDKcOgDibfS6" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td><td id="xdx_236_zRuZGuNzyQX1" style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_23A_zOhC6nexFOia" style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p id="xdx_238_zSZRbRiSxxt6" style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23B_zrI7iK4CTjS3" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"></span></p></ix:exclude>

</ix:nonNumeric><ix:nonNumeric contextRef="From2019-10-01to2020-09-30" escape="true" name="us-gaap:IncomeTaxDisclosureTextBlock"><p id="xdx_80A_eus-gaap--IncomeTaxDisclosureTextBlock_zZZIEtMTz8z9" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: top; text-align: left"><td style="width: 7%"><span style="font: 10pt Times New Roman, Times, Serif">Note
                                         6</span></td>
    <td style="width: 93%"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline"><span id="xdx_826_z45949lVo8y4">Income Taxes</span></span></span></td></tr>
</table>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 7pt 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company&#8217;s U.S. and foreign loss before income taxes are set forth below:</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 7pt 42.55pt; text-align: justify"></p>

<ix:nonNumeric contextRef="From2019-10-01to2020-09-30" escape="true" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_89C_eus-gaap--ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_zhsAwSMkIYY" summary="xdx: Disclosure - Income Taxes (Details)" style="font: 10pt Times New Roman, Times, Serif; visibility: visible; border-collapse: collapse; margin-left: 50pt; margin-right: 30pt; width: 90%">
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="display: none"><span id="xdx_8B9_zmKV9lDcS5U5" style="display: none">Schedule of Income before Income Tax, Domestic and Foreign</span></span></td><td style="border-bottom: Black 1pt solid; text-align: center">&#160;</td>
    <td colspan="3" id="xdx_496_20191001__20200930_zGfc4t7ylrWg" style="border-bottom: Black 1pt solid; text-align: center">2020</td><td style="border-bottom: Black 1pt solid; text-align: center">&#160;</td>
    <td colspan="3" id="xdx_49B_20181001__20190930_zgXT42mjUx59" style="border-bottom: Black 1pt solid; text-align: center">2019</td></tr>
<tr id="xdx_408_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: left">United States</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td title="United States" style="width: 12%; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" contextRef="From2019-10-01to2020-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">18,096,148</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td title="United States" style="width: 12%; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" contextRef="From2018-10-012019-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">18,031,016</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
<tr id="xdx_40D_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_i_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 1pt solid">Foreign</td><td style="border-bottom: Black 1pt solid">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td title="Foreign" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" contextRef="From2019-10-01to2020-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">8,161,658</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; text-align: left">)</td><td style="border-bottom: Black 1pt solid">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td title="Foreign" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" contextRef="From2018-10-012019-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">8,181,782</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; text-align: left">)</td></tr>
<tr id="xdx_404_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 2.5pt double">Total</td><td style="border-bottom: Black 2.5pt double">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td title="Total" style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" contextRef="From2019-10-01to2020-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">26,257,806</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; text-align: left">)</td><td style="border-bottom: Black 2.5pt double">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td title="Total" style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" contextRef="From2018-10-012019-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">26,212,798</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; text-align: left">)</td></tr>
</table>



</ix:nonNumeric><p id="xdx_8AB_zwggrXkvERbe" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 7pt 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 7pt 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
components of net deferred income tax assets as of September 30, 2020 and 2019 are as follows:</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 7pt 42.55pt; text-align: justify"></p>

<ix:nonNumeric contextRef="From2019-10-01to2020-09-30" escape="true" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_89C_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zw392Ke84AT9" summary="xdx: Disclosure - Income Taxes (Details 1)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 50pt; margin-right: 30pt">
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; text-align: left"><span id="xdx_8BA_zNDtTCZntjHk" style="display: none">Schedule of deferred tax asset and liabilities&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: center">&#160;</td>
    <td colspan="3" id="xdx_496_20200930_zVi2ustoktHk" style="border-bottom: Black 1pt solid; text-align: center">2020</td><td style="border-bottom: Black 1pt solid; text-align: center">&#160;</td>
    <td colspan="3" id="xdx_49F_20190930_zuHSA5cToaE8" style="border-bottom: Black 1pt solid; text-align: center">2019</td></tr>
<tr id="xdx_401_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: left">Net operating loss carryforwards</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">23,397,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="AsOf2019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">18,704,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_40F_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Research and development tax credit carry forwards</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,069,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" contextRef="AsOf2019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,162,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_401_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">8,283,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="AsOf2019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">6,570,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40D_ecustom--DeferredTaxAssetsUnpaidCharges_iI_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Unpaid charges</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="avxl:DeferredTaxAssetsUnpaidCharges" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">83,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="avxl:DeferredTaxAssetsUnpaidCharges" contextRef="AsOf2019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">69,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40C_eus-gaap--DeferredTaxAssetsGoodwillAndIntangibleAssets_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Intangible asset costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">132,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" contextRef="AsOf2019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">30,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_403_eus-gaap--DeferredTaxAssetsUnrealizedCurrencyLosses_iI_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Foreign exchange and other</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsUnrealizedCurrencyLosses" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">27,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsUnrealizedCurrencyLosses" contextRef="AsOf2019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">15,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_408_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pp0p0_di_zhZhv1bqptZe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 1pt solid; text-align: left">Valuation allowance deferred tax assets</td><td style="border-bottom: Black 1pt solid">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">33,991,000</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; text-align: left">)</td><td style="border-bottom: Black 1pt solid">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">26,550,000</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; text-align: left">)</td></tr>
<tr id="xdx_40F_eus-gaap--DeferredTaxAssetsNet_iI_pp0p0_d0_zPHyywcRkcAb" style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 2.5pt double; text-align: left">Net deferred tax assets</td><td style="border-bottom: Black 2.5pt double">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="AsOf2020-09-30" format="ixt:zerodash" decimals="0" scale="0" unitRef="USD">&#8212;</ix:nonFraction>&#160;&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="AsOf2019-09-30" format="ixt:zerodash" decimals="0" scale="0" unitRef="USD">&#8212;</ix:nonFraction>&#160;&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td></tr>
</table>



</ix:nonNumeric><p id="xdx_8A3_zqLzdsiXZl9" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 7pt 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-indent: 0.25in"></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">A
reconciliation of income tax expense at the statutory federal income tax rate and income taxes as reflected in the consolidated
financial statements for the years ended September 30, 2020 and 2019 is as follows:</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"></p>

<ix:nonNumeric contextRef="From2019-10-01to2020-09-30" escape="true" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_89F_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zgqgnyyzqQA5" summary="xdx: Disclosure - Income Taxes (Details 2)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; margin-left: 50pt; margin-right: 30pt; width: 90%">
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; text-align: left"><span id="xdx_8B7_zyDBegXhrH9d" style="display: none">Schedule of Effective Income Tax Rate Reconciliation</span>&#160;</td><td style="border-bottom: Black 1pt solid; text-align: center">&#160;</td>
    <td colspan="3" id="xdx_498_20191001__20200930_znkPTYEv6Qyf" style="border-bottom: Black 1pt solid; text-align: center">2020</td><td style="border-bottom: Black 1pt solid; text-align: center">&#160;</td>
    <td colspan="3" id="xdx_499_20181001__20190930_zD0ElrIeVuK2" style="border-bottom: Black 1pt solid; text-align: center">2019</td></tr>
<tr id="xdx_400_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: left">Income tax benefit at statutory federal rate</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" contextRef="From2019-10-01to2020-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,519,000</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" contextRef="From2018-10-012019-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,505,000</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
<tr id="xdx_401_eus-gaap--IncomeTaxReconciliationForeignIncomeTaxRateDifferential_i_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Foreign income taxed at other rates</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" contextRef="From2019-10-01to2020-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">723,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" contextRef="From2018-10-012019-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">825,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
<tr id="xdx_40F_eus-gaap--IncomeTaxReconciliationOtherAdjustments_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other permanent differences</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationOtherAdjustments" contextRef="From2019-10-01to2020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">35,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationOtherAdjustments" contextRef="From2018-10-012019-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">140,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40C_ecustom--IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopmentCreditBenefit_i_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Research and development credit benefit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="avxl:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopmentCreditBenefit" contextRef="From2019-10-01to2020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,267,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="avxl:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopmentCreditBenefit" contextRef="From2018-10-012019-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">914,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_401_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_z1PYeXsbnRgi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">State and local taxes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" contextRef="From2019-10-01to2020-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,911,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" contextRef="From2018-10-012019-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,487,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
<tr id="xdx_40C_eus-gaap--IncomeTaxReconciliationPriorYearIncomeTaxes_i_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Adjustment and true up to prior year tax provision</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes" contextRef="From2019-10-01to2020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">373,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes" contextRef="From2018-10-012019-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">194,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_405_eus-gaap--EffectOfExchangeRateOnCash_d0_zqtfu3RSRnmg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Effect of change in statutory rates</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:EffectOfExchangeRateOnCash" contextRef="From2019-10-01to2020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">36,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:EffectOfExchangeRateOnCash" contextRef="From2018-10-012019-09-30" format="ixt:zerodash" decimals="0" unitRef="USD">&#8212;</ix:nonFraction>&#160;&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_408_eus-gaap--TaxesExcludingIncomeAndExciseTaxes_i_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">State minimum and excise taxes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:TaxesExcludingIncomeAndExciseTaxes" contextRef="From2019-10-01to2020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">22,664</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:TaxesExcludingIncomeAndExciseTaxes" contextRef="From2018-10-012019-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">82,181</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_400_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_zdxGf7UkZNn1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 1pt solid; text-align: left">Change in valuation allowances</td><td style="border-bottom: Black 1pt solid">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="From2019-10-01to2020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,442,000</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="From2018-10-012019-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,569,000</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td></tr>
<tr id="xdx_405_eus-gaap--DeferredIncomeTaxExpenseBenefit_i_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 2.5pt double; text-align: left">Income tax expense</td><td style="border-bottom: Black 2.5pt double">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="From2019-10-01to2020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">22,664</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="From2018-10-012019-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">82,181</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td></tr>
</table>



</ix:nonNumeric><p id="xdx_8AB_zx4bzKWbO3h5" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt"></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">As
of September 30, 2020, the Company had U.S. federal net operating loss carryforwards of approximately $<span id="xdx_903_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsForeign_iI_pp0n3_dm_c20200930_zhXEaby3lZqi" title="U.S. federal net operating loss carryforwards"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" scale="6" unitRef="USD">76.8</ix:nonFraction></span> million (2019: $<span id="xdx_90E_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsForeign_iI_pp0n3_dm_c20190930_zQJbU4NKSC9h" title="U.S. federal net operating loss carryforwards"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign" contextRef="AsOf2019-09-30" format="ixt:numdotdecimal" decimals="0" scale="6" unitRef="USD">60.8</ix:nonFraction></span>
million) which will begin to expire in <span id="xdx_905_ecustom--OperatingLossCarryForwardsExpirationYear1_c20191001__20200930" title="Operating loss carry-forwards, expiration year"><ix:nonNumeric contextRef="From2019-10-01to2020-09-30" name="avxl:OperatingLossCarryForwardsExpirationYear1">2027</ix:nonNumeric></span> and state and local net operating loss carryforwards of approximately $<span id="xdx_902_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_pp0n3_dm_c20200930_za50T4BqhqH6" title="State net operating loss carryforwards"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" scale="6" unitRef="USD">103.1</ix:nonFraction></span> million
(2019: $<span id="xdx_907_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_pp0n3_dm_c20190930_zLFm0TeuzsYk" title="State net operating loss carryforwards"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" contextRef="AsOf2019-09-30" format="ixt:numdotdecimal" decimals="0" scale="6" unitRef="USD">64.0</ix:nonFraction></span> million) which will begin to expire in 2036, The Company had approximately $<span id="xdx_906_eus-gaap--OperatingLossCarryforwards_iI_pp0n3_dm_c20200930__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_zTBjPg21TyNh" title="Operating loss carry-forwards"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2020-09-30_us-gaap_ForeignCountryMember" format="ixt:numdotdecimal" decimals="0" scale="6" unitRef="USD">4.3</ix:nonFraction></span> million (Approximately AUD$ <span id="xdx_908_eus-gaap--OperatingLossCarryforwards_iI_pp0n3_dm_c20200930__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember__srt--CurrencyAxis__currency--AUD_zcrplpdrDq66" title="Operating loss carry-forwards"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2020-09-30_us-gaap_ForeignCountryMember_currency_AUD" format="ixt:numdotdecimal" decimals="0" scale="6" unitRef="USD">6.0</ix:nonFraction></span> million)
(2019: $<span id="xdx_90A_eus-gaap--OperatingLossCarryforwards_iI_pp0n3_dm_c20190930__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_zqeV6iN57JN8" title="Operating loss carry-forwards"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2019-09-30_us-gaap_ForeignCountryMember" format="ixt:numdotdecimal" decimals="0" scale="6" unitRef="USD">3.5</ix:nonFraction></span> million) of net operating loss carryforwards in Australia, which have an indefinite life, available to offset future
taxable income in those jurisdictions.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 42; Value: 1 -->
    <div id="xdx_23F_zUemjLBys6hg" style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" id="xdx_236_z3n6L79WVdza" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td><td id="xdx_23C_zvm0qoQPfXgj" style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_23D_zFWKji5TLXNe" style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p id="xdx_23A_zmSPIepHH0wj" style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23E_zDOPwcR4Eetj" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p></ix:exclude>

<ix:exclude><table cellpadding="0" cellspacing="0" id="xdx_23A_z1WzTzq0oGOd" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: top; text-align: left"><td style="width: 7%"><span style="font: 10pt Times New Roman, Times, Serif">Note
                                         6</span></td>
    <td style="width: 93%"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Income taxes </span>- (continued)</span></td></tr>
</table></ix:exclude>

<ix:exclude><p id="xdx_23C_zNdLDEdj3rGj" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p></ix:exclude>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company evaluates its valuation allowance requirements based on available evidence. When circumstances change, and this causes
a change in management&#8217;s judgment about the recoverability of deferred tax assets, the impact of the change on the valuation
allowance is reflected in current income. Because management of the Company does not currently believe that it is more likely
than not that the Company will receive the benefit of these assets, a valuation allowance has been established at September 30,
2020 and 2019.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Uncertain
Tax Positions</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company files income tax returns in the U.S. federal jurisdiction and various state and local and foreign jurisdictions. The Company&#8217;s
tax returns are subject to tax examinations by U.S. federal and state tax authorities, or examinations by foreign tax authorities
until the respective statutes of limitation expire. The Company is subject to tax examinations by tax authorities for all taxation
years commencing on or after 2013.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Under
the provisions of the Internal Revenue Code, the net operating loss (&#8220;NOL&#8221;) carryforwards are subject to review and
possible adjustment by the Internal Revenue Service and state tax authorities. NOL and tax credit carryforwards may become subject
to an annual limitation in the event of an over 50% cumulative change in the ownership interest of significant stockholders over
a three-year period, as defined under Sections 382 and 383 of the Internal Revenue Code, as well as similar state tax provisions.
This could limit the amount of NOLs that the Company could be entitled to utilize annually to offset future taxable income or
tax liabilities. The amount of the annual limitation, if any, would be determined based on the value of the Company immediately
prior to the ownership change. Subsequent ownership changes may affect the limitation in future years<span style="background-color: white">.
The Company completed a Section 382 analysis through the fiscal year ended September 30, 2020 and currently does not believe Section
382 will apply to limit the utilization of available NOLs.</span></span></p>

</ix:nonNumeric><p id="xdx_813_zbx9n1urls9h" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="background-color: white">&#160;</span></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="background-color: white"></span></span></p>

<!-- Field: Page; Sequence: 42; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"></p>


<p style="font: italic bold 10.5pt Times New Roman, Times, Serif; margin: 12pt 0 3pt; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"><span id="item9"></span><b><i>ITEM
9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL MATTERS</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Not
Applicable</span></p>

<p style="font: italic bold 10.5pt Times New Roman, Times, Serif"><span style="font: normal 10pt Times New Roman, Times, Serif"><span id="item9a"></span><b><i>ITEM
9A. CONTROLS AND PROCEDURES</i></b></span></p>

<p style="font: 10.5pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-bottom: 12pt; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Disclosure
Controls and Procedures</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-bottom: 12pt; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif">We
maintain disclosure controls and procedures that are designed to provide reasonable assurance that material information required
to be disclosed in our periodic reports filed under the Exchange Act is recorded, processed, summarized, and reported within the
time periods specified in the SEC&#8217;s rules and forms and to provide reasonable assurance that such information is accumulated
and communicated to our management, our chief executive officer and our principal financial officer, to allow timely decisions
regarding required disclosure.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-bottom: 12pt; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif">We
carried out an evaluation, under the supervision and with the participation of our management, including our principal executive
and principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures, as
defined in&#160;Rule&#160;13(a)-15(e) under the Exchange Act. Based on this evaluation, our principal executive officer and principal
financial officer concluded that our disclosure controls and procedures were effective as of September 30, 2020.</span></p>

<p style="font: 10.5pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-bottom: 12pt; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Management&#8217;s
Annual Report on Internal Control over Financial Reporting </i></b></span></p>

<p style="font: 10.5pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Our
management is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rules&#160;13a-15(f)
and 15d-15(f) under the Exchange Act. Under the supervision and with the participation of our management, including our Principal
Executive Officer and Principal Financial Officer, we conducted an evaluation of the effectiveness of our internal control over
financial reporting based on criteria established in the framework in&#160;Internal Control &#8212; Integrated Framework (2013)
issued by the Committee of Sponsoring Organizations of the Treadway Commission (&#8220;COSO&#8221;).</span></p>

<p style="font: 10.5pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Because
of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections
of any evaluation of effectiveness to future periods are subject to the risks that controls may become inadequate because of changes
in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></p>

<p style="font: 10.5pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Based
on this evaluation, our management concluded that our internal controls over financial reporting were effective as of September
30, 2020.</span>&#160;</p>

<p style="font: 10.5pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Changes
in Internal Control over Financial Reporting</i></b></span></p>

<p style="font: 10.5pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">During
the quarter ended September 30, 2020, there were no changes in our internal control over financial reporting identified in management&#8217;s
evaluation pursuant to Rules 13a 15(d) or 15d 15(d) of the Exchange Act that materially affected, or are reasonably likely to
materially affect, our internal controls over financial reporting.</span></p>

<p style="font: italic bold 10.5pt Times New Roman, Times, Serif"><span style="font: normal 10pt Times New Roman, Times, Serif"><span id="item9b"></span><b><i>ITEM
9B OTHER INFORMATION</i></b></span></p>

<p style="font: 10.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<p style="font: 10.5pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">None.</span></p>

<!-- Field: Page; Sequence: 42; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

    <p style="font: bold 10.5pt Times New Roman, Times, Serif; margin: 12pt 0 0"><span style="font: 10pt Times New Roman, Times, Serif"><span id="part3"></span>PART
III</span></p>

<p style="font: italic bold 10.5pt Times New Roman, Times, Serif; margin: 12pt 0 3pt"><span style="font: normal 10pt Times New Roman, Times, Serif"><span id="item10"></span><b><i>ITEM
10 DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</i></b>
</span></p>

<p style="font: 10.5pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-bottom: 12pt; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Directors
and Executive Officers</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Our
directors are to be elected at our annual meeting and each director elected is to hold office until his or her successor is elected
and qualified. Our board of directors may remove our officers at any time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Our
directors and executive officers, their age, positions held, and duration of such, are as follows:</span></p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 28%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Name</b></span></td>
    <td style="width: 37%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Position</b></span></td>
    <td style="width: 10%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Age</b></span></td>
    <td style="width: 25%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Date
    first appointed</b></span></td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"><span style="font: 10pt Times New Roman, Times, Serif">Christopher
    Missling, PhD</span></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"><span style="font: 10pt Times New Roman, Times, Serif">Director,
    President, Chief Executive Officer, Secretary</span></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">55</span></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">July
    5, 2013</span></td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Athanasios
    Skarpelos</span></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Director</span></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">54</span></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">January
    9, 2013</span></td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Claus
    van der Velden, PhD</span></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Director</span></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">48</span></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">March
    2, 2018</span></td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Elliot
    Favus, MD</span></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Director</span></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">46</span></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">May
    7, 2014</span></td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Steffen
    Thomas, PhD</span></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Director</span></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">54</span></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">June
    15, 2015</span></td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Peter
    Donhauser, D.O.</span></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Director</span></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">55</span></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">February
    8, 2017</span></td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Sandra
    Boenisch, CPA, CGA</span></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"><span style="font: 10pt Times New Roman, Times, Serif">Principal
    Financial Officer, Treasurer</span></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">39
    </span></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">October
    1, 2015</span></td></tr>
</table>
<p style="font: 10.5pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-bottom: 12pt; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Business
Experience</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
following is a brief account of the education and business experience of directors and executive officers during at least the
past five years, indicating their principal occupation during the period, and the name and principal business of the organization
by which they were employed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Christopher
Missling, PhD</span>. Christopher Missling has over twenty years of healthcare industry experience in big pharmaceutical, biotech
industry and investment banking. Most recently, from March 2007 until his appointment by our Company, Dr. Missling served as the
head of healthcare investment banking at Brimberg &amp; Co. in New York, New York. Also, Dr. Missling served as the Chief Financial
Officer of Curis, Inc. (NASDAQ:CRIS) and ImmunoGen, Inc. (NASDAQ:IMGN). Dr. Missling earned his MS and PhD from the University
of Munich and an MBA from Northwestern University Kellogg School of Management and WHU Otto Beisheim School of Management.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Athanasios
Skarpelos</span>. Athanasios (Tom) Skarpelos is a self-employed investor with over 20 years of experience working with
private and public companies. For more than 12 years, he has been focused on biotechnology companies involved in drug
discovery and drug development projects. His experience has led to relationships with researchers at academic institutes in
Europe and North America. Mr. Skarpelos is a founder of Anavex.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Claus
van der Velden, PhD</span>. Claus van der Velden, PhD, brings significant expertise in management, accounting, internal controls
and risk management. Since July of 2011, he has served as corporate head of Management Accounting, Internal Audit and Risk Management
at Stroeer SE &amp; Co KGaA, a publicly listed German digital media company. Previously, Dr. van der Velden served as the Director
of Corporate Business Controlling for the Nutrition &amp; Health business unit at Cognis, a worldwide supplier of global nutritional
ingredients and specialty chemicals. In this position, he was also a compliance representative and a member of the global leadership
team. After the acquisition of Cognis by BASF, he was responsible for the management accounting processes of the BASF Nutrition
&amp; Health division, developing and producing mostly natural-source ingredients for the food and healthcare industries. Dr.
van der Velden started his career as a strategy consultant at an international marketing and strategy consultancy firm. He studied
in Kiel and Stockholm and received a degree in economics from the University of Kiel and later obtained his doctorate in business
management from the WHU-Otto Beisheim School of Management where he also previously taught economics.</span></p>

<!-- Field: Page; Sequence: 42; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Elliot
Favus, MD.</span> Elliot Favus is Chief Executive Officer of Favus Institutional Research, a healthcare research firm serving institutional
investors. He has been a healthcare equity research analyst on Wall Street since 2006, starting at Lazard Capital Markets and
subsequently at Och-Ziff Capital Management Group. Prior to working on Wall Street, Dr. Favus was an Instructor in medicine at
Mount Sinai School of Medicine in New York. He attended the University of Michigan (BA, 1996), the University of Chicago Pritzker
School of Medicine (MD, 2001) and the NYU-Bellevue Hospital Internal Medicine Residency Program (2004). He is board-certified
in Internal Medicine (2004) and has 10 years of basic science laboratory experience working on human genetics projects at Harvard
Medical School, the University of Chicago and the University of Pittsburgh.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Steffen
Thomas, PhD. </span>Steffen Thomas, has over 15 years of experience as a European patent attorney and is currently practicing at
Epping Hermann Fischer, a major intellectual property law firm in Europe. Previously, he worked for Japan-based Takeda Pharmaceutical
Company, the largest pharmaceutical company in Asia and a top firm worldwide, as an in-house patent attorney. Prior to that, he
worked for Nycomed Pharma, acquired by Takeda in 2011 for approximately USD $10 billion. Dr. Thomas&#8217; legal practice covers
drafting of patent applications, prosecuting patent applications before national and international patent offices, defending and
challenging patents in opposition, appeal, and nullity proceedings, enforcing patents before the infringement courts, and preparing
opinions on patentability and infringement in the technical field of chemistry. Dr. Thomas has particular expertise in small molecule
pharmaceuticals. He holds MS and PhD degrees in Chemistry from the University of Munich.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Peter
Donhauser, D.O.</span> Peter Donhauser, had more than 20 years of expertise in clinical research prior to practicing osteopathic
medicine with an integrated medical approach in private practice beginning in 2000. He worked at the University Hospital of Munich
in the fields of geriatrics and neuromusculoskeletal diseases.&#160; During this time, he was a clinical trial investigator in
multiple Phase 3 studies, including studies sponsored by Merck Sharp &amp; Dohme, Merck, Boehringer Mannheim, Roche, Servier and
Sanofi. He received his human medicine degree at the University of Munich and Doctor of Osteopathic Medicine (D.O.) from the German-American
Academy for Osteopathy, or DAAO, a member of the European Register for Osteopathic Physicians, or EROP, at the Philadelphia College
of Osteopathic Medicine.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Sandra
Boenisch, CPA, CGA.</span> Ms. Boenisch is a Chartered Professional Accountant (CPA, CGA) with over 15 years of accounting, audit,
and financial reporting experience in a variety of industries, both in the United States and Canada. Ms. Boenisch was an independent
consultant, providing financial reporting services to a range of public companies in the United States and Canada since January
2012. From 2008 until 2012, Ms. Boenisch was employed at BDO Canada LLP (Vancouver, BC) where she was hired as a Senior Accountant
and was later promoted to Manager, Audit Assurance. Ms. Boenisch specialized in managing assurance engagements for public companies
in the United States and Canada. Prior to that, Ms. Boenisch worked for another public accounting firm from 2001 to 2008. As an
independent consultant, Ms. Boenisch has acquired considerable experience in finance, governance, and regulatory compliance. She
holds a BComm from Laurentian University.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-bottom: 12pt; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Family
Relationships</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">There
are no family relationships between any director or executive officer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-bottom: 12pt; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Involvement
in Certain Legal Proceedings</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">There
are no material proceedings to which any director or executive officer or any associate of any such director or officer is a party
adverse to our Company or has a material interest adverse to our Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-bottom: 12pt; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Compliance
with Section 16(a) of the Securities Exchange Act of 1934 </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Section
16(a) of the Securities Exchange Act of 1934 requires our executive officers and directors and persons who own more than 10% of
our common stock to file with the Securities and Exchange Commission initial statements of beneficial ownership, reports of changes
in ownership and annual reports concerning their ownership of our common stock and other equity securities, on Forms 3, 4 and
5 respectively. Executive officers, directors and greater than 10% shareholders are required by the Securities and Exchange Commission
regulations to furnish us with copies of all Section 16(a) reports that they file.</span></p>

<!-- Field: Page; Sequence: 42; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Based
solely on the copies of such reports and amendments thereto received by us, or written representations that no filings were required,
we believe that all Section 16(a) filing requirements applicable to our executive officers and directors and 10% stockholders
were met for the year ended September 30, 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Code
of Ethics</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
have adopted a code of ethics that applies to our directors, principal executive officer, principal financial officer, principal
accounting officer or controller, or persons performing similar functions, and to all employees. We have posted our policy on
our website at <span style="text-decoration: underline">www.anavex.com</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-bottom: 12pt; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Audit
Committee and Audit Committee Financial Experts </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
members of the Audit Committee are Claus van der Velden (Chairman), Athanasios Skarpelos and Steffen Thomas. Our board of directors
has determined that Claus van der Velden is an &#8220;audit committee financial expert&#8221; as defined by applicable SEC and
Nasdaq rules.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Audit Committee oversees and reports to our board of directors on various auditing and accounting-related matters, including,
among other things, the maintenance of the integrity of our financial statements, reporting process and internal controls; the
selection, evaluation, compensation and retention of our independent registered public accounting firm; legal and regulatory compliance,
including our disclosure controls and procedures; and oversight over our risk management policies and procedures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Audit Committee operates under a charter that was adopted by our board of directors. The Audit Committee met five times during
fiscal 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Nominating
and Corporate Governance Committee</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
members of our Nominating and Corporate Governance Committee are Claus van der Velden (Chairman), Steffen Thomas and Peter Donhauser.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Nominating and Corporate Governance Committee is appointed by the Board to oversee and evaluate the Board's performance and the
company's compliance with corporate governance regulations, guidelines and principles, to identify individuals qualified to become
Board members, to recommend to the Board proposed nominees for Board membership, and to recommend to the Board directors to serve
on each standing committee. The Nominating and Corporate Governance Committee did not meet but did act by written consent during
fiscal 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Compensation
Committee</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
members of our Compensation Committee are Claus van der Velden (Chairman), Steffen Thomas and Peter Donhauser.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Compensation Committee assists our board of directors in discharging its responsibilities relating to compensation of our directors
and executive officers. Its responsibilities include, among other things, reviewing, approving and recommending compensation programs
and arrangements applicable to our officers; determining the objectives of our executive officer compensation programs; overseeing
the evaluation of our senior executives; administering our incentive compensation plans and equity-based plans, including reviewing
and granting equity awards to our executive officers; and reviewing and approving director compensation and benefits. The Compensation
Committee can delegate to other members of our board of directors, or an officer or officers of the Company, the authority to
review and grant stock-based compensation for employees who are not executive officers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Compensation Committee has the responsibilities and authority designated by Nasdaq rules. Specifically, the Compensation Committee
has the sole discretion to select and receive advice from a compensation consultant, legal counsel or other adviser and is directly
responsible for oversight of their work. The Compensation Committee must also determine reasonable compensation to be paid to
such advisors by us.</span></p>

<!-- Field: Page; Sequence: 42; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><span style="font: 10pt Times New Roman, Times, Serif">Prior
to the formation of our Compensation Committee, our board of directors performed the functions that would have been handled by
the Compensation Committee.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Compensation Committee operates under a charter that was adopted by our board of directors. The Compensation Committee met one
time during fiscal 2020 and also acted by written consent as required.</span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 12pt 0"><span style="font: normal 10pt Times New Roman, Times, Serif"><span id="item11"></span><b><i>ITEM
11. EXECUTIVE COMPENSATION</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company&#8217;s compensation objectives are to offer our executive officers&#8217; compensation and benefits that are competitive
and meet our goals of attracting, retaining and motivating highly skilled, talented management, which is necessary for the Company
to achieve its financial and strategic objectives and create long-term value for our stockholders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">A
significant portion of the Company&#8217;s executive compensation opportunity is related to factors that directly and indirectly
influence shareholder value, including long-term stock performance and operational performance. We believe the levels of compensation
we provide should be competitive, reasonable and appropriate for our business needs and circumstances.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: #252525"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Our
Executive Compensation Program and Philosophy</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
intent of the Company&#8217;s compensation program is to attract and retain talent, to create incentives for and to reward excellent
performance. We seek to compensate our executives in a manner that is competitive, rewards performance that creates shareholder
value, recognizes individual contributions, and encourages long-term value creation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Compensation Committee meets at least twice per year to review and evaluate executive compensation and each executive officer&#8217;s
performance. The Compensation Committee utilizes quantitative and qualitative factors, including the accomplishment of initiatives,
attitude, and leadership and applies overall judgment to assess performance, taking into account the financial condition of the
Company. Ultimately, the Compensation Committee seeks to evaluate, based on the achievement of financial and nonfinancial objectives,
the variable compensation, including special awards, of executive officers of the Company and decide on the base salary and target
discretionary bonus for such persons taking into account relevant benchmark data.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Compensation Committee believes that a significant portion of each executive&#8217;s compensation opportunity should be tied to
variable compensation and value creation for shareholders. The Compensation Committee believes this mix provides an appropriate
balance between the financial security required to attract and retain qualified individuals, and the Compensation Committee&#8217;s
goal of ensuring that executive compensation rewards performance that benefits shareholders over the long term.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: #252525"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Compensation
Consultants</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Compensation Committee makes recommendations to the Board for all compensation for executives, including the structure and design
of the compensation programs. The Compensation Committee is responsible for retaining and terminating compensation consultants
and determining the terms and conditions of their engagement. During fiscal 2020, the Compensation Committee did not engage any
compensation consultants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: #252525"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Annual
Discretionary Cash Bonuses</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company has an annual discretionary cash bonus program. The Compensation Committee, or board of directors works with the Chief
Executive Officer to evaluate the Company&#8217;s financial performance and overall financial condition to determine if discretionary
bonuses are to be paid.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: #252525"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Benefits</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company&#8217;s executives are entitled to participate in employee benefit plans, programs and arrangements implemented by the
Company and generally available to all salaried employees, such as medical, dental and insurance programs. Executives are also
allowed to participate in the Company&#8217;s tax-qualified 401(k) Plan offered to all similarly situated full-time employees.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<!-- Field: Page; Sequence: 42; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-bottom: 12pt; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Summary
Compensation </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
particulars of compensation paid to our named executive officers for the last two completed fiscal years:</span></p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="padding: 2.25pt; width: 25%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"><br />
                                         <br /></span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>Name
        and Principal&#160;</b><br />
        <b>Position</b></span></p></td>
    <td style="font: 12pt Arial, Helvetica, Sans-Serif; padding: 2.25pt; width: 8%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><br />
    <br />
    <br />
    <b>Year</b></span></td>
    <td style="font: 12pt Arial, Helvetica, Sans-Serif; padding: 2.25pt; width: 12%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><br />
    <br />
    <b>Salary&#160;</b><br />
    <b>($)</b></span></td>
    <td style="font: 12pt Arial, Helvetica, Sans-Serif; padding: 2.25pt; width: 9%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><br />
    <br />
    <b>Bonus&#160;</b><br />
    <b>($)</b></span></td>
    <td style="font: 12pt Arial, Helvetica, Sans-Serif; padding: 2.25pt; width: 12%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><br />
    <b>Stock&#160;</b><br />
    <b>Awards&#160;</b><br />
    <b>($)</b></span></td>
    <td style="font: 12pt Arial, Helvetica, Sans-Serif; padding: 2.25pt; width: 12%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><br />
    <b>Option&#160;</b><br />
    <b>Awards&#160;</b><br />
    <b>($)</b></span></td>
    <td style="font: 12pt Arial, Helvetica, Sans-Serif; padding: 2.25pt; width: 12%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Other&#160;&#160;</b><br />
    <b>Compen-&#160;</b><br />
    <b>sation&#160;</b><br />
    <b>($)</b></span></td>
    <td style="font: 12pt Arial, Helvetica, Sans-Serif; padding: 2.25pt; width: 10%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><br />
    <br />
    <b>Total&#160;</b><br />
    <b>($)</b></span></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding: 2.25pt"><p style="font: 9pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">Christopher
                                Missling, PhD</span></p>
        <p style="font: 9pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">President,
        Chief Executive Officer, and Director</span></p></td>
    <td style="padding: 2.25pt"><p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">2020</span></p>
        <p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">2019</span></p></td>
    <td style="padding: 2.25pt"><p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">550,000</span></p>
        <p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">512,500</span></p></td>
    <td style="padding: 2.25pt"><p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">55,000</span></p>
        <p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">50,000</span></p></td>
    <td style="padding: 2.25pt"><p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">-</span></p>
        <p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">-</span></p></td>
    <td style="padding: 2.25pt"><p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">1,224,648</span></p>
        <p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">2,806,339</span></p></td>
    <td style="padding: 2.25pt"><p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">11,400</span></p>
        <p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">11,200</span></p></td>
    <td style="padding: 2.25pt"><p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">1,841,048</span></p>
        <p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">3,380,039</span></p></td></tr>
<tr style="vertical-align: top; background-color: White">
    <td style="padding: 2.25pt">&#160;</td>
    <td style="padding: 2.25pt">&#160;</td>
    <td style="padding: 2.25pt">&#160;</td>
    <td style="padding: 2.25pt">&#160;</td>
    <td style="padding: 2.25pt">&#160;</td>
    <td style="padding: 2.25pt">&#160;</td>
    <td style="padding: 2.25pt">&#160;</td>
    <td style="padding: 2.25pt">&#160;</td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding: 2.25pt"><p style="font: 9pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">Sandra
                                Boenisch<sup>(1)</sup></span></p>
        <p style="font: 9pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">Principal
        Financial Officer and Treasurer</span></p></td>
    <td style="padding: 2.25pt"><p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">2020</span></p>
        <p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">2019</span></p>
        <p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p></td>
    <td style="padding: 2.25pt"><p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">117,041</span></p>
        <p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">72,327</span></p>
        <p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p></td>
    <td style="padding: 2.25pt"><p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">22,313</span></p>
        <p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">13,561</span></p>
        <p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p></td>
    <td style="padding: 2.25pt"><p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">-</span></p>
        <p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">-</span></p>
        <p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p></td>
    <td style="padding: 2.25pt"><p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">155,864</span></p>
        <p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">138,672</span></p>
        <p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p></td>
    <td style="padding: 2.25pt"><p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">-</span></p>
        <p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">-</span></p>
        <p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p></td>
    <td style="padding: 2.25pt"><p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">295,218</span></p>
        <p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">224,560</span></p></td></tr>
<tr style="vertical-align: top; background-color: White">
    <td style="font: 12pt Arial, Helvetica, Sans-Serif; padding: 2.25pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 12pt Arial, Helvetica, Sans-Serif; padding: 2.25pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 12pt Arial, Helvetica, Sans-Serif; padding: 2.25pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 12pt Arial, Helvetica, Sans-Serif; padding: 2.25pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 12pt Arial, Helvetica, Sans-Serif; padding: 2.25pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 12pt Arial, Helvetica, Sans-Serif; padding: 2.25pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 12pt Arial, Helvetica, Sans-Serif; padding: 2.25pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 12pt Arial, Helvetica, Sans-Serif; padding: 2.25pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>
<table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 10pt"><tr style="vertical-align: top">
<td style="width: 6.55pt"></td><td style="width: 21.8pt"><span style="font: 10pt Times New Roman, Times, Serif">(1)</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">Compensation
                                         to Ms. Boenisch denominated in Canadian Dollars has been translated to US dollars
                                         at an exchange rate of 0.7438 during the year ended September 30, 2020 (2019: 0.7534).</span></td></tr></table>

<p style="font: 10.5pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-bottom: 12pt; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Employment
Agreements</i></b></span></p>

<p style="font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0 12pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>Christopher
Missling</b></span></p>

<p style="font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
and Dr. Missling entered into an employment agreement dated July 5, 2013, as amended and extended (the &#8220;CEO Employment Agreement&#8221;),
whereby we currently pay to Dr. Missling an annual base salary of $550,000. In addition, Dr. Missling is eligible to earn an annual
cash bonus for each whole or partial calendar year of up to twenty percent of his base salary, and to participate in our employee
benefit plans. We have agreed to indemnify Dr. Missling in connection with his provision of services to us.</span></p>

<p style="font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0 12pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>Sandra
Boenisch</b></span></p>

<p style="font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
and Ms. Boenisch entered into an amended and restated employment agreement dated October 4, 2017, as amended and extended, whereby
we currently pay Ms. Boenisch an annual base salary of $200,000 Canadian dollars, effective March 1, 2020. Ms. Boenisch is eligible
for discretionary salary increases.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-bottom: 12pt; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Outstanding
Equity Awards at Fiscal Year-End </i></b></span></p>

<p style="font: 10.5pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
following table sets forth for each named executive officer and director certain information concerning the outstanding equity
awards as of September 30, 2020.</span></p>

<!-- Field: Page; Sequence: 42; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

    <p style="font: 10.5pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top; background-color: #D9D9D9">
    <td colspan="6" style="font: 12pt Arial, Helvetica, Sans-Serif; padding: 2.25pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Option
    Awards</span></td>
    <td colspan="4" style="font: 12pt Arial, Helvetica, Sans-Serif; padding: 2.25pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;Stock
    Awards</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="font: 12pt Arial, Helvetica, Sans-Serif; padding: 2.25pt; width: 9%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><br />
    <br />
    <br />
    <br />
    <br />
    <br />
    <br />
    <br />
    <br />
    <br />
    <br />
    <br />
    <br />
    <br />
    Name</span></td>
    <td style="padding: 2.25pt; width: 11%"><p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><br />
                                         <br />
                                         <br />
                                         <br />
                                         <br />
                                         <br />
                                         <br /></span></p>
        <p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>
        <p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><br />
        Number of&#160;<br />
        Securities&#160;<br />
        Underlying&#160;<br />
        Exercisable<br />
        Options&#160;<br />
        (#)</span></p></td>
    <td style="font: 12pt Arial, Helvetica, Sans-Serif; padding: 2.25pt; width: 12%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><br />
    <br />
    <br />
    <br />
    <br />
    <br />
    <br />
    <br />
    <br />
    Number of&#160;<br />
    Securities&#160;<br />
    Underlying&#160;<br />
    Unexercisable&#160;<br />
    Options&#160;<br />
    (#)</span></td>
    <td style="font: 12pt Arial, Helvetica, Sans-Serif; padding: 2.25pt; width: 8%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><br />
    <br />
    Equity Incentive&#160;<br />
    Plan Awards:&#160;<br />
    Number of&#160;<br />
    Securities&#160;<br />
    Underlying&#160;<br />
    Unexercised&#160;<br />
    Unearned Options&#160;<br />
    (#)</span></td>
    <td style="font: 12pt Arial, Helvetica, Sans-Serif; padding: 2.25pt; width: 10%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><br />
    <br />
    <br />
    <br />
    <br />
    <br />
    <br />
    <br />
    <br />
    <br />
    <br />
    Option Exercise&#160;<br />
    Price&#160;<br />
    ($)</span></td>
    <td style="font: 12pt Arial, Helvetica, Sans-Serif; padding: 2.25pt; width: 17%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><br />
    <br />
    <br />
    <br />
    <br />
    <br />
    <br />
    <br />
    <br />
    <br />
    <br />
    <br />
    Option&#160;<br />
    Expiration&#160;<br />
    Date</span></td>
    <td style="font: 12pt Arial, Helvetica, Sans-Serif; padding: 2.25pt; width: 7%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><br />
    <br />
    <br />
    <br />
    <br />
    <br />
    Number of&#160;<br />
    Shares of&#160;<br />
    Units of Stock&#160;<br />
    that have not&#160;<br />
    Vested&#160;<br />
    (#)</span></td>
    <td style="font: 12pt Arial, Helvetica, Sans-Serif; padding: 2.25pt; width: 8%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><br />
    <br />
    <br />
    <br />
    <br />
    <br />
    <br />
    Market&#160;<br />
    Value of&#160;<br />
    Shares or&#160;<br />
    Units of&#160;<br />
    Stock that&#160;<br />
    have not&#160;<br />
    Vested&#160;<br />
    ($)</span></td>
    <td style="font: 12pt Arial, Helvetica, Sans-Serif; padding: 2.25pt; width: 9%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Equity&#160;<br />
    Incentive&#160;<br />
    Plan&#160;<br />
    Awards:&#160;<br />
    Number&#160;<br />
    of&#160;<br />
    Unearned&#160;<br />
    Shares,&#160;<br />
    Units or&#160;<br />
    Other&#160;<br />
    Rights&#160;<br />
    that have&#160;<br />
    not&#160;<br />
    Vested&#160;<br />
    (#)</span></td>
    <td style="font: 12pt Arial, Helvetica, Sans-Serif; padding: 2.25pt; width: 9%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Equity&#160;<br />
    Incentive&#160;<br />
    Plan&#160;<br />
    Awards:&#160;<br />
    Market or&#160;<br />
    Payout&#160;<br />
    Value of&#160;<br />
    Unearned&#160;<br />
    Shares,&#160;<br />
    Units or&#160;<br />
    Other&#160;<br />
    Rights that&#160;<br />
    have not&#160;<br />
    Vested&#160;<br />
    ($)</span></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 12pt Arial, Helvetica, Sans-Serif; padding: 2.25pt"><span style="font: 10pt Times New Roman, Times, Serif">Christopher
    Missling</span></td>
    <td style="padding: 2.25pt"><p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">500,000</span></p>
        <p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">125,000</span></p>
        <p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">500,000</span></p>
        <p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">187,500</span></p>
        <p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">379,625</span></p>
        <p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">861,429</span></p>
        <p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">500,000</span></p>
        <p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">450,000</span></p>
        <p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">366,666</span></p>
        <p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">450,000</span></p>
        <p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">409,500</span></p>
        <p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">250,000</span></p>
        <p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">-</span></p>
        <p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p></td>
    <td style="padding: 2.25pt"><p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">-</span></p>
        <p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">-</span></p>
        <p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">-</span></p>
        <p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">-</span></p>
        <p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">-</span></p>
        <p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">-</span></p>
        <p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">-</span></p>
        <p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">-</span></p>
        <p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">33,334</span></p>
        <p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">-</span></p>
        <p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">-</span></p>
        <p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">500,000</span></p>
        <p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">550,000</span></p></td>
    <td style="padding: 2.25pt"><p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">-</span></p>
        <p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">-</span></p>
        <p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">-</span></p>
        <p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">-</span></p>
        <p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">-</span></p>
        <p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">-</span></p>
        <p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">-</span></p>
        <p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">-</span></p>
        <p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">-</span></p>
        <p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">-</span></p>
        <p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">-</span></p>
        <p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">-</span></p>
        <p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">-</span></p></td>
    <td style="padding: 2.25pt"><p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">1.60</span></p>
        <p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">1.32</span></p>
        <p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">0.92</span></p>
        <p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">5.04</span></p>
        <p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">6.26</span></p>
        <p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">7.06</span></p>
        <p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">3.28</span></p>
        <p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">5.92</span></p>
        <p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">3.30</span></p>
        <p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">2.30</span></p>
        <p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">2.58</span></p>
        <p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">3.15</span></p>
        <p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">2.96</span></p></td>
    <td style="padding: 2.25pt"><p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">July
                                5, 2023</span></p>
        <p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">May
        8, 2024</span></p>
        <p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">April
        2, 2025</span></p>
        <p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Sept
        18, 2025</span></p>
        <p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">July
        5, 2026</span></p>
        <p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">July
        18, 2026</span></p>
        <p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Sept
        22, 2026</span></p>
        <p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">May
        12, 2027</span></p>
        <p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Dec
        13, 2027</span></p>
        <p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">May
        15, 2028</span></p>
        <p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Oct.
        1, 2028</span></p>
        <p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">May
        3, 2029</span></p>
        <p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">January
        6, 2030</span></p></td>
    <td style="font: 12pt Arial, Helvetica, Sans-Serif; padding: 2.25pt 2.25pt 12pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">-</span></td>
    <td style="font: 12pt Arial, Helvetica, Sans-Serif; padding: 2.25pt 2.25pt 12pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">-</span></td>
    <td style="font: 12pt Arial, Helvetica, Sans-Serif; padding: 2.25pt 2.25pt 12pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">-</span></td>
    <td style="font: 12pt Arial, Helvetica, Sans-Serif; padding: 2.25pt 2.25pt 12pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">-</span></td></tr>
<tr style="vertical-align: top; background-color: White">
    <td style="font: 12pt Arial, Helvetica, Sans-Serif; padding: 2.25pt">&#160;</td>
    <td style="padding: 2.25pt">&#160;</td>
    <td style="padding: 2.25pt">&#160;</td>
    <td style="padding: 2.25pt">&#160;</td>
    <td style="padding: 2.25pt">&#160;</td>
    <td style="padding: 2.25pt">&#160;</td>
    <td style="font: 12pt Arial, Helvetica, Sans-Serif; padding: 2.25pt 2.25pt 12pt; text-align: center">&#160;</td>
    <td style="font: 12pt Arial, Helvetica, Sans-Serif; padding: 2.25pt 2.25pt 12pt; text-align: center">&#160;</td>
    <td style="font: 12pt Arial, Helvetica, Sans-Serif; padding: 2.25pt 2.25pt 12pt; text-align: center">&#160;</td>
    <td style="font: 12pt Arial, Helvetica, Sans-Serif; padding: 2.25pt 2.25pt 12pt; text-align: center">&#160;</td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 12pt Arial, Helvetica, Sans-Serif; padding: 2.25pt 2.25pt 12pt"><span style="font: 10pt Times New Roman, Times, Serif">Sandra
    Boenisch</span></td>
    <td style="padding: 2.25pt"><p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">25,000</span></p>
        <p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">106,696</span></p>
        <p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">35,000</span></p>
        <p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">27,500</span></p>
        <p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">30,000</span></p>
        <p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">27,300<br />
        -</span></p>
        <p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">-</span></p></td>
    <td style="padding: 2.25pt"><p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">-</span></p>
        <p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">-</span></p>
        <p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">-</span></p>
        <p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">2,500</span></p>
        <p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">-</span></p>
        <p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">-<br />
        35,000</span></p>
        <p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">70,000</span></p></td>
    <td style="padding: 2.25pt"><p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">-</span></p>
        <p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">-</span></p>
        <p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">-</span></p>
        <p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">-</span></p>
        <p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">-</span></p>
        <p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">-<br />
        -</span></p>
        <p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">-</span></p></td>
    <td style="padding: 2.25pt"><p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">5.68</span></p>
        <p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">3.28</span></p>
        <p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">5.92</span></p>
        <p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">3.30</span></p>
        <p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">2.30</span></p>
        <p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">2.58<br />
        2.93</span></p>
        <p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">2.96</span></p></td>
    <td style="padding: 2.25pt"><p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Oct
                                2, 2025</span></p>
        <p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Sept
        22, 2026</span></p>
        <p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">May
        12, 2027</span></p>
        <p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Dec
        13, 2027</span></p>
        <p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">May
        15, 2028</span></p>
        <p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Oct.
        1, 2028</span></p>
        <p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">June
        4, 2029</span></p>
        <p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">January
        6, 2030</span></p></td>
    <td style="font: 12pt Arial, Helvetica, Sans-Serif; padding: 2.25pt 2.25pt 12pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">-</span></td>
    <td style="font: 12pt Arial, Helvetica, Sans-Serif; padding: 2.25pt 2.25pt 12pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">-</span></td>
    <td style="font: 12pt Arial, Helvetica, Sans-Serif; padding: 2.25pt 2.25pt 12pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">-</span></td>
    <td style="font: 12pt Arial, Helvetica, Sans-Serif; padding: 2.25pt 2.25pt 12pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">-</span></td></tr>
</table>
<p style="font: 10.5pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Stock
Option Plans</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">For
a description of our Equity Compensation Plans, please see Item 5 to this annual report on Form 10-K.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-bottom: 12pt; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Compensation
of Directors </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
table below shows the compensation of our directors who were not our named executive officers for the fiscal year ended September
30, 2020:</span></p>

<!-- Field: Page; Sequence: 42; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="padding: 2.25pt; width: 26%"><p style="font: 10.5pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"><br />
                                         <br />
                                         <br />
                                         <br /></span></p>
        <p style="font: 10.5pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>Name</b></span></p></td>
    <td style="padding: 2.25pt; width: 12%"><p style="font: 10.5pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>
        <p style="font: 10.5pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Fees
        Earned or Paid in Cash</b><br />
        <b>($)</b></span></p></td>
    <td style="padding: 2.25pt; width: 9%"><p style="font: 10.5pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>
        <p style="font: 10.5pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>
        <p style="font: 10.5pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Stock&#160;</b><br />
        <b>Awards&#160;</b><br />
        <b>($)</b></span></p></td>
    <td style="padding: 2.25pt; width: 10%"><p style="font: 10.5pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>
        <p style="font: 10.5pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>
        <p style="font: 10.5pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Option&#160;</b><br />
        <b>Awards&#160;</b><br />
        <b>($) <sup>(1)</sup></b></span></p></td>
    <td style="font: 12pt Arial, Helvetica, Sans-Serif; padding: 2.25pt; width: 12%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Non-Equity
    Incentive Plan Compensation ($)</b></span></td>
    <td style="font: 12pt Arial, Helvetica, Sans-Serif; padding: 2.25pt; width: 12%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Nonqualified
    Deferred Compensation Earnings ($)</b></span></td>
    <td style="padding: 2.25pt; width: 10%"><p style="font: 10.5pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>
        <p style="font: 10.5pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>
        <p style="font: 10.5pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>All
        Other Compensation&#160;($)</b></span></p></td>
    <td style="padding: 2.25pt; width: 9%"><p style="font: 10.5pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><br />
                                         <br /></span></p>
        <p style="font: 10.5pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>
        <p style="font: 10.5pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Total&#160;</b><br />
        <b>($)</b></span></p></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 12pt Arial, Helvetica, Sans-Serif; padding: 2.25pt"><span style="font: 10pt Times New Roman, Times, Serif">Athanasios
    Skarpelos</span></td>
    <td style="font: 12pt Arial, Helvetica, Sans-Serif; padding: 2.25pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">-</span></td>
    <td style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-top: 2.25pt; padding-right: 2.25pt; padding-left: 2.25pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">-</span></td>
    <td style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-top: 2.25pt; padding-right: 2.25pt; padding-left: 2.25pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">111,320</span></td>
    <td style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-top: 2.25pt; padding-right: 2.25pt; padding-left: 2.25pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">-</span></td>
    <td style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-top: 2.25pt; padding-right: 2.25pt; padding-left: 2.25pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">-</span></td>
    <td style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-top: 2.25pt; padding-right: 2.25pt; padding-left: 2.25pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">-</span></td>
    <td style="font: 11pt Calibri, Helvetica, Sans-Serif; padding-top: 2.25pt; padding-right: 2.25pt; padding-left: 2.25pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">111,320</span></td></tr>
<tr style="vertical-align: top; background-color: White">
    <td style="font: 12pt Arial, Helvetica, Sans-Serif; padding: 2.25pt"><span style="font: 10pt Times New Roman, Times, Serif">Claus
    van der Velden</span></td>
    <td style="font: 12pt Arial, Helvetica, Sans-Serif; padding: 2.25pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">16,000</span></td>
    <td style="font: 12pt Arial, Helvetica, Sans-Serif; padding: 2.25pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">-</span></td>
    <td style="font: 12pt Arial, Helvetica, Sans-Serif; padding: 2.25pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">111,320</span></td>
    <td style="font: 12pt Arial, Helvetica, Sans-Serif; padding: 2.25pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">-</span></td>
    <td style="font: 12pt Arial, Helvetica, Sans-Serif; padding: 2.25pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">-</span></td>
    <td style="font: 12pt Arial, Helvetica, Sans-Serif; padding: 2.25pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">-</span></td>
    <td style="font: 12pt Arial, Helvetica, Sans-Serif; padding: 2.25pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">127,320</span></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 12pt Arial, Helvetica, Sans-Serif; padding: 2.25pt"><span style="font: 10pt Times New Roman, Times, Serif">Elliot
    Favus</span></td>
    <td style="font: 12pt Arial, Helvetica, Sans-Serif; padding: 2.25pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">-</span></td>
    <td style="font: 12pt Arial, Helvetica, Sans-Serif; padding: 2.25pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">-</span></td>
    <td style="font: 12pt Arial, Helvetica, Sans-Serif; padding: 2.25pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">111,320</span></td>
    <td style="font: 12pt Arial, Helvetica, Sans-Serif; padding: 2.25pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">-</span></td>
    <td style="font: 12pt Arial, Helvetica, Sans-Serif; padding: 2.25pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">-</span></td>
    <td style="font: 12pt Arial, Helvetica, Sans-Serif; padding: 2.25pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">-</span></td>
    <td style="font: 12pt Arial, Helvetica, Sans-Serif; padding: 2.25pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">111,320</span></td></tr>
<tr style="vertical-align: top; background-color: White">
    <td style="font: 12pt Arial, Helvetica, Sans-Serif; padding: 2.25pt"><span style="font: 10pt Times New Roman, Times, Serif">Steffen
    Thomas</span></td>
    <td style="font: 12pt Arial, Helvetica, Sans-Serif; padding: 2.25pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">-</span></td>
    <td style="font: 12pt Arial, Helvetica, Sans-Serif; padding: 2.25pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">-</span></td>
    <td style="font: 12pt Arial, Helvetica, Sans-Serif; padding: 2.25pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">111,320</span></td>
    <td style="font: 12pt Arial, Helvetica, Sans-Serif; padding: 2.25pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">-</span></td>
    <td style="font: 12pt Arial, Helvetica, Sans-Serif; padding: 2.25pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">-</span></td>
    <td style="font: 12pt Arial, Helvetica, Sans-Serif; padding: 2.25pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">-</span></td>
    <td style="font: 12pt Arial, Helvetica, Sans-Serif; padding: 2.25pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">111,320</span></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 12pt Arial, Helvetica, Sans-Serif; padding: 2.25pt"><span style="font: 10pt Times New Roman, Times, Serif">Peter
    Donhauser</span></td>
    <td style="font: 12pt Arial, Helvetica, Sans-Serif; padding: 2.25pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">-</span></td>
    <td style="font: 12pt Arial, Helvetica, Sans-Serif; padding: 2.25pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">-</span></td>
    <td style="font: 12pt Arial, Helvetica, Sans-Serif; padding: 2.25pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">111,320</span></td>
    <td style="font: 12pt Arial, Helvetica, Sans-Serif; padding: 2.25pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">-</span></td>
    <td style="font: 12pt Arial, Helvetica, Sans-Serif; padding: 2.25pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">-</span></td>
    <td style="font: 12pt Arial, Helvetica, Sans-Serif; padding: 2.25pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">-</span></td>
    <td style="font: 12pt Arial, Helvetica, Sans-Serif; padding: 2.25pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">111,320</span></td></tr>
</table>
<p style="font: 10.5pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">&#160;</p>

<p style="font: 9pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">(1)
At September 30, 2020, the aggregate number of outstanding vested and unvested stock option awards held by each director was:
Mr. Skarpelos options to purchase 245,500 shares, Mr. Van der Velden options to purchase 145,500 shares, Mr. Favus options to
purchase 290,500 shares, Mr. Thomas options to purchase 245,500 shares and Mr. Donhauser options to purchase 145,500 shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
currently compensate Claus van der Velden $4,000 per quarter for performing the functions of Chairman of our Audit Committee,
Compensation Committee and Nominating and Corporate Governance Committee.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
addition, directors are entitled to reimbursement for reasonable travel and other out-of-pocket expenses incurred in connection
with attendance at meetings of our board of directors. Our board of directors may award further special remuneration to any director
undertaking any special services on our behalf other than services ordinarily required of a director.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-bottom: 12pt; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Retirement
or Similar Benefit Plans</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">There
are no arrangements or plans in which we provide retirement or similar benefits for our directors or executive officers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-bottom: 12pt; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Resignation,
Retirement, Other Termination, or Change in Control Arrangements</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Our
Employment Agreement with Dr. Missling contains provisions regarding our obligations upon his termination and upon a change of
control. In the event of a change of control, as such term is defined in the employment agreement, all previously granted but
unvested stock options held by Dr. Missling shall vest. Depending on the nature of the termination of Dr. Missling&#8217;s services,
certain of his salary, bonus and granted securities shall vest in the amounts at such time as set forth in the Employment Agreement.
A copy of Dr. Missling&#8217;s Second Amendment to Employment Agreement is set forth in its entirety as an exhibit hereto.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Our
employment agreement with Sandra Boenisch contains provisions regarding our obligations to Ms. Boenisch upon a change of control.
In the event of a change of control, as such term is defined in the employment agreement, all of the remaining unvested option
shares granted to Ms. Boenisch will immediately vest with no restrictions on purchase or sales. A copy of Ms. Boenisch&#8217;s
employment agreement is set forth in its entirety as an exhibit hereto.</span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 12pt 0 3pt; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"><span id="item12"></span><b><i>ITEM
12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
following table sets forth, as of December 28, 2020, certain information with respect to the beneficial ownership of our common
stock by each stockholder known by us to be the beneficial owner of more than 5% of our common stock and by each of our current
directors and our named executive officers and by our current directors and executive officers as a group. We have determined
the number and percentage of shares beneficially owned by such person in accordance with Rule 13d-3 under the Securities Exchange
Act of 1934. This information does not necessarily indicate beneficial ownership for any other purpose.</span></p>

<!-- Field: Page; Sequence: 42; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="padding: 2.25pt 2.25pt 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Title
    of class</b></span></td>
    <td style="padding: 2.25pt 2.25pt 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Name
    and address of</b><br />
    <b>beneficial owner</b></span></td>
    <td colspan="2" style="padding: 2.25pt 2.25pt 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Amount
    and nature of</b><br />
    <b>beneficial ownership</b></span></td>
    <td style="padding: 2.25pt 2.25pt 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Percent
    of</b><br />
    <b>class <sup>(1)</sup></b></span></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding: 2.25pt 2.25pt 12pt; width: 18%"><span style="font: 10pt Times New Roman, Times, Serif">Common
    Stock </span></td>
    <td style="width: 31%; padding-top: 2.25pt; padding-right: 2.25pt; padding-left: 2.25pt"><span style="font: 10pt Times New Roman, Times, Serif">Christopher
    Missling (CEO/Director)</span></td>
    <td style="padding: 2.25pt 2.25pt 12pt; width: 21%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">6,031,264<sup>(2)</sup></span></td>
    <td style="padding: 2.25pt 2.25pt 12pt; width: 9%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding: 2.25pt 2.25pt 12pt; width: 21%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">8.4%</span></td></tr>
<tr style="vertical-align: top; background-color: White">
    <td style="padding: 2.25pt 2.25pt 12pt"><span style="font: 10pt Times New Roman, Times, Serif">Common Stock
    </span></td>
    <td style="padding-top: 2.25pt; padding-right: 2.25pt; padding-left: 2.25pt"><span style="font: 10pt Times New Roman, Times, Serif">Athanasios
    Skarpelos (Director)</span></td>
    <td style="padding: 2.25pt 2.25pt 12pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">1,551,958<sup>(3)</sup></span></td>
    <td style="padding: 2.25pt 2.25pt 12pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding: 2.25pt 2.25pt 12pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">2.3%</span></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding: 2.25pt 2.25pt 12pt"><span style="font: 10pt Times New Roman, Times, Serif">Common Stock</span></td>
    <td style="padding-top: 2.25pt; padding-right: 2.25pt; padding-left: 2.25pt"><span style="font: 10pt Times New Roman, Times, Serif">Claus
    van der Velden (Director)</span></td>
    <td style="padding: 2.25pt 2.25pt 12pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">128,834<sup>(4)</sup></span></td>
    <td style="padding: 2.25pt 2.25pt 12pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding: 2.25pt 2.25pt 12pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">*</span></td></tr>
<tr style="vertical-align: top; background-color: White">
    <td style="padding: 2.25pt 2.25pt 12pt"><span style="font: 10pt Times New Roman, Times, Serif">Common Stock</span></td>
    <td style="padding-top: 2.25pt; padding-right: 2.25pt; padding-left: 2.25pt"><span style="font: 10pt Times New Roman, Times, Serif">Elliot
    Favus (Director)</span></td>
    <td style="padding: 2.25pt 2.25pt 12pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">290,500<sup>(5)</sup></span></td>
    <td style="padding: 2.25pt 2.25pt 12pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding: 2.25pt 2.25pt 12pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">*</span></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding: 2.25pt 2.25pt 12pt"><span style="font: 10pt Times New Roman, Times, Serif">Common Stock</span></td>
    <td style="padding-top: 2.25pt; padding-right: 2.25pt; padding-left: 2.25pt"><span style="font: 10pt Times New Roman, Times, Serif">Steffen
    Thomas (Director)</span></td>
    <td style="padding: 2.25pt 2.25pt 12pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">245,500<sup>(6)</sup></span></td>
    <td style="padding: 2.25pt 2.25pt 12pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding: 2.25pt 2.25pt 12pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">*</span></td></tr>
<tr style="vertical-align: top; background-color: White">
    <td style="padding: 2.25pt 2.25pt 12pt"><span style="font: 10pt Times New Roman, Times, Serif">Common Stock</span></td>
    <td style="padding-top: 2.25pt; padding-right: 2.25pt; padding-left: 2.25pt"><span style="font: 10pt Times New Roman, Times, Serif">Peter
    Donhauser (Director)</span></td>
    <td style="padding: 2.25pt 2.25pt 12pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">145,500<sup>(7)</sup></span></td>
    <td style="padding: 2.25pt 2.25pt 12pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding: 2.25pt 2.25pt 12pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">*</span></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding: 2.25pt 2.25pt 12pt"><span style="font: 10pt Times New Roman, Times, Serif">Common Stock</span></td>
    <td style="padding-top: 2.25pt; padding-right: 2.25pt; padding-left: 2.25pt"><span style="font: 10pt Times New Roman, Times, Serif">Sandra
    Boenisch (Principal Financial Officer)</span></td>
    <td style="padding: 2.25pt 2.25pt 12pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">276,959<sup>(8)</sup></span></td>
    <td style="padding: 2.25pt 2.25pt 12pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding: 2.25pt 2.25pt 12pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">*</span></td></tr>
<tr style="vertical-align: top; background-color: White">
    <td style="padding: 2.25pt 2.25pt 12pt"><span style="font: 10pt Times New Roman, Times, Serif">Common Stock</span></td>
    <td style="padding: 2.25pt 2.25pt 10pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>Directors
    &amp; Executive Officers as a group (7 persons)</b></span></td>
    <td style="padding: 2.25pt 2.25pt 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">8,670,515</span></td>
    <td style="padding: 2.25pt 2.25pt 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding: 2.25pt 2.25pt 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">11.8%</span></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding: 2.25pt 2.25pt 12pt"><span style="font: 10pt Times New Roman, Times, Serif">Common Stock</span></td>
    <td style="padding: 2.25pt 2.25pt 10pt"><span style="font: 10pt Times New Roman, Times, Serif">BlackRock,
    Inc.</span></td>
    <td style="padding: 2.25pt 2.25pt 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">3,480,213</span></td>
    <td style="padding: 2.25pt 2.25pt 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding: 2.25pt 2.25pt 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">5.2%</span></td></tr>
<tr style="vertical-align: top; background-color: White">
    <td style="padding: 2.25pt 2.25pt 12pt"><span style="font: 10pt Times New Roman, Times, Serif">*Less than
    1%</span></td>
    <td style="padding: 2.25pt 2.25pt 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding: 2.25pt 2.25pt 10pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding: 2.25pt 2.25pt 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding: 2.25pt 2.25pt 10pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>
<table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 10pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">(1)</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Percentage
                                         of ownership is based on <span style="background-color: White">66,962,957</span> of our
                                         common stock issued and outstanding as of December 28, 2020. Except as otherwise indicated,
                                         we believe that the beneficial owners of the common stock listed above, based on information
                                         furnished by such owners, have sole investment and voting power with respect to such
                                         shares, subject to community property laws where applicable. Beneficial ownership is
                                         determined in accordance with the rules of the Securities and Exchange Commission and
                                         generally includes voting or investment power with respect to securities. Shares of common
                                         stock subject to options or warrants currently exercisable or exercisable within 60 days,
                                         are deemed outstanding for purposes of computing the percentage ownership of the person
                                         holding such option or warrants but are not deemed outstanding for purposes of computing
                                         the percentage ownership of any other person.</span></td></tr></table>

<p style="font: 9pt Times New Roman, Times, Serif; margin: 0 0 10pt 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 12pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">(2)</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Includes
                                         options to purchase 500,000 shares of our common stock at $1.60 per share, options to
                                         purchase 125,000 shares of our common stock at $1.32 per share, options to purchase 500,000
                                         shares of our common stock at $0.92 per share, options to purchase 187,500 shares of
                                         our common stock at $5.04 per share, options to purchase 379,625 shares of our common
                                         stock at $6.26 per share, options to purchase 861,429 shares of our common stock at $7.06
                                         per share, options to purchase 500,000 shares of our common stock at $3.28 per share,
                                         and options to purchase 450,000 shares of our common stock at $5.92 per share, options
                                         to purchase 400,000 shares of our common stock at $3.30 per share, options to purchase
                                         450,000 shares of our common stock at $2.30 per share, options to purchase 409,500 shares
                                         of our common stock at $2.58 per share and options to purchase 250,000 shares of our
                                         common stock at $3.15 per share that are vested or are vesting within 60 days. Excludes
                                         options to purchase 500,000 shares of our common stock at $3.15 per share and options
                                         to purchase 550,000 shares of our common stock at $2.96 per share that do not vest within
                                         60 days.</span></td></tr></table>

<!-- Field: Page; Sequence: 42; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

    <p style="font: 9pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; margin-top: 12pt; margin-bottom: 10pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">(3)</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Includes
                                         options to purchase 50,000 shares of our common stock at $0.92 per share and options
                                         to purchase 100,000 shares of our common stock at $3.28 per share, options to purchase
                                         45,500 shares of our common stock at $2.58 per share and options to purchase 50,000 shares
                                         of our common stock at $2.96 per share that have vested or are vesting within 60 days.</span></td></tr></table>

<p style="font: 9pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">(4)</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Includes
                                         options to purchase 33,334 shares of our common stock at $2.60 per share, options to
                                         purchase 45,500 shares of our common stock at $2.58 per share and options to purchase
                                         50,000 shares of our common stock at $2.96 per share that have vested or are vesting
                                         within 60 days. Excludes&#160;options to purchase 16,666 shares of our common stock at
                                         $2.60 per share that are not vesting within 60 days.</span></td></tr></table>

<p style="font: 9pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">(5)</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Includes&#160;options
                                         to purchase 37,500 shares of our common stock at $1.20 per share, options to purchase
                                         50,000 shares of our common stock at $0.92 per share, options to purchase 1,500 shares
                                         of our common stock at $5.64 per share, options to purchase 1,500 shares of our common
                                         stock at 5.57 per share, options to purchase 1,500 shares of our common stock at $4.90
                                         per share, options to purchase 1,500 shares of our common stock at $5.66 per share, options
                                         to purchase 1,500 shares of our common stock at $6.11 per share, options to purchase
                                         100,000 shares of our common stock at $3.28 per share, options to purchase 45,500 shares
                                         of our common stock at $2.58 per share and options to purchase 50,000 shares of our common
                                         stock at $2.96 per share that have vested or are vesting within 60 days.</span></td></tr></table>

<p style="font: 9pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">(6)</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Includes&#160;
                                         options to purchase 50,000 shares of our common stock at $1.76 per share and options
                                         to purchase 100,000 shares of our common stock at $3.28 per share, options to purchase
                                         45,500 shares of our common stock at $2.58 per share, and options to purchase 50,000
                                         shares of our common stock at $2.96 per share that have vested or are vesting within
                                         60 days. </span></td></tr></table>

<p style="font: 9pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; margin-bottom: 10pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">(7)</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Includes
                                         options to purchase 50,000 shares of our common stock at $5.39 per share, options to
                                         purchase 45,500 shares of our common stock at $2.58 per share and options to purchase
                                         50,000 shares of our common stock at $2.96 per share that have vested or are vesting
                                         within 60 days.</span></td></tr></table>

<p style="font: 9pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; margin-bottom: 10pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">(8)</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Includes
                                         options to purchase 25,000 shares of our common stock at $5.68 per share, options to
                                         purchase 106,696 shares of our common stock at $3.28 per share, options to purchase 35,000
                                         shares of our common stock at $5.92 per share, options to purchase 30,000 shares of our
                                         common stock at $3.30 per share, and options to purchase 30,000 shares of our common
                                         stock at $2.30 per share, and options to purchase 27,300 shares of our common stock at
                                         $2.58 per share that have vested or are vesting within 60 days. Excludes options to purchase
                                         35,000 shares of common stock at $2.93 per share and options to purchase 70,000 shares
                                         of our common stock at $2.96 per share that do not vest within 60 days.</span></td></tr></table>

<p style="font: 10.5pt Times New Roman, Times, Serif; margin: 0 0 0 35.45pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Change
in Control</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
are unaware of any contract or other arrangement the operation of which may at a subsequent date result in a change of control
of our Company.</span></p>

<!-- Field: Page; Sequence: 42; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-bottom: 12pt; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-bottom: 12pt; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Securities
Authorized for Issuance under Equity Compensation Plans or Individual Compensation Arrangements </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
following table summarizes certain information regarding our equity compensation plan or individual compensation arrangements
at September 30, 2020:</span></p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td colspan="4" style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Equity
    Compensation Plan Information</b></span></td></tr>
<tr style="vertical-align: top">
    <td style="width: 25%; padding-right: 5.4pt; padding-left: 5.4pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Plan
        Category</b></span></p></td>
    <td style="width: 25%; padding-right: 5.4pt; padding-left: 5.4pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Number
        of securities to be issued upon exercise of outstanding options, warrants and rights</b><br />
        <b>(a)</b></span></p></td>
    <td style="width: 25%; padding-right: 5.4pt; padding-left: 5.4pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Weighted-average
        exercise price of outstanding options, warrants and rights</b><br />
        <b>(b)</b></span></p></td>
    <td style="width: 25%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Number
    of securities remaining available for future issuances under equity compensation plans (excluding securities reflected in
    column (a))</b><br />
    <b>(c)</b></span></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"><span style="font: 10pt Times New Roman, Times, Serif">Equity
    compensation plans approved by security holders</span></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">12,050,553</span></p></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">3.82</span></p></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">3,308,036</span></p></td></tr>
<tr style="vertical-align: top; background-color: White">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"><span style="font: 10pt Times New Roman, Times, Serif">Equity
    compensation plans not approved by security holders</span></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">-</span></p></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">-</span></p></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">-</span></p></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>Total</b></span></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><b>12,050,553</b></span></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><b>3.82</b></span></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">3,308,036</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-bottom: 12pt; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Stock
Option Plan </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">2019
Stock Option Plan</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">On
January 15, 2019, the Board approved the 2019 Omnibus Incentive Plan (the &#8220;2019 Plan&#8221;), which provides for the grant
of stock options and restricted stock awards to directors, officers, employees, consultants and advisors of the Company. The 2019
Plan was approved by our stockholders on April 5, 2019.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Under
the terms of the 2019 Plan, 6,000,000 shares of Common Stock are available for issuance, in addition to the shares available under
the 2015 Plan. Any awards outstanding under the Company&#8217;s 2015 Omnibus Incentive Plan (the &#8220;2015 Plan&#8221;) or the
Company&#8217;s 2007 Stock Option Plan (the &#8220;2007 Plan&#8221;) will remain subject to and be paid under the 2015 Plan or
the 2007 Plan, respectively, and any shares subject to outstanding awards under the 2015 Plan or the 2007 Plan that subsequently
cease to be subject to such awards (other than by reason of settlement of the awards in shares) will automatically become available
for issuance under the 2019 Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
2019 Plan provides that it may be administered by the Board, or the Board may delegate such responsibility to a committee. The
exercise price will be determined by the board of directors at the time of grant shall be at least equal to the fair market value
on such date. If the grantee is a 10% stockholder on the grant date, then the exercise price shall not be less than 110% of fair
market value of the Company&#8217;s shares of common stock on the grant date. Stock options may be granted under the 2019 Plan
for an exercise period of up to ten years from the date of grant of the option or such lesser periods as may be determined by
the board, subject to earlier termination in accordance with the terms of the 2019 Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
purpose of the 2019 Plan is to retain the services of valued key employees and consultants of our Company and such other persons,
and to encourage such persons to acquire a greater proprietary interest in our Company, thereby strengthening their incentive
to achieve the objectives of the shareholders of our Company. The purpose is also to serve as an aid and inducement in the hiring
of new employees and to provide an equity incentive to consultants.</span></p>

<!-- Field: Page; Sequence: 42; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

    <p style="font: italic bold 14pt Times New Roman, Times, Serif; margin: 12pt 0 0"><span style="font: normal 10pt Times New Roman, Times, Serif"><span id="item13"></span><b><i>
ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-bottom: 0; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Transactions
with related persons</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">There
have been no transactions, since October 1, 2018, or currently proposed transactions, in which we were or are to be a participant
and the amount involved exceeds the lesser of $120,000 or one percent of the average of the smaller reporting company's total
assets at year end for the last two completed fiscal years, and in which any of the following persons had or will have a direct
or indirect material interest.</span></p>

<table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 10pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">i.</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">any
                                         director or executive officer of our Company;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 10pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">ii.</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">any
                                         beneficial owner of shares carrying more than 5% of the voting rights attached to our
                                         outstanding shares of common stock; and</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 10pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">iii.</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">any
                                         member of the immediate family (including spouse, parents, children, siblings and in-laws)
                                         of any of the foregoing persons.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-bottom: 12pt; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Compensation
of Named Executive Officers and Directors</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">For
information regarding compensation of named executive officers and directors, please see &#8220;Item 11. Executive Compensation.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-bottom: 12pt; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Director
Independence</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Under
the NASDAQ Stock Market Rules, the Board has a responsibility to make an affirmative determination that those members of its Board
that serve as independent directors do not have any relationships with the Company and its businesses that would impair their
independence. The Board has determined that that Christopher Missling, PhD is not independent as that term is defined by NASDAQ
5605(a)(2) because Mr. Missling serves as our President, Chief Executive Officer, and Secretary.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Board has determined that that Claus van der Velden, Elliot Favus, Athanasios Skarpelos, Steffen Thomas and Peter Donhauser are
independent as that term is defined by NASDAQ 5605(a)(2) and the applicable rules of the Securities and Exchange Commission.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<!-- Field: Page; Sequence: 42; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->
    <p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 12pt 0 3pt"><span style="font: normal 10pt Times New Roman, Times, Serif"><span id="item14"></span><b><i>
ITEM 14. PRINCIPAL ACCOUNTING FEES AND SERVICES</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-bottom: 12pt; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Fees
Paid to Our Independent Registered Public Accounting Firm </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
following table sets forth the aggregate fees billed or expected to be billed to our Company for professional services rendered
by our independent registered public accounting firm, for the fiscal years ended September 30, 2020 and 2019:</span></p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="font: 10pt Arial, Helvetica, Sans-Serif; width: 54%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Arial, Helvetica, Sans-Serif; width: 23%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">2020</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Arial, Helvetica, Sans-Serif; width: 23%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">2019</span></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Arial, Helvetica, Sans-Serif; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Audit
    Fees</span></td>
    <td style="font: 10pt Arial, Helvetica, Sans-Serif; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">$305,751</span></td>
    <td style="font: 10pt Arial, Helvetica, Sans-Serif; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">$229,763</span></td></tr>
<tr style="vertical-align: top; background-color: White">
    <td style="font: 10pt Arial, Helvetica, Sans-Serif; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Audit
    Related Fees</span></td>
    <td style="font: 10pt Arial, Helvetica, Sans-Serif; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">-</span></td>
    <td style="font: 10pt Arial, Helvetica, Sans-Serif; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">-</span></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Arial, Helvetica, Sans-Serif; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Tax
    Fees</span></td>
    <td style="font: 10pt Arial, Helvetica, Sans-Serif; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">-</span></td>
    <td style="font: 10pt Arial, Helvetica, Sans-Serif; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">-</span></td></tr>
<tr style="vertical-align: top; background-color: White">
    <td style="font: 10pt Arial, Helvetica, Sans-Serif; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">All
    Other Fees</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Arial, Helvetica, Sans-Serif; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">-</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Arial, Helvetica, Sans-Serif; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">-</span></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Arial, Helvetica, Sans-Serif; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Total
    Fees</span></td>
    <td style="font: 10pt Arial, Helvetica, Sans-Serif; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">$305,751</span></td>
    <td style="font: 10pt Arial, Helvetica, Sans-Serif; padding-top: 6pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">$229,763</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Audit
Fees</span>. Consist of fees billed for professional services rendered for the audits of our financial statements, reviews of our
interim financial statements included in quarterly reports, services performed in connection with regular filings with the Securities
and Exchange Commission for the fiscal years ended September 30, 2020 and 2019 in connection with statutory and regulatory filings
or engagements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-bottom: 12pt; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Policy
on Pre-Approval by Audit Committee of Services Performed by Independent Registered Public Accounting Firm </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Our
Audit Committee pre-approves all services provided by our independent registered public accounting firm. All of the above services
and fees were reviewed and approved by our Audit Committee before the respective services were rendered.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Our
Audit Committee has considered the nature and amount of fees billed or expected to be billed by BDO USA, LLP and believes that
the provision of services for activities unrelated to the audit was compatible with maintaining BDO USA, LLP&#8217;s independence.</span></p>


<!-- Field: Page; Sequence: 42; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: bold 10pt Times New Roman, Times, Serif"></p>

<p style="font: bold 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><span id="part4"></span>PART
IV</span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 2pt 0 3pt"><span style="font: normal 10pt Times New Roman, Times, Serif"><span id="item15"></span><b><i>ITEM
15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 2pt 0 0"><span style="font: 10pt Times New Roman, Times, Serif; text-transform: uppercase"><b>&#160;</b></span></p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="border: Black 1pt solid; width: 12%; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>Exhibit
    </b><br />
    <b>Number </b></span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; width: 88%; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font: 10pt Times New Roman, Times, Serif"><br />
    <b>Description</b></span></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>(3)
    </b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>Articles
    of Incorporation and Bylaws </b></span></td></tr>
<tr style="vertical-align: top; background-color: White">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font: 10pt Times New Roman, Times, Serif">3.1
    </span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font: 10pt Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1314052/000113707005000007/ex31.htm" style="-sec-extract: exhibit">Articles of Incorporation (incorporated by reference to our Registration Statement on Form SB-2 filed on January 13, 2005)</a></span></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font: 10pt Times New Roman, Times, Serif">3.2
    </span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font: 10pt Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/1314052/000108503707002199/exhibit3_1.htm" style="-sec-extract: exhibit">Bylaws (incorporated by reference to our Current Report on Form 8-K filed on September 28, 2007)</a></span></td></tr>
<tr style="vertical-align: top; background-color: White">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font: 10pt Times New Roman, Times, Serif">3.3
    </span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font: 10pt Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/1314052/000108503707000198/form8kexh99_1.htm" style="-sec-extract: exhibit">Articles of Merger filed with the Secretary of State of Nevada on January 10, 2007 and which is effective January 25, 2007 (incorporated by reference to our Current Report on Form 8-K filed on January 25, 2007)</a></span></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>(10)
    </b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>Material
    Contracts</b></span></td></tr>
<tr style="vertical-align: top; background-color: White">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 2.25pt; padding-left: 2.25pt"><span style="font: 10pt Times New Roman, Times, Serif">10.1</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 2.25pt; padding-left: 2.25pt"><span style="font: 10pt Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/1314052/000161577415003756/s102397_ex10-91.htm" style="-sec-extract: exhibit">2015 Omnibus Incentive Plan (incorporated by reference to our Annual Report on Form 10-K filed on December 29, 2015)</a></span></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 2.25pt; padding-left: 2.25pt"><span style="font: 10pt Times New Roman, Times, Serif">10.2</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 2.25pt; padding-left: 2.25pt"><span style="font: 10pt Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/1314052/000161577419002242/s115994_def14a.htm" style="-sec-extract: exhibit">2019 Omnibus Incentive Plan (incorporated by reference to our Proxy Statement, dated February 11, 2019, as filed on February 11, 2019).</a></span></td></tr>
<tr style="vertical-align: top; background-color: White">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 2.25pt; padding-left: 2.25pt"><span style="font: 10pt Times New Roman, Times, Serif">10.3</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 2.25pt; padding-left: 2.25pt"><span style="font: 10pt Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/1314052/000121390019010601/f8k060719ex10-1_anavexlife.htm" style="-sec-extract: exhibit">Purchase Agreement, dated as of June 7, 2019, by and between the Company and Lincoln Park Capital Fund, LLC (incorporated by reference to our Current Report on Form 8-K filed on June 12, 2019)</a></span></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 2.25pt; padding-left: 2.25pt"><span style="font: 10pt Times New Roman, Times, Serif">10.4
    </span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 2.25pt; padding-left: 2.25pt"><span style="font: 10pt Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/1314052/000121390019010601/f8k060719ex4-1_anavexlife.htm" style="-sec-extract: exhibit">Registration Rights Agreement, dated as of June 7, 2019, by and between the Company and Lincoln Park Capital Fund, LLC (incorporated by reference to our Current Report on Form 8-K filed on June 12, 2019)</a></span></td></tr>
<tr style="vertical-align: top; background-color: White">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 2.25pt; padding-left: 2.25pt"><span style="font: 10pt Times New Roman, Times, Serif">10.5
    </span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 2.25pt; padding-left: 2.25pt"><span style="font: 10pt Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1314052/000173112220000712/e2009_10-1.htm" style="-sec-extract: exhibit">First Amendment to Purchase Agreement, dated as of July 1, 2020, by and between the Company and Lincoln Park Capital Fund, LLC &#160;(incorporated by reference to our Current Report on Form 8-K filed on July 2, 2020)</a></span></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 2.25pt; padding-left: 2.25pt"><span style="font: 10pt Times New Roman, Times, Serif">10.6</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 2.25pt; padding-left: 2.25pt"><span style="font: 10pt Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/1314052/000161577416006259/s103666_ex10-1.htm" style="-sec-extract: exhibit">First Amendment to Employment Agreement, dated as of July 5, 2016, by and between the Company and Christopher Missling, PhD (incorporated by reference to our Current Report on Form 8-K filed on July 7, 2016)</a></span></td></tr>
<tr style="vertical-align: top; background-color: White">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 2.25pt; padding-left: 2.25pt"><span style="font: 10pt Times New Roman, Times, Serif">10.7</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 2.25pt; padding-left: 2.25pt"><span style="font: 10pt Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/1314052/000161577416006410/s103735_ex10-1.htm" style="-sec-extract: exhibit">Amended and Restated First Amendment to Employment Agreement, dated as of July 18, 2016, by and between the Company and Christopher Missling, PhD (incorporated by reference to our Current Report on Form 8-K filed on July 22, 2016)</a></span></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 2.25pt; padding-left: 2.25pt"><span style="font: 10pt Times New Roman, Times, Serif">10.8</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 2.25pt; padding-left: 2.25pt"><span style="font: 10pt Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/1314052/000161577419007324/s118023_ex10-1.htm" style="-sec-extract: exhibit">Second Amendment to Employment Agreement, dated as of May 3, 2019 by and between the Company and Christopher Missling, PhD (incorporated by reference to our Quarterly Report on Form 10-Q filed on May 9, 2019)</a> </span></td></tr>
<tr style="vertical-align: top; background-color: White">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 2.25pt; padding-left: 2.25pt"><span style="font: 10pt Times New Roman, Times, Serif">10.9</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 2.25pt; padding-left: 2.25pt"><span style="font: 10pt Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/1314052/000161577417007272/s108360_ex10-7.htm" style="-sec-extract: exhibit">Amended and Restated Employment Agreement by and between the Company and with Sandra Boenisch (incorporated by reference to our Annual Report on Form 10-K filed on December 11, 2017)</a></span></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 2.25pt; padding-left: 2.25pt"><span style="font: 10pt Times New Roman, Times, Serif">10.10</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 2.25pt; padding-left: 2.25pt"><span style="font: 10pt Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/1314052/000173112220000103/e1699_10-1.htm" style="-sec-extract: exhibit">Amendment No. 1 to Amended and Restated Employment Agreement between the Company and Sandra Boenisch, dated February 4, 2020 &#160;(incorporated by reference to our Quarterly Report on Form 10-Q filed on February 6, 2020)</a></span></td></tr>
<tr style="vertical-align: top; background-color: White">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 2.25pt; padding-left: 2.25pt"><span style="font: 10pt Times New Roman, Times, Serif">10.11</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 2.25pt; padding-left: 2.25pt"><span style="font: 10pt Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/1314052/000173112220000432/e1889_ex1-1.htm">Amended and Restated Sales Agreement, dated May 1, 2020, by and among Anavex Life Sciences Corp., Cantor Fitzgerald&#160;&amp; Co. and SVB Leerink LLC (incorporated by reference to our Current Report on Form 8-K filed on May 1, 2020)</a></span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 42; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --><p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>Exhibit
    Number</b></span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>Description</b></span></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="border: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt; width: 12%"><span style="font: 10pt Times New Roman, Times, Serif"><b>14</b></span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt; width: 88%"><span style="font: 10pt Times New Roman, Times, Serif"><b>Code
    of Ethics</b></span></td></tr>
<tr style="vertical-align: top; background-color: White">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font: 10pt Times New Roman, Times, Serif">14.1</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font: 10pt Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/1314052/000161577416008914/s104917_ex14-1.htm" style="-sec-extract: exhibit">Code of Ethics Adopted on September 13, 2016 (incorporated by reference to our Annual Report on Form 10-K filed on December 14, 2016)</a></span></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>(21)</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>Subsidiaries</b></span></td></tr>
<tr style="vertical-align: top; background-color: White">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font: 10pt Times New Roman, Times, Serif">21.1*</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font: 10pt Times New Roman, Times, Serif"><a href="e2298_ex21-1.htm">Subsidiaries of the Registrant</a></span></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>(23)</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>Consent</b></span></td></tr>
<tr style="vertical-align: top; background-color: White">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font: 10pt Times New Roman, Times, Serif">23.1*</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><a href="e2298_ex23-1.htm"><span style="font: 10pt Times New Roman, Times, Serif">Consent of Independent Registered Public Accounting Firm</span></a></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>(31)
    </b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>Section
    302 Certifications</b></span></td></tr>
<tr style="vertical-align: top; background-color: White">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font: 10pt Times New Roman, Times, Serif">31.1*</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><a href="e2298_ex31-1.htm"><span style="font: 10pt Times New Roman, Times, Serif">Section 302 Certification of Christopher Missling, PhD.</span></a></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font: 10pt Times New Roman, Times, Serif">31.2*</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><a href="e2298_ex31-2.htm"><span style="font: 10pt Times New Roman, Times, Serif">Section 302 Certification of Sandra Boenisch</span></a></td></tr>
<tr style="vertical-align: top; background-color: White">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>(32)
    </b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>Section
    906 Certifications</b></span></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font: 10pt Times New Roman, Times, Serif">32.1*</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><a href="e2298_ex32-1.htm"><span style="font: 10pt Times New Roman, Times, Serif">Section 906 Certification of Christopher Missling, PhD and Sandra Boenisch</span></a></td></tr>
<tr style="vertical-align: top; background-color: White">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>(99)</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>Additional
    Exhibits</b></span></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font: 10pt Times New Roman, Times, Serif">99.1</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font: 10pt Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/1314052/000161577417007272/s108360_ex99-1.htm" style="-sec-extract: exhibit">Insider Trading Policy Adopted August 9, 2017 (incorporated by reference to our Annual Report on Form 10-K filed on December 11, 2017)</a></span></td></tr>
<tr style="vertical-align: top; background-color: White">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>(101)</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>XBRL</b></span></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font: 10pt Times New Roman, Times, Serif">101.INS*</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font: 10pt Times New Roman, Times, Serif">XBRL
    INSTANCE DOCUMENT</span></td></tr>
<tr style="vertical-align: top; background-color: White">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font: 10pt Times New Roman, Times, Serif">101.SCH*</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font: 10pt Times New Roman, Times, Serif">XBRL
    TAXONOMY EXTENSION SCHEMA</span></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font: 10pt Times New Roman, Times, Serif">101.CAL*</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font: 10pt Times New Roman, Times, Serif">XBRL
    TAXONOMY EXTENSION CALCULATION LINKBASE</span></td></tr>
<tr style="vertical-align: top; background-color: White">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font: 10pt Times New Roman, Times, Serif">101.DEF*</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font: 10pt Times New Roman, Times, Serif">XBRL
    TAXONOMY EXTENSION DEFINITION LINKBASE</span></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font: 10pt Times New Roman, Times, Serif">101.LAB*</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font: 10pt Times New Roman, Times, Serif">XBRL
    TAXONOMY EXTENSION LABEL LINKBASE</span></td></tr>
<tr style="vertical-align: top; background-color: White">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font: 10pt Times New Roman, Times, Serif">101.PRE*</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font: 10pt Times New Roman, Times, Serif">XBRL
    TAXONOMY EXTENSION PRESENTATION LINKBASE</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">*
Filed herewith.</span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 12pt 0 3pt"><span style="font: normal 10pt Times New Roman, Times, Serif"><span id="item16"></span><b><i>ITEM
16. FORM 10-K SUMMARY</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><span style="font: 10pt Times New Roman, Times, Serif">Not
Applicable.&#160;</span></p>


<!-- Field: Page; Sequence: 42; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>SIGNATURES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 9pt 0 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">Pursuant
to the requirements of Section&#160;13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report
to be signed on its behalf by the undersigned thereunto duly authorized.</span></p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="background-color: white">
    <td style="width: 44%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 3%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 6%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 44%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="background-color: white">
    <td style="vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif"><b>Date: December
    28, 2020</b></span></td>
    <td style="vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif"><b>ANAVEX
    LIFE SCIENCES CORP.</b></span></td></tr>
<tr style="background-color: white">
    <td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="background-color: white">
    <td style="vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">By:</span></td>
    <td style="vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><p style="border-bottom: black 0.75pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0.75pt"><span style="font: 10pt Times New Roman, Times, Serif"><i>/s/
                                    Christopher Missling, PhD</i></span></p></td></tr>
<tr style="background-color: white">
    <td style="vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">Name:</span></td>
    <td style="vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">Christopher Missling,
    PhD</span></td></tr>
<tr style="background-color: white">
    <td style="vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">Title:</span></td>
    <td style="vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">Chief
                                       Executive Officer (Principal Executive Officer)</span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 9pt 0 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">Pursuant
to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf
of the registrant and in the capacities and on the dates indicated.</span></p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap"><p style="border-bottom: black 0.75pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Signatures</b></span></p></td>
    <td style="padding-bottom: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="white-space: nowrap"><p style="border-bottom: black 0.75pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Title(s)</b></span></p></td>
    <td style="padding-bottom: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="white-space: nowrap"><p style="border-bottom: black 0.75pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Date</b></span></p></td></tr>
<tr style="vertical-align: bottom">
    <td><p style="border-bottom: black 0.75pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0.75pt"><span style="font: 10pt Times New Roman, Times, Serif"><i>/s/
        Christopher Missling, PhD</i></span></p></td>
    <td style="padding-bottom: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="padding-bottom: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">December
    28, 2020</span></td></tr>
<tr>
    <td style="vertical-align: top; padding-bottom: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">Christopher
    Missling, PhD</span></td>
    <td style="vertical-align: bottom; padding-bottom: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; padding-bottom: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">Chief
    Executive Officer (Principal Executive Officer)</span></td>
    <td style="vertical-align: bottom; padding-bottom: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="padding-bottom: 10pt; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr>
    <td style="vertical-align: top; width: 29%"><p style="border-bottom: black 0.75pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0.75pt"><span style="font: 10pt Times New Roman, Times, Serif"><i>/s/
                                         Sandra Boenisch</i></span></p></td>
    <td style="vertical-align: bottom; width: 1%; padding-bottom: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; width: 46%; padding-bottom: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; width: 1%; padding-bottom: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; width: 22%; padding-bottom: 10pt; line-height: 115%"><span style="font: 10pt/115% Times New Roman, Times, Serif">December
    28, 2020</span></td>
    <td style="padding-bottom: 10pt; width: 1%; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr>
    <td style="vertical-align: top; padding-bottom: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">Sandra
    Boenisch, CPA, CGA</span></td>
    <td style="vertical-align: bottom; padding-bottom: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; padding-bottom: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">Principal
    Financial Officer and Treasurer (Principal Accounting Officer)</span></td>
    <td style="vertical-align: bottom; padding-bottom: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="padding-bottom: 10pt; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr>
    <td style="vertical-align: top"><p style="border-bottom: black 0.75pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0.75pt"><span style="font: 10pt Times New Roman, Times, Serif"><i>/s/
                                    Athanasios Skarpelos</i></span></p></td>
    <td style="vertical-align: bottom; padding-bottom: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; padding-bottom: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; padding-bottom: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; padding-bottom: 10pt; line-height: 115%"><span style="font: 10pt/115% Times New Roman, Times, Serif">December
    28, 2020</span></td>
    <td style="padding-bottom: 10pt; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr>
    <td style="vertical-align: top; padding-bottom: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">Athanasios
    Skarpelos</span></td>
    <td style="vertical-align: bottom; padding-bottom: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; padding-bottom: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">Director</span></td>
    <td style="vertical-align: bottom; padding-bottom: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="padding-bottom: 10pt; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr>
    <td style="vertical-align: top"><p style="border-bottom: black 0.75pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0.75pt"><span style="font: 10pt Times New Roman, Times, Serif"><i>/s/
                                    Claus van der Velden, PhD</i></span></p></td>
    <td style="vertical-align: bottom; padding-bottom: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; padding-bottom: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; padding-bottom: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; padding-bottom: 10pt; line-height: 115%"><span style="font: 10pt/115% Times New Roman, Times, Serif">December
    28, 2020</span></td>
    <td style="padding-bottom: 10pt; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr>
    <td style="vertical-align: top; padding-bottom: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">Claus
    van der Velden, PhD</span></td>
    <td style="vertical-align: bottom; padding-bottom: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; padding-bottom: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">Director</span></td>
    <td style="vertical-align: bottom; padding-bottom: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="padding-bottom: 10pt; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr>
    <td style="vertical-align: top"><p style="border-bottom: black 0.75pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0.75pt"><span style="font: 10pt Times New Roman, Times, Serif"><i>/s/
                                    Elliot Favus, MD</i></span></p></td>
    <td style="vertical-align: bottom; padding-bottom: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; padding-bottom: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; padding-bottom: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; padding-bottom: 10pt; line-height: 115%"><span style="font: 10pt/115% Times New Roman, Times, Serif">December
    28, 2020</span></td>
    <td style="padding-bottom: 10pt; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr>
    <td style="vertical-align: top; padding-bottom: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">Elliot
    Favus, MD</span></td>
    <td style="vertical-align: bottom; padding-bottom: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; padding-bottom: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">Director</span></td>
    <td style="vertical-align: bottom; padding-bottom: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="padding-bottom: 10pt; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr>
    <td style="vertical-align: top"><p style="border-bottom: black 0.75pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0.75pt"><span style="font: 10pt Times New Roman, Times, Serif"><i>/s/
                                    Steffen Thomas, PhD</i></span></p></td>
    <td style="vertical-align: bottom; padding-bottom: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; padding-bottom: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; padding-bottom: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; padding-bottom: 10pt; line-height: 115%"><span style="font: 10pt/115% Times New Roman, Times, Serif">December
    28, 2020</span></td>
    <td style="padding-bottom: 10pt; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr>
    <td style="vertical-align: top; padding-bottom: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">Steffen
    Thomas, PhD</span></td>
    <td style="vertical-align: bottom; padding-bottom: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; padding-bottom: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">Director</span></td>
    <td style="vertical-align: bottom; padding-bottom: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="vertical-align: top; padding-bottom: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr>
    <td style="vertical-align: top"><p style="border-bottom: black 0.75pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0.75pt"><span style="font: 10pt Times New Roman, Times, Serif"><i>/s/
                                    Peter Donhauser, D.O.</i></span></p></td>
    <td style="vertical-align: bottom; padding-bottom: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top; padding-bottom: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; padding-bottom: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; padding-bottom: 10pt; line-height: 115%"><span style="font: 10pt/115% Times New Roman, Times, Serif">December
    28, 2020</span></td>
    <td style="padding-bottom: 10pt; line-height: 115%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr>
    <td style="vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">Peter Donhauser,
    D.O.</span></td>
    <td style="vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">Director</span></td>
    <td style="vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<!-- Field: Page; Sequence: 42; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

    <p style="font: 10.5pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>



<p style="margin: 0"></p>

</body>
</html>
<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- 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 -->
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>2
<FILENAME>e2298_ex21-1.htm
<DESCRIPTION>EXHIBIT 21.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit
21.1</FONT></P>

<P STYLE="font: 12pt/12pt Times New Roman, Times, Serif; margin: 9pt 0 24pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SUBSIDIARIES
OF THE REGISTRANT</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 12pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR>
    <TD STYLE="width: 57%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 2%; line-height: 12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 41%; line-height: 12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1pt solid; padding-bottom: 0.75pt; line-height: 12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Name
    of Subsidiary</B></FONT></TD>
    <TD STYLE="line-height: 12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; padding-bottom: 0.75pt; line-height: 12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Jurisdiction
    of Incorporation or Organization</B></FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; line-height: 12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anavex
    Australia Pty Limited</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Australia</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; line-height: 12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anavex
    Germany GmbH</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Germany</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; line-height: 12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anavex
    Canada Ltd.</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ontario,
    Canada</FONT></TD></TR>
</TABLE>
<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>e2298_ex23-1.htm
<DESCRIPTION>EXHIBIT 23.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
23.1</B>&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Consent
of Independent Registered Public Accounting Firm</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anavex
Life Sciences Corp.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
York, New York</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (No. 333-218292, No. 333-207600 and
No. 333-232550) and Form S-8 (No. 333-219934) of Anavex Life Sciences Corp. and subsidiaries of our report dated December 28,
2020, relating to the consolidated financial statements, which appears in this Annual Report on Form 10-K.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
BDO USA, LLP</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
York, New York</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
28, 2020</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">BDO
USA, LLP, a Delaware limited liability partnership, is the U.S. member of BDO International Limited, a UK company limited by guarantee,
and forms part of the international BDO network of independent member firms.</FONT></P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">BDO
is the brand name for the BDO network and for each of the BDO Member Firms.</FONT></P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>e2298_ex31-1.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
31.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I,
Christopher Missling, certify that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I have
    reviewed this Annual Report on Form 10-K of Anavex Life Sciences Corp.;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
    on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary
    to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect
    to the period covered by this report;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
    on my knowledge, the financial statements, and other financial information included in this report, fairly present in all
    material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods
    presented in this report;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    registrant&rsquo;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls
    and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as
    defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 3%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</FONT></TD>
    <TD STYLE="width: 94%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
    such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
    to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to
    us by others within those entities, particularly during the period in which this report is being prepared;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed such internal
    control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision,
    to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements
    for external purposes in accordance with generally accepted accounting principles;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluated the effectiveness
    of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness
    of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosed in this
    report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s
    most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially
    affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting;
    and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    registrant&rsquo;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control
    over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors
    (or persons performing the equivalent functions):</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All significant
    deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably
    likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information;
    and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any fraud, whether
    or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s internal
    control over financial reporting.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: December 28, 2020</FONT></TD>
    <TD STYLE="width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Christopher Missling</I></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Christopher Missling, PhD </FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer, President, Secretary<BR>
    (Principal Executive Officer)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>e2298_ex31-2.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
31.2</B>&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I,
Sandra Boenisch, certify that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I have
    reviewed this Annual Report on Form 10-K of Anavex Life Sciences Corp.;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
    on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary
    to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect
    to the period covered by this report;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
    on my knowledge, the financial statements, and other financial information included in this report, fairly present in all
    material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods
    presented in this report;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    registrant&rsquo;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls
    and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as
    defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 3%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</FONT></TD>
    <TD STYLE="width: 94%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
    such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
    to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to
    us by others within those entities, particularly during the period in which this report is being prepared;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed such internal
    control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision,
    to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements
    for external purposes in accordance with generally accepted accounting principles;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluated the effectiveness
    of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness
    of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosed in this
    report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s
    most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially
    affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting;
    and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    registrant&rsquo;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control
    over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors
    (or persons performing the equivalent functions):</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All significant
    deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably
    likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information;
    and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any fraud, whether
    or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s internal
    control over financial reporting.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: December 28, 2020</FONT></TD>
    <TD STYLE="width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Sandra Boenisch</I></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sandra Boenisch, CPA, CGA</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Principal Financial Officer, Treasurer<BR>
    (Principal Financial and Accounting Officer)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>e2298_ex32-1.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
32.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the Annual Report of Anavex Life Sciences Corp. (the &ldquo;Company&rdquo;) on Form 10-K for the fiscal year ending
September 30, 2020 as filed with the Securities and Exchange Commission (the &ldquo;Report&rdquo;), we, Christopher Missling,
Chief Executive Officer (Principal Executive Officer) and Sandra Boenisch, Principal Financial Officer (Principal Financial and
Accounting Officer) of the Company, hereby certify as of the date hereof, solely for purposes of Title 18, Chapter 63, Section
1350 of the United States Code, that to the best of our knowledge:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="width: 97%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934,
    and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The information
    contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the
    Company at the dates and for the periods indicated.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: December 28, 2020</FONT></TD>
    <TD STYLE="width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Christopher Missling</I></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Christopher Missling, PhD</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer, President, Secretary
    (Principal Executive Officer)</FONT></TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 169.65pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Sandra Boenisch </I></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sandra Boenisch, CPA, CGA</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Principal Financial Officer, Treasurer<BR>
    (Principal Financial and Accounting Officer)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &+ PP# 2(  A$! Q$!_\0
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M[5_ZA]]_WY_^O0!H45G_ -J_]0^^_P"_/_UZ/[5_ZA]]_P!^?_KT :%%9_\
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M /7H_M7_ *A]]_WY_P#KT :%4=1U2#2UB,ZN1(Q V <8&2>2/R&3[4W^U?\
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MO_GYF_[\FC_A97AO_GYF_P"_)KP^BC^RJ'G_ %\@_M6OY?=_P3W#_A97AO\
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M9Z^U5V^('BQ())F:,11R^2[>2N _I^E"^NO:4?Z^0/ZDMXR_KYEC_A4VL?\
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M_'_XJC_A&/!__/K9?]_C_P#%4O[0H_R,?]GUOYU_7R/'TU&R%HUB8KD6OD[
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M9@1?H%X+-,<;N,CZ\BK*^(-2C8LG@F]#'J?+]\_W?6D?7+UQ@^!K[DY/R?\
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M^_[\-_A1_P (IK__ $![[_OPW^%'MJ?\R^\/8U/Y7]QD;F]3^=&YO4_G6O\
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M$#Q7UPRE58?.HSNSC&>I.#Q[4T^)/%XM#=&^N?)&<G<,C!P>.O7CI1[+&?\
M/U?U\@]K@_\ GT_Z^9U__"H[+_H*3?\ ?H?XT?\ "H[+_H*3?]^A_C7*G7/&
M@EBC^V7.^5_+50ZD[L9VGT/L<5#!XF\77(<PWUTWENL;<@89C@#ZYH]EC/\
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MJ/?_ ,)/K1 P2 J9520-Q^7IS4?67_S\7W?\ GV,/Y'_ .!?\$?_ ,(%>?\
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MDLO^@I-_WZ'^-'_"I++_ *"DW_?H?XUPW_";>(_^@M/^8H_X3;Q'_P!!:?\
M,4>PQO\ S\7]?(/;X'_GV_Z^9W/_  J2R_Z"DW_?H?XT?\*DLO\ H*3?]^A_
MC7#?\)MXC_Z"T_YBC_A-O$?_ $%I_P Q1[#&_P#/Q?U\@]O@?^?;_KYG<_\
M"I++_H*3?]^A_C1_PJ2R_P"@I-_WZ'^-<-_PFWB/_H+3_F*/^$V\1_\ 06G_
M #%'L,;_ ,_%_7R#V^!_Y]O^OF=S_P *DLO^@I-_WZ'^-'_"H[+_ *"DW_?H
M?XUPW_";>(_^@M/^8JU8^)O%6H/*L.K39CC,AW-C..P]SVI.CC4KNHOZ^0U6
MP3=E3?\ 7S.O_P"%1V7_ $%)O^_0_P :/^%1V7_04F_[]#_&N2_X27Q1L#_V
MQ)Y9MOM._/&W.,=.N>/K5@:SXI%_'9RZ\8I9$#IN)(;/5>!U&"#]*ET\8O\
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M9)=^\DD_>^]@$X&>^* *L'B..2W\V:SGA;; Q1BI($K%5Z'VR?ZU%9^)TO\
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M_@$E'_"8^!O^@=%_X!)5JO-*WLI$/#P;O[6)YGI=U;VJ2K="1XGQN@$89)
M>I)^4YZ$59BUIXHK8!I1)!:21*P X<GY3[\!1^%>A_\ "8^!O^@=%_X!)1_P
MF/@;_H'1?^ 24/$3;NZ3!8>"5E61P-SJ>GWD?EO%<0)^Z?;$H/S+NW 9/ RW
M!I6\0+)&P: JS;W)"C(8R[U7/7:>A'XUWO\ PF/@;_H'1?\ @$E'_"8^!O\
MH'1?^ 24O;3_ .?4A^QA_P _8G 0:I96ET\T NF\^X$TF]0"@&X@#GDY;KQP
M*DCUZ!60^1(NYHYIMH'SRAU+'Z87CW)KN_\ A,? W_0.B_\  )*/^$Q\#?\
M0.B_\ DH=:;WI2!48+:K$\MU"2.>Z,D3,RD<YA6+'X+Q^-;WA_5]#L]':UU6
MWO3<)=&XMY[0 /$=H7@D^WTKM/\ A,? W_0.B_\  )*/^$Q\#?\ 0.B_\ DI
M5*LZD.25*5BJ5*-*?M(58W*/_"=^&W@075GJ5[/'$\2W%Q&F_:W49!'7 J'_
M (37PL)&=='N@6;<0!@9ZYQN]JU/^$Q\#?\ 0.B_\ DH_P"$Q\#?] Z+_P
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M>^:[(_#GQ&22==0EA@_O9.1^51+\,-=2%85UB%8E;<J!W !ZY Q1];HV^/\
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M )_[/_Q[_"C_ (5+J?\ S_V?_CW^%'U[#_SA]1Q'\AY[17H7_"I=3_Y_[/\
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MU/6RW"U:5Y3TOT"BBBO*/5"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M *"]_P#^!+_XT?\ "1:W_P!!>_\ _ E_\:S,&C!H]G#L@]K/NS3_ .$BUO\
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MBBO&/9"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^_X_^(KS.BC^S\/_ "_B_P#,/[0Q'\WX+_(],_X6M;_]"_'_ -_Q_P#$4?\
M"UK?_H7X_P#O^/\ XBO,Z*/[/P_\OXO_ ##^T,1_-^"_R/3/^%K6_P#T+\?_
M '_'_P 11_PM:W_Z%^/_ +_C_P"(KS.BC^S\/_+^+_S#^T,1_-^"_P CTS_A
M:UO_ -"_'_W_ !_\11_PM:W_ .A?C_[_ (_^(KS.BC^S\/\ R_B_\P_M#$?S
M?@O\CTS_ (6M;_\ 0OQ_]_Q_\11_PM:W_P"A?C_[_C_XBO,Z*/[/P_\ +^+_
M ,P_M#$?S?@O\CV'P_\ $G3]1U%;2XLEL/,X23S REO0\#'UKO:^8E!9@%!)
M/3%>]^"X-8M_#L*:P^9/^62M]]$[!CZ_RKS,PP=.DE.#MY'IY=C*E9N$U?S.
MBHHHKRCU@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH K?VA9?\_EO_P!_5_QH_M&R_P"?RW_[^K_C3OL5K_S[0_\ ?L5Y[IOB
M#Q-K<$EUIGAC3);99&C#,R@Y'U8>H[5I"E*:;70SJ58P:3Z]E<] _M&R_P"?
MRW_[^K_C1_:-E_S^6_\ W]7_ !KB_M'C;_H4]*_[^)_\71]H\;?]"GI7_?Q/
M_BZOV#[K[T1]87\K^YG:?VC9?\_EO_W]7_&C^T;+_G\M_P#OZO\ C7%_:/&W
M_0IZ5_W\3_XNC[1XV_Z%/2O^_B?_ !='L'W7WH/K"_E?W,[3^T;+_G\M_P#O
MZO\ C1_:-E_S^6__ ']7_&N+^T>-O^A3TK_OXG_Q='VCQM_T*>E?]_$_^+H]
M@^Z^]!]87\K^YG:?VC9?\_EO_P!_5_QH_M&R_P"?RW_[^K_C7%_:/&W_ $*>
ME?\ ?Q/_ (NC[1XV_P"A3TK_ +^)_P#%T>P?=?>@^L+^5_<SM/[1LO\ G\M_
M^_J_XT?VC9?\_EO_ -_5_P :XO[1XV_Z%/2O^_B?_%T?:/&W_0IZ5_W\3_XN
MCV#[K[T'UA?RO[F=I_:-E_S^6_\ W]7_ !H_M&R_Y_+?_OZO^-<7]H\;?]"G
MI7_?Q/\ XNC[1XV_Z%/2O^_B?_%T>P?=?>@^L+^5_<SM/[1LO^?RW_[^K_C1
M_:-E_P _EO\ ]_5_QKB_M'C;_H4]*_[^)_\ %T?:/&W_ $*>E?\ ?Q/_ (NC
MV#[K[T'UA?RO[F=I_:-E_P _EO\ ]_5_QH_M&R_Y_+?_ +^K_C7)^&]8O;_Q
M%>:-K&BV-K/;P"7]T W4CCJ1T:NN^Q6G_/K#_P!^Q6<X.#LS2G44U=#?[1LO
M^?RW_P"_J_XT?VC9?\_EO_W]7_&G?8K3_GUA_P"_8H^Q6G_/K#_W[%06-_M&
MR_Y_+?\ [^K_ (T?VC9?\_EO_P!_5_QIWV*T_P"?6'_OV*0V5H 3]EA_[]B@
M#C-8\%:#K.JW&H3:P4DF()5)4P. /Z51_P"%;>'/^@W)_P!_8ZQF^+**Q'_"
M-VG'_33_ .QIO_"W(O\ H7;/_OY_]C7JQ6.BDD]/D>3*6 DVVM?F;?\ PK;P
MY_T&Y/\ O['1_P *V\.?]!N3_O['6)_PMN/_ *%RT_[^?_8T?\+;C_Z%RT_[
M^?\ V-/_ &_O^0O^$_M^9M_\*V\.?]!N3_O['1_PK;PY_P!!N3_O['6)_P +
M<B_Z%RS_ ._G_P!C1_PMR+_H7+/_ +^?_8T?[?W_ ""^7]OS-O\ X5MX<_Z#
M<G_?V.C_ (5MX<_Z#<G_ ']CK$_X6Y%_T+EI_P!_/_L:/^%MQCKX<M/^_G_V
M-'^W]_R#_A/[?F;?_"MO#G_0;D_[^QT?\*V\.?\ 0;D_[^QUB?\ "VX_^A<M
M/^_G_P!C1_PMN/./^$<M,_\ 73_[&C_;^_Y!?+^WYFW_ ,*V\.?]!N3_ +^Q
MUH:;X1TO28YX[+Q"R)/M\Q6,+!L9QU!]37*?\+;C_P"A<M/^_G_V-'_"VX\X
M_P"$<M,_]=/_ +&IE''25I:KY#C/ Q=XZ/YG>P:>+9"D'BIHU+%BJK!C)Z_P
MU)Y$O_0W2?E!_P#$UY]_PMR+_H7+3_OY_P#8T?\ "VXQ_P RY:?]_/\ [&L_
MJ^)_E7_DIK]9PJ^T_P#R8[F^TJ/4[&6RN_%4DEO*,.G[D9&<]0N:P?\ A6WA
MS_H-R?\ ?V.L3_A;<9Z>'+3_ +^?_8T?\+<B_P"A=L_^_@_^)JX0QL%:.GW&
M<ZF"F[RU^\V_^%;>'/\ H-R?]_8Z/^%;>'/^@W)_W]CK$_X6W'_T+EI_W\_^
MQH/Q;C R?#=H ?63_P"QJ_\ ;^_Y$_\ "?V_,V_^%;>'/^@W)_W]CH_X5MX<
M_P"@W)_W]CK$_P"%N1?]"[9_]_!_\32CXM(1D>&[0CU\S_[&C_;^_P"07R_M
M^9M?\*V\.?\ 0;D_[^QT?\*V\.?]!N3_ +^QUB_\+:3_ *%NT_[^?_8T?\+:
M3_H6[3_OY_\ 8T?[?W_(/^$_M^9M?\*V\.?]!N3_ +^QT?\ "MO#G_0;D_[^
MQUB_\+:3_H6[3_OY_P#8T?\ "VD_Z%NT_P"_G_V-'^W]_P @_P"$_M^9M?\
M"MO#G_0;D_[^QT?\*V\.?]!N3_O['6+_ ,+:3_H6[3_OY_\ 8T?\+:3_ *%N
MT_[^?_8T?[?W_(/^$_M^9M?\*V\.?]!N3_O['1_PK;PY_P!!N3_O['6+_P +
M:3_H6[3_ +^?_8T?\+:3_H6[3_OY_P#8T?[?W_(/^$_M^9UFA^#?#>B:@MZ+
M];F5/]6)I4PI]<#O77?VC9?\_EO_ -_5_P :\E_X6TG_ $+=K_W\_P#L:/\
MA;2?]"W:?]_/_L:PJ8;%57S3U?JC>GBL)27+#1>C/6O[1LO^?RW_ ._J_P"-
M']HV7_/Y;_\ ?U?\:\E_X6RN,_\ "-6N/]__ .QI5^*X8,5\,6Q"C)(;.![_
M "UG]1K]OQ1I]?H=_P &>L_VC9?\_EO_ -_5_P :/[1LO^?RW_[^K_C7DO\
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M_?U?\:/[1LO^?RW_ ._J_P"-.^Q6G_/K#_W[%'V*T_Y]8?\ OV* &_VC9?\
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M^T-8?$+[!QVO.THT^1Y[>606JQR>2ZG:P+<87IP16/7I/_"F]6_Z"-E_X_\
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M6H_^!3_XUE45IR1[&?M)]S5_X2;7O^@UJ/\ X%/_ (T?\)-KW_0:U'_P*?\
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M(1& )]:5HM=>V:V:.^:!B28RK$$DY/Z\U[#_ ,)OH'_0R7W_ (##_P"-T?\
M";Z!_P!#)??^ P_^-T?6*_\ SZ?X_P"0?5J'_/Y?A_F>*_V5J/\ SXW/_?H_
MX4?V5J/_ #XW/_?H_P"%>U?\)OH'_0R7W_@,/_C='_";Z!_T,E]_X##_ .-T
M_K.(_P"?3_'_ "%]5P__ #]7X?YGBO\ 96H_\^-S_P!^C_A1_96H_P#/C<_]
M^C_A7M7_  F^@?\ 0R7W_@,/_C='_";Z!_T,E]_X##_XW1]9Q'_/I_C_ )!]
M5P__ #]7X?YGBO\ 96H_\^-S_P!^C_A1_96H_P#/C<_]^C_A7M7_  F^@?\
M0R7W_@,/_C='_";Z!_T,E]_X##_XW1]9Q'_/I_C_ )!]5P__ #]7X?YGBO\
M96H_\^-S_P!^C_A1_96H_P#/C<_]^C_A7M7_  F^@?\ 0R7W_@,/_C='_";Z
M!_T,E]_X##_XW1]9Q'_/I_C_ )!]5P__ #]7X?YGBO\ 96H_\^-S_P!^C_A1
M_96H_P#/C<_]^C_A7M7_  F^@?\ 0R7W_@,/_C='_";Z!_T,E]_X##_XW1]9
MQ'_/I_C_ )!]5P__ #]7X?YGG?@WP%>^(+_?>Q2VUA$1YCLNUG_V5SW]^U>[
MVEI;V%I%:VL2Q01+M1%' %8ND7UKKL#RZ=KUU,J'##9&I7Z@IFM+[!<?]!6[
M_P"^8O\ XBO-Q5:I4E::M;H>EA:%.G&\'>_4O451^P7'_05N_P#OF+_XBC[!
M<?\ 05N_^^8O_B*YCJ+U%4?L%Q_T%;O_ +YB_P#B*/L%Q_T%;O\ [YB_^(H
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MQ<Y.[=GGU[_6G"A2E]G\63.O5C]J_P D=?\ \)S9?]"KI'_?D?X4?\)S9?\
M0JZ1_P!^1_A7&45I]5H]OQ?^9G];K=_P7^1V?_"<V7_0JZ1_WY'^%'_"<V7_
M $*ND?\ ?D?X5QE%'U6CV_%_YA];K=_P7^1V?_"<V7_0JZ1_WY'^%'_"<V7_
M $*ND?\ ?D?X5QE%'U6CV_%_YA];K=_P7^1V?_"<V7_0JZ1_WY'^%'_"<V7_
M $*ND?\ ?D?X5QE%'U6CV_%_YA];K=_P7^1V?_"<V7_0JZ1_WY'^%'_"<V7_
M $*ND?\ ?D?X5QE%'U6CV_%_YA];K=_P7^1V?_"<V7_0JZ1_WY'^%'_"<V7_
M $*ND?\ ?D?X5QE%'U6CV_%_YA];K=_P7^1V?_"<V7_0JZ1_WY'^%'_"<V7_
M $*ND?\ ?D?X5QE%'U6CV_%_YA];K=_P7^1V?_"<V7_0JZ1_WY'^%'_"<V7_
M $*ND?\ ?D?X5QE%'U6CV_%_YA];K=_P7^1ZYX/\>:?=W7]FRV-MIOF',7D@
M*C,>Q]">*]!KYC&<\=:]X\$/K$GAV(ZP/G_Y8EO]84[;O\YQUKR<QPD*?[R#
MWZ'KY;C)U?W<U>W4Z2BBBO)/7"BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KA_AY?6=OX=E2>[@B?[4Y
MVO(%.,+ZUW%<X_@/PT[LYTT98Y.)G _+=712G34)0G?6VWE<YZT*CG&<+:7W
M\[&O_:VF_P#00M?^_P O^-']K:;_ -!"U_[_ "_XUC_\(#X9_P"@;_Y'D_\
MBJ/^$!\,_P#0-_\ (\G_ ,53MA^\ON7^8KXGM'[W_D;']K:;_P!!"U_[_+_C
M1_:VF_\ 00M?^_R_XUC_ /" ^&?^@;_Y'D_^*H_X0'PS_P! W_R/)_\ %46P
M_>7W+_,+XGM'[W_D;']K:;_T$+7_ +_+_C1_:VF_]!"U_P"_R_XUC_\ " ^&
M?^@;_P"1Y/\ XJC_ (0'PS_T#?\ R/)_\51;#]Y?<O\ ,+XGM'[W_D;']K:;
M_P!!"U_[_+_C1_:VF_\ 00M?^_R_XUC_ /" ^&?^@;_Y'D_^*H_X0'PS_P!
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M? W@4:8$U/5(P;P\Q0MR(O<_[7\OKT[^O/? WCL:ALTO5I0+KI#.Q_UOL?\
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M \U'_"0/_P _ME_X#S4>QJ_RO[@^L4OYE]Z.DHKF_P#A('_Y_;+_ ,!YJ/\
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M_P 57F8FO4Q$^:2TZ(]3#4*>'ARQ>O5FM163]JO_ /G\TO\ \>_^*H^U7_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M!T&3CFM.B@""TM(+&#R+:,1Q;F<*.@+,6./3DGBIZ** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
(@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>img_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" &W G # 2(  A$! Q$!_\0
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MZ8.0#]&J*^#O!O[>.N?L@?#_ /;"TGXEZQ>>)=<^ .HW/BCP]+>D&?6-#U6
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MEW#83SP)>3W&BO##))&C+$72"9@9"JD1-SD8KZ%HHH \._:#_9;UGXO?M@?
M#XC6&J:;::9\([W7;G4K2='-Q?+?Z8]G&(2OR@J[!FW?P].:\N_X*(ZT_B?]
MLC]DKPKIFD^)-2U33/B(WB>^EM-%NYK"PT^/1]5MFFGNUC-O$?-FB4([ASO!
M QS7V%10!X=^PW^RUK'[+.G?%6#6-3TW5#X^^)6N^-K,V:.OV6VOYDDCADW=
M9$"D,5^7IBF^$_V5=6\/?\%&?&OQGDU/39-#\4^ ](\)Q:>JO]KAGL[V^N'E
M8XV>6RW:@8.<J> .ON=% 'PU\*_V(?VFOV1/#-]\+O@S\2?A)9_!\ZE=W7AZ
M]\2Z!>7OB+P9:W5P]P]G#''*MM>+$\DGDM,5(#*K!@H%?1%E^R/X.^#@\3>+
M/A=\.OA9H'Q6U;3[E8]<;0(;$ZA=R_O";N:VC$S123A7D"DDXSR0*]=HH ^"
MOV=?^";?Q8UNU^./@WX_O\(/$OPN^/FM77B;Q#9>%;C6++44O)8+"!;>.1F7
M%MLL@6^;>2Y&2IQ5KP5_P0X\$^!/VVM3\?V>J>)Y?!-]\/&\(II=]XPUC4+P
M7<LMTLSN;B=TDM3:W&U87W(L@+A WS5]UT4 ? WP:_X)D?&34!\#? WQ<\;?
M#?Q!\(_V<[N.\\/KHVDW4>M>*GM;&?3[ :AYK&&!8K:=O,6'>)G SM!(KU?]
MK+_@FKX;^*_P7\)^#/A[H'@7P5I6D_$3P_XTU6R724BLM3AT^\BFFB:*)-KR
M211[!O!4\ \5]144 ?/G_!1']CG4?VI_V&_$?PM\!7'ASPGJ=Y<:9=Z4]W:L
MNFV\EGJ5M?!'CAPP1OLY4[.1NS71?LN+\?UU#6?^%U/\'FM/+B_LG_A"4U)9
M-^7\WS_M9(QC9MV<YW9[5[#10!X=_P $W_V7-8_8O_8U\)?#;7]3TS6-5\/2
MZB\UWIZNMO*+G4;FZ3:' ;A)U4Y[J<<5XI\>_P#@E[XM^+/Q$^,VLV?B7P[:
MP?$KXB>!/&5C'-'-OL[?0/L'VB&7 (,DIM'V;>/F7<1S7VY10!\T>*?V(=>U
M[X^?M'^+8]:TB.S^-/P_TKPAID+)(9=/N+2'5(WEFXP8V-_&1M)/R-D=,_*/
MQT_X(;_$7XB>%O"NE17_ ,#O&L5C\'-(^&+MX\T6\U)/!UY9VTD,VJ:+$K>6
MLDYD5B9 CJT$1W, 4/ZBT4 ?A#^V?^S%'\-_VLY]%^(WB#3=%C\$?"GPCX7T
M2/7_  9XB\0Z7\1)+.UF^U6UH-+GMQ);&?:KVEQYSO(V[8%.#]C^+_\ @G]\
M3OV\O@5X]\8:W:^'?A=XG^.OP'T#P3-X:N8I@/"^IP7-[=2K(JKE80+M$"#+
MJ4((XY_1>B@#X2_X*I?LE^,]9\->,/BEX:BNM?N/#OP'\5^!(=!T>-FU?4+W
M4#9/');@JRD*MJ^5P7;("J2:^>/^")]M#\'OVL-#\.> 1X2^*N@:_P"$9+;Q
M7XML/!OB+1+WP*MFL1LM/-QJMS,A@FEDE"V4"Q-&T9D* #%?KI10!\G?'/\
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MZ&+P)_X2\'^-'_$75^V9_P!#%X$_\)>#_&OS&HH _3G_ (BZOVS/^AB\"?\
MA+P?XT?\1=7[9G_0Q>!/_"7@_P :_,:B@#].?^(NK]LS_H8O G_A+P?XT?\
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M[27NM1>RM_L\#R+<2Q95,D+E4!('&<XQTK^)*O[*_P#@W<_Y0L_ #_L R_\
MI;<4 ?:-%%% '\(/[5G_ "=%\2?^QIU3_P!*Y:X&N^_:L_Y.B^)/_8TZI_Z5
MRUP- !1110 4444 %%%% !1110 4444 %%%% !1110 444#DTTK@.09IU(%Q
M4D-LUP^U023[UW4*,Y-0@KMDMK=C8XC(X [UNZ3X1N-17Y(W;UVJ37<?!/\
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MTVIK# ND)Z9%;X6DJE:--NUVD*3LKGZ0_P#!#C]C72OBGXRF\4:[IZW=OIC
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MS5-A8L0ZLRRB0M7R/\5_C7XI^.'Q-O/&7BK6;K5O$]^83/J#!8I7,,211'Y
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MHHH _A!_:L_Y.B^)/_8TZI_Z5RUP-=]^U9_R=%\2?^QIU3_TKEK@: "BBB@
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M@]0?2NH^#/P-\9?M$^.[?PQX$\+Z[XO\0W*/+'I^DV;W4YC09=RJ D(HY+'
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M\N(UA.SYNO%?SX_M721S_%S63$<H;@X-?N-_P4/^)^G_  ]^!.H@RQQ7CQL
MBG&.*_ SXC^(G\0>([JY=MS3REL_C7^FF5VP_!:=5R_?3E)<^]F]#]J^BOE=
M94,1CG?ED[*YS$J8-1,G>IW'-1,,DU^38RE%2=D?V7%D=%*1@TE>0U9F@444
M4@"K"IMA4^HJO5^VC#VZY]*]G)</[:I.*WM^J,JKM9GK?[%7BN7PU\<]!F0_
M\O*@\^IK^A[X9ZL=5\ Z7=D@F2%0?RK^:[X5^(AX/\6V=^ V;>4/Q[5^YO\
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M-W,F7YJ-BI7WJ2YCP<U 3@5_,>83G"K)26Y^R0U0QR">*_LJ_P"#=S_E"S\
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MR^1!=WMK"PQG+N<@1FNI_P""C_[9G@W]K;X;>!'\,PW.EZA;>+/&_B"_T>2
MJFCPZMK"WEI"L@ 23$60=G *XKW_ ,(_\%9?A!\*/CI\/_AS9^ O#'B/X$>&
M_!D7PPU;Q;+9:C!XAO-(U"!CK=W'!]H$(9KV[N[B-7@9_DBYW %0#YI^-_\
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MHOX4^+L7[5PT?Q?XCNV^+'QET3Q9H'FQ7$?V[1[/^ULM)G_5F,3V6V-N?D7
M_=\ 'RI\-?V)?C#\8X]?;PI\+_'OB$^%;S^SM76PT.YG?3KK<5^SR*J$K,"#
MF/&X;22  :[_ . ?_!.C5?C)\*/$OB+4O$$/A.^T'_A(Q'I5[8.T]T="T=]2
MOU)W#RRN;:'D'#W&3C:0?T@^&&J:;_P4#_:=\">.O".I_$K0/"?AO]I?7?%F
MDZUI'A>ZOK/Q/'?WFF7)::2)P-.NH(H0'>]"1_9Y2ZNWE2(?GK1_^"D7P]^
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M.!D9P<5F2RO<2M)(S.[DLS,<EB>I)IM% !1110 4444 %%%% !1110 4444
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MW^V9_P!&^>._^^(/_CE'_$/W^V9_T;YX[_[X@_\ CE 'QW17V)_Q#]_MF?\
M1OGCO_OB#_XY1_Q#]_MF?]&^>._^^(/_ (Y0!\=T5]B?\0_?[9G_ $;YX[_[
MX@_^.4?\0_?[9G_1OGCO_OB#_P".4 ?'=%?8G_$/W^V9_P!&^>._^^(/_CE'
M_$/W^V9_T;YX[_[X@_\ CE 'QW17V)_Q#]_MF?\ 1OGCO_OB#_XY1_Q#]_MF
M?]&^>._^^(/_ (Y0!\=T5]B?\0_?[9G_ $;YX[_[X@_^.4?\0_?[9G_1OGCO
M_OB#_P".4 ?'=%?8G_$/W^V9_P!&^>._^^(/_CE'_$/W^V9_T;YX[_[X@_\
MCE 'QW17V)_Q#]_MF?\ 1OGCO_OB#_XY1_Q#]_MF?]&^>._^^(/_ (Y0!\=T
M5]B?\0_?[9G_ $;YX[_[X@_^.4?\0_?[9G_1OGCO_OB#_P".4 ?'=%?8G_$/
MW^V9_P!&^>._^^(/_CE'_$/W^V9_T;YX[_[X@_\ CE 'QW17V)_Q#]_MF?\
M1OGCO_OB#_XY1_Q#]_MF?]&^>._^^(/_ (Y0!\=T5]B?\0_?[9G_ $;YX[_[
MX@_^.4?\0_?[9G_1OGCO_OB#_P".4 ?'=%?8G_$/W^V9_P!&^>._^^(/_CE'
M_$/W^V9_T;YX[_[X@_\ CE 'QW17V)_Q#]_MF?\ 1OGCO_OB#_XY1_Q#]_MF
M?]&^>._^^(/_ (Y0!\=T5]B?\0_?[9G_ $;YX[_[X@_^.4?\0_?[9G_1OGCO
M_OB#_P".4 ?'=%?8G_$/W^V9_P!&^>._^^(/_CE'_$/W^V9_T;YX[_[X@_\
MCE 'QW17V)_Q#]_MF?\ 1OGCO_OB#_XY1_Q#]_MF?]&^>._^^(/_ (Y0!\=T
M5]B?\0_?[9G_ $;YX[_[X@_^.4?\0_?[9G_1OGCO_OB#_P".4 ?'=%?8G_$/
MW^V9_P!&^>._^^(/_CE'_$/W^V9_T;YX[_[X@_\ CE 'QW17V)_Q#]_MF?\
M1OGCO_OB#_XY1_Q#]_MF?]&^>._^^(/_ (Y0!\=T5]B?\0_?[9G_ $;YX[_[
MX@_^.4?\0_?[9G_1OGCO_OB#_P".4 ?'=%?8G_$/W^V9_P!&^>._^^(/_CE'
M_$/W^V9_T;YX[_[X@_\ CE 'QW17V)_Q#]_MF?\ 1OGCO_OB#_XY1_Q#]_MF
M?]&^>._^^(/_ (Y0!\=T5]B?\0_?[9G_ $;YX[_[X@_^.4?\0_?[9G_1OGCO
M_OB#_P".4 ?'=%?8G_$/W^V9_P!&^>._^^(/_CE'_$/W^V9_T;YX[_[X@_\
MCE 'QW17V)_Q#]_MF?\ 1OGCO_OB#_XY1_Q#]_MF?]&^>._^^(/_ (Y0!\=T
M5]B?\0_?[9G_ $;YX[_[X@_^.4?\0_?[9G_1OGCO_OB#_P".4 ?'=%?8G_$/
MW^V9_P!&^>._^^(/_CE'_$/W^V9_T;YX[_[X@_\ CE 'QW17V)_Q#]_MF?\
M1OGCO_OB#_XY1_Q#]_MF?]&^>._^^(/_ (Y0!\=T5]B?\0_?[9G_ $;YX[_[
MX@_^.4?\0_?[9G_1OGCO_OB#_P".4 ?'=%?8G_$/W^V9_P!&^>._^^(/_CE'
M_$/W^V9_T;YX[_[X@_\ CE 'QW17V)_Q#]_MF?\ 1OGCO_OB#_XY1_Q#]_MF
M?]&^>._^^(/_ (Y0!\=T5]B?\0_?[9G_ $;YX[_[X@_^.4?\0_?[9G_1OGCO
M_OB#_P".4 ?'=%?8G_$/W^V9_P!&^>._^^(/_CE'_$/W^V9_T;YX[_[X@_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !17SW^W)XT\>>
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M "#6_P!]/_0UJW537?\ D&M_OI_Z&M %NBBB@ HHHH **** *>@?\@F+\?\
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M_P#?;?XT 7**I_V!:?\ /(_]]M_C1_8%I_SR/_?;?XT 7**I_P!@6G_/(_\
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M+Q>8N ^UB5W#@XR.M7J "LO4/^1MTW_KA<?SBK4K+U#_ )&W3?\ KA<?SBH
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M"J-SLQVJHSA0!L:A_P C;IO_ %PN/YQ4 6?[0N/^?&?_ +^)_P#%4?VA<?\
M/C/_ -_$_P#BJMT4 5/[0N/^?&?_ +^)_P#%4?VA<?\ /C/_ -_$_P#BJMT4
M 5/[0N/^?&?_ +^)_P#%55UF^G;3V!LIE^=.2Z?WQ[UJU4UW_D&M_OI_Z&M
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M&EQ,+^'="EP'7@-++;1&'S6RR[@_S%0#[3:VL5C:QP0QI##"H2-$4*J*!@
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MR?#U/AAIOC+1+2\U*[BOM*FOIIP\OD1CR'N-T:Q,68@1J=I^9@?MJ@ HHHH
M**** "BBB@ HHHH *_-[_@H'\>+6V\:7WBW3M:L_"^H6-U-X#\17OA7XJW.G
M7-_+ ]Q=0Z?+!%HUX9)8K222Y:2$)+:B>X4R (6K](:^.[+_ ()U>/O OCO4
M/$'ASQYX4NI/"\7B)OAS9ZKH$ICT2[U^_6[O[K4)$GS>/$/,BA"+#\DC!RQ8
MM0![-^QM\"?"OPB^&<6K>&;6&V'C*STZ^E6WUIM8L[>&*P@MK6VM+DJN^TB@
MB18V"C<"7/S.37Q+^RH=&7]HWX2Q65KJEQX_MO$^L2>)OAK-'KG]D?#J&5;P
MK?V<5Q*;2V>#*P^;L,=S]L<VXBW(*^F_VAO"FK_L4_\ !,*+PUX)UW6;-O F
MB:1H4WB*VLENM0TS3$GMK:_U2.#:RM-!9FXN NUE5HQ\I VGR7X>^)O ?PN_
M:9^#NG? OXZ^*/BKJ/B_4I[?Q3H5W\0I_&=K=:,+*>67591+-,+*2*X2U"RQ
MF)9#+Y6U]PV@'WO7YM?%;_@FC\=-=^+_ ,0M;NM2\"^,AXK\+RRSZE%92Z;>
M:U>PZY::A::9*9+J4)$MM;+;*P01*F<@,SL?TEHH \1_8]\"^)=.\5?%CQGX
MET"Z\(O\1_%$6JV.B75S!/=6=O!IEC8B2<P.\0EE:U=]J.V$,8)W9 ]7UBW6
MY\4Z:K%U'D7'*,5/6+N*UZR]0_Y&W3?^N%Q_.*@"S_8T?_/6Z_[_ +_XT?V-
M'_SUNO\ O^_^-<_\6_B9<?"S0H]130=0UNV,B12_9)H(V@+R)&F1*ZYRSCIG
M&#FNAT2]N-2TF">ZLI=.N)5S);22([PGT+(2I_ F@!/[&C_YZW7_ '_?_&N<
MUF2;7]6DT?1[F[B:' O[X3,19@C/EIDX,Q'X(#D_P@W?$NN76I:F=$TB39>E
M0UW=X#+IT9Z'G@RL/NJ?]X\ !M70="MO#>EQ6=I'Y<,63R2S.Q.69B>68DDD
MGDDFO(JU)XNHZ%%VA'24ENWUA%_^E26WPKWKN';"*H152:O)[+_VY_HNN[TL
MI5]'\'V6@Z=':6@N(((LX43OR2<EB<Y+$DDD\DDTFM:3&FGL1)<_?3K.Y_C'
MO6K537?^0:W^^G_H:UZE.G&G%0@K):)+9(Y)2<FY2=VP_L:/_GK=?]_W_P :
M/[&C_P">MU_W_?\ QJW15DE3^QH_^>MU_P!_W_QH_L:/_GK=?]_W_P :MT4
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M7_?]_P#&C^QH_P#GK=?]_P!_\:MT4 96M:3&FG,?,N?OIUG?^^/>K7]CQ_\
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M_L.>%_'>D>([?Q1K'BGQ/=>+?!H\#ZM?7MW%'<W5B)KF42?N(HT2<-=28=%
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M\%?MI?%+7/V\;SP;<Z=IX\*B_-A%8+:8ND"R%9"6!+J8X0EP97 A=6*)EB"
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MMK>PMM9N?A.GC6>^:X:^6XB\XV\[0?962SE2W4(;AKEOF8(P !]T?L_^$(_
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M!@"O(R0>NWCT_P#9TN-8?X66-]K6F7*ZSJ1>>[E<J);CYB$9MS9^X% '8 8
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M=>-R<?(/]JK7]H3_ //C<?\ ?2?_ !5 %NBJG]H3_P#/C<?]])_\51_:$_\
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M_P"?&X_[Z3_XJJNB7\RZ5"!9SL,'D,GJ?]J@#5HJ.WF:9,M$\1]&()_0FI*
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MK(CG<S;(E9F988]WEQJS,5C1 22,UZ/10 4444 %%%% !1110 4444 %%%%
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M^AK0!;HHHH **** "BBB@"GH'_()B_'_ -"-7*IZ!_R"8OQ_]"-7* "BBB@
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MM,WVA)G5X=R!)$7>Q4F@#VFBBB@ HHHH **** "BBB@ HHQ[TG0CF@!:***
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(H **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>9
<FILENAME>avxl-20200930.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.6a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 8KlZs7xRiXgen8uCandcSaqOicPtxJFzCZkhv2p0fUnaPyQrP5CIViwQuvf2kRwM -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:avxl="http://anavex.com/20200930" elementFormDefault="qualified" targetNamespace="http://anavex.com/20200930">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://anavex.com/role/Cover" id="Cover">
	  <link:definition>00000001 - Document - Cover</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/ConsolidatedBalanceSheets" id="ConsolidatedBalanceSheets">
	  <link:definition>00000002 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/ConsolidatedBalanceSheetsParenthetical" id="ConsolidatedBalanceSheetsParenthetical">
	  <link:definition>00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/ConsolidatedStatementsOfOperations" id="ConsolidatedStatementsOfOperations">
	  <link:definition>00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/ConsolidatedStatementsOfCashFlows" id="ConsolidatedStatementsOfCashFlows">
	  <link:definition>00000005 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/ConsolidatedStatementOfChangesInStockholdersEquity" id="ConsolidatedStatementOfChangesInStockholdersEquity">
	  <link:definition>00000006 - Statement - CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/BusinessDescriptionAndBasisOfPresentation" id="BusinessDescriptionAndBasisOfPresentation">
	  <link:definition>00000007 - Disclosure - Business Description and Basis of Presentation</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
	  <link:definition>00000008 - Disclosure - Summary of Significant Accounting Policies</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/OtherIncome" id="OtherIncome">
	  <link:definition>00000009 - Disclosure - Other Income</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/EquityOfferingAgreements" id="EquityOfferingAgreements">
	  <link:definition>00000010 - Disclosure - Equity Offering Agreements</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/Commitments" id="Commitments">
	  <link:definition>00000011 - Disclosure - Commitments</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/IncomeTaxes" id="IncomeTaxes">
	  <link:definition>00000012 - Disclosure - Income Taxes</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/SummaryOfSignificantAccountingPoliciesPolicies" id="SummaryOfSignificantAccountingPoliciesPolicies">
	  <link:definition>00000013 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/CommitmentsTables" id="CommitmentsTables">
	  <link:definition>00000014 - Disclosure - Commitments (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/IncomeTaxesTables" id="IncomeTaxesTables">
	  <link:definition>00000015 - Disclosure - Income Taxes (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" id="SummaryOfSignificantAccountingPoliciesDetailsNarrative">
	  <link:definition>00000016 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/OtherIncomeDetailsNarrative" id="OtherIncomeDetailsNarrative">
	  <link:definition>00000017 - Disclosure - Other Income (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/EquityOfferingAgreementsDetailsNarrative" id="EquityOfferingAgreementsDetailsNarrative">
	  <link:definition>00000018 - Disclosure - Equity Offering Agreements (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/CommitmentsDetails" id="CommitmentsDetails">
	  <link:definition>00000019 - Disclosure - Commitments (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/CommitmentsDetails1" id="CommitmentsDetails1">
	  <link:definition>00000020 - Disclosure - Commitments (Details 1)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/CommitmentsDetails2" id="CommitmentsDetails2">
	  <link:definition>00000021 - Disclosure - Commitments (Details 2)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/CommitmentsDetails3" id="CommitmentsDetails3">
	  <link:definition>00000022 - Disclosure - Commitments (Details 3)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/CommitmentsDetails4" id="CommitmentsDetails4">
	  <link:definition>00000023 - Disclosure - Commitments (Details 4)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/CommitmentsDetailsNarrative" id="CommitmentsDetailsNarrative">
	  <link:definition>00000024 - Disclosure - Commitments (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/IncomeTaxesDetails" id="IncomeTaxesDetails">
	  <link:definition>00000025 - Disclosure - Income Taxes (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/IncomeTaxesDetails1" id="IncomeTaxesDetails1">
	  <link:definition>00000026 - Disclosure - Income Taxes (Details 1)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/IncomeTaxesDetails2" id="IncomeTaxesDetails2">
	  <link:definition>00000027 - Disclosure - Income Taxes (Details 2)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/IncomeTaxesDetailsNarrative" id="IncomeTaxesDetailsNarrative">
	  <link:definition>00000028 - Disclosure - Income Taxes (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="avxl-20200930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="avxl-20200930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="avxl-20200930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="avxl-20200930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd" />
    <import namespace="http://fasb.org/us-gaap/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd" />
    <import namespace="http://fasb.org/us-types/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2020-01-31" schemaLocation="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd" />
    <import namespace="http://xbrl.sec.gov/currency/2020-01-31" schemaLocation="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd" />
    <import namespace="http://fasb.org/srt/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd" />
    <import namespace="http://fasb.org/srt-types/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd" />
    <element id="avxl_ClinicalStudyGrantMember" name="ClinicalStudyGrantMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_NYCBiotechCreditMember" name="NYCBiotechCreditMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_PurchaseAgreementMember" name="PurchaseAgreementMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_LincolnParkCapitalFundLLCMember" name="LincolnParkCapitalFundLLCMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_PurchaseAgreement1Member" name="PurchaseAgreement1Member" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_EquityOfferingSalesAgreementMember" name="EquityOfferingSalesAgreementMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_CantorFitzgeraldAndCoMember" name="CantorFitzgeraldAndCoMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_PurchaseWarrantsMember" name="PurchaseWarrantsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_PurchaseWarrants1Member" name="PurchaseWarrants1Member" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_PurchaseWarrants2Member" name="PurchaseWarrants2Member" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_StockOptionPlan2015Member" name="StockOptionPlan2015Member" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_StockOptionPlan2019Member" name="StockOptionPlan2019Member" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_NonOperatingIncomeFromGrant" name="NonOperatingIncomeFromGrant" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_ResearchAndDevelopmentIncentiveIncome" name="ResearchAndDevelopmentIncentiveIncome" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_DeferredCharges" name="DeferredCharges" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_StockIssuedDuringPeriodValueAcquisitions2" name="StockIssuedDuringPeriodValueAcquisitions2" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_StockIssuedDuringPeriodSharesAcquisitions2" name="StockIssuedDuringPeriodSharesAcquisitions2" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2" name="CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2" name="CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1" name="CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement1" name="CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement1" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_SharesIssuedPursuantToCashlessExerciseOfWarrants" name="SharesIssuedPursuantToCashlessExerciseOfWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_SharesIssuedPursuantToCashlessExerciseOfOptions" name="SharesIssuedPursuantToCashlessExerciseOfOptions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_SharesIssuedPursuantToCashlessExerciseOfOptionsInShares" name="SharesIssuedPursuantToCashlessExerciseOfOptionsInShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_SharesIssuedDuringPeriodValueUnderSalesAgreement" name="SharesIssuedDuringPeriodValueUnderSalesAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_SharesIssuedDuringPeriodSharesUnderSalesAgreement" name="SharesIssuedDuringPeriodSharesUnderSalesAgreement" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_SharesIssuedPursuantToCashlessExerciseOfWarrantsInShares" name="SharesIssuedPursuantToCashlessExerciseOfWarrantsInShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_DisclosureOtherIncomeAbstract" name="DisclosureOtherIncomeAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_OtherIncomeDisclosureTextBlock" name="OtherIncomeDisclosureTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_DisclosureEquityOfferingAgreementsAbstract" name="DisclosureEquityOfferingAgreementsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_EquityOfferingAgreementsTextBlock" name="EquityOfferingAgreementsTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_GrantIncomePolicyTextBlock" name="GrantIncomePolicyTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock" name="ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_CashRefundAvailableDescription" name="CashRefundAvailableDescription" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_FundingOfDeferredIncomeAwardedGrant" name="FundingOfDeferredIncomeAwardedGrant" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_StockIssuedDuringPeriodSharesNewIssues4" name="StockIssuedDuringPeriodSharesNewIssues4" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_StockIssuedDuringPeriodValueNewIssues3" name="StockIssuedDuringPeriodValueNewIssues3" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_StockIssuedDuringPeriodSharesNewIssues3" name="StockIssuedDuringPeriodSharesNewIssues3" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_ValueOfSharesObligatedToPurchase" name="ValueOfSharesObligatedToPurchase" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_AgreementTerm" name="AgreementTerm" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_PercentageOfGrossProceedsFromSales" name="PercentageOfGrossProceedsFromSales" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_NumberOfSharesObligatedToPurchaseProrataBasic" name="NumberOfSharesObligatedToPurchaseProrataBasic" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_StockIssuedDuringPeriodValueNewIssues4" name="StockIssuedDuringPeriodValueNewIssues4" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_NumberOfStockSold" name="NumberOfStockSold" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_GrossProceedsFromSaleOfCommonStock" name="GrossProceedsFromSaleOfCommonStock" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_NumberOfSharesAvailable" name="NumberOfSharesAvailable" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" nillable="true" xbrli:periodType="instant" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExercised" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExercised" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExpired" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExpired" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_SharesIssuedPursuantToCashlessExerciseOfWarrantInShares" name="SharesIssuedPursuantToCashlessExerciseOfWarrantInShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_StockIssuedPursuantToCashlessExerciseOfWarrants" name="StockIssuedPursuantToCashlessExerciseOfWarrants" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_SharesIssuedPursuantToCashlessExercisesOfOption" name="SharesIssuedPursuantToCashlessExercisesOfOption" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_NumberOfCashlessExerciseOption" name="NumberOfCashlessExerciseOption" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_DeferredTaxAssetsUnpaidCharges" name="DeferredTaxAssetsUnpaidCharges" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopmentCreditBenefit" name="IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopmentCreditBenefit" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_OperatingLossCarryForwardsExpirationYear1" name="OperatingLossCarryForwardsExpirationYear1" nillable="true" xbrli:periodType="duration" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>10
<FILENAME>avxl-20200930_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.6a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://anavex.com/role/Cover" xlink:href="avxl-20200930.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/ConsolidatedBalanceSheets" xlink:href="avxl-20200930.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="avxl-20200930.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/ConsolidatedStatementsOfOperations" xlink:href="avxl-20200930.xsd#ConsolidatedStatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="avxl-20200930.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/ConsolidatedStatementOfChangesInStockholdersEquity" xlink:href="avxl-20200930.xsd#ConsolidatedStatementOfChangesInStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/BusinessDescriptionAndBasisOfPresentation" xlink:href="avxl-20200930.xsd#BusinessDescriptionAndBasisOfPresentation" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="avxl-20200930.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/OtherIncome" xlink:href="avxl-20200930.xsd#OtherIncome" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/EquityOfferingAgreements" xlink:href="avxl-20200930.xsd#EquityOfferingAgreements" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/Commitments" xlink:href="avxl-20200930.xsd#Commitments" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/IncomeTaxes" xlink:href="avxl-20200930.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="avxl-20200930.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsTables" xlink:href="avxl-20200930.xsd#CommitmentsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/IncomeTaxesTables" xlink:href="avxl-20200930.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="avxl-20200930.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/OtherIncomeDetailsNarrative" xlink:href="avxl-20200930.xsd#OtherIncomeDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/EquityOfferingAgreementsDetailsNarrative" xlink:href="avxl-20200930.xsd#EquityOfferingAgreementsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsDetails" xlink:href="avxl-20200930.xsd#CommitmentsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsDetails1" xlink:href="avxl-20200930.xsd#CommitmentsDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsDetails2" xlink:href="avxl-20200930.xsd#CommitmentsDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsDetails3" xlink:href="avxl-20200930.xsd#CommitmentsDetails3" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsDetails4" xlink:href="avxl-20200930.xsd#CommitmentsDetails4" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsDetailsNarrative" xlink:href="avxl-20200930.xsd#CommitmentsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/IncomeTaxesDetails" xlink:href="avxl-20200930.xsd#IncomeTaxesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/IncomeTaxesDetails1" xlink:href="avxl-20200930.xsd#IncomeTaxesDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/IncomeTaxesDetails2" xlink:href="avxl-20200930.xsd#IncomeTaxesDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/IncomeTaxesDetailsNarrative" xlink:href="avxl-20200930.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/ConsolidatedBalanceSheets" xlink:title="00000002 - Statement - CONSOLIDATED BALANCE SHEETS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesReceivable" xlink:label="loc_us-gaapIncomeTaxesReceivable" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapIncomeTaxesReceivable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapPrepaidExpenseCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaapAdditionalPaidInCapitalCommonStock" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapitalCommonStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:title="00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/ConsolidatedStatementsOfOperations" xlink:title="00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200930.xsd#avxl_NonOperatingIncomeFromGrant" xlink:label="loc_avxlNonOperatingIncomeFromGrant" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_avxlNonOperatingIncomeFromGrant" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200930.xsd#avxl_ResearchAndDevelopmentIncentiveIncome" xlink:label="loc_avxlResearchAndDevelopmentIncentiveIncome" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_avxlResearchAndDevelopmentIncentiveIncome" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="loc_us-gaapInterestIncomeExpenseNet" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapInterestIncomeExpenseNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts" xlink:label="loc_us-gaapDebtRelatedCommitmentFeesAndDebtIssuanceCosts" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapDebtRelatedCommitmentFeesAndDebtIssuanceCosts" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" weight="-1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentIncomeTaxExpenseBenefit" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapCurrentIncomeTaxExpenseBenefit" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/ConsolidatedStatementsOfCashFlows" xlink:title="00000005 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200930.xsd#avxl_DeferredCharges" xlink:label="loc_avxlDeferredCharges" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_avxlDeferredCharges" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnRestructuringOfDebt" xlink:label="loc_us-gaapGainsLossesOnRestructuringOfDebt" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapGainsLossesOnRestructuringOfDebt" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInIncomeTaxesReceivable" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInIncomeTaxesReceivable" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpense" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfStockIssuanceCosts" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapPaymentsOfStockIssuanceCosts" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfDebtIssuanceCosts" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapPaymentsOfDebtIssuanceCosts" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/ConsolidatedStatementOfChangesInStockholdersEquity" xlink:title="00000006 - Statement - CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS&apos; EQUITY" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/BusinessDescriptionAndBasisOfPresentation" xlink:title="00000007 - Disclosure - Business Description and Basis of Presentation" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="00000008 - Disclosure - Summary of Significant Accounting Policies" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/OtherIncome" xlink:title="00000009 - Disclosure - Other Income" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/EquityOfferingAgreements" xlink:title="00000010 - Disclosure - Equity Offering Agreements" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/Commitments" xlink:title="00000011 - Disclosure - Commitments" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/IncomeTaxes" xlink:title="00000012 - Disclosure - Income Taxes" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000013 - Disclosure - Summary of Significant Accounting Policies (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsTables" xlink:title="00000014 - Disclosure - Commitments (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/IncomeTaxesTables" xlink:title="00000015 - Disclosure - Income Taxes (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000016 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/OtherIncomeDetailsNarrative" xlink:title="00000017 - Disclosure - Other Income (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/EquityOfferingAgreementsDetailsNarrative" xlink:title="00000018 - Disclosure - Equity Offering Agreements (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsDetails" xlink:title="00000019 - Disclosure - Commitments (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsDetails1" xlink:title="00000020 - Disclosure - Commitments (Details 1)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsDetails2" xlink:title="00000021 - Disclosure - Commitments (Details 2)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsDetails3" xlink:title="00000022 - Disclosure - Commitments (Details 3)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsDetails4" xlink:title="00000023 - Disclosure - Commitments (Details 4)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsDetailsNarrative" xlink:title="00000024 - Disclosure - Commitments (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/IncomeTaxesDetails" xlink:title="00000025 - Disclosure - Income Taxes (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/IncomeTaxesDetails1" xlink:title="00000026 - Disclosure - Income Taxes (Details 1)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/IncomeTaxesDetails2" xlink:title="00000027 - Disclosure - Income Taxes (Details 2)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/IncomeTaxesDetailsNarrative" xlink:title="00000028 - Disclosure - Income Taxes (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>11
<FILENAME>avxl-20200930_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.6a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://anavex.com/role/Cover" xlink:href="avxl-20200930.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/ConsolidatedBalanceSheets" xlink:href="avxl-20200930.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="avxl-20200930.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/ConsolidatedStatementsOfOperations" xlink:href="avxl-20200930.xsd#ConsolidatedStatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="avxl-20200930.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/ConsolidatedStatementOfChangesInStockholdersEquity" xlink:href="avxl-20200930.xsd#ConsolidatedStatementOfChangesInStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/BusinessDescriptionAndBasisOfPresentation" xlink:href="avxl-20200930.xsd#BusinessDescriptionAndBasisOfPresentation" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="avxl-20200930.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/OtherIncome" xlink:href="avxl-20200930.xsd#OtherIncome" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/EquityOfferingAgreements" xlink:href="avxl-20200930.xsd#EquityOfferingAgreements" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/Commitments" xlink:href="avxl-20200930.xsd#Commitments" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/IncomeTaxes" xlink:href="avxl-20200930.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="avxl-20200930.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsTables" xlink:href="avxl-20200930.xsd#CommitmentsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/IncomeTaxesTables" xlink:href="avxl-20200930.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="avxl-20200930.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/OtherIncomeDetailsNarrative" xlink:href="avxl-20200930.xsd#OtherIncomeDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/EquityOfferingAgreementsDetailsNarrative" xlink:href="avxl-20200930.xsd#EquityOfferingAgreementsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsDetails" xlink:href="avxl-20200930.xsd#CommitmentsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsDetails1" xlink:href="avxl-20200930.xsd#CommitmentsDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsDetails2" xlink:href="avxl-20200930.xsd#CommitmentsDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsDetails3" xlink:href="avxl-20200930.xsd#CommitmentsDetails3" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsDetails4" xlink:href="avxl-20200930.xsd#CommitmentsDetails4" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsDetailsNarrative" xlink:href="avxl-20200930.xsd#CommitmentsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/IncomeTaxesDetails" xlink:href="avxl-20200930.xsd#IncomeTaxesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/IncomeTaxesDetails1" xlink:href="avxl-20200930.xsd#IncomeTaxesDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/IncomeTaxesDetails2" xlink:href="avxl-20200930.xsd#IncomeTaxesDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/IncomeTaxesDetailsNarrative" xlink:href="avxl-20200930.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/ConsolidatedBalanceSheets" xlink:title="00000002 - Statement - CONSOLIDATED BALANCE SHEETS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:title="00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/ConsolidatedStatementsOfOperations" xlink:title="00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/ConsolidatedStatementsOfCashFlows" xlink:title="00000005 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/ConsolidatedStatementOfChangesInStockholdersEquity" xlink:title="00000006 - Statement - CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS&apos; EQUITY">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200930.xsd#avxl_StockIssuedDuringPeriodValueAcquisitions2" xlink:label="loc_avxlStockIssuedDuringPeriodValueAcquisitions2_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlStockIssuedDuringPeriodValueAcquisitions2_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200930.xsd#avxl_StockIssuedDuringPeriodSharesAcquisitions2" xlink:label="loc_avxlStockIssuedDuringPeriodSharesAcquisitions2_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlStockIssuedDuringPeriodSharesAcquisitions2_50" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200930.xsd#avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2" xlink:label="loc_avxlCommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlCommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2_50" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200930.xsd#avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2" xlink:label="loc_avxlCommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlCommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2_50" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueAcquisitions_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueAcquisitions_50" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions_50" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200930.xsd#avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1" xlink:label="loc_avxlCommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlCommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1_50" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200930.xsd#avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement1" xlink:label="loc_avxlCommitmentSharesIssuedValueUndertermsOfPurchaseAgreement1_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlCommitmentSharesIssuedValueUndertermsOfPurchaseAgreement1_50" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200930.xsd#avxl_SharesIssuedPursuantToCashlessExerciseOfWarrants" xlink:label="loc_avxlSharesIssuedPursuantToCashlessExerciseOfWarrants_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlSharesIssuedPursuantToCashlessExerciseOfWarrants_50" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200930.xsd#avxl_SharesIssuedPursuantToCashlessExerciseOfOptions" xlink:label="loc_avxlSharesIssuedPursuantToCashlessExerciseOfOptions_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlSharesIssuedPursuantToCashlessExerciseOfOptions_50" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200930.xsd#avxl_SharesIssuedPursuantToCashlessExerciseOfOptionsInShares" xlink:label="loc_avxlSharesIssuedPursuantToCashlessExerciseOfOptionsInShares_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlSharesIssuedPursuantToCashlessExerciseOfOptionsInShares_50" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200930.xsd#avxl_SharesIssuedDuringPeriodValueUnderSalesAgreement" xlink:label="loc_avxlSharesIssuedDuringPeriodValueUnderSalesAgreement_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlSharesIssuedDuringPeriodValueUnderSalesAgreement_50" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200930.xsd#avxl_SharesIssuedDuringPeriodSharesUnderSalesAgreement" xlink:label="loc_avxlSharesIssuedDuringPeriodSharesUnderSalesAgreement_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlSharesIssuedDuringPeriodSharesUnderSalesAgreement_50" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200930.xsd#avxl_SharesIssuedPursuantToCashlessExerciseOfWarrantsInShares" xlink:label="loc_avxlSharesIssuedPursuantToCashlessExerciseOfWarrantsInShares_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlSharesIssuedPursuantToCashlessExerciseOfWarrantsInShares_50" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_50" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss_50" xlink:type="arc" order="18" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/BusinessDescriptionAndBasisOfPresentation" xlink:title="00000007 - Disclosure - Business Description and Basis of Presentation" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="00000008 - Disclosure - Summary of Significant Accounting Policies" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/OtherIncome" xlink:title="00000009 - Disclosure - Other Income" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/EquityOfferingAgreements" xlink:title="00000010 - Disclosure - Equity Offering Agreements" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/Commitments" xlink:title="00000011 - Disclosure - Commitments" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/IncomeTaxes" xlink:title="00000012 - Disclosure - Income Taxes" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000013 - Disclosure - Summary of Significant Accounting Policies (Policies)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsTables" xlink:title="00000014 - Disclosure - Commitments (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/IncomeTaxesTables" xlink:title="00000015 - Disclosure - Income Taxes (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000016 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/OtherIncomeDetailsNarrative" xlink:title="00000017 - Disclosure - Other Income (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ReinsurancePremiumsForInsuranceCompaniesByProductSegmentLineItems" xlink:label="loc_srtReinsurancePremiumsForInsuranceCompaniesByProductSegmentLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_srtReinsurancePremiumsForInsuranceCompaniesByProductSegmentLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtProductOrServiceAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200930.xsd#avxl_ClinicalStudyGrantMember" xlink:label="loc_avxlClinicalStudyGrantMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_avxlClinicalStudyGrantMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200930.xsd#avxl_NYCBiotechCreditMember" xlink:label="loc_avxlNYCBiotechCreditMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_avxlNYCBiotechCreditMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CurrencyAxis" xlink:label="loc_srtCurrencyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtCurrencyAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currencyAllCurrenciesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtCurrencyAxis" xlink:to="loc_currencyAllCurrenciesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currencyAllCurrenciesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtCurrencyAxis" xlink:to="loc_currencyAllCurrenciesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_AUD" xlink:label="loc_currencyAUD_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currencyAllCurrenciesDomain" xlink:to="loc_currencyAUD_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200930.xsd#avxl_FundingOfDeferredIncomeAwardedGrant" xlink:label="loc_avxlFundingOfDeferredIncomeAwardedGrant_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtReinsurancePremiumsForInsuranceCompaniesByProductSegmentLineItems" xlink:to="loc_avxlFundingOfDeferredIncomeAwardedGrant_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200930.xsd#avxl_NonOperatingIncomeFromGrant" xlink:label="loc_avxlNonOperatingIncomeFromGrant_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtReinsurancePremiumsForInsuranceCompaniesByProductSegmentLineItems" xlink:to="loc_avxlNonOperatingIncomeFromGrant_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:label="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtReinsurancePremiumsForInsuranceCompaniesByProductSegmentLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_70" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/EquityOfferingAgreementsDetailsNarrative" xlink:title="00000018 - Disclosure - Equity Offering Agreements (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityListingsLineItems" xlink:label="loc_deiEntityListingsLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200930.xsd#avxl_PurchaseAgreementMember" xlink:label="loc_avxlPurchaseAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_avxlPurchaseAgreementMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200930.xsd#avxl_PurchaseAgreement1Member" xlink:label="loc_avxlPurchaseAgreement1Member_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_avxlPurchaseAgreement1Member_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200930.xsd#avxl_EquityOfferingSalesAgreementMember" xlink:label="loc_avxlEquityOfferingSalesAgreementMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_avxlEquityOfferingSalesAgreementMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200930.xsd#avxl_LincolnParkCapitalFundLLCMember" xlink:label="loc_avxlLincolnParkCapitalFundLLCMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_avxlLincolnParkCapitalFundLLCMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200930.xsd#avxl_CantorFitzgeraldAndCoMember" xlink:label="loc_avxlCantorFitzgeraldAndCoMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_avxlCantorFitzgeraldAndCoMember_50" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_20" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_90" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200930.xsd#avxl_StockIssuedDuringPeriodSharesNewIssues4" xlink:label="loc_avxlStockIssuedDuringPeriodSharesNewIssues4_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_avxlStockIssuedDuringPeriodSharesNewIssues4_90" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200930.xsd#avxl_StockIssuedDuringPeriodValueNewIssues3" xlink:label="loc_avxlStockIssuedDuringPeriodValueNewIssues3_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_avxlStockIssuedDuringPeriodValueNewIssues3_90" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200930.xsd#avxl_StockIssuedDuringPeriodSharesNewIssues3" xlink:label="loc_avxlStockIssuedDuringPeriodSharesNewIssues3_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_avxlStockIssuedDuringPeriodSharesNewIssues3_90" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200930.xsd#avxl_ValueOfSharesObligatedToPurchase" xlink:label="loc_avxlValueOfSharesObligatedToPurchase_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_avxlValueOfSharesObligatedToPurchase_90" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200930.xsd#avxl_AgreementTerm" xlink:label="loc_avxlAgreementTerm_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_avxlAgreementTerm_90" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationDescription" xlink:label="loc_us-gaapUnrecordedUnconditionalPurchaseObligationDescription_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_us-gaapUnrecordedUnconditionalPurchaseObligationDescription_90" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200930.xsd#avxl_PercentageOfGrossProceedsFromSales" xlink:label="loc_avxlPercentageOfGrossProceedsFromSales_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_avxlPercentageOfGrossProceedsFromSales_90" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200930.xsd#avxl_NumberOfSharesObligatedToPurchaseProrataBasic" xlink:label="loc_avxlNumberOfSharesObligatedToPurchaseProrataBasic_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_avxlNumberOfSharesObligatedToPurchaseProrataBasic_90" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200930.xsd#avxl_StockIssuedDuringPeriodValueNewIssues4" xlink:label="loc_avxlStockIssuedDuringPeriodValueNewIssues4_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_avxlStockIssuedDuringPeriodValueNewIssues4_90" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock_90" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200930.xsd#avxl_NumberOfStockSold" xlink:label="loc_avxlNumberOfStockSold_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_avxlNumberOfStockSold_90" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200930.xsd#avxl_GrossProceedsFromSaleOfCommonStock" xlink:label="loc_avxlGrossProceedsFromSaleOfCommonStock_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_avxlGrossProceedsFromSaleOfCommonStock_90" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200930.xsd#avxl_NumberOfSharesAvailable" xlink:label="loc_avxlNumberOfSharesAvailable_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_avxlNumberOfSharesAvailable_90" xlink:type="arc" order="13" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsDetails" xlink:title="00000019 - Disclosure - Commitments (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200930.xsd#avxl_PurchaseWarrantsMember" xlink:label="loc_avxlPurchaseWarrantsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_avxlPurchaseWarrantsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200930.xsd#avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200930.xsd#avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExercised" xlink:label="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExercised_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExercised_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200930.xsd#avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExpired" xlink:label="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExpired_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExpired_60" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200930.xsd#avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod" xlink:label="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod_60" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200930.xsd#avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice" xlink:label="loc_avxlShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_avxlShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice_60" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsDetails1" xlink:title="00000020 - Disclosure - Commitments (Details 1)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200930.xsd#avxl_PurchaseWarrants1Member" xlink:label="loc_avxlPurchaseWarrants1Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_avxlPurchaseWarrants1Member_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200930.xsd#avxl_PurchaseWarrants2Member" xlink:label="loc_avxlPurchaseWarrants2Member_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_avxlPurchaseWarrants2Member_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate_40" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsDetails2" xlink:title="00000021 - Disclosure - Commitments (Details 2)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200930.xsd#avxl_StockOptionPlan2015Member" xlink:label="loc_avxlStockOptionPlan2015Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_avxlStockOptionPlan2015Member_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_60" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_60" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_60" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_60" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_60" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_60" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_60" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_60" xlink:type="arc" order="15" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsDetails3" xlink:title="00000022 - Disclosure - Commitments (Details 3)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaapLossContingenciesLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaapLossContingenciesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapLossContingenciesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense_70" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsDetails4" xlink:title="00000023 - Disclosure - Commitments (Details 4)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsDetailsNarrative" xlink:title="00000024 - Disclosure - Commitments (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200930.xsd#avxl_StockOptionPlan2015Member" xlink:label="loc_avxlStockOptionPlan2015Member_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_avxlStockOptionPlan2015Member_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200930.xsd#avxl_StockOptionPlan2019Member" xlink:label="loc_avxlStockOptionPlan2019Member_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_avxlStockOptionPlan2019Member_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="loc_us-gaapLeaseAndRentalExpense_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapLeaseAndRentalExpense_90" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200930.xsd#avxl_SharesIssuedPursuantToCashlessExerciseOfWarrantInShares" xlink:label="loc_avxlSharesIssuedPursuantToCashlessExerciseOfWarrantInShares_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_avxlSharesIssuedPursuantToCashlessExerciseOfWarrantInShares_90" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200930.xsd#avxl_StockIssuedPursuantToCashlessExerciseOfWarrants" xlink:label="loc_avxlStockIssuedPursuantToCashlessExerciseOfWarrants_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_avxlStockIssuedPursuantToCashlessExerciseOfWarrants_90" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance_90" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_90" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_90" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200930.xsd#avxl_SharesIssuedPursuantToCashlessExercisesOfOption" xlink:label="loc_avxlSharesIssuedPursuantToCashlessExercisesOfOption_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_avxlSharesIssuedPursuantToCashlessExercisesOfOption_90" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200930.xsd#avxl_NumberOfCashlessExerciseOption" xlink:label="loc_avxlNumberOfCashlessExerciseOption_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_avxlNumberOfCashlessExerciseOption_90" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense_90" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_90" xlink:type="arc" order="9" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/IncomeTaxesDetails" xlink:title="00000025 - Disclosure - Income Taxes (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/IncomeTaxesDetails1" xlink:title="00000026 - Disclosure - Income Taxes (Details 1)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/IncomeTaxesDetails2" xlink:title="00000027 - Disclosure - Income Taxes (Details 2)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/IncomeTaxesDetailsNarrative" xlink:title="00000028 - Disclosure - Income Taxes (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaapOperatingLossCarryforwardsLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaapOperatingLossCarryforwardsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwardsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_us-gaapIncomeTaxAuthorityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCountryMember" xlink:label="loc_us-gaapForeignCountryMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapForeignCountryMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CurrencyAxis" xlink:label="loc_srtCurrencyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_srtCurrencyAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currencyAllCurrenciesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtCurrencyAxis" xlink:to="loc_currencyAllCurrenciesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currencyAllCurrenciesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtCurrencyAxis" xlink:to="loc_currencyAllCurrenciesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_AUD" xlink:label="loc_currencyAUD_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currencyAllCurrenciesDomain" xlink:to="loc_currencyAUD_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsForeign_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsForeign_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200930.xsd#avxl_OperatingLossCarryForwardsExpirationYear1" xlink:label="loc_avxlOperatingLossCarryForwardsExpirationYear1_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_avxlOperatingLossCarryForwardsExpirationYear1_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaapOperatingLossCarryforwards_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwards_70" xlink:type="arc" order="3" />
    </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>12
<FILENAME>avxl-20200930_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.6a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductOrServiceAxis_lbl" xml:lang="en-US">Product and Service [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20200930.xsd#avxl_ClinicalStudyGrantMember" xlink:label="avxl_ClinicalStudyGrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ClinicalStudyGrantMember" xlink:to="avxl_ClinicalStudyGrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ClinicalStudyGrantMember_lbl" xml:lang="en-US">Clinical Study Grant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CurrencyAxis" xlink:label="srt_CurrencyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CurrencyAxis" xlink:to="srt_CurrencyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CurrencyAxis_lbl" xml:lang="en-US">Currency [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_AUD" xlink:label="currency_AUD" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="currency_AUD" xlink:to="currency_AUD_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="currency_AUD_lbl" xml:lang="en-US">Australia, Dollars</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20200930.xsd#avxl_NYCBiotechCreditMember" xlink:label="avxl_NYCBiotechCreditMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_NYCBiotechCreditMember" xlink:to="avxl_NYCBiotechCreditMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_NYCBiotechCreditMember_lbl" xml:lang="en-US">NYC Biotech Credit [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20200930.xsd#avxl_PurchaseAgreementMember" xlink:label="avxl_PurchaseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_PurchaseAgreementMember" xlink:to="avxl_PurchaseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_PurchaseAgreementMember_lbl" xml:lang="en-US">2015 Purchase Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Legal Entity [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20200930.xsd#avxl_LincolnParkCapitalFundLLCMember" xlink:label="avxl_LincolnParkCapitalFundLLCMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_LincolnParkCapitalFundLLCMember" xlink:to="avxl_LincolnParkCapitalFundLLCMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_LincolnParkCapitalFundLLCMember_lbl" xml:lang="en-US">Lincoln Park Capital Fund, LLC [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20200930.xsd#avxl_PurchaseAgreement1Member" xlink:label="avxl_PurchaseAgreement1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_PurchaseAgreement1Member" xlink:to="avxl_PurchaseAgreement1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_PurchaseAgreement1Member_lbl" xml:lang="en-US">2019 Purchase Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20200930.xsd#avxl_EquityOfferingSalesAgreementMember" xlink:label="avxl_EquityOfferingSalesAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_EquityOfferingSalesAgreementMember" xlink:to="avxl_EquityOfferingSalesAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_EquityOfferingSalesAgreementMember_lbl" xml:lang="en-US">Equity Offering Sales Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20200930.xsd#avxl_CantorFitzgeraldAndCoMember" xlink:label="avxl_CantorFitzgeraldAndCoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_CantorFitzgeraldAndCoMember" xlink:to="avxl_CantorFitzgeraldAndCoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_CantorFitzgeraldAndCoMember_lbl" xml:lang="en-US">Cantor Fitzgerald &amp;amp;amp; Co [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20200930.xsd#avxl_PurchaseWarrantsMember" xlink:label="avxl_PurchaseWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_PurchaseWarrantsMember" xlink:to="avxl_PurchaseWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_PurchaseWarrantsMember_lbl" xml:lang="en-US">Purchase Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20200930.xsd#avxl_PurchaseWarrants1Member" xlink:label="avxl_PurchaseWarrants1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_PurchaseWarrants1Member" xlink:to="avxl_PurchaseWarrants1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_PurchaseWarrants1Member_lbl" xml:lang="en-US">Purchase Warrants 1 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20200930.xsd#avxl_PurchaseWarrants2Member" xlink:label="avxl_PurchaseWarrants2Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_PurchaseWarrants2Member" xlink:to="avxl_PurchaseWarrants2Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_PurchaseWarrants2Member_lbl" xml:lang="en-US">Purchase Warrants 2 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20200930.xsd#avxl_StockOptionPlan2015Member" xlink:label="avxl_StockOptionPlan2015Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockOptionPlan2015Member" xlink:to="avxl_StockOptionPlan2015Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_StockOptionPlan2015Member_lbl" xml:lang="en-US">2015 Omnibus Incentive Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20200930.xsd#avxl_StockOptionPlan2019Member" xlink:label="avxl_StockOptionPlan2019Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockOptionPlan2019Member" xlink:to="avxl_StockOptionPlan2019Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_StockOptionPlan2019Member_lbl" xml:lang="en-US">2019 Omnibus Incentive Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Income Statement Location [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and Development Expense [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCountryMember" xlink:to="us-gaap_ForeignCountryMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCountryMember_lbl" xml:lang="en-US">Foreign Tax Authority [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesReceivable" xlink:label="us-gaap_IncomeTaxesReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesReceivable" xlink:to="us-gaap_IncomeTaxesReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesReceivable_lbl" xml:lang="en-US">Incentive and tax receivables</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xml:lang="en-US">Prepaid expenses and deposits</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">Liabilities and Stockholders' Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and Contingencies - Note 5</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Capital stock Authorized: 10,000,000 preferred stock, par value $0.001 per share</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Capital stock Authorized: 100,000,000 common shares, par value $0.001 per share Issued and outstanding: 62,045,198 common shares (2019 - 52,650,521)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US">Additional paid-in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total Stockholders' Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total Liabilities and Stockholders' Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common shares, authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common shares, par value (in dollars per share)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common shares, issued</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common shares, outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">Other income (expenses)</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20200930.xsd#avxl_NonOperatingIncomeFromGrant" xlink:label="avxl_NonOperatingIncomeFromGrant" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_NonOperatingIncomeFromGrant" xlink:to="avxl_NonOperatingIncomeFromGrant_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_NonOperatingIncomeFromGrant_lbl" xml:lang="en-US">Grant income</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20200930.xsd#avxl_ResearchAndDevelopmentIncentiveIncome" xlink:label="avxl_ResearchAndDevelopmentIncentiveIncome" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ResearchAndDevelopmentIncentiveIncome" xlink:to="avxl_ResearchAndDevelopmentIncentiveIncome_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ResearchAndDevelopmentIncentiveIncome_lbl" xml:lang="en-US">Research and development incentive income</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="us-gaap_InterestIncomeExpenseNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNet" xlink:to="us-gaap_InterestIncomeExpenseNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeExpenseNet_lbl" xml:lang="en-US">Interest income, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xml:lang="en-US">Gain on settlement of accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts" xlink:label="us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts" xlink:to="us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts_lbl" xml:lang="en-US">Financing related charges</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xml:lang="en-US">Foreign exchange gain (loss), net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Total other income, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US">Net loss before provision for income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Income tax expense, current</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss and comprehensive loss</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDilutedAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract_lbl" xml:lang="en-US">Net Loss per share</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US">Basic and diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_lbl" xml:lang="en-US">Weighted average number of shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US">Basic and diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US">Cash Flows used in Operating Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operations:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20200930.xsd#avxl_DeferredCharges" xlink:label="avxl_DeferredCharges" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_DeferredCharges" xlink:to="avxl_DeferredCharges_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_DeferredCharges_lbl" xml:lang="en-US">Deferred costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnRestructuringOfDebt" xlink:label="us-gaap_GainsLossesOnRestructuringOfDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnRestructuringOfDebt" xlink:to="us-gaap_GainsLossesOnRestructuringOfDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainsLossesOnRestructuringOfDebt_lbl" xml:lang="en-US">Gain on settlement of accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in non-cash working capital balances related to operations:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:label="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:to="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_lbl" xml:lang="en-US">Incentive and tax receivables</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xml:lang="en-US">Prepaid expenses and deposits</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US">Accrued liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US">Cash Flows provided by Financing Activities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Issuance of common shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US">Share issue costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts_lbl" xml:lang="en-US">Deferred financing charges</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xml:lang="en-US">Increase (decrease) in cash and cash equivalents during the period</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_Cash_lbl" xml:lang="en-US">Cash and cash equivalents, beginning of year</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_Cash_2_lbl" xml:lang="en-US">Cash and cash equivalents, end of year</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">Beginning balance, value</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balance Beginning (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20200930.xsd#avxl_StockIssuedDuringPeriodValueAcquisitions2" xlink:label="avxl_StockIssuedDuringPeriodValueAcquisitions2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockIssuedDuringPeriodValueAcquisitions2" xlink:to="avxl_StockIssuedDuringPeriodValueAcquisitions2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_StockIssuedDuringPeriodValueAcquisitions2_lbl" xml:lang="en-US">Purchase shares</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20200930.xsd#avxl_StockIssuedDuringPeriodSharesAcquisitions2" xlink:label="avxl_StockIssuedDuringPeriodSharesAcquisitions2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockIssuedDuringPeriodSharesAcquisitions2" xlink:to="avxl_StockIssuedDuringPeriodSharesAcquisitions2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_StockIssuedDuringPeriodSharesAcquisitions2_lbl" xml:lang="en-US">Shares issued under 2015 Purchase Agreement - Purchase shares (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20200930.xsd#avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2" xlink:label="avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2" xlink:to="avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2_lbl" xml:lang="en-US">Commitment shares</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20200930.xsd#avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2" xlink:label="avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2" xlink:to="avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2_lbl" xml:lang="en-US">Shares issued under 2015 Purchase Agreement - Commitment shares (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl" xml:lang="en-US">Purchase shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl" xml:lang="en-US">Shares issued under 2019 Purchase Agreement - Purchase shares (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20200930.xsd#avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1" xlink:label="avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1" xlink:to="avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1_lbl" xml:lang="en-US">Commitment shares</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20200930.xsd#avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement1" xlink:label="avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement1" xlink:to="avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement1_lbl" xml:lang="en-US">Shares issued under 2019 Purchase Agreement - Commitment shares (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20200930.xsd#avxl_SharesIssuedPursuantToCashlessExerciseOfWarrants" xlink:label="avxl_SharesIssuedPursuantToCashlessExerciseOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_SharesIssuedPursuantToCashlessExerciseOfWarrants" xlink:to="avxl_SharesIssuedPursuantToCashlessExerciseOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_SharesIssuedPursuantToCashlessExerciseOfWarrants_lbl" xml:lang="en-US">Shares issued pursuant to cashless exercise of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20200930.xsd#avxl_SharesIssuedPursuantToCashlessExerciseOfOptions" xlink:label="avxl_SharesIssuedPursuantToCashlessExerciseOfOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_SharesIssuedPursuantToCashlessExerciseOfOptions" xlink:to="avxl_SharesIssuedPursuantToCashlessExerciseOfOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_SharesIssuedPursuantToCashlessExerciseOfOptions_lbl" xml:lang="en-US">Shares issued pursuant to cashless exercise of options</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20200930.xsd#avxl_SharesIssuedPursuantToCashlessExerciseOfOptionsInShares" xlink:label="avxl_SharesIssuedPursuantToCashlessExerciseOfOptionsInShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_SharesIssuedPursuantToCashlessExerciseOfOptionsInShares" xlink:to="avxl_SharesIssuedPursuantToCashlessExerciseOfOptionsInShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_SharesIssuedPursuantToCashlessExerciseOfOptionsInShares_lbl" xml:lang="en-US">Shares issued pursuant to cashless exercise of options (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20200930.xsd#avxl_SharesIssuedDuringPeriodValueUnderSalesAgreement" xlink:label="avxl_SharesIssuedDuringPeriodValueUnderSalesAgreement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_SharesIssuedDuringPeriodValueUnderSalesAgreement" xlink:to="avxl_SharesIssuedDuringPeriodValueUnderSalesAgreement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_SharesIssuedDuringPeriodValueUnderSalesAgreement_lbl" xml:lang="en-US">Shares issued under Sales Agreement, net of shares issue costs</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20200930.xsd#avxl_SharesIssuedDuringPeriodSharesUnderSalesAgreement" xlink:label="avxl_SharesIssuedDuringPeriodSharesUnderSalesAgreement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_SharesIssuedDuringPeriodSharesUnderSalesAgreement" xlink:to="avxl_SharesIssuedDuringPeriodSharesUnderSalesAgreement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_SharesIssuedDuringPeriodSharesUnderSalesAgreement_lbl" xml:lang="en-US">Shares issued under Sales Agreement, net of shares issue costs (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20200930.xsd#avxl_SharesIssuedPursuantToCashlessExerciseOfWarrantsInShares" xlink:label="avxl_SharesIssuedPursuantToCashlessExerciseOfWarrantsInShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_SharesIssuedPursuantToCashlessExerciseOfWarrantsInShares" xlink:to="avxl_SharesIssuedPursuantToCashlessExerciseOfWarrantsInShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_SharesIssuedPursuantToCashlessExerciseOfWarrantsInShares_lbl" xml:lang="en-US">Shares issued pursuant to cashless exercise of warrants (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">Share based compensation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_3_lbl" xml:lang="en-US">Ending balance, value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_2_lbl" xml:lang="en-US">Balance Ending (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US">Business Description and Basis of Presentation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20200930.xsd#avxl_DisclosureOtherIncomeAbstract" xlink:label="avxl_DisclosureOtherIncomeAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_DisclosureOtherIncomeAbstract" xlink:to="avxl_DisclosureOtherIncomeAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_DisclosureOtherIncomeAbstract_lbl" xml:lang="en-US">Other Income</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20200930.xsd#avxl_OtherIncomeDisclosureTextBlock" xlink:label="avxl_OtherIncomeDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_OtherIncomeDisclosureTextBlock" xlink:to="avxl_OtherIncomeDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="avxl_OtherIncomeDisclosureTextBlock_lbl" xml:lang="en-US">Other Income</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20200930.xsd#avxl_DisclosureEquityOfferingAgreementsAbstract" xlink:label="avxl_DisclosureEquityOfferingAgreementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_DisclosureEquityOfferingAgreementsAbstract" xlink:to="avxl_DisclosureEquityOfferingAgreementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_DisclosureEquityOfferingAgreementsAbstract_lbl" xml:lang="en-US">Equity Offering Agreements</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20200930.xsd#avxl_EquityOfferingAgreementsTextBlock" xlink:label="avxl_EquityOfferingAgreementsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_EquityOfferingAgreementsTextBlock" xlink:to="avxl_EquityOfferingAgreementsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="avxl_EquityOfferingAgreementsTextBlock_lbl" xml:lang="en-US">Equity Offering Agreements</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsDisclosureTextBlock" xlink:label="us-gaap_CommitmentsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsDisclosureTextBlock" xlink:to="us-gaap_CommitmentsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsDisclosureTextBlock_lbl" xml:lang="en-US">Commitments</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US">Principles of Consolidation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash and equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development Expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionIncentives" xlink:label="us-gaap_RevenueRecognitionIncentives" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionIncentives" xlink:to="us-gaap_RevenueRecognitionIncentives_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionIncentives_lbl" xml:lang="en-US">Research and Development Incentive Income</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Basic and Diluted Loss per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US">Financial Instruments</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xml:lang="en-US">Foreign Currency Translation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Segment and Geographic Reporting</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20200930.xsd#avxl_GrantIncomePolicyTextBlock" xlink:label="avxl_GrantIncomePolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_GrantIncomePolicyTextBlock" xlink:to="avxl_GrantIncomePolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_GrantIncomePolicyTextBlock_lbl" xml:lang="en-US">Grant Income</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationForfeituresPolicyTextBlock" xlink:label="us-gaap_ShareBasedCompensationForfeituresPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationForfeituresPolicyTextBlock" xlink:to="us-gaap_ShareBasedCompensationForfeituresPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationForfeituresPolicyTextBlock_lbl" xml:lang="en-US">Stock-based Compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US">Fair Value Measurements</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US">Schedule of exercisable share purchase warrants outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20200930.xsd#avxl_ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock" xlink:label="avxl_ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock" xlink:to="avxl_ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock_lbl" xml:lang="en-US">Schedule of share purchase warrants outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:to="us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_lbl" xml:lang="en-US">Schedule of outstanding stock purchase options</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US">Schedule of general and administrative expenses and research and development expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Schedule of weighted average assumptions for fair value of each option award</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xml:lang="en-US">Schedule of Income before Income Tax, Domestic and Foreign</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of deferred tax asset and liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20200930.xsd#avxl_CashRefundAvailableDescription" xlink:label="avxl_CashRefundAvailableDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_CashRefundAvailableDescription" xlink:to="avxl_CashRefundAvailableDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_CashRefundAvailableDescription_lbl" xml:lang="en-US">Cash Refund Available description</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:label="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:to="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants_lbl" xml:lang="en-US">Loss per share for potentially dilutive common shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ReinsurancePremiumsForInsuranceCompaniesByProductSegmentLineItems" xlink:label="srt_ReinsurancePremiumsForInsuranceCompaniesByProductSegmentLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ReinsurancePremiumsForInsuranceCompaniesByProductSegmentLineItems" xlink:to="srt_ReinsurancePremiumsForInsuranceCompaniesByProductSegmentLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ReinsurancePremiumsForInsuranceCompaniesByProductSegmentLineItems_lbl" xml:lang="en-US">SEC Schedule, 12-17, Insurance Companies, Reinsurance [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20200930.xsd#avxl_FundingOfDeferredIncomeAwardedGrant" xlink:label="avxl_FundingOfDeferredIncomeAwardedGrant" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_FundingOfDeferredIncomeAwardedGrant" xlink:to="avxl_FundingOfDeferredIncomeAwardedGrant_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_FundingOfDeferredIncomeAwardedGrant_lbl" xml:lang="en-US">Awarded grant funding amount</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_lbl" xml:lang="en-US">Research and development incentive income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityListingsLineItems" xlink:label="dei_EntityListingsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityListingsLineItems" xlink:to="dei_EntityListingsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityListingsLineItems_lbl" xml:lang="en-US">Entity Listings [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Number of share issued</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20200930.xsd#avxl_StockIssuedDuringPeriodSharesNewIssues4" xlink:label="avxl_StockIssuedDuringPeriodSharesNewIssues4" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockIssuedDuringPeriodSharesNewIssues4" xlink:to="avxl_StockIssuedDuringPeriodSharesNewIssues4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_StockIssuedDuringPeriodSharesNewIssues4_lbl" xml:lang="en-US">Number of shares issued for aggregate purchase price</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20200930.xsd#avxl_StockIssuedDuringPeriodValueNewIssues3" xlink:label="avxl_StockIssuedDuringPeriodValueNewIssues3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockIssuedDuringPeriodValueNewIssues3" xlink:to="avxl_StockIssuedDuringPeriodValueNewIssues3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_StockIssuedDuringPeriodValueNewIssues3_lbl" xml:lang="en-US">Number of shares issued for aggregate purchase price, value</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20200930.xsd#avxl_StockIssuedDuringPeriodSharesNewIssues3" xlink:label="avxl_StockIssuedDuringPeriodSharesNewIssues3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockIssuedDuringPeriodSharesNewIssues3" xlink:to="avxl_StockIssuedDuringPeriodSharesNewIssues3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_StockIssuedDuringPeriodSharesNewIssues3_lbl" xml:lang="en-US">Number of shares issued for commitment</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20200930.xsd#avxl_ValueOfSharesObligatedToPurchase" xlink:label="avxl_ValueOfSharesObligatedToPurchase" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ValueOfSharesObligatedToPurchase" xlink:to="avxl_ValueOfSharesObligatedToPurchase_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ValueOfSharesObligatedToPurchase_lbl" xml:lang="en-US">Total number of shares obligated to purchase</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20200930.xsd#avxl_AgreementTerm" xlink:label="avxl_AgreementTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_AgreementTerm" xlink:to="avxl_AgreementTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_AgreementTerm_lbl" xml:lang="en-US">Agreement term</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationDescription" xlink:label="us-gaap_UnrecordedUnconditionalPurchaseObligationDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecordedUnconditionalPurchaseObligationDescription" xlink:to="us-gaap_UnrecordedUnconditionalPurchaseObligationDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecordedUnconditionalPurchaseObligationDescription_lbl" xml:lang="en-US">Description of purchases price</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20200930.xsd#avxl_PercentageOfGrossProceedsFromSales" xlink:label="avxl_PercentageOfGrossProceedsFromSales" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_PercentageOfGrossProceedsFromSales" xlink:to="avxl_PercentageOfGrossProceedsFromSales_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_PercentageOfGrossProceedsFromSales_lbl" xml:lang="en-US">Percentage of gross proceeds from sales</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20200930.xsd#avxl_NumberOfSharesObligatedToPurchaseProrataBasic" xlink:label="avxl_NumberOfSharesObligatedToPurchaseProrataBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_NumberOfSharesObligatedToPurchaseProrataBasic" xlink:to="avxl_NumberOfSharesObligatedToPurchaseProrataBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_NumberOfSharesObligatedToPurchaseProrataBasic_lbl" xml:lang="en-US">Pro rata basic number of shares obligated to purchase</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20200930.xsd#avxl_StockIssuedDuringPeriodValueNewIssues4" xlink:label="avxl_StockIssuedDuringPeriodValueNewIssues4" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockIssuedDuringPeriodValueNewIssues4" xlink:to="avxl_StockIssuedDuringPeriodValueNewIssues4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_StockIssuedDuringPeriodValueNewIssues4_lbl" xml:lang="en-US">Amount of shares remain available</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_2_lbl" xml:lang="en-US">Proceeds from sale of common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20200930.xsd#avxl_NumberOfStockSold" xlink:label="avxl_NumberOfStockSold" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_NumberOfStockSold" xlink:to="avxl_NumberOfStockSold_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_NumberOfStockSold_lbl" xml:lang="en-US">Number of stock sold</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20200930.xsd#avxl_GrossProceedsFromSaleOfCommonStock" xlink:label="avxl_GrossProceedsFromSaleOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_GrossProceedsFromSaleOfCommonStock" xlink:to="avxl_GrossProceedsFromSaleOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_GrossProceedsFromSaleOfCommonStock_lbl" xml:lang="en-US">Gross proceeds from sale of common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20200930.xsd#avxl_NumberOfSharesAvailable" xlink:label="avxl_NumberOfSharesAvailable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_NumberOfSharesAvailable" xlink:to="avxl_NumberOfSharesAvailable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_NumberOfSharesAvailable_lbl" xml:lang="en-US">Number of shares available</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US">Share Purchase Warrants Balance, at beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20200930.xsd#avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" xlink:label="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" xlink:to="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price Balance, at beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xml:lang="en-US">Share Purchase Warrants Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20200930.xsd#avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExercised" xlink:label="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExercised" xlink:to="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExercised_lbl" xml:lang="en-US">Weighted Average Exercise Price, Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_lbl" xml:lang="en-US">Share Purchase Warrants Expired</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20200930.xsd#avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExpired" xlink:label="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExpired" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExpired" xlink:to="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExpired_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExpired_lbl" xml:lang="en-US">Weighted Average Exercise Price, Expired</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20200930.xsd#avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod" xlink:label="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod" xlink:to="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod_lbl" xml:lang="en-US">Share Purchase Warrants Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20200930.xsd#avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice" xlink:label="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice" xlink:to="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Granted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2_lbl" xml:lang="en-US">Share Purchase Warrants Balance, at ending</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" xlink:to="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted Average Exercise Price Balance, at ending</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US">Number</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Exercise Price</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:to="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl" xml:lang="en-US">Expiry Date</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Options Outstanding at beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price Outstanding at beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Aggregate intrinsic value Outstanding at beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Options Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Grant Date Fair Value Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Options Forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price Forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Options Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price Exercised</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xml:lang="en-US">Options Outstanding at ending</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted Average Exercise Price Outstanding at ending</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2_lbl" xml:lang="en-US">Aggregate intrinsic value Outstanding at ending</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Options Exercisable at ending</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price Exercisable at ending</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Aggregate intrinsic value Exercisable at ending</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_LossContingenciesTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingenciesTable_lbl" xml:lang="en-US">Loss Contingencies [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingenciesLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingenciesLineItems_lbl" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Total share based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Risk-free interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected life of options (years)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Annualized volatility</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Dividend rate</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="us-gaap_LeaseAndRentalExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseAndRentalExpense" xlink:to="us-gaap_LeaseAndRentalExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseAndRentalExpense_lbl" xml:lang="en-US">Operating Leases, Rent Expense</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20200930.xsd#avxl_SharesIssuedPursuantToCashlessExerciseOfWarrantInShares" xlink:label="avxl_SharesIssuedPursuantToCashlessExerciseOfWarrantInShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_SharesIssuedPursuantToCashlessExerciseOfWarrantInShares" xlink:to="avxl_SharesIssuedPursuantToCashlessExerciseOfWarrantInShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="avxl_SharesIssuedPursuantToCashlessExerciseOfWarrantInShares_lbl" xml:lang="en-US">Shares issued pursuant to cashless exercise of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20200930.xsd#avxl_StockIssuedPursuantToCashlessExerciseOfWarrants" xlink:label="avxl_StockIssuedPursuantToCashlessExerciseOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockIssuedPursuantToCashlessExerciseOfWarrants" xlink:to="avxl_StockIssuedPursuantToCashlessExerciseOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_StockIssuedPursuantToCashlessExerciseOfWarrants_lbl" xml:lang="en-US">Stock issued pursuant to cashless exercise of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US">Maximum number of common shares reserved for future issuance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xml:lang="en-US">Additional shares of common stock available for issuance</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20200930.xsd#avxl_SharesIssuedPursuantToCashlessExercisesOfOption" xlink:label="avxl_SharesIssuedPursuantToCashlessExercisesOfOption" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_SharesIssuedPursuantToCashlessExercisesOfOption" xlink:to="avxl_SharesIssuedPursuantToCashlessExercisesOfOption_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_SharesIssuedPursuantToCashlessExercisesOfOption_lbl" xml:lang="en-US">Shares issued pursuant to cashless exercises of option</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20200930.xsd#avxl_NumberOfCashlessExerciseOption" xlink:label="avxl_NumberOfCashlessExerciseOption" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_NumberOfCashlessExerciseOption" xlink:to="avxl_NumberOfCashlessExerciseOption_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_NumberOfCashlessExerciseOption_lbl" xml:lang="en-US">Number of cashless exercise option</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_2_lbl" xml:lang="en-US">Share based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US">Remaining stock based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xml:lang="en-US">United States</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xml:lang="en-US">Foreign</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating loss carryforwards</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xml:lang="en-US">Research and development tax credit carry forwards</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US">Stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20200930.xsd#avxl_DeferredTaxAssetsUnpaidCharges" xlink:label="avxl_DeferredTaxAssetsUnpaidCharges" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_DeferredTaxAssetsUnpaidCharges" xlink:to="avxl_DeferredTaxAssetsUnpaidCharges_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_DeferredTaxAssetsUnpaidCharges_lbl" xml:lang="en-US">Unpaid charges</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" xml:lang="en-US">Intangible asset costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses" xlink:label="us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses" xlink:to="us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses_lbl" xml:lang="en-US">Foreign exchange and other</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Valuation allowance deferred tax assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US">Net deferred tax assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Income tax benefit at statutory federal rate</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:to="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_lbl" xml:lang="en-US">Foreign income taxed at other rates</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl" xml:lang="en-US">Other permanent differences</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20200930.xsd#avxl_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopmentCreditBenefit" xlink:label="avxl_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopmentCreditBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopmentCreditBenefit" xlink:to="avxl_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopmentCreditBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopmentCreditBenefit_lbl" xml:lang="en-US">Research and development credit benefit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US">State and local taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" xlink:to="us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes_lbl" xml:lang="en-US">Adjustment and true up to prior year tax provision</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCash" xlink:label="us-gaap_EffectOfExchangeRateOnCash" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCash" xlink:to="us-gaap_EffectOfExchangeRateOnCash_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectOfExchangeRateOnCash_lbl" xml:lang="en-US">Effect of change in statutory rates</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxesExcludingIncomeAndExciseTaxes" xlink:label="us-gaap_TaxesExcludingIncomeAndExciseTaxes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxesExcludingIncomeAndExciseTaxes" xlink:to="us-gaap_TaxesExcludingIncomeAndExciseTaxes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxesExcludingIncomeAndExciseTaxes_lbl" xml:lang="en-US">State minimum and excise taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Change in valuation allowances</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Income tax expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_OperatingLossCarryforwardsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsTable_lbl" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_lbl" xml:lang="en-US">U.S. federal net operating loss carryforwards</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20200930.xsd#avxl_OperatingLossCarryForwardsExpirationYear1" xlink:label="avxl_OperatingLossCarryForwardsExpirationYear1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_OperatingLossCarryForwardsExpirationYear1" xlink:to="avxl_OperatingLossCarryForwardsExpirationYear1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_OperatingLossCarryForwardsExpirationYear1_lbl" xml:lang="en-US">Operating loss carry-forwards, expiration year</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl" xml:lang="en-US">State net operating loss carryforwards</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US">Operating loss carry-forwards</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_FundingOfDeferredIncomeAwardedGrant" xlink:to="avxl_FundingOfDeferredIncomeAwardedGrant_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_FundingOfDeferredIncomeAwardedGrant_doc" xml:lang="en-US">Information related to funding of deferred income awarded grant.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ClinicalStudyGrantMember" xlink:to="avxl_ClinicalStudyGrantMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_ClinicalStudyGrantMember_doc" xml:lang="en-US">Information by clinical study grant.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ValueOfSharesObligatedToPurchase" xlink:to="avxl_ValueOfSharesObligatedToPurchase_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_ValueOfSharesObligatedToPurchase_doc" xml:lang="en-US">Information related to value of shares obligated to purchase initially.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_PurchaseAgreement1Member" xlink:to="avxl_PurchaseAgreement1Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_PurchaseAgreement1Member_doc" xml:lang="en-US">Represents the information pertaining to purchase agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_LincolnParkCapitalFundLLCMember" xlink:to="avxl_LincolnParkCapitalFundLLCMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_LincolnParkCapitalFundLLCMember_doc" xml:lang="en-US">Information related to type of legal entity.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_AgreementTerm" xlink:to="avxl_AgreementTerm_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_AgreementTerm_doc" xml:lang="en-US">Terms of the agreement under agreements.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_NumberOfSharesObligatedToPurchaseProrataBasic" xlink:to="avxl_NumberOfSharesObligatedToPurchaseProrataBasic_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_NumberOfSharesObligatedToPurchaseProrataBasic_doc" xml:lang="en-US">Information related to number of shares obligated to purchase prorata basic.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_PercentageOfGrossProceedsFromSales" xlink:to="avxl_PercentageOfGrossProceedsFromSales_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_PercentageOfGrossProceedsFromSales_doc" xml:lang="en-US">Represents information related to percentage of gross proceeds from sales.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockIssuedDuringPeriodSharesNewIssues4" xlink:to="avxl_StockIssuedDuringPeriodSharesNewIssues4_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_StockIssuedDuringPeriodSharesNewIssues4_doc" xml:lang="en-US">Number of new stock issued during the period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockIssuedDuringPeriodValueNewIssues3" xlink:to="avxl_StockIssuedDuringPeriodValueNewIssues3_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_StockIssuedDuringPeriodValueNewIssues3_doc" xml:lang="en-US">Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockIssuedDuringPeriodSharesNewIssues3" xlink:to="avxl_StockIssuedDuringPeriodSharesNewIssues3_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_StockIssuedDuringPeriodSharesNewIssues3_doc" xml:lang="en-US">Number of new stock issued during the period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockIssuedDuringPeriodValueNewIssues4" xlink:to="avxl_StockIssuedDuringPeriodValueNewIssues4_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_StockIssuedDuringPeriodValueNewIssues4_doc" xml:lang="en-US">Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_EquityOfferingSalesAgreementMember" xlink:to="avxl_EquityOfferingSalesAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_EquityOfferingSalesAgreementMember_doc" xml:lang="en-US">Represents information related to equity offering sales agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_CantorFitzgeraldAndCoMember" xlink:to="avxl_CantorFitzgeraldAndCoMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_CantorFitzgeraldAndCoMember_doc" xml:lang="en-US">Represents information related to cantor fitzgerald and co.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockOptionPlan2015Member" xlink:to="avxl_StockOptionPlan2015Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_StockOptionPlan2015Member_doc" xml:lang="en-US">Information related to type of plan.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_PurchaseWarrantsMember" xlink:to="avxl_PurchaseWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_PurchaseWarrantsMember_doc" xml:lang="en-US">Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" xlink:to="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_doc" xml:lang="en-US">Information related to share based compensation arrangement by share based payment award equity instruments other than options outstanding weighted average exercise price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_OperatingLossCarryForwardsExpirationYear1" xlink:to="avxl_OperatingLossCarryForwardsExpirationYear1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_OperatingLossCarryForwardsExpirationYear1_doc" xml:lang="en-US">The expiration date of each operating loss carryforward included in total operating loss carryforwards, or the applicable range of such expiration dates.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_DeferredTaxAssetsUnpaidCharges" xlink:to="avxl_DeferredTaxAssetsUnpaidCharges_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_DeferredTaxAssetsUnpaidCharges_doc" xml:lang="en-US">It represents as a deferred tax assets unpaid charges.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_PurchaseAgreementMember" xlink:to="avxl_PurchaseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_PurchaseAgreementMember_doc" xml:lang="en-US">Terms of the purchase agreement under purchase agreements.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_2_lbl" xml:lang="en-US">Assets [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_2_lbl" xml:lang="en-US">Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_4_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_2_lbl" xml:lang="en-US">Operating Expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts" xlink:to="us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts_2_lbl" xml:lang="en-US">Debt Related Commitment Fees and Debt Issuance Costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_2_lbl" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_lbl" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_2_lbl" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnRestructuringOfDebt" xlink:to="us-gaap_GainsLossesOnRestructuringOfDebt_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainsLossesOnRestructuringOfDebt_2_lbl" xml:lang="en-US">Gains (Losses) on Restructuring of Debt</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:to="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_2_lbl" xml:lang="en-US">Increase (Decrease) in Income Taxes Receivable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_2_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_2_lbl" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_2_lbl" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts_2_lbl" xml:lang="en-US">Payments of Debt Issuance Costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_2_lbl" xml:lang="en-US">Cash and Cash Equivalents, Period Increase (Decrease)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Cash_3_lbl" xml:lang="en-US">Cash</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_3_lbl" xml:lang="en-US">Shares, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodValueAcquisitions_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions_2_lbl" xml:lang="en-US">Stock Issued During Period, Value, Acquisitions</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1" xlink:to="avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1_2_lbl" xml:lang="en-US">CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_OtherIncomeDisclosureTextBlock" xlink:to="avxl_OtherIncomeDisclosureTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_OtherIncomeDisclosureTextBlock_2_lbl" xml:lang="en-US">OtherIncomeDisclosureTextBlock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_EquityOfferingAgreementsTextBlock" xlink:to="avxl_EquityOfferingAgreementsTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_EquityOfferingAgreementsTextBlock_2_lbl" xml:lang="en-US">EquityOfferingAgreementsTextBlock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_2_lbl" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_2_lbl" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Compensation Earned</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" xlink:to="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_4_lbl" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Expirations</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_SharesIssuedPursuantToCashlessExerciseOfWarrantInShares" xlink:to="avxl_SharesIssuedPursuantToCashlessExerciseOfWarrantInShares_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_SharesIssuedPursuantToCashlessExerciseOfWarrantInShares_2_lbl" xml:lang="en-US">SharesIssuedPursuantToCashlessExerciseOfWarrantInShares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_2_lbl" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>13
<FILENAME>avxl-20200930_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.6a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://anavex.com/role/Cover" xlink:href="avxl-20200930.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/ConsolidatedBalanceSheets" xlink:href="avxl-20200930.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="avxl-20200930.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/ConsolidatedStatementsOfOperations" xlink:href="avxl-20200930.xsd#ConsolidatedStatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="avxl-20200930.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/ConsolidatedStatementOfChangesInStockholdersEquity" xlink:href="avxl-20200930.xsd#ConsolidatedStatementOfChangesInStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/BusinessDescriptionAndBasisOfPresentation" xlink:href="avxl-20200930.xsd#BusinessDescriptionAndBasisOfPresentation" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="avxl-20200930.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/OtherIncome" xlink:href="avxl-20200930.xsd#OtherIncome" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/EquityOfferingAgreements" xlink:href="avxl-20200930.xsd#EquityOfferingAgreements" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/Commitments" xlink:href="avxl-20200930.xsd#Commitments" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/IncomeTaxes" xlink:href="avxl-20200930.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="avxl-20200930.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsTables" xlink:href="avxl-20200930.xsd#CommitmentsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/IncomeTaxesTables" xlink:href="avxl-20200930.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="avxl-20200930.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/OtherIncomeDetailsNarrative" xlink:href="avxl-20200930.xsd#OtherIncomeDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/EquityOfferingAgreementsDetailsNarrative" xlink:href="avxl-20200930.xsd#EquityOfferingAgreementsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsDetails" xlink:href="avxl-20200930.xsd#CommitmentsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsDetails1" xlink:href="avxl-20200930.xsd#CommitmentsDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsDetails2" xlink:href="avxl-20200930.xsd#CommitmentsDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsDetails3" xlink:href="avxl-20200930.xsd#CommitmentsDetails3" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsDetails4" xlink:href="avxl-20200930.xsd#CommitmentsDetails4" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsDetailsNarrative" xlink:href="avxl-20200930.xsd#CommitmentsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/IncomeTaxesDetails" xlink:href="avxl-20200930.xsd#IncomeTaxesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/IncomeTaxesDetails1" xlink:href="avxl-20200930.xsd#IncomeTaxesDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/IncomeTaxesDetails2" xlink:href="avxl-20200930.xsd#IncomeTaxesDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/IncomeTaxesDetailsNarrative" xlink:href="avxl-20200930.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/ConsolidatedBalanceSheets" xlink:title="00000002 - Statement - CONSOLIDATED BALANCE SHEETS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesReceivable" xlink:label="loc_us-gaapIncomeTaxesReceivable" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapIncomeTaxesReceivable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapPrepaidExpenseCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaapAdditionalPaidInCapitalCommonStock" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapAdditionalPaidInCapitalCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:title="00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/ConsolidatedStatementsOfOperations" xlink:title="00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingExpensesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaapNonoperatingIncomeExpenseAbstract" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200930.xsd#avxl_NonOperatingIncomeFromGrant" xlink:label="loc_avxlNonOperatingIncomeFromGrant" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_avxlNonOperatingIncomeFromGrant" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200930.xsd#avxl_ResearchAndDevelopmentIncentiveIncome" xlink:label="loc_avxlResearchAndDevelopmentIncentiveIncome" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_avxlResearchAndDevelopmentIncentiveIncome" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="loc_us-gaapInterestIncomeExpenseNet" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapInterestIncomeExpenseNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts" xlink:label="loc_us-gaapDebtRelatedCommitmentFeesAndDebtIssuanceCosts" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapDebtRelatedCommitmentFeesAndDebtIssuanceCosts" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentIncomeTaxExpenseBenefit" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapCurrentIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="loc_us-gaapEarningsPerShareBasicAndDilutedAbstract" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareBasicAndDilutedAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaapEarningsPerShareBasicAndDiluted" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareBasicAndDilutedAbstract" xlink:to="loc_us-gaapEarningsPerShareBasicAndDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:label="loc_us-gaapEarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaapWeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/ConsolidatedStatementsOfCashFlows" xlink:title="00000005 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200930.xsd#avxl_DeferredCharges" xlink:label="loc_avxlDeferredCharges" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_avxlDeferredCharges" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnRestructuringOfDebt" xlink:label="loc_us-gaapGainsLossesOnRestructuringOfDebt" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapGainsLossesOnRestructuringOfDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInIncomeTaxesReceivable" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInIncomeTaxesReceivable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpense" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfStockIssuanceCosts" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapPaymentsOfStockIssuanceCosts" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfDebtIssuanceCosts" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapPaymentsOfDebtIssuanceCosts" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCash" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash_2" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCash_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/ConsolidatedStatementOfChangesInStockholdersEquity" xlink:title="00000006 - Statement - CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS&apos; EQUITY">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="40" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapRetainedEarningsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200930.xsd#avxl_StockIssuedDuringPeriodValueAcquisitions2" xlink:label="loc_avxlStockIssuedDuringPeriodValueAcquisitions2" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlStockIssuedDuringPeriodValueAcquisitions2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200930.xsd#avxl_StockIssuedDuringPeriodSharesAcquisitions2" xlink:label="loc_avxlStockIssuedDuringPeriodSharesAcquisitions2" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlStockIssuedDuringPeriodSharesAcquisitions2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200930.xsd#avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2" xlink:label="loc_avxlCommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlCommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200930.xsd#avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2" xlink:label="loc_avxlCommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlCommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueAcquisitions" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueAcquisitions" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200930.xsd#avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1" xlink:label="loc_avxlCommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlCommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200930.xsd#avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement1" xlink:label="loc_avxlCommitmentSharesIssuedValueUndertermsOfPurchaseAgreement1" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlCommitmentSharesIssuedValueUndertermsOfPurchaseAgreement1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200930.xsd#avxl_SharesIssuedPursuantToCashlessExerciseOfWarrants" xlink:label="loc_avxlSharesIssuedPursuantToCashlessExerciseOfWarrants" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlSharesIssuedPursuantToCashlessExerciseOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200930.xsd#avxl_SharesIssuedPursuantToCashlessExerciseOfOptions" xlink:label="loc_avxlSharesIssuedPursuantToCashlessExerciseOfOptions" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlSharesIssuedPursuantToCashlessExerciseOfOptions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200930.xsd#avxl_SharesIssuedPursuantToCashlessExerciseOfOptionsInShares" xlink:label="loc_avxlSharesIssuedPursuantToCashlessExerciseOfOptionsInShares" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlSharesIssuedPursuantToCashlessExerciseOfOptionsInShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200930.xsd#avxl_SharesIssuedDuringPeriodValueUnderSalesAgreement" xlink:label="loc_avxlSharesIssuedDuringPeriodValueUnderSalesAgreement" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlSharesIssuedDuringPeriodValueUnderSalesAgreement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200930.xsd#avxl_SharesIssuedDuringPeriodSharesUnderSalesAgreement" xlink:label="loc_avxlSharesIssuedDuringPeriodSharesUnderSalesAgreement" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlSharesIssuedDuringPeriodSharesUnderSalesAgreement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200930.xsd#avxl_SharesIssuedPursuantToCashlessExerciseOfWarrantsInShares" xlink:label="loc_avxlSharesIssuedPursuantToCashlessExerciseOfWarrantsInShares" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlSharesIssuedPursuantToCashlessExerciseOfWarrantsInShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_2" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_2" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/BusinessDescriptionAndBasisOfPresentation" xlink:title="00000007 - Disclosure - Business Description and Basis of Presentation">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="00000008 - Disclosure - Summary of Significant Accounting Policies">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapSignificantAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSignificantAccountingPoliciesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/OtherIncome" xlink:title="00000009 - Disclosure - Other Income">
      <link:loc xlink:type="locator" xlink:href="avxl-20200930.xsd#avxl_DisclosureOtherIncomeAbstract" xlink:label="loc_avxlDisclosureOtherIncomeAbstract" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200930.xsd#avxl_OtherIncomeDisclosureTextBlock" xlink:label="loc_avxlOtherIncomeDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avxlDisclosureOtherIncomeAbstract" xlink:to="loc_avxlOtherIncomeDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/EquityOfferingAgreements" xlink:title="00000010 - Disclosure - Equity Offering Agreements">
      <link:loc xlink:type="locator" xlink:href="avxl-20200930.xsd#avxl_DisclosureEquityOfferingAgreementsAbstract" xlink:label="loc_avxlDisclosureEquityOfferingAgreementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200930.xsd#avxl_EquityOfferingAgreementsTextBlock" xlink:label="loc_avxlEquityOfferingAgreementsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avxlDisclosureEquityOfferingAgreementsAbstract" xlink:to="loc_avxlEquityOfferingAgreementsTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/Commitments" xlink:title="00000011 - Disclosure - Commitments">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapCommitmentsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/IncomeTaxes" xlink:title="00000012 - Disclosure - Income Taxes">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaapIncomeTaxDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000013 - Disclosure - Summary of Significant Accounting Policies (Policies)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaapUseOfEstimates" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapUseOfEstimates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaapConsolidationPolicyTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapConsolidationPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaapResearchAndDevelopmentExpensePolicy" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpensePolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionIncentives" xlink:label="loc_us-gaapRevenueRecognitionIncentives" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapRevenueRecognitionIncentives" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaapEarningsPerSharePolicyTextBlock" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapEarningsPerSharePolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="loc_us-gaapForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaapSegmentReportingPolicyPolicyTextBlock" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSegmentReportingPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200930.xsd#avxl_GrantIncomePolicyTextBlock" xlink:label="loc_avxlGrantIncomePolicyTextBlock" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_avxlGrantIncomePolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaapIncomeTaxPolicyTextBlock" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapIncomeTaxPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationForfeituresPolicyTextBlock" xlink:label="loc_us-gaapShareBasedCompensationForfeituresPolicyTextBlock" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapShareBasedCompensationForfeituresPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaapFairValueMeasurementPolicyPolicyTextBlock" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsTables" xlink:title="00000014 - Disclosure - Commitments (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200930.xsd#avxl_ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock" xlink:label="loc_avxlScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_avxlScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:label="loc_us-gaapScheduleOfStockOptionsRollForwardTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfStockOptionsRollForwardTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/IncomeTaxesTables" xlink:title="00000015 - Disclosure - Income Taxes (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="loc_us-gaapScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000016 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200930.xsd#avxl_CashRefundAvailableDescription" xlink:label="loc_avxlCashRefundAvailableDescription" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_avxlCashRefundAvailableDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:label="loc_us-gaapIncrementalCommonSharesAttributableToCallOptionsAndWarrants" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapIncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/OtherIncomeDetailsNarrative" xlink:title="00000017 - Disclosure - Other Income (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="avxl-20200930.xsd#avxl_DisclosureOtherIncomeAbstract" xlink:label="loc_avxlDisclosureOtherIncomeAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avxlDisclosureOtherIncomeAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ReinsurancePremiumsForInsuranceCompaniesByProductSegmentLineItems" xlink:label="loc_srtReinsurancePremiumsForInsuranceCompaniesByProductSegmentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtReinsurancePremiumsForInsuranceCompaniesByProductSegmentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtProductOrServiceAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200930.xsd#avxl_ClinicalStudyGrantMember" xlink:label="loc_avxlClinicalStudyGrantMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_avxlClinicalStudyGrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200930.xsd#avxl_NYCBiotechCreditMember" xlink:label="loc_avxlNYCBiotechCreditMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_avxlNYCBiotechCreditMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CurrencyAxis" xlink:label="loc_srtCurrencyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtCurrencyAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currencyAllCurrenciesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtCurrencyAxis" xlink:to="loc_currencyAllCurrenciesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_AUD" xlink:label="loc_currencyAUD" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currencyAllCurrenciesDomain" xlink:to="loc_currencyAUD" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200930.xsd#avxl_FundingOfDeferredIncomeAwardedGrant" xlink:label="loc_avxlFundingOfDeferredIncomeAwardedGrant" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtReinsurancePremiumsForInsuranceCompaniesByProductSegmentLineItems" xlink:to="loc_avxlFundingOfDeferredIncomeAwardedGrant" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200930.xsd#avxl_NonOperatingIncomeFromGrant" xlink:label="loc_avxlNonOperatingIncomeFromGrant" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtReinsurancePremiumsForInsuranceCompaniesByProductSegmentLineItems" xlink:to="loc_avxlNonOperatingIncomeFromGrant" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:label="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtReinsurancePremiumsForInsuranceCompaniesByProductSegmentLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/EquityOfferingAgreementsDetailsNarrative" xlink:title="00000018 - Disclosure - Equity Offering Agreements (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="avxl-20200930.xsd#avxl_DisclosureEquityOfferingAgreementsAbstract" xlink:label="loc_avxlDisclosureEquityOfferingAgreementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avxlDisclosureEquityOfferingAgreementsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityListingsLineItems" xlink:label="loc_deiEntityListingsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiEntityListingsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200930.xsd#avxl_PurchaseAgreementMember" xlink:label="loc_avxlPurchaseAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_avxlPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200930.xsd#avxl_PurchaseAgreement1Member" xlink:label="loc_avxlPurchaseAgreement1Member" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_avxlPurchaseAgreement1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200930.xsd#avxl_EquityOfferingSalesAgreementMember" xlink:label="loc_avxlEquityOfferingSalesAgreementMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_avxlEquityOfferingSalesAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200930.xsd#avxl_LincolnParkCapitalFundLLCMember" xlink:label="loc_avxlLincolnParkCapitalFundLLCMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_avxlLincolnParkCapitalFundLLCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200930.xsd#avxl_CantorFitzgeraldAndCoMember" xlink:label="loc_avxlCantorFitzgeraldAndCoMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_avxlCantorFitzgeraldAndCoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200930.xsd#avxl_StockIssuedDuringPeriodSharesNewIssues4" xlink:label="loc_avxlStockIssuedDuringPeriodSharesNewIssues4" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_avxlStockIssuedDuringPeriodSharesNewIssues4" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200930.xsd#avxl_StockIssuedDuringPeriodValueNewIssues3" xlink:label="loc_avxlStockIssuedDuringPeriodValueNewIssues3" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_avxlStockIssuedDuringPeriodValueNewIssues3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200930.xsd#avxl_StockIssuedDuringPeriodSharesNewIssues3" xlink:label="loc_avxlStockIssuedDuringPeriodSharesNewIssues3" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_avxlStockIssuedDuringPeriodSharesNewIssues3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200930.xsd#avxl_ValueOfSharesObligatedToPurchase" xlink:label="loc_avxlValueOfSharesObligatedToPurchase" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_avxlValueOfSharesObligatedToPurchase" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200930.xsd#avxl_AgreementTerm" xlink:label="loc_avxlAgreementTerm" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_avxlAgreementTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationDescription" xlink:label="loc_us-gaapUnrecordedUnconditionalPurchaseObligationDescription" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_us-gaapUnrecordedUnconditionalPurchaseObligationDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200930.xsd#avxl_PercentageOfGrossProceedsFromSales" xlink:label="loc_avxlPercentageOfGrossProceedsFromSales" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_avxlPercentageOfGrossProceedsFromSales" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200930.xsd#avxl_NumberOfSharesObligatedToPurchaseProrataBasic" xlink:label="loc_avxlNumberOfSharesObligatedToPurchaseProrataBasic" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_avxlNumberOfSharesObligatedToPurchaseProrataBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200930.xsd#avxl_StockIssuedDuringPeriodValueNewIssues4" xlink:label="loc_avxlStockIssuedDuringPeriodValueNewIssues4" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_avxlStockIssuedDuringPeriodValueNewIssues4" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200930.xsd#avxl_NumberOfStockSold" xlink:label="loc_avxlNumberOfStockSold" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_avxlNumberOfStockSold" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200930.xsd#avxl_GrossProceedsFromSaleOfCommonStock" xlink:label="loc_avxlGrossProceedsFromSaleOfCommonStock" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_avxlGrossProceedsFromSaleOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200930.xsd#avxl_NumberOfSharesAvailable" xlink:label="loc_avxlNumberOfSharesAvailable" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_avxlNumberOfSharesAvailable" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsDetails" xlink:title="00000019 - Disclosure - Commitments (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200930.xsd#avxl_PurchaseWarrantsMember" xlink:label="loc_avxlPurchaseWarrantsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_avxlPurchaseWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200930.xsd#avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200930.xsd#avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExercised" xlink:label="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExercised" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200930.xsd#avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExpired" xlink:label="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExpired" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExpired" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200930.xsd#avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod" xlink:label="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200930.xsd#avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice" xlink:label="loc_avxlShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_avxlShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200930.xsd#avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsDetails1" xlink:title="00000020 - Disclosure - Commitments (Details 1)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200930.xsd#avxl_PurchaseWarrants1Member" xlink:label="loc_avxlPurchaseWarrants1Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_avxlPurchaseWarrants1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200930.xsd#avxl_PurchaseWarrants2Member" xlink:label="loc_avxlPurchaseWarrants2Member" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_avxlPurchaseWarrants2Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsDetails2" xlink:title="00000021 - Disclosure - Commitments (Details 2)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200930.xsd#avxl_StockOptionPlan2015Member" xlink:label="loc_avxlStockOptionPlan2015Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_avxlStockOptionPlan2015Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsDetails3" xlink:title="00000022 - Disclosure - Commitments (Details 3)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaapLossContingenciesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLossContingenciesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaapLossContingenciesLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapLossContingenciesLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsDetails4" xlink:title="00000023 - Disclosure - Commitments (Details 4)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsDetailsNarrative" xlink:title="00000024 - Disclosure - Commitments (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200930.xsd#avxl_StockOptionPlan2015Member" xlink:label="loc_avxlStockOptionPlan2015Member" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_avxlStockOptionPlan2015Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200930.xsd#avxl_StockOptionPlan2019Member" xlink:label="loc_avxlStockOptionPlan2019Member" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_avxlStockOptionPlan2019Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="loc_us-gaapLeaseAndRentalExpense" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapLeaseAndRentalExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200930.xsd#avxl_SharesIssuedPursuantToCashlessExerciseOfWarrantInShares" xlink:label="loc_avxlSharesIssuedPursuantToCashlessExerciseOfWarrantInShares" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_avxlSharesIssuedPursuantToCashlessExerciseOfWarrantInShares" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200930.xsd#avxl_StockIssuedPursuantToCashlessExerciseOfWarrants" xlink:label="loc_avxlStockIssuedPursuantToCashlessExerciseOfWarrants" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_avxlStockIssuedPursuantToCashlessExerciseOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200930.xsd#avxl_SharesIssuedPursuantToCashlessExercisesOfOption" xlink:label="loc_avxlSharesIssuedPursuantToCashlessExercisesOfOption" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_avxlSharesIssuedPursuantToCashlessExercisesOfOption" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200930.xsd#avxl_NumberOfCashlessExerciseOption" xlink:label="loc_avxlNumberOfCashlessExerciseOption" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_avxlNumberOfCashlessExerciseOption" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/IncomeTaxesDetails" xlink:title="00000025 - Disclosure - Income Taxes (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/IncomeTaxesDetails1" xlink:title="00000026 - Disclosure - Income Taxes (Details 1)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200930.xsd#avxl_DeferredTaxAssetsUnpaidCharges" xlink:label="loc_avxlDeferredTaxAssetsUnpaidCharges" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_avxlDeferredTaxAssetsUnpaidCharges" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="loc_us-gaapDeferredTaxAssetsGoodwillAndIntangibleAssets" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses" xlink:label="loc_us-gaapDeferredTaxAssetsUnrealizedCurrencyLosses" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsUnrealizedCurrencyLosses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaapDeferredTaxAssetsNet" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsNet" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/IncomeTaxesDetails2" xlink:title="00000027 - Disclosure - Income Taxes (Details 2)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapIncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaapIncomeTaxReconciliationForeignIncomeTaxRateDifferential" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="loc_us-gaapIncomeTaxReconciliationOtherAdjustments" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationOtherAdjustments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200930.xsd#avxl_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopmentCreditBenefit" xlink:label="loc_avxlIncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopmentCreditBenefit" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_avxlIncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopmentCreditBenefit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaapIncomeTaxReconciliationStateAndLocalIncomeTaxes" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" xlink:label="loc_us-gaapIncomeTaxReconciliationPriorYearIncomeTaxes" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationPriorYearIncomeTaxes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCash" xlink:label="loc_us-gaapEffectOfExchangeRateOnCash" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectOfExchangeRateOnCash" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxesExcludingIncomeAndExciseTaxes" xlink:label="loc_us-gaapTaxesExcludingIncomeAndExciseTaxes" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapTaxesExcludingIncomeAndExciseTaxes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapIncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredIncomeTaxExpenseBenefit" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredIncomeTaxExpenseBenefit" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/IncomeTaxesDetailsNarrative" xlink:title="00000028 - Disclosure - Income Taxes (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaapOperatingLossCarryforwardsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapOperatingLossCarryforwardsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaapOperatingLossCarryforwardsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_us-gaapOperatingLossCarryforwardsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_us-gaapIncomeTaxAuthorityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCountryMember" xlink:label="loc_us-gaapForeignCountryMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapForeignCountryMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CurrencyAxis" xlink:label="loc_srtCurrencyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_srtCurrencyAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currencyAllCurrenciesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtCurrencyAxis" xlink:to="loc_currencyAllCurrenciesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_AUD" xlink:label="loc_currencyAUD" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currencyAllCurrenciesDomain" xlink:to="loc_currencyAUD" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsForeign" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200930.xsd#avxl_OperatingLossCarryForwardsExpirationYear1" xlink:label="loc_avxlOperatingLossCarryForwardsExpirationYear1" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_avxlOperatingLossCarryForwardsExpirationYear1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaapOperatingLossCarryforwards" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwards" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>e2298_10k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:avxl="http://anavex.com/20200930"
  xmlns:currency="http://xbrl.sec.gov/currency/2020-01-31"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2020-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="avxl-20200930.xsd" xlink:type="simple"/>
    <context id="From2019-10-01to2020-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2020-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
        </entity>
        <period>
            <instant>2020-12-28</instant>
        </period>
    </context>
    <context id="AsOf2020-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="AsOf2019-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="From2018-10-012019-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2018-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="AsOf2018-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="AsOf2018-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="AsOf2018-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="From2018-10-012019-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="From2018-10-012019-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="From2018-10-012019-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2019-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="AsOf2019-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="AsOf2019-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="From2019-10-012020-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="From2019-10-012020-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="From2019-10-012020-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2020-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="AsOf2020-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="AsOf2020-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="From2016-10-012017-09-30_custom_ClinicalStudyGrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">avxl:ClinicalStudyGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-10-01</startDate>
            <endDate>2017-09-30</endDate>
        </period>
    </context>
    <context id="From2019-10-012020-09-30_currency_AUD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:AUD</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="From2018-10-012019-09-30_currency_AUD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:AUD</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="From2018-10-012019-09-30_custom_NYCBiotechCreditMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">avxl:NYCBiotechCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="From2018-10-012019-09-30_custom_PurchaseAgreementMember_custom_LincolnParkCapitalFundLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:PurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="From2019-06-062019-06-07_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:PurchaseAgreement1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-06</startDate>
            <endDate>2019-06-07</endDate>
        </period>
    </context>
    <context id="From2019-10-012020-09-30_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:PurchaseAgreement1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="From2019-10-012020-09-30_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:PurchaseAgreement1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="From2018-10-012019-09-30_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:PurchaseAgreement1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="From2020-04-292020-05-01_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:EquityOfferingSalesAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:CantorFitzgeraldAndCoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-29</startDate>
            <endDate>2020-05-01</endDate>
        </period>
    </context>
    <context id="From2019-10-012020-09-30_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:EquityOfferingSalesAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:CantorFitzgeraldAndCoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2020-09-30_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:EquityOfferingSalesAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:CantorFitzgeraldAndCoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="AsOf2018-09-30_custom_PurchaseWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:PurchaseWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="From2018-10-012019-09-30_custom_PurchaseWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:PurchaseWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2019-09-30_custom_PurchaseWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:PurchaseWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="From2019-10-012020-09-30_custom_PurchaseWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:PurchaseWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2020-09-30_custom_PurchaseWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:PurchaseWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="AsOf2020-09-30_custom_PurchaseWarrants1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:PurchaseWarrants1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="AsOf2020-09-30_custom_PurchaseWarrants2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:PurchaseWarrants2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="AsOf2020-09-30_custom_StockOptionPlan2015Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="AsOf2019-09-30_custom_StockOptionPlan2015Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="From2019-10-012020-09-30_custom_StockOptionPlan2019Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2020-09-30_custom_StockOptionPlan2019Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="AsOf2019-09-30_custom_StockOptionPlan2019Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="AsOf2018-09-30_custom_StockOptionPlan2015Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="From2018-10-012019-09-30_custom_StockOptionPlan2015Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="From2019-10-012020-09-30_custom_StockOptionPlan2015Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="From2019-10-012020-09-30_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="From2018-10-012019-09-30_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="From2019-10-012020-09-30_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="From2018-10-012019-09-30_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2020-09-30_us-gaap_ForeignCountryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="AsOf2020-09-30_us-gaap_ForeignCountryMember_currency_AUD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:AUD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="AsOf2019-09-30_us-gaap_ForeignCountryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2019-10-01to2020-09-30">0001314052</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2019-10-01to2020-09-30">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus contextRef="From2019-10-01to2020-09-30">2020</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="From2019-10-01to2020-09-30">FY</dei:DocumentFiscalPeriodFocus>
    <dei:CurrentFiscalYearEndDate contextRef="From2019-10-01to2020-09-30">--09-30</dei:CurrentFiscalYearEndDate>
    <avxl:StockIssuedDuringPeriodValueAcquisitions2
      contextRef="From2018-10-012019-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0249"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2
      contextRef="From2018-10-012019-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0256"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2
      contextRef="From2018-10-012019-09-30"
      id="xdx2ixbrl0257"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="From2018-10-012019-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0263"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:SharesIssuedPursuantToCashlessExerciseOfWarrants
      contextRef="From2018-10-012019-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0277"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:SharesIssuedPursuantToCashlessExerciseOfWarrants
      contextRef="From2018-10-012019-09-30"
      id="xdx2ixbrl0278"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2018-10-012019-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0282"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2018-10-012019-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0284"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2018-10-012019-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0287"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2018-10-012019-09-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0288"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="From2019-10-012020-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0301"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1
      contextRef="From2019-10-012020-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0308"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1
      contextRef="From2019-10-01to2020-09-30"
      id="xdx2ixbrl0309"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:SharesIssuedPursuantToCashlessExerciseOfOptions
      contextRef="From2019-10-012020-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0315"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:SharesIssuedPursuantToCashlessExerciseOfOptions
      contextRef="From2019-10-01to2020-09-30"
      id="xdx2ixbrl0316"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2019-10-012020-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0327"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2019-10-012020-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0329"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2019-10-012020-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0332"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2019-10-012020-09-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0333"
      unitRef="USD"
      xsi:nil="true"/>
    <dei:DocumentType contextRef="From2019-10-01to2020-09-30">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="From2019-10-01to2020-09-30">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="From2019-10-01to2020-09-30">2020-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="From2019-10-01to2020-09-30">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="From2019-10-01to2020-09-30">001-37606</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="From2019-10-01to2020-09-30">ANAVEX LIFE SCIENCES CORP.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2019-10-01to2020-09-30">NV</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="From2019-10-01to2020-09-30">98-0608404</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2019-10-01to2020-09-30">51 W 52nd Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2019-10-01to2020-09-30">7th Floor</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2019-10-01to2020-09-30">New York</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2019-10-01to2020-09-30">NY</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressCountry contextRef="From2019-10-01to2020-09-30">US</dei:EntityAddressCountry>
    <dei:EntityAddressPostalZipCode contextRef="From2019-10-01to2020-09-30">10019</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2019-10-01to2020-09-30">844</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2019-10-01to2020-09-30">689-3939</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="From2019-10-01to2020-09-30">Common     Stock, $0.001 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2019-10-01to2020-09-30">AVXL</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2019-10-01to2020-09-30">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="From2019-10-01to2020-09-30">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="From2019-10-01to2020-09-30">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="From2019-10-01to2020-09-30">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="From2019-10-01to2020-09-30">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="From2019-10-01to2020-09-30">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="From2019-10-01to2020-09-30">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2019-10-01to2020-09-30">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="From2019-10-01to2020-09-30">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat contextRef="AsOf2020-03-31" decimals="0" unitRef="USD">177399544</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding contextRef="AsOf2020-12-28" decimals="INF" unitRef="Shares">66962957</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2020-09-30" decimals="0" unitRef="USD">29249018</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2019-09-30" decimals="0" unitRef="USD">22185630</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:IncomeTaxesReceivable contextRef="AsOf2020-09-30" decimals="0" unitRef="USD">4849340</us-gaap:IncomeTaxesReceivable>
    <us-gaap:IncomeTaxesReceivable contextRef="AsOf2019-09-30" decimals="0" unitRef="USD">2642745</us-gaap:IncomeTaxesReceivable>
    <us-gaap:PrepaidExpenseCurrent contextRef="AsOf2020-09-30" decimals="0" unitRef="USD">443839</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent contextRef="AsOf2019-09-30" decimals="0" unitRef="USD">500998</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:Assets contextRef="AsOf2020-09-30" decimals="0" unitRef="USD">34542197</us-gaap:Assets>
    <us-gaap:Assets contextRef="AsOf2019-09-30" decimals="0" unitRef="USD">25329373</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2020-09-30" decimals="0" unitRef="USD">3989054</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2019-09-30" decimals="0" unitRef="USD">3523332</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="AsOf2020-09-30" decimals="0" unitRef="USD">3316574</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="AsOf2019-09-30" decimals="0" unitRef="USD">1516342</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:Liabilities contextRef="AsOf2020-09-30" decimals="0" unitRef="USD">7305628</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="AsOf2019-09-30" decimals="0" unitRef="USD">5039674</us-gaap:Liabilities>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2020-09-30" decimals="INF" unitRef="Shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2019-09-30" decimals="INF" unitRef="Shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2020-09-30"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2019-09-30"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockValue contextRef="AsOf2020-09-30" decimals="0" unitRef="USD">-0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue contextRef="AsOf2019-09-30" decimals="0" unitRef="USD">-0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2020-09-30" decimals="INF" unitRef="Shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2019-09-30" decimals="INF" unitRef="Shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2020-09-30"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2019-09-30"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2020-09-30" decimals="INF" unitRef="Shares">62045198</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2020-09-30" decimals="INF" unitRef="Shares">62045198</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2019-09-30" decimals="INF" unitRef="Shares">52650521</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2019-09-30" decimals="INF" unitRef="Shares">52650521</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="AsOf2020-09-30" decimals="0" unitRef="USD">62047</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="AsOf2019-09-30" decimals="0" unitRef="USD">52652</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="AsOf2020-09-30" decimals="0" unitRef="USD">186851752</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="AsOf2019-09-30" decimals="0" unitRef="USD">153633807</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2020-09-30" decimals="0" unitRef="USD">-159677230</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2019-09-30" decimals="0" unitRef="USD">-133396760</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-09-30" decimals="0" unitRef="USD">27236569</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-09-30" decimals="0" unitRef="USD">20289699</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2020-09-30" decimals="0" unitRef="USD">34542197</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2019-09-30" decimals="0" unitRef="USD">25329373</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2019-10-01to2020-09-30"
      decimals="0"
      unitRef="USD">5856609</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2018-10-012019-09-30"
      decimals="0"
      unitRef="USD">6846599</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2019-10-01to2020-09-30"
      decimals="0"
      unitRef="USD">25231623</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2018-10-012019-09-30"
      decimals="0"
      unitRef="USD">22260349</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:OperatingExpenses
      contextRef="From2019-10-01to2020-09-30"
      decimals="0"
      unitRef="USD">31088232</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2018-10-012019-09-30"
      decimals="0"
      unitRef="USD">29106948</us-gaap:OperatingExpenses>
    <avxl:NonOperatingIncomeFromGrant
      contextRef="From2019-10-01to2020-09-30"
      decimals="0"
      unitRef="USD">149888</avxl:NonOperatingIncomeFromGrant>
    <avxl:NonOperatingIncomeFromGrant
      contextRef="From2018-10-012019-09-30"
      decimals="0"
      unitRef="USD">298943</avxl:NonOperatingIncomeFromGrant>
    <avxl:ResearchAndDevelopmentIncentiveIncome
      contextRef="From2019-10-01to2020-09-30"
      decimals="0"
      unitRef="USD">4375025</avxl:ResearchAndDevelopmentIncentiveIncome>
    <avxl:ResearchAndDevelopmentIncentiveIncome
      contextRef="From2018-10-012019-09-30"
      decimals="0"
      unitRef="USD">2465691</avxl:ResearchAndDevelopmentIncentiveIncome>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="From2019-10-01to2020-09-30"
      decimals="0"
      unitRef="USD">179973</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="From2018-10-012019-09-30"
      decimals="0"
      unitRef="USD">207280</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2019-10-01to2020-09-30"
      decimals="0"
      unitRef="USD">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2018-10-012019-09-30"
      decimals="0"
      unitRef="USD">115758</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:DebtRelatedCommitmentFeesAndDebtIssuanceCosts
      contextRef="From2019-10-01to2020-09-30"
      decimals="0"
      unitRef="USD">-0</us-gaap:DebtRelatedCommitmentFeesAndDebtIssuanceCosts>
    <us-gaap:DebtRelatedCommitmentFeesAndDebtIssuanceCosts
      contextRef="From2018-10-012019-09-30"
      decimals="0"
      unitRef="USD">151133</us-gaap:DebtRelatedCommitmentFeesAndDebtIssuanceCosts>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="From2019-10-01to2020-09-30"
      decimals="0"
      unitRef="USD">125540</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="From2018-10-012019-09-30"
      decimals="0"
      unitRef="USD">-42389</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2019-10-01to2020-09-30"
      decimals="0"
      unitRef="USD">4830426</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2018-10-012019-09-30"
      decimals="0"
      unitRef="USD">2894150</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2019-10-01to2020-09-30"
      decimals="0"
      unitRef="USD">-26257806</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2018-10-012019-09-30"
      decimals="0"
      unitRef="USD">-26212798</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="From2019-10-01to2020-09-30"
      decimals="0"
      unitRef="USD">22664</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="From2018-10-012019-09-30"
      decimals="0"
      unitRef="USD">82181</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="From2019-10-01to2020-09-30"
      decimals="0"
      unitRef="USD">-26280470</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2018-10-012019-09-30"
      decimals="0"
      unitRef="USD">-26294979</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="From2019-10-01to2020-09-30"
      decimals="INF"
      unitRef="USDPShares">-0.45</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="From2018-10-012019-09-30"
      decimals="INF"
      unitRef="USDPShares">-0.54</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="From2019-10-01to2020-09-30"
      decimals="INF"
      unitRef="Shares">58194894</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="From2018-10-012019-09-30"
      decimals="INF"
      unitRef="Shares">48906470</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:NetIncomeLoss
      contextRef="From2019-10-01to2020-09-30"
      decimals="0"
      unitRef="USD">-26280470</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2018-10-012019-09-30"
      decimals="0"
      unitRef="USD">-26294979</us-gaap:NetIncomeLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="From2019-10-01to2020-09-30"
      decimals="0"
      unitRef="USD">4876906</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2018-10-012019-09-30"
      decimals="0"
      unitRef="USD">6430873</us-gaap:ShareBasedCompensation>
    <avxl:DeferredCharges
      contextRef="From2019-10-01to2020-09-30"
      decimals="0"
      unitRef="USD">0</avxl:DeferredCharges>
    <avxl:DeferredCharges
      contextRef="From2018-10-012019-09-30"
      decimals="0"
      unitRef="USD">151133</avxl:DeferredCharges>
    <us-gaap:GainsLossesOnRestructuringOfDebt
      contextRef="From2019-10-01to2020-09-30"
      decimals="0"
      unitRef="USD">-0</us-gaap:GainsLossesOnRestructuringOfDebt>
    <us-gaap:GainsLossesOnRestructuringOfDebt
      contextRef="From2018-10-012019-09-30"
      decimals="0"
      unitRef="USD">115758</us-gaap:GainsLossesOnRestructuringOfDebt>
    <us-gaap:IncreaseDecreaseInIncomeTaxesReceivable
      contextRef="From2019-10-01to2020-09-30"
      decimals="0"
      unitRef="USD">2206595</us-gaap:IncreaseDecreaseInIncomeTaxesReceivable>
    <us-gaap:IncreaseDecreaseInIncomeTaxesReceivable
      contextRef="From2018-10-012019-09-30"
      decimals="0"
      unitRef="USD">772388</us-gaap:IncreaseDecreaseInIncomeTaxesReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="From2019-10-01to2020-09-30"
      decimals="0"
      unitRef="USD">-57159</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="From2018-10-012019-09-30"
      decimals="0"
      unitRef="USD">-803196</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2019-10-01to2020-09-30"
      decimals="0"
      unitRef="USD">465722</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2018-10-012019-09-30"
      decimals="0"
      unitRef="USD">683797</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="From2019-10-01to2020-09-30"
      decimals="0"
      unitRef="USD">1800232</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="From2018-10-012019-09-30"
      decimals="0"
      unitRef="USD">587009</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2019-10-01to2020-09-30"
      decimals="0"
      unitRef="USD">-21287046</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2018-10-012019-09-30"
      decimals="0"
      unitRef="USD">-18527117</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2019-10-01to2020-09-30"
      decimals="0"
      unitRef="USD">28754198</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2018-10-012019-09-30"
      decimals="0"
      unitRef="USD">17832109</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="From2019-10-01to2020-09-30"
      decimals="0"
      unitRef="USD">403764</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="From2018-10-012019-09-30"
      decimals="0"
      unitRef="USD">-0</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="From2019-10-01to2020-09-30"
      decimals="0"
      unitRef="USD">-0</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="From2018-10-012019-09-30"
      decimals="0"
      unitRef="USD">50000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2019-10-01to2020-09-30"
      decimals="0"
      unitRef="USD">28350434</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2018-10-012019-09-30"
      decimals="0"
      unitRef="USD">17782109</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease
      contextRef="From2019-10-01to2020-09-30"
      decimals="0"
      unitRef="USD">7063388</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
    <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease
      contextRef="From2018-10-012019-09-30"
      decimals="0"
      unitRef="USD">-745008</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
    <us-gaap:Cash contextRef="AsOf2019-09-30" decimals="0" unitRef="USD">22185630</us-gaap:Cash>
    <us-gaap:Cash contextRef="AsOf2018-09-30" decimals="0" unitRef="USD">22930638</us-gaap:Cash>
    <us-gaap:Cash contextRef="AsOf2020-09-30" decimals="0" unitRef="USD">29249018</us-gaap:Cash>
    <us-gaap:Cash contextRef="AsOf2019-09-30" decimals="0" unitRef="USD">22185630</us-gaap:Cash>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2018-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">45933472</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2018-09-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">45935</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2018-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">129377542</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2018-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-107101781</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2018-09-30" decimals="0" unitRef="USD">22321696</us-gaap:StockholdersEquity>
    <avxl:StockIssuedDuringPeriodSharesAcquisitions2
      contextRef="From2018-10-012019-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">4848995</avxl:StockIssuedDuringPeriodSharesAcquisitions2>
    <avxl:StockIssuedDuringPeriodValueAcquisitions2
      contextRef="From2018-10-012019-09-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">4849</avxl:StockIssuedDuringPeriodValueAcquisitions2>
    <avxl:StockIssuedDuringPeriodValueAcquisitions2
      contextRef="From2018-10-012019-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">13192755</avxl:StockIssuedDuringPeriodValueAcquisitions2>
    <avxl:StockIssuedDuringPeriodValueAcquisitions2
      contextRef="From2018-10-012019-09-30"
      decimals="0"
      unitRef="USD">13197604</avxl:StockIssuedDuringPeriodValueAcquisitions2>
    <avxl:CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2
      contextRef="From2018-10-012019-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">23701</avxl:CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2>
    <avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2
      contextRef="From2018-10-012019-09-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">24</avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2>
    <avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2
      contextRef="From2018-10-012019-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">-24</avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="From2018-10-012019-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">1500000</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="From2018-10-012019-09-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">1500</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="From2018-10-012019-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">4633005</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="From2018-10-012019-09-30"
      decimals="0"
      unitRef="USD">4634505</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <avxl:CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement1
      contextRef="From2018-10-012019-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">339415</avxl:CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement1>
    <avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1
      contextRef="From2018-10-012019-09-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">339</avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1>
    <avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1
      contextRef="From2018-10-012019-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">-339</avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1>
    <avxl:SharesIssuedPursuantToCashlessExerciseOfWarrantsInShares
      contextRef="From2018-10-012019-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">4938</avxl:SharesIssuedPursuantToCashlessExerciseOfWarrantsInShares>
    <avxl:SharesIssuedPursuantToCashlessExerciseOfWarrants
      contextRef="From2018-10-012019-09-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">5</avxl:SharesIssuedPursuantToCashlessExerciseOfWarrants>
    <avxl:SharesIssuedPursuantToCashlessExerciseOfWarrants
      contextRef="From2018-10-012019-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">-5</avxl:SharesIssuedPursuantToCashlessExerciseOfWarrants>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2018-10-012019-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">6430873</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2018-10-012019-09-30"
      decimals="0"
      unitRef="USD">6430873</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="From2018-10-012019-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-26294979</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2018-10-012019-09-30"
      decimals="0"
      unitRef="USD">-26294979</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2019-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">52650521</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2019-09-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">52652</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2019-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">153633807</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2019-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-133396760</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-09-30" decimals="0" unitRef="USD">20289699</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="From2019-10-012020-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">7564584</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="From2019-10-012020-09-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">7565</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="From2019-10-012020-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">21246733</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="From2019-10-01to2020-09-30"
      decimals="0"
      unitRef="USD">21254298</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <avxl:CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement1
      contextRef="From2019-10-012020-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">68943</avxl:CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement1>
    <avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1
      contextRef="From2019-10-012020-09-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">69</avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1>
    <avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1
      contextRef="From2019-10-012020-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">-69</avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1>
    <avxl:SharesIssuedPursuantToCashlessExerciseOfOptionsInShares
      contextRef="From2019-10-012020-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">721</avxl:SharesIssuedPursuantToCashlessExerciseOfOptionsInShares>
    <avxl:SharesIssuedPursuantToCashlessExerciseOfOptions
      contextRef="From2019-10-012020-09-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">1</avxl:SharesIssuedPursuantToCashlessExerciseOfOptions>
    <avxl:SharesIssuedPursuantToCashlessExerciseOfOptions
      contextRef="From2019-10-012020-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">-1</avxl:SharesIssuedPursuantToCashlessExerciseOfOptions>
    <avxl:SharesIssuedDuringPeriodSharesUnderSalesAgreement
      contextRef="From2019-10-012020-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">1760429</avxl:SharesIssuedDuringPeriodSharesUnderSalesAgreement>
    <avxl:SharesIssuedDuringPeriodValueUnderSalesAgreement
      contextRef="From2019-10-012020-09-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">1760</avxl:SharesIssuedDuringPeriodValueUnderSalesAgreement>
    <avxl:SharesIssuedDuringPeriodValueUnderSalesAgreement
      contextRef="From2019-10-012020-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">7094376</avxl:SharesIssuedDuringPeriodValueUnderSalesAgreement>
    <avxl:SharesIssuedDuringPeriodValueUnderSalesAgreement
      contextRef="From2019-10-01to2020-09-30"
      decimals="0"
      unitRef="USD">7096136</avxl:SharesIssuedDuringPeriodValueUnderSalesAgreement>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2019-10-012020-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">4876906</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2019-10-01to2020-09-30"
      decimals="0"
      unitRef="USD">4876906</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="From2019-10-012020-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-26280470</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2019-10-01to2020-09-30"
      decimals="0"
      unitRef="USD">-26280470</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2020-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">62045198</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-09-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">62047</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">186851752</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-159677230</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-09-30" decimals="0" unitRef="USD">27236569</us-gaap:StockholdersEquity>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="From2019-10-01to2020-09-30">&lt;p id="xdx_808_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_z75PDRB2VO23" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"/&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
&lt;tr style="vertical-align: top; text-align: left"&gt;
    &lt;td style="width: 7%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Note 1&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 93%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_824_zUqaA1Rg7Ipk"&gt;Business Description
    and Basis of Presentation&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"/&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Business&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Anavex
Life Sciences Corp. (&#x201c;Anavex&#x201d; or the &#x201c;Company&#x201d;) is a clinical stage biopharmaceutical company engaged
in the development of differentiated therapeutics by applying precision medicine to central nervous system (&#x201c;CNS&#x201d;)
diseases with high unmet need. Anavex analyzes genomic data from clinical studies to identify biomarkers, which are used to select
patients that will receive the therapeutic benefit for the treatment of neurodegenerative and neurodevelopmental diseases. The
Company&#x2019;s lead compound ANAVEX&lt;sup&gt;&#xae;&lt;/sup&gt;2-73 is being developed to treat Alzheimer&#x2019;s disease, Parkinson&#x2019;s
disease and potentially other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological
monogenic disorder caused by mutations in the X-linked gene, methyl-CpG-binding protein 2 (&#x201c;MECP2&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 12pt 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Basis
of Presentation&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;These
consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission
(&#x201c;SEC&#x201d;) and the instructions to Form 10-K and have been prepared under the accounting principles generally accepted
in the United States of America (&#x201c;U.S. GAAP&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Liquidity&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;All
of the Company&#x2019;s potential drug compounds are in the clinical development stage and the Company cannot be certain that its
research and development efforts will be successful or, if successful, that its potential drug compounds will ever be approved
for sales to pharmaceutical companies or generate commercial revenues. To date, we have not generated any revenues from our operations.
The Company expects the business to continue to experience negative cash flows for the foreseeable future and cannot predict when,
if ever, our business might become profitable.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company believes that its existing cash and cash equivalents, along with existing financial commitments from third parties, will
be sufficient to meet its cash commitments for in excess of two years after the date that these consolidated financial statements
are issued. The process of drug development can be costly, and the timing and outcomes of clinical trials is uncertain.&#160;The
assumptions upon which the Company has based its estimates are routinely evaluated and may be subject to change.&#160;The actual
amount of the Company&#x2019;s expenditures will vary depending upon a number of factors including but not limited to the design,
timing and duration of future clinical trials, the progress of the Company&#x2019;s research and development programs and the level
of financial resources available. The Company has the ability to adjust its operating plan spending levels based on the timing
of future clinical trials.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 12pt 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Other
than our rights related to the 2019 Purchase Agreement and the Sales Agreement (each as defined below in Note 4), there can be
no assurance that additional financing will be available to us when needed or, if available, that it can be obtained on commercially
reasonable terms. If the Company is not able to obtain the additional financing on a timely basis, if and when it is needed, it
will be forced to delay or scale down some or all of its research and development activities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;In
December 2019, a novel strain of coronavirus, COVID-19, was reported to have surfaced in Wuhan, China. In March 2020, the World
Health Organization (&#x201c;WHO&#x201d;) declared COVID-19 to be a global pandemic as a result of the rapid spread of the virus
beyond its point of origin.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;









&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
global outbreak of COVID-19 continues to rapidly evolve as of the date these consolidated financial statements are issued. As
such, it is uncertain as to the full magnitude that the outbreak will have on the Company&#x2019;s financial condition and future
results of operations. Management is actively monitoring the global situation on its business, including on its clinical trials
and operations and financial condition. The effects of COVID-19 did not have a material impact on the Company&#x2019;s result of
operations or financial condition for the year ended September 30, 2020. However, given the daily evolution of the COVID-19 situation,
and the global responses to curb its spread, the Company is not able to estimate the effects COVID-19 may have on its future results
of operations or financial condition.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 12pt 42.6pt; text-align: justify; text-indent: -0.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;On
March 27, 2020, the President of the United States signed into law the &#x201c;Coronavirus Aid, Relief, and Economic Security (CARES)
Act.&#x201d; The CARES Act, among other things, includes provisions relating to refundable payroll tax credits, deferment of employer
side social security payments, net operating loss carryback periods, alternative minimum tax credit refunds, modifications to
the net interest deduction limitations, increased limitations on qualified charitable contributions, and technical corrections
to tax depreciation methods for qualified improvement property. The enactment of the CARES Act did not have any material impact
on the Company&#x2019;s consolidated financial statements or deferred tax assets or liabilities.&lt;/span&gt;&lt;/p&gt;

</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="From2019-10-01to2020-09-30">&lt;p id="xdx_801_eus-gaap--SignificantAccountingPoliciesTextBlock_zPAEJlyL59U1" style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
&lt;tr style="vertical-align: top; text-align: left"&gt;&lt;td style="width: 7%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Note
                                         2&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 93%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_82A_znJJvmOlL31k"&gt;Summary of Significant
    Accounting Policies&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_84D_eus-gaap--UseOfEstimates_zqf4ghFK9O8l" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 42.55pt"/&gt;&lt;td style="width: 18pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;a)&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span id="xdx_869_zEAgumzB06sa" style="font: 10pt Times New Roman, Times, Serif"&gt;Use
                                         of Estimates&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify; margin-left: 42.55pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect
the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenue and
expenses in the reporting period. The Company regularly evaluates estimates and assumptions related to accounting for research
and development costs, incentive income receivable, valuation and recoverability of deferred tax assets, asset impairment, stock-based
compensation and loss contingencies. The Company bases its estimates and assumptions on current facts, historical experience and
various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making
judgments about the book values of assets and liabilities and the accrual of costs and expenses that are not readily apparent
from other sources. The actual results experienced by the Company may differ materially and adversely from the Company&#x2019;s
estimates. To the extent there are material differences between the estimates and the actual results, future results of operations
will be affected.&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84E_eus-gaap--ConsolidationPolicyTextBlock_zhaxDESkVTBc" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;



&lt;table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 42.5pt"/&gt;&lt;td style="width: 18pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;b)&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_86C_zg9HiwiTiKfl" style="text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Principles
                                         of Consolidation&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify; margin-left: 42.55pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;These
consolidated financial statements include the accounts of Anavex Life Sciences Corp. and its wholly-owned subsidiaries, Anavex
Australia Pty Limited. (&#x201c;Anavex Australia&#x201d;), a company incorporated under the laws of Australia, Anavex Germany GmbH,
a company incorporated under the laws of Germany, and Anavex Canada Ltd., a company incorporated under the laws of the Province
of Ontario, Canada. All inter-company transactions and balances have been eliminated.&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84B_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zPqyXkDd3gml" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 42.55pt"/&gt;&lt;td style="width: 18pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;c)&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_861_zvIIr6UoDIAj" style="text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Cash
                                         and equivalents&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify; margin-left: 42.55pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company considers only those investments which are highly liquid, readily convertible to cash and that mature within three months
from the date of purchase to be cash equivalents.&lt;/span&gt;&lt;/p&gt;








&lt;p id="xdx_847_eus-gaap--ResearchAndDevelopmentExpensePolicy_zYhMikPyjcA6" style="font: 10pt Arial, Helvetica, Sans-Serif; text-indent: 40pt; text-align: left; margin-top: 0; margin-bottom: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"/&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 42.55pt"/&gt;&lt;td style="width: 18pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;d)&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_86F_zXm5kmXnzwQa" style="text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Research
                                         and Development Expenses&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i/&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Research
and development costs are expensed as incurred. These expenses are comprised of the costs of the Company&#x2019;s proprietary research
and development efforts, including preclinical studies, clinical trials, manufacturing costs, employee salaries and benefits and
stock based compensation expense, contract services including external research and development expenses incurred under arrangements
with third parties such as contract research organizations (&#x201c;CROs&#x201d;), facilities costs, overhead costs and other related
expenses. Milestone payments made by the Company to third parties are expensed when the specific milestone has been achieved.
Manufacturing costs are expensed as incurred in accordance with Accounting Standard Codification (&#x201c;ASC&#x201d;) 730, Research
and Development, as these materials have no alternative future use outside of their intended use.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Nonrefundable
advance payments for goods or services that will be used or rendered for future research and development activities are deferred
and amortized over the period that the goods are delivered, or the related services are performed, subject to an assessment of
recoverability. The Company makes estimates of costs incurred in relation to external CROs, and clinical site costs. The Company
analyzes the progress of clinical trials, including levels of patient enrollment, invoices received and contracted costs when
evaluating the adequacy of the amount expensed and the related prepaid asset and accrued liability. Significant judgments and
estimates must be made and used in determining the accrued balance and expense in any accounting period. The Company reviews and
accrues CRO expenses and clinical trial study expenses based on work performed and relies upon estimates of those costs applicable
to the stage of completion of a study. Accrued CRO costs are subject to revisions as such trials progress to completion. Revisions
are charged to expense in the period in which the facts that give rise to the revision become known. With respect to clinical
site costs, the financial terms of these agreements are subject to negotiation and vary from contract to contract. Payments under
these contracts may be uneven and depend on factors such as the achievement of certain events, the successful recruitment of patients,
the completion of portions of the clinical trial or similar conditions. The objective of our policy is to record expenses in our
financial statements based on the actual services received and efforts expended. As such, expense accruals related to clinical
site costs are recognized based on our estimate of the degree of completion of the event or events specified in the specific clinical
study or trial contract.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;In
addition, the Company incurs expenses in respect of intellectual property costs relating to patents and trademarks. The probability
of success and length of time to develop commercial applications of the compounds subject to the underlying patent and trademark costs
is difficult to determine and numerous risks and uncertainties exist with respect to the timely completion of the development
projects. There is no assurance the compounds subject to the underlying patents and trademarks will ever be successfully commercialized.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Due
to these risks and uncertainties, the patent and trademark costs do not meet the definition of an asset and thus are expensed
as incurred within general and administrative expenses.&lt;/span&gt;&lt;/p&gt;










&lt;p id="xdx_84E_eus-gaap--RevenueRecognitionIncentives_zuSeUQhdS7m6" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-indent: 40pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 42.55pt"/&gt;&lt;td style="width: 18pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;e)&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_861_zyUp2pHZqMX2" style="text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Research
                                         and Development Incentive Income&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i/&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company is eligible to obtain certain research and development tax credits, including the New York City Biotechnology Tax Credit
(&#x201c;NYC Biotech credit&#x201d;), and the Australian research and development tax incentive credit (the &#x201c;Australia R&amp;amp;D
credit&#x201d;) through a program administered through the Australian Tax Office (the &#x201c;ATO&#x201d;), which provides for a
cash refund based on a percentage of certain research and development activities undertaken in Australia by the Company&#x2019;s
wholly owned subsidiary, Anavex Australia Pty Ltd. (&#x201c;Anavex Australia&#x201d;). &lt;span id="xdx_90F_ecustom--CashRefundAvailableDescription_c20191001__20200930_zYDIUwSyjgIe" title="Cash Refund Available description"&gt;The cash refund is available to eligible
companies with an annual aggregate revenue of less than $20.0 million Australian during the reimbursable period.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
tax incentives are available on the basis of specific criteria with which the Company must comply. Although the tax incentive
may be administered through the local tax authority, the Company has accounted for the incentives outside of the scope of ASC
Topic 740, Income Taxes (&#x201c;ASC 740&#x201d;), since the incentives are not linked to the Company&#x2019;s taxable income and
can be realized regardless of whether the Company has generated taxable income in the respective jurisdictions.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;With
respect to the Australia R&amp;amp;D credit, Anavex Australia may be eligible to receive the cash refund for certain research and
development expenses incurred by Anavex Australia outside of Australia, to the extent such expenses are pre-approved by the Australian
authority pursuant to an advanced overseas finding application. The Company accrues for the amount of cash refund it expects to
receive in relation to research and development expenses outside of Australia only to the extent it has received advanced approval
from the Department of Industry, Innovation and Science in Australia, pursuant to an approved advanced overseas finding application.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company recognizes the amount of cash refund it expects to receive related to the NYC Biotech credit and Australian research and
development tax incentive program when there is reasonable assurance that the cash refund will be received, when the relevant
expenditures have been incurred, and when the amount can be reliably measured. This amount is included in Incentive and tax receivables
in the accompanying consolidated balance sheets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;In
addition, Anavex Australia and Anavex Canada incur Goods and Services Tax (GST) on certain services provided by local vendors.
As a domestic entity in those jurisdictions, Anavex Australia and Anavex Canada are entitled to a refund of the GST paid. Similarly,
Anavex Germany incurs Value Added Tax (VAT) on certain services provided by local vendors, to which it is entitled to a refund
of such VAT paid. The Company&#x2019;s estimate of the amount of cash refund it expects to receive related to GST and VAT incurred
is included in Incentive and tax receivables in the accompanying consolidated balance sheets.&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_847_eus-gaap--EarningsPerSharePolicyTextBlock_z9bhd4heuAOg" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 42.55pt"/&gt;&lt;td style="width: 18pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;f)&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_863_z5HZwLOz94rl" style="text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Basic
                                         and Diluted Loss per Share&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify; margin-left: 42.55pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Basic
income/(loss) per common share is computed by dividing net income/(loss) available to common stockholders by the weighted average
number of common shares outstanding during the period. Diluted income/(loss) per common share is computed by dividing net income/(loss)
available to common stockholders by the sum of (1) the weighted-average number of common shares outstanding during the period,
(2) the dilutive effect of the assumed exercise of options and warrants using the treasury stock method and (3) the dilutive effect
of other potentially dilutive securities. For purposes of the diluted net loss per share calculation, options and warrants are
potentially dilutive securities and are excluded from the calculation of diluted net loss per share because their effect would
be anti-dilutive.&lt;/span&gt;&lt;/p&gt;












&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;As
of September 30, 2020, diluted loss per share excludes &lt;span id="xdx_90A_eus-gaap--IncrementalCommonSharesAttributableToCallOptionsAndWarrants_c20191001__20200930_pii" title="Loss per share for potentially dilutive common shares"&gt;10,576,266&lt;/span&gt; (2019 &#x2013; &lt;span id="xdx_900_eus-gaap--IncrementalCommonSharesAttributableToCallOptionsAndWarrants_c20181001__20190930_pii" title="Loss per share for potentially dilutive common shares"&gt;8,812,933&lt;/span&gt;) potentially dilutive common shares
related to outstanding options and warrants, as their effect was anti-dilutive.&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_849_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zHovEUI4h1bd" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 42.55pt"/&gt;&lt;td style="width: 18pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;g)&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_86D_zNfEIBZhcqt3" style="text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Financial
                                         Instruments&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify; margin-left: 42.55pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
book value of the Company&#x2019;s financial instruments, consisting of cash and equivalents, incentive and tax receivables, and
accounts payable and accrued liabilities approximate their fair value due to the short-term maturity of such instruments. Unless
otherwise noted, it is management&#x2019;s opinion that the Company is not exposed to significant interest, currency or credit
risks arising from these financial instruments.&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_845_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zCbIp40N19gf" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 42.55pt"/&gt;&lt;td style="width: 18pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;h)&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_863_zVPPTBc3bS78" style="text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Foreign
                                         Currency Translation&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify; margin-left: 42.55pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
functional currency of the Company is the US dollar. Monetary items denominated in a foreign currency are translated into US dollars
at exchange rates prevailing at the balance sheet date and non-monetary items are translated at exchange rates prevailing when
the assets were acquired, or obligations incurred. Foreign currency denominated expense items are translated at exchange rates
prevailing on the transaction date. Unrealized gains or losses arising from the translations are credited or charged to income
in the period in which they occur.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify; margin-left: 42.55pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company has determined that the functional currency of Anavex Australia Pty Limited, Anavex Germany GmbH, and Anavex Canada Ltd.
is the US dollar.&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84C_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zTUojE9iNMp7" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 42.55pt"/&gt;&lt;td style="width: 18pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;i)&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_86C_znNVXLYjswP3"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Segment
                                         and Geographic Reporting&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify; margin-left: 42.55pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Operating
segments are defined as components of an enterprise for which separate discrete information is available for evaluation by the
chief operating decision maker or decision-making group, in deciding how to allocate resources and in assessing performance. The
Company views its operations and manages its business as one operating segment, which is the business of developing novel therapies
for the management of CNS diseases.&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_849_ecustom--GrantIncomePolicyTextBlock_zbwzoBiBjCk8" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 42.55pt"/&gt;&lt;td style="width: 18pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;j)&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_86C_zsAUiTgEYkNb" style="text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Grant
                                         Income&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Grant
income is recognized at the fair value of the grant when it is received, and all substantive conditions have been satisfied. Grants
received from government and other agencies in advance of the specific research and development costs to which they relate are
deferred and recognized in the consolidated statement of operations in the period they are earned and when the related research
and development costs are incurred.&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84A_eus-gaap--IncomeTaxPolicyTextBlock_zy1jE2n57rK2" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 42.55pt"/&gt;&lt;td style="width: 18pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;k)&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_869_zPTgLOqDBPqg" style="text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Income
                                         Taxes&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify; margin-left: 42.55pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company follows the provisions of ASC 740, which requires the asset and liability method of accounting for income taxes. Under
the asset and liability method, deferred tax assets and liabilities are recognized for the future tax consequences attributable
to temporary differences between the financial statements carrying amounts of existing assets and liabilities and their respective
tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the
years in which those temporary differences are expected to be recovered or settled.&lt;/span&gt;&lt;/p&gt;











&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify; margin-left: 42.55pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: justify; margin-right: 0; margin-left: 42.55pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company follows the provisions of ASC 740 regarding accounting for uncertainty in income taxes. The Company initially recognizes
tax positions in the financial statements when it is more likely than not the position will be sustained upon examination by the
tax authorities. Such tax positions are initially and subsequently measured as the largest amount of tax benefit that is greater
than 50% likely of being realized upon ultimate settlement with the tax authority assuming full knowledge of the position and
all relevant facts. Application requires numerous estimates based on available information. The Company considers many factors
when evaluating and estimating its tax positions and tax benefits, and its recognized tax positions and tax benefits may not accurately
anticipate actual outcomes. As additional information is obtained, there may be a need to periodically adjust the recognized tax
positions and tax benefits. These periodic adjustments may have a material impact on the consolidated statements of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify; margin-left: 42.55pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company recognizes interest and penalties related to current income tax expense on the interest income, net line, in the accompanying
consolidated statement of operations. Accrued interest and penalties, if any, are included in accrued liabilities on the consolidated
balance sheets.&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_844_eus-gaap--ShareBasedCompensationForfeituresPolicyTextBlock_z4JyiDfbV3kl" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 42.55pt"/&gt;&lt;td style="width: 18pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;l)&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_861_zrffvkOwY1mi" style="text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Stock-based
                                         Compensation&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify; margin-left: 42.55pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company accounts for all stock-based payments and awards under the fair value method.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify; margin-left: 42.55pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company accounts for the granting of share purchase options and warrants to employees using the fair value method whereby all
awards to employees will be recorded at fair value on the date of the grant. The fair value of all share purchase options and
warrants are expensed over their contractual vesting period, or over the expected performance period for only the portion of awards
expected to vest, in the case of milestone-based vesting, with a corresponding increase to additional paid-in capital.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: justify"/&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: justify; margin-right: 0; margin-left: 42.55pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Share
purchase options and warrants issued to non-employees are measured at the fair value of the equity instruments issued. Compensation
expense for share purchase options and warrants issued to non-employees is recorded over the service performance period. Prior
to the Company&#x2019;s adoption of ASU No. 2018-07, Compensation-Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based
Payment Accounting on October 1, 2019, options and warrants subject to vesting were periodically re-measured until the counterparty
performance was complete, and any change therein was recognized over the vesting period of the award and in the same manner as
if the Company had paid cash instead of paying with or using equity based instruments. After the adoption of ASU No. 2018-07,
the Company measures equity-classified share-based payment awards issued to nonemployees on the grant date, rather than remeasuring
the awards through the performance completion date as previously required (see Note 2 n)).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: justify; margin-right: 0; margin-left: 42.55pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Compensation
costs for stock-based payments with graded vesting are recognized on a straight-line basis.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: justify; margin-right: 0; margin-left: 42.55pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company uses the Black-Scholes option valuation model to calculate the fair value of share purchase options and warrants at the
date of the grant. Option pricing models require the input of highly subjective assumptions, including the expected price volatility.
Changes in these assumptions can materially affect the fair value estimates.&lt;/span&gt;&lt;/p&gt;





&lt;p id="xdx_84F_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zrtONMDFaYfk" style="font: 10pt Arial, Helvetica, Sans-Serif; text-indent: 40pt; text-align: left; margin-top: 0; margin-bottom: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"/&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 42.55pt"/&gt;&lt;td style="width: 18pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;m)&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_86A_zvoqyRoz7lO3" style="text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Fair
                                         Value Measurements&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Fair
value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in
the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at
the measurement date. Assets and liabilities that are measured at fair value are reported using a three-level fair value hierarchy
that prioritizes the inputs used to measure fair value. This hierarchy maximizes the use of observable inputs and minimizes the
use of unobservable inputs. The three levels of inputs used to measure fair value are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Level
1 - 	quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access
at the measurement date;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Level
2 - observable inputs other than Level 1, quoted prices for similar assets or liabilities in active 		markets, quoted prices
for identical or similar assets and liabilities in markets that are not active, and model-derived prices whose inputs are observable
or whose significant value drivers are observable; and&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 60.55pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Level
3 - 	assets and liabilities whose significant value drivers are unobservable by little or no market activity and that are significant
to the fair value of the assets or liabilities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;At
September 30, 2020 and 2019, the Company did not have any Level 3 assets or liabilities.&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_847_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_ztjvIPjOXAKb" style="font: 10pt Arial, Helvetica, Sans-Serif; text-indent: 40pt; text-align: left; margin-top: 0; margin-right: 0; margin-bottom: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 42.55pt"/&gt;&lt;td style="width: 18pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;n)&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_86D_zQI1JnzoS1gj" style="text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Recent
                                         Accounting Pronouncements&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;


&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Recently
Adopted Accounting Pronouncements&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;In
February 2016, Topic 842, Leases was issued to replace the leases requirements in Topic 840, Leases. The main difference
between previous U.S. GAAP and Topic 842 is the recognition of lease assets and lease liabilities by lessees for those leases
classified as operating leases under previous U.S. GAAP. A lessee should recognize in the balance sheet a liability to make
lease payments (the lease liability) and a right-of-use asset representing its right to use the underlying asset for the
lease term. For leases with a term of 12 months or less, a lessee is permitted to make an accounting policy election by class
of underlying asset not to recognize lease assets and lease liabilities. If a lessee makes this election, it should recognize
lease expense for such leases generally on a straight-line basis over the lease term. The accounting applied by a lessor is
largely unchanged from that applied under previous U.S. GAAP. The Company elected the package of practical expedients
permitted under the transition guidance that allowed, among other things, the historical lease classifications to be carried
forward without reassessment. Further, the Company elected to not recognize lease assets and lease liabilities for leases
with a term of 12 months or less. The adoption of this standard on October 1, 2019 did not have any impact on the Company's
consolidated results of operations, financial condition, cash flows, and financial statement disclosures.&lt;/span&gt;&lt;/p&gt;















&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;In
June 2018, the FASB issued ASU No. 2018-07, Compensation-Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based
Payment Accounting, which simplifies the accounting for share-based payments to nonemployees for goods and services by aligning
it with the accounting for share-based payments to employees, with certain exceptions. The new guidance was effective for the
Company beginning on October 1, 2019 and was required to be applied retrospectively with the cumulative effect recognized at the
date of initial application. The adoption of this standard on October 1, 2019 did not have any material impact on the Company's
consolidated results of operations, financial condition, cash flows, and financial statement disclosures.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Recent
Accounting Pronouncements Not Yet Adopted&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;In
December 2019, the FASB issued ASU 2019-12, "Simplifying the Accounting for Income Taxes (ASC 740)", which is intended
to simplify various aspects related to accounting for income taxes by removing certain exceptions to the general principles in
Topic 740 and clarifying and amending existing guidance to improve consistent application. ASU 2019-12 is effective for the Company
on October 1, 2021. Early adoption is permitted. The Company is currently evaluating the impact of this guidance on its consolidated
financial statements but does not expect such guidance to have a material impact.&lt;/span&gt;&lt;/p&gt;

</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:UseOfEstimates contextRef="From2019-10-01to2020-09-30">&lt;p id="xdx_84D_eus-gaap--UseOfEstimates_zqf4ghFK9O8l" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 42.55pt"/&gt;&lt;td style="width: 18pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;a)&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span id="xdx_869_zEAgumzB06sa" style="font: 10pt Times New Roman, Times, Serif"&gt;Use
                                         of Estimates&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify; margin-left: 42.55pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect
the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenue and
expenses in the reporting period. The Company regularly evaluates estimates and assumptions related to accounting for research
and development costs, incentive income receivable, valuation and recoverability of deferred tax assets, asset impairment, stock-based
compensation and loss contingencies. The Company bases its estimates and assumptions on current facts, historical experience and
various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making
judgments about the book values of assets and liabilities and the accrual of costs and expenses that are not readily apparent
from other sources. The actual results experienced by the Company may differ materially and adversely from the Company&#x2019;s
estimates. To the extent there are material differences between the estimates and the actual results, future results of operations
will be affected.&lt;/span&gt;&lt;/p&gt;

</us-gaap:UseOfEstimates>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="From2019-10-01to2020-09-30">&lt;p id="xdx_84E_eus-gaap--ConsolidationPolicyTextBlock_zhaxDESkVTBc" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;



&lt;table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 42.5pt"/&gt;&lt;td style="width: 18pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;b)&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_86C_zg9HiwiTiKfl" style="text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Principles
                                         of Consolidation&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify; margin-left: 42.55pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;These
consolidated financial statements include the accounts of Anavex Life Sciences Corp. and its wholly-owned subsidiaries, Anavex
Australia Pty Limited. (&#x201c;Anavex Australia&#x201d;), a company incorporated under the laws of Australia, Anavex Germany GmbH,
a company incorporated under the laws of Germany, and Anavex Canada Ltd., a company incorporated under the laws of the Province
of Ontario, Canada. All inter-company transactions and balances have been eliminated.&lt;/span&gt;&lt;/p&gt;

</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="From2019-10-01to2020-09-30">&lt;p id="xdx_84B_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zPqyXkDd3gml" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 42.55pt"/&gt;&lt;td style="width: 18pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;c)&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_861_zvIIr6UoDIAj" style="text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Cash
                                         and equivalents&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify; margin-left: 42.55pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company considers only those investments which are highly liquid, readily convertible to cash and that mature within three months
from the date of purchase to be cash equivalents.&lt;/span&gt;&lt;/p&gt;








</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="From2019-10-01to2020-09-30">&lt;p id="xdx_847_eus-gaap--ResearchAndDevelopmentExpensePolicy_zYhMikPyjcA6" style="font: 10pt Arial, Helvetica, Sans-Serif; text-indent: 40pt; text-align: left; margin-top: 0; margin-bottom: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"/&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 42.55pt"/&gt;&lt;td style="width: 18pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;d)&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_86F_zXm5kmXnzwQa" style="text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Research
                                         and Development Expenses&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i/&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Research
and development costs are expensed as incurred. These expenses are comprised of the costs of the Company&#x2019;s proprietary research
and development efforts, including preclinical studies, clinical trials, manufacturing costs, employee salaries and benefits and
stock based compensation expense, contract services including external research and development expenses incurred under arrangements
with third parties such as contract research organizations (&#x201c;CROs&#x201d;), facilities costs, overhead costs and other related
expenses. Milestone payments made by the Company to third parties are expensed when the specific milestone has been achieved.
Manufacturing costs are expensed as incurred in accordance with Accounting Standard Codification (&#x201c;ASC&#x201d;) 730, Research
and Development, as these materials have no alternative future use outside of their intended use.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Nonrefundable
advance payments for goods or services that will be used or rendered for future research and development activities are deferred
and amortized over the period that the goods are delivered, or the related services are performed, subject to an assessment of
recoverability. The Company makes estimates of costs incurred in relation to external CROs, and clinical site costs. The Company
analyzes the progress of clinical trials, including levels of patient enrollment, invoices received and contracted costs when
evaluating the adequacy of the amount expensed and the related prepaid asset and accrued liability. Significant judgments and
estimates must be made and used in determining the accrued balance and expense in any accounting period. The Company reviews and
accrues CRO expenses and clinical trial study expenses based on work performed and relies upon estimates of those costs applicable
to the stage of completion of a study. Accrued CRO costs are subject to revisions as such trials progress to completion. Revisions
are charged to expense in the period in which the facts that give rise to the revision become known. With respect to clinical
site costs, the financial terms of these agreements are subject to negotiation and vary from contract to contract. Payments under
these contracts may be uneven and depend on factors such as the achievement of certain events, the successful recruitment of patients,
the completion of portions of the clinical trial or similar conditions. The objective of our policy is to record expenses in our
financial statements based on the actual services received and efforts expended. As such, expense accruals related to clinical
site costs are recognized based on our estimate of the degree of completion of the event or events specified in the specific clinical
study or trial contract.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;In
addition, the Company incurs expenses in respect of intellectual property costs relating to patents and trademarks. The probability
of success and length of time to develop commercial applications of the compounds subject to the underlying patent and trademark costs
is difficult to determine and numerous risks and uncertainties exist with respect to the timely completion of the development
projects. There is no assurance the compounds subject to the underlying patents and trademarks will ever be successfully commercialized.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Due
to these risks and uncertainties, the patent and trademark costs do not meet the definition of an asset and thus are expensed
as incurred within general and administrative expenses.&lt;/span&gt;&lt;/p&gt;










</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:RevenueRecognitionIncentives contextRef="From2019-10-01to2020-09-30">&lt;p id="xdx_84E_eus-gaap--RevenueRecognitionIncentives_zuSeUQhdS7m6" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-indent: 40pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 42.55pt"/&gt;&lt;td style="width: 18pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;e)&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_861_zyUp2pHZqMX2" style="text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Research
                                         and Development Incentive Income&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i/&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company is eligible to obtain certain research and development tax credits, including the New York City Biotechnology Tax Credit
(&#x201c;NYC Biotech credit&#x201d;), and the Australian research and development tax incentive credit (the &#x201c;Australia R&amp;amp;D
credit&#x201d;) through a program administered through the Australian Tax Office (the &#x201c;ATO&#x201d;), which provides for a
cash refund based on a percentage of certain research and development activities undertaken in Australia by the Company&#x2019;s
wholly owned subsidiary, Anavex Australia Pty Ltd. (&#x201c;Anavex Australia&#x201d;). &lt;span id="xdx_90F_ecustom--CashRefundAvailableDescription_c20191001__20200930_zYDIUwSyjgIe" title="Cash Refund Available description"&gt;The cash refund is available to eligible
companies with an annual aggregate revenue of less than $20.0 million Australian during the reimbursable period.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
tax incentives are available on the basis of specific criteria with which the Company must comply. Although the tax incentive
may be administered through the local tax authority, the Company has accounted for the incentives outside of the scope of ASC
Topic 740, Income Taxes (&#x201c;ASC 740&#x201d;), since the incentives are not linked to the Company&#x2019;s taxable income and
can be realized regardless of whether the Company has generated taxable income in the respective jurisdictions.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;With
respect to the Australia R&amp;amp;D credit, Anavex Australia may be eligible to receive the cash refund for certain research and
development expenses incurred by Anavex Australia outside of Australia, to the extent such expenses are pre-approved by the Australian
authority pursuant to an advanced overseas finding application. The Company accrues for the amount of cash refund it expects to
receive in relation to research and development expenses outside of Australia only to the extent it has received advanced approval
from the Department of Industry, Innovation and Science in Australia, pursuant to an approved advanced overseas finding application.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company recognizes the amount of cash refund it expects to receive related to the NYC Biotech credit and Australian research and
development tax incentive program when there is reasonable assurance that the cash refund will be received, when the relevant
expenditures have been incurred, and when the amount can be reliably measured. This amount is included in Incentive and tax receivables
in the accompanying consolidated balance sheets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;In
addition, Anavex Australia and Anavex Canada incur Goods and Services Tax (GST) on certain services provided by local vendors.
As a domestic entity in those jurisdictions, Anavex Australia and Anavex Canada are entitled to a refund of the GST paid. Similarly,
Anavex Germany incurs Value Added Tax (VAT) on certain services provided by local vendors, to which it is entitled to a refund
of such VAT paid. The Company&#x2019;s estimate of the amount of cash refund it expects to receive related to GST and VAT incurred
is included in Incentive and tax receivables in the accompanying consolidated balance sheets.&lt;/span&gt;&lt;/p&gt;

</us-gaap:RevenueRecognitionIncentives>
    <avxl:CashRefundAvailableDescription contextRef="From2019-10-01to2020-09-30">The cash refund is available to eligible
companies with an annual aggregate revenue of less than $20.0 million Australian during the reimbursable period.</avxl:CashRefundAvailableDescription>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2019-10-01to2020-09-30">&lt;p id="xdx_847_eus-gaap--EarningsPerSharePolicyTextBlock_z9bhd4heuAOg" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 42.55pt"/&gt;&lt;td style="width: 18pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;f)&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_863_z5HZwLOz94rl" style="text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Basic
                                         and Diluted Loss per Share&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify; margin-left: 42.55pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Basic
income/(loss) per common share is computed by dividing net income/(loss) available to common stockholders by the weighted average
number of common shares outstanding during the period. Diluted income/(loss) per common share is computed by dividing net income/(loss)
available to common stockholders by the sum of (1) the weighted-average number of common shares outstanding during the period,
(2) the dilutive effect of the assumed exercise of options and warrants using the treasury stock method and (3) the dilutive effect
of other potentially dilutive securities. For purposes of the diluted net loss per share calculation, options and warrants are
potentially dilutive securities and are excluded from the calculation of diluted net loss per share because their effect would
be anti-dilutive.&lt;/span&gt;&lt;/p&gt;












&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;As
of September 30, 2020, diluted loss per share excludes &lt;span id="xdx_90A_eus-gaap--IncrementalCommonSharesAttributableToCallOptionsAndWarrants_c20191001__20200930_pii" title="Loss per share for potentially dilutive common shares"&gt;10,576,266&lt;/span&gt; (2019 &#x2013; &lt;span id="xdx_900_eus-gaap--IncrementalCommonSharesAttributableToCallOptionsAndWarrants_c20181001__20190930_pii" title="Loss per share for potentially dilutive common shares"&gt;8,812,933&lt;/span&gt;) potentially dilutive common shares
related to outstanding options and warrants, as their effect was anti-dilutive.&lt;/span&gt;&lt;/p&gt;

</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants
      contextRef="From2019-10-01to2020-09-30"
      decimals="INF"
      unitRef="Shares">10576266</us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants>
    <us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants
      contextRef="From2018-10-012019-09-30"
      decimals="INF"
      unitRef="Shares">8812933</us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="From2019-10-01to2020-09-30">&lt;p id="xdx_849_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zHovEUI4h1bd" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 42.55pt"/&gt;&lt;td style="width: 18pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;g)&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_86D_zNfEIBZhcqt3" style="text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Financial
                                         Instruments&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify; margin-left: 42.55pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
book value of the Company&#x2019;s financial instruments, consisting of cash and equivalents, incentive and tax receivables, and
accounts payable and accrued liabilities approximate their fair value due to the short-term maturity of such instruments. Unless
otherwise noted, it is management&#x2019;s opinion that the Company is not exposed to significant interest, currency or credit
risks arising from these financial instruments.&lt;/span&gt;&lt;/p&gt;

</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="From2019-10-01to2020-09-30">&lt;p id="xdx_845_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zCbIp40N19gf" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 42.55pt"/&gt;&lt;td style="width: 18pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;h)&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_863_zVPPTBc3bS78" style="text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Foreign
                                         Currency Translation&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify; margin-left: 42.55pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
functional currency of the Company is the US dollar. Monetary items denominated in a foreign currency are translated into US dollars
at exchange rates prevailing at the balance sheet date and non-monetary items are translated at exchange rates prevailing when
the assets were acquired, or obligations incurred. Foreign currency denominated expense items are translated at exchange rates
prevailing on the transaction date. Unrealized gains or losses arising from the translations are credited or charged to income
in the period in which they occur.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify; margin-left: 42.55pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company has determined that the functional currency of Anavex Australia Pty Limited, Anavex Germany GmbH, and Anavex Canada Ltd.
is the US dollar.&lt;/span&gt;&lt;/p&gt;

</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="From2019-10-01to2020-09-30">&lt;p id="xdx_84C_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zTUojE9iNMp7" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 42.55pt"/&gt;&lt;td style="width: 18pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;i)&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_86C_znNVXLYjswP3"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Segment
                                         and Geographic Reporting&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify; margin-left: 42.55pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Operating
segments are defined as components of an enterprise for which separate discrete information is available for evaluation by the
chief operating decision maker or decision-making group, in deciding how to allocate resources and in assessing performance. The
Company views its operations and manages its business as one operating segment, which is the business of developing novel therapies
for the management of CNS diseases.&lt;/span&gt;&lt;/p&gt;

</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <avxl:GrantIncomePolicyTextBlock contextRef="From2019-10-01to2020-09-30">&lt;p id="xdx_849_ecustom--GrantIncomePolicyTextBlock_zbwzoBiBjCk8" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 42.55pt"/&gt;&lt;td style="width: 18pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;j)&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_86C_zsAUiTgEYkNb" style="text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Grant
                                         Income&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Grant
income is recognized at the fair value of the grant when it is received, and all substantive conditions have been satisfied. Grants
received from government and other agencies in advance of the specific research and development costs to which they relate are
deferred and recognized in the consolidated statement of operations in the period they are earned and when the related research
and development costs are incurred.&lt;/span&gt;&lt;/p&gt;

</avxl:GrantIncomePolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="From2019-10-01to2020-09-30">&lt;p id="xdx_84A_eus-gaap--IncomeTaxPolicyTextBlock_zy1jE2n57rK2" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 42.55pt"/&gt;&lt;td style="width: 18pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;k)&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_869_zPTgLOqDBPqg" style="text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Income
                                         Taxes&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify; margin-left: 42.55pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company follows the provisions of ASC 740, which requires the asset and liability method of accounting for income taxes. Under
the asset and liability method, deferred tax assets and liabilities are recognized for the future tax consequences attributable
to temporary differences between the financial statements carrying amounts of existing assets and liabilities and their respective
tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the
years in which those temporary differences are expected to be recovered or settled.&lt;/span&gt;&lt;/p&gt;











&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify; margin-left: 42.55pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: justify; margin-right: 0; margin-left: 42.55pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company follows the provisions of ASC 740 regarding accounting for uncertainty in income taxes. The Company initially recognizes
tax positions in the financial statements when it is more likely than not the position will be sustained upon examination by the
tax authorities. Such tax positions are initially and subsequently measured as the largest amount of tax benefit that is greater
than 50% likely of being realized upon ultimate settlement with the tax authority assuming full knowledge of the position and
all relevant facts. Application requires numerous estimates based on available information. The Company considers many factors
when evaluating and estimating its tax positions and tax benefits, and its recognized tax positions and tax benefits may not accurately
anticipate actual outcomes. As additional information is obtained, there may be a need to periodically adjust the recognized tax
positions and tax benefits. These periodic adjustments may have a material impact on the consolidated statements of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify; margin-left: 42.55pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company recognizes interest and penalties related to current income tax expense on the interest income, net line, in the accompanying
consolidated statement of operations. Accrued interest and penalties, if any, are included in accrued liabilities on the consolidated
balance sheets.&lt;/span&gt;&lt;/p&gt;

</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ShareBasedCompensationForfeituresPolicyTextBlock contextRef="From2019-10-01to2020-09-30">&lt;p id="xdx_844_eus-gaap--ShareBasedCompensationForfeituresPolicyTextBlock_z4JyiDfbV3kl" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 42.55pt"/&gt;&lt;td style="width: 18pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;l)&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_861_zrffvkOwY1mi" style="text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Stock-based
                                         Compensation&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify; margin-left: 42.55pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company accounts for all stock-based payments and awards under the fair value method.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify; margin-left: 42.55pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company accounts for the granting of share purchase options and warrants to employees using the fair value method whereby all
awards to employees will be recorded at fair value on the date of the grant. The fair value of all share purchase options and
warrants are expensed over their contractual vesting period, or over the expected performance period for only the portion of awards
expected to vest, in the case of milestone-based vesting, with a corresponding increase to additional paid-in capital.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: justify"/&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: justify; margin-right: 0; margin-left: 42.55pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Share
purchase options and warrants issued to non-employees are measured at the fair value of the equity instruments issued. Compensation
expense for share purchase options and warrants issued to non-employees is recorded over the service performance period. Prior
to the Company&#x2019;s adoption of ASU No. 2018-07, Compensation-Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based
Payment Accounting on October 1, 2019, options and warrants subject to vesting were periodically re-measured until the counterparty
performance was complete, and any change therein was recognized over the vesting period of the award and in the same manner as
if the Company had paid cash instead of paying with or using equity based instruments. After the adoption of ASU No. 2018-07,
the Company measures equity-classified share-based payment awards issued to nonemployees on the grant date, rather than remeasuring
the awards through the performance completion date as previously required (see Note 2 n)).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: justify; margin-right: 0; margin-left: 42.55pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Compensation
costs for stock-based payments with graded vesting are recognized on a straight-line basis.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: justify; margin-right: 0; margin-left: 42.55pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company uses the Black-Scholes option valuation model to calculate the fair value of share purchase options and warrants at the
date of the grant. Option pricing models require the input of highly subjective assumptions, including the expected price volatility.
Changes in these assumptions can materially affect the fair value estimates.&lt;/span&gt;&lt;/p&gt;





</us-gaap:ShareBasedCompensationForfeituresPolicyTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="From2019-10-01to2020-09-30">&lt;p id="xdx_84F_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zrtONMDFaYfk" style="font: 10pt Arial, Helvetica, Sans-Serif; text-indent: 40pt; text-align: left; margin-top: 0; margin-bottom: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"/&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 42.55pt"/&gt;&lt;td style="width: 18pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;m)&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_86A_zvoqyRoz7lO3" style="text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Fair
                                         Value Measurements&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Fair
value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in
the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at
the measurement date. Assets and liabilities that are measured at fair value are reported using a three-level fair value hierarchy
that prioritizes the inputs used to measure fair value. This hierarchy maximizes the use of observable inputs and minimizes the
use of unobservable inputs. The three levels of inputs used to measure fair value are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Level
1 - 	quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access
at the measurement date;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Level
2 - observable inputs other than Level 1, quoted prices for similar assets or liabilities in active 		markets, quoted prices
for identical or similar assets and liabilities in markets that are not active, and model-derived prices whose inputs are observable
or whose significant value drivers are observable; and&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 60.55pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Level
3 - 	assets and liabilities whose significant value drivers are unobservable by little or no market activity and that are significant
to the fair value of the assets or liabilities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;At
September 30, 2020 and 2019, the Company did not have any Level 3 assets or liabilities.&lt;/span&gt;&lt;/p&gt;

</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2019-10-01to2020-09-30">&lt;p id="xdx_847_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_ztjvIPjOXAKb" style="font: 10pt Arial, Helvetica, Sans-Serif; text-indent: 40pt; text-align: left; margin-top: 0; margin-right: 0; margin-bottom: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 42.55pt"/&gt;&lt;td style="width: 18pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;n)&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_86D_zQI1JnzoS1gj" style="text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Recent
                                         Accounting Pronouncements&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;


&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Recently
Adopted Accounting Pronouncements&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;In
February 2016, Topic 842, Leases was issued to replace the leases requirements in Topic 840, Leases. The main difference
between previous U.S. GAAP and Topic 842 is the recognition of lease assets and lease liabilities by lessees for those leases
classified as operating leases under previous U.S. GAAP. A lessee should recognize in the balance sheet a liability to make
lease payments (the lease liability) and a right-of-use asset representing its right to use the underlying asset for the
lease term. For leases with a term of 12 months or less, a lessee is permitted to make an accounting policy election by class
of underlying asset not to recognize lease assets and lease liabilities. If a lessee makes this election, it should recognize
lease expense for such leases generally on a straight-line basis over the lease term. The accounting applied by a lessor is
largely unchanged from that applied under previous U.S. GAAP. The Company elected the package of practical expedients
permitted under the transition guidance that allowed, among other things, the historical lease classifications to be carried
forward without reassessment. Further, the Company elected to not recognize lease assets and lease liabilities for leases
with a term of 12 months or less. The adoption of this standard on October 1, 2019 did not have any impact on the Company's
consolidated results of operations, financial condition, cash flows, and financial statement disclosures.&lt;/span&gt;&lt;/p&gt;















&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;In
June 2018, the FASB issued ASU No. 2018-07, Compensation-Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based
Payment Accounting, which simplifies the accounting for share-based payments to nonemployees for goods and services by aligning
it with the accounting for share-based payments to employees, with certain exceptions. The new guidance was effective for the
Company beginning on October 1, 2019 and was required to be applied retrospectively with the cumulative effect recognized at the
date of initial application. The adoption of this standard on October 1, 2019 did not have any material impact on the Company's
consolidated results of operations, financial condition, cash flows, and financial statement disclosures.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Recent
Accounting Pronouncements Not Yet Adopted&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;In
December 2019, the FASB issued ASU 2019-12, "Simplifying the Accounting for Income Taxes (ASC 740)", which is intended
to simplify various aspects related to accounting for income taxes by removing certain exceptions to the general principles in
Topic 740 and clarifying and amending existing guidance to improve consistent application. ASU 2019-12 is effective for the Company
on October 1, 2021. Early adoption is permitted. The Company is currently evaluating the impact of this guidance on its consolidated
financial statements but does not expect such guidance to have a material impact.&lt;/span&gt;&lt;/p&gt;

</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <avxl:OtherIncomeDisclosureTextBlock contextRef="From2019-10-01to2020-09-30">&lt;p id="xdx_80C_ecustom--OtherIncomeDisclosureTextBlock_zz32Y6XIRnG8" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
&lt;tr style="vertical-align: top; text-align: left"&gt;&lt;td style="width: 7%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Note
                                         3&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 93%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_821_zKYw3RGdgpj5"&gt;Other Income&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Grant
income&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;During
the year ended September 30, 2017, the Company was awarded grant funding in the amount of $&lt;span id="xdx_90C_ecustom--FundingOfDeferredIncomeAwardedGrant_c20161001__20170930__srt--ProductOrServiceAxis__custom--ClinicalStudyGrantMember_pp0p0" title="Awarded grant funding amount"&gt;597,886&lt;/span&gt;. The grant was received in
equal quarterly installments over a period of two years ending during the year ended September 30, 2020, in exchange for a commitment
to complete clinical testing for a therapeutic drug candidate for the treatment of Rett syndrome.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
grant income was deferred when received and amortized to other income as the related research and development expenditures were
incurred. During the year ended September 30, 2020, the Company recognized $&lt;span id="xdx_902_ecustom--NonOperatingIncomeFromGrant_c20191001__20200930_pp0p0" title="Grant income"&gt;&lt;span id="xdx_901_ecustom--NonOperatingIncomeFromGrant_pp0p0_c20191001__20200930_zv7vl8S7LZyb" title="Grant income"&gt;149,888&lt;/span&gt;&lt;/span&gt; (2019: $&lt;span id="xdx_902_ecustom--NonOperatingIncomeFromGrant_pp0p0_c20181001__20190930_zbzFY1ZJTIl5" title="Grant income"&gt;298,943&lt;/span&gt;) of this grant on its statement
of operations as a component of other income. At September 30, 2020, the Company had recognized the full amount of grant funding.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;










&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"/&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Research
and development incentive income&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Research
and development incentive income during the years ended September 30, 2020 and 2019 represents the receipt by Anavex Australia,
of the Australia R&amp;amp;D Credit, as well as receipt by the Company of the New York City Biotechnology Credit (&#x201c;NYC Biotech
credit&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;During
the year ended September 30, 2020, the Company recorded research and development incentive income of $&lt;span id="xdx_908_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pp0p0_c20191001__20200930_zKLsquhZRyJ" title="Research and development incentive income"&gt;4,375,025&lt;/span&gt; (AUD &lt;span id="xdx_900_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pp0p0_uUSD_c20191001__20200930__srt--CurrencyAxis__currency--AUD_zIbRUdKipgo6" title="Research and development incentive income"&gt;6,392,266&lt;/span&gt;)
(2019: $&lt;span id="xdx_905_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pp0p0_c20181001__20190930_zrSpdSG54Xoh" title="Research and development incentive income"&gt;2,215,691&lt;/span&gt; (AUD &lt;span id="xdx_900_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pp0p0_uUSD_c20181001__20190930__srt--CurrencyAxis__currency--AUD_zjdwEUNoiJr8" title="Research and development incentive income"&gt;3,281,300&lt;/span&gt;)) in respect of the Australia R&amp;amp;D Credit for eligible research and development expenses incurred
during the year, or expenditures to which the Company became eligible during the year.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;During
the year ended September 30, 2019, the Company recorded research and development incentive income of $&lt;span id="xdx_904_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pp0p0_c20181001__20190930__srt--ProductOrServiceAxis__custom--NYCBiotechCreditMember_zo7NuVdY2sah" title="Research and development incentive income"&gt;250,000&lt;/span&gt; in respect of the
NYC Biotech Credit. The Company was no longer eligible for the NYC Biotech Credit for the fiscal year ended September 30, 2020.&lt;/span&gt;&lt;/p&gt;

</avxl:OtherIncomeDisclosureTextBlock>
    <avxl:FundingOfDeferredIncomeAwardedGrant
      contextRef="From2016-10-012017-09-30_custom_ClinicalStudyGrantMember"
      decimals="0"
      unitRef="USD">597886</avxl:FundingOfDeferredIncomeAwardedGrant>
    <avxl:NonOperatingIncomeFromGrant
      contextRef="From2019-10-01to2020-09-30"
      decimals="0"
      unitRef="USD">149888</avxl:NonOperatingIncomeFromGrant>
    <avxl:NonOperatingIncomeFromGrant
      contextRef="From2019-10-01to2020-09-30"
      decimals="0"
      unitRef="USD">149888</avxl:NonOperatingIncomeFromGrant>
    <avxl:NonOperatingIncomeFromGrant
      contextRef="From2018-10-012019-09-30"
      decimals="0"
      unitRef="USD">298943</avxl:NonOperatingIncomeFromGrant>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="From2019-10-01to2020-09-30"
      decimals="0"
      unitRef="USD">4375025</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="From2019-10-012020-09-30_currency_AUD"
      decimals="0"
      unitRef="USD">6392266</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="From2018-10-012019-09-30"
      decimals="0"
      unitRef="USD">2215691</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="From2018-10-012019-09-30_currency_AUD"
      decimals="0"
      unitRef="USD">3281300</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="From2018-10-012019-09-30_custom_NYCBiotechCreditMember"
      decimals="0"
      unitRef="USD">250000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <avxl:EquityOfferingAgreementsTextBlock contextRef="From2019-10-01to2020-09-30">&lt;p id="xdx_809_ecustom--EquityOfferingAgreementsTextBlock_ziXhn4RIZmh8" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
&lt;tr style="vertical-align: top; text-align: left"&gt;&lt;td style="width: 7%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Note
                                         4&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 93%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_820_zwBBPE1lB1T7"&gt;Equity Offering Agreements&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2015
Purchase Agreement&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;On
October 21, 2015, the Company entered into a $50,000,000 purchase agreement (the &#x201c;2015 Purchase Agreement&#x201d;) with Lincoln
Park Capital Fund, LLC (&#x201c;Lincoln Park&#x201d;), pursuant to which the Company could sell and issue to Lincoln Park, and Lincoln
Park was obligated to purchase, up to $50,000,000 in value of its shares of common stock from time to time over a 36-month period.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;During
the year ended September 30, 2019, the Company issued to Lincoln Park an aggregate of &lt;span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pii_c20181001__20190930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zBSOc3VRAqDg"&gt;4,872,696&lt;/span&gt; shares of common stock under the
2015 Purchase Agreement, including &lt;span id="xdx_900_ecustom--StockIssuedDuringPeriodSharesNewIssues4_pii_c20181001__20190930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zbGbfUNv9rEa"&gt;4,848,995&lt;/span&gt; shares of common stock for an aggregate purchase price of $&lt;span id="xdx_905_ecustom--StockIssuedDuringPeriodValueNewIssues3_pp0p0_c20181001__20190930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zakyZTGUPy7e"&gt;13,197,604&lt;/span&gt; and &lt;span id="xdx_906_ecustom--StockIssuedDuringPeriodSharesNewIssues3_pii_c20181001__20190930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_z3OHjx3k46g7"&gt;23,701&lt;/span&gt;
as commitment shares. At September 30, 2019, all remaining purchase amounts available for issuance under the 2015 Purchase Agreement
had been utilized and the 2015 Purchase Agreement has expired pursuant to its terms. As such, no further shares will be sold under
the 2015 Purchase Agreement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;












&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2019
Purchase Agreement&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;On
June 7, 2019, the Company entered into a $&lt;span id="xdx_90D_ecustom--ValueOfSharesObligatedToPurchase_c20190606__20190607__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pp0p0" title="Total number of shares obligated to purchase"&gt;50,000,000&lt;/span&gt; purchase agreement (the &#x201c;2019 Purchase Agreement&#x201d;) with Lincoln
Park, as amended on July 1, 2020 (the &#x201c;Amendment Date&#x201d;), pursuant to which the Company may sell and issue to Lincoln
Park, and Lincoln Park is obligated to purchase, up to $50,000,000 in value of its shares of common stock from time to time from
June 12, 2019, the date a prospectus supplement under which shares of common stock issuable under the 2019 Purchase Agreement
was filed with the SEC, until July 1, 2022, which is the first day of the next month following the &lt;span id="xdx_90A_ecustom--AgreementTerm_dtM_c20190606__20190607__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zswYi1t0JfHa" title="Agreement term"&gt;36&lt;/span&gt;-month anniversary of June
12, 2019.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_904_eus-gaap--UnrecordedUnconditionalPurchaseObligationDescription_c20190606__20190607__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember" title="Description of purchases price"&gt;The
Company may direct Lincoln Park, at its sole discretion, and subject to certain conditions, to purchase up to 200,000 shares of
common stock on any business day (a &#x201c;Regular Purchase&#x201d;). The amount of a Regular Purchase may be increased under certain
circumstances up to 250,000 shares, provided that Lincoln Park&#x2019;s committed obligation for Regular Purchases on any business
day shall not exceed $2,000,000. In the event the Company purchases the full amount allowed for a Regular Purchase on any given
business day, the Company may also direct Lincoln Park to purchase additional amounts as accelerated and additional accelerated
purchases. The purchase price of shares of common stock related to the future funding will be based on the then prevailing market
prices of such shares at the time of sales as described in the 2019 Purchase Agreement.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company&#x2019;s sale of shares of Common Stock to Lincoln Park subsequent to the Amendment Date is limited to &lt;span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pii_c20191001__20200930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zPOm8p4VLhr9"&gt;12,016,457&lt;/span&gt; shares
of Common Stock, representing &lt;span id="xdx_909_ecustom--PercentageOfGrossProceedsFromSales_pii_dp_c20191001__20200930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zRBtmNmXF893"&gt;19.99%&lt;/span&gt; of the shares of the Common Stock outstanding on the Amendment Date unless (i) shareholder
approval is obtained to issue more than such amount or (ii) the average price of all applicable sales of Common Stock to Lincoln
Park under the 2019 Purchase Agreement after the Amendment Date equals or exceeds the lower of (A) the closing price of the Common
Stock on the Nasdaq Capital Market immediately preceding the Amendment Date or (B) the average of the closing prices of the Common
Stock on the Nasdaq Capital Market for the five Business Days immediately preceding the Amendment Date, and it also limits the
Company&#x2019;s sale of shares to Lincoln Park to the extent it would cause Lincoln Park to beneficially own more than 4.99% of
the Company&#x2019;s outstanding shares of Common Stock at any given time.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 12pt 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;In
consideration for entering into the 2019 Purchase Agreement, the Company issued to Lincoln Park &lt;span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20190606__20190607__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pii" title="Number of share issued"&gt;324,383&lt;/span&gt; shares of common stock
as a commitment fee and agreed to issue up to &lt;span id="xdx_90D_ecustom--NumberOfSharesObligatedToPurchaseProrataBasic_c20190606__20190607__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pii" title="Pro rata basic number of shares obligated to purchase"&gt;162,191&lt;/span&gt; shares pro rata, when and if, Lincoln Park purchases at the Company&#x2019;s
discretion the $50,000,000 aggregate commitment.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 12pt 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"/&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;During
the year ended September 30, 2020, the Company issued to Lincoln Park an aggregate of &lt;span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pii_c20191001__20200930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zvwjbRADkBf8"&gt;7,633,527&lt;/span&gt; (2019 -&lt;span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pii_c20181001__20190930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zPc8aJO5yWMc"&gt;1,839,415&lt;/span&gt;) shares of common
stock under the 2019 Purchase Agreement, including &lt;span id="xdx_903_ecustom--StockIssuedDuringPeriodSharesNewIssues4_pii_c20191001__20200930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zLfnMaZbIml3"&gt;7,564,584&lt;/span&gt; (2019: &lt;span id="xdx_90B_ecustom--StockIssuedDuringPeriodSharesNewIssues4_pii_c20181001__20190930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zawTt1F3bA38"&gt;1,500,000&lt;/span&gt;) shares of common stock for an aggregate purchase
price of $&lt;span id="xdx_90D_ecustom--StockIssuedDuringPeriodValueNewIssues3_pp0p0_c20191001__20200930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zfCGnkrPJQT9"&gt;21,254,298&lt;/span&gt; (2019: $&lt;span id="xdx_90F_ecustom--StockIssuedDuringPeriodValueNewIssues3_pp0p0_c20181001__20190930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zCy4fdXcsxGj"&gt;4,634,505&lt;/span&gt;) and &lt;span id="xdx_90E_ecustom--StockIssuedDuringPeriodSharesNewIssues3_pii_c20191001__20200930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zopjK80y29bf"&gt;68,943&lt;/span&gt; (2019: &lt;span id="xdx_904_ecustom--StockIssuedDuringPeriodSharesNewIssues3_pii_c20181001__20190930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zq4SbVkWgwld"&gt;339,415&lt;/span&gt;) commitment shares. At September 30, 2020, an amount of $&lt;span id="xdx_901_ecustom--StockIssuedDuringPeriodValueNewIssues4_pp0p0_c20191001__20200930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zVupzoNiHA3c"&gt;24,111,197&lt;/span&gt;
(2019: $&lt;span id="xdx_906_ecustom--StockIssuedDuringPeriodValueNewIssues4_pp0p0_c20181001__20190930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zwZUOHdnEb8h"&gt;45,365,495&lt;/span&gt;) remained available under the 2019 Purchase Agreement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;










&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Sales
Agreement&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company entered into a Controlled Equity Offering Sales Agreement on July 6, 2018, which was amended and restated on May 1, 2020
(the &#x201c;Sales Agreement&#x201d;) with Cantor Fitzgerald&#160;&amp;amp; Co. and SVB Leerink LLC (together the &#x201c;Sales Agents&#x201d;),
pursuant to which the Company may offer and sell shares of common stock, for aggregate gross sale proceeds of up to $&lt;span id="xdx_906_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20200429__20200501__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_pp0p0" title="Gross sale proceeds"&gt;50,000,000&lt;/span&gt;
from time to time through the Sales Agents (the &#x201c;Offering&#x201d;).&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Upon
delivery of a placement notice based on the Company&#x2019;s instructions and subject to the terms and conditions of the Sales
Agreement, the Sales Agents may sell the Shares by methods deemed to be an &#x201c;at the market offering&#x201d; offering, in negotiated
transactions at market prices prevailing at the time of sale or at prices related to such prevailing market prices, or by any
other method permitted by law, including negotiated transactions, subject to the prior written consent of the Company. The Company
is not obligated to make any sales of Shares under the Sales Agreement. The Company or Sales Agents may suspend or terminate the
offering of Shares upon notice to the other party, subject to certain conditions.&#160; The Sales Agents will act as agent on
a commercially reasonable efforts basis consistent with their normal trading and sales practices and applicable state and federal
law, rules&#160;and regulations and the rules&#160;of Nasdaq.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company has agreed to pay the Sales Agents commissions for their services of up to &lt;span id="xdx_900_ecustom--PercentageOfGrossProceedsFromSales_c20191001__20200930__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_pii" title="Percentage of gross proceeds from sales"&gt;3.0%&lt;/span&gt; of the gross proceeds from the sale of
the Shares pursuant to the Sales Agreement.&#160; The Company also agreed to provide the Sales Agents with customary indemnification
and contribution rights. During the year ended September 30, 2020, &lt;span id="xdx_90A_ecustom--NumberOfStockSold_c20191001__20200930__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_zv0uaeXjvJ81" title="Number of stock sold"&gt;1,760,429&lt;/span&gt; shares were sold pursuant to the Offering for gross
proceeds of $&lt;span id="xdx_902_ecustom--GrossProceedsFromSaleOfCommonStock_c20191001__20200930__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_zAjwJC284hj2" title="Gross proceeds from sale of common stock"&gt;7,499,900&lt;/span&gt; (net proceeds of $&lt;span id="xdx_902_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20191001__20200930__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_zCdrqBUHX8K3" title="Proceeds from sale of common stock"&gt;7,096,136&lt;/span&gt; after deducting offering expenses). At September 30, 2020, an amount of $&lt;span id="xdx_90D_ecustom--NumberOfSharesAvailable_iI_c20200930__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_zAAUcfZJULHi" title="Number of shares available"&gt;42,500,100&lt;/span&gt;
remained available under the Sales Agreement.&lt;/span&gt;&lt;/p&gt;

</avxl:EquityOfferingAgreementsTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2018-10-012019-09-30_custom_PurchaseAgreementMember_custom_LincolnParkCapitalFundLLCMember"
      decimals="INF"
      unitRef="Shares">4872696</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <avxl:StockIssuedDuringPeriodSharesNewIssues4
      contextRef="From2018-10-012019-09-30_custom_PurchaseAgreementMember_custom_LincolnParkCapitalFundLLCMember"
      decimals="INF"
      unitRef="Shares">4848995</avxl:StockIssuedDuringPeriodSharesNewIssues4>
    <avxl:StockIssuedDuringPeriodValueNewIssues3
      contextRef="From2018-10-012019-09-30_custom_PurchaseAgreementMember_custom_LincolnParkCapitalFundLLCMember"
      decimals="0"
      unitRef="USD">13197604</avxl:StockIssuedDuringPeriodValueNewIssues3>
    <avxl:StockIssuedDuringPeriodSharesNewIssues3
      contextRef="From2018-10-012019-09-30_custom_PurchaseAgreementMember_custom_LincolnParkCapitalFundLLCMember"
      decimals="INF"
      unitRef="Shares">23701</avxl:StockIssuedDuringPeriodSharesNewIssues3>
    <avxl:ValueOfSharesObligatedToPurchase
      contextRef="From2019-06-062019-06-07_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember"
      decimals="0"
      unitRef="USD">50000000</avxl:ValueOfSharesObligatedToPurchase>
    <avxl:AgreementTerm contextRef="From2019-06-062019-06-07_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember">P36M</avxl:AgreementTerm>
    <us-gaap:UnrecordedUnconditionalPurchaseObligationDescription contextRef="From2019-06-062019-06-07_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember">The
Company may direct Lincoln Park, at its sole discretion, and subject to certain conditions, to purchase up to 200,000 shares of
common stock on any business day (a &#x201c;Regular Purchase&#x201d;). The amount of a Regular Purchase may be increased under certain
circumstances up to 250,000 shares, provided that Lincoln Park&#x2019;s committed obligation for Regular Purchases on any business
day shall not exceed $2,000,000. In the event the Company purchases the full amount allowed for a Regular Purchase on any given
business day, the Company may also direct Lincoln Park to purchase additional amounts as accelerated and additional accelerated
purchases. The purchase price of shares of common stock related to the future funding will be based on the then prevailing market
prices of such shares at the time of sales as described in the 2019 Purchase Agreement.</us-gaap:UnrecordedUnconditionalPurchaseObligationDescription>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2019-10-012020-09-30_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">12016457</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <avxl:PercentageOfGrossProceedsFromSales
      contextRef="From2019-10-012020-09-30_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Pure">0.1999</avxl:PercentageOfGrossProceedsFromSales>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2019-06-062019-06-07_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember"
      decimals="INF"
      unitRef="Shares">324383</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <avxl:NumberOfSharesObligatedToPurchaseProrataBasic
      contextRef="From2019-06-062019-06-07_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember"
      decimals="INF"
      unitRef="Shares">162191</avxl:NumberOfSharesObligatedToPurchaseProrataBasic>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2019-10-012020-09-30_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember"
      decimals="INF"
      unitRef="Shares">7633527</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2018-10-012019-09-30_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember"
      decimals="INF"
      unitRef="Shares">1839415</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <avxl:StockIssuedDuringPeriodSharesNewIssues4
      contextRef="From2019-10-012020-09-30_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember"
      decimals="INF"
      unitRef="Shares">7564584</avxl:StockIssuedDuringPeriodSharesNewIssues4>
    <avxl:StockIssuedDuringPeriodSharesNewIssues4
      contextRef="From2018-10-012019-09-30_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember"
      decimals="INF"
      unitRef="Shares">1500000</avxl:StockIssuedDuringPeriodSharesNewIssues4>
    <avxl:StockIssuedDuringPeriodValueNewIssues3
      contextRef="From2019-10-012020-09-30_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember"
      decimals="0"
      unitRef="USD">21254298</avxl:StockIssuedDuringPeriodValueNewIssues3>
    <avxl:StockIssuedDuringPeriodValueNewIssues3
      contextRef="From2018-10-012019-09-30_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember"
      decimals="0"
      unitRef="USD">4634505</avxl:StockIssuedDuringPeriodValueNewIssues3>
    <avxl:StockIssuedDuringPeriodSharesNewIssues3
      contextRef="From2019-10-012020-09-30_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember"
      decimals="INF"
      unitRef="Shares">68943</avxl:StockIssuedDuringPeriodSharesNewIssues3>
    <avxl:StockIssuedDuringPeriodSharesNewIssues3
      contextRef="From2018-10-012019-09-30_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember"
      decimals="INF"
      unitRef="Shares">339415</avxl:StockIssuedDuringPeriodSharesNewIssues3>
    <avxl:StockIssuedDuringPeriodValueNewIssues4
      contextRef="From2019-10-012020-09-30_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember"
      decimals="0"
      unitRef="USD">24111197</avxl:StockIssuedDuringPeriodValueNewIssues4>
    <avxl:StockIssuedDuringPeriodValueNewIssues4
      contextRef="From2018-10-012019-09-30_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember"
      decimals="0"
      unitRef="USD">45365495</avxl:StockIssuedDuringPeriodValueNewIssues4>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2020-04-292020-05-01_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember"
      decimals="0"
      unitRef="USD">50000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <avxl:PercentageOfGrossProceedsFromSales
      contextRef="From2019-10-012020-09-30_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember"
      decimals="INF"
      unitRef="Pure">0.030</avxl:PercentageOfGrossProceedsFromSales>
    <avxl:NumberOfStockSold
      contextRef="From2019-10-012020-09-30_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember"
      decimals="INF"
      unitRef="Shares">1760429</avxl:NumberOfStockSold>
    <avxl:GrossProceedsFromSaleOfCommonStock
      contextRef="From2019-10-012020-09-30_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember"
      decimals="0"
      unitRef="USD">7499900</avxl:GrossProceedsFromSaleOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2019-10-012020-09-30_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember"
      decimals="0"
      unitRef="USD">7096136</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <avxl:NumberOfSharesAvailable
      contextRef="AsOf2020-09-30_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember"
      decimals="INF"
      unitRef="Shares">42500100</avxl:NumberOfSharesAvailable>
    <us-gaap:CommitmentsDisclosureTextBlock contextRef="From2019-10-01to2020-09-30">&lt;p id="xdx_80D_eus-gaap--CommitmentsDisclosureTextBlock_zhdF2fjEldOk" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
&lt;tr style="vertical-align: top; text-align: left"&gt;&lt;td style="width: 7%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Note
                                         5&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 93%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_821_zDBqjo45kMGk"&gt;Commitments&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 42.75pt"/&gt;&lt;td style="width: 18pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;a)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Lease&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; color: gray"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;During
the year ended September 30, 2020 the Company incurred office lease expense of $&lt;span id="xdx_90E_eus-gaap--LeaseAndRentalExpense_c20191001__20200930_pp0p0"&gt;233,423
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(2019: $&lt;span id="xdx_904_eus-gaap--LeaseAndRentalExpense_c20181001__20190930_pp0p0"&gt;190,416&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; color: gray"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 42.75pt"/&gt;&lt;td style="width: 18pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;b)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Litigation&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 60.75pt"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif; background-color: white"&gt;The
Company is subject to claims and legal proceedings that arise in the ordinary course of business. Such matters are inherently
uncertain, and there can be no guarantee that the outcome of any such matter will be decided favorably to the Company or that
the resolution of any such matter will not have a material adverse effect upon the Company's consolidated financial statements.
The Company does not believe that any of such pending claims and legal proceedings will have a material adverse effect on its
consolidated financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 60.75pt; color: gray"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;












&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"/&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 42.75pt"/&gt;&lt;td style="width: 18pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;c)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Share
                                         Purchase Warrants&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 58.5pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
following table summarizes the warrant activity during the years ended September 30, 2020 and 2019:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"/&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_892_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zCeX6ZSscUs4" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%; margin-left: 50pt" summary="xdx: Disclosure - Commitments (Details)"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="3" style="text-align: left"&gt;&#160;&lt;span id="xdx_8B7_zpVFSbMks2pe" style="display: none"&gt;Schedule of exercisable share purchase warrants outstanding&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;Weighted Average Exercise&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Number of Shares&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Exercise Price ($)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 60%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Balance , September 30 , 2018&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pii_c20181001__20190930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zmTtd7r9uibd" style="width: 15%; text-align: right" title="Share Purchase Warrants Balance, at beginning"&gt;678,379&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_iS_pii_c20181001__20190930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zfsfjDTFyuCc" style="width: 15%; text-align: right" title="Weighted Average Exercise Price Balance, at beginning"&gt;2.87&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pii_di_c20181001__20190930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zz1loBMAaAkh" style="text-align: right" title="Share Purchase Warrants Exercised"&gt;(8,750&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExercised_c20181001__20190930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_pii" style="text-align: right" title="Weighted Average Exercise Price, Exercised"&gt;1.13&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_pii_di_c20181001__20190930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zonaDXZ9QF17" style="border-bottom: Black 1pt solid; text-align: right" title="Share Purchase Warrants Expired"&gt;(319,629&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;)&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExpired_c20181001__20190930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_pii" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Expired"&gt;1.46&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Balance , September 30 , 2019&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pii_c20191001__20200930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zYN80Ghjgly9" style="text-align: right" title="Share Purchase Warrants Balance, at beginning"&gt;350,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_iS_pii_c20191001__20200930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zQxXXV1tAT3c" style="text-align: right" title="Weighted Average Exercise Price Balance, at beginning"&gt;4.19&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod_c20191001__20200930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_pii" style="border-bottom: Black 1pt solid; text-align: right" title="Share Purchase Warrants Granted"&gt;150,000&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice_c20191001__20200930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_pii" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Granted"&gt;3.17&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Balance,
                                                                            September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pii_c20191001__20200930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_z8toB2rDxIb" style="border-bottom: Black 1pt solid; text-align: right" title="Share Purchase Warrants Balance, at ending"&gt;500,000&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_iE_pii_c20191001__20200930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zPE1MCG6ernb" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price Balance, at ending"&gt;3.88&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;



&lt;p id="xdx_8AF_zscZ3vRd44Dl" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"/&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 6pt 42.55pt; text-align: justify; text-indent: -0.8pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;During
the year ended September 30, 2019, the Company issued &lt;span id="xdx_902_ecustom--SharesIssuedPursuantToCashlessExerciseOfWarrantInShares_pii_c20191001__20200930_zMG6cZW4sGOj" title="Shares issued pursuant to cashless exercise of warrants"&gt;4,938&lt;/span&gt; shares in connection with the exercise of &lt;span id="xdx_90A_ecustom--StockIssuedPursuantToCashlessExerciseOfWarrants_c20191001__20200930_pii" title="Stock issued pursuant to cashless exercise of warrants"&gt;8,750&lt;/span&gt; warrants on a cashless
basis.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 6pt 42.55pt; text-align: justify; text-indent: -0.8pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;At
September 30, 2020 the Company had share purchase warrants outstanding as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 6pt 42.55pt; text-align: justify; text-indent: -0.8pt"/&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89F_ecustom--ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock_zNtmAaOFD1Mh" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 50%; margin-left: 50pt" summary="xdx: Disclosure - Commitments (Details 1)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_8BC_zFut8NusmD2i" style="display: none"&gt;Schedule of share purchase warrants outstanding&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="3" style="text-align: center"&gt;Number&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;Exercise Price&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;Expiry Date&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_c20200930__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_pii" style="width: 12%; text-align: right" title="Number"&gt;350,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_c20200930__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_pii" style="width: 12%; text-align: right" title="Exercise Price"&gt;4.19&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98F_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_c20200930__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member" style="width: 56%; text-align: right" title="Expiry Date"&gt;June 30, 2021&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_c20200930__us-gaap--AwardTypeAxis__custom--PurchaseWarrants2Member_pii" style="text-align: right" title="Number"&gt;150,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_c20200930__us-gaap--AwardTypeAxis__custom--PurchaseWarrants2Member_pii" style="text-align: right" title="Exercise Price"&gt;3.17&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98E_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_c20200930__us-gaap--AwardTypeAxis__custom--PurchaseWarrants2Member" style="text-align: right" title="Expiry Date"&gt;May 6, 2024&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_c20200930_pii" style="text-align: right" title="Number"&gt;500,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;



&lt;p id="xdx_8A7_zpbNf3kB7Fx3" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 6pt 42.55pt; text-align: justify; text-indent: -0.8pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;










&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"/&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 42.75pt"/&gt;&lt;td style="width: 18pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;d)&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Stock&#x2013;based
                                         Compensation Plan&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2015
Stock Option Plan&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify; text-indent: -1in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;On
September 18, 2015, the Company&#x2019;s board of directors approved a 2015 Omnibus Incentive Plan (the &#x201c;2015 Plan&#x201d;),
which provided for the grant of stock options and restricted stock awards to directors, officers, employees and consultants of
the Company.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
maximum number of our common shares reserved for issue under the plan was &lt;span id="xdx_90D_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_c20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pii" title="Maximum number of common shares reserved for future issuance"&gt;6,050,553&lt;/span&gt; shares, subject to adjustment in the event
of a change of the Company&#x2019;s capitalization. At September 30, 2020, &lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zu0sesh6W6Ia"&gt;146,371&lt;/span&gt; (2019: &lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20190930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zMoDUtlMbv3k"&gt;146,371&lt;/span&gt;) options remain available for
issue under the 2015 Plan.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2019
Stock Option Plan&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;On
January 15, 2019, the Board approved the 2019 Omnibus Incentive Plan (the &#x201c;2019 Plan&#x201d;), which provides for the grant
of stock options and restricted stock awards to directors, officers, employees, consultants and advisors of the Company. Under
the terms of the 2019 Plan, &lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2019Member_pii" title="Additional shares of common stock available for issuance"&gt;6,000,000&lt;/span&gt; additional shares of Common Stock are available for issuance under the 2019 Plan, in addition
to the shares available under the 2015 Plan. Any awards outstanding under the 2015 Plan or the Company&#x2019;s 2007 Stock Option
Plan (the &#x201c;2007 Plan&#x201d;) will remain subject to and be paid under the 2015 Plan or the 2007 Plan, respectively, and
any shares subject to outstanding awards under the 2015 Plan or the 2007 Plan that subsequently cease to be subject to such awards
(other than by reason of settlement of the awards in shares) will automatically become available for issuance under the 2019 Plan.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
2019 Plan provides that it may be administered by the Board, or the Board may delegate such responsibility to a committee. The
exercise price will be determined by the board of directors at the time of grant shall be at least equal to the fair market value
on such date. If the grantee is a 10% stockholder on the grant date, then the exercise price shall not be less than 110% of fair
market value of the Company&#x2019;s shares of common stock on the grant date. Stock options may be granted under the 2019 Plan
for an exercise period of up to ten years from the date of grant of the option or such lesser periods as may be determined by
the board, subject to earlier termination in accordance with the terms of the 2019 Plan. At September 30, 2020, &lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2019Member_zTfo6dJQhPY6"&gt;3,161,665&lt;/span&gt; (2019:
&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20190930__us-gaap--PlanNameAxis__custom--StockOptionPlan2019Member_zYBl353Lyqr6"&gt;4,788,333&lt;/span&gt;) options remain available for issue under the 2019 Plan.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 56.7pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;A
summary of the status of Company&#x2019;s outstanding stock purchase options is presented below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"/&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_896_eus-gaap--ScheduleOfStockOptionsRollForwardTableTextBlock_zm10SLpqS2u6" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 50pt; margin-right: 30pt" summary="xdx: Disclosure - Commitments (Details 2)"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span id="xdx_8BE_zhSeLDdBnF7f" style="display: none"&gt;Schedule of outstanding stock purchase options&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Number of Shares&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Weighted Average Exercise Price&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Weighted Average Grant Date Fair Value ($)&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Aggregate intrinsic value ($)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 26%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Outstanding, September 30, 2018&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pii_c20181001__20190930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zh9Gqg9kHKJf" style="width: 15%; text-align: right" title="Options Outstanding at beginning"&gt;6,506,917&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pii_c20181001__20190930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zba4eDIJnP5e" style="width: 15%; text-align: right" title="Weighted Average Exercise Price Outstanding at beginning"&gt;3.83&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 15%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20181001__20190930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zEKezIwO51H3" style="width: 15%; text-align: right" title="Aggregate intrinsic value Outstanding at beginning"&gt;2,353,088&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20181001__20190930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pii" style="text-align: right" title="Options Granted"&gt;2,265,399&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20181001__20190930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pii" style="text-align: right" title="Weighted Average Exercise Price Granted"&gt;2.79&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20181001__20190930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pii" style="text-align: right" title="Weighted Average Grant Date Fair Value Granted"&gt;2.27&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pii_di_c20181001__20190930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zJKYxHhyezg5" style="border-bottom: Black 1pt solid; text-align: right" title="Options Forfeited"&gt;(309,383&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;)&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20181001__20190930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pii" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price Forfeited"&gt;3.25&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Outstanding, September 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pii_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zQTunKIezEq2" style="border-bottom: Black 1pt solid; text-align: right" title="Options Outstanding at beginning"&gt;8,462,933&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pii_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_z8T1R15cmUx3" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price Outstanding at beginning"&gt;3.58&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zKBvON9vvBTe" style="border-bottom: Black 1pt solid; text-align: right"&gt;4,115,032&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pii" style="text-align: right" title="Options Granted"&gt;1,695,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pii" style="text-align: right" title="Weighted Average Exercise Price Granted"&gt;2.96&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pii" style="text-align: right" title="Weighted Average Grant Date Fair Value Granted"&gt;2.27&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right" title="Aggregate intrinsic value Outstanding at ending"/&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pii_di_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zC4oNndN1Jgc" style="text-align: right" title="Options Forfeited"&gt;(68,332&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pii" style="text-align: right" title="Weighted Average Exercise Price Forfeited"&gt;3.01&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pii_di_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zgKsNRQ2uz4f" style="border-bottom: Black 1pt solid; text-align: right" title="Options Exercised"&gt;(13,335&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;)&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pii" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price Exercised"&gt;3.15&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Outstanding, September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pii_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_z71n7ruaXmj2" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Outstanding at ending"&gt;10,076,266&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pii_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zAOoelwUl4pf" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Outstanding at ending"&gt;3.48&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zBdK6aD3ajf2" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value Outstanding at ending"&gt;14,982,581&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Exercisable, September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zCSeOZ8OIdRg" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Exercisable at ending"&gt;7,412,100&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pii_c20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zQ46uv7GgYnj" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Exercisable at ending"&gt;3.66&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_c20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value Exercisable at ending"&gt;10,763,906&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;



&lt;p id="xdx_8A7_z0jlJsnN3pI4" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"/&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 6pt 42.55pt; text-align: justify; text-indent: -0.8pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"/&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 6pt 42.55pt; text-align: justify; text-indent: -0.8pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;During
the year ended September 30, 2020, the Company issued &lt;span id="xdx_90C_ecustom--SharesIssuedPursuantToCashlessExercisesOfOption_c20191001__20200930_zXcjR5fThcF3" title="Shares issued pursuant to cashless exercises of option"&gt;721&lt;/span&gt; shares in connection with the exercise of &lt;span id="xdx_904_ecustom--NumberOfCashlessExerciseOption_c20191001__20200930_zROVJdJcKIm9" title="Number of cashless exercise option"&gt;13,335&lt;/span&gt; options on a cashless
basis.&lt;/span&gt;&lt;/p&gt;











&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
aggregate intrinsic value is calculated as the difference between the exercise price of the underlying awards and the quoted market
price of the Company&#x2019;s stock for the options that were in-the-money on the applicable date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company recognized stock-based compensation expense of $&lt;span id="xdx_908_eus-gaap--AllocatedShareBasedCompensationExpense_c20191001__20200930_pp0p0" title="Share based compensation"&gt;4,876,906&lt;/span&gt; during the year ended September 30, 2020 (2019: $&lt;span id="xdx_903_eus-gaap--AllocatedShareBasedCompensationExpense_c20181001__20190930_pp0p0" title="Share based compensation"&gt;6,430,873&lt;/span&gt;)
in connection with the issuance and vesting 	of stock options and warrants in exchange for services. These amounts have been
included in general and 	administrative expenses and research and development expenses on the Company&#x2019;s consolidated
statements of 	operations as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"/&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_895_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_z10fcU3yhNC" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%; margin-left: 50pt; margin-right: 30pt" summary="xdx: Disclosure - Commitments (Details 3)"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span id="xdx_8B3_zLXz9RQiDpaf" style="display: none"&gt;Schedule of general and administrative expenses and research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;2019&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 56%; text-align: left"&gt;General and administrative&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AllocatedShareBasedCompensationExpense_c20191001__20200930__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pp0p0" style="width: 12%; text-align: right" title="Total share based compensation"&gt;2,210,789&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--AllocatedShareBasedCompensationExpense_c20181001__20190930__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pp0p0" style="width: 12%; text-align: right" title="Total share based compensation"&gt;3,203,165&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Research and development&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--AllocatedShareBasedCompensationExpense_c20191001__20200930__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation"&gt;2,666,117&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--AllocatedShareBasedCompensationExpense_c20181001__20190930__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation"&gt;3,227,708&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Total share based compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--AllocatedShareBasedCompensationExpense_c20191001__20200930_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Total share based compensation"&gt;4,876,906&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--AllocatedShareBasedCompensationExpense_c20181001__20190930_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Total share based compensation"&gt;6,430,873&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;



&lt;p id="xdx_8A6_zzfKjvViDfk6" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 6pt 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;An
amount of approximately $&lt;span id="xdx_900_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_pp0p0_c20200930_zOWoVSb0HVs4" title="Remaining stock based compensation"&gt;4,040,812&lt;/span&gt; in stock-based compensation is expected to be recorded over the remaining term 	of such
options and warrants through 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
fair value of each option and warrant award is estimated on the date of grant using the Black Scholes option pricing model based
on the following weighted average assumptions:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify; text-indent: 1in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify; text-indent: 1in"/&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_887_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zIt31fNFgdO6" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; margin-left: 50pt; margin-right: 30pt; width: 80%" summary="xdx: Disclosure - Commitments (Details 4)"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span id="xdx_8B3_z2ukEIarV4Xg" style="display: none"&gt;Schedule of weighted average assumptions for fair value of each option award&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;2020&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;2019&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 56%; text-align: left"&gt;Risk-free interest rate&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pii_dp_c20191001__20200930_zi7JAzbq67Lc" style="width: 12%; text-align: right" title="Risk-free interest rate"&gt;1.57&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pii_dp_c20181001__20190930_zLa7ChuAS8b7" style="width: 12%; text-align: right" title="Risk-free interest rate"&gt;2.50&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Expected life of option (years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20191001__20200930_zmlZr7zJWeca" style="text-align: right" title="Expected life of options (years)"&gt;5.53&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20181001__20190930_zUSNWh7Xc5vc" style="text-align: right" title="Expected life of options (years)"&gt;6.05&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Annualized volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pii_dp_c20191001__20200930_zL7d4I6ZUXZh" style="text-align: right" title="Annualized volatility"&gt;95.99&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pii_dp_c20181001__20190930_zL6bXerDkGPa" style="text-align: right" title="Annualized volatility"&gt;104.45&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Dividend rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c20191001__20200930_pii" style="text-align: right" title="Dividend rate"&gt;0.00&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c20181001__20190930_pii" style="text-align: right" title="Dividend rate"&gt;0.00&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;



&lt;p id="xdx_8A2_zVuVHQXNSVHb" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: left; text-indent: 0pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
fair value of stock compensation charges recognized during the years ended September 30, 2020 and 2019 was determined with reference
to the quoted market price of the Company&#x2019;s shares on the grant date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;






</us-gaap:CommitmentsDisclosureTextBlock>
    <us-gaap:LeaseAndRentalExpense
      contextRef="From2019-10-01to2020-09-30"
      decimals="0"
      unitRef="USD">233423</us-gaap:LeaseAndRentalExpense>
    <us-gaap:LeaseAndRentalExpense
      contextRef="From2018-10-012019-09-30"
      decimals="0"
      unitRef="USD">190416</us-gaap:LeaseAndRentalExpense>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="From2019-10-01to2020-09-30">&lt;table cellpadding="0" cellspacing="0" id="xdx_892_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zCeX6ZSscUs4" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%; margin-left: 50pt" summary="xdx: Disclosure - Commitments (Details)"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="3" style="text-align: left"&gt;&#160;&lt;span id="xdx_8B7_zpVFSbMks2pe" style="display: none"&gt;Schedule of exercisable share purchase warrants outstanding&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;Weighted Average Exercise&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Number of Shares&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Exercise Price ($)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 60%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Balance , September 30 , 2018&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pii_c20181001__20190930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zmTtd7r9uibd" style="width: 15%; text-align: right" title="Share Purchase Warrants Balance, at beginning"&gt;678,379&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_iS_pii_c20181001__20190930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zfsfjDTFyuCc" style="width: 15%; text-align: right" title="Weighted Average Exercise Price Balance, at beginning"&gt;2.87&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pii_di_c20181001__20190930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zz1loBMAaAkh" style="text-align: right" title="Share Purchase Warrants Exercised"&gt;(8,750&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExercised_c20181001__20190930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_pii" style="text-align: right" title="Weighted Average Exercise Price, Exercised"&gt;1.13&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_pii_di_c20181001__20190930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zonaDXZ9QF17" style="border-bottom: Black 1pt solid; text-align: right" title="Share Purchase Warrants Expired"&gt;(319,629&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;)&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExpired_c20181001__20190930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_pii" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Expired"&gt;1.46&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Balance , September 30 , 2019&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pii_c20191001__20200930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zYN80Ghjgly9" style="text-align: right" title="Share Purchase Warrants Balance, at beginning"&gt;350,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_iS_pii_c20191001__20200930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zQxXXV1tAT3c" style="text-align: right" title="Weighted Average Exercise Price Balance, at beginning"&gt;4.19&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod_c20191001__20200930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_pii" style="border-bottom: Black 1pt solid; text-align: right" title="Share Purchase Warrants Granted"&gt;150,000&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice_c20191001__20200930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_pii" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Granted"&gt;3.17&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Balance,
                                                                            September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pii_c20191001__20200930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_z8toB2rDxIb" style="border-bottom: Black 1pt solid; text-align: right" title="Share Purchase Warrants Balance, at ending"&gt;500,000&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_iE_pii_c20191001__20200930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zPE1MCG6ernb" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price Balance, at ending"&gt;3.88&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;



</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2018-09-30_custom_PurchaseWarrantsMember"
      decimals="INF"
      unitRef="Shares">678379</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2018-09-30_custom_PurchaseWarrantsMember"
      decimals="INF"
      unitRef="USDPShares">2.87</avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="From2018-10-012019-09-30_custom_PurchaseWarrantsMember"
      decimals="INF"
      unitRef="Shares">8750</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExercised
      contextRef="From2018-10-012019-09-30_custom_PurchaseWarrantsMember"
      decimals="INF"
      unitRef="USDPShares">1.13</avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations
      contextRef="From2018-10-012019-09-30_custom_PurchaseWarrantsMember"
      decimals="INF"
      unitRef="Shares">319629</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations>
    <avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExpired
      contextRef="From2018-10-012019-09-30_custom_PurchaseWarrantsMember"
      decimals="INF"
      unitRef="USDPShares">1.46</avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExpired>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2019-09-30_custom_PurchaseWarrantsMember"
      decimals="INF"
      unitRef="Shares">350000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2019-09-30_custom_PurchaseWarrantsMember"
      decimals="INF"
      unitRef="USDPShares">4.19</avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice>
    <avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod
      contextRef="From2019-10-012020-09-30_custom_PurchaseWarrantsMember"
      decimals="INF"
      unitRef="Shares">150000</avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod>
    <avxl:ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice
      contextRef="From2019-10-012020-09-30_custom_PurchaseWarrantsMember"
      decimals="INF"
      unitRef="USDPShares">3.17</avxl:ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2020-09-30_custom_PurchaseWarrantsMember"
      decimals="INF"
      unitRef="Shares">500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2020-09-30_custom_PurchaseWarrantsMember"
      decimals="INF"
      unitRef="USDPShares">3.88</avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice>
    <avxl:SharesIssuedPursuantToCashlessExerciseOfWarrantInShares
      contextRef="From2019-10-01to2020-09-30"
      decimals="INF"
      unitRef="Shares">4938</avxl:SharesIssuedPursuantToCashlessExerciseOfWarrantInShares>
    <avxl:StockIssuedPursuantToCashlessExerciseOfWarrants
      contextRef="From2019-10-01to2020-09-30"
      decimals="INF"
      unitRef="Shares">8750</avxl:StockIssuedPursuantToCashlessExerciseOfWarrants>
    <avxl:ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock contextRef="From2019-10-01to2020-09-30">&lt;table cellpadding="0" cellspacing="0" id="xdx_89F_ecustom--ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock_zNtmAaOFD1Mh" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 50%; margin-left: 50pt" summary="xdx: Disclosure - Commitments (Details 1)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_8BC_zFut8NusmD2i" style="display: none"&gt;Schedule of share purchase warrants outstanding&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="3" style="text-align: center"&gt;Number&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;Exercise Price&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;Expiry Date&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_c20200930__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_pii" style="width: 12%; text-align: right" title="Number"&gt;350,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_c20200930__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_pii" style="width: 12%; text-align: right" title="Exercise Price"&gt;4.19&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98F_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_c20200930__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member" style="width: 56%; text-align: right" title="Expiry Date"&gt;June 30, 2021&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_c20200930__us-gaap--AwardTypeAxis__custom--PurchaseWarrants2Member_pii" style="text-align: right" title="Number"&gt;150,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_c20200930__us-gaap--AwardTypeAxis__custom--PurchaseWarrants2Member_pii" style="text-align: right" title="Exercise Price"&gt;3.17&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98E_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_c20200930__us-gaap--AwardTypeAxis__custom--PurchaseWarrants2Member" style="text-align: right" title="Expiry Date"&gt;May 6, 2024&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_c20200930_pii" style="text-align: right" title="Number"&gt;500,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;



</avxl:ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="AsOf2020-09-30_custom_PurchaseWarrants1Member"
      decimals="INF"
      unitRef="Shares">350000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2020-09-30_custom_PurchaseWarrants1Member"
      decimals="INF"
      unitRef="USDPShares">4.19</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate contextRef="AsOf2020-09-30_custom_PurchaseWarrants1Member">2021-06-30</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="AsOf2020-09-30_custom_PurchaseWarrants2Member"
      decimals="INF"
      unitRef="Shares">150000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2020-09-30_custom_PurchaseWarrants2Member"
      decimals="INF"
      unitRef="USDPShares">3.17</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate contextRef="AsOf2020-09-30_custom_PurchaseWarrants2Member">2024-05-06</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber contextRef="AsOf2020-09-30" decimals="INF" unitRef="Shares">500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="AsOf2020-09-30_custom_StockOptionPlan2015Member"
      decimals="INF"
      unitRef="Shares">6050553</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="AsOf2020-09-30_custom_StockOptionPlan2015Member"
      decimals="INF"
      unitRef="Shares">146371</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="AsOf2019-09-30_custom_StockOptionPlan2015Member"
      decimals="INF"
      unitRef="Shares">146371</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="From2019-10-012020-09-30_custom_StockOptionPlan2019Member"
      decimals="INF"
      unitRef="Shares">6000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="AsOf2020-09-30_custom_StockOptionPlan2019Member"
      decimals="INF"
      unitRef="Shares">3161665</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="AsOf2019-09-30_custom_StockOptionPlan2019Member"
      decimals="INF"
      unitRef="Shares">4788333</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock contextRef="From2019-10-01to2020-09-30">&lt;table cellpadding="0" cellspacing="0" id="xdx_896_eus-gaap--ScheduleOfStockOptionsRollForwardTableTextBlock_zm10SLpqS2u6" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 50pt; margin-right: 30pt" summary="xdx: Disclosure - Commitments (Details 2)"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span id="xdx_8BE_zhSeLDdBnF7f" style="display: none"&gt;Schedule of outstanding stock purchase options&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Number of Shares&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Weighted Average Exercise Price&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Weighted Average Grant Date Fair Value ($)&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Aggregate intrinsic value ($)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 26%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Outstanding, September 30, 2018&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pii_c20181001__20190930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zh9Gqg9kHKJf" style="width: 15%; text-align: right" title="Options Outstanding at beginning"&gt;6,506,917&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pii_c20181001__20190930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zba4eDIJnP5e" style="width: 15%; text-align: right" title="Weighted Average Exercise Price Outstanding at beginning"&gt;3.83&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 15%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20181001__20190930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zEKezIwO51H3" style="width: 15%; text-align: right" title="Aggregate intrinsic value Outstanding at beginning"&gt;2,353,088&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20181001__20190930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pii" style="text-align: right" title="Options Granted"&gt;2,265,399&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20181001__20190930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pii" style="text-align: right" title="Weighted Average Exercise Price Granted"&gt;2.79&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20181001__20190930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pii" style="text-align: right" title="Weighted Average Grant Date Fair Value Granted"&gt;2.27&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pii_di_c20181001__20190930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zJKYxHhyezg5" style="border-bottom: Black 1pt solid; text-align: right" title="Options Forfeited"&gt;(309,383&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;)&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20181001__20190930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pii" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price Forfeited"&gt;3.25&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Outstanding, September 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pii_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zQTunKIezEq2" style="border-bottom: Black 1pt solid; text-align: right" title="Options Outstanding at beginning"&gt;8,462,933&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pii_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_z8T1R15cmUx3" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price Outstanding at beginning"&gt;3.58&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zKBvON9vvBTe" style="border-bottom: Black 1pt solid; text-align: right"&gt;4,115,032&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pii" style="text-align: right" title="Options Granted"&gt;1,695,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pii" style="text-align: right" title="Weighted Average Exercise Price Granted"&gt;2.96&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pii" style="text-align: right" title="Weighted Average Grant Date Fair Value Granted"&gt;2.27&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right" title="Aggregate intrinsic value Outstanding at ending"/&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pii_di_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zC4oNndN1Jgc" style="text-align: right" title="Options Forfeited"&gt;(68,332&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pii" style="text-align: right" title="Weighted Average Exercise Price Forfeited"&gt;3.01&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pii_di_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zgKsNRQ2uz4f" style="border-bottom: Black 1pt solid; text-align: right" title="Options Exercised"&gt;(13,335&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;)&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pii" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price Exercised"&gt;3.15&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Outstanding, September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pii_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_z71n7ruaXmj2" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Outstanding at ending"&gt;10,076,266&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pii_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zAOoelwUl4pf" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Outstanding at ending"&gt;3.48&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zBdK6aD3ajf2" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value Outstanding at ending"&gt;14,982,581&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Exercisable, September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zCSeOZ8OIdRg" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Exercisable at ending"&gt;7,412,100&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pii_c20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zQ46uv7GgYnj" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Exercisable at ending"&gt;3.66&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_c20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value Exercisable at ending"&gt;10,763,906&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;



</us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2018-09-30_custom_StockOptionPlan2015Member"
      decimals="INF"
      unitRef="Shares">6506917</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2018-09-30_custom_StockOptionPlan2015Member"
      decimals="INF"
      unitRef="USDPShares">3.83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2018-09-30_custom_StockOptionPlan2015Member"
      decimals="0"
      unitRef="USD">2353088</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2018-10-012019-09-30_custom_StockOptionPlan2015Member"
      decimals="INF"
      unitRef="Shares">2265399</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2018-10-012019-09-30_custom_StockOptionPlan2015Member"
      decimals="INF"
      unitRef="USDPShares">2.79</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2018-10-012019-09-30_custom_StockOptionPlan2015Member"
      decimals="INF"
      unitRef="USDPShares">2.27</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="From2018-10-012019-09-30_custom_StockOptionPlan2015Member"
      decimals="INF"
      unitRef="Shares">309383</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="From2018-10-012019-09-30_custom_StockOptionPlan2015Member"
      decimals="INF"
      unitRef="USDPShares">3.25</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2019-09-30_custom_StockOptionPlan2015Member"
      decimals="INF"
      unitRef="Shares">8462933</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2019-09-30_custom_StockOptionPlan2015Member"
      decimals="INF"
      unitRef="USDPShares">3.58</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2019-09-30_custom_StockOptionPlan2015Member"
      decimals="0"
      unitRef="USD">4115032</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2019-10-012020-09-30_custom_StockOptionPlan2015Member"
      decimals="INF"
      unitRef="Shares">1695000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2019-10-012020-09-30_custom_StockOptionPlan2015Member"
      decimals="INF"
      unitRef="USDPShares">2.96</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2019-10-012020-09-30_custom_StockOptionPlan2015Member"
      decimals="INF"
      unitRef="USDPShares">2.27</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="From2019-10-012020-09-30_custom_StockOptionPlan2015Member"
      decimals="INF"
      unitRef="Shares">68332</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="From2019-10-012020-09-30_custom_StockOptionPlan2015Member"
      decimals="INF"
      unitRef="USDPShares">3.01</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2019-10-012020-09-30_custom_StockOptionPlan2015Member"
      decimals="INF"
      unitRef="Shares">13335</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2019-10-012020-09-30_custom_StockOptionPlan2015Member"
      decimals="INF"
      unitRef="USDPShares">3.15</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2020-09-30_custom_StockOptionPlan2015Member"
      decimals="INF"
      unitRef="Shares">10076266</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2020-09-30_custom_StockOptionPlan2015Member"
      decimals="INF"
      unitRef="USDPShares">3.48</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2020-09-30_custom_StockOptionPlan2015Member"
      decimals="0"
      unitRef="USD">14982581</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2020-09-30_custom_StockOptionPlan2015Member"
      decimals="INF"
      unitRef="Shares">7412100</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2020-09-30_custom_StockOptionPlan2015Member"
      decimals="INF"
      unitRef="USDPShares">3.66</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="AsOf2020-09-30_custom_StockOptionPlan2015Member"
      decimals="0"
      unitRef="USD">10763906</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <avxl:SharesIssuedPursuantToCashlessExercisesOfOption
      contextRef="From2019-10-01to2020-09-30"
      decimals="INF"
      unitRef="Shares">721</avxl:SharesIssuedPursuantToCashlessExercisesOfOption>
    <avxl:NumberOfCashlessExerciseOption
      contextRef="From2019-10-01to2020-09-30"
      decimals="INF"
      unitRef="Shares">13335</avxl:NumberOfCashlessExerciseOption>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2019-10-01to2020-09-30"
      decimals="0"
      unitRef="USD">4876906</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2018-10-012019-09-30"
      decimals="0"
      unitRef="USD">6430873</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="From2019-10-01to2020-09-30">&lt;table cellpadding="0" cellspacing="0" id="xdx_895_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_z10fcU3yhNC" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%; margin-left: 50pt; margin-right: 30pt" summary="xdx: Disclosure - Commitments (Details 3)"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span id="xdx_8B3_zLXz9RQiDpaf" style="display: none"&gt;Schedule of general and administrative expenses and research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;2019&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 56%; text-align: left"&gt;General and administrative&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AllocatedShareBasedCompensationExpense_c20191001__20200930__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pp0p0" style="width: 12%; text-align: right" title="Total share based compensation"&gt;2,210,789&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--AllocatedShareBasedCompensationExpense_c20181001__20190930__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pp0p0" style="width: 12%; text-align: right" title="Total share based compensation"&gt;3,203,165&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Research and development&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--AllocatedShareBasedCompensationExpense_c20191001__20200930__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation"&gt;2,666,117&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--AllocatedShareBasedCompensationExpense_c20181001__20190930__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation"&gt;3,227,708&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Total share based compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--AllocatedShareBasedCompensationExpense_c20191001__20200930_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Total share based compensation"&gt;4,876,906&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--AllocatedShareBasedCompensationExpense_c20181001__20190930_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Total share based compensation"&gt;6,430,873&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;



</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2019-10-012020-09-30_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="0"
      unitRef="USD">2210789</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2018-10-012019-09-30_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="0"
      unitRef="USD">3203165</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2019-10-012020-09-30_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="0"
      unitRef="USD">2666117</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2018-10-012019-09-30_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="0"
      unitRef="USD">3227708</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2019-10-01to2020-09-30"
      decimals="0"
      unitRef="USD">4876906</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2018-10-012019-09-30"
      decimals="0"
      unitRef="USD">6430873</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="AsOf2020-09-30" decimals="0" unitRef="USD">4040812</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="From2019-10-01to2020-09-30">&lt;table cellpadding="0" cellspacing="0" id="xdx_887_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zIt31fNFgdO6" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; margin-left: 50pt; margin-right: 30pt; width: 80%" summary="xdx: Disclosure - Commitments (Details 4)"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span id="xdx_8B3_z2ukEIarV4Xg" style="display: none"&gt;Schedule of weighted average assumptions for fair value of each option award&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;2020&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;2019&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 56%; text-align: left"&gt;Risk-free interest rate&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pii_dp_c20191001__20200930_zi7JAzbq67Lc" style="width: 12%; text-align: right" title="Risk-free interest rate"&gt;1.57&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pii_dp_c20181001__20190930_zLa7ChuAS8b7" style="width: 12%; text-align: right" title="Risk-free interest rate"&gt;2.50&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Expected life of option (years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20191001__20200930_zmlZr7zJWeca" style="text-align: right" title="Expected life of options (years)"&gt;5.53&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20181001__20190930_zUSNWh7Xc5vc" style="text-align: right" title="Expected life of options (years)"&gt;6.05&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Annualized volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pii_dp_c20191001__20200930_zL7d4I6ZUXZh" style="text-align: right" title="Annualized volatility"&gt;95.99&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pii_dp_c20181001__20190930_zL6bXerDkGPa" style="text-align: right" title="Annualized volatility"&gt;104.45&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Dividend rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c20191001__20200930_pii" style="text-align: right" title="Dividend rate"&gt;0.00&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c20181001__20190930_pii" style="text-align: right" title="Dividend rate"&gt;0.00&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2019-10-01to2020-09-30"
      decimals="INF"
      unitRef="Pure">0.0157</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2018-10-012019-09-30"
      decimals="INF"
      unitRef="Pure">0.0250</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2019-10-01to2020-09-30">P5Y6M10D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2018-10-012019-09-30">P6Y18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2019-10-01to2020-09-30"
      decimals="INF"
      unitRef="Pure">0.9599</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2018-10-012019-09-30"
      decimals="INF"
      unitRef="Pure">1.0445</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2019-10-01to2020-09-30"
      decimals="INF"
      unitRef="Pure">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2018-10-012019-09-30"
      decimals="INF"
      unitRef="Pure">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="From2019-10-01to2020-09-30">&lt;p id="xdx_80A_eus-gaap--IncomeTaxDisclosureTextBlock_zZZIEtMTz8z9" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
&lt;tr style="vertical-align: top; text-align: left"&gt;&lt;td style="width: 7%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Note
                                         6&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 93%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_826_z45949lVo8y4"&gt;Income Taxes&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 7pt 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company&#x2019;s U.S. and foreign loss before income taxes are set forth below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 7pt 42.55pt; text-align: justify"/&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89C_eus-gaap--ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_zhsAwSMkIYY" style="font: 10pt Times New Roman, Times, Serif; visibility: visible; border-collapse: collapse; margin-left: 50pt; margin-right: 30pt; width: 90%" summary="xdx: Disclosure - Income Taxes (Details)"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="display: none"&gt;&lt;span id="xdx_8B9_zmKV9lDcS5U5" style="display: none"&gt;Schedule of Income before Income Tax, Domestic and Foreign&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_496_20191001__20200930_zGfc4t7ylrWg" style="border-bottom: Black 1pt solid; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_49B_20181001__20190930_zgXT42mjUx59" style="border-bottom: Black 1pt solid; text-align: center"&gt;2019&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_408_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 56%; text-align: left"&gt;United States&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right" title="United States"&gt;(18,096,148&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right" title="United States"&gt;(18,031,016&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40D_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_i_pp0p0" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="border-bottom: Black 1pt solid"&gt;Foreign&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right" title="Foreign"&gt;(8,161,658&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;)&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right" title="Foreign"&gt;(8,181,782&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_404_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="border-bottom: Black 2.5pt double"&gt;Total&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right" title="Total"&gt;(26,257,806&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;)&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right" title="Total"&gt;(26,212,798&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;



&lt;p id="xdx_8AB_zwggrXkvERbe" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 7pt 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 7pt 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
components of net deferred income tax assets as of September 30, 2020 and 2019 are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 7pt 42.55pt; text-align: justify"/&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89C_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zw392Ke84AT9" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 50pt; margin-right: 30pt" summary="xdx: Disclosure - Income Taxes (Details 1)"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span id="xdx_8BA_zNDtTCZntjHk" style="display: none"&gt;Schedule of deferred tax asset and liabilities&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_496_20200930_zVi2ustoktHk" style="border-bottom: Black 1pt solid; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_49F_20190930_zuHSA5cToaE8" style="border-bottom: Black 1pt solid; text-align: center"&gt;2019&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_401_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 56%; text-align: left"&gt;Net operating loss carryforwards&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;23,397,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;18,704,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40F_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_pp0p0" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Research and development tax credit carry forwards&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,069,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,162,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_401_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Stock-based compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8,283,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,570,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40D_ecustom--DeferredTaxAssetsUnpaidCharges_iI_pp0p0" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Unpaid charges&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;83,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;69,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40C_eus-gaap--DeferredTaxAssetsGoodwillAndIntangibleAssets_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Intangible asset costs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;132,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;30,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_403_eus-gaap--DeferredTaxAssetsUnrealizedCurrencyLosses_iI_pp0p0" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Foreign exchange and other&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;27,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;15,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_408_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pp0p0_di_zhZhv1bqptZe" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;Valuation allowance deferred tax assets&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(33,991,000&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;)&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(26,550,000&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40F_eus-gaap--DeferredTaxAssetsNet_iI_pp0p0_d0_zPHyywcRkcAb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;Net deferred tax assets&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#x2014;&#160;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#x2014;&#160;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;



&lt;p id="xdx_8A3_zqLzdsiXZl9" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 7pt 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-indent: 0.25in"/&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;A
reconciliation of income tax expense at the statutory federal income tax rate and income taxes as reflected in the consolidated
financial statements for the years ended September 30, 2020 and 2019 is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"/&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89F_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zgqgnyyzqQA5" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; margin-left: 50pt; margin-right: 30pt; width: 90%" summary="xdx: Disclosure - Income Taxes (Details 2)"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span id="xdx_8B7_zyDBegXhrH9d" style="display: none"&gt;Schedule of Effective Income Tax Rate Reconciliation&lt;/span&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_498_20191001__20200930_znkPTYEv6Qyf" style="border-bottom: Black 1pt solid; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_499_20181001__20190930_zD0ElrIeVuK2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2019&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_400_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 56%; text-align: left"&gt;Income tax benefit at statutory federal rate&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;(5,519,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;(5,505,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_401_eus-gaap--IncomeTaxReconciliationForeignIncomeTaxRateDifferential_i_pp0p0" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Foreign income taxed at other rates&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(723,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(825,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40F_eus-gaap--IncomeTaxReconciliationOtherAdjustments_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Other permanent differences&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;35,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;140,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40C_ecustom--IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopmentCreditBenefit_i_pp0p0" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Research and development credit benefit&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,267,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;914,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_401_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_z1PYeXsbnRgi" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;State and local taxes&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,911,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,487,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40C_eus-gaap--IncomeTaxReconciliationPriorYearIncomeTaxes_i_pp0p0" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Adjustment and true up to prior year tax provision&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;373,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;194,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_405_eus-gaap--EffectOfExchangeRateOnCash_d0_zqtfu3RSRnmg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Effect of change in statutory rates&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;36,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&#160;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_408_eus-gaap--TaxesExcludingIncomeAndExciseTaxes_i_pp0p0" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;State minimum and excise taxes&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;22,664&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;82,181&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_400_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_zdxGf7UkZNn1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;Change in valuation allowances&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;7,442,000&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;6,569,000&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_405_eus-gaap--DeferredIncomeTaxExpenseBenefit_i_pp0p0" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;Income tax expense&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;22,664&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;82,181&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;



&lt;p id="xdx_8AB_zx4bzKWbO3h5" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"/&gt;&lt;/p&gt;

&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt"/&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;As
of September 30, 2020, the Company had U.S. federal net operating loss carryforwards of approximately $&lt;span id="xdx_903_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsForeign_iI_pp0n3_dm_c20200930_zhXEaby3lZqi" title="U.S. federal net operating loss carryforwards"&gt;76.8&lt;/span&gt; million (2019: $&lt;span id="xdx_90E_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsForeign_iI_pp0n3_dm_c20190930_zQJbU4NKSC9h" title="U.S. federal net operating loss carryforwards"&gt;60.8&lt;/span&gt;
million) which will begin to expire in &lt;span id="xdx_905_ecustom--OperatingLossCarryForwardsExpirationYear1_c20191001__20200930" title="Operating loss carry-forwards, expiration year"&gt;2027&lt;/span&gt; and state and local net operating loss carryforwards of approximately $&lt;span id="xdx_902_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_pp0n3_dm_c20200930_za50T4BqhqH6" title="State net operating loss carryforwards"&gt;103.1&lt;/span&gt; million
(2019: $&lt;span id="xdx_907_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_pp0n3_dm_c20190930_zLFm0TeuzsYk" title="State net operating loss carryforwards"&gt;64.0&lt;/span&gt; million) which will begin to expire in 2036, The Company had approximately $&lt;span id="xdx_906_eus-gaap--OperatingLossCarryforwards_iI_pp0n3_dm_c20200930__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_zTBjPg21TyNh" title="Operating loss carry-forwards"&gt;4.3&lt;/span&gt; million (Approximately AUD$ &lt;span id="xdx_908_eus-gaap--OperatingLossCarryforwards_iI_pp0n3_dm_c20200930__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember__srt--CurrencyAxis__currency--AUD_zcrplpdrDq66" title="Operating loss carry-forwards"&gt;6.0&lt;/span&gt; million)
(2019: $&lt;span id="xdx_90A_eus-gaap--OperatingLossCarryforwards_iI_pp0n3_dm_c20190930__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_zqeV6iN57JN8" title="Operating loss carry-forwards"&gt;3.5&lt;/span&gt; million) of net operating loss carryforwards in Australia, which have an indefinite life, available to offset future
taxable income in those jurisdictions.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;










&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"/&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company evaluates its valuation allowance requirements based on available evidence. When circumstances change, and this causes
a change in management&#x2019;s judgment about the recoverability of deferred tax assets, the impact of the change on the valuation
allowance is reflected in current income. Because management of the Company does not currently believe that it is more likely
than not that the Company will receive the benefit of these assets, a valuation allowance has been established at September 30,
2020 and 2019.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Uncertain
Tax Positions&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company files income tax returns in the U.S. federal jurisdiction and various state and local and foreign jurisdictions. The Company&#x2019;s
tax returns are subject to tax examinations by U.S. federal and state tax authorities, or examinations by foreign tax authorities
until the respective statutes of limitation expire. The Company is subject to tax examinations by tax authorities for all taxation
years commencing on or after 2013.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Under
the provisions of the Internal Revenue Code, the net operating loss (&#x201c;NOL&#x201d;) carryforwards are subject to review and
possible adjustment by the Internal Revenue Service and state tax authorities. NOL and tax credit carryforwards may become subject
to an annual limitation in the event of an over 50% cumulative change in the ownership interest of significant stockholders over
a three-year period, as defined under Sections 382 and 383 of the Internal Revenue Code, as well as similar state tax provisions.
This could limit the amount of NOLs that the Company could be entitled to utilize annually to offset future taxable income or
tax liabilities. The amount of the annual limitation, if any, would be determined based on the value of the Company immediately
prior to the ownership change. Subsequent ownership changes may affect the limitation in future years&lt;span style="background-color: white"&gt;.
The Company completed a Section 382 analysis through the fiscal year ended September 30, 2020 and currently does not believe Section
382 will apply to limit the utilization of available NOLs.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock contextRef="From2019-10-01to2020-09-30">&lt;table cellpadding="0" cellspacing="0" id="xdx_89C_eus-gaap--ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_zhsAwSMkIYY" style="font: 10pt Times New Roman, Times, Serif; visibility: visible; border-collapse: collapse; margin-left: 50pt; margin-right: 30pt; width: 90%" summary="xdx: Disclosure - Income Taxes (Details)"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="display: none"&gt;&lt;span id="xdx_8B9_zmKV9lDcS5U5" style="display: none"&gt;Schedule of Income before Income Tax, Domestic and Foreign&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_496_20191001__20200930_zGfc4t7ylrWg" style="border-bottom: Black 1pt solid; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_49B_20181001__20190930_zgXT42mjUx59" style="border-bottom: Black 1pt solid; text-align: center"&gt;2019&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_408_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 56%; text-align: left"&gt;United States&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right" title="United States"&gt;(18,096,148&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right" title="United States"&gt;(18,031,016&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40D_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_i_pp0p0" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="border-bottom: Black 1pt solid"&gt;Foreign&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right" title="Foreign"&gt;(8,161,658&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;)&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right" title="Foreign"&gt;(8,181,782&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_404_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="border-bottom: Black 2.5pt double"&gt;Total&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right" title="Total"&gt;(26,257,806&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;)&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right" title="Total"&gt;(26,212,798&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;



</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="From2019-10-01to2020-09-30"
      decimals="0"
      unitRef="USD">-18096148</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="From2018-10-012019-09-30"
      decimals="0"
      unitRef="USD">-18031016</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="From2019-10-01to2020-09-30"
      decimals="0"
      unitRef="USD">-8161658</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="From2018-10-012019-09-30"
      decimals="0"
      unitRef="USD">-8181782</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="From2019-10-01to2020-09-30"
      decimals="0"
      unitRef="USD">-26257806</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="From2018-10-012019-09-30"
      decimals="0"
      unitRef="USD">-26212798</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="From2019-10-01to2020-09-30">&lt;table cellpadding="0" cellspacing="0" id="xdx_89C_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zw392Ke84AT9" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 50pt; margin-right: 30pt" summary="xdx: Disclosure - Income Taxes (Details 1)"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span id="xdx_8BA_zNDtTCZntjHk" style="display: none"&gt;Schedule of deferred tax asset and liabilities&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_496_20200930_zVi2ustoktHk" style="border-bottom: Black 1pt solid; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_49F_20190930_zuHSA5cToaE8" style="border-bottom: Black 1pt solid; text-align: center"&gt;2019&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_401_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 56%; text-align: left"&gt;Net operating loss carryforwards&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;23,397,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;18,704,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40F_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_pp0p0" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Research and development tax credit carry forwards&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,069,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,162,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_401_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Stock-based compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8,283,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,570,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40D_ecustom--DeferredTaxAssetsUnpaidCharges_iI_pp0p0" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Unpaid charges&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;83,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;69,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40C_eus-gaap--DeferredTaxAssetsGoodwillAndIntangibleAssets_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Intangible asset costs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;132,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;30,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_403_eus-gaap--DeferredTaxAssetsUnrealizedCurrencyLosses_iI_pp0p0" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Foreign exchange and other&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;27,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;15,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_408_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pp0p0_di_zhZhv1bqptZe" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;Valuation allowance deferred tax assets&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(33,991,000&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;)&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(26,550,000&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40F_eus-gaap--DeferredTaxAssetsNet_iI_pp0p0_d0_zPHyywcRkcAb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;Net deferred tax assets&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#x2014;&#160;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#x2014;&#160;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;



</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="AsOf2020-09-30" decimals="0" unitRef="USD">23397000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="AsOf2019-09-30" decimals="0" unitRef="USD">18704000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment contextRef="AsOf2020-09-30" decimals="0" unitRef="USD">2069000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment contextRef="AsOf2019-09-30" decimals="0" unitRef="USD">1162000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="AsOf2020-09-30" decimals="0" unitRef="USD">8283000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="AsOf2019-09-30" decimals="0" unitRef="USD">6570000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <avxl:DeferredTaxAssetsUnpaidCharges contextRef="AsOf2020-09-30" decimals="0" unitRef="USD">83000</avxl:DeferredTaxAssetsUnpaidCharges>
    <avxl:DeferredTaxAssetsUnpaidCharges contextRef="AsOf2019-09-30" decimals="0" unitRef="USD">69000</avxl:DeferredTaxAssetsUnpaidCharges>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets contextRef="AsOf2020-09-30" decimals="0" unitRef="USD">132000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets contextRef="AsOf2019-09-30" decimals="0" unitRef="USD">30000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsUnrealizedCurrencyLosses contextRef="AsOf2020-09-30" decimals="0" unitRef="USD">27000</us-gaap:DeferredTaxAssetsUnrealizedCurrencyLosses>
    <us-gaap:DeferredTaxAssetsUnrealizedCurrencyLosses contextRef="AsOf2019-09-30" decimals="0" unitRef="USD">15000</us-gaap:DeferredTaxAssetsUnrealizedCurrencyLosses>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="AsOf2020-09-30" decimals="0" unitRef="USD">33991000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="AsOf2019-09-30" decimals="0" unitRef="USD">26550000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet contextRef="AsOf2020-09-30" decimals="0" unitRef="USD">0</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet contextRef="AsOf2019-09-30" decimals="0" unitRef="USD">0</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="From2019-10-01to2020-09-30">&lt;table cellpadding="0" cellspacing="0" id="xdx_89F_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zgqgnyyzqQA5" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; margin-left: 50pt; margin-right: 30pt; width: 90%" summary="xdx: Disclosure - Income Taxes (Details 2)"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span id="xdx_8B7_zyDBegXhrH9d" style="display: none"&gt;Schedule of Effective Income Tax Rate Reconciliation&lt;/span&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_498_20191001__20200930_znkPTYEv6Qyf" style="border-bottom: Black 1pt solid; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_499_20181001__20190930_zD0ElrIeVuK2" style="border-bottom: Black 1pt solid; text-align: center"&gt;2019&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_400_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 56%; text-align: left"&gt;Income tax benefit at statutory federal rate&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;(5,519,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;(5,505,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_401_eus-gaap--IncomeTaxReconciliationForeignIncomeTaxRateDifferential_i_pp0p0" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Foreign income taxed at other rates&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(723,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(825,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40F_eus-gaap--IncomeTaxReconciliationOtherAdjustments_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Other permanent differences&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;35,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;140,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40C_ecustom--IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopmentCreditBenefit_i_pp0p0" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Research and development credit benefit&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,267,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;914,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_401_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_z1PYeXsbnRgi" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;State and local taxes&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,911,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,487,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40C_eus-gaap--IncomeTaxReconciliationPriorYearIncomeTaxes_i_pp0p0" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Adjustment and true up to prior year tax provision&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;373,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;194,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_405_eus-gaap--EffectOfExchangeRateOnCash_d0_zqtfu3RSRnmg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Effect of change in statutory rates&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;36,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&#160;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_408_eus-gaap--TaxesExcludingIncomeAndExciseTaxes_i_pp0p0" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;State minimum and excise taxes&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;22,664&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;82,181&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_400_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_zdxGf7UkZNn1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;Change in valuation allowances&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;7,442,000&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;6,569,000&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_405_eus-gaap--DeferredIncomeTaxExpenseBenefit_i_pp0p0" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;Income tax expense&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;22,664&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;82,181&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;



</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="From2019-10-01to2020-09-30"
      decimals="0"
      unitRef="USD">-5519000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="From2018-10-012019-09-30"
      decimals="0"
      unitRef="USD">-5505000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential
      contextRef="From2019-10-01to2020-09-30"
      decimals="0"
      unitRef="USD">-723000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential
      contextRef="From2018-10-012019-09-30"
      decimals="0"
      unitRef="USD">-825000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="From2019-10-01to2020-09-30"
      decimals="0"
      unitRef="USD">35000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="From2018-10-012019-09-30"
      decimals="0"
      unitRef="USD">140000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <avxl:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopmentCreditBenefit
      contextRef="From2019-10-01to2020-09-30"
      decimals="0"
      unitRef="USD">1267000</avxl:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopmentCreditBenefit>
    <avxl:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopmentCreditBenefit
      contextRef="From2018-10-012019-09-30"
      decimals="0"
      unitRef="USD">914000</avxl:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopmentCreditBenefit>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="From2019-10-01to2020-09-30"
      decimals="0"
      unitRef="USD">-2911000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="From2018-10-012019-09-30"
      decimals="0"
      unitRef="USD">-1487000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes
      contextRef="From2019-10-01to2020-09-30"
      decimals="0"
      unitRef="USD">373000</us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes
      contextRef="From2018-10-012019-09-30"
      decimals="0"
      unitRef="USD">194000</us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes>
    <us-gaap:EffectOfExchangeRateOnCash
      contextRef="From2019-10-01to2020-09-30"
      decimals="0"
      unitRef="USD">36000</us-gaap:EffectOfExchangeRateOnCash>
    <us-gaap:EffectOfExchangeRateOnCash
      contextRef="From2018-10-012019-09-30"
      decimals="0"
      unitRef="USD">0</us-gaap:EffectOfExchangeRateOnCash>
    <us-gaap:TaxesExcludingIncomeAndExciseTaxes
      contextRef="From2019-10-01to2020-09-30"
      decimals="0"
      unitRef="USD">22664</us-gaap:TaxesExcludingIncomeAndExciseTaxes>
    <us-gaap:TaxesExcludingIncomeAndExciseTaxes
      contextRef="From2018-10-012019-09-30"
      decimals="0"
      unitRef="USD">82181</us-gaap:TaxesExcludingIncomeAndExciseTaxes>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2019-10-01to2020-09-30"
      decimals="0"
      unitRef="USD">7442000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2018-10-012019-09-30"
      decimals="0"
      unitRef="USD">6569000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="From2019-10-01to2020-09-30"
      decimals="0"
      unitRef="USD">22664</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="From2018-10-012019-09-30"
      decimals="0"
      unitRef="USD">82181</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign contextRef="AsOf2020-09-30" decimals="0" unitRef="USD">76800000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign contextRef="AsOf2019-09-30" decimals="0" unitRef="USD">60800000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign>
    <avxl:OperatingLossCarryForwardsExpirationYear1 contextRef="From2019-10-01to2020-09-30">2027</avxl:OperatingLossCarryForwardsExpirationYear1>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal contextRef="AsOf2020-09-30" decimals="0" unitRef="USD">103100000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal contextRef="AsOf2019-09-30" decimals="0" unitRef="USD">64000000.0</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2020-09-30_us-gaap_ForeignCountryMember"
      decimals="0"
      unitRef="USD">4300000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2020-09-30_us-gaap_ForeignCountryMember_currency_AUD"
      decimals="0"
      unitRef="USD">6000000.0</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2019-09-30_us-gaap_ForeignCountryMember"
      decimals="0"
      unitRef="USD">3500000</us-gaap:OperatingLossCarryforwards>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140429214193832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 28, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--09-30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37606<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ANAVEX LIFE SCIENCES CORP.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001314052<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">98-0608404<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">NV<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">51 W 52nd Street<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">7th Floor<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">New York<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">US<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">10019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">844<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">689-3939<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common
    Stock, $0.001 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">AVXL<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 177,399,544<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66,962,957<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140429214224600">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 29,249,018<span></span>
</td>
<td class="nump">$ 22,185,630<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesReceivable', window );">Incentive and tax receivables</a></td>
<td class="nump">4,849,340<span></span>
</td>
<td class="nump">2,642,745<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses and deposits</a></td>
<td class="nump">443,839<span></span>
</td>
<td class="nump">500,998<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">34,542,197<span></span>
</td>
<td class="nump">25,329,373<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">3,989,054<span></span>
</td>
<td class="nump">3,523,332<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">3,316,574<span></span>
</td>
<td class="nump">1,516,342<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total Liabilities</a></td>
<td class="nump">7,305,628<span></span>
</td>
<td class="nump">5,039,674<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Capital stock Authorized: 10,000,000 preferred stock, par value $0.001 per share</a></td>
<td class="nump">(0)<span></span>
</td>
<td class="nump">(0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Capital stock Authorized: 100,000,000 common shares, par value $0.001 per share Issued and outstanding: 62,045,198 common shares (2019 - 52,650,521)</a></td>
<td class="nump">62,047<span></span>
</td>
<td class="nump">52,652<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">186,851,752<span></span>
</td>
<td class="nump">153,633,807<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(159,677,230)<span></span>
</td>
<td class="num">(133,396,760)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Stockholders' Equity</a></td>
<td class="nump">27,236,569<span></span>
</td>
<td class="nump">20,289,699<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total Liabilities and Stockholders' Equity</a></td>
<td class="nump">$ 34,542,197<span></span>
</td>
<td class="nump">$ 25,329,373<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.5(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.10)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6787-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140429216535352">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common shares, authorized</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common shares, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common shares, issued</a></td>
<td class="nump">62,045,198<span></span>
</td>
<td class="nump">52,650,521<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common shares, outstanding</a></td>
<td class="nump">62,045,198<span></span>
</td>
<td class="nump">52,650,521<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140429214166488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">$ 5,856,609<span></span>
</td>
<td class="nump">$ 6,846,599<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">25,231,623<span></span>
</td>
<td class="nump">22,260,349<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="num">(31,088,232)<span></span>
</td>
<td class="num">(29,106,948)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expenses)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_NonOperatingIncomeFromGrant', window );">Grant income</a></td>
<td class="nump">149,888<span></span>
</td>
<td class="nump">298,943<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_ResearchAndDevelopmentIncentiveIncome', window );">Research and development incentive income</a></td>
<td class="nump">4,375,025<span></span>
</td>
<td class="nump">2,465,691<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNet', window );">Interest income, net</a></td>
<td class="nump">179,973<span></span>
</td>
<td class="nump">207,280<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain on settlement of accounts payable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">115,758<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts', window );">Financing related charges</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(151,133)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign exchange gain (loss), net</a></td>
<td class="nump">125,540<span></span>
</td>
<td class="num">(42,389)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income, net</a></td>
<td class="nump">4,830,426<span></span>
</td>
<td class="nump">2,894,150<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Net loss before provision for income taxes</a></td>
<td class="num">(26,257,806)<span></span>
</td>
<td class="num">(26,212,798)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Income tax expense, current</a></td>
<td class="num">(22,664)<span></span>
</td>
<td class="num">(82,181)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss and comprehensive loss</a></td>
<td class="num">$ (26,280,470)<span></span>
</td>
<td class="num">$ (26,294,979)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract', window );"><strong>Net Loss per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted</a></td>
<td class="num">$ (0.45)<span></span>
</td>
<td class="num">$ (0.54)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract', window );"><strong>Weighted average number of shares outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Basic and diluted</a></td>
<td class="nump">58,194,894<span></span>
</td>
<td class="nump">48,906,470<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_NonOperatingIncomeFromGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_NonOperatingIncomeFromGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_ResearchAndDevelopmentIncentiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_ResearchAndDevelopmentIncentiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the charge against earnings during the period for commitment fees and debt issuance expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109240200&amp;loc=d3e30690-110894<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121605123&amp;loc=d3e30226-110892<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=120253306&amp;loc=d3e28228-110885<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of operating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.10)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140429217531656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>Cash Flows used in Operating Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (26,280,470)<span></span>
</td>
<td class="num">$ (26,294,979)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operations:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">4,876,906<span></span>
</td>
<td class="nump">6,430,873<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_DeferredCharges', window );">Deferred costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">151,133<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnRestructuringOfDebt', window );">Gain on settlement of accounts payable</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(115,758)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in non-cash working capital balances related to operations:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable', window );">Incentive and tax receivables</a></td>
<td class="num">(2,206,595)<span></span>
</td>
<td class="num">(772,388)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses and deposits</a></td>
<td class="nump">57,159<span></span>
</td>
<td class="nump">803,196<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">465,722<span></span>
</td>
<td class="nump">683,797<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued liabilities</a></td>
<td class="nump">1,800,232<span></span>
</td>
<td class="nump">587,009<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(21,287,046)<span></span>
</td>
<td class="num">(18,527,117)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Cash Flows provided by Financing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Issuance of common shares</a></td>
<td class="nump">28,754,198<span></span>
</td>
<td class="nump">17,832,109<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Share issue costs</a></td>
<td class="num">(403,764)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Deferred financing charges</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(50,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">28,350,434<span></span>
</td>
<td class="nump">17,782,109<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Increase (decrease) in cash and cash equivalents during the period</a></td>
<td class="nump">7,063,388<span></span>
</td>
<td class="num">(745,008)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash and cash equivalents, beginning of year</a></td>
<td class="nump">22,185,630<span></span>
</td>
<td class="nump">22,930,638<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash and cash equivalents, end of year</a></td>
<td class="nump">$ 29,249,018<span></span>
</td>
<td class="nump">$ 22,185,630<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_DeferredCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_DeferredCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631418-115840<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631419-115840<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnRestructuringOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For a debtor, the aggregate gain (loss) recognized on the restructuring of payables arises from the difference between the book value of the debt before the restructuring and the fair value of the payments on the debt after restructuring is complete.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 60<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6402221&amp;loc=d3e15743-112638<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnRestructuringOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in income taxes receivable, which represents the amount due from tax authorities for refunds of overpayments or recoveries of income taxes paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInIncomeTaxesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140429218386248">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY - USD ($)<br></strong></div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Sep. 30, 2018</a></td>
<td class="nump">$ 45,935<span></span>
</td>
<td class="nump">$ 129,377,542<span></span>
</td>
<td class="num">$ (107,101,781)<span></span>
</td>
<td class="nump">$ 22,321,696<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance Beginning (in shares) at Sep. 30, 2018</a></td>
<td class="nump">45,933,472<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_StockIssuedDuringPeriodValueAcquisitions2', window );">Purchase shares</a></td>
<td class="nump">$ 4,849<span></span>
</td>
<td class="nump">13,192,755<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">13,197,604<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_StockIssuedDuringPeriodSharesAcquisitions2', window );">Shares issued under 2015 Purchase Agreement - Purchase shares (in shares)</a></td>
<td class="nump">4,848,995<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2', window );">Commitment shares</a></td>
<td class="nump">$ 24<span></span>
</td>
<td class="num">(24)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2', window );">Shares issued under 2015 Purchase Agreement - Commitment shares (in shares)</a></td>
<td class="nump">23,701<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Purchase shares</a></td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="nump">4,633,005<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">4,634,505<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Shares issued under 2019 Purchase Agreement - Purchase shares (in shares)</a></td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1', window );">Commitment shares</a></td>
<td class="nump">$ 339<span></span>
</td>
<td class="num">(339)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement1', window );">Shares issued under 2019 Purchase Agreement - Commitment shares (in shares)</a></td>
<td class="nump">339,415<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_SharesIssuedPursuantToCashlessExerciseOfWarrants', window );">Shares issued pursuant to cashless exercise of warrants</a></td>
<td class="nump">$ 5<span></span>
</td>
<td class="num">(5)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_SharesIssuedPursuantToCashlessExerciseOfWarrantsInShares', window );">Shares issued pursuant to cashless exercise of warrants (in shares)</a></td>
<td class="nump">4,938<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">6,430,873<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">6,430,873<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(26,294,979)<span></span>
</td>
<td class="num">(26,294,979)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Sep. 30, 2019</a></td>
<td class="nump">$ 52,652<span></span>
</td>
<td class="nump">153,633,807<span></span>
</td>
<td class="num">(133,396,760)<span></span>
</td>
<td class="nump">20,289,699<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance Ending (in shares) at Sep. 30, 2019</a></td>
<td class="nump">52,650,521<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Purchase shares</a></td>
<td class="nump">$ 7,565<span></span>
</td>
<td class="nump">21,246,733<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">21,254,298<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Shares issued under 2019 Purchase Agreement - Purchase shares (in shares)</a></td>
<td class="nump">7,564,584<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1', window );">Commitment shares</a></td>
<td class="nump">$ 69<span></span>
</td>
<td class="num">(69)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement1', window );">Shares issued under 2019 Purchase Agreement - Commitment shares (in shares)</a></td>
<td class="nump">68,943<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_SharesIssuedPursuantToCashlessExerciseOfOptions', window );">Shares issued pursuant to cashless exercise of options</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_SharesIssuedPursuantToCashlessExerciseOfOptionsInShares', window );">Shares issued pursuant to cashless exercise of options (in shares)</a></td>
<td class="nump">721<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_SharesIssuedDuringPeriodValueUnderSalesAgreement', window );">Shares issued under Sales Agreement, net of shares issue costs</a></td>
<td class="nump">$ 1,760<span></span>
</td>
<td class="nump">7,094,376<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,096,136<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_SharesIssuedDuringPeriodSharesUnderSalesAgreement', window );">Shares issued under Sales Agreement, net of shares issue costs (in shares)</a></td>
<td class="nump">1,760,429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">4,876,906<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">4,876,906<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(26,280,470)<span></span>
</td>
<td class="num">(26,280,470)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Sep. 30, 2020</a></td>
<td class="nump">$ 62,047<span></span>
</td>
<td class="nump">$ 186,851,752<span></span>
</td>
<td class="num">$ (159,677,230)<span></span>
</td>
<td class="nump">$ 27,236,569<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance Ending (in shares) at Sep. 30, 2020</a></td>
<td class="nump">62,045,198<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_SharesIssuedDuringPeriodSharesUnderSalesAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_SharesIssuedDuringPeriodSharesUnderSalesAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_SharesIssuedDuringPeriodValueUnderSalesAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_SharesIssuedDuringPeriodValueUnderSalesAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_SharesIssuedPursuantToCashlessExerciseOfOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_SharesIssuedPursuantToCashlessExerciseOfOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_SharesIssuedPursuantToCashlessExerciseOfOptionsInShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_SharesIssuedPursuantToCashlessExerciseOfOptionsInShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_SharesIssuedPursuantToCashlessExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_SharesIssuedPursuantToCashlessExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_SharesIssuedPursuantToCashlessExerciseOfWarrantsInShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_SharesIssuedPursuantToCashlessExerciseOfWarrantsInShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_StockIssuedDuringPeriodSharesAcquisitions2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_StockIssuedDuringPeriodSharesAcquisitions2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_StockIssuedDuringPeriodValueAcquisitions2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_StockIssuedDuringPeriodValueAcquisitions2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326096&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued pursuant to acquisitions during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140429216382200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Description and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Business Description and Basis of Presentation</a></td>
<td class="text"><p id="xdx_808_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_z75PDRB2VO23" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"/>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: top; text-align: left">
    <td style="width: 7%"><span style="font: 10pt Times New Roman, Times, Serif">Note 1</span></td>
    <td style="width: 93%"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline"><span id="xdx_824_zUqaA1Rg7Ipk">Business Description
    and Basis of Presentation</span></span></span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"/>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Business</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Anavex
Life Sciences Corp. (&#8220;Anavex&#8221; or the &#8220;Company&#8221;) is a clinical stage biopharmaceutical company engaged
in the development of differentiated therapeutics by applying precision medicine to central nervous system (&#8220;CNS&#8221;)
diseases with high unmet need. Anavex analyzes genomic data from clinical studies to identify biomarkers, which are used to select
patients that will receive the therapeutic benefit for the treatment of neurodegenerative and neurodevelopmental diseases. The
Company&#8217;s lead compound ANAVEX<sup>&#174;</sup>2-73 is being developed to treat Alzheimer&#8217;s disease, Parkinson&#8217;s
disease and potentially other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological
monogenic disorder caused by mutations in the X-linked gene, methyl-CpG-binding protein 2 (&#8220;MECP2&#8221;).</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 12pt 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Basis
of Presentation</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">These
consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission
(&#8220;SEC&#8221;) and the instructions to Form 10-K and have been prepared under the accounting principles generally accepted
in the United States of America (&#8220;U.S. GAAP&#8221;).</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Liquidity</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">All
of the Company&#8217;s potential drug compounds are in the clinical development stage and the Company cannot be certain that its
research and development efforts will be successful or, if successful, that its potential drug compounds will ever be approved
for sales to pharmaceutical companies or generate commercial revenues. To date, we have not generated any revenues from our operations.
The Company expects the business to continue to experience negative cash flows for the foreseeable future and cannot predict when,
if ever, our business might become profitable.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company believes that its existing cash and cash equivalents, along with existing financial commitments from third parties, will
be sufficient to meet its cash commitments for in excess of two years after the date that these consolidated financial statements
are issued. The process of drug development can be costly, and the timing and outcomes of clinical trials is uncertain.&#160;The
assumptions upon which the Company has based its estimates are routinely evaluated and may be subject to change.&#160;The actual
amount of the Company&#8217;s expenditures will vary depending upon a number of factors including but not limited to the design,
timing and duration of future clinical trials, the progress of the Company&#8217;s research and development programs and the level
of financial resources available. The Company has the ability to adjust its operating plan spending levels based on the timing
of future clinical trials.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 12pt 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Other
than our rights related to the 2019 Purchase Agreement and the Sales Agreement (each as defined below in Note 4), there can be
no assurance that additional financing will be available to us when needed or, if available, that it can be obtained on commercially
reasonable terms. If the Company is not able to obtain the additional financing on a timely basis, if and when it is needed, it
will be forced to delay or scale down some or all of its research and development activities.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
December 2019, a novel strain of coronavirus, COVID-19, was reported to have surfaced in Wuhan, China. In March 2020, the World
Health Organization (&#8220;WHO&#8221;) declared COVID-19 to be a global pandemic as a result of the rapid spread of the virus
beyond its point of origin.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>









<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
global outbreak of COVID-19 continues to rapidly evolve as of the date these consolidated financial statements are issued. As
such, it is uncertain as to the full magnitude that the outbreak will have on the Company&#8217;s financial condition and future
results of operations. Management is actively monitoring the global situation on its business, including on its clinical trials
and operations and financial condition. The effects of COVID-19 did not have a material impact on the Company&#8217;s result of
operations or financial condition for the year ended September 30, 2020. However, given the daily evolution of the COVID-19 situation,
and the global responses to curb its spread, the Company is not able to estimate the effects COVID-19 may have on its future results
of operations or financial condition.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 12pt 42.6pt; text-align: justify; text-indent: -0.05pt"><span style="font: 10pt Times New Roman, Times, Serif">On
March 27, 2020, the President of the United States signed into law the &#8220;Coronavirus Aid, Relief, and Economic Security (CARES)
Act.&#8221; The CARES Act, among other things, includes provisions relating to refundable payroll tax credits, deferment of employer
side social security payments, net operating loss carryback periods, alternative minimum tax credit refunds, modifications to
the net interest deduction limitations, increased limitations on qualified charitable contributions, and technical corrections
to tax depreciation methods for qualified improvement property. The enactment of the CARES Act did not have any material impact
on the Company&#8217;s consolidated financial statements or deferred tax assets or liabilities.</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140429230517304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><p id="xdx_801_eus-gaap--SignificantAccountingPoliciesTextBlock_zPAEJlyL59U1" style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: top; text-align: left"><td style="width: 7%"><span style="font: 10pt Times New Roman, Times, Serif">Note
                                         2</span></td>
    <td style="width: 93%"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline"><span id="xdx_82A_znJJvmOlL31k">Summary of Significant
    Accounting Policies</span></span></span></td></tr>
</table>

<p id="xdx_84D_eus-gaap--UseOfEstimates_zqf4ghFK9O8l" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 42.55pt"/><td style="width: 18pt"><span style="font: 10pt Times New Roman, Times, Serif">a)</span></td><td style="text-align: justify"><span id="xdx_869_zEAgumzB06sa" style="font: 10pt Times New Roman, Times, Serif">Use
                                         of Estimates</span></td></tr></table>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify; margin-left: 42.55pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect
the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenue and
expenses in the reporting period. The Company regularly evaluates estimates and assumptions related to accounting for research
and development costs, incentive income receivable, valuation and recoverability of deferred tax assets, asset impairment, stock-based
compensation and loss contingencies. The Company bases its estimates and assumptions on current facts, historical experience and
various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making
judgments about the book values of assets and liabilities and the accrual of costs and expenses that are not readily apparent
from other sources. The actual results experienced by the Company may differ materially and adversely from the Company&#8217;s
estimates. To the extent there are material differences between the estimates and the actual results, future results of operations
will be affected.</span></p>

<p id="xdx_84E_eus-gaap--ConsolidationPolicyTextBlock_zhaxDESkVTBc" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>



<table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 42.5pt"/><td style="width: 18pt"><span style="font: 10pt Times New Roman, Times, Serif">b)</span></td><td id="xdx_86C_zg9HiwiTiKfl" style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Principles
                                         of Consolidation</span></td></tr></table>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify; margin-left: 42.55pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">These
consolidated financial statements include the accounts of Anavex Life Sciences Corp. and its wholly-owned subsidiaries, Anavex
Australia Pty Limited. (&#8220;Anavex Australia&#8221;), a company incorporated under the laws of Australia, Anavex Germany GmbH,
a company incorporated under the laws of Germany, and Anavex Canada Ltd., a company incorporated under the laws of the Province
of Ontario, Canada. All inter-company transactions and balances have been eliminated.</span></p>

<p id="xdx_84B_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zPqyXkDd3gml" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 42.55pt"/><td style="width: 18pt"><span style="font: 10pt Times New Roman, Times, Serif">c)</span></td><td id="xdx_861_zvIIr6UoDIAj" style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Cash
                                         and equivalents</span></td></tr></table>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify; margin-left: 42.55pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company considers only those investments which are highly liquid, readily convertible to cash and that mature within three months
from the date of purchase to be cash equivalents.</span></p>








<p id="xdx_847_eus-gaap--ResearchAndDevelopmentExpensePolicy_zYhMikPyjcA6" style="font: 10pt Arial, Helvetica, Sans-Serif; text-indent: 40pt; text-align: left; margin-top: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"/></p>

<table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 42.55pt"/><td style="width: 18pt"><span style="font: 10pt Times New Roman, Times, Serif">d)</span></td><td id="xdx_86F_zXm5kmXnzwQa" style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Research
                                         and Development Expenses</span></td></tr></table>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i/></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Research
and development costs are expensed as incurred. These expenses are comprised of the costs of the Company&#8217;s proprietary research
and development efforts, including preclinical studies, clinical trials, manufacturing costs, employee salaries and benefits and
stock based compensation expense, contract services including external research and development expenses incurred under arrangements
with third parties such as contract research organizations (&#8220;CROs&#8221;), facilities costs, overhead costs and other related
expenses. Milestone payments made by the Company to third parties are expensed when the specific milestone has been achieved.
Manufacturing costs are expensed as incurred in accordance with Accounting Standard Codification (&#8220;ASC&#8221;) 730, Research
and Development, as these materials have no alternative future use outside of their intended use.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Nonrefundable
advance payments for goods or services that will be used or rendered for future research and development activities are deferred
and amortized over the period that the goods are delivered, or the related services are performed, subject to an assessment of
recoverability. The Company makes estimates of costs incurred in relation to external CROs, and clinical site costs. The Company
analyzes the progress of clinical trials, including levels of patient enrollment, invoices received and contracted costs when
evaluating the adequacy of the amount expensed and the related prepaid asset and accrued liability. Significant judgments and
estimates must be made and used in determining the accrued balance and expense in any accounting period. The Company reviews and
accrues CRO expenses and clinical trial study expenses based on work performed and relies upon estimates of those costs applicable
to the stage of completion of a study. Accrued CRO costs are subject to revisions as such trials progress to completion. Revisions
are charged to expense in the period in which the facts that give rise to the revision become known. With respect to clinical
site costs, the financial terms of these agreements are subject to negotiation and vary from contract to contract. Payments under
these contracts may be uneven and depend on factors such as the achievement of certain events, the successful recruitment of patients,
the completion of portions of the clinical trial or similar conditions. The objective of our policy is to record expenses in our
financial statements based on the actual services received and efforts expended. As such, expense accruals related to clinical
site costs are recognized based on our estimate of the degree of completion of the event or events specified in the specific clinical
study or trial contract.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
addition, the Company incurs expenses in respect of intellectual property costs relating to patents and trademarks. The probability
of success and length of time to develop commercial applications of the compounds subject to the underlying patent and trademark costs
is difficult to determine and numerous risks and uncertainties exist with respect to the timely completion of the development
projects. There is no assurance the compounds subject to the underlying patents and trademarks will ever be successfully commercialized.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Due
to these risks and uncertainties, the patent and trademark costs do not meet the definition of an asset and thus are expensed
as incurred within general and administrative expenses.</span></p>










<p id="xdx_84E_eus-gaap--RevenueRecognitionIncentives_zuSeUQhdS7m6" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-indent: 40pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 42.55pt"/><td style="width: 18pt"><span style="font: 10pt Times New Roman, Times, Serif">e)</span></td><td id="xdx_861_zyUp2pHZqMX2" style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Research
                                         and Development Incentive Income</span></td></tr></table>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i/></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company is eligible to obtain certain research and development tax credits, including the New York City Biotechnology Tax Credit
(&#8220;NYC Biotech credit&#8221;), and the Australian research and development tax incentive credit (the &#8220;Australia R&amp;D
credit&#8221;) through a program administered through the Australian Tax Office (the &#8220;ATO&#8221;), which provides for a
cash refund based on a percentage of certain research and development activities undertaken in Australia by the Company&#8217;s
wholly owned subsidiary, Anavex Australia Pty Ltd. (&#8220;Anavex Australia&#8221;). <span id="xdx_90F_ecustom--CashRefundAvailableDescription_c20191001__20200930_zYDIUwSyjgIe" title="Cash Refund Available description">The cash refund is available to eligible
companies with an annual aggregate revenue of less than $20.0 million Australian during the reimbursable period.</span></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
tax incentives are available on the basis of specific criteria with which the Company must comply. Although the tax incentive
may be administered through the local tax authority, the Company has accounted for the incentives outside of the scope of ASC
Topic 740, Income Taxes (&#8220;ASC 740&#8221;), since the incentives are not linked to the Company&#8217;s taxable income and
can be realized regardless of whether the Company has generated taxable income in the respective jurisdictions.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">With
respect to the Australia R&amp;D credit, Anavex Australia may be eligible to receive the cash refund for certain research and
development expenses incurred by Anavex Australia outside of Australia, to the extent such expenses are pre-approved by the Australian
authority pursuant to an advanced overseas finding application. The Company accrues for the amount of cash refund it expects to
receive in relation to research and development expenses outside of Australia only to the extent it has received advanced approval
from the Department of Industry, Innovation and Science in Australia, pursuant to an approved advanced overseas finding application.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company recognizes the amount of cash refund it expects to receive related to the NYC Biotech credit and Australian research and
development tax incentive program when there is reasonable assurance that the cash refund will be received, when the relevant
expenditures have been incurred, and when the amount can be reliably measured. This amount is included in Incentive and tax receivables
in the accompanying consolidated balance sheets.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
addition, Anavex Australia and Anavex Canada incur Goods and Services Tax (GST) on certain services provided by local vendors.
As a domestic entity in those jurisdictions, Anavex Australia and Anavex Canada are entitled to a refund of the GST paid. Similarly,
Anavex Germany incurs Value Added Tax (VAT) on certain services provided by local vendors, to which it is entitled to a refund
of such VAT paid. The Company&#8217;s estimate of the amount of cash refund it expects to receive related to GST and VAT incurred
is included in Incentive and tax receivables in the accompanying consolidated balance sheets.</span></p>

<p id="xdx_847_eus-gaap--EarningsPerSharePolicyTextBlock_z9bhd4heuAOg" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 42.55pt"/><td style="width: 18pt"><span style="font: 10pt Times New Roman, Times, Serif">f)</span></td><td id="xdx_863_z5HZwLOz94rl" style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Basic
                                         and Diluted Loss per Share</span></td></tr></table>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify; margin-left: 42.55pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Basic
income/(loss) per common share is computed by dividing net income/(loss) available to common stockholders by the weighted average
number of common shares outstanding during the period. Diluted income/(loss) per common share is computed by dividing net income/(loss)
available to common stockholders by the sum of (1) the weighted-average number of common shares outstanding during the period,
(2) the dilutive effect of the assumed exercise of options and warrants using the treasury stock method and (3) the dilutive effect
of other potentially dilutive securities. For purposes of the diluted net loss per share calculation, options and warrants are
potentially dilutive securities and are excluded from the calculation of diluted net loss per share because their effect would
be anti-dilutive.</span></p>












<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">As
of September 30, 2020, diluted loss per share excludes <span id="xdx_90A_eus-gaap--IncrementalCommonSharesAttributableToCallOptionsAndWarrants_c20191001__20200930_pii" title="Loss per share for potentially dilutive common shares">10,576,266</span> (2019 &#8211; <span id="xdx_900_eus-gaap--IncrementalCommonSharesAttributableToCallOptionsAndWarrants_c20181001__20190930_pii" title="Loss per share for potentially dilutive common shares">8,812,933</span>) potentially dilutive common shares
related to outstanding options and warrants, as their effect was anti-dilutive.</span></p>

<p id="xdx_849_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zHovEUI4h1bd" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 42.55pt"/><td style="width: 18pt"><span style="font: 10pt Times New Roman, Times, Serif">g)</span></td><td id="xdx_86D_zNfEIBZhcqt3" style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Financial
                                         Instruments</span></td></tr></table>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify; margin-left: 42.55pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
book value of the Company&#8217;s financial instruments, consisting of cash and equivalents, incentive and tax receivables, and
accounts payable and accrued liabilities approximate their fair value due to the short-term maturity of such instruments. Unless
otherwise noted, it is management&#8217;s opinion that the Company is not exposed to significant interest, currency or credit
risks arising from these financial instruments.</span></p>

<p id="xdx_845_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zCbIp40N19gf" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 42.55pt"/><td style="width: 18pt"><span style="font: 10pt Times New Roman, Times, Serif">h)</span></td><td id="xdx_863_zVPPTBc3bS78" style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Foreign
                                         Currency Translation</span></td></tr></table>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify; margin-left: 42.55pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
functional currency of the Company is the US dollar. Monetary items denominated in a foreign currency are translated into US dollars
at exchange rates prevailing at the balance sheet date and non-monetary items are translated at exchange rates prevailing when
the assets were acquired, or obligations incurred. Foreign currency denominated expense items are translated at exchange rates
prevailing on the transaction date. Unrealized gains or losses arising from the translations are credited or charged to income
in the period in which they occur.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify; margin-left: 42.55pt"><span style="font: 10pt Times New Roman, Times, Serif">The
Company has determined that the functional currency of Anavex Australia Pty Limited, Anavex Germany GmbH, and Anavex Canada Ltd.
is the US dollar.</span></p>

<p id="xdx_84C_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zTUojE9iNMp7" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 42.55pt"/><td style="width: 18pt"><span style="font: 10pt Times New Roman, Times, Serif">i)</span></td><td id="xdx_86C_znNVXLYjswP3"><span style="font: 10pt Times New Roman, Times, Serif">Segment
                                         and Geographic Reporting</span></td></tr></table>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify; margin-left: 42.55pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Operating
segments are defined as components of an enterprise for which separate discrete information is available for evaluation by the
chief operating decision maker or decision-making group, in deciding how to allocate resources and in assessing performance. The
Company views its operations and manages its business as one operating segment, which is the business of developing novel therapies
for the management of CNS diseases.</span></p>

<p id="xdx_849_ecustom--GrantIncomePolicyTextBlock_zbwzoBiBjCk8" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top">
<td style="width: 42.55pt"/><td style="width: 18pt"><span style="font: 10pt Times New Roman, Times, Serif">j)</span></td><td id="xdx_86C_zsAUiTgEYkNb" style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Grant
                                         Income</span></td></tr></table>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Grant
income is recognized at the fair value of the grant when it is received, and all substantive conditions have been satisfied. Grants
received from government and other agencies in advance of the specific research and development costs to which they relate are
deferred and recognized in the consolidated statement of operations in the period they are earned and when the related research
and development costs are incurred.</span></p>

<p id="xdx_84A_eus-gaap--IncomeTaxPolicyTextBlock_zy1jE2n57rK2" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 42.55pt"/><td style="width: 18pt"><span style="font: 10pt Times New Roman, Times, Serif">k)</span></td><td id="xdx_869_zPTgLOqDBPqg" style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Income
                                         Taxes</span></td></tr></table>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify; margin-left: 42.55pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company follows the provisions of ASC 740, which requires the asset and liability method of accounting for income taxes. Under
the asset and liability method, deferred tax assets and liabilities are recognized for the future tax consequences attributable
to temporary differences between the financial statements carrying amounts of existing assets and liabilities and their respective
tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the
years in which those temporary differences are expected to be recovered or settled.</span></p>











<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify; margin-left: 42.55pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: justify; margin-right: 0; margin-left: 42.55pt"><span style="font: 10pt Times New Roman, Times, Serif">The
Company follows the provisions of ASC 740 regarding accounting for uncertainty in income taxes. The Company initially recognizes
tax positions in the financial statements when it is more likely than not the position will be sustained upon examination by the
tax authorities. Such tax positions are initially and subsequently measured as the largest amount of tax benefit that is greater
than 50% likely of being realized upon ultimate settlement with the tax authority assuming full knowledge of the position and
all relevant facts. Application requires numerous estimates based on available information. The Company considers many factors
when evaluating and estimating its tax positions and tax benefits, and its recognized tax positions and tax benefits may not accurately
anticipate actual outcomes. As additional information is obtained, there may be a need to periodically adjust the recognized tax
positions and tax benefits. These periodic adjustments may have a material impact on the consolidated statements of operations.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify; margin-left: 42.55pt"><span style="font: 10pt Times New Roman, Times, Serif">The
Company recognizes interest and penalties related to current income tax expense on the interest income, net line, in the accompanying
consolidated statement of operations. Accrued interest and penalties, if any, are included in accrued liabilities on the consolidated
balance sheets.</span></p>

<p id="xdx_844_eus-gaap--ShareBasedCompensationForfeituresPolicyTextBlock_z4JyiDfbV3kl" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 42.55pt"/><td style="width: 18pt"><span style="font: 10pt Times New Roman, Times, Serif">l)</span></td><td id="xdx_861_zrffvkOwY1mi" style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Stock-based
                                         Compensation</span></td></tr></table>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify; margin-left: 42.55pt">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company accounts for all stock-based payments and awards under the fair value method.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify; margin-left: 42.55pt"><span style="font: 10pt Times New Roman, Times, Serif">The
Company accounts for the granting of share purchase options and warrants to employees using the fair value method whereby all
awards to employees will be recorded at fair value on the date of the grant. The fair value of all share purchase options and
warrants are expensed over their contractual vesting period, or over the expected performance period for only the portion of awards
expected to vest, in the case of milestone-based vesting, with a corresponding increase to additional paid-in capital.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: justify"/>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: justify; margin-right: 0; margin-left: 42.55pt"><span style="font: 10pt Times New Roman, Times, Serif">Share
purchase options and warrants issued to non-employees are measured at the fair value of the equity instruments issued. Compensation
expense for share purchase options and warrants issued to non-employees is recorded over the service performance period. Prior
to the Company&#8217;s adoption of ASU No. 2018-07, Compensation-Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based
Payment Accounting on October 1, 2019, options and warrants subject to vesting were periodically re-measured until the counterparty
performance was complete, and any change therein was recognized over the vesting period of the award and in the same manner as
if the Company had paid cash instead of paying with or using equity based instruments. After the adoption of ASU No. 2018-07,
the Company measures equity-classified share-based payment awards issued to nonemployees on the grant date, rather than remeasuring
the awards through the performance completion date as previously required (see Note 2 n)).</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: justify; margin-right: 0; margin-left: 42.55pt"><span style="font: 10pt Times New Roman, Times, Serif">Compensation
costs for stock-based payments with graded vesting are recognized on a straight-line basis.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: justify; margin-right: 0; margin-left: 42.55pt"><span style="font: 10pt Times New Roman, Times, Serif">The
Company uses the Black-Scholes option valuation model to calculate the fair value of share purchase options and warrants at the
date of the grant. Option pricing models require the input of highly subjective assumptions, including the expected price volatility.
Changes in these assumptions can materially affect the fair value estimates.</span></p>





<p id="xdx_84F_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zrtONMDFaYfk" style="font: 10pt Arial, Helvetica, Sans-Serif; text-indent: 40pt; text-align: left; margin-top: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif"/></p>

<table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 42.55pt"/><td style="width: 18pt"><span style="font: 10pt Times New Roman, Times, Serif">m)</span></td><td id="xdx_86A_zvoqyRoz7lO3" style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Fair
                                         Value Measurements</span></td></tr></table>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Fair
value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in
the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at
the measurement date. Assets and liabilities that are measured at fair value are reported using a three-level fair value hierarchy
that prioritizes the inputs used to measure fair value. This hierarchy maximizes the use of observable inputs and minimizes the
use of unobservable inputs. The three levels of inputs used to measure fair value are as follows:</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt"><span style="font: 10pt Times New Roman, Times, Serif">Level
1 - 	quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access
at the measurement date;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Level
2 - observable inputs other than Level 1, quoted prices for similar assets or liabilities in active 		markets, quoted prices
for identical or similar assets and liabilities in markets that are not active, and model-derived prices whose inputs are observable
or whose significant value drivers are observable; and</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 60.55pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Level
3 - 	assets and liabilities whose significant value drivers are unobservable by little or no market activity and that are significant
to the fair value of the assets or liabilities.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">At
September 30, 2020 and 2019, the Company did not have any Level 3 assets or liabilities.</span></p>

<p id="xdx_847_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_ztjvIPjOXAKb" style="font: 10pt Arial, Helvetica, Sans-Serif; text-indent: 40pt; text-align: left; margin-top: 0; margin-right: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 42.55pt"/><td style="width: 18pt"><span style="font: 10pt Times New Roman, Times, Serif">n)</span></td><td id="xdx_86D_zQI1JnzoS1gj" style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Recent
                                         Accounting Pronouncements</span></td></tr></table>


<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Recently
Adopted Accounting Pronouncements</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
February 2016, Topic 842, Leases was issued to replace the leases requirements in Topic 840, Leases. The main difference
between previous U.S. GAAP and Topic 842 is the recognition of lease assets and lease liabilities by lessees for those leases
classified as operating leases under previous U.S. GAAP. A lessee should recognize in the balance sheet a liability to make
lease payments (the lease liability) and a right-of-use asset representing its right to use the underlying asset for the
lease term. For leases with a term of 12 months or less, a lessee is permitted to make an accounting policy election by class
of underlying asset not to recognize lease assets and lease liabilities. If a lessee makes this election, it should recognize
lease expense for such leases generally on a straight-line basis over the lease term. The accounting applied by a lessor is
largely unchanged from that applied under previous U.S. GAAP. The Company elected the package of practical expedients
permitted under the transition guidance that allowed, among other things, the historical lease classifications to be carried
forward without reassessment. Further, the Company elected to not recognize lease assets and lease liabilities for leases
with a term of 12 months or less. The adoption of this standard on October 1, 2019 did not have any impact on the Company's
consolidated results of operations, financial condition, cash flows, and financial statement disclosures.</span></p>















<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
June 2018, the FASB issued ASU No. 2018-07, Compensation-Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based
Payment Accounting, which simplifies the accounting for share-based payments to nonemployees for goods and services by aligning
it with the accounting for share-based payments to employees, with certain exceptions. The new guidance was effective for the
Company beginning on October 1, 2019 and was required to be applied retrospectively with the cumulative effect recognized at the
date of initial application. The adoption of this standard on October 1, 2019 did not have any material impact on the Company's
consolidated results of operations, financial condition, cash flows, and financial statement disclosures.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Recent
Accounting Pronouncements Not Yet Adopted</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
December 2019, the FASB issued ASU 2019-12, "Simplifying the Accounting for Income Taxes (ASC 740)", which is intended
to simplify various aspects related to accounting for income taxes by removing certain exceptions to the general principles in
Topic 740 and clarifying and amending existing guidance to improve consistent application. ASU 2019-12 is effective for the Company
on October 1, 2021. Early adoption is permitted. The Company is currently evaluating the impact of this guidance on its consolidated
financial statements but does not expect such guidance to have a material impact.</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140429216460648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Income<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_DisclosureOtherIncomeAbstract', window );"><strong>Other Income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_OtherIncomeDisclosureTextBlock', window );">Other Income</a></td>
<td class="text"><p id="xdx_80C_ecustom--OtherIncomeDisclosureTextBlock_zz32Y6XIRnG8" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: top; text-align: left"><td style="width: 7%"><span style="font: 10pt Times New Roman, Times, Serif">Note
                                         3</span></td>
    <td style="width: 93%"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline"><span id="xdx_821_zKYw3RGdgpj5">Other Income</span></span></span></td></tr>
</table>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Grant
income</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">During
the year ended September 30, 2017, the Company was awarded grant funding in the amount of $<span id="xdx_90C_ecustom--FundingOfDeferredIncomeAwardedGrant_c20161001__20170930__srt--ProductOrServiceAxis__custom--ClinicalStudyGrantMember_pp0p0" title="Awarded grant funding amount">597,886</span>. The grant was received in
equal quarterly installments over a period of two years ending during the year ended September 30, 2020, in exchange for a commitment
to complete clinical testing for a therapeutic drug candidate for the treatment of Rett syndrome.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">The
grant income was deferred when received and amortized to other income as the related research and development expenditures were
incurred. During the year ended September 30, 2020, the Company recognized $<span id="xdx_902_ecustom--NonOperatingIncomeFromGrant_c20191001__20200930_pp0p0" title="Grant income"><span id="xdx_901_ecustom--NonOperatingIncomeFromGrant_pp0p0_c20191001__20200930_zv7vl8S7LZyb" title="Grant income">149,888</span></span> (2019: $<span id="xdx_902_ecustom--NonOperatingIncomeFromGrant_pp0p0_c20181001__20190930_zbzFY1ZJTIl5" title="Grant income">298,943</span>) of this grant on its statement
of operations as a component of other income. At September 30, 2020, the Company had recognized the full amount of grant funding.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>










<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"/></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Research
and development incentive income</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Research
and development incentive income during the years ended September 30, 2020 and 2019 represents the receipt by Anavex Australia,
of the Australia R&amp;D Credit, as well as receipt by the Company of the New York City Biotechnology Credit (&#8220;NYC Biotech
credit&#8221;).</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">During
the year ended September 30, 2020, the Company recorded research and development incentive income of $<span id="xdx_908_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pp0p0_c20191001__20200930_zKLsquhZRyJ" title="Research and development incentive income">4,375,025</span> (AUD <span id="xdx_900_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pp0p0_uUSD_c20191001__20200930__srt--CurrencyAxis__currency--AUD_zIbRUdKipgo6" title="Research and development incentive income">6,392,266</span>)
(2019: $<span id="xdx_905_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pp0p0_c20181001__20190930_zrSpdSG54Xoh" title="Research and development incentive income">2,215,691</span> (AUD <span id="xdx_900_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pp0p0_uUSD_c20181001__20190930__srt--CurrencyAxis__currency--AUD_zjdwEUNoiJr8" title="Research and development incentive income">3,281,300</span>)) in respect of the Australia R&amp;D Credit for eligible research and development expenses incurred
during the year, or expenditures to which the Company became eligible during the year.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">During
the year ended September 30, 2019, the Company recorded research and development incentive income of $<span id="xdx_904_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pp0p0_c20181001__20190930__srt--ProductOrServiceAxis__custom--NYCBiotechCreditMember_zo7NuVdY2sah" title="Research and development incentive income">250,000</span> in respect of the
NYC Biotech Credit. The Company was no longer eligible for the NYC Biotech Credit for the fiscal year ended September 30, 2020.</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_DisclosureOtherIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_DisclosureOtherIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_OtherIncomeDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_OtherIncomeDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140429224053576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Offering Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_DisclosureEquityOfferingAgreementsAbstract', window );"><strong>Equity Offering Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_EquityOfferingAgreementsTextBlock', window );">Equity Offering Agreements</a></td>
<td class="text"><p id="xdx_809_ecustom--EquityOfferingAgreementsTextBlock_ziXhn4RIZmh8" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: top; text-align: left"><td style="width: 7%"><span style="font: 10pt Times New Roman, Times, Serif">Note
                                         4</span></td>
    <td style="width: 93%"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline"><span id="xdx_820_zwBBPE1lB1T7">Equity Offering Agreements</span></span></span></td></tr>
</table>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">2015
Purchase Agreement</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">On
October 21, 2015, the Company entered into a $50,000,000 purchase agreement (the &#8220;2015 Purchase Agreement&#8221;) with Lincoln
Park Capital Fund, LLC (&#8220;Lincoln Park&#8221;), pursuant to which the Company could sell and issue to Lincoln Park, and Lincoln
Park was obligated to purchase, up to $50,000,000 in value of its shares of common stock from time to time over a 36-month period.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">During
the year ended September 30, 2019, the Company issued to Lincoln Park an aggregate of <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pii_c20181001__20190930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zBSOc3VRAqDg">4,872,696</span> shares of common stock under the
2015 Purchase Agreement, including <span id="xdx_900_ecustom--StockIssuedDuringPeriodSharesNewIssues4_pii_c20181001__20190930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zbGbfUNv9rEa">4,848,995</span> shares of common stock for an aggregate purchase price of $<span id="xdx_905_ecustom--StockIssuedDuringPeriodValueNewIssues3_pp0p0_c20181001__20190930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zakyZTGUPy7e">13,197,604</span> and <span id="xdx_906_ecustom--StockIssuedDuringPeriodSharesNewIssues3_pii_c20181001__20190930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_z3OHjx3k46g7">23,701</span>
as commitment shares. At September 30, 2019, all remaining purchase amounts available for issuance under the 2015 Purchase Agreement
had been utilized and the 2015 Purchase Agreement has expired pursuant to its terms. As such, no further shares will be sold under
the 2015 Purchase Agreement.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>












<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">2019
Purchase Agreement</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">On
June 7, 2019, the Company entered into a $<span id="xdx_90D_ecustom--ValueOfSharesObligatedToPurchase_c20190606__20190607__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pp0p0" title="Total number of shares obligated to purchase">50,000,000</span> purchase agreement (the &#8220;2019 Purchase Agreement&#8221;) with Lincoln
Park, as amended on July 1, 2020 (the &#8220;Amendment Date&#8221;), pursuant to which the Company may sell and issue to Lincoln
Park, and Lincoln Park is obligated to purchase, up to $50,000,000 in value of its shares of common stock from time to time from
June 12, 2019, the date a prospectus supplement under which shares of common stock issuable under the 2019 Purchase Agreement
was filed with the SEC, until July 1, 2022, which is the first day of the next month following the <span id="xdx_90A_ecustom--AgreementTerm_dtM_c20190606__20190607__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zswYi1t0JfHa" title="Agreement term">36</span>-month anniversary of June
12, 2019.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_904_eus-gaap--UnrecordedUnconditionalPurchaseObligationDescription_c20190606__20190607__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember" title="Description of purchases price">The
Company may direct Lincoln Park, at its sole discretion, and subject to certain conditions, to purchase up to 200,000 shares of
common stock on any business day (a &#8220;Regular Purchase&#8221;). The amount of a Regular Purchase may be increased under certain
circumstances up to 250,000 shares, provided that Lincoln Park&#8217;s committed obligation for Regular Purchases on any business
day shall not exceed $2,000,000. In the event the Company purchases the full amount allowed for a Regular Purchase on any given
business day, the Company may also direct Lincoln Park to purchase additional amounts as accelerated and additional accelerated
purchases. The purchase price of shares of common stock related to the future funding will be based on the then prevailing market
prices of such shares at the time of sales as described in the 2019 Purchase Agreement.</span></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company&#8217;s sale of shares of Common Stock to Lincoln Park subsequent to the Amendment Date is limited to <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pii_c20191001__20200930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zPOm8p4VLhr9">12,016,457</span> shares
of Common Stock, representing <span id="xdx_909_ecustom--PercentageOfGrossProceedsFromSales_pii_dp_c20191001__20200930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zRBtmNmXF893">19.99%</span> of the shares of the Common Stock outstanding on the Amendment Date unless (i) shareholder
approval is obtained to issue more than such amount or (ii) the average price of all applicable sales of Common Stock to Lincoln
Park under the 2019 Purchase Agreement after the Amendment Date equals or exceeds the lower of (A) the closing price of the Common
Stock on the Nasdaq Capital Market immediately preceding the Amendment Date or (B) the average of the closing prices of the Common
Stock on the Nasdaq Capital Market for the five Business Days immediately preceding the Amendment Date, and it also limits the
Company&#8217;s sale of shares to Lincoln Park to the extent it would cause Lincoln Park to beneficially own more than 4.99% of
the Company&#8217;s outstanding shares of Common Stock at any given time.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 12pt 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
consideration for entering into the 2019 Purchase Agreement, the Company issued to Lincoln Park <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20190606__20190607__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pii" title="Number of share issued">324,383</span> shares of common stock
as a commitment fee and agreed to issue up to <span id="xdx_90D_ecustom--NumberOfSharesObligatedToPurchaseProrataBasic_c20190606__20190607__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pii" title="Pro rata basic number of shares obligated to purchase">162,191</span> shares pro rata, when and if, Lincoln Park purchases at the Company&#8217;s
discretion the $50,000,000 aggregate commitment.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 12pt 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"/></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">During
the year ended September 30, 2020, the Company issued to Lincoln Park an aggregate of <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pii_c20191001__20200930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zvwjbRADkBf8">7,633,527</span> (2019 -<span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pii_c20181001__20190930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zPc8aJO5yWMc">1,839,415</span>) shares of common
stock under the 2019 Purchase Agreement, including <span id="xdx_903_ecustom--StockIssuedDuringPeriodSharesNewIssues4_pii_c20191001__20200930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zLfnMaZbIml3">7,564,584</span> (2019: <span id="xdx_90B_ecustom--StockIssuedDuringPeriodSharesNewIssues4_pii_c20181001__20190930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zawTt1F3bA38">1,500,000</span>) shares of common stock for an aggregate purchase
price of $<span id="xdx_90D_ecustom--StockIssuedDuringPeriodValueNewIssues3_pp0p0_c20191001__20200930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zfCGnkrPJQT9">21,254,298</span> (2019: $<span id="xdx_90F_ecustom--StockIssuedDuringPeriodValueNewIssues3_pp0p0_c20181001__20190930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zCy4fdXcsxGj">4,634,505</span>) and <span id="xdx_90E_ecustom--StockIssuedDuringPeriodSharesNewIssues3_pii_c20191001__20200930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zopjK80y29bf">68,943</span> (2019: <span id="xdx_904_ecustom--StockIssuedDuringPeriodSharesNewIssues3_pii_c20181001__20190930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zq4SbVkWgwld">339,415</span>) commitment shares. At September 30, 2020, an amount of $<span id="xdx_901_ecustom--StockIssuedDuringPeriodValueNewIssues4_pp0p0_c20191001__20200930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zVupzoNiHA3c">24,111,197</span>
(2019: $<span id="xdx_906_ecustom--StockIssuedDuringPeriodValueNewIssues4_pp0p0_c20181001__20190930__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zwZUOHdnEb8h">45,365,495</span>) remained available under the 2019 Purchase Agreement.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>










<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Sales
Agreement</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company entered into a Controlled Equity Offering Sales Agreement on July 6, 2018, which was amended and restated on May 1, 2020
(the &#8220;Sales Agreement&#8221;) with Cantor Fitzgerald&#160;&amp; Co. and SVB Leerink LLC (together the &#8220;Sales Agents&#8221;),
pursuant to which the Company may offer and sell shares of common stock, for aggregate gross sale proceeds of up to $<span id="xdx_906_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20200429__20200501__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_pp0p0" title="Gross sale proceeds">50,000,000</span>
from time to time through the Sales Agents (the &#8220;Offering&#8221;).&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Upon
delivery of a placement notice based on the Company&#8217;s instructions and subject to the terms and conditions of the Sales
Agreement, the Sales Agents may sell the Shares by methods deemed to be an &#8220;at the market offering&#8221; offering, in negotiated
transactions at market prices prevailing at the time of sale or at prices related to such prevailing market prices, or by any
other method permitted by law, including negotiated transactions, subject to the prior written consent of the Company. The Company
is not obligated to make any sales of Shares under the Sales Agreement. The Company or Sales Agents may suspend or terminate the
offering of Shares upon notice to the other party, subject to certain conditions.&#160; The Sales Agents will act as agent on
a commercially reasonable efforts basis consistent with their normal trading and sales practices and applicable state and federal
law, rules&#160;and regulations and the rules&#160;of Nasdaq.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company has agreed to pay the Sales Agents commissions for their services of up to <span id="xdx_900_ecustom--PercentageOfGrossProceedsFromSales_c20191001__20200930__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_pii" title="Percentage of gross proceeds from sales">3.0%</span> of the gross proceeds from the sale of
the Shares pursuant to the Sales Agreement.&#160; The Company also agreed to provide the Sales Agents with customary indemnification
and contribution rights. During the year ended September 30, 2020, <span id="xdx_90A_ecustom--NumberOfStockSold_c20191001__20200930__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_zv0uaeXjvJ81" title="Number of stock sold">1,760,429</span> shares were sold pursuant to the Offering for gross
proceeds of $<span id="xdx_902_ecustom--GrossProceedsFromSaleOfCommonStock_c20191001__20200930__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_zAjwJC284hj2" title="Gross proceeds from sale of common stock">7,499,900</span> (net proceeds of $<span id="xdx_902_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20191001__20200930__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_zCdrqBUHX8K3" title="Proceeds from sale of common stock">7,096,136</span> after deducting offering expenses). At September 30, 2020, an amount of $<span id="xdx_90D_ecustom--NumberOfSharesAvailable_iI_c20200930__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_zAAUcfZJULHi" title="Number of shares available">42,500,100</span>
remained available under the Sales Agreement.</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_DisclosureEquityOfferingAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_DisclosureEquityOfferingAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_EquityOfferingAgreementsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_EquityOfferingAgreementsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140429216138184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsDisclosureTextBlock', window );">Commitments</a></td>
<td class="text"><p id="xdx_80D_eus-gaap--CommitmentsDisclosureTextBlock_zhdF2fjEldOk" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: top; text-align: left"><td style="width: 7%"><span style="font: 10pt Times New Roman, Times, Serif">Note
                                         5</span></td>
    <td style="width: 93%"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline"><span id="xdx_821_zDBqjo45kMGk">Commitments</span></span></span></td></tr>
</table>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 42.75pt"/><td style="width: 18pt"><span style="font: 10pt Times New Roman, Times, Serif">a)</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">Lease</span></td></tr></table>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; color: gray"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">During
the year ended September 30, 2020 the Company incurred office lease expense of $<span id="xdx_90E_eus-gaap--LeaseAndRentalExpense_c20191001__20200930_pp0p0">233,423
</span></span><span style="font: 10pt Times New Roman, Times, Serif">(2019: $<span id="xdx_904_eus-gaap--LeaseAndRentalExpense_c20181001__20190930_pp0p0">190,416</span></span><span style="font: 10pt Times New Roman, Times, Serif">).</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; color: gray"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 42.75pt"/><td style="width: 18pt"><span style="font: 10pt Times New Roman, Times, Serif">b)</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">Litigation</span></td></tr></table>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 60.75pt"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">The
Company is subject to claims and legal proceedings that arise in the ordinary course of business. Such matters are inherently
uncertain, and there can be no guarantee that the outcome of any such matter will be decided favorably to the Company or that
the resolution of any such matter will not have a material adverse effect upon the Company's consolidated financial statements.
The Company does not believe that any of such pending claims and legal proceedings will have a material adverse effect on its
consolidated financial statements.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 60.75pt; color: gray"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>












<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"/></p>

<table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 42.75pt"/><td style="width: 18pt"><span style="font: 10pt Times New Roman, Times, Serif">c)</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">Share
                                         Purchase Warrants</span></td></tr></table>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 58.5pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
following table summarizes the warrant activity during the years ended September 30, 2020 and 2019:</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"/>

<table cellpadding="0" cellspacing="0" id="xdx_892_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zCeX6ZSscUs4" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%; margin-left: 50pt" summary="xdx: Disclosure - Commitments (Details)">
<tr style="vertical-align: bottom">
    <td colspan="3" style="text-align: left">&#160;<span id="xdx_8B7_zpVFSbMks2pe" style="display: none">Schedule of exercisable share purchase warrants outstanding</span></td><td>&#160;</td>
    <td colspan="3">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Weighted Average Exercise</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Number of Shares</td><td style="border-bottom: Black 1pt solid">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Exercise Price ($)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 60%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Balance , September 30 , 2018</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pii_c20181001__20190930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zmTtd7r9uibd" style="width: 15%; text-align: right" title="Share Purchase Warrants Balance, at beginning">678,379</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_iS_pii_c20181001__20190930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zfsfjDTFyuCc" style="width: 15%; text-align: right" title="Weighted Average Exercise Price Balance, at beginning">2.87</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Exercised</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pii_di_c20181001__20190930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zz1loBMAaAkh" style="text-align: right" title="Share Purchase Warrants Exercised">(8,750</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExercised_c20181001__20190930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_pii" style="text-align: right" title="Weighted Average Exercise Price, Exercised">1.13</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Expired</span></td><td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_pii_di_c20181001__20190930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zonaDXZ9QF17" style="border-bottom: Black 1pt solid; text-align: right" title="Share Purchase Warrants Expired">(319,629</td><td style="border-bottom: Black 1pt solid; text-align: left">)</td><td style="border-bottom: Black 1pt solid">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExpired_c20181001__20190930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_pii" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Expired">1.46</td><td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Balance , September 30 , 2019</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pii_c20191001__20200930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zYN80Ghjgly9" style="text-align: right" title="Share Purchase Warrants Balance, at beginning">350,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_iS_pii_c20191001__20200930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zQxXXV1tAT3c" style="text-align: right" title="Weighted Average Exercise Price Balance, at beginning">4.19</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Granted</span></td><td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod_c20191001__20200930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_pii" style="border-bottom: Black 1pt solid; text-align: right" title="Share Purchase Warrants Granted">150,000</td><td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice_c20191001__20200930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_pii" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Granted">3.17</td><td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Balance,
                                                                            September 30, 2020</span></td><td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pii_c20191001__20200930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_z8toB2rDxIb" style="border-bottom: Black 1pt solid; text-align: right" title="Share Purchase Warrants Balance, at ending">500,000</td><td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_iE_pii_c20191001__20200930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zPE1MCG6ernb" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price Balance, at ending">3.88</td><td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td></tr>
</table>



<p id="xdx_8AF_zscZ3vRd44Dl" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"/></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 6pt 42.55pt; text-align: justify; text-indent: -0.8pt"><span style="font: 10pt Times New Roman, Times, Serif">During
the year ended September 30, 2019, the Company issued <span id="xdx_902_ecustom--SharesIssuedPursuantToCashlessExerciseOfWarrantInShares_pii_c20191001__20200930_zMG6cZW4sGOj" title="Shares issued pursuant to cashless exercise of warrants">4,938</span> shares in connection with the exercise of <span id="xdx_90A_ecustom--StockIssuedPursuantToCashlessExerciseOfWarrants_c20191001__20200930_pii" title="Stock issued pursuant to cashless exercise of warrants">8,750</span> warrants on a cashless
basis.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 6pt 42.55pt; text-align: justify; text-indent: -0.8pt"><span style="font: 10pt Times New Roman, Times, Serif">At
September 30, 2020 the Company had share purchase warrants outstanding as follows:</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 6pt 42.55pt; text-align: justify; text-indent: -0.8pt"/>

<table cellpadding="0" cellspacing="0" id="xdx_89F_ecustom--ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock_zNtmAaOFD1Mh" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 50%; margin-left: 50pt" summary="xdx: Disclosure - Commitments (Details 1)">
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_8BC_zFut8NusmD2i" style="display: none">Schedule of share purchase warrants outstanding</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="3" style="text-align: center">Number</td><td style="text-align: center">&#160;</td>
    <td colspan="3" style="text-align: center">Exercise Price</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">Expiry Date</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_c20200930__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_pii" style="width: 12%; text-align: right" title="Number">350,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_c20200930__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_pii" style="width: 12%; text-align: right" title="Exercise Price">4.19</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td id="xdx_98F_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_c20200930__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member" style="width: 56%; text-align: right" title="Expiry Date">June 30, 2021</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_c20200930__us-gaap--AwardTypeAxis__custom--PurchaseWarrants2Member_pii" style="text-align: right" title="Number">150,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_c20200930__us-gaap--AwardTypeAxis__custom--PurchaseWarrants2Member_pii" style="text-align: right" title="Exercise Price">3.17</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td id="xdx_98E_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_c20200930__us-gaap--AwardTypeAxis__custom--PurchaseWarrants2Member" style="text-align: right" title="Expiry Date">May 6, 2024</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_c20200930_pii" style="text-align: right" title="Number">500,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">&#160;</td></tr>
</table>



<p id="xdx_8A7_zpbNf3kB7Fx3" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 6pt 42.55pt; text-align: justify; text-indent: -0.8pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>










<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"/></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 42.75pt"/><td style="width: 18pt"><span style="font: 10pt Times New Roman, Times, Serif">d)</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Stock&#8211;based
                                         Compensation Plan</span></td></tr></table>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">2015
Stock Option Plan</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify; text-indent: -1in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">On
September 18, 2015, the Company&#8217;s board of directors approved a 2015 Omnibus Incentive Plan (the &#8220;2015 Plan&#8221;),
which provided for the grant of stock options and restricted stock awards to directors, officers, employees and consultants of
the Company.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
maximum number of our common shares reserved for issue under the plan was <span id="xdx_90D_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_c20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pii" title="Maximum number of common shares reserved for future issuance">6,050,553</span> shares, subject to adjustment in the event
of a change of the Company&#8217;s capitalization. At September 30, 2020, <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zu0sesh6W6Ia">146,371</span> (2019: <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20190930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zMoDUtlMbv3k">146,371</span>) options remain available for
issue under the 2015 Plan.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">2019
Stock Option Plan</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">On
January 15, 2019, the Board approved the 2019 Omnibus Incentive Plan (the &#8220;2019 Plan&#8221;), which provides for the grant
of stock options and restricted stock awards to directors, officers, employees, consultants and advisors of the Company. Under
the terms of the 2019 Plan, <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2019Member_pii" title="Additional shares of common stock available for issuance">6,000,000</span> additional shares of Common Stock are available for issuance under the 2019 Plan, in addition
to the shares available under the 2015 Plan. Any awards outstanding under the 2015 Plan or the Company&#8217;s 2007 Stock Option
Plan (the &#8220;2007 Plan&#8221;) will remain subject to and be paid under the 2015 Plan or the 2007 Plan, respectively, and
any shares subject to outstanding awards under the 2015 Plan or the 2007 Plan that subsequently cease to be subject to such awards
(other than by reason of settlement of the awards in shares) will automatically become available for issuance under the 2019 Plan.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
2019 Plan provides that it may be administered by the Board, or the Board may delegate such responsibility to a committee. The
exercise price will be determined by the board of directors at the time of grant shall be at least equal to the fair market value
on such date. If the grantee is a 10% stockholder on the grant date, then the exercise price shall not be less than 110% of fair
market value of the Company&#8217;s shares of common stock on the grant date. Stock options may be granted under the 2019 Plan
for an exercise period of up to ten years from the date of grant of the option or such lesser periods as may be determined by
the board, subject to earlier termination in accordance with the terms of the 2019 Plan. At September 30, 2020, <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2019Member_zTfo6dJQhPY6">3,161,665</span> (2019:
<span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20190930__us-gaap--PlanNameAxis__custom--StockOptionPlan2019Member_zYBl353Lyqr6">4,788,333</span>) options remain available for issue under the 2019 Plan.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">A
summary of the status of Company&#8217;s outstanding stock purchase options is presented below:</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"/>

<table cellpadding="0" cellspacing="0" id="xdx_896_eus-gaap--ScheduleOfStockOptionsRollForwardTableTextBlock_zm10SLpqS2u6" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 50pt; margin-right: 30pt" summary="xdx: Disclosure - Commitments (Details 2)">
<tr style="vertical-align: bottom">
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: left"><span id="xdx_8BE_zhSeLDdBnF7f" style="display: none">Schedule of outstanding stock purchase options&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: center">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Number of Shares</td><td style="border-bottom: Black 1pt solid; text-align: center">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Weighted Average Exercise Price</td><td style="border-bottom: Black 1pt solid; text-align: center">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Weighted Average Grant Date Fair Value ($)</td><td style="border-bottom: Black 1pt solid; text-align: center">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Aggregate intrinsic value ($)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 26%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Outstanding, September 30, 2018</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pii_c20181001__20190930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zh9Gqg9kHKJf" style="width: 15%; text-align: right" title="Options Outstanding at beginning">6,506,917</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pii_c20181001__20190930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zba4eDIJnP5e" style="width: 15%; text-align: right" title="Weighted Average Exercise Price Outstanding at beginning">3.83</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 15%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20181001__20190930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zEKezIwO51H3" style="width: 15%; text-align: right" title="Aggregate intrinsic value Outstanding at beginning">2,353,088</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Granted</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20181001__20190930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pii" style="text-align: right" title="Options Granted">2,265,399</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20181001__20190930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pii" style="text-align: right" title="Weighted Average Exercise Price Granted">2.79</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20181001__20190930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pii" style="text-align: right" title="Weighted Average Grant Date Fair Value Granted">2.27</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Forfeited</span></td><td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pii_di_c20181001__20190930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zJKYxHhyezg5" style="border-bottom: Black 1pt solid; text-align: right" title="Options Forfeited">(309,383</td><td style="border-bottom: Black 1pt solid; text-align: left">)</td><td style="border-bottom: Black 1pt solid">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20181001__20190930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pii" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price Forfeited">3.25</td><td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Outstanding, September 30, 2019</span></td><td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pii_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zQTunKIezEq2" style="border-bottom: Black 1pt solid; text-align: right" title="Options Outstanding at beginning">8,462,933</td><td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pii_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_z8T1R15cmUx3" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price Outstanding at beginning">3.58</td><td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zKBvON9vvBTe" style="border-bottom: Black 1pt solid; text-align: right">4,115,032</td><td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Granted</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pii" style="text-align: right" title="Options Granted">1,695,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pii" style="text-align: right" title="Weighted Average Exercise Price Granted">2.96</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pii" style="text-align: right" title="Weighted Average Grant Date Fair Value Granted">2.27</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right" title="Aggregate intrinsic value Outstanding at ending"/><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Forfeited</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pii_di_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zC4oNndN1Jgc" style="text-align: right" title="Options Forfeited">(68,332</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pii" style="text-align: right" title="Weighted Average Exercise Price Forfeited">3.01</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Exercised</span></td><td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pii_di_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zgKsNRQ2uz4f" style="border-bottom: Black 1pt solid; text-align: right" title="Options Exercised">(13,335</td><td style="border-bottom: Black 1pt solid; text-align: left">)</td><td style="border-bottom: Black 1pt solid">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pii" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price Exercised">3.15</td><td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Outstanding, September 30, 2020</span></td><td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pii_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_z71n7ruaXmj2" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Outstanding at ending">10,076,266</td><td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pii_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zAOoelwUl4pf" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Outstanding at ending">3.48</td><td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zBdK6aD3ajf2" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value Outstanding at ending">14,982,581</td><td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Exercisable, September 30, 2020</span></td><td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zCSeOZ8OIdRg" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Exercisable at ending">7,412,100</td><td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pii_c20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zQ46uv7GgYnj" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Exercisable at ending">3.66</td><td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_c20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value Exercisable at ending">10,763,906</td><td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td></tr>
</table>



<p id="xdx_8A7_z0jlJsnN3pI4" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"/>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 6pt 42.55pt; text-align: justify; text-indent: -0.8pt"><span style="font: 10pt Times New Roman, Times, Serif"/></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 6pt 42.55pt; text-align: justify; text-indent: -0.8pt"><span style="font: 10pt Times New Roman, Times, Serif">During
the year ended September 30, 2020, the Company issued <span id="xdx_90C_ecustom--SharesIssuedPursuantToCashlessExercisesOfOption_c20191001__20200930_zXcjR5fThcF3" title="Shares issued pursuant to cashless exercises of option">721</span> shares in connection with the exercise of <span id="xdx_904_ecustom--NumberOfCashlessExerciseOption_c20191001__20200930_zROVJdJcKIm9" title="Number of cashless exercise option">13,335</span> options on a cashless
basis.</span></p>











<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
aggregate intrinsic value is calculated as the difference between the exercise price of the underlying awards and the quoted market
price of the Company&#8217;s stock for the options that were in-the-money on the applicable date.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company recognized stock-based compensation expense of $<span id="xdx_908_eus-gaap--AllocatedShareBasedCompensationExpense_c20191001__20200930_pp0p0" title="Share based compensation">4,876,906</span> during the year ended September 30, 2020 (2019: $<span id="xdx_903_eus-gaap--AllocatedShareBasedCompensationExpense_c20181001__20190930_pp0p0" title="Share based compensation">6,430,873</span>)
in connection with the issuance and vesting 	of stock options and warrants in exchange for services. These amounts have been
included in general and 	administrative expenses and research and development expenses on the Company&#8217;s consolidated
statements of 	operations as follows:</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"/>

<table cellpadding="0" cellspacing="0" id="xdx_895_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_z10fcU3yhNC" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%; margin-left: 50pt; margin-right: 30pt" summary="xdx: Disclosure - Commitments (Details 3)">
<tr style="vertical-align: bottom">
    <td style="text-align: left"><span id="xdx_8B3_zLXz9RQiDpaf" style="display: none">Schedule of general and administrative expenses and research and development expenses</span></td><td style="text-align: center">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">2020</td><td style="border-bottom: Black 1pt solid; text-align: center">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">2019</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: left">General and administrative</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--AllocatedShareBasedCompensationExpense_c20191001__20200930__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pp0p0" style="width: 12%; text-align: right" title="Total share based compensation">2,210,789</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--AllocatedShareBasedCompensationExpense_c20181001__20190930__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pp0p0" style="width: 12%; text-align: right" title="Total share based compensation">3,203,165</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Research and development</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--AllocatedShareBasedCompensationExpense_c20191001__20200930__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation">2,666,117</td><td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--AllocatedShareBasedCompensationExpense_c20181001__20190930__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation">3,227,708</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total share based compensation</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--AllocatedShareBasedCompensationExpense_c20191001__20200930_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Total share based compensation">4,876,906</td><td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--AllocatedShareBasedCompensationExpense_c20181001__20190930_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Total share based compensation">6,430,873</td><td style="text-align: left">&#160;</td></tr>
</table>



<p id="xdx_8A6_zzfKjvViDfk6" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 6pt 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">An
amount of approximately $<span id="xdx_900_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_pp0p0_c20200930_zOWoVSb0HVs4" title="Remaining stock based compensation">4,040,812</span> in stock-based compensation is expected to be recorded over the remaining term 	of such
options and warrants through 2023.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
fair value of each option and warrant award is estimated on the date of grant using the Black Scholes option pricing model based
on the following weighted average assumptions:</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify; text-indent: 1in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify; text-indent: 1in"/>

<table cellpadding="0" cellspacing="0" id="xdx_887_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zIt31fNFgdO6" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; margin-left: 50pt; margin-right: 30pt; width: 80%" summary="xdx: Disclosure - Commitments (Details 4)">
<tr style="vertical-align: bottom">
    <td style="text-align: left"><span id="xdx_8B3_z2ukEIarV4Xg" style="display: none">Schedule of weighted average assumptions for fair value of each option award&#160;</span></td><td style="text-align: center">&#160;</td>
    <td colspan="3" style="text-align: center">2020</td><td style="text-align: center">&#160;</td>
    <td colspan="3" style="text-align: center">2019</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: left">Risk-free interest rate</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pii_dp_c20191001__20200930_zi7JAzbq67Lc" style="width: 12%; text-align: right" title="Risk-free interest rate">1.57</td><td style="width: 1%; text-align: left">%</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pii_dp_c20181001__20190930_zLa7ChuAS8b7" style="width: 12%; text-align: right" title="Risk-free interest rate">2.50</td><td style="width: 1%; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected life of option (years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20191001__20200930_zmlZr7zJWeca" style="text-align: right" title="Expected life of options (years)">5.53</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20181001__20190930_zUSNWh7Xc5vc" style="text-align: right" title="Expected life of options (years)">6.05</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Annualized volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pii_dp_c20191001__20200930_zL7d4I6ZUXZh" style="text-align: right" title="Annualized volatility">95.99</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pii_dp_c20181001__20190930_zL6bXerDkGPa" style="text-align: right" title="Annualized volatility">104.45</td><td style="text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Dividend rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c20191001__20200930_pii" style="text-align: right" title="Dividend rate">0.00</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c20181001__20190930_pii" style="text-align: right" title="Dividend rate">0.00</td><td style="text-align: left">%</td></tr>
</table>



<p id="xdx_8A2_zVuVHQXNSVHb" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: left; text-indent: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
fair value of stock compensation charges recognized during the years ended September 30, 2020 and 2019 was determined with reference
to the quoted market price of the Company&#8217;s shares on the grant date.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>






<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140429238781400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p id="xdx_80A_eus-gaap--IncomeTaxDisclosureTextBlock_zZZIEtMTz8z9" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: top; text-align: left"><td style="width: 7%"><span style="font: 10pt Times New Roman, Times, Serif">Note
                                         6</span></td>
    <td style="width: 93%"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline"><span id="xdx_826_z45949lVo8y4">Income Taxes</span></span></span></td></tr>
</table>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 7pt 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company&#8217;s U.S. and foreign loss before income taxes are set forth below:</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 7pt 42.55pt; text-align: justify"/>

<table cellpadding="0" cellspacing="0" id="xdx_89C_eus-gaap--ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_zhsAwSMkIYY" style="font: 10pt Times New Roman, Times, Serif; visibility: visible; border-collapse: collapse; margin-left: 50pt; margin-right: 30pt; width: 90%" summary="xdx: Disclosure - Income Taxes (Details)">
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="display: none"><span id="xdx_8B9_zmKV9lDcS5U5" style="display: none">Schedule of Income before Income Tax, Domestic and Foreign</span></span></td><td style="border-bottom: Black 1pt solid; text-align: center">&#160;</td>
    <td colspan="3" id="xdx_496_20191001__20200930_zGfc4t7ylrWg" style="border-bottom: Black 1pt solid; text-align: center">2020</td><td style="border-bottom: Black 1pt solid; text-align: center">&#160;</td>
    <td colspan="3" id="xdx_49B_20181001__20190930_zgXT42mjUx59" style="border-bottom: Black 1pt solid; text-align: center">2019</td></tr>
<tr id="xdx_408_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: left">United States</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right" title="United States">(18,096,148</td><td style="width: 1%; text-align: left">)</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right" title="United States">(18,031,016</td><td style="width: 1%; text-align: left">)</td></tr>
<tr id="xdx_40D_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_i_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 1pt solid">Foreign</td><td style="border-bottom: Black 1pt solid">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right" title="Foreign">(8,161,658</td><td style="border-bottom: Black 1pt solid; text-align: left">)</td><td style="border-bottom: Black 1pt solid">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right" title="Foreign">(8,181,782</td><td style="border-bottom: Black 1pt solid; text-align: left">)</td></tr>
<tr id="xdx_404_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 2.5pt double">Total</td><td style="border-bottom: Black 2.5pt double">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right" title="Total">(26,257,806</td><td style="border-bottom: Black 2.5pt double; text-align: left">)</td><td style="border-bottom: Black 2.5pt double">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right" title="Total">(26,212,798</td><td style="border-bottom: Black 2.5pt double; text-align: left">)</td></tr>
</table>



<p id="xdx_8AB_zwggrXkvERbe" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 7pt 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 7pt 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
components of net deferred income tax assets as of September 30, 2020 and 2019 are as follows:</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 7pt 42.55pt; text-align: justify"/>

<table cellpadding="0" cellspacing="0" id="xdx_89C_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zw392Ke84AT9" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 50pt; margin-right: 30pt" summary="xdx: Disclosure - Income Taxes (Details 1)">
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; text-align: left"><span id="xdx_8BA_zNDtTCZntjHk" style="display: none">Schedule of deferred tax asset and liabilities&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: center">&#160;</td>
    <td colspan="3" id="xdx_496_20200930_zVi2ustoktHk" style="border-bottom: Black 1pt solid; text-align: center">2020</td><td style="border-bottom: Black 1pt solid; text-align: center">&#160;</td>
    <td colspan="3" id="xdx_49F_20190930_zuHSA5cToaE8" style="border-bottom: Black 1pt solid; text-align: center">2019</td></tr>
<tr id="xdx_401_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: left">Net operating loss carryforwards</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">23,397,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">18,704,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_40F_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Research and development tax credit carry forwards</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,069,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,162,000</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_401_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,283,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,570,000</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40D_ecustom--DeferredTaxAssetsUnpaidCharges_iI_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Unpaid charges</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">83,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">69,000</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40C_eus-gaap--DeferredTaxAssetsGoodwillAndIntangibleAssets_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Intangible asset costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">132,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">30,000</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_403_eus-gaap--DeferredTaxAssetsUnrealizedCurrencyLosses_iI_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Foreign exchange and other</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">27,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15,000</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_408_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pp0p0_di_zhZhv1bqptZe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 1pt solid; text-align: left">Valuation allowance deferred tax assets</td><td style="border-bottom: Black 1pt solid">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(33,991,000</td><td style="border-bottom: Black 1pt solid; text-align: left">)</td><td style="border-bottom: Black 1pt solid">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(26,550,000</td><td style="border-bottom: Black 1pt solid; text-align: left">)</td></tr>
<tr id="xdx_40F_eus-gaap--DeferredTaxAssetsNet_iI_pp0p0_d0_zPHyywcRkcAb" style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 2.5pt double; text-align: left">Net deferred tax assets</td><td style="border-bottom: Black 2.5pt double">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#8212;&#160;&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#8212;&#160;&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td></tr>
</table>



<p id="xdx_8A3_zqLzdsiXZl9" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 7pt 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-indent: 0.25in"/>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">A
reconciliation of income tax expense at the statutory federal income tax rate and income taxes as reflected in the consolidated
financial statements for the years ended September 30, 2020 and 2019 is as follows:</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"/>

<table cellpadding="0" cellspacing="0" id="xdx_89F_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zgqgnyyzqQA5" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; margin-left: 50pt; margin-right: 30pt; width: 90%" summary="xdx: Disclosure - Income Taxes (Details 2)">
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; text-align: left"><span id="xdx_8B7_zyDBegXhrH9d" style="display: none">Schedule of Effective Income Tax Rate Reconciliation</span>&#160;</td><td style="border-bottom: Black 1pt solid; text-align: center">&#160;</td>
    <td colspan="3" id="xdx_498_20191001__20200930_znkPTYEv6Qyf" style="border-bottom: Black 1pt solid; text-align: center">2020</td><td style="border-bottom: Black 1pt solid; text-align: center">&#160;</td>
    <td colspan="3" id="xdx_499_20181001__20190930_zD0ElrIeVuK2" style="border-bottom: Black 1pt solid; text-align: center">2019</td></tr>
<tr id="xdx_400_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: left">Income tax benefit at statutory federal rate</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(5,519,000</td><td style="width: 1%; text-align: left">)</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(5,505,000</td><td style="width: 1%; text-align: left">)</td></tr>
<tr id="xdx_401_eus-gaap--IncomeTaxReconciliationForeignIncomeTaxRateDifferential_i_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Foreign income taxed at other rates</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(723,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(825,000</td><td style="text-align: left">)</td></tr>
<tr id="xdx_40F_eus-gaap--IncomeTaxReconciliationOtherAdjustments_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other permanent differences</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">35,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">140,000</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40C_ecustom--IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopmentCreditBenefit_i_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Research and development credit benefit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,267,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">914,000</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_401_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_z1PYeXsbnRgi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">State and local taxes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,911,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,487,000</td><td style="text-align: left">)</td></tr>
<tr id="xdx_40C_eus-gaap--IncomeTaxReconciliationPriorYearIncomeTaxes_i_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Adjustment and true up to prior year tax provision</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">373,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">194,000</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_405_eus-gaap--EffectOfExchangeRateOnCash_d0_zqtfu3RSRnmg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Effect of change in statutory rates</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">36,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_408_eus-gaap--TaxesExcludingIncomeAndExciseTaxes_i_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">State minimum and excise taxes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">22,664</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">82,181</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_400_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_zdxGf7UkZNn1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 1pt solid; text-align: left">Change in valuation allowances</td><td style="border-bottom: Black 1pt solid">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">7,442,000</td><td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">6,569,000</td><td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td></tr>
<tr id="xdx_405_eus-gaap--DeferredIncomeTaxExpenseBenefit_i_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 2.5pt double; text-align: left">Income tax expense</td><td style="border-bottom: Black 2.5pt double">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">22,664</td><td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">82,181</td><td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td></tr>
</table>



<p id="xdx_8AB_zx4bzKWbO3h5" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"/></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt"/>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">As
of September 30, 2020, the Company had U.S. federal net operating loss carryforwards of approximately $<span id="xdx_903_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsForeign_iI_pp0n3_dm_c20200930_zhXEaby3lZqi" title="U.S. federal net operating loss carryforwards">76.8</span> million (2019: $<span id="xdx_90E_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsForeign_iI_pp0n3_dm_c20190930_zQJbU4NKSC9h" title="U.S. federal net operating loss carryforwards">60.8</span>
million) which will begin to expire in <span id="xdx_905_ecustom--OperatingLossCarryForwardsExpirationYear1_c20191001__20200930" title="Operating loss carry-forwards, expiration year">2027</span> and state and local net operating loss carryforwards of approximately $<span id="xdx_902_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_pp0n3_dm_c20200930_za50T4BqhqH6" title="State net operating loss carryforwards">103.1</span> million
(2019: $<span id="xdx_907_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_pp0n3_dm_c20190930_zLFm0TeuzsYk" title="State net operating loss carryforwards">64.0</span> million) which will begin to expire in 2036, The Company had approximately $<span id="xdx_906_eus-gaap--OperatingLossCarryforwards_iI_pp0n3_dm_c20200930__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_zTBjPg21TyNh" title="Operating loss carry-forwards">4.3</span> million (Approximately AUD$ <span id="xdx_908_eus-gaap--OperatingLossCarryforwards_iI_pp0n3_dm_c20200930__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember__srt--CurrencyAxis__currency--AUD_zcrplpdrDq66" title="Operating loss carry-forwards">6.0</span> million)
(2019: $<span id="xdx_90A_eus-gaap--OperatingLossCarryforwards_iI_pp0n3_dm_c20190930__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_zqeV6iN57JN8" title="Operating loss carry-forwards">3.5</span> million) of net operating loss carryforwards in Australia, which have an indefinite life, available to offset future
taxable income in those jurisdictions.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>










<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"/></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company evaluates its valuation allowance requirements based on available evidence. When circumstances change, and this causes
a change in management&#8217;s judgment about the recoverability of deferred tax assets, the impact of the change on the valuation
allowance is reflected in current income. Because management of the Company does not currently believe that it is more likely
than not that the Company will receive the benefit of these assets, a valuation allowance has been established at September 30,
2020 and 2019.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Uncertain
Tax Positions</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company files income tax returns in the U.S. federal jurisdiction and various state and local and foreign jurisdictions. The Company&#8217;s
tax returns are subject to tax examinations by U.S. federal and state tax authorities, or examinations by foreign tax authorities
until the respective statutes of limitation expire. The Company is subject to tax examinations by tax authorities for all taxation
years commencing on or after 2013.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Under
the provisions of the Internal Revenue Code, the net operating loss (&#8220;NOL&#8221;) carryforwards are subject to review and
possible adjustment by the Internal Revenue Service and state tax authorities. NOL and tax credit carryforwards may become subject
to an annual limitation in the event of an over 50% cumulative change in the ownership interest of significant stockholders over
a three-year period, as defined under Sections 382 and 383 of the Internal Revenue Code, as well as similar state tax provisions.
This could limit the amount of NOLs that the Company could be entitled to utilize annually to offset future taxable income or
tax liabilities. The amount of the annual limitation, if any, would be determined based on the value of the Company immediately
prior to the ownership change. Subsequent ownership changes may affect the limitation in future years<span style="background-color: white">.
The Company completed a Section 382 analysis through the fiscal year ended September 30, 2020 and currently does not believe Section
382 will apply to limit the utilization of available NOLs.</span></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140429220403560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p id="xdx_84D_eus-gaap--UseOfEstimates_zqf4ghFK9O8l" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 42.55pt"/><td style="width: 18pt"><span style="font: 10pt Times New Roman, Times, Serif">a)</span></td><td style="text-align: justify"><span id="xdx_869_zEAgumzB06sa" style="font: 10pt Times New Roman, Times, Serif">Use
                                         of Estimates</span></td></tr></table>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify; margin-left: 42.55pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect
the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenue and
expenses in the reporting period. The Company regularly evaluates estimates and assumptions related to accounting for research
and development costs, incentive income receivable, valuation and recoverability of deferred tax assets, asset impairment, stock-based
compensation and loss contingencies. The Company bases its estimates and assumptions on current facts, historical experience and
various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making
judgments about the book values of assets and liabilities and the accrual of costs and expenses that are not readily apparent
from other sources. The actual results experienced by the Company may differ materially and adversely from the Company&#8217;s
estimates. To the extent there are material differences between the estimates and the actual results, future results of operations
will be affected.</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><p id="xdx_84E_eus-gaap--ConsolidationPolicyTextBlock_zhaxDESkVTBc" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>



<table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 42.5pt"/><td style="width: 18pt"><span style="font: 10pt Times New Roman, Times, Serif">b)</span></td><td id="xdx_86C_zg9HiwiTiKfl" style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Principles
                                         of Consolidation</span></td></tr></table>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify; margin-left: 42.55pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">These
consolidated financial statements include the accounts of Anavex Life Sciences Corp. and its wholly-owned subsidiaries, Anavex
Australia Pty Limited. (&#8220;Anavex Australia&#8221;), a company incorporated under the laws of Australia, Anavex Germany GmbH,
a company incorporated under the laws of Germany, and Anavex Canada Ltd., a company incorporated under the laws of the Province
of Ontario, Canada. All inter-company transactions and balances have been eliminated.</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and equivalents</a></td>
<td class="text"><p id="xdx_84B_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zPqyXkDd3gml" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 42.55pt"/><td style="width: 18pt"><span style="font: 10pt Times New Roman, Times, Serif">c)</span></td><td id="xdx_861_zvIIr6UoDIAj" style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Cash
                                         and equivalents</span></td></tr></table>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify; margin-left: 42.55pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company considers only those investments which are highly liquid, readily convertible to cash and that mature within three months
from the date of purchase to be cash equivalents.</span></p>








<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text"><p id="xdx_847_eus-gaap--ResearchAndDevelopmentExpensePolicy_zYhMikPyjcA6" style="font: 10pt Arial, Helvetica, Sans-Serif; text-indent: 40pt; text-align: left; margin-top: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"/></p>

<table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 42.55pt"/><td style="width: 18pt"><span style="font: 10pt Times New Roman, Times, Serif">d)</span></td><td id="xdx_86F_zXm5kmXnzwQa" style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Research
                                         and Development Expenses</span></td></tr></table>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i/></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Research
and development costs are expensed as incurred. These expenses are comprised of the costs of the Company&#8217;s proprietary research
and development efforts, including preclinical studies, clinical trials, manufacturing costs, employee salaries and benefits and
stock based compensation expense, contract services including external research and development expenses incurred under arrangements
with third parties such as contract research organizations (&#8220;CROs&#8221;), facilities costs, overhead costs and other related
expenses. Milestone payments made by the Company to third parties are expensed when the specific milestone has been achieved.
Manufacturing costs are expensed as incurred in accordance with Accounting Standard Codification (&#8220;ASC&#8221;) 730, Research
and Development, as these materials have no alternative future use outside of their intended use.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Nonrefundable
advance payments for goods or services that will be used or rendered for future research and development activities are deferred
and amortized over the period that the goods are delivered, or the related services are performed, subject to an assessment of
recoverability. The Company makes estimates of costs incurred in relation to external CROs, and clinical site costs. The Company
analyzes the progress of clinical trials, including levels of patient enrollment, invoices received and contracted costs when
evaluating the adequacy of the amount expensed and the related prepaid asset and accrued liability. Significant judgments and
estimates must be made and used in determining the accrued balance and expense in any accounting period. The Company reviews and
accrues CRO expenses and clinical trial study expenses based on work performed and relies upon estimates of those costs applicable
to the stage of completion of a study. Accrued CRO costs are subject to revisions as such trials progress to completion. Revisions
are charged to expense in the period in which the facts that give rise to the revision become known. With respect to clinical
site costs, the financial terms of these agreements are subject to negotiation and vary from contract to contract. Payments under
these contracts may be uneven and depend on factors such as the achievement of certain events, the successful recruitment of patients,
the completion of portions of the clinical trial or similar conditions. The objective of our policy is to record expenses in our
financial statements based on the actual services received and efforts expended. As such, expense accruals related to clinical
site costs are recognized based on our estimate of the degree of completion of the event or events specified in the specific clinical
study or trial contract.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
addition, the Company incurs expenses in respect of intellectual property costs relating to patents and trademarks. The probability
of success and length of time to develop commercial applications of the compounds subject to the underlying patent and trademark costs
is difficult to determine and numerous risks and uncertainties exist with respect to the timely completion of the development
projects. There is no assurance the compounds subject to the underlying patents and trademarks will ever be successfully commercialized.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Due
to these risks and uncertainties, the patent and trademark costs do not meet the definition of an asset and thus are expensed
as incurred within general and administrative expenses.</span></p>










<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionIncentives', window );">Research and Development Incentive Income</a></td>
<td class="text"><p id="xdx_84E_eus-gaap--RevenueRecognitionIncentives_zuSeUQhdS7m6" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-indent: 40pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 42.55pt"/><td style="width: 18pt"><span style="font: 10pt Times New Roman, Times, Serif">e)</span></td><td id="xdx_861_zyUp2pHZqMX2" style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Research
                                         and Development Incentive Income</span></td></tr></table>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i/></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company is eligible to obtain certain research and development tax credits, including the New York City Biotechnology Tax Credit
(&#8220;NYC Biotech credit&#8221;), and the Australian research and development tax incentive credit (the &#8220;Australia R&amp;D
credit&#8221;) through a program administered through the Australian Tax Office (the &#8220;ATO&#8221;), which provides for a
cash refund based on a percentage of certain research and development activities undertaken in Australia by the Company&#8217;s
wholly owned subsidiary, Anavex Australia Pty Ltd. (&#8220;Anavex Australia&#8221;). <span id="xdx_90F_ecustom--CashRefundAvailableDescription_c20191001__20200930_zYDIUwSyjgIe" title="Cash Refund Available description">The cash refund is available to eligible
companies with an annual aggregate revenue of less than $20.0 million Australian during the reimbursable period.</span></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
tax incentives are available on the basis of specific criteria with which the Company must comply. Although the tax incentive
may be administered through the local tax authority, the Company has accounted for the incentives outside of the scope of ASC
Topic 740, Income Taxes (&#8220;ASC 740&#8221;), since the incentives are not linked to the Company&#8217;s taxable income and
can be realized regardless of whether the Company has generated taxable income in the respective jurisdictions.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">With
respect to the Australia R&amp;D credit, Anavex Australia may be eligible to receive the cash refund for certain research and
development expenses incurred by Anavex Australia outside of Australia, to the extent such expenses are pre-approved by the Australian
authority pursuant to an advanced overseas finding application. The Company accrues for the amount of cash refund it expects to
receive in relation to research and development expenses outside of Australia only to the extent it has received advanced approval
from the Department of Industry, Innovation and Science in Australia, pursuant to an approved advanced overseas finding application.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company recognizes the amount of cash refund it expects to receive related to the NYC Biotech credit and Australian research and
development tax incentive program when there is reasonable assurance that the cash refund will be received, when the relevant
expenditures have been incurred, and when the amount can be reliably measured. This amount is included in Incentive and tax receivables
in the accompanying consolidated balance sheets.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
addition, Anavex Australia and Anavex Canada incur Goods and Services Tax (GST) on certain services provided by local vendors.
As a domestic entity in those jurisdictions, Anavex Australia and Anavex Canada are entitled to a refund of the GST paid. Similarly,
Anavex Germany incurs Value Added Tax (VAT) on certain services provided by local vendors, to which it is entitled to a refund
of such VAT paid. The Company&#8217;s estimate of the amount of cash refund it expects to receive related to GST and VAT incurred
is included in Incentive and tax receivables in the accompanying consolidated balance sheets.</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Basic and Diluted Loss per Share</a></td>
<td class="text"><p id="xdx_847_eus-gaap--EarningsPerSharePolicyTextBlock_z9bhd4heuAOg" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 42.55pt"/><td style="width: 18pt"><span style="font: 10pt Times New Roman, Times, Serif">f)</span></td><td id="xdx_863_z5HZwLOz94rl" style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Basic
                                         and Diluted Loss per Share</span></td></tr></table>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify; margin-left: 42.55pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Basic
income/(loss) per common share is computed by dividing net income/(loss) available to common stockholders by the weighted average
number of common shares outstanding during the period. Diluted income/(loss) per common share is computed by dividing net income/(loss)
available to common stockholders by the sum of (1) the weighted-average number of common shares outstanding during the period,
(2) the dilutive effect of the assumed exercise of options and warrants using the treasury stock method and (3) the dilutive effect
of other potentially dilutive securities. For purposes of the diluted net loss per share calculation, options and warrants are
potentially dilutive securities and are excluded from the calculation of diluted net loss per share because their effect would
be anti-dilutive.</span></p>












<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">As
of September 30, 2020, diluted loss per share excludes <span id="xdx_90A_eus-gaap--IncrementalCommonSharesAttributableToCallOptionsAndWarrants_c20191001__20200930_pii" title="Loss per share for potentially dilutive common shares">10,576,266</span> (2019 &#8211; <span id="xdx_900_eus-gaap--IncrementalCommonSharesAttributableToCallOptionsAndWarrants_c20181001__20190930_pii" title="Loss per share for potentially dilutive common shares">8,812,933</span>) potentially dilutive common shares
related to outstanding options and warrants, as their effect was anti-dilutive.</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Financial Instruments</a></td>
<td class="text"><p id="xdx_849_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zHovEUI4h1bd" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 42.55pt"/><td style="width: 18pt"><span style="font: 10pt Times New Roman, Times, Serif">g)</span></td><td id="xdx_86D_zNfEIBZhcqt3" style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Financial
                                         Instruments</span></td></tr></table>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify; margin-left: 42.55pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
book value of the Company&#8217;s financial instruments, consisting of cash and equivalents, incentive and tax receivables, and
accounts payable and accrued liabilities approximate their fair value due to the short-term maturity of such instruments. Unless
otherwise noted, it is management&#8217;s opinion that the Company is not exposed to significant interest, currency or credit
risks arising from these financial instruments.</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency Translation</a></td>
<td class="text"><p id="xdx_845_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zCbIp40N19gf" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 42.55pt"/><td style="width: 18pt"><span style="font: 10pt Times New Roman, Times, Serif">h)</span></td><td id="xdx_863_zVPPTBc3bS78" style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Foreign
                                         Currency Translation</span></td></tr></table>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify; margin-left: 42.55pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
functional currency of the Company is the US dollar. Monetary items denominated in a foreign currency are translated into US dollars
at exchange rates prevailing at the balance sheet date and non-monetary items are translated at exchange rates prevailing when
the assets were acquired, or obligations incurred. Foreign currency denominated expense items are translated at exchange rates
prevailing on the transaction date. Unrealized gains or losses arising from the translations are credited or charged to income
in the period in which they occur.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify; margin-left: 42.55pt"><span style="font: 10pt Times New Roman, Times, Serif">The
Company has determined that the functional currency of Anavex Australia Pty Limited, Anavex Germany GmbH, and Anavex Canada Ltd.
is the US dollar.</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment and Geographic Reporting</a></td>
<td class="text"><p id="xdx_84C_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zTUojE9iNMp7" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 42.55pt"/><td style="width: 18pt"><span style="font: 10pt Times New Roman, Times, Serif">i)</span></td><td id="xdx_86C_znNVXLYjswP3"><span style="font: 10pt Times New Roman, Times, Serif">Segment
                                         and Geographic Reporting</span></td></tr></table>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify; margin-left: 42.55pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Operating
segments are defined as components of an enterprise for which separate discrete information is available for evaluation by the
chief operating decision maker or decision-making group, in deciding how to allocate resources and in assessing performance. The
Company views its operations and manages its business as one operating segment, which is the business of developing novel therapies
for the management of CNS diseases.</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_GrantIncomePolicyTextBlock', window );">Grant Income</a></td>
<td class="text"><p id="xdx_849_ecustom--GrantIncomePolicyTextBlock_zbwzoBiBjCk8" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top">
<td style="width: 42.55pt"/><td style="width: 18pt"><span style="font: 10pt Times New Roman, Times, Serif">j)</span></td><td id="xdx_86C_zsAUiTgEYkNb" style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Grant
                                         Income</span></td></tr></table>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Grant
income is recognized at the fair value of the grant when it is received, and all substantive conditions have been satisfied. Grants
received from government and other agencies in advance of the specific research and development costs to which they relate are
deferred and recognized in the consolidated statement of operations in the period they are earned and when the related research
and development costs are incurred.</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p id="xdx_84A_eus-gaap--IncomeTaxPolicyTextBlock_zy1jE2n57rK2" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 42.55pt"/><td style="width: 18pt"><span style="font: 10pt Times New Roman, Times, Serif">k)</span></td><td id="xdx_869_zPTgLOqDBPqg" style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Income
                                         Taxes</span></td></tr></table>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify; margin-left: 42.55pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company follows the provisions of ASC 740, which requires the asset and liability method of accounting for income taxes. Under
the asset and liability method, deferred tax assets and liabilities are recognized for the future tax consequences attributable
to temporary differences between the financial statements carrying amounts of existing assets and liabilities and their respective
tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the
years in which those temporary differences are expected to be recovered or settled.</span></p>











<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify; margin-left: 42.55pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: justify; margin-right: 0; margin-left: 42.55pt"><span style="font: 10pt Times New Roman, Times, Serif">The
Company follows the provisions of ASC 740 regarding accounting for uncertainty in income taxes. The Company initially recognizes
tax positions in the financial statements when it is more likely than not the position will be sustained upon examination by the
tax authorities. Such tax positions are initially and subsequently measured as the largest amount of tax benefit that is greater
than 50% likely of being realized upon ultimate settlement with the tax authority assuming full knowledge of the position and
all relevant facts. Application requires numerous estimates based on available information. The Company considers many factors
when evaluating and estimating its tax positions and tax benefits, and its recognized tax positions and tax benefits may not accurately
anticipate actual outcomes. As additional information is obtained, there may be a need to periodically adjust the recognized tax
positions and tax benefits. These periodic adjustments may have a material impact on the consolidated statements of operations.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify; margin-left: 42.55pt"><span style="font: 10pt Times New Roman, Times, Serif">The
Company recognizes interest and penalties related to current income tax expense on the interest income, net line, in the accompanying
consolidated statement of operations. Accrued interest and penalties, if any, are included in accrued liabilities on the consolidated
balance sheets.</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationForfeituresPolicyTextBlock', window );">Stock-based Compensation</a></td>
<td class="text"><p id="xdx_844_eus-gaap--ShareBasedCompensationForfeituresPolicyTextBlock_z4JyiDfbV3kl" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 42.55pt"/><td style="width: 18pt"><span style="font: 10pt Times New Roman, Times, Serif">l)</span></td><td id="xdx_861_zrffvkOwY1mi" style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Stock-based
                                         Compensation</span></td></tr></table>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify; margin-left: 42.55pt">&#160;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company accounts for all stock-based payments and awards under the fair value method.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify; margin-left: 42.55pt"><span style="font: 10pt Times New Roman, Times, Serif">The
Company accounts for the granting of share purchase options and warrants to employees using the fair value method whereby all
awards to employees will be recorded at fair value on the date of the grant. The fair value of all share purchase options and
warrants are expensed over their contractual vesting period, or over the expected performance period for only the portion of awards
expected to vest, in the case of milestone-based vesting, with a corresponding increase to additional paid-in capital.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: justify"/>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: justify; margin-right: 0; margin-left: 42.55pt"><span style="font: 10pt Times New Roman, Times, Serif">Share
purchase options and warrants issued to non-employees are measured at the fair value of the equity instruments issued. Compensation
expense for share purchase options and warrants issued to non-employees is recorded over the service performance period. Prior
to the Company&#8217;s adoption of ASU No. 2018-07, Compensation-Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based
Payment Accounting on October 1, 2019, options and warrants subject to vesting were periodically re-measured until the counterparty
performance was complete, and any change therein was recognized over the vesting period of the award and in the same manner as
if the Company had paid cash instead of paying with or using equity based instruments. After the adoption of ASU No. 2018-07,
the Company measures equity-classified share-based payment awards issued to nonemployees on the grant date, rather than remeasuring
the awards through the performance completion date as previously required (see Note 2 n)).</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: justify; margin-right: 0; margin-left: 42.55pt"><span style="font: 10pt Times New Roman, Times, Serif">Compensation
costs for stock-based payments with graded vesting are recognized on a straight-line basis.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: justify; margin-right: 0; margin-left: 42.55pt"><span style="font: 10pt Times New Roman, Times, Serif">The
Company uses the Black-Scholes option valuation model to calculate the fair value of share purchase options and warrants at the
date of the grant. Option pricing models require the input of highly subjective assumptions, including the expected price volatility.
Changes in these assumptions can materially affect the fair value estimates.</span></p>





<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p id="xdx_84F_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zrtONMDFaYfk" style="font: 10pt Arial, Helvetica, Sans-Serif; text-indent: 40pt; text-align: left; margin-top: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif"/></p>

<table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 42.55pt"/><td style="width: 18pt"><span style="font: 10pt Times New Roman, Times, Serif">m)</span></td><td id="xdx_86A_zvoqyRoz7lO3" style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Fair
                                         Value Measurements</span></td></tr></table>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Fair
value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in
the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at
the measurement date. Assets and liabilities that are measured at fair value are reported using a three-level fair value hierarchy
that prioritizes the inputs used to measure fair value. This hierarchy maximizes the use of observable inputs and minimizes the
use of unobservable inputs. The three levels of inputs used to measure fair value are as follows:</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt"><span style="font: 10pt Times New Roman, Times, Serif">Level
1 - 	quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access
at the measurement date;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Level
2 - observable inputs other than Level 1, quoted prices for similar assets or liabilities in active 		markets, quoted prices
for identical or similar assets and liabilities in markets that are not active, and model-derived prices whose inputs are observable
or whose significant value drivers are observable; and</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 60.55pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Level
3 - 	assets and liabilities whose significant value drivers are unobservable by little or no market activity and that are significant
to the fair value of the assets or liabilities.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">At
September 30, 2020 and 2019, the Company did not have any Level 3 assets or liabilities.</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><p id="xdx_847_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_ztjvIPjOXAKb" style="font: 10pt Arial, Helvetica, Sans-Serif; text-indent: 40pt; text-align: left; margin-top: 0; margin-right: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 42.55pt"/><td style="width: 18pt"><span style="font: 10pt Times New Roman, Times, Serif">n)</span></td><td id="xdx_86D_zQI1JnzoS1gj" style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Recent
                                         Accounting Pronouncements</span></td></tr></table>


<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Recently
Adopted Accounting Pronouncements</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
February 2016, Topic 842, Leases was issued to replace the leases requirements in Topic 840, Leases. The main difference
between previous U.S. GAAP and Topic 842 is the recognition of lease assets and lease liabilities by lessees for those leases
classified as operating leases under previous U.S. GAAP. A lessee should recognize in the balance sheet a liability to make
lease payments (the lease liability) and a right-of-use asset representing its right to use the underlying asset for the
lease term. For leases with a term of 12 months or less, a lessee is permitted to make an accounting policy election by class
of underlying asset not to recognize lease assets and lease liabilities. If a lessee makes this election, it should recognize
lease expense for such leases generally on a straight-line basis over the lease term. The accounting applied by a lessor is
largely unchanged from that applied under previous U.S. GAAP. The Company elected the package of practical expedients
permitted under the transition guidance that allowed, among other things, the historical lease classifications to be carried
forward without reassessment. Further, the Company elected to not recognize lease assets and lease liabilities for leases
with a term of 12 months or less. The adoption of this standard on October 1, 2019 did not have any impact on the Company's
consolidated results of operations, financial condition, cash flows, and financial statement disclosures.</span></p>















<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
June 2018, the FASB issued ASU No. 2018-07, Compensation-Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based
Payment Accounting, which simplifies the accounting for share-based payments to nonemployees for goods and services by aligning
it with the accounting for share-based payments to employees, with certain exceptions. The new guidance was effective for the
Company beginning on October 1, 2019 and was required to be applied retrospectively with the cumulative effect recognized at the
date of initial application. The adoption of this standard on October 1, 2019 did not have any material impact on the Company's
consolidated results of operations, financial condition, cash flows, and financial statement disclosures.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Recent
Accounting Pronouncements Not Yet Adopted</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
December 2019, the FASB issued ASU 2019-12, "Simplifying the Accounting for Income Taxes (ASC 740)", which is intended
to simplify various aspects related to accounting for income taxes by removing certain exceptions to the general principles in
Topic 740 and clarifying and amending existing guidance to improve consistent application. ASU 2019-12 is effective for the Company
on October 1, 2021. Early adoption is permitted. The Company is currently evaluating the impact of this guidance on its consolidated
financial statements but does not expect such guidance to have a material impact.</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_GrantIncomePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_GrantIncomePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13279-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI http://asc.fasb.org/topic&amp;trid=2175825<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32847-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116657188&amp;loc=SL116659661-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32280-109318<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionIncentives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for sales incentives.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionIncentives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationForfeituresPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy election for determining cost for share-based payment arrangement by either estimating forfeiture expected to occur or by recognizing effect of forfeiture upon occurrence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 1D<br> -URI http://asc.fasb.org/extlink&amp;oid=121326096&amp;loc=SL116886442-113899<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121326096&amp;loc=d3e4549-113899<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (m)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationForfeituresPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140429220230744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of exercisable share purchase warrants outstanding</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_892_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zCeX6ZSscUs4" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%; margin-left: 50pt" summary="xdx: Disclosure - Commitments (Details)">
<tr style="vertical-align: bottom">
    <td colspan="3" style="text-align: left">&#160;<span id="xdx_8B7_zpVFSbMks2pe" style="display: none">Schedule of exercisable share purchase warrants outstanding</span></td><td>&#160;</td>
    <td colspan="3">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Weighted Average Exercise</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Number of Shares</td><td style="border-bottom: Black 1pt solid">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Exercise Price ($)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 60%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Balance , September 30 , 2018</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pii_c20181001__20190930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zmTtd7r9uibd" style="width: 15%; text-align: right" title="Share Purchase Warrants Balance, at beginning">678,379</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_iS_pii_c20181001__20190930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zfsfjDTFyuCc" style="width: 15%; text-align: right" title="Weighted Average Exercise Price Balance, at beginning">2.87</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Exercised</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pii_di_c20181001__20190930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zz1loBMAaAkh" style="text-align: right" title="Share Purchase Warrants Exercised">(8,750</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExercised_c20181001__20190930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_pii" style="text-align: right" title="Weighted Average Exercise Price, Exercised">1.13</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Expired</span></td><td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_pii_di_c20181001__20190930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zonaDXZ9QF17" style="border-bottom: Black 1pt solid; text-align: right" title="Share Purchase Warrants Expired">(319,629</td><td style="border-bottom: Black 1pt solid; text-align: left">)</td><td style="border-bottom: Black 1pt solid">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExpired_c20181001__20190930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_pii" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Expired">1.46</td><td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Balance , September 30 , 2019</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pii_c20191001__20200930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zYN80Ghjgly9" style="text-align: right" title="Share Purchase Warrants Balance, at beginning">350,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_iS_pii_c20191001__20200930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zQxXXV1tAT3c" style="text-align: right" title="Weighted Average Exercise Price Balance, at beginning">4.19</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Granted</span></td><td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod_c20191001__20200930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_pii" style="border-bottom: Black 1pt solid; text-align: right" title="Share Purchase Warrants Granted">150,000</td><td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice_c20191001__20200930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_pii" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Granted">3.17</td><td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Balance,
                                                                            September 30, 2020</span></td><td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pii_c20191001__20200930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_z8toB2rDxIb" style="border-bottom: Black 1pt solid; text-align: right" title="Share Purchase Warrants Balance, at ending">500,000</td><td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_iE_pii_c20191001__20200930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zPE1MCG6ernb" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price Balance, at ending">3.88</td><td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td></tr>
</table>



<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock', window );">Schedule of share purchase warrants outstanding</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_89F_ecustom--ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock_zNtmAaOFD1Mh" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 50%; margin-left: 50pt" summary="xdx: Disclosure - Commitments (Details 1)">
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_8BC_zFut8NusmD2i" style="display: none">Schedule of share purchase warrants outstanding</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="3" style="text-align: center">Number</td><td style="text-align: center">&#160;</td>
    <td colspan="3" style="text-align: center">Exercise Price</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">Expiry Date</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_c20200930__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_pii" style="width: 12%; text-align: right" title="Number">350,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_c20200930__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_pii" style="width: 12%; text-align: right" title="Exercise Price">4.19</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td id="xdx_98F_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_c20200930__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member" style="width: 56%; text-align: right" title="Expiry Date">June 30, 2021</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_c20200930__us-gaap--AwardTypeAxis__custom--PurchaseWarrants2Member_pii" style="text-align: right" title="Number">150,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_c20200930__us-gaap--AwardTypeAxis__custom--PurchaseWarrants2Member_pii" style="text-align: right" title="Exercise Price">3.17</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td id="xdx_98E_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_c20200930__us-gaap--AwardTypeAxis__custom--PurchaseWarrants2Member" style="text-align: right" title="Expiry Date">May 6, 2024</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_c20200930_pii" style="text-align: right" title="Number">500,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">&#160;</td></tr>
</table>



<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock', window );">Schedule of outstanding stock purchase options</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_896_eus-gaap--ScheduleOfStockOptionsRollForwardTableTextBlock_zm10SLpqS2u6" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 50pt; margin-right: 30pt" summary="xdx: Disclosure - Commitments (Details 2)">
<tr style="vertical-align: bottom">
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: left"><span id="xdx_8BE_zhSeLDdBnF7f" style="display: none">Schedule of outstanding stock purchase options&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: center">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Number of Shares</td><td style="border-bottom: Black 1pt solid; text-align: center">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Weighted Average Exercise Price</td><td style="border-bottom: Black 1pt solid; text-align: center">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Weighted Average Grant Date Fair Value ($)</td><td style="border-bottom: Black 1pt solid; text-align: center">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Aggregate intrinsic value ($)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 26%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Outstanding, September 30, 2018</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pii_c20181001__20190930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zh9Gqg9kHKJf" style="width: 15%; text-align: right" title="Options Outstanding at beginning">6,506,917</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pii_c20181001__20190930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zba4eDIJnP5e" style="width: 15%; text-align: right" title="Weighted Average Exercise Price Outstanding at beginning">3.83</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 15%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20181001__20190930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zEKezIwO51H3" style="width: 15%; text-align: right" title="Aggregate intrinsic value Outstanding at beginning">2,353,088</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Granted</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20181001__20190930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pii" style="text-align: right" title="Options Granted">2,265,399</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20181001__20190930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pii" style="text-align: right" title="Weighted Average Exercise Price Granted">2.79</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20181001__20190930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pii" style="text-align: right" title="Weighted Average Grant Date Fair Value Granted">2.27</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Forfeited</span></td><td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pii_di_c20181001__20190930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zJKYxHhyezg5" style="border-bottom: Black 1pt solid; text-align: right" title="Options Forfeited">(309,383</td><td style="border-bottom: Black 1pt solid; text-align: left">)</td><td style="border-bottom: Black 1pt solid">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20181001__20190930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pii" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price Forfeited">3.25</td><td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Outstanding, September 30, 2019</span></td><td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pii_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zQTunKIezEq2" style="border-bottom: Black 1pt solid; text-align: right" title="Options Outstanding at beginning">8,462,933</td><td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pii_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_z8T1R15cmUx3" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price Outstanding at beginning">3.58</td><td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zKBvON9vvBTe" style="border-bottom: Black 1pt solid; text-align: right">4,115,032</td><td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Granted</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pii" style="text-align: right" title="Options Granted">1,695,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pii" style="text-align: right" title="Weighted Average Exercise Price Granted">2.96</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pii" style="text-align: right" title="Weighted Average Grant Date Fair Value Granted">2.27</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right" title="Aggregate intrinsic value Outstanding at ending"/><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Forfeited</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pii_di_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zC4oNndN1Jgc" style="text-align: right" title="Options Forfeited">(68,332</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pii" style="text-align: right" title="Weighted Average Exercise Price Forfeited">3.01</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Exercised</span></td><td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pii_di_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zgKsNRQ2uz4f" style="border-bottom: Black 1pt solid; text-align: right" title="Options Exercised">(13,335</td><td style="border-bottom: Black 1pt solid; text-align: left">)</td><td style="border-bottom: Black 1pt solid">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pii" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price Exercised">3.15</td><td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Outstanding, September 30, 2020</span></td><td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pii_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_z71n7ruaXmj2" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Outstanding at ending">10,076,266</td><td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pii_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zAOoelwUl4pf" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Outstanding at ending">3.48</td><td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zBdK6aD3ajf2" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value Outstanding at ending">14,982,581</td><td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Exercisable, September 30, 2020</span></td><td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zCSeOZ8OIdRg" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Exercisable at ending">7,412,100</td><td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pii_c20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zQ46uv7GgYnj" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Exercisable at ending">3.66</td><td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_c20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value Exercisable at ending">10,763,906</td><td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td></tr>
</table>



<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of general and administrative expenses and research and development expenses</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_895_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_z10fcU3yhNC" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%; margin-left: 50pt; margin-right: 30pt" summary="xdx: Disclosure - Commitments (Details 3)">
<tr style="vertical-align: bottom">
    <td style="text-align: left"><span id="xdx_8B3_zLXz9RQiDpaf" style="display: none">Schedule of general and administrative expenses and research and development expenses</span></td><td style="text-align: center">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">2020</td><td style="border-bottom: Black 1pt solid; text-align: center">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">2019</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: left">General and administrative</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--AllocatedShareBasedCompensationExpense_c20191001__20200930__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pp0p0" style="width: 12%; text-align: right" title="Total share based compensation">2,210,789</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--AllocatedShareBasedCompensationExpense_c20181001__20190930__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pp0p0" style="width: 12%; text-align: right" title="Total share based compensation">3,203,165</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Research and development</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--AllocatedShareBasedCompensationExpense_c20191001__20200930__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation">2,666,117</td><td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--AllocatedShareBasedCompensationExpense_c20181001__20190930__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation">3,227,708</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total share based compensation</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--AllocatedShareBasedCompensationExpense_c20191001__20200930_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Total share based compensation">4,876,906</td><td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--AllocatedShareBasedCompensationExpense_c20181001__20190930_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Total share based compensation">6,430,873</td><td style="text-align: left">&#160;</td></tr>
</table>



<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of weighted average assumptions for fair value of each option award</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_887_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zIt31fNFgdO6" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; margin-left: 50pt; margin-right: 30pt; width: 80%" summary="xdx: Disclosure - Commitments (Details 4)">
<tr style="vertical-align: bottom">
    <td style="text-align: left"><span id="xdx_8B3_z2ukEIarV4Xg" style="display: none">Schedule of weighted average assumptions for fair value of each option award&#160;</span></td><td style="text-align: center">&#160;</td>
    <td colspan="3" style="text-align: center">2020</td><td style="text-align: center">&#160;</td>
    <td colspan="3" style="text-align: center">2019</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: left">Risk-free interest rate</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pii_dp_c20191001__20200930_zi7JAzbq67Lc" style="width: 12%; text-align: right" title="Risk-free interest rate">1.57</td><td style="width: 1%; text-align: left">%</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pii_dp_c20181001__20190930_zLa7ChuAS8b7" style="width: 12%; text-align: right" title="Risk-free interest rate">2.50</td><td style="width: 1%; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected life of option (years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20191001__20200930_zmlZr7zJWeca" style="text-align: right" title="Expected life of options (years)">5.53</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20181001__20190930_zUSNWh7Xc5vc" style="text-align: right" title="Expected life of options (years)">6.05</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Annualized volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pii_dp_c20191001__20200930_zL7d4I6ZUXZh" style="text-align: right" title="Annualized volatility">95.99</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pii_dp_c20181001__20190930_zL6bXerDkGPa" style="text-align: right" title="Annualized volatility">104.45</td><td style="text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Dividend rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c20191001__20200930_pii" style="text-align: right" title="Dividend rate">0.00</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c20181001__20190930_pii" style="text-align: right" title="Dividend rate">0.00</td><td style="text-align: left">%</td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140429239949880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Schedule of Income before Income Tax, Domestic and Foreign</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_89C_eus-gaap--ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_zhsAwSMkIYY" style="font: 10pt Times New Roman, Times, Serif; visibility: visible; border-collapse: collapse; margin-left: 50pt; margin-right: 30pt; width: 90%" summary="xdx: Disclosure - Income Taxes (Details)">
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="display: none"><span id="xdx_8B9_zmKV9lDcS5U5" style="display: none">Schedule of Income before Income Tax, Domestic and Foreign</span></span></td><td style="border-bottom: Black 1pt solid; text-align: center">&#160;</td>
    <td colspan="3" id="xdx_496_20191001__20200930_zGfc4t7ylrWg" style="border-bottom: Black 1pt solid; text-align: center">2020</td><td style="border-bottom: Black 1pt solid; text-align: center">&#160;</td>
    <td colspan="3" id="xdx_49B_20181001__20190930_zgXT42mjUx59" style="border-bottom: Black 1pt solid; text-align: center">2019</td></tr>
<tr id="xdx_408_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: left">United States</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right" title="United States">(18,096,148</td><td style="width: 1%; text-align: left">)</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right" title="United States">(18,031,016</td><td style="width: 1%; text-align: left">)</td></tr>
<tr id="xdx_40D_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_i_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 1pt solid">Foreign</td><td style="border-bottom: Black 1pt solid">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right" title="Foreign">(8,161,658</td><td style="border-bottom: Black 1pt solid; text-align: left">)</td><td style="border-bottom: Black 1pt solid">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right" title="Foreign">(8,181,782</td><td style="border-bottom: Black 1pt solid; text-align: left">)</td></tr>
<tr id="xdx_404_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 2.5pt double">Total</td><td style="border-bottom: Black 2.5pt double">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right" title="Total">(26,257,806</td><td style="border-bottom: Black 2.5pt double; text-align: left">)</td><td style="border-bottom: Black 2.5pt double">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right" title="Total">(26,212,798</td><td style="border-bottom: Black 2.5pt double; text-align: left">)</td></tr>
</table>



<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of deferred tax asset and liabilities</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_89C_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zw392Ke84AT9" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 50pt; margin-right: 30pt" summary="xdx: Disclosure - Income Taxes (Details 1)">
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; text-align: left"><span id="xdx_8BA_zNDtTCZntjHk" style="display: none">Schedule of deferred tax asset and liabilities&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: center">&#160;</td>
    <td colspan="3" id="xdx_496_20200930_zVi2ustoktHk" style="border-bottom: Black 1pt solid; text-align: center">2020</td><td style="border-bottom: Black 1pt solid; text-align: center">&#160;</td>
    <td colspan="3" id="xdx_49F_20190930_zuHSA5cToaE8" style="border-bottom: Black 1pt solid; text-align: center">2019</td></tr>
<tr id="xdx_401_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: left">Net operating loss carryforwards</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">23,397,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">18,704,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_40F_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Research and development tax credit carry forwards</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,069,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,162,000</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_401_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,283,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,570,000</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40D_ecustom--DeferredTaxAssetsUnpaidCharges_iI_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Unpaid charges</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">83,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">69,000</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40C_eus-gaap--DeferredTaxAssetsGoodwillAndIntangibleAssets_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Intangible asset costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">132,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">30,000</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_403_eus-gaap--DeferredTaxAssetsUnrealizedCurrencyLosses_iI_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Foreign exchange and other</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">27,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15,000</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_408_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pp0p0_di_zhZhv1bqptZe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 1pt solid; text-align: left">Valuation allowance deferred tax assets</td><td style="border-bottom: Black 1pt solid">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(33,991,000</td><td style="border-bottom: Black 1pt solid; text-align: left">)</td><td style="border-bottom: Black 1pt solid">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(26,550,000</td><td style="border-bottom: Black 1pt solid; text-align: left">)</td></tr>
<tr id="xdx_40F_eus-gaap--DeferredTaxAssetsNet_iI_pp0p0_d0_zPHyywcRkcAb" style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 2.5pt double; text-align: left">Net deferred tax assets</td><td style="border-bottom: Black 2.5pt double">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#8212;&#160;&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#8212;&#160;&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td></tr>
</table>



<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Effective Income Tax Rate Reconciliation</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_89F_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zgqgnyyzqQA5" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; margin-left: 50pt; margin-right: 30pt; width: 90%" summary="xdx: Disclosure - Income Taxes (Details 2)">
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; text-align: left"><span id="xdx_8B7_zyDBegXhrH9d" style="display: none">Schedule of Effective Income Tax Rate Reconciliation</span>&#160;</td><td style="border-bottom: Black 1pt solid; text-align: center">&#160;</td>
    <td colspan="3" id="xdx_498_20191001__20200930_znkPTYEv6Qyf" style="border-bottom: Black 1pt solid; text-align: center">2020</td><td style="border-bottom: Black 1pt solid; text-align: center">&#160;</td>
    <td colspan="3" id="xdx_499_20181001__20190930_zD0ElrIeVuK2" style="border-bottom: Black 1pt solid; text-align: center">2019</td></tr>
<tr id="xdx_400_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: left">Income tax benefit at statutory federal rate</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(5,519,000</td><td style="width: 1%; text-align: left">)</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(5,505,000</td><td style="width: 1%; text-align: left">)</td></tr>
<tr id="xdx_401_eus-gaap--IncomeTaxReconciliationForeignIncomeTaxRateDifferential_i_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Foreign income taxed at other rates</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(723,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(825,000</td><td style="text-align: left">)</td></tr>
<tr id="xdx_40F_eus-gaap--IncomeTaxReconciliationOtherAdjustments_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other permanent differences</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">35,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">140,000</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40C_ecustom--IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopmentCreditBenefit_i_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Research and development credit benefit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,267,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">914,000</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_401_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_z1PYeXsbnRgi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">State and local taxes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,911,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,487,000</td><td style="text-align: left">)</td></tr>
<tr id="xdx_40C_eus-gaap--IncomeTaxReconciliationPriorYearIncomeTaxes_i_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Adjustment and true up to prior year tax provision</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">373,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">194,000</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_405_eus-gaap--EffectOfExchangeRateOnCash_d0_zqtfu3RSRnmg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Effect of change in statutory rates</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">36,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_408_eus-gaap--TaxesExcludingIncomeAndExciseTaxes_i_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">State minimum and excise taxes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">22,664</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">82,181</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_400_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_zdxGf7UkZNn1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 1pt solid; text-align: left">Change in valuation allowances</td><td style="border-bottom: Black 1pt solid">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">7,442,000</td><td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">6,569,000</td><td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td></tr>
<tr id="xdx_405_eus-gaap--DeferredIncomeTaxExpenseBenefit_i_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 2.5pt double; text-align: left">Income tax expense</td><td style="border-bottom: Black 2.5pt double">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">22,664</td><td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">82,181</td><td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td></tr>
</table>



<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140429220350040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details Narrative) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_CashRefundAvailableDescription', window );">Cash Refund Available description</a></td>
<td class="text">The cash refund is available to eligible
companies with an annual aggregate revenue of less than $20.0 million Australian during the reimbursable period.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants', window );">Loss per share for potentially dilutive common shares</a></td>
<td class="nump">10,576,266<span></span>
</td>
<td class="nump">8,812,933<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_CashRefundAvailableDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_CashRefundAvailableDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of call options and warrants using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1828-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1757-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1707-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140429214048968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Income (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ReinsurancePremiumsForInsuranceCompaniesByProductSegmentLineItems', window );"><strong>SEC Schedule, 12-17, Insurance Companies, Reinsurance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_NonOperatingIncomeFromGrant', window );">Grant income</a></td>
<td class="nump">$ 149,888<span></span>
</td>
<td class="nump">$ 298,943<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned', window );">Research and development incentive income</a></td>
<td class="nump">4,375,025<span></span>
</td>
<td class="nump">2,215,691<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CurrencyAxis=currency_AUD', window );">Australia, Dollars</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ReinsurancePremiumsForInsuranceCompaniesByProductSegmentLineItems', window );"><strong>SEC Schedule, 12-17, Insurance Companies, Reinsurance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned', window );">Research and development incentive income</a></td>
<td class="nump">$ 6,392,266<span></span>
</td>
<td class="nump">3,281,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=avxl_ClinicalStudyGrantMember', window );">Clinical Study Grant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ReinsurancePremiumsForInsuranceCompaniesByProductSegmentLineItems', window );"><strong>SEC Schedule, 12-17, Insurance Companies, Reinsurance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_FundingOfDeferredIncomeAwardedGrant', window );">Awarded grant funding amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 597,886<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=avxl_NYCBiotechCreditMember', window );">NYC Biotech Credit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ReinsurancePremiumsForInsuranceCompaniesByProductSegmentLineItems', window );"><strong>SEC Schedule, 12-17, Insurance Companies, Reinsurance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned', window );">Research and development incentive income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_FundingOfDeferredIncomeAwardedGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Information related to funding of deferred income awarded grant.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_FundingOfDeferredIncomeAwardedGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_NonOperatingIncomeFromGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_NonOperatingIncomeFromGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ReinsurancePremiumsForInsuranceCompaniesByProductSegmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ReinsurancePremiumsForInsuranceCompaniesByProductSegmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23221-108380<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23199-108380<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_AUD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_AUD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=avxl_ClinicalStudyGrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=avxl_ClinicalStudyGrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=avxl_NYCBiotechCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=avxl_NYCBiotechCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140429213045800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Offering Agreements (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 01, 2020</div></th>
<th class="th"><div>Jun. 07, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityListingsLineItems', window );"><strong>Entity Listings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from sale of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,754,198<span></span>
</td>
<td class="nump">$ 17,832,109<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=avxl_PurchaseAgreementMember', window );">2015 Purchase Agreement [Member] | Lincoln Park Capital Fund, LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityListingsLineItems', window );"><strong>Entity Listings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of share issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,872,696<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_StockIssuedDuringPeriodSharesNewIssues4', window );">Number of shares issued for aggregate purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,848,995<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_StockIssuedDuringPeriodValueNewIssues3', window );">Number of shares issued for aggregate purchase price, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,197,604<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_StockIssuedDuringPeriodSharesNewIssues3', window );">Number of shares issued for commitment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,701<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=avxl_PurchaseAgreement1Member', window );">2019 Purchase Agreement [Member] | Lincoln Park Capital Fund, LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityListingsLineItems', window );"><strong>Entity Listings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of share issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">324,383<span></span>
</td>
<td class="nump">7,633,527<span></span>
</td>
<td class="nump">1,839,415<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_StockIssuedDuringPeriodSharesNewIssues4', window );">Number of shares issued for aggregate purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,564,584<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_StockIssuedDuringPeriodValueNewIssues3', window );">Number of shares issued for aggregate purchase price, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,254,298<span></span>
</td>
<td class="nump">$ 4,634,505<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_StockIssuedDuringPeriodSharesNewIssues3', window );">Number of shares issued for commitment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68,943<span></span>
</td>
<td class="nump">339,415<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_ValueOfSharesObligatedToPurchase', window );">Total number of shares obligated to purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_AgreementTerm', window );">Agreement term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecordedUnconditionalPurchaseObligationDescription', window );">Description of purchases price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The
Company may direct Lincoln Park, at its sole discretion, and subject to certain conditions, to purchase up to 200,000 shares of
common stock on any business day (a &#8220;Regular Purchase&#8221;). The amount of a Regular Purchase may be increased under certain
circumstances up to 250,000 shares, provided that Lincoln Park&#8217;s committed obligation for Regular Purchases on any business
day shall not exceed $2,000,000. In the event the Company purchases the full amount allowed for a Regular Purchase on any given
business day, the Company may also direct Lincoln Park to purchase additional amounts as accelerated and additional accelerated
purchases. The purchase price of shares of common stock related to the future funding will be based on the then prevailing market
prices of such shares at the time of sales as described in the 2019 Purchase Agreement.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_NumberOfSharesObligatedToPurchaseProrataBasic', window );">Pro rata basic number of shares obligated to purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">162,191<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_StockIssuedDuringPeriodValueNewIssues4', window );">Amount of shares remain available</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,111,197<span></span>
</td>
<td class="nump">$ 45,365,495<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=avxl_PurchaseAgreement1Member', window );">2019 Purchase Agreement [Member] | Lincoln Park Capital Fund, LLC [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityListingsLineItems', window );"><strong>Entity Listings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of share issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,016,457<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_PercentageOfGrossProceedsFromSales', window );">Percentage of gross proceeds from sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=avxl_EquityOfferingSalesAgreementMember', window );">Equity Offering Sales Agreement [Member] | Cantor Fitzgerald &amp;amp;amp; Co [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityListingsLineItems', window );"><strong>Entity Listings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_PercentageOfGrossProceedsFromSales', window );">Percentage of gross proceeds from sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from sale of common stock</a></td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,096,136<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_NumberOfStockSold', window );">Number of stock sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,760,429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_GrossProceedsFromSaleOfCommonStock', window );">Gross proceeds from sale of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,499,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_NumberOfSharesAvailable', window );">Number of shares available</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,500,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_AgreementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Terms of the agreement under agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_AgreementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_GrossProceedsFromSaleOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_GrossProceedsFromSaleOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_NumberOfSharesAvailable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_NumberOfSharesAvailable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_NumberOfSharesObligatedToPurchaseProrataBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Information related to number of shares obligated to purchase prorata basic.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_NumberOfSharesObligatedToPurchaseProrataBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_NumberOfStockSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_NumberOfStockSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_PercentageOfGrossProceedsFromSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents information related to percentage of gross proceeds from sales.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_PercentageOfGrossProceedsFromSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_StockIssuedDuringPeriodSharesNewIssues3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_StockIssuedDuringPeriodSharesNewIssues3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_StockIssuedDuringPeriodSharesNewIssues4">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_StockIssuedDuringPeriodSharesNewIssues4</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_StockIssuedDuringPeriodValueNewIssues3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_StockIssuedDuringPeriodValueNewIssues3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_StockIssuedDuringPeriodValueNewIssues4">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_StockIssuedDuringPeriodValueNewIssues4</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_ValueOfSharesObligatedToPurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Information related to value of shares obligated to purchase initially.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_ValueOfSharesObligatedToPurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityListingsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityListingsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecordedUnconditionalPurchaseObligationDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Describes the nature of an unconditional purchase obligation that is not recognized as a liability on the balance sheet.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecordedUnconditionalPurchaseObligationDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=avxl_PurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=avxl_PurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=avxl_LincolnParkCapitalFundLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=avxl_LincolnParkCapitalFundLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=avxl_PurchaseAgreement1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=avxl_PurchaseAgreement1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=avxl_EquityOfferingSalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=avxl_EquityOfferingSalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=avxl_CantorFitzgeraldAndCoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=avxl_CantorFitzgeraldAndCoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140429214195256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments (Details) - Purchase Warrants [Member] - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Share Purchase Warrants Balance, at beginning</a></td>
<td class="nump">350,000<span></span>
</td>
<td class="nump">678,379<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Balance, at beginning</a></td>
<td class="nump">$ 4.19<span></span>
</td>
<td class="nump">$ 2.87<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Share Purchase Warrants Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,750)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExercised', window );">Weighted Average Exercise Price, Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.13<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations', window );">Share Purchase Warrants Expired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(319,629)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExpired', window );">Weighted Average Exercise Price, Expired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.46<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod', window );">Share Purchase Warrants Granted</a></td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice', window );">Weighted Average Exercise Price, Granted</a></td>
<td class="nump">$ 3.17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Share Purchase Warrants Balance, at ending</a></td>
<td class="nump">500,000<span></span>
</td>
<td class="nump">350,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Balance, at ending</a></td>
<td class="nump">$ 3.88<span></span>
</td>
<td class="nump">$ 4.19<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Information related to share based compensation arrangement by share based payment award equity instruments other than options outstanding weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExpired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExpired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of non-option equity instruments exercised by participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares under non-option equity instrument agreements for which rights to exercise lapsed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=avxl_PurchaseWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=avxl_PurchaseWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140429215082712">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments (Details 1)<br></strong></div></th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number</a></td>
<td class="nump">500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=avxl_PurchaseWarrants1Member', window );">Purchase Warrants 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number</a></td>
<td class="nump">350,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Exercise Price | $ / shares</a></td>
<td class="nump">$ 4.19<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Expiry Date</a></td>
<td class="text">Jun. 30,  2021<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=avxl_PurchaseWarrants2Member', window );">Purchase Warrants 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number</a></td>
<td class="nump">150,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Exercise Price | $ / shares</a></td>
<td class="nump">$ 3.17<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Expiry Date</a></td>
<td class="text">May  06,  2024<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=avxl_PurchaseWarrants1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=avxl_PurchaseWarrants1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=avxl_PurchaseWarrants2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=avxl_PurchaseWarrants2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140429213994232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments (Details 2) - 2015 Omnibus Incentive Plan [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options Outstanding at beginning</a></td>
<td class="nump">8,462,933<span></span>
</td>
<td class="nump">6,506,917<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Outstanding at beginning</a></td>
<td class="nump">$ 3.58<span></span>
</td>
<td class="nump">$ 3.83<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value Outstanding at beginning</a></td>
<td class="nump">$ 4,115,032<span></span>
</td>
<td class="nump">$ 2,353,088<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options Granted</a></td>
<td class="nump">1,695,000<span></span>
</td>
<td class="nump">2,265,399<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Granted</a></td>
<td class="nump">$ 2.96<span></span>
</td>
<td class="nump">$ 2.79<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value Granted</a></td>
<td class="nump">$ 2.27<span></span>
</td>
<td class="nump">$ 2.27<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Options Forfeited</a></td>
<td class="num">(68,332)<span></span>
</td>
<td class="num">(309,383)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Forfeited</a></td>
<td class="nump">$ 3.01<span></span>
</td>
<td class="nump">$ 3.25<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options Exercised</a></td>
<td class="num">(13,335)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Exercised</a></td>
<td class="nump">$ 3.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options Outstanding at ending</a></td>
<td class="nump">10,076,266<span></span>
</td>
<td class="nump">8,462,933<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Outstanding at ending</a></td>
<td class="nump">$ 3.48<span></span>
</td>
<td class="nump">$ 3.58<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value Outstanding at ending</a></td>
<td class="nump">$ 14,982,581<span></span>
</td>
<td class="nump">$ 4,115,032<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options Exercisable at ending</a></td>
<td class="nump">7,412,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Exercisable at ending</a></td>
<td class="nump">$ 3.66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate intrinsic value Exercisable at ending</a></td>
<td class="nump">$ 10,763,906<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=avxl_StockOptionPlan2015Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=avxl_StockOptionPlan2015Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140429220355496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments (Details 3) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share based compensation</a></td>
<td class="nump">$ 4,876,906<span></span>
</td>
<td class="nump">$ 6,430,873<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share based compensation</a></td>
<td class="nump">2,210,789<span></span>
</td>
<td class="nump">3,203,165<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share based compensation</a></td>
<td class="nump">$ 2,666,117<span></span>
</td>
<td class="nump">$ 3,227,708<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140429230256856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments (Details 4)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">1.57%<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life of options (years)</a></td>
<td class="text">5 years 6 months 10 days<span></span>
</td>
<td class="text">6 years 18 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Annualized volatility</a></td>
<td class="nump">95.99%<span></span>
</td>
<td class="nump">104.45%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140429213344792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseAndRentalExpense', window );">Operating Leases, Rent Expense</a></td>
<td class="nump">$ 233,423<span></span>
</td>
<td class="nump">$ 190,416<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_SharesIssuedPursuantToCashlessExerciseOfWarrantInShares', window );">Shares issued pursuant to cashless exercise of warrants</a></td>
<td class="nump">4,938<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_StockIssuedPursuantToCashlessExerciseOfWarrants', window );">Stock issued pursuant to cashless exercise of warrants</a></td>
<td class="nump">8,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_SharesIssuedPursuantToCashlessExercisesOfOption', window );">Shares issued pursuant to cashless exercises of option</a></td>
<td class="nump">721<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_NumberOfCashlessExerciseOption', window );">Number of cashless exercise option</a></td>
<td class="nump">13,335<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share based compensation</a></td>
<td class="nump">$ 4,876,906<span></span>
</td>
<td class="nump">$ 6,430,873<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Remaining stock based compensation</a></td>
<td class="nump">$ 4,040,812<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=avxl_StockOptionPlan2015Member', window );">2015 Omnibus Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Maximum number of common shares reserved for future issuance</a></td>
<td class="nump">6,050,553<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</a></td>
<td class="nump">146,371<span></span>
</td>
<td class="nump">146,371<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=avxl_StockOptionPlan2019Member', window );">2019 Omnibus Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</a></td>
<td class="nump">3,161,665<span></span>
</td>
<td class="nump">4,788,333<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Additional shares of common stock available for issuance</a></td>
<td class="nump">6,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_NumberOfCashlessExerciseOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_NumberOfCashlessExerciseOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_SharesIssuedPursuantToCashlessExerciseOfWarrantInShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_SharesIssuedPursuantToCashlessExerciseOfWarrantInShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_SharesIssuedPursuantToCashlessExercisesOfOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_SharesIssuedPursuantToCashlessExercisesOfOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_StockIssuedPursuantToCashlessExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_StockIssuedPursuantToCashlessExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseAndRentalExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseAndRentalExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=avxl_StockOptionPlan2015Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=avxl_StockOptionPlan2015Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=avxl_StockOptionPlan2019Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=avxl_StockOptionPlan2019Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140429224090280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">United States</a></td>
<td class="num">$ (18,096,148)<span></span>
</td>
<td class="num">$ (18,031,016)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign</a></td>
<td class="num">(8,161,658)<span></span>
</td>
<td class="num">(8,181,782)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Total</a></td>
<td class="num">$ (26,257,806)<span></span>
</td>
<td class="num">$ (26,212,798)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140429223975304">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes (Details 1) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 23,397,000<span></span>
</td>
<td class="nump">$ 18,704,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Research and development tax credit carry forwards</a></td>
<td class="nump">2,069,000<span></span>
</td>
<td class="nump">1,162,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">8,283,000<span></span>
</td>
<td class="nump">6,570,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_DeferredTaxAssetsUnpaidCharges', window );">Unpaid charges</a></td>
<td class="nump">83,000<span></span>
</td>
<td class="nump">69,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets', window );">Intangible asset costs</a></td>
<td class="nump">132,000<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses', window );">Foreign exchange and other</a></td>
<td class="nump">27,000<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance deferred tax assets</a></td>
<td class="num">(33,991,000)<span></span>
</td>
<td class="num">(26,550,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred tax assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_DeferredTaxAssetsUnpaidCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represents as a deferred tax assets unpaid charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_DeferredTaxAssetsUnpaidCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from unrealized losses on foreign currency transactions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140429213986776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details 2) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Income tax benefit at statutory federal rate</a></td>
<td class="num">$ (5,519,000)<span></span>
</td>
<td class="num">$ (5,505,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential', window );">Foreign income taxed at other rates</a></td>
<td class="num">(723,000)<span></span>
</td>
<td class="num">(825,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Other permanent differences</a></td>
<td class="nump">35,000<span></span>
</td>
<td class="nump">140,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopmentCreditBenefit', window );">Research and development credit benefit</a></td>
<td class="nump">1,267,000<span></span>
</td>
<td class="nump">914,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State and local taxes</a></td>
<td class="num">(2,911,000)<span></span>
</td>
<td class="num">(1,487,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes', window );">Adjustment and true up to prior year tax provision</a></td>
<td class="nump">373,000<span></span>
</td>
<td class="nump">194,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCash', window );">Effect of change in statutory rates</a></td>
<td class="nump">36,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxesExcludingIncomeAndExciseTaxes', window );">State minimum and excise taxes</a></td>
<td class="nump">22,664<span></span>
</td>
<td class="nump">82,181<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowances</a></td>
<td class="nump">7,442,000<span></span>
</td>
<td class="nump">6,569,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">$ 22,664<span></span>
</td>
<td class="nump">$ 82,181<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopmentCreditBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopmentCreditBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of effect of exchange rate changes on cash balances held in foreign currencies. Excludes cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to revisions of previously reported income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxesExcludingIncomeAndExciseTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>All taxes not related to income of the entity or excise or sales taxes levied on the revenue of the entity that are not reported elsewhere. These taxes could include production, real estate, personal property, and pump tax.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxesExcludingIncomeAndExciseTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140429223984536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign', window );">U.S. federal net operating loss carryforwards</a></td>
<td class="nump">$ 76,800,000<span></span>
</td>
<td class="nump">$ 60,800,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_OperatingLossCarryForwardsExpirationYear1', window );">Operating loss carry-forwards, expiration year</a></td>
<td class="text">2027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal', window );">State net operating loss carryforwards</a></td>
<td class="nump">$ 103,100,000<span></span>
</td>
<td class="nump">64,000,000.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign Tax Authority [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carry-forwards</a></td>
<td class="nump">4,300,000<span></span>
</td>
<td class="nump">$ 3,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign Tax Authority [Member] | Australia, Dollars</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carry-forwards</a></td>
<td class="nump">$ 6,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_OperatingLossCarryForwardsExpirationYear1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The expiration date of each operating loss carryforward included in total operating loss carryforwards, or the applicable range of such expiration dates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_OperatingLossCarryForwardsExpirationYear1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible foreign operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_AUD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_AUD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>43
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( &^+G%$'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    " !OBYQ1;#^]\>X    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9+/
M2@,Q$(=?17+?G=T45,(V%\53"X(%Q5M(IFUP\X=D9+=O;W9MMX@^@)!+9G[Y
MYAM(IZ/0(>%S"A$36<PWH^M]%CJNV9$H"H"LC^A4KDO"E^8^)*>H7-,!HM(?
MZH# F^86')(RBA1,P"HN1"8[HX5.J"BD,][H!1\_4S_#C ;LT:&G#&W= I/3
MQ'@:^PZN@ E&F%S^+J!9B'/U3^S< 79.CMDNJ6$8ZF$UY\H.+;QM-R_SNI7U
MF9376%YE*^@4<<TNDU]7#X^[)R9YPYNJY16_W[5W@I?3O$^N/_RNPBX8N[?_
MV/@B*#OX]2_D%U!+ P04    " !OBYQ1F5R<(Q &  "<)P  $P   'AL+W1H
M96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03<VEVV[29A.U.
M'X416(UL>621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X
M8-DOV]:[MR_>X%<R)!%!,!FGK_# "J5,7K5::0##.'W)$Q+#W(*+"$MX%,O6
M7.!;&B\CUNJTV]U6A&ELH1A'9&!]7BQH0-!445IO7R"TY1\S^!7+5(UEHP$3
M5T$FN8BT\OELQ?S:WCYES^DZ'3*!;C ;6"!_SF^GY$Y:B.%4PL3 :F<_5FO'
MT=)(@(+)?90%NDGVH],5"#(-.SJ=6,YV?/;$[9^,RMIT-&T:X./Q>#BVR]*+
M<!P$X%&[GL*=]&R_I$$)M*-IT&38]MJND::JC5-/T_=]W^N;:)P*C5M/TVMW
MW=..B<:MT'@-OO%/A\.NB<:KT'3K:28G_:YKI.D6:$)&X^MZ$A6UY4#3( !8
M<';6S-(#EEXI^G64&MD=N]U!7/!8[CF)$?[&Q036:=(9EC1&<IV0!0X -\31
M3%!\KT&VBN#"DM)<D-;/*;50&@B:R('U1X(AQ=RO_?67N\FD,WJ=?3K.:Y1_
M::L!I^V[F\^3_'/HY)^GD]=-0LYPO"P)\?LC6V&')VX[$W(Z'&="?,_V]I&E
M)3+/[_D*ZTX\9Q]6EK!=S\_DGHQR([O=]EA]]D]';B/7J<"S(M>41B1%G\@M
MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7
MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V<
M/!T3$LV4"P9!AI<D)A*I.7Y-2!/^*Z7:_IS30/"4+R3Z2I&/:;,CIW0FS>@S
M&L%&KQMUAVC2/'K^!?F<-0H<D1L= F<;LT8AA&F[\!ZO)(Z:K<(1*T(^8ADV
M&G*U%H&V<:F$8%H2QM%X3M*T$?Q9K#63/F#([,V1=<[6D0X1DEXW0CYBSHN0
M$;\>ACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0'
MHYI9";V$5FJ?JH<T/J@>,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y
M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RS<C'5*^3*=@Y
MG\#L_6@^GO'M^MDDA*^:62TC%I!+@;-!)+C\B\KP*L0)Z&1;)0G+5--E-XH2
MGD(;;NE3]4J5U^6ON2BX/%ODZ:^A=#XLS_D\7^>TS0LS0[=R2^JVE+ZU)CA*
M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D*
MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-#
MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B
M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P
MOFH]M!5.S_Y9K<B?#!%.%@L22&.4%Z9*HO,94[[G*TG$53B_13.V$I<8O./F
MQW%.4[@2=K8/ C*YNSFI>F4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W
MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2
MD 83 <V4R43P H)DIAR F/H+O?(,N2D5SJT^.7]%+(.&3E[2)1(4BK ,!2$7
M<N/O[Y-J=XS7^BR!;814,F35%\I#B<$],W)#V%0E\Z[:)@N%V^)4S;L:OB9@
M2\-Z;ITM)__;7M0]M!<]1O.CF> >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F
M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+
M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5
M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0    (
M &^+G%$MSR[8P04  *D8   8    >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL
MI9E=;]LV%(:OVU]!&+WH@#B6*'\6B0''<3:CJ>M%:=ILV 4MT;802?0H*D[^
M_8X^++H9?:1AN4@D6>?UHT/J/8?,Q5[(IV3+N2(O41@GEZVM4KM/G4[B;7G$
MDG.QXS%\LA8R8@I.Y::3["1G?AX4A1UJ6?U.Q(*X-;[(KRWE^$*D*@QBOI0D
M2:.(R=<K'HK]9<MN'2[<!9NMRBYTQA<[MN$N5]]V2PEGG4K%#R(>)X&(B>3K
MR];$_G3M#+* _(Z'@.^3HV.2/<I*B*?L9.Y?MJR,B(?<4YD$@S_/?,K#,%,"
MCK]+T5;UG5G@\?%!_29_>'B8%4OX5(3? U]M+UO#%O'YFJ6ANA/[WWCY0+U,
MSQ-ADO\F^^+>;K=%O#11(BJ#@2 *XN(O>RD3<13@]$X$T#* O@FP3WV#4P8X
M30.Z94 WSTSQ*'D>KIEBXPLI]D1F=X-:=I G,X^&QP_B;-Q=)>'3 .+4>"J>
MN21M\LV])A\__'+142":?=3Q2H&K0H">$+ I^2)BM4W(+/:Y_[- !V@J)'I
MNJ*HHLMWY\2QS@BUJ&4 FN+AU]P[)W1X,OP:#__")'R[;0K_Z6F<*L%.KN>@
M"?YSLDJ4A$G^%R+9K22[N63WU!,*+X573Y'[UQTWC1@>;EOMSPA%KZ+HH3(3
M0/!SC)N0;4P8>/R:A0E'./H51[]9-B9QG+*0W/&=D,K$@^LHF6(X@PIGT'!P
M) -WS,WM-!*N59>B8<4T;,:TY#(0?O:F$G +X]S!E0[OYOMW[VK>CU'%-FK&
M=A,D'@Q?B7@#EQ,3'ZYV\X@@V98V1>L_03UR)D\CU8C5),H^LFH;%9JF4KZ%
MPH:R1J[=MD9M!T6C&HVB6K-8!>H5R$).%FFTXM((A(M8EMUV!GVKCR%IW[6=
M)DAW?!-DU@MY6[#(G"=<:+*8/,Q^D-OYS8RXT_EL,9VY9/KU;GF.<6HSMW$[
M+CFG,+(21G4.5?2%?.:O1E)<RH(,.G;7ZE&,3!N\C3MT27;/7LC<![Q@'7@L
M-S1DB'')T;!M]:UAU^IBA-KZ;=RS2\)Y[ D)%IO#G1%7P0M!A"13D4)2(;?"
M-P\\KKYXP"!U0;!Q%R\A)[XO>9*<'0[(+=Q'OL9F,ERR9Y/OI$?AW8>KT/IA
MG+I(V+BWHYSW>V'DQ"4':@O=@1 2 ]25PL;-_2W@-#N#8;X7^]@(A\LM8%'R
M"(L2K&75%8/B)O^6K9J#2RF>@]@SCG*-Y@(K9E27#8K[_+_25KP51B!<Z9N+
M >EB01L5BPIH*1(%SO='L#OYIM8HVF!\(XQ-5PV*FWT^IR:P@CZ-@@L,NYBU
M45T6*.[EMR+OAK8BQBIJC4A_"!5^Y*"IT>6 XMY]'RBH[F)-;/IQ]0MQN9=*
MR)81"U>:BB@2\7L"/ZX2WM,9^6"=PQ"2'70TSRQ$&W&JJP/%_1LZ<#^(-\1]
MC58B-'+B I.''[<8B2X!%/?K0Z[([,7;LGC#3_8B-4*+B7L]^1UCTG9/&]G]
M=QZ&[:<8+!1&E"4PW7PR3Y+TQ'S#-1<"0]-&3QL9_8,(P:F8+/I*:>R]:Y10
M($>[N]/(W0\->+&>RZ<6V+QY45"C^,@3C$R;N]/(W.>QXK+80\N6 ^R :B3#
M%6O(M,L[C9<$T(E!-=P(<]&IT5F(N,T\CX,,B/B%($9XM#/3:(7@1BP,R56:
MP,>)>2QQG9J= T=[OM-H*3"+N-QDL^M74( ."NQRQV)S[G#!N@T$1YN_TV@M
MX&[!+E"@_[?IXVAS=QJU_LMT%09>UF0RTV2_+E5ZN4JV"?X\M@<#9S3J977Z
MV82@7=UIU-@7U>Q0R=PM@ZZ&?$T5-#5Q5G],6YBE<O\(J]\?]>FH-WA#U3G:
MV\WF1;Y'GA O:^**;=[J:K4//\EWGSOZ]F(3_PO+IE5"0KZ&4.M\ %F1Q;YX
M<:+$+M\I7@FE1)0?;CGSN<QN@,_70JC#2?8%U7\GQO\ 4$L#!!0    ( &^+
MG%&FY0"O*P0  &X-   8    >&PO=V]R:W-H965T<R]S:&5E=#(N>&ULG5=K
M;Z,X%/TK5C32SDII\0,3J-)(:=K55.K.5)/.[F<'G,8J8,8V33N_?FV2D@<F
M$^V'-@;N/9QC+O=<QFNI7O2*<P/>BKS4UX.5,=55$.ATQ0NF+V7%2WME*57!
MC#U4SX&N%&=9DU3D 88P"@HFRL%DW)Q[5).QK$TN2OZH@*Z+@JGW&Y[+]?4
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M',PG:IU?W5,BOAX>#DZ>_:_'22@Q\?'<,TU1A;13>3($4E#S(L-" P7TID=
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MRT;^SSXI'Y(;GE^<N.%*;[ABNF4CIO*'K,^^_[9KM[;#U;0:_N"C\MU$7-E
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ML&?_=M.U=+7K 29.1B:W)'>IL8DLBB,DQ1[")NS/?4_?P33B-SW\!7U!:C?
MH0\=[M$ Y^I-U>Z(IYXTH0M^=.$:MRS%=QJ.3QQH"CN)3WK2&<<GX#7K77=7
MYLXGM,&#=8WX'SZ0/3C0&/F%DZKK64?:*E &?HG@#JE 5UCRU>SP_8#%_+A[
MW($RI*PI?Q>7%KW S?NW?K1\XD2(',H*1.\UJ602-B04*'R($&5N?R[)%_9M
MXXB8G6AYG9%SVPL&?;M'\D1WMFMUV7[C<H!&RB["LJ3%8HU9OD;$)5O\^5!\
M)W7Q&%9,X.@M!><B([INVH+1*HLS>LO;F\ F^Q6@_BF3 9C! ?P8EM21- 2T
M*I8[8R>-. -=2#$=WD(MH.S802$WP:]S^Z9M*"<D^0-4& J93']D,H#"JFT+
MLJ!N5#;V$R%P#6QL$!J4"-&(/HPA[[@*<F9:1A$%X,8')KQ*POL=J]ZI!Q9$
M*OOBLY D=U9T8+IU!AH$^PCVC-3B,EH $ B743S[E2(M8].&L8WW3%.[-%-(
M.05^0/8IZ(MP)]4!WARRI=6C(<(.)/R,3H/BI=P^V83.GU6[WYG%#MYI11R4
MK?:=RVCP%?C*%VUH;S;PIJ, +AI#@:%E-@B0AMJ"$#5A%XP/MF$4VF-11@T%
M^?(LWP7O*8E$HO\QTQ".<TY5%HJX692 AFZ$C<32-"=,L"<2DLC:FF(_5(M-
M'.NPCA%["T<LI6 9*=3U-:JFR),MDL26Y!_'\YH[5#V8 %G-0UY)4$G%QLQG
MC[\;KQ!'33)',6;4-,U1*NCXL('W3E5'HK8ZE<V&LE4VP%Y0*,&XE1,-HW#A
M0I::R=9SN!8^-R@='5.BV3B6%]"A?EOT9M0IQ/VX^)Q<CMY@.(JNLVXE^5O"
MSL02Z9.@#$Y#D>.(<:[@?1!_K9XD$$+BY'3N8T.H<F[_#@=)=&R4WL!A,QK&
M;"_%A>1#(*?U,SI&R'BG9V_<JNW+,:.[0W1GZ!(#%Q]>_I[;=\'9<10TLGSX
MV7." 3?7('=61T8L88F'="U$1M%)#B#J4FQ.0"LC=N'N<"BZG"S2+P<$:9)D
MV8>KU8+]S AV2:7/Z3FGEXILIEH)!TU DD %B"]*OE:4O67>0#3(/8:.EB*%
M([SK15<0MU)4@&O,T:0BZGJ2YT1'._$PBIIDV0)H[5KX-(LJI8GCI%QP1!%8
MOB"2',?O;.Q* TX2C"HPI7#0BT/3X4SMCKG<J2P"#!#7,L$%(Q5LZH@LS.-1
M:5XW%"R%R;,)!.%HX"?<#'I.9"#X5BC/@G% GZ0=.SVFQ YXMA9Z,!9S.G*#
M==9]5&G2;0MUI\A"5)DD/7?-B@P+YRUKMD$-NN!&[3H6I[J;J2X1]>0F"Y\:
M$GY@FZAV[#Z9IBE)0KHA14)Z7.:4X,JNXJ?%(S<#;8T:!SF&CT+HT*A=, 1P
MGTK?"VA*? *VQS$X8=F790(F##$$) M[2%>(&N A[X>.H\(?.^ ^TP7H.$"1
M16JZ0I8R%8HYMS\,P8-[=^JPHBVG>6F+EDLE-=H3<E*RQ#*&@"8)K_UZF$)2
MDT)2S>!6E%IT$#N71! \D5BS-XCXVKA[\K37L23W6DIR:3)*O*80MPJI9+M@
M9Q><WDG\AP)=3D26T[P*YWWCMO8?B*0WJ.J]*-O>Y>NFK=K5SGZ@VV[X-A/
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M"PY.R0#K6X6WQNZ"#AA^V;GZ#U!+ P04    " !OBYQ1ZF#ZKWD)  "8%P
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MQCE3\;\K)='_: /6%P9.=@]T0/\Q_N(_4$L#!!0    ( &^+G%$TJWEM) @
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M7@<]_]DZC)=QN%P0$1W6<;A:)Z#XK"POB2]9ALEB%:ZCI9=#YS@)5QMBH6C
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M\![9#EA>/AE)X=:JO2^<U!U>E.&]RX\7%];#<!GF33]E.B4!*7$#!)N!A^>
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MK2Z,4DS&*+*6441GZ(/R<Q#"8E^(^/'7.P)1)<&9*89\9:J!LONUHQ2DJG4
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M+K<HUC4@)0I@&%1%VH/I;"(>!L/\4CU=OFQD$%#P.8NX.^#+%$J#+R9B*5%
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MV#"3#$46II,(9*8NZK+IGB25/V2-E$YI8M@#H33 -(^SAVW\.'CJIZ@2X30
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MGIT)L/,_M/6&OWX[K]NV7O,_\>TGV^ !^ONBIHQ4?\ "X7O(/_PO4$L#!!0
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MACD.8-UO]_V+54N_4=\KB_NY?US@!Y'0[@+29TK9X<4)&#^Q+OX"4$L#!!0
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M,*(I.3T:[$^RD*8T3!.GY(2,AK.,H<:CLKQR=BP-63(+LRCM<)Q,63C+T>1
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MW(D=E,.&MJ6ZY;N_H'<H-'P9+Z7]1;ON;#1U4-9*Q:L>K!54K.Z>]$<?B ,
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M_E>L: ^MM#6. PE4@%3H?E1JI:JLVT.U!Y,<Q&IL9[:![K^?[8244D";U+Z
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MN^I_8[H.@C[G@&&P6"U'2=<MZ7J2]#KY%T]@EU2+:U0%I"J)D:147"KRB!_
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M*&N [U,IS=/ +M!VU+O_ 5!+ P04    " !OBYQ1EN:5E?$"  !D"0  &0
M 'AL+W=O<FMS:&5E=',O<VAE970R."YX;6RU5EMOVC 4_BM6M(=6:LD- E2
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M?E;F^<BF+<2]9.GA6N=P)77]&U!+ P04    " !OBYQ1+P""5$P!  !K$0
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M8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ ;XN<49E<G",0!@  G"<  !,
M             ( !S $  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4
M" !OBYQ1+<\NV,$%  "I&   &               @($-"   >&PO=V]R:W-H
M965T<R]S:&5E=#$N>&UL4$L! A0#%     @ ;XN<4:;E *\K!   ;@T  !@
M             ("!! X  'AL+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4
M Q0    ( &^+G%'].[I3L (   D(   8              " @642  !X;"]W
M;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4    " !OBYQ1N*[>^ZX$  #&
M#P  &               @(%+%0  >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL
M4$L! A0#%     @ ;XN<41/["?;^!   #A$  !@              ("!+QH
M 'AL+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0    ( &^+G%$,3K?4
M" 8  ) >   8              " @6,?  !X;"]W;W)K<VAE971S+W-H965T
M-BYX;6Q02P$"% ,4    " !OBYQ1!7S]??4)  "#%P  &
M@(&A)0  >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%     @ ;XN<
M40+7!9*X&P  #E(  !@              ("!S"\  'AL+W=O<FMS:&5E=',O
M<VAE970X+GAM;%!+ 0(4 Q0    ( &^+G%%&8P[(2 ,  .('   8
M      " @;I+  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"% ,4
M" !OBYQ1IK H/$T'  #E$0  &0              @($X3P  >&PO=V]R:W-H
M965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( &^+G%'J8/JO>0D  )@7   9
M              " @;Q6  !X;"]W;W)K<VAE971S+W-H965T,3$N>&UL4$L!
M A0#%     @ ;XN<432K>6TD"   4Q,  !D              ("!;&   'AL
M+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4    " !OBYQ1 "&9&\$<
M   ;60  &0              @('':   >&PO=V]R:W-H965T<R]S:&5E=#$S
M+GAM;%!+ 0(4 Q0    ( &^+G%'N&8D.X@0  &X-   9              "
M@;^%  !X;"]W;W)K<VAE971S+W-H965T,30N>&UL4$L! A0#%     @ ;XN<
M41$T8LQK!   N0H  !D              ("!V(H  'AL+W=O<FMS:&5E=',O
M<VAE970Q-2YX;6Q02P$"% ,4    " !OBYQ1Y ".]-$"  !R!@  &0
M        @(%ZCP  >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0
M   ( &^+G%'"%VPV1@,  ,X*   9              " @8*2  !X;"]W;W)K
M<VAE971S+W-H965T,3<N>&UL4$L! A0#%     @ ;XN<41-\_ ^9!@  9QD
M !D              ("!_Y4  'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q0
M2P$"% ,4    " !OBYQ1^1TF CP#  #Z"@  &0              @('/G
M>&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    ( &^+G%%<:O]P
MM (  -,(   9              " @4*@  !X;"]W;W)K<VAE971S+W-H965T
M,C N>&UL4$L! A0#%     @ ;XN<42H!=3(0!   > \  !D
M ("!+:,  'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"% ,4    " !O
MBYQ1.7!V[\8"   +"   &0              @(%TIP  >&PO=V]R:W-H965T
M<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( &^+G%%M?]_KJP(  )P'   9
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M970R-RYX;6Q02P$"% ,4    " !OBYQ1EN:5E?$"  !D"0  &0
M    @(%%NP  >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    (
M &^+G%'(&6'Y- (  -L)   -              "  6V^  !X;"]S='EL97,N
M>&UL4$L! A0#%     @ ;XN<49>*NQS     $P(   L              ( !
MS,   %]R96QS+RYR96QS4$L! A0#%     @ ;XN<45WA69[D @  %A,   \
M             ( !M<$  'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( &^+
MG%$O ()43 $  &L1   :              "  <;$  !X;"]?<F5L<R]W;W)K
M8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( &^+G%$BX&C7>P$  #H2   3
M          "  4K&  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     D "0
*LPD  /;'      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>56</ContextCount>
  <ElementCount>268</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>19</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="e2298_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="e2298_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="e2298_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="e2298_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/ConsolidatedStatementsOfOperations</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="e2298_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/ConsolidatedStatementsOfCashFlows</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="e2298_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Statement - CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/ConsolidatedStatementOfChangesInStockholdersEquity</Role>
      <ShortName>CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="e2298_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00000007 - Disclosure - Business Description and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/BusinessDescriptionAndBasisOfPresentation</Role>
      <ShortName>Business Description and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="e2298_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>00000008 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="e2298_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>00000009 - Disclosure - Other Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/OtherIncome</Role>
      <ShortName>Other Income</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="e2298_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>00000010 - Disclosure - Equity Offering Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/EquityOfferingAgreements</Role>
      <ShortName>Equity Offering Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="e2298_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>00000011 - Disclosure - Commitments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/Commitments</Role>
      <ShortName>Commitments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="e2298_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>00000012 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="e2298_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>00000013 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://anavex.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>13</Position>
    </Report>
    <Report instance="e2298_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>00000014 - Disclosure - Commitments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/CommitmentsTables</Role>
      <ShortName>Commitments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://anavex.com/role/Commitments</ParentRole>
      <Position>14</Position>
    </Report>
    <Report instance="e2298_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>00000015 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://anavex.com/role/IncomeTaxes</ParentRole>
      <Position>15</Position>
    </Report>
    <Report instance="e2298_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>00000016 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative</Role>
      <ShortName>Summary of Significant Accounting Policies (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/SummaryOfSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>16</Position>
    </Report>
    <Report instance="e2298_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>00000017 - Disclosure - Other Income (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/OtherIncomeDetailsNarrative</Role>
      <ShortName>Other Income (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/OtherIncome</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="e2298_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>00000018 - Disclosure - Equity Offering Agreements (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/EquityOfferingAgreementsDetailsNarrative</Role>
      <ShortName>Equity Offering Agreements (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/EquityOfferingAgreements</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="e2298_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>00000019 - Disclosure - Commitments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/CommitmentsDetails</Role>
      <ShortName>Commitments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/CommitmentsTables</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="e2298_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>00000020 - Disclosure - Commitments (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/CommitmentsDetails1</Role>
      <ShortName>Commitments (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/CommitmentsTables</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="e2298_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>00000021 - Disclosure - Commitments (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/CommitmentsDetails2</Role>
      <ShortName>Commitments (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/CommitmentsTables</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="e2298_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>00000022 - Disclosure - Commitments (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/CommitmentsDetails3</Role>
      <ShortName>Commitments (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/CommitmentsTables</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="e2298_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>00000023 - Disclosure - Commitments (Details 4)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/CommitmentsDetails4</Role>
      <ShortName>Commitments (Details 4)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/CommitmentsTables</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="e2298_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>00000024 - Disclosure - Commitments (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/CommitmentsDetailsNarrative</Role>
      <ShortName>Commitments (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/CommitmentsTables</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="e2298_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>00000025 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/IncomeTaxesTables</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="e2298_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>00000026 - Disclosure - Income Taxes (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/IncomeTaxesDetails1</Role>
      <ShortName>Income Taxes (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/IncomeTaxesTables</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="e2298_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>00000027 - Disclosure - Income Taxes (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/IncomeTaxesDetails2</Role>
      <ShortName>Income Taxes (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/IncomeTaxesTables</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="e2298_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>00000028 - Disclosure - Income Taxes (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/IncomeTaxesDetailsNarrative</Role>
      <ShortName>Income Taxes (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/IncomeTaxesTables</ParentRole>
      <Position>28</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" original="e2298_10k.htm">e2298_10k.htm</File>
    <File>avxl-20200930.xsd</File>
    <File>avxl-20200930_cal.xml</File>
    <File>avxl-20200930_def.xml</File>
    <File>avxl-20200930_lab.xml</File>
    <File>avxl-20200930_pre.xml</File>
    <File>e2298_ex21-1.htm</File>
    <File>e2298_ex23-1.htm</File>
    <File>e2298_ex31-1.htm</File>
    <File>e2298_ex31-2.htm</File>
    <File>e2298_ex32-1.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>image_001.jpg</File>
    <File>img_002.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/currency/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>49
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "e2298_10k.htm": {
   "axisCustom": 0,
   "axisStandard": 9,
   "contextCount": 56,
   "dts": {
    "calculationLink": {
     "local": [
      "avxl-20200930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "avxl-20200930_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "e2298_10k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "avxl-20200930_lab.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml",
      "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "avxl-20200930_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "avxl-20200930.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd"
     ]
    }
   },
   "elementCount": 301,
   "entityCount": 1,
   "hidden": {
    "http://anavex.com/20200930": 9,
    "http://fasb.org/us-gaap/2020-01-31": 10,
    "http://xbrl.sec.gov/dei/2020-01-31": 5,
    "total": 24
   },
   "keyCustom": 44,
   "keyStandard": 224,
   "memberCustom": 12,
   "memberStandard": 7,
   "nsprefix": "avxl",
   "nsuri": "http://anavex.com/20200930",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "e2298_10k.htm",
      "contextRef": "From2019-10-01to2020-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00000001 - Document - Cover",
     "role": "http://anavex.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "e2298_10k.htm",
      "contextRef": "From2019-10-01to2020-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "e2298_10k.htm",
      "contextRef": "From2019-10-01to2020-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "avxl:EquityOfferingAgreementsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000010 - Disclosure - Equity Offering Agreements",
     "role": "http://anavex.com/role/EquityOfferingAgreements",
     "shortName": "Equity Offering Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "e2298_10k.htm",
      "contextRef": "From2019-10-01to2020-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "avxl:EquityOfferingAgreementsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "e2298_10k.htm",
      "contextRef": "From2019-10-01to2020-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000011 - Disclosure - Commitments",
     "role": "http://anavex.com/role/Commitments",
     "shortName": "Commitments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "e2298_10k.htm",
      "contextRef": "From2019-10-01to2020-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "e2298_10k.htm",
      "contextRef": "From2019-10-01to2020-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000012 - Disclosure - Income Taxes",
     "role": "http://anavex.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "e2298_10k.htm",
      "contextRef": "From2019-10-01to2020-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e2298_10k.htm",
      "contextRef": "From2019-10-01to2020-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UseOfEstimates",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000013 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://anavex.com/role/SummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e2298_10k.htm",
      "contextRef": "From2019-10-01to2020-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UseOfEstimates",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e2298_10k.htm",
      "contextRef": "From2019-10-01to2020-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000014 - Disclosure - Commitments (Tables)",
     "role": "http://anavex.com/role/CommitmentsTables",
     "shortName": "Commitments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e2298_10k.htm",
      "contextRef": "From2019-10-01to2020-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e2298_10k.htm",
      "contextRef": "From2019-10-01to2020-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000015 - Disclosure - Income Taxes (Tables)",
     "role": "http://anavex.com/role/IncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e2298_10k.htm",
      "contextRef": "From2019-10-01to2020-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:RevenueRecognitionIncentives",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e2298_10k.htm",
      "contextRef": "From2019-10-01to2020-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "avxl:CashRefundAvailableDescription",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000016 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)",
     "role": "http://anavex.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative",
     "shortName": "Summary of Significant Accounting Policies (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:RevenueRecognitionIncentives",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e2298_10k.htm",
      "contextRef": "From2019-10-01to2020-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "avxl:CashRefundAvailableDescription",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "e2298_10k.htm",
      "contextRef": "From2019-10-01to2020-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "avxl:NonOperatingIncomeFromGrant",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000017 - Disclosure - Other Income (Details Narrative)",
     "role": "http://anavex.com/role/OtherIncomeDetailsNarrative",
     "shortName": "Other Income (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "avxl:OtherIncomeDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e2298_10k.htm",
      "contextRef": "From2019-10-01to2020-09-30",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "e2298_10k.htm",
      "contextRef": "From2019-10-01to2020-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromIssuanceOfCommonStock",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000018 - Disclosure - Equity Offering Agreements (Details Narrative)",
     "role": "http://anavex.com/role/EquityOfferingAgreementsDetailsNarrative",
     "shortName": "Equity Offering Agreements (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "avxl:EquityOfferingAgreementsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e2298_10k.htm",
      "contextRef": "From2018-10-012019-09-30_custom_PurchaseAgreementMember_custom_LincolnParkCapitalFundLLCMember",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e2298_10k.htm",
      "contextRef": "AsOf2019-09-30_custom_PurchaseWarrantsMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000019 - Disclosure - Commitments (Details)",
     "role": "http://anavex.com/role/CommitmentsDetails",
     "shortName": "Commitments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e2298_10k.htm",
      "contextRef": "AsOf2018-09-30_custom_PurchaseWarrantsMember",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "e2298_10k.htm",
      "contextRef": "AsOf2020-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000002 - Statement - CONSOLIDATED BALANCE SHEETS",
     "role": "http://anavex.com/role/ConsolidatedBalanceSheets",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "e2298_10k.htm",
      "contextRef": "AsOf2020-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "avxl:ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e2298_10k.htm",
      "contextRef": "AsOf2020-09-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000020 - Disclosure - Commitments (Details 1)",
     "role": "http://anavex.com/role/CommitmentsDetails1",
     "shortName": "Commitments (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "avxl:ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e2298_10k.htm",
      "contextRef": "AsOf2020-09-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e2298_10k.htm",
      "contextRef": "AsOf2019-09-30_custom_StockOptionPlan2015Member",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000021 - Disclosure - Commitments (Details 2)",
     "role": "http://anavex.com/role/CommitmentsDetails2",
     "shortName": "Commitments (Details 2)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e2298_10k.htm",
      "contextRef": "AsOf2018-09-30_custom_StockOptionPlan2015Member",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e2298_10k.htm",
      "contextRef": "From2019-10-01to2020-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000022 - Disclosure - Commitments (Details 3)",
     "role": "http://anavex.com/role/CommitmentsDetails3",
     "shortName": "Commitments (Details 3)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e2298_10k.htm",
      "contextRef": "From2019-10-012020-09-30_us-gaap_GeneralAndAdministrativeExpenseMember",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e2298_10k.htm",
      "contextRef": "From2019-10-01to2020-09-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000023 - Disclosure - Commitments (Details 4)",
     "role": "http://anavex.com/role/CommitmentsDetails4",
     "shortName": "Commitments (Details 4)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e2298_10k.htm",
      "contextRef": "From2019-10-01to2020-09-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e2298_10k.htm",
      "contextRef": "From2019-10-01to2020-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:LeaseAndRentalExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000024 - Disclosure - Commitments (Details Narrative)",
     "role": "http://anavex.com/role/CommitmentsDetailsNarrative",
     "shortName": "Commitments (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e2298_10k.htm",
      "contextRef": "From2019-10-01to2020-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:LeaseAndRentalExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e2298_10k.htm",
      "contextRef": "From2019-10-01to2020-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000025 - Disclosure - Income Taxes (Details)",
     "role": "http://anavex.com/role/IncomeTaxesDetails",
     "shortName": "Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e2298_10k.htm",
      "contextRef": "From2019-10-01to2020-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e2298_10k.htm",
      "contextRef": "AsOf2020-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000026 - Disclosure - Income Taxes (Details 1)",
     "role": "http://anavex.com/role/IncomeTaxesDetails1",
     "shortName": "Income Taxes (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e2298_10k.htm",
      "contextRef": "AsOf2020-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e2298_10k.htm",
      "contextRef": "From2019-10-01to2020-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000027 - Disclosure - Income Taxes (Details 2)",
     "role": "http://anavex.com/role/IncomeTaxesDetails2",
     "shortName": "Income Taxes (Details 2)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e2298_10k.htm",
      "contextRef": "From2019-10-01to2020-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e2298_10k.htm",
      "contextRef": "AsOf2020-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000028 - Disclosure - Income Taxes (Details Narrative)",
     "role": "http://anavex.com/role/IncomeTaxesDetailsNarrative",
     "shortName": "Income Taxes (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e2298_10k.htm",
      "contextRef": "AsOf2020-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "e2298_10k.htm",
      "contextRef": "AsOf2020-09-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "role": "http://anavex.com/role/ConsolidatedBalanceSheetsParenthetical",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "e2298_10k.htm",
      "contextRef": "AsOf2020-09-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "e2298_10k.htm",
      "contextRef": "From2019-10-01to2020-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS",
     "role": "http://anavex.com/role/ConsolidatedStatementsOfOperations",
     "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "e2298_10k.htm",
      "contextRef": "From2019-10-01to2020-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "e2298_10k.htm",
      "contextRef": "From2019-10-01to2020-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000005 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "role": "http://anavex.com/role/ConsolidatedStatementsOfCashFlows",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "e2298_10k.htm",
      "contextRef": "From2019-10-01to2020-09-30",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "e2298_10k.htm",
      "contextRef": "AsOf2018-09-30_us-gaap_CommonStockMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000006 - Statement - CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY",
     "role": "http://anavex.com/role/ConsolidatedStatementOfChangesInStockholdersEquity",
     "shortName": "CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "e2298_10k.htm",
      "contextRef": "AsOf2018-09-30_us-gaap_CommonStockMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "e2298_10k.htm",
      "contextRef": "From2019-10-01to2020-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000007 - Disclosure - Business Description and Basis of Presentation",
     "role": "http://anavex.com/role/BusinessDescriptionAndBasisOfPresentation",
     "shortName": "Business Description and Basis of Presentation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "e2298_10k.htm",
      "contextRef": "From2019-10-01to2020-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "e2298_10k.htm",
      "contextRef": "From2019-10-01to2020-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000008 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://anavex.com/role/SummaryOfSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "e2298_10k.htm",
      "contextRef": "From2019-10-01to2020-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "e2298_10k.htm",
      "contextRef": "From2019-10-01to2020-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "avxl:OtherIncomeDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000009 - Disclosure - Other Income",
     "role": "http://anavex.com/role/OtherIncome",
     "shortName": "Other Income",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "e2298_10k.htm",
      "contextRef": "From2019-10-01to2020-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "avxl:OtherIncomeDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 19,
   "tag": {
    "avxl_AgreementTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Terms of the agreement under agreements.",
        "label": "Agreement term"
       }
      }
     },
     "localname": "AgreementTerm",
     "nsuri": "http://anavex.com/20200930",
     "presentation": [
      "http://anavex.com/role/EquityOfferingAgreementsDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "avxl_CantorFitzgeraldAndCoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information related to cantor fitzgerald and co.",
        "label": "Cantor Fitzgerald &amp;amp;amp; Co [Member]"
       }
      }
     },
     "localname": "CantorFitzgeraldAndCoMember",
     "nsuri": "http://anavex.com/20200930",
     "presentation": [
      "http://anavex.com/role/EquityOfferingAgreementsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "avxl_CashRefundAvailableDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Refund Available description"
       }
      }
     },
     "localname": "CashRefundAvailableDescription",
     "nsuri": "http://anavex.com/20200930",
     "presentation": [
      "http://anavex.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "avxl_ClinicalStudyGrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by clinical study grant.",
        "label": "Clinical Study Grant [Member]"
       }
      }
     },
     "localname": "ClinicalStudyGrantMember",
     "nsuri": "http://anavex.com/20200930",
     "presentation": [
      "http://anavex.com/role/OtherIncomeDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1",
        "verboseLabel": "Commitment shares"
       }
      }
     },
     "localname": "CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1",
     "nsuri": "http://anavex.com/20200930",
     "presentation": [
      "http://anavex.com/role/ConsolidatedStatementOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitment shares"
       }
      }
     },
     "localname": "CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2",
     "nsuri": "http://anavex.com/20200930",
     "presentation": [
      "http://anavex.com/role/ConsolidatedStatementOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued under 2019 Purchase Agreement - Commitment shares (in shares)"
       }
      }
     },
     "localname": "CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement1",
     "nsuri": "http://anavex.com/20200930",
     "presentation": [
      "http://anavex.com/role/ConsolidatedStatementOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued under 2015 Purchase Agreement - Commitment shares (in shares)"
       }
      }
     },
     "localname": "CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2",
     "nsuri": "http://anavex.com/20200930",
     "presentation": [
      "http://anavex.com/role/ConsolidatedStatementOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "avxl_DeferredCharges": {
     "auth_ref": [],
     "calculation": {
      "http://anavex.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred costs"
       }
      }
     },
     "localname": "DeferredCharges",
     "nsuri": "http://anavex.com/20200930",
     "presentation": [
      "http://anavex.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avxl_DeferredTaxAssetsUnpaidCharges": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represents as a deferred tax assets unpaid charges.",
        "label": "Unpaid charges"
       }
      }
     },
     "localname": "DeferredTaxAssetsUnpaidCharges",
     "nsuri": "http://anavex.com/20200930",
     "presentation": [
      "http://anavex.com/role/IncomeTaxesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avxl_DisclosureEquityOfferingAgreementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Offering Agreements"
       }
      }
     },
     "localname": "DisclosureEquityOfferingAgreementsAbstract",
     "nsuri": "http://anavex.com/20200930",
     "xbrltype": "stringItemType"
    },
    "avxl_DisclosureOtherIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Income"
       }
      }
     },
     "localname": "DisclosureOtherIncomeAbstract",
     "nsuri": "http://anavex.com/20200930",
     "xbrltype": "stringItemType"
    },
    "avxl_EquityOfferingAgreementsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "EquityOfferingAgreementsTextBlock",
        "verboseLabel": "Equity Offering Agreements"
       }
      }
     },
     "localname": "EquityOfferingAgreementsTextBlock",
     "nsuri": "http://anavex.com/20200930",
     "presentation": [
      "http://anavex.com/role/EquityOfferingAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "avxl_EquityOfferingSalesAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information related to equity offering sales agreement.",
        "label": "Equity Offering Sales Agreement [Member]"
       }
      }
     },
     "localname": "EquityOfferingSalesAgreementMember",
     "nsuri": "http://anavex.com/20200930",
     "presentation": [
      "http://anavex.com/role/EquityOfferingAgreementsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "avxl_FundingOfDeferredIncomeAwardedGrant": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information related to funding of deferred income awarded grant.",
        "label": "Awarded grant funding amount"
       }
      }
     },
     "localname": "FundingOfDeferredIncomeAwardedGrant",
     "nsuri": "http://anavex.com/20200930",
     "presentation": [
      "http://anavex.com/role/OtherIncomeDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avxl_GrantIncomePolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Grant Income"
       }
      }
     },
     "localname": "GrantIncomePolicyTextBlock",
     "nsuri": "http://anavex.com/20200930",
     "presentation": [
      "http://anavex.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "avxl_GrossProceedsFromSaleOfCommonStock": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Gross proceeds from sale of common stock"
       }
      }
     },
     "localname": "GrossProceedsFromSaleOfCommonStock",
     "nsuri": "http://anavex.com/20200930",
     "presentation": [
      "http://anavex.com/role/EquityOfferingAgreementsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avxl_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopmentCreditBenefit": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development credit benefit"
       }
      }
     },
     "localname": "IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopmentCreditBenefit",
     "nsuri": "http://anavex.com/20200930",
     "presentation": [
      "http://anavex.com/role/IncomeTaxesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avxl_LincolnParkCapitalFundLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information related to type of legal entity.",
        "label": "Lincoln Park Capital Fund, LLC [Member]"
       }
      }
     },
     "localname": "LincolnParkCapitalFundLLCMember",
     "nsuri": "http://anavex.com/20200930",
     "presentation": [
      "http://anavex.com/role/EquityOfferingAgreementsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "avxl_NYCBiotechCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "NYC Biotech Credit [Member]"
       }
      }
     },
     "localname": "NYCBiotechCreditMember",
     "nsuri": "http://anavex.com/20200930",
     "presentation": [
      "http://anavex.com/role/OtherIncomeDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "avxl_NonOperatingIncomeFromGrant": {
     "auth_ref": [],
     "calculation": {
      "http://anavex.com/role/ConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Grant income"
       }
      }
     },
     "localname": "NonOperatingIncomeFromGrant",
     "nsuri": "http://anavex.com/20200930",
     "presentation": [
      "http://anavex.com/role/ConsolidatedStatementsOfOperations",
      "http://anavex.com/role/OtherIncomeDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avxl_NumberOfCashlessExerciseOption": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of cashless exercise option"
       }
      }
     },
     "localname": "NumberOfCashlessExerciseOption",
     "nsuri": "http://anavex.com/20200930",
     "presentation": [
      "http://anavex.com/role/CommitmentsDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "avxl_NumberOfSharesAvailable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of shares available"
       }
      }
     },
     "localname": "NumberOfSharesAvailable",
     "nsuri": "http://anavex.com/20200930",
     "presentation": [
      "http://anavex.com/role/EquityOfferingAgreementsDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "avxl_NumberOfSharesObligatedToPurchaseProrataBasic": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information related to number of shares obligated to purchase prorata basic.",
        "label": "Pro rata basic number of shares obligated to purchase"
       }
      }
     },
     "localname": "NumberOfSharesObligatedToPurchaseProrataBasic",
     "nsuri": "http://anavex.com/20200930",
     "presentation": [
      "http://anavex.com/role/EquityOfferingAgreementsDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "avxl_NumberOfStockSold": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of stock sold"
       }
      }
     },
     "localname": "NumberOfStockSold",
     "nsuri": "http://anavex.com/20200930",
     "presentation": [
      "http://anavex.com/role/EquityOfferingAgreementsDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "avxl_OperatingLossCarryForwardsExpirationYear1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The expiration date of each operating loss carryforward included in total operating loss carryforwards, or the applicable range of such expiration dates.",
        "label": "Operating loss carry-forwards, expiration year"
       }
      }
     },
     "localname": "OperatingLossCarryForwardsExpirationYear1",
     "nsuri": "http://anavex.com/20200930",
     "presentation": [
      "http://anavex.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "gYearItemType"
    },
    "avxl_OtherIncomeDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "OtherIncomeDisclosureTextBlock",
        "verboseLabel": "Other Income"
       }
      }
     },
     "localname": "OtherIncomeDisclosureTextBlock",
     "nsuri": "http://anavex.com/20200930",
     "presentation": [
      "http://anavex.com/role/OtherIncome"
     ],
     "xbrltype": "textBlockItemType"
    },
    "avxl_PercentageOfGrossProceedsFromSales": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information related to percentage of gross proceeds from sales.",
        "label": "Percentage of gross proceeds from sales"
       }
      }
     },
     "localname": "PercentageOfGrossProceedsFromSales",
     "nsuri": "http://anavex.com/20200930",
     "presentation": [
      "http://anavex.com/role/EquityOfferingAgreementsDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "avxl_PurchaseAgreement1Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to purchase agreement.",
        "label": "2019 Purchase Agreement [Member]"
       }
      }
     },
     "localname": "PurchaseAgreement1Member",
     "nsuri": "http://anavex.com/20200930",
     "presentation": [
      "http://anavex.com/role/EquityOfferingAgreementsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "avxl_PurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Terms of the purchase agreement under purchase agreements.",
        "label": "2015 Purchase Agreement [Member]"
       }
      }
     },
     "localname": "PurchaseAgreementMember",
     "nsuri": "http://anavex.com/20200930",
     "presentation": [
      "http://anavex.com/role/EquityOfferingAgreementsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "avxl_PurchaseWarrants1Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase Warrants 1 [Member]"
       }
      }
     },
     "localname": "PurchaseWarrants1Member",
     "nsuri": "http://anavex.com/20200930",
     "presentation": [
      "http://anavex.com/role/CommitmentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "avxl_PurchaseWarrants2Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase Warrants 2 [Member]"
       }
      }
     },
     "localname": "PurchaseWarrants2Member",
     "nsuri": "http://anavex.com/20200930",
     "presentation": [
      "http://anavex.com/role/CommitmentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "avxl_PurchaseWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Purchase Warrants [Member]"
       }
      }
     },
     "localname": "PurchaseWarrantsMember",
     "nsuri": "http://anavex.com/20200930",
     "presentation": [
      "http://anavex.com/role/CommitmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "avxl_ResearchAndDevelopmentIncentiveIncome": {
     "auth_ref": [],
     "calculation": {
      "http://anavex.com/role/ConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development incentive income"
       }
      }
     },
     "localname": "ResearchAndDevelopmentIncentiveIncome",
     "nsuri": "http://anavex.com/20200930",
     "presentation": [
      "http://anavex.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avxl_ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of share purchase warrants outstanding"
       }
      }
     },
     "localname": "ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock",
     "nsuri": "http://anavex.com/20200930",
     "presentation": [
      "http://anavex.com/role/CommitmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Purchase Warrants Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod",
     "nsuri": "http://anavex.com/20200930",
     "presentation": [
      "http://anavex.com/role/CommitmentsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information related to share based compensation arrangement by share based payment award equity instruments other than options outstanding weighted average exercise price.",
        "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice",
        "periodEndLabel": "Weighted Average Exercise Price Balance, at ending",
        "periodStartLabel": "Weighted Average Exercise Price Balance, at beginning"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://anavex.com/20200930",
     "presentation": [
      "http://anavex.com/role/CommitmentsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price, Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExercised",
     "nsuri": "http://anavex.com/20200930",
     "presentation": [
      "http://anavex.com/role/CommitmentsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExpired": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price, Expired"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExpired",
     "nsuri": "http://anavex.com/20200930",
     "presentation": [
      "http://anavex.com/role/CommitmentsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice",
     "nsuri": "http://anavex.com/20200930",
     "presentation": [
      "http://anavex.com/role/CommitmentsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "avxl_SharesIssuedDuringPeriodSharesUnderSalesAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued under Sales Agreement, net of shares issue costs (in shares)"
       }
      }
     },
     "localname": "SharesIssuedDuringPeriodSharesUnderSalesAgreement",
     "nsuri": "http://anavex.com/20200930",
     "presentation": [
      "http://anavex.com/role/ConsolidatedStatementOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "avxl_SharesIssuedDuringPeriodValueUnderSalesAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued under Sales Agreement, net of shares issue costs"
       }
      }
     },
     "localname": "SharesIssuedDuringPeriodValueUnderSalesAgreement",
     "nsuri": "http://anavex.com/20200930",
     "presentation": [
      "http://anavex.com/role/ConsolidatedStatementOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avxl_SharesIssuedPursuantToCashlessExerciseOfOptions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued pursuant to cashless exercise of options"
       }
      }
     },
     "localname": "SharesIssuedPursuantToCashlessExerciseOfOptions",
     "nsuri": "http://anavex.com/20200930",
     "presentation": [
      "http://anavex.com/role/ConsolidatedStatementOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avxl_SharesIssuedPursuantToCashlessExerciseOfOptionsInShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued pursuant to cashless exercise of options (in shares)"
       }
      }
     },
     "localname": "SharesIssuedPursuantToCashlessExerciseOfOptionsInShares",
     "nsuri": "http://anavex.com/20200930",
     "presentation": [
      "http://anavex.com/role/ConsolidatedStatementOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "avxl_SharesIssuedPursuantToCashlessExerciseOfWarrantInShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SharesIssuedPursuantToCashlessExerciseOfWarrantInShares",
        "verboseLabel": "Shares issued pursuant to cashless exercise of warrants"
       }
      }
     },
     "localname": "SharesIssuedPursuantToCashlessExerciseOfWarrantInShares",
     "nsuri": "http://anavex.com/20200930",
     "presentation": [
      "http://anavex.com/role/CommitmentsDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "avxl_SharesIssuedPursuantToCashlessExerciseOfWarrants": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued pursuant to cashless exercise of warrants"
       }
      }
     },
     "localname": "SharesIssuedPursuantToCashlessExerciseOfWarrants",
     "nsuri": "http://anavex.com/20200930",
     "presentation": [
      "http://anavex.com/role/ConsolidatedStatementOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avxl_SharesIssuedPursuantToCashlessExerciseOfWarrantsInShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued pursuant to cashless exercise of warrants (in shares)"
       }
      }
     },
     "localname": "SharesIssuedPursuantToCashlessExerciseOfWarrantsInShares",
     "nsuri": "http://anavex.com/20200930",
     "presentation": [
      "http://anavex.com/role/ConsolidatedStatementOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "avxl_SharesIssuedPursuantToCashlessExercisesOfOption": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued pursuant to cashless exercises of option"
       }
      }
     },
     "localname": "SharesIssuedPursuantToCashlessExercisesOfOption",
     "nsuri": "http://anavex.com/20200930",
     "presentation": [
      "http://anavex.com/role/CommitmentsDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "avxl_StockIssuedDuringPeriodSharesAcquisitions2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued under 2015 Purchase Agreement - Purchase shares (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesAcquisitions2",
     "nsuri": "http://anavex.com/20200930",
     "presentation": [
      "http://anavex.com/role/ConsolidatedStatementOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "avxl_StockIssuedDuringPeriodSharesNewIssues3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Number of shares issued for commitment"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues3",
     "nsuri": "http://anavex.com/20200930",
     "presentation": [
      "http://anavex.com/role/EquityOfferingAgreementsDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "avxl_StockIssuedDuringPeriodSharesNewIssues4": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Number of shares issued for aggregate purchase price"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues4",
     "nsuri": "http://anavex.com/20200930",
     "presentation": [
      "http://anavex.com/role/EquityOfferingAgreementsDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "avxl_StockIssuedDuringPeriodValueAcquisitions2": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueAcquisitions2",
     "nsuri": "http://anavex.com/20200930",
     "presentation": [
      "http://anavex.com/role/ConsolidatedStatementOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avxl_StockIssuedDuringPeriodValueNewIssues3": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.",
        "label": "Number of shares issued for aggregate purchase price, value"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues3",
     "nsuri": "http://anavex.com/20200930",
     "presentation": [
      "http://anavex.com/role/EquityOfferingAgreementsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avxl_StockIssuedDuringPeriodValueNewIssues4": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.",
        "label": "Amount of shares remain available"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues4",
     "nsuri": "http://anavex.com/20200930",
     "presentation": [
      "http://anavex.com/role/EquityOfferingAgreementsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avxl_StockIssuedPursuantToCashlessExerciseOfWarrants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock issued pursuant to cashless exercise of warrants"
       }
      }
     },
     "localname": "StockIssuedPursuantToCashlessExerciseOfWarrants",
     "nsuri": "http://anavex.com/20200930",
     "presentation": [
      "http://anavex.com/role/CommitmentsDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "avxl_StockOptionPlan2015Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information related to type of plan.",
        "label": "2015 Omnibus Incentive Plan [Member]"
       }
      }
     },
     "localname": "StockOptionPlan2015Member",
     "nsuri": "http://anavex.com/20200930",
     "presentation": [
      "http://anavex.com/role/CommitmentsDetails2",
      "http://anavex.com/role/CommitmentsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "avxl_StockOptionPlan2019Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "2019 Omnibus Incentive Plan [Member]"
       }
      }
     },
     "localname": "StockOptionPlan2019Member",
     "nsuri": "http://anavex.com/20200930",
     "presentation": [
      "http://anavex.com/role/CommitmentsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "avxl_ValueOfSharesObligatedToPurchase": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information related to value of shares obligated to purchase initially.",
        "label": "Total number of shares obligated to purchase"
       }
      }
     },
     "localname": "ValueOfSharesObligatedToPurchase",
     "nsuri": "http://anavex.com/20200930",
     "presentation": [
      "http://anavex.com/role/EquityOfferingAgreementsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "currency_AUD": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Australia, Dollars"
       }
      }
     },
     "localname": "AUD",
     "nsuri": "http://xbrl.sec.gov/currency/2020-01-31",
     "presentation": [
      "http://anavex.com/role/IncomeTaxesDetailsNarrative",
      "http://anavex.com/role/OtherIncomeDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_AllCurrenciesDomain": {
     "auth_ref": [],
     "localname": "AllCurrenciesDomain",
     "nsuri": "http://xbrl.sec.gov/currency/2020-01-31",
     "presentation": [
      "http://anavex.com/role/IncomeTaxesDetailsNarrative",
      "http://anavex.com/role/OtherIncomeDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r243"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r243"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r240",
      "r242",
      "r243"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentPeriodStartDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.",
        "label": "Document Period Start Date"
       }
      }
     },
     "localname": "DocumentPeriodStartDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyEventDate": {
     "auth_ref": [
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date of event requiring a shell company report.",
        "label": "Document Shell Company Event Date"
       }
      }
     },
     "localname": "DocumentShellCompanyEventDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r232"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "auth_ref": [
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
        "label": "Entity Bankruptcy Proceedings, Reporting Current"
       }
      }
     },
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/EquityOfferingAgreementsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Elected Not To Use the Extended Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r246"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityListingsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Entity Listings [Line Items]"
       }
      }
     },
     "localname": "EntityListingsLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/EquityOfferingAgreementsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r243"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_Extension": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extension number for local phone number.",
        "label": "Extension"
       }
      }
     },
     "localname": "Extension",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/EquityOfferingAgreementsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r237"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r231"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_Security12gTitle": {
     "auth_ref": [
      "r234"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(g) registered security.",
        "label": "Title of 12(g) Security"
       }
      }
     },
     "localname": "Security12gTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SecurityReportingObligation": {
     "auth_ref": [
      "r238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
        "label": "Security Reporting Obligation"
       }
      }
     },
     "localname": "SecurityReportingObligation",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "securityReportingObligationItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r247"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "srt_CurrencyAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Currency [Axis]"
       }
      }
     },
     "localname": "CurrencyAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://anavex.com/role/IncomeTaxesDetailsNarrative",
      "http://anavex.com/role/OtherIncomeDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r87",
      "r112",
      "r113",
      "r203",
      "r220",
      "r221"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://anavex.com/role/OtherIncomeDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r87",
      "r112",
      "r113",
      "r203",
      "r220",
      "r221"
     ],
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://anavex.com/role/OtherIncomeDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ReinsurancePremiumsForInsuranceCompaniesByProductSegmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SEC Schedule, 12-17, Insurance Companies, Reinsurance [Line Items]"
       }
      }
     },
     "localname": "ReinsurancePremiumsForInsuranceCompaniesByProductSegmentLineItems",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://anavex.com/role/OtherIncomeDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r14"
     ],
     "calculation": {
      "http://anavex.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r16"
     ],
     "calculation": {
      "http://anavex.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r8"
     ],
     "calculation": {
      "http://anavex.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r45",
      "r46",
      "r47",
      "r140",
      "r141",
      "r142"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/ConsolidatedStatementOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net loss to net cash used in operations:"
       }
      }
     },
     "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r115",
      "r118",
      "r146",
      "r147"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "Share based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/ConsolidatedStatementOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r118",
      "r136",
      "r145"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Total share based compensation",
        "verboseLabel": "Share based compensation"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsDetails3",
      "http://anavex.com/role/CommitmentsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/EquityOfferingAgreementsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r41",
      "r73",
      "r81",
      "r85",
      "r90",
      "r181",
      "r184",
      "r190",
      "r205",
      "r213"
     ],
     "calculation": {
      "http://anavex.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets [Default Label]",
        "totalLabel": "Total Assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r119",
      "r139"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsDetails",
      "http://anavex.com/role/CommitmentsDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_Cash": {
     "auth_ref": [
      "r13",
      "r227",
      "r228"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash",
        "periodEndLabel": "Cash and cash equivalents, end of year",
        "periodStartLabel": "Cash and cash equivalents, beginning of year"
       }
      }
     },
     "localname": "Cash",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r2",
      "r13",
      "r38"
     ],
     "calculation": {
      "http://anavex.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease": {
     "auth_ref": [],
     "calculation": {
      "http://anavex.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.",
        "label": "Cash and Cash Equivalents, Period Increase (Decrease)",
        "totalLabel": "Increase (decrease) in cash and cash equivalents during the period"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r5",
      "r39",
      "r40"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r17",
      "r97",
      "r208",
      "r216"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies - Note 5"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsDisclosureTextBlock": {
     "auth_ref": [
      "r96"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights.",
        "label": "Commitments"
       }
      }
     },
     "localname": "CommitmentsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/Commitments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Maximum number of common shares reserved for future issuance"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r45",
      "r46"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/ConsolidatedStatementOfChangesInStockholdersEquity",
      "http://anavex.com/role/EquityOfferingAgreementsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common shares, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common shares, authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common shares, issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r7",
      "r109"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common shares, outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r7"
     ],
     "calculation": {
      "http://anavex.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Capital stock Authorized: 100,000,000 common shares, par value $0.001 per share Issued and outstanding: 62,045,198 common shares (2019 - 52,650,521)"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r40",
      "r183"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Principles of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r42",
      "r166",
      "r172",
      "r174"
     ],
     "calculation": {
      "http://anavex.com/role/ConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.",
        "label": "Current Income Tax Expense (Benefit)",
        "negatedLabel": "Income tax expense, current"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://anavex.com/role/ConsolidatedStatementsOfOperations": {
       "order": 5.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the charge against earnings during the period for commitment fees and debt issuance expenses.",
        "label": "Debt Related Commitment Fees and Debt Issuance Costs",
        "negatedLabel": "Financing related charges"
       }
      }
     },
     "localname": "DebtRelatedCommitmentFeesAndDebtIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r36",
      "r42",
      "r167",
      "r172",
      "r173",
      "r174"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Income tax expense"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/IncomeTaxesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.",
        "label": "Intangible asset costs"
       }
      }
     },
     "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/IncomeTaxesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "auth_ref": [
      "r164",
      "r165"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.",
        "label": "Research and development tax credit carry forwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/IncomeTaxesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r159"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Net deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/IncomeTaxesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r164",
      "r165"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/IncomeTaxesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign": {
     "auth_ref": [
      "r164",
      "r165"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible foreign operating loss carryforwards.",
        "label": "U.S. federal net operating loss carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsForeign",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal": {
     "auth_ref": [
      "r164",
      "r165"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.",
        "label": "State net operating loss carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r164",
      "r165"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost",
        "verboseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/IncomeTaxesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses": {
     "auth_ref": [
      "r164",
      "r165"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from unrealized losses on foreign currency transactions.",
        "label": "Foreign exchange and other"
       }
      }
     },
     "localname": "DeferredTaxAssetsUnrealizedCurrencyLosses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/IncomeTaxesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r158"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Valuation allowance deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/IncomeTaxesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r61"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Basic and diluted"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDilutedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Loss per share"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDilutedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average number of shares outstanding"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r40",
      "r63",
      "r64"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Basic and Diluted Loss per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCash": {
     "auth_ref": [
      "r195"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of effect of exchange rate changes on cash balances held in foreign currencies. Excludes cash equivalents.",
        "label": "Effect of change in statutory rates"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCash",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/IncomeTaxesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r137"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Remaining stock based compensation"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r45",
      "r46",
      "r47",
      "r49",
      "r54",
      "r56",
      "r65",
      "r91",
      "r109",
      "r110",
      "r140",
      "r141",
      "r142",
      "r169",
      "r170",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r222",
      "r223",
      "r224"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/ConsolidatedStatementOfChangesInStockholdersEquity",
      "http://anavex.com/role/EquityOfferingAgreementsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r40",
      "r188",
      "r189"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Financial Instruments"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ForeignCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile.",
        "label": "Foreign Tax Authority [Member]"
       }
      }
     },
     "localname": "ForeignCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "auth_ref": [
      "r191",
      "r192",
      "r193",
      "r194"
     ],
     "calculation": {
      "http://anavex.com/role/ConsolidatedStatementsOfOperations": {
       "order": 6.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.",
        "label": "Foreign exchange gain (loss), net"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r40",
      "r202"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Foreign Currency Translation"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r36",
      "r106",
      "r107"
     ],
     "calculation": {
      "http://anavex.com/role/ConsolidatedStatementsOfOperations": {
       "order": 4.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "Gain on settlement of accounts payable"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainsLossesOnRestructuringOfDebt": {
     "auth_ref": [
      "r108"
     ],
     "calculation": {
      "http://anavex.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For a debtor, the aggregate gain (loss) recognized on the restructuring of payables arises from the difference between the book value of the debt before the restructuring and the fair value of the payments on the debt after restructuring is complete.",
        "label": "Gains (Losses) on Restructuring of Debt",
        "negatedLabel": "Gain on settlement of accounts payable"
       }
      }
     },
     "localname": "GainsLossesOnRestructuringOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r27"
     ],
     "calculation": {
      "http://anavex.com/role/ConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r26"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "auth_ref": [
      "r43",
      "r175"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.",
        "label": "United States"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r24",
      "r73",
      "r80",
      "r83",
      "r84",
      "r86",
      "r204",
      "r209",
      "r212",
      "r219"
     ],
     "calculation": {
      "http://anavex.com/role/ConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Net loss before provision for income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "auth_ref": [
      "r43",
      "r175"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.",
        "label": "Foreign"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r43",
      "r73",
      "r80",
      "r83",
      "r84",
      "r86"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.",
        "label": "Total"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r94"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsDetails3"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement."
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r155"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes."
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r154",
      "r156",
      "r161",
      "r171",
      "r176",
      "r177",
      "r178",
      "r179"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r23",
      "r40",
      "r151",
      "r152",
      "r156",
      "r157",
      "r160",
      "r168",
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "verboseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r153"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.",
        "label": "Change in valuation allowances"
       }
      }
     },
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/IncomeTaxesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential": {
     "auth_ref": [
      "r153"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit).",
        "label": "Foreign income taxed at other rates"
       }
      }
     },
     "localname": "IncomeTaxReconciliationForeignIncomeTaxRateDifferential",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/IncomeTaxesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r153"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Income tax benefit at statutory federal rate"
       }
      }
     },
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/IncomeTaxesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationOtherAdjustments": {
     "auth_ref": [
      "r153"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Other permanent differences"
       }
      }
     },
     "localname": "IncomeTaxReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/IncomeTaxesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes": {
     "auth_ref": [
      "r153"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to revisions of previously reported income tax expense (benefit).",
        "label": "Adjustment and true up to prior year tax provision"
       }
      }
     },
     "localname": "IncomeTaxReconciliationPriorYearIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/IncomeTaxesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r153"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).",
        "label": "State and local taxes"
       }
      }
     },
     "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/IncomeTaxesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesReceivable": {
     "auth_ref": [
      "r20",
      "r207",
      "r217"
     ],
     "calculation": {
      "http://anavex.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes.",
        "label": "Incentive and tax receivables"
       }
      }
     },
     "localname": "IncomeTaxesReceivable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://anavex.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "verboseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://anavex.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "verboseLabel": "Accrued liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInIncomeTaxesReceivable": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://anavex.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in income taxes receivable, which represents the amount due from tax authorities for refunds of overpayments or recoveries of income taxes paid.",
        "label": "Increase (Decrease) in Income Taxes Receivable",
        "negatedLabel": "Incentive and tax receivables"
       }
      }
     },
     "localname": "IncreaseDecreaseInIncomeTaxesReceivable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in non-cash working capital balances related to operations:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpense": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://anavex.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.",
        "label": "Increase (Decrease) in Prepaid Expense",
        "negatedLabel": "Prepaid expenses and deposits"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants": {
     "auth_ref": [
      "r57",
      "r58",
      "r59",
      "r62"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of call options and warrants using the treasury stock method.",
        "label": "Loss per share for potentially dilutive common shares"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToCallOptionsAndWarrants",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_InterestIncomeExpenseNet": {
     "auth_ref": [
      "r211"
     ],
     "calculation": {
      "http://anavex.com/role/ConsolidatedStatementsOfOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of operating interest income (expense).",
        "label": "Interest income, net"
       }
      }
     },
     "localname": "InterestIncomeExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseAndRentalExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "Operating Leases, Rent Expense"
       }
      }
     },
     "localname": "LeaseAndRentalExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r15",
      "r41",
      "r82",
      "r90",
      "r182",
      "r184",
      "r185",
      "r190"
     ],
     "calculation": {
      "http://anavex.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total Liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r12",
      "r41",
      "r90",
      "r190",
      "r206",
      "r215"
     ],
     "calculation": {
      "http://anavex.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total Liabilities and Stockholders' Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Stockholders' Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsDetails3"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r97",
      "r98",
      "r99",
      "r100",
      "r101",
      "r102",
      "r103",
      "r104",
      "r105"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsDetails3"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://anavex.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flows provided by Financing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r33",
      "r34",
      "r37"
     ],
     "calculation": {
      "http://anavex.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flows used in Operating Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r0",
      "r21",
      "r22",
      "r25",
      "r37",
      "r41",
      "r48",
      "r50",
      "r51",
      "r52",
      "r53",
      "r55",
      "r56",
      "r60",
      "r73",
      "r80",
      "r83",
      "r84",
      "r86",
      "r90",
      "r190",
      "r210",
      "r218"
     ],
     "calculation": {
      "http://anavex.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://anavex.com/role/ConsolidatedStatementsOfOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net loss",
        "totalLabel": "Net loss and comprehensive loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/ConsolidatedStatementOfChangesInStockholdersEquity",
      "http://anavex.com/role/ConsolidatedStatementsOfCashFlows",
      "http://anavex.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r28"
     ],
     "calculation": {
      "http://anavex.com/role/ConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other income, net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other income (expenses)"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://anavex.com/role/ConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "negatedTotalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating expenses"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r162"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating loss carry-forwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Operating Loss Carryforwards [Line Items]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "auth_ref": [
      "r163"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.",
        "label": "Operating Loss Carryforwards [Table]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/IncomeTaxesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r1",
      "r186"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Business Description and Basis of Presentation"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/BusinessDescriptionAndBasisOfPresentation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PaymentsOfDebtIssuanceCosts": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://anavex.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.",
        "label": "Payments of Debt Issuance Costs",
        "negatedLabel": "Deferred financing charges"
       }
      }
     },
     "localname": "PaymentsOfDebtIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r32"
     ],
     "calculation": {
      "http://anavex.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "negatedLabel": "Share issue costs"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r119",
      "r139"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsDetails2",
      "http://anavex.com/role/CommitmentsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsDetails2",
      "http://anavex.com/role/CommitmentsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred stock, authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r6"
     ],
     "calculation": {
      "http://anavex.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Capital stock Authorized: 10,000,000 preferred stock, par value $0.001 per share"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "auth_ref": [
      "r3",
      "r4",
      "r92",
      "r93"
     ],
     "calculation": {
      "http://anavex.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid expenses and deposits"
       }
      }
     },
     "localname": "PrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r30"
     ],
     "calculation": {
      "http://anavex.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Issuance of common shares",
        "verboseLabel": "Proceeds from sale of common stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/ConsolidatedStatementsOfCashFlows",
      "http://anavex.com/role/EquityOfferingAgreementsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned": {
     "auth_ref": [
      "r149",
      "r150"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Compensation Earned",
        "verboseLabel": "Research and development incentive income"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/OtherIncomeDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r148",
      "r230"
     ],
     "calculation": {
      "http://anavex.com/role/ConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r40",
      "r148"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r9",
      "r110",
      "r143",
      "r214",
      "r225",
      "r226"
     ],
     "calculation": {
      "http://anavex.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r45",
      "r46",
      "r47",
      "r49",
      "r54",
      "r56",
      "r91",
      "r140",
      "r141",
      "r142",
      "r169",
      "r170",
      "r222",
      "r224"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/ConsolidatedStatementOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueRecognitionIncentives": {
     "auth_ref": [
      "r40"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for sales incentives.",
        "label": "Research and Development Incentive Income"
       }
      }
     },
     "localname": "RevenueRecognitionIncentives",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r159"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of deferred tax asset and liabilities"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r153"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r118",
      "r135",
      "r145"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Schedule of general and administrative expenses and research and development expenses"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "auth_ref": [
      "r43"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions.",
        "label": "Schedule of Income before Income Tax, Domestic and Foreign"
       }
      }
     },
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r119",
      "r139"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsDetails",
      "http://anavex.com/role/CommitmentsDetails1",
      "http://anavex.com/role/CommitmentsDetails2",
      "http://anavex.com/role/CommitmentsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r130"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of weighted average assumptions for fair value of each option award"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the change in stock options.",
        "label": "Schedule of outstanding stock purchase options"
       }
      }
     },
     "localname": "ScheduleOfStockOptionsRollForwardTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "auth_ref": [
      "r111",
      "r117"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Schedule of exercisable share purchase warrants outstanding"
       }
      }
     },
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r40",
      "r74",
      "r75",
      "r76",
      "r77",
      "r78",
      "r79",
      "r88"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment and Geographic Reporting"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://anavex.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r127"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Share Purchase Warrants Balance, at ending",
        "periodStartLabel": "Share Purchase Warrants Balance, at beginning"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r133"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Dividend rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsDetails4"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r132"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Annualized volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsDetails4"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r134"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsDetails4"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsDetails",
      "http://anavex.com/role/CommitmentsDetails1",
      "http://anavex.com/role/CommitmentsDetails2",
      "http://anavex.com/role/CommitmentsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": {
     "auth_ref": [
      "r124"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of non-option equity instruments exercised by participants.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised",
        "negatedLabel": "Share Purchase Warrants Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations": {
     "auth_ref": [
      "r126"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares under non-option equity instrument agreements for which rights to exercise lapsed.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Expirations",
        "negatedLabel": "Share Purchase Warrants Expired"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.",
        "label": "Additional shares of common stock available for issuance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r139"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r123"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Options Exercisable at ending"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsDetails2"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r123"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Weighted Average Exercise Price Exercisable at ending"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsDetails2"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r125"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Options Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsDetails2"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Options Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsDetails2"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r128"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Weighted Average Grant Date Fair Value Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsDetails2"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r139"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "periodEndLabel": "Aggregate intrinsic value Outstanding at ending",
        "periodStartLabel": "Aggregate intrinsic value Outstanding at beginning"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r122",
      "r139"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Options Outstanding at ending",
        "periodStartLabel": "Options Outstanding at beginning"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsDetails2"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r121"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted Average Exercise Price Outstanding at ending",
        "periodStartLabel": "Weighted Average Exercise Price Outstanding at beginning"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsDetails2"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r129"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Number"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsDetails1"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r129"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsDetails1"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r117",
      "r120"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsDetails",
      "http://anavex.com/role/CommitmentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Weighted Average Exercise Price Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsDetails2"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Weighted Average Exercise Price Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsDetails2"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Weighted Average Exercise Price Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsDetails2"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationForfeituresPolicyTextBlock": {
     "auth_ref": [
      "r114",
      "r116",
      "r138"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy election for determining cost for share-based payment arrangement by either estimating forfeiture expected to occur or by recognizing effect of forfeiture upon occurrence.",
        "label": "Stock-based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationForfeituresPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r131",
      "r144"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Expected life of options (years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsDetails4"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r139"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Aggregate intrinsic value Exercisable at ending"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Balance Ending (in shares)",
        "periodStartLabel": "Balance Beginning (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/ConsolidatedStatementOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r44"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/SummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r19",
      "r45",
      "r46",
      "r47",
      "r49",
      "r54",
      "r56",
      "r65",
      "r91",
      "r109",
      "r110",
      "r140",
      "r141",
      "r142",
      "r169",
      "r170",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r222",
      "r223",
      "r224"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/ConsolidatedStatementOfChangesInStockholdersEquity",
      "http://anavex.com/role/EquityOfferingAgreementsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/ConsolidatedStatementOfChangesInStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r45",
      "r46",
      "r47",
      "r65",
      "r203"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/ConsolidatedStatementOfChangesInStockholdersEquity",
      "http://anavex.com/role/EquityOfferingAgreementsDetailsNarrative",
      "http://anavex.com/role/OtherIncomeDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": {
     "auth_ref": [
      "r6",
      "r7",
      "r110"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued during the period pursuant to acquisitions.",
        "label": "Shares issued under 2019 Purchase Agreement - Purchase shares (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesAcquisitions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/ConsolidatedStatementOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r6",
      "r7",
      "r109",
      "r110"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Number of share issued"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/EquityOfferingAgreementsDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r6",
      "r7",
      "r109",
      "r110",
      "r124"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Options Exercised"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsDetails2"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueAcquisitions": {
     "auth_ref": [
      "r19",
      "r109",
      "r110"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued pursuant to acquisitions during the period.",
        "label": "Stock Issued During Period, Value, Acquisitions",
        "verboseLabel": "Purchase shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueAcquisitions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/ConsolidatedStatementOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r7",
      "r10",
      "r11",
      "r41",
      "r89",
      "r90",
      "r190"
     ],
     "calculation": {
      "http://anavex.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance, value",
        "periodStartLabel": "Beginning balance, value",
        "totalLabel": "Total Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/ConsolidatedBalanceSheets",
      "http://anavex.com/role/ConsolidatedStatementOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxesExcludingIncomeAndExciseTaxes": {
     "auth_ref": [
      "r26"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All taxes not related to income of the entity or excise or sales taxes levied on the revenue of the entity that are not reported elsewhere. These taxes could include production, real estate, personal property, and pump tax.",
        "label": "State minimum and excise taxes"
       }
      }
     },
     "localname": "TaxesExcludingIncomeAndExciseTaxes",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/IncomeTaxesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r180"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/EquityOfferingAgreementsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UnrecordedUnconditionalPurchaseObligationDescription": {
     "auth_ref": [
      "r95"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the nature of an unconditional purchase obligation that is not recognized as a liability on the balance sheet.",
        "label": "Description of purchases price"
       }
      }
     },
     "localname": "UnrecordedUnconditionalPurchaseObligationDescription",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/EquityOfferingAgreementsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r66",
      "r67",
      "r68",
      "r69",
      "r70",
      "r71",
      "r72"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingMaturityDate": {
     "auth_ref": [
      "r187"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in CCYY-MM-DD format.",
        "label": "Expiry Date"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingMaturityDate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsDetails1"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted",
        "verboseLabel": "Basic and diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 4
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14453-108349"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14472-108349"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=121555522&loc=d3e12021-110248"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=121555522&loc=d3e12053-110248"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=117329964&loc=d3e12317-112629"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=117329964&loc=d3e12355-112629"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=6402221&loc=d3e15743-112638"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=SL116886442-113899"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=d3e4534-113899"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=d3e4549-113899"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(4)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(m)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11149-113907"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11178-113907"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32247-109318"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32280-109318"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32705-109319"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32857-109319"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330215-122817"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13279-108611"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=120253306&loc=d3e28228-110885"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=121605123&loc=d3e30226-110892"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=109240200&loc=d3e30690-110894"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450222&loc=d3e30840-110895"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "830",
   "URI": "http://asc.fasb.org/topic&trid=2175825"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.10)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.10)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.5(c))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "740",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116657188&loc=SL116659661-227067"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r231": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r232": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r233": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r234": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "g"
  },
  "r235": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12, 13, 15d"
  },
  "r236": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r237": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r238": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d"
  },
  "r239": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r240": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r241": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r242": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r243": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r244": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r245": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r246": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r247": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  },
  "r248": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r249": {
   "Name": "Securities Act",
   "Number": "Section",
   "Publisher": "SEC",
   "Section": "12"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4273-108586"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6787-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(h)(1)(i))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1707-109256"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1757-109256"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "26",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1828-109256"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=68074540&loc=d3e5879-108316"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14394-108349"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>50
<FILENAME>0001731122-20-001338-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001731122-20-001338-xbrl.zip
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M;/M#Q;^6;><5_]H7//X?4$L#!!0    ( &^+G%'WPMH!O D  )IJ   5
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M&=UAX9J'Y^\<V</70DU'S&1V&?OA\NCX?V>:/[ER$A0?]9396;6^<;Z&##U
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M[ IT!\U&H"8&.374 OL"DY-G(Y 3XYD:<CQP@\J$_"'_*R%QY7]02P,$%
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MZ$0Z=^FM+L!+<2\AY9CU'.SZEA7H#3EWR+:&[@ ]VSYRRE@IK*:@>TFGJ%P
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M72-SF6*&9LY6B)=XA1WRS 7M\_B"63"*#]B8[B'3?R!WV)L2;\$T%3@<:?+
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M(K>5"J*\[IU#T"DA]DQ^S<>,=>8O'J'TSB,FQA;E(9;!N0QT7EA:46-R*@@
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MJ?VQB:TT "Y"VX]ZJJ.D,!@QVM72_@K9#M^E,MF#9"L%/K"2-^Z=F2E5%+B
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M+-C$=$ VDJ9'QR6!K. WR614 $,L&Y1=DNUT$%.B,R94J@&CW!TN@CC%T45
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MUIZ[Z%=QQ2-;\!6;^N1!<,H29)=97*T]#>>*B&GZOYFI>=6_W@%L"3GVFQ4
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M+E@ZQAA&TB%ZWCDZ JP4&UFILMC:78!2I8U^K?2!D'.1Y[C(>VC8%7)).#7
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M(TA^\W4</,8)G=[AG(ZL?)WL*4LB3'(VPA:O/:ZTO;I+Q@PUJLDI6UTPW<]
MP-(=@#MUWADU$_AG))( 1U6[>9Y)P1,=+69\>FF(E!LT]T,-11B<*D-S\MO@
ME?EQ9I=))^QT,#0";@V.2DDP'#+"DU::2F&T$=)@R$.V.));@]YDG;QC"IEA
M=UBD%H9$)"-"!9>8/$J@]44-"_K[76\C6,^0!<L9EX&I/7)PXQ+;MXX+OEW(
M%KPR'CV*TU#/#:.&T[7(?NBM%4B].)@NIA^C?'M^K<&]ZI8..F9!YAC] (-K
MMX3M/Q,LY@ZFE6^EI.,5(QW4SGI15PP,E_38Y!7K3<PZIYP)HL6V>,I(_'<<
M_8A.WA^]?\__#VVJY(38$?60"'IFJ:+__O[[]^]/T 83E+/ %QAL:\3R&#=9
M)#'7?9@*9+?C:LJ 89@&V!!Z[?@5B@ J3J#<Q"YQY43$>[ML%V#U(_KCZ='[
M/_QP=/+Q?[430]^>OC_Y2/O"'TZ/_OC#^Z,?3D^^@T'1113Q>(<@N0WBZ"HM
M2ZI1KCI7U$+1J:=O;4C+Y>_5 D-U:ZC2)*!61&P]_CA.42AT85#P#A=!G.+H
M(B IBY2EDY;M>INPB+%SO&0WMVM*Q$;1)07M#6E2L%\+# 6MH2KFH94@BH0D
M#.[)2\@:TU6";L/Y=$#;P7M=*5AS5"T^]53U(-;GE1L1(_<O8&T=C=DR@L4W
M2[2]"R7 =XO:\RP1^;]S<JTF9[*2O[FNS@#]M+>K 6;$M(*I")QHSW.#6@,B
MWVX#<D-X.'7$YV"WF'!#K8I$K^R/?WT&Z7FHTP3*QQZXO;S<S9"_I9.**$N2
M@.2[:3*0*:YTHJJW:S1J>%J;L>D4#>)@&-B/4;6^W%B6@=89-@P:V!-::7JB
MVY ^T$(-(OT&]GYGNM7!@^K[Q,JE;=NLI+WV>6W(QOY.B$(DFP)?#\%B+@N4
M1OKCXG8J7@FE.2IN(P^76OW'Q#O\RJ8]&3[5L9#Z7&9/P*-6VOW1$"UD^7"(
M) J&4&9\B@,B5'IWG3^XX[(W="0.6!A">52A[^2L0=XEH7IA-RFE%09#JCZ$
MTF5?E7Q]: 0&FW["*066+-)H$:WC-&9&L.-1I5D:ZWNU7#++TH0FOWI4P+#,
M#F>7:Z467]H-6GHP.'>'<TP+E!T"/<?/.,DVK*,U,ZY'Q^UFJ 7\]CZH00$,
MUVQ0=IE6Z90'X&HM&#R3^FC;OMSSR&@U(KKAS4?!FQ2OV&+"0]^NE ZE>ALJ
M SHF?L[2&IIP!TMS>CPM"SV7O+(VH\FS7B4P_94M4O6UJ[%P\[^MF+?WJE;P
M_))P0KW_^.$]IQ/[A:&\::.\I)7T$PFD\R7]XB[(8PN:<:9/UCM5+ %*_A/[
M5C)D)EJH!]OZ<@*!4V6-I:(SJ@PRI":-E18,^@R!:NL>,6Z5MU!,P[*IEJD*
M3,NN:/6FG[%^G4HG[G:AR@RZO5*EEO7.-$N \EJ5$"]9=(12#,3U_BF(T_PZ
MR^G(>I->O+"^=QOG3^)"NW/\J..4A9[3I05;,UJ+"WU*8.AFBU0:(*D>8@ON
MN"B2^JK! .3Q7F;&'>8!NKOC7)>8A\VQ;VSC*J!$.,MR[7TI ]-PR=!1YC79
M.B@!'Y-.TWQS#/@NF<L;,NDLE(B44/@4D!64R>AE1G"\2L5IZ/"5OU_#'MW+
M4M8*6>/]A)=4YB%XT132H!1<<G>$:4WF#E 'T^,.QRS15:2 \ NE:;K":,4Z
MXV\3JOH=( = .SL?.IL'LF8R:*T$5JAX'TS-XEQCF000KX0!K*&P6;PXD+VE
MAI53_"PM&U#C3D#JV) @(Q'MY\DK>ULGIR5"N5#0XDMXF0@OVKA]/%..[K?T
M9RTZ.2Q@ENQ@M:_Y#>VV4#HC1*S#1X\\8;0AV7.<L[N]Z3^KI<V"902CT997
MN=0%4/8_GW"*E]HSD'U*3@.MK QHA5H9-:#YT59H-9$R[ [5<A7]"(60KH>F
MS637-G6#8UO&J:^A@M?R+YH"L/H\%31M+\7O:\[6&X*?*$O8JB?[&09'J@._
M58CTIR"/0S9[C),M;30].W[6VBYY-="D)N,L5<%,IX;A51&4\1?:Y2H]5HTK
M"U <',&]0^&<AFM<2NP#";F#H!K?*S^/\Y!VV%O2&VHZ.C5 U.PS>0!E=4D=
M"I5[\'<I_@N.5T]L_31XIA.?%48I?\*6;0V4=P6!"\RO("\$8O'F[LV2%T;C
MV(%=!SPV,9?DW\_@)O?'I>24^A398Y9CDQ^[EQ4'TL<WGA)CSZ=<)MG7OH[<
MK.+IL3<M>,TC;Y(\F'[7 J3Q43?^"@[7 G<ZA?K4#-TM6Y&*V,N*7W(<7>TB
ML!9A$3^+^WT5"V5] 983)>YXEC]A@726!R9(&4RCF-0<Y;M1HL5L:;(H3M'N
M1,XN95,;@K,2= JISA2X= M!,'JH1?3OVUQ<ZLL6W2DQ^ +\0W:'657%"6Y9
M]9!9LK+ON<+9LW5[)Z6;0FS?:#EOGF!:E2-#Y=LTZVQ1D;%WT41F;/-7+.32
M7]G?_.V]JAO-ZB[X1QCMNYK)\I @MBW!T>D\,8VP4Q?7"+CEW"HEP?#6"$]V
M:+/P]^-')LTW!RKQF0+NS\L+GLY$;%?' K6(LR!Z#;@Z7+[SW7N%&T!)[Z57
M%VN%+ 0/1@_1"GN]P[13W(;%EC!_TCHV6:GF+3398(0V,EFA VU;VA+O(8<G
MTV&<8-H)GF/QW\; 75Z#W7];B'4"CJ.-!AK6"1ZRU/;>&8Z&+,U1>3QGSIRJ
M-$N/N9?U-2._LREJ>:TY>@P2%L^<U['*U"4#YX'))3'P760[;;]L'O)VLHTJ
MM+YW&.P#?&99-K#]!+!UN735_/)2;829D&T=^$Q4XCW 1YIERSKO*5J7B*3G
MEX0:,\PL["A!VRJT!7P8KUXJK>F\P#BD("15[P34&-/+P8[>0=!0C?E@WLRT
MW_K9>^\(ZN;??AM\X(*#A^%6;1BI%IGI1"BPVJOS3MWZ4.D<^]V#$P= ^9$%
M8M$<!J8,9KU@4G,,^]V;,@/T^(IV9YWM]KQ=/KR1A1A'_ A5=6K[9MG_6)^%
MGMOG-BS-:+^TT:,$AK.V2*7E@%*6K<.VGH\$0K[@E6][WBRY$3970IA5G%+.
M GR+;09Y:%-_"ZS2OB)_QI1?,0]ISVEGB>VE(T8-/P2SNE#$( Z77K:7A=3;
MF<MZ) 5U6XB]4[&W5P+5K=S/=3R(F90>MW8FU?0"=]R%-IMBQB[2B/V'O4+X
M'"2L>=YB$F=1=^%#4V3#DG!ZB'R$<:TCY0/T8=%X!'+%AA+_C+Z-2L'O$'_N
M.1>W*_(_\"YQ%/$X 50\87:\DV8$A^&&4G+/2!W3G#)(U-!]$9"BCT>F":^*
M"$?H$:_BE)US8[./5QP03U'>QM)V&],MROLB-5\*T<0UH+PQ_=6BI#T<@'HP
M[*EUA;P<<GK0[9:U)<"L!RAAZ8\N_<K%@)Q4JF%=QRGF =9]1C8$O;!# JID
M2"T%CR5=: :F,%'$98UTF;781[Y+[Z,K[QTZ#3BE8ZSU>%E&FQV)YR"!-%O+
M5_H\/\UG]1Z?WT?X;)EC^0C?)T$6M*,/>SY4+//.];I"O2J(HW/N[XLY!7_T
M=!%2FN<QWRTY[=@V5-G928#!!M5G!*PUO0\+H^!*T5T4R1.;#TZSCS",7^7S
MSB,)IM3VS3"#27T44ZB"YI@>KW(O(2_?JT7;E Z>Z/3]R0^H9M]B1;#P6(Y1
MAY(.NK_=G=?-1WC%WU\8V@*3=7ZSK)#5:)5TW2<U9_3=W^2:SN.3@D'OO?&K
MGM$5"<[;JZJ!\ZY_*M9:)>:9M ,,[N&L14J0*6L/?[\.6N+WE%WT5(L2=FZ1
M:99GI>YV 6.84=+\VD(76ICN0-PSN[>SDE/VIX:5B4H? #WU9EGP4U;VW@&/
M16S9YWX\>*?X9%(GZ\2[?S'$Y/V=XA,H/? T9AR:;SR O%:)@?>-;:EKD9+W
MKGD2^/OUT[/ZQKK5M8:=%!2+OBO$948)SO.+%TS".,<WRU\"PEYD55[:,CP-
M=RMM(\W;K;<-3  &CT>B-M-W4R;$[CL(RZ00+M-BT09?R]0\4_5FHW* QR4!
MCJ@=XP;SM-0_+)JV0>_)TDPD!H.D5ZE0F*!T=DE!)6W7V+'DK=(Y2!)WP$]#
M9L>.@K2:PIVC^X#"J_V9OJ*R2\,+E8>8I^2P30+PR#L M8V?RQ5W_BU_O[#Q
M#L&$IX,&,K8Q QU/64,BWCG;:V O:;4IP&9M'^QI:0MP=C:%.R&G!<Z?T)D[
M>M9VF!Z%!OU$LSAX&W.-RY$?LD44\27R(+D-XN@J+>_WX\8^=N^_O<-B21W?
M8_(<AUAT%^PJYU7*4^'CG6:Q?OYL/=T:/FLA:FX-GR5/[\W6L:'J\];#[G&&
M&+7] =X!' /*;BU<\,C< 0';\$*? 9Z TH/4!3^7]0!N^+HAJR"-_\Y;YAF=
MM&=)'/%_+-+HEL*DO0;_Y\VR/%M,^XKJ,$;?+443I>UR()JT.)JTGB1A,$/*
ME-9T6TPS[2/42IV?*VRFSUS#.@>TRP+<ZU=[%=CNI<4'_%)\2O27'DV?S<$T
M/D,A3=8.%7F\C2:I-TP:S[9YG++9V3G.0Q)OZF;)WCC,67ML9@:C\947K;(5
M&5HJH<633 8%I].B7N"M"8U6&@Q)>R%J[LAEKE.E :YOOX_I;&@9AT%:R/;U
M]=BVRD[C'@<9U'+>K33!T'$07&E^NUVO _+*NKQ&.DC!V+E>+JH[;?X>L[B%
M7].SV2BX>]7(!OCNC2.3M'<J64.4W%PFB83H3 1I@.EW(:TTG%'$#GK-$;,X
MJ !4*Z@>R+(#(U:4;I9+S#:QZDTGG=,T6-M#/V-KDJ+3Z5.%U@-9XI76";D:
MJO1V>XUSC5XZG,;^R4+)&;NL#:A)U:L!JJ.R1>N.21-=M%8'-.?LZCE^A?8*
MI\Q1V[6BG@GBP#2<7MTVQKS6K6-#$O#>^^V#6G^40[P)U$H%[9(!-P-M +=?
M*^Q3\D1:RW4\LP9$6MI[>PTE&/RJ'WBS[B"-&HY? .J#WGGX1R<.AE/]&!5W
MI%(-1%4@]V(*N_KZ,+.*9YX9^R^3/&2F]?5=.ZI!.9S^A46E7>1%O X*[>WF
M72&7U%$#;)*E+0&&'DI874)\$0%\M1@,4K1VR/@Z[6N_OV12<>LM]8-O^TIZ
M>3!DL@ I/^094]=\PT*C*<-:"0!AF?IZ<SNZV>D"N*?>@H VBG"8. "M]O;K
MQL77,+AXAW-,"Y19=HZ?<9)MV 2C?"E7&*<I#RM-ESP<8$J3A19J8#AHC[7+
MP$J3L["ABTIE,'1\QND6-V*)ZY?!=3Z:6<4M ?O!MYFGEP=$N5Z0UES;O?(^
MS9[5-)R[" B[?IB]+\(#>.T&XEXME\RS-*%)OAX5,/RSPRG'5^=Q*/@7)]L"
M1^@ZRW/VL@OBJ<!@WF40$WY6HA%]=Y7F!=FN=[Z%IEPL=5VR<) Y32Y:*8)A
MY!"T75[NHI(;&D#(F!$<K]*S+2$XI2V,!&G.WOMBC\>F$?]G(MZ2M>L@]TC/
M*6GW-;M%Y+&)P2'WGA9(A!?IH2I!U$@"!N_O\8JUPCN\R4@=Z/=JQW%+7:=1
MFD/,:05IVBB"X>D0M%*(IM#E[L%/.%N18/-$O84ZK9E"6WYB1Y6%XVMF5Z^T
MLV"6?LAU%(M>U#MG[/!U6<(50$U4ZGT7N\Y)+^YE!\RB"]+)0@F LL0)?_.+
MSX$^=<]UT[%ZB>-B2TO-<O@;G(SS)Y5&&"D=.QZ0AO>^;D_@\@MK]-NQ.*U_
M9GE:W\/\^6<<L%UH-JH/<=\&Z'N91]N:I9Q+]RF#H>I0Q-(4@^HCG@!JI "D
MI_V,OS;.$)$LI7^&N+%08,?4X<FX?6Q]G)'M)]>'I0&&OB.!RXOF;&V\=4ZL
ME18,.M^'3SC:)OAF*5\V\CDK<'7-TPVYBU=/^K#]"=)SZDKL:W;+IQB;&!C*
M[VN!Y&64Z;%XC?)Z+_;PK[@2A=T")NX?KV_[RG8WK,QUF=W.0K[I4$*H#=L!
MX$\4&V?RX]-R=YG=GN;N+K,;F9!W:D^!WD1K!U2>I8<O;P*^RY*$3AXH[,A(
M^-&I>.S-;4TT].%]27BG]WZX3<1N$!CE+,T=R2>ZO7QJ7E^L-TGVBJO;Z]0S
MY47"L?";4<K8A[_C2-QT=\9N5+5O 9/GYZ>MS%1LZE8U<68 V]\\%II:Z@JG
MF 0)W_8(HG6<QNR<!P_'P640&/]&FN$[42-\!X,*%>L,UKSL;H-7AG3!>K)F
M!\=6!T2!YOEV+7X;.HY-DHFG86[" M*,@A/D +"13FB6J65^Q6R:A&FS?*8M
M=(51L$L,+3."EFR)B]_1R:=( 6V<67G'%@,$K4&*#8]/F$+'N\-"]#]Y$8>+
M-"J# @:VP)&I^FER>Q6!NHV-2A)@H]K'#E,K*K?9'GG":+?I=H2JQ/F(5B8/
MK<V<XR4F!%,'_(5V)9B?5[^.@\<XB0MV[=2PMC(P-3]M9)3)ZK8Q*"F ;6(,
M?E-;B,KT4!&\L-$$BVB79)<D-/Y?+)<X9,YHW27<!04/.T]#"IF/L0,;P9@D
M/<VM1ANOF3X-3@]@FQAMA*EAU(DV!@C$TD7MA.=ZKC7(G^[P<IM&B^<@3ACZ
MQHVIJC7)/@UW#Z]:0=^]KFH4]TXW>XS*LWQ""]5JM,.M]6#TK)3>8B,\2-C%
M(5GY[LJB*$C\N"UXN\G.@B0I)S)TP-&\FSI)BHY#SO8UO1.5-C8Y[S2?SH9N
M,ZC/TXB=#39+W60%.]Y%4WE%$3MVP[K9D&<WT2/8RJ:1DZ+1+.B_NDV"_O3;
M'8[3?$O8HPNWM"3B[3JG$X&KZC>VZ!:DU"WZ]'I+LF@;%F60\'6<XJL"K[N-
M8J(T732+2<UG#6.2!+TWC2FMD#R.BS-4>1U'Z.3T^.1_'J$Z652G>X0:"-"O
M+%G$T]W[[AV-_W&YY3LUNPE'>2DM6T7"$0]Y5@V45FK./)$!1M3NB(6.=T8.
M!"I=BBY$T(H'KB]%.BA8LW@B&#Z)^OCZ@HTS*SXZL:OUV-53#]DM)G1(6=/6
MR"^YS9N[(NQ(*(XT(]W$>?B_P&#/XNF_ZF!D!M""\N<PSGBRO;DU%M<GV^/)
M#HSD58/+<?C]*GM^%^%8M#7Z1[>)T9]^NZ (BM?K.&?A@[G.<S%*NJ"[!51&
M6H.8]YZZ'YO\X!J31I7XI&/]1$MQ;%=+]T[M9_R5?]+-#6V5G2ZO#3)(>NZO
M5],["T?![1+S\W;]2&=Q=8B:>'IUKK!**Z1_4,;FV:JZ"YH<9LPN1M).SSN]
M1H#M(5?]L"];+0A6*X)7;.6U#AC;D#B<ZR$#C2'\W$AMQX<!12!I^B:>QI0^
MWG740--.C74*UED\@3I[OS>$?;*J;_KIC!G8[\$FH ;L$ :&]37>,Y&MO)NF
M?(SV,8D9W2,ZZRD)KS*W7\<9O6SAU[SJ4X!!*$N4728]9$60H+3+IZQ* !59
MW9/-Q*?ZI8X'3-8JTSH"SIBB!%;3HO45!@=4D*15O$H&%50(QM3P2TIPF+'%
MQ2\IK93ZJ?B2=R6;Z6_ZO>S]DG)Z[_8>QK9NYQZ1CG>:3@"^2^CFB["T ZLZ
MJWQ6;Y^.UFQ!+EC1+O<GDN7Y+<E"C*/\DM;U?9!("QG66LYZ-WL3ZBZO7\4[
MP8;AE*[VKA7Y@0;"]Z!+7<3*#N5,>R92":_.,(93,TA0!/SR297= Q-P1K51
MAM6L&Z0-@X!C(,O7S&>(R:!'?M>H5Q?-:KH\9%E-TO0]N]28,FQQ _::FAJK
MY!_R_=P&SPA>!W&*@BH4S42Q&=VF9A?.+& 1#3?+,MBHT$2L]BK]=@IMF]$>
MLJ+#Z Q4K!:K^"BF.O>XQ?*XSY+NUKE.R/WXTP4HCS&5!(R6K(-E6 _B1Z1S
M*CK;+9,*?TK9$)N&V&@YO'72UH3&[9-]*C (8XU3OHU2[>NZ[D)$V&@UUO3[
M5@U13^ZL!%;CN-9R,)AB!M>[X&SE#O@]K-TZZ+X+T\D_O:J/W3XH&#=#^KZ/
M:.]5+'VGLT<E[KU!S&61Z: 0UU;<?(F:F:#'UY9@F1'B.:%?>5Y0PGOZ2DQ7
M8->:.+(I$_9_+>R8@NB_*'9(JG!:V52F2,W+HDGUM*AK<%%S8PM+W);7> 6$
MAZ(^/ 5I>03G<Y8^X[S D1C;IZZLX?D?1",=6ZR3M.6AF3MM\AL1P% $I#"M
M;[@V7ME)H&H=%E6GT-"G(&%++4<HH'T$7L5I.N/MC[.50>,*P5_*2U\6XLZ7
M"W'O);YENV+*54/_H-PM ONWM;N^[!L1I+X"5(ET.Y!*!94ZJ%)"7&N>CL2S
M,T&[5E%V4ME6QNN.2\V;Y4&X# ,*;Q(OP2(_-XW]HVCL*8^'C69Q"NQMM?4#
M:KV#&_M-?9FNF<* ] ;&_4&%[V#4M\+C?4D 4"$,'.:/INLH (_MFYB(QQA=
M]MN-3 ]^?)<*</81OL[Q'V*,[UIK/\I3S3<WQG.;('6Q): W/[ZW"M[[Z,[1
M_&./[<TB&#&R'V;G4#Y!*J+]W-9&)^LWT."5A>F@:;?R?>N-6&6L[1#.=?VU
M4FT @)W1[-XE8;;4D?'.9_PRO1M@<%JXRXJP;_\N4!U([^"P* 8/]1:=",0I
MYV'M0KN-L1=[2Q?I/)/1T<:/V8?&O>^V'9Y?=;@;I(!H#*Q$]MDB[>?X :RA
M5H_U\(:_2",Z-.&0'_AC/S6*<YY8J\'9'\2ZZLA"G62,&YBW=T_,D\'J8P+_
M*(UY0(05%%!OJ^';.A P$/T#=1(CPJK:+@*,+J1RRJFIXJ'QAHD_!\664#?J
M/"ATC=U>W66S'&I4LP'9ZH*A^D# ,BDW,7E%3 (&(_=MNJY<T0/W.9TXEWZ]
MR+G#]7N,[+:T4APUY-]2 .U>X?G.<S_0INK:'83H][EOUC.$T/_#= )7:4'B
M-(]#?C?/_'75S>] &[JZV&9JVNW,WGAC5AHK7R%:W7$=5^+EX^%ON^'RS<*\
MVHWD-Z;,5"/*G ZIL1J*:LIFJL@&S-1S/MMTOO-$$3&.&ILV+$!I_QSN\I0(
M0#7.Z8MV4*.=+OO#:<R3VSS49SZLQK]/:?&/;$GN,HC)G([S8!2@.H%YBGB^
MT;L7PN%T!K/8W=LA<$V^5HV8+N+*;ZM?N,S($L?%EM:H)LY]UIP.J7T;BFK*
M-JS(YLT</.LU4>>(EQH'T^KZG!=%"?CPQP?# -5>9RKD23WS@1@.9T2>Q_"A
M/CJT?L'T!AG_6)9.[R4O(Q("\U*KT5#K5UN5J8 ;"<=:H!OH#NT.A+YNH++'
MZS W$,1!#7*C"GC2(6X0@K<SP(TQ>^CP9M4; )XR>8KZ 72N9'XC+>-^O)Q\
M^@<*27G;G)OET-(;9:C/6(JWS4*-L:.C*=[22;FR;;'W"V:-0U;D \I?'EM,
M4[9/*9/#\7I'6M8SG67R;[C!>8@\ML[]0!NG:S?/,NNWV)#GF[>";?:/_07W
MV%]P;7?DQ%13,V7HO''/6G!2>YXE-UA->$X3[?UBP.WU.LOSLRPM*""<AC'.
M38_*Z81=MA,SX";'U9)@^&F$U^46$T8M:5B/J4G&7/<\DF92\$HG";B14M?@
M'BOKA6A#K6MHKXHM$IXXCM2.&3O7G^:Z;LM6V27OAAG4Y*"=)A@^#H+;Y>9#
M5@2)>,$5\7&:/>U;Z\*@YNBI0ATON<CS[5HX'7=Q_OLEP<SCP+0FBCO]90T.
M\CV(R>W08IQD6FN;*9AFZ,K2;@MFHL=+*LN<8BZ,"*S+*<9,$52%4M\M@\EZ
M\LFJ188',5FU+KA))JN]N<%JGG.:J+@HALN@)%[RYYVS<DGYVU<<D/P[0 UT
MJEZK,OFO64*32>+BU=7HJLOY8,=7<U'.-L*JLX75B)W8*BT]I>DV2.*_T_;\
M7,N_X29\'C_'$4XCUPVXG>_!-U]5,<[>>)N9ONVFJ["TVW K$4!.\36F-K+K
MYZB)06)>6='(.EW ,\%MK=VI!,$0T(1.WOW'[!&Q=(6X5GZ$F!8JE>9\7R07
ML?BW6Y)O@[1XR,Z"_"G!>1VM>[,L+S"\2H5"Q]S]DG+[AL=X8]MWP ]/QRDK
MGS%YS'*LBC&;P ;E*P(YBGER:%.FAXH,A66*"%>;W716\K6\#G,N4N_.EUB8
MIB;ST"3<D7B<<3OR#M/WWI7N 5IB*4O%.4FG&;^I [/.4F[!6;")Z6@BVMP=
MSC%YQM%E1BZW[. @*R7VJH%F1!J1CLMQ?[2939]@<"+>2;XO\B[3?PY>XO5V
MC5(>;LC8'/*4Q:9+CDB9'EIF!"UYBKQ=L"1A\'VTZRXB+&^6HN 6ST&<L!UU
M6G+\"HJI9PJ]V1W$=-*RT*9Y-=B<%YBV.+.!2A?J6&R'-C-$C1S1XRMJRI6Y
M(I[M$?I<M_;2'ZOSYNV<Y_Y&6O<BBF*F4G60BVWQE!&V5#97;9IR/*@VWE]T
MDS9S?79OIZ7WVBBM[-8*U8C<&**YEQJTFNY48_->JP#YS5($48Z?3S:2 #;K
MEXP;.-NO];VS>@_0>TSK\]UNXTPDK1J;-.W3<K)/PQD%[:#7C#.+PR"8%4;U
MNUR\KY-GW+W<.>2X/;='3 V+?R-QJY\-A1J\=['>)-DKQO=TDAN'6&UB_4(J
M'\IS'I38_'Z6Y<7GK/@;+NYPF*U2-IPW+Z?1%*RCO%VZG$Z+L]FXG&3LO3_U
M8:T4T(?70<RNR"_=3Z@M^RJEF# +;K^D%!7Q[5L*N]P\HP9^PM1AQD+N(7C!
M^3G](R_B4%/J>Z7HLA5.8'JS;>V1')@6L[\-W7;P)67WXJ'[@@Z-0%;^1QAY
M2?\9K[H^\10) B=\Q_ ]^5ZF=LAT;YO097OY]6!Y_G.<9H2_(2Z"T!=IU$Y%
M/#'^,RZ>,OJ%#9S\DK+IRG<\ N M:=^BW;/IC<W^D-OJGC8K3UG!:-KG>(D)
MP1$U<Y'GN,CK6"=^KC$@Y)66!7=H-<4Y* 6736N$:<VF,4 =#+6'8Y;6@7"!
MLCK<+6%'5<.F&E#67J6W) MQSK?C:>$_T19ZCI]QDFU80[0MKMYDO/+7TD@C
MB7O2@,MD.^#RY%D(HR"-4+031T7P@D*:?EP(?B/@!*=_5+^5"X"M#;$T^H13
MO(R+7+TVP=8>;$MZDJR\-I0)"\O8F";(!]KB\XPV*F/^CJ=?SM)L4DF6?4DW
M01R=4=@K==ATGX:S32H[Z/4FE5G<>Q=OCU%> F(R*!1"0'OJG[(L^AHG"9\C
M%!1^_)A@\<FVS1F3\-JS6AAG[#$-^MYYN0?H+E%W8BA@<K1_RZ&$*RM:'L'B
M+./9EGY(PU<V69"ZQ!'Z7JG:9Y:1ISIEN"3M0:Q97T3XA?:FZ0IS!SDKGC !
MRE)VYD^X'$F2?36$T5MI>F6FWA0C)V4U:*_'V$/NTK$61$$E2:=K(C4^5^/=
M*-0>]#.VGEQQ4:_L:X UTHW*P>WM=N!4"UA@F5,O*;,(@#2,DYB3OOZYG&&5
M4ZI%<8DC3(*$[7EN*:37G;[^'/[$>;C?#)FX>.3MCHDR -,ZYK!*]FB9#&]0
MCR(==K%J7B6!EB)-0,?J-:52.CXMF\_C)>TP<%K$P< R[D\-0/NQ-=FBI?0E
M!;U-6.+7><MQW0KHX$+YSQUFSGG8 \P-P[F(_GUKL\MNH0V U#J3+$C<585.
M6@U>Z98*3L8-)NL@95L<4<GK<']R:I94-7@_9VF$HVU8L 60<O!1[]J<\1V8
M<F!2+1-.G8.S)=MYBJ9>XITV>>\-8#Z;K#<$R\W TKD!W9OS$$AJ^C7-.6E$
MJ0SK5?2I .C=^TRTZ.5U27@G^WZXY5TT]@ "8S,C8L)]$]C.R"V),_(WV@I'
M4U>= @#:FDRSH*Q*'3I=#9CEH[65"\/Y6I M1ML-.[.X88D@=A$JGV%N2/8<
MYV!.-EQ0/RHL;I87Y5HYFS3<I.QXG::H3 I.3P?U F\=Z=%*@^%@+T3IUEVN
MP(\UBFV..&TL6@":N/%V0\U*MN)A2-:6Z"! ?XES8Q=IH^B2<_:&-+G7KP6&
M@]90U2/U.D[Y_3^L!\1<YP"&[#/>>*[2\;MR4R0,8( ?41 6X_Z 5,$T@\E,
MZ3:3L[JC?I8W!8$TD\HZS1)[SRZ65LO'OF"/":HM0HT*&&K:X33L<.!I+G:=
MAFOZ$'[3RW&]6BZY9FE"DVL]*F"X9H?3<*$P?PRLJ0?KG3F]?=<]#\Y9:<)@
MH62*'1.OP;U%9X]U&".OH3U/-^"@D_G$]9B$@!YB,YRP'IX*&$J/ABX%CW]_
M_WT=II#.?,Q-LV$F8[\L,Z0N2BQ.G[*UM.YS5D.5G6US#3:HWL&RUO3.Q%%P
M]?WKCFS'%=N.F,=9)L)700^NDVUM6NS?DCO) >UPE4:/['9;:7FG_$0&J%?
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M8I!( 8DDRH[H2!SL.T+-=+R<V*KWK 7-!%CQ]Q<6!\C/2]PLY9M\FI6\9U(
MZGPJ"Z0N<G227H+A6?R^6$0]C_,PR?(MP0_XI?B44"9+-6X6AU*KEBB5SXMJ
MU?R?EZV9DNLKJ%<#2AW9 Y5>O.K3]!K7\1"\W&9)'+XJZZA/%D#M6$/4A$-0
M#>I\<QWT:_E?IHRXMJ_(9_5[JHVS6BQR@P1A\9#1\9J=G[K,".\0\N;AKHN
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M_2C*A0HUH_:R>&UI_$&[SEJ6J&M%WW*L;H6 SY<ZP,5OT8XAM=@I8%ZKT]$
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M<<&RE]DOYV(QG-TASN*<;\E7^2OMF :KCW68JG/X*88V&T"Z2M4!$N*]8@$
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MPGZ;/OKQF8UY'T[0-F [&'1I_26B\;I>A-1\"N]5.M?-5\G+ZUC[%M3#64*
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M9#_3E\4+Y(_0W\QYDYKK]?6G]WF3^ 7N>)/N(Y>6*<EFM[O8I#S0<5\WR;S
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M]50WBCF\]=S)Z#*R?4)U-64<LZV^)_&AR:3Q,6WU7WMOW@9G<Z$,#]$X^MW
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MNNWOMG2AVZ.:B!O.1MC2)4L'4<SE'[A@=:6H5DSI73R=,:!EZ()!3AZXNNP
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M)'0(SU9+$W=!(#,Z&++IJ;Q=:10+:BYK#(EX9?3"#)56P.P.N= UZGYU7%K
M^EKQ^CW2EF8&,*)VRJ"<F-OPY.ZBHE2J;,!0>!9/!C3Z64_Z9H1#'IY9K0P:
MDEU*JPB!!B>-I(*0(FP<D=.CO,IO9#^F?"DKXI&(5C2S-A;.O&X<4Q?$0K@8
MT<*I/KJ/W1M; *V-'W./3ED:6J^.<.+_R,;@(1KP5&;317M"&-6<B$_O3GS9
M-PK U:D4(@XQ84;1.;L1$TR\8O!Z'L">#K)12<>8&*VN:TZNEX:ISPBQ6O@W
MRS*L6\5N]F.ZFB@5J.(X76-L+W;DYJX!3KYO8F@?96IU/ZR_R>C7VF)N7K^
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M(&D.(=W/? \QU26GW*X[;/8T:M'3$IVE'\ZB (P]DZ%_ID8TARI@U6N&\?%
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M R.RT$+QJOEM=0@'DE(/HM\Y;%LAF%)YZVYCT3EXF66Z#UFF[666Z7M#0?]
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M9W[7T=GO@HUI&W[YTFJF):,"'B%IZDJ2>G-KK1A^,#$MK7S.DMTP.\U $_G
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ML>6J-S#7.=RC8)$<>Y+L)@(QVM16F)H@Z\+2-@?1>1W(0'9*/;G4JJXD163
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M^K*8S1$32XAR!6V)^"!Q$41^FI=N5Z&ZK#7(>Y;"%8S?Y0?T3%1U>7IVZA3
M,))<4<S#/O1(=%[)#' P#H1VH[ G8&I<"%!@&W901 :L%RY9BY5,6BH:M,L
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M9[$7RI$)"UUC.$U;@VR Z5),.M,'TX0@V0A80"LOXYCO?*D7HJDA#K@:"%<
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M8E_VR&:\JTS&X*45*AD%S3571IEA&^& BGH2'TY+HP S#*0TL%%_C9:&4B?
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MCBS?>H8-IT\\YC47XLWT9.3R6'LB>]Q?L*2+/P!-IMPWBHK,6%6AYG+^3LX
M"[D<@?!TX>>[=L!AFWKKO/G3>?!K=O\$FU_H//9,-_M?1^8\O&0AEB3[!WA
MFEIZ]HT6<RUBR_G<(TI+( P90"T(Y\52REY54<KUXT\"^5F3[N\-T7V]E+0
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ML)I.R7B++ 4:5/4N:Y4)MG)*5"201*G-DL2!(E!\PI/)J:.$^CH\MXX!V:*
M-5R:*JVL%*#@"P$<H9B]"?2A&.GQ4;NNE8;L*GQ/:GGI/9*(X,8TUU?57U#P
M;=*D;UH3M;<<N8C+'$)F]'38%>QIY@C M\A^)*_9C+3\BE,C%3?(B^6>BJ+A
MM[Q)LEJ2UNP,Z+\0^O']3K$N8M6Z$TY!<X+A5J0'*9+>6Y'4(IGW5M!YZ6&
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M^U#5-<T:YP:7W!JS$&8-^+.QPSOW$#(I+64BU<4\[]KKS8798,KK2#@5R7Y
MTBG@$X<SO8^1,^MV2+6U'<F8W&I:ZAXQX$!@)^V-G/1^8WS86HR#]E&SV6I&
M[9?:0/)RW(F4;JFF!)?GLKEJ05@0[ZZ\,(+VV/8&Z<@]OG6O**U-&D'5$8HQ
MHZQ,\@^OE+T[8WWZ';#/$G10YVS'8RBP[7N#O]VF-6>*.?[,WDO':8SZE-=M
M]T;F;=OOR'TJ;2*)S^$P@,MJC-#=+A\5'PFF,^U&?U]A)Y23+-"@]+;&J \
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M0W(I-P3@]\7##=:<($FD/4P>LNIP'@N.[7S9GF6NA(#!S$#D0FHW8FM&UN^
M0>E@=+U+P!4!?C)7:2F.SBO6S$4U]^;*J/-$_SEL<';J=J*4!7T$8>N 3$0?
MG*05S&6_:6=O)CG3L!!FH)U+#EE@JJ9D)C5R5B(KU<4"4X&<>-)??P"OA;84
M2Q2/LMTP1680C+N7.UE6@0&[:I=7PDPP=MR.7TEQJQ5"BC'%RHR)_[4VNZ!?
M!9>PW*'D.>4H!<T,ZO\E(D:CY>0R<3YY=5:,A]/Z'-!R:[Q[>%A8-W0)3,YK
M<)=<7H PQM>Z$O^CNT.VP7SKY$3RJ;T&MI/ 9A=(7E+:MGQ.E)3QR!(P[KI>
MD8?!#:U/KW9L2.^X=QY%H^0.E!%IF^R.^3,0G%^_\[T-XV\32U+3.!\/7;7W
M/H/_^>.'#/Y]S> ?P&DC_CL0^LG4_ 3)1%?J@NK!BOC\=#X?D*\MCW0*]FP<
M2\['Z&Y(=CXFXGMHD*)M8V-NAODDD+.D!ZN^AB271H*;?%1*5DLT5-VEF3=+
MI&4]V=/Z89OE*21_<UT+N-?&P8+#9K)LKYG03(]T4/1VIV1!(=\]6G3?ZP7E
M%K)*N+WH48SP W*J]!6=3'Y79[&Y^%HR":@X*LSZY:9EZ!5B,$BQI>MJ(Z.0
M]K_OR)%89 JW$O'0=/HR7R M8_(C1;_'QD.V&=_]I#I"6Y,E_:@L/#*C:.TN
M6>SE$M5[74X%_X;%7UMKPB[$?V,^WXMXX^V6$^F4"2KF(VYCY-HWOK!2ZDYY
M:!EF1.G9.$O*\R<3+J]"WT]O4K8J%+\K9RLYO..C_=%$J%O*[I/9\OL/BB[D
ML.%2RVV2 QG@H%YI^I:F7RHK-6.U;UE9N3]3./Z66^@%D=YM7FM/6+SHV 6H
M/C2!XD:E=TJC;*_#FL84,6BX:;>@+)Q=0+7CAO/MT5R\[">DQUE1@(D)SMC.
M 6'ERN@L.:U_W59=<N# ;B3+@NE[MA(?AGPE BK$6$9Z*=6%ONZNFIGR,ICL
M86"98QI?FO=V])8=-S1@X#R,^8@%F6K&>(F),,1'N=C2)6.&K-D!/E0M@/H>
MS5D,C?G&\AF7%GRUO#%M<X:'_&^VJZW2%,SE71^.YJ<8\24*7"!P2)'=U*7D
M"C;H3"27TQ8'IKS)%%)Q@"SR3LP'@+?J@A]'67%,J#0X&7*BH7I"$3"1@C/8
MX2*OE+;+SNO)\1%\E]"<9MQN?5U<84H\$WS=5;-N.^OI-TX'5DE+YIYW.AT/
M(=%7T"$UR2TI_(_QT[5T[J: K#"CEEUCR=XLMY$ QL,,7@/=+R#1TS1N<CW<
MZ>!-;_<Y%I)&/9B @WS:Q"ZI_#C .]VE,: Z9XI K]-;,&KI)X^GCQ_S_X=W
M<=G5BYIB23EK_>3QV#>+U2BBHV<M"*[29Z(N(.IBDJ',3<QIBF]9"_G^XMZ%
M=[.]-.+ P .C7BR2[%6 6NV=#Y',&ADH\_T7+27:;(0DTQ6<C:1;]ZS938N:
MJ, '8VNVA0J2\112J:MF7CRZYI!S0E56OK(;AM?EM>KQ00"F5>R3&$(:UV#;
MOIF IJ#.Y MY,V@BV!6OQHH9^KH5]#'W5PDB;4E(W[7!-7'M3T;['!33!Y&O
MHOK8@9ZNFKS_]CJ=<_#!N$*NVHV005Q#=Q;3!+T[*:\$6^!R#-,\CSZ$DKVE
M<M7%A<ECY#D(Z^BE#$[0JIP,P)1ZF=N>/=^WS 7=JV*KT=8-B&3P*WF";/*\
M..5!3S!J##07!U((TM*Z%-%<97KG!$^']U4+UUMI3WN\@SF<FLA^,:\!).S?
M+;24.7Q#1*2#0X2;P -M.T54CT%X[AN+"@_IA/@9&0+!T#E!<.4,V$&A>72>
M,*%H:E[M.3$18;/4A8TUKX0;_0H-T"&9 LX!22NL*7'0M$S"5FMNU63LM)*J
M\::Z M@P&U+O6F$LS3V0(V+[SVZ8"O#,@$6L15D6';A,(%!CZ,;R$1F/Q,Q/
M<@4W A^;MYFT(.1 VICX,9HM,=+*@.ZJJV?;&_,^L&SP[XZ+DR A$MV1>ET7
M-3-;7,)+!2M4D[M=6T/J;M==R&E[<!Y4)#C(3A&T.3L$I #!N"&[H[?5$J9D
MJ]0&FXDR.,.L(D(II_\RQNK==M%A.;$,."1AVA6G\I@'^4=X',OUY%6:SF"J
M"PL>$[#NF.YZ%NI58*T?'\7K3@TQF=XTV/8=8B<N0K54EGZV5TPGP^3;I^4!
MKX^/_FN;#,O74X4>D<LSB&Y4DU>6V3LUD9/)9Y@(963"ST:^XR1-- G%>WVF
MZ=,7 .*G=_/'9T[O%+]G5R 33(6\@AC+_]HF(_P$XWWZ>"I2*56$,!3WP@M*
M!DHVN><HQ1_^UR\?I\ARN;1R_JZO!AOE/\HF15=<Q+;*_APLX QFWS-)8B\\
M/9L,'&@DC9)C?P0[^:ZV3C^GK$N&."WX.<F.%&-#C+,L:"!L@@><MU8 XZ#\
M<O?:OJ]\A]"FYH$D_.@ 8&H:'&ZHSH<+1CM?.7U:FZ*0NAZ^2SM>VR41$+.N
M%FQ41IBG8%F!*/0/>GN-^5YQW6C5(5U//(#).2 ;R0N  L]K?V=[ XFI,OQ-
MPTB/CSC4B*/97N8%DE-6 ?#AASI3/>A%[U;L>F"65D_ !978=HRS86?0!:)K
M.T5SR^74P[\U8[JAG1X_DHU)$3,2=_5M^Z="*T^U8 ,%NT(\FISK_4:&+1'&
M^##)RR=NJKZ%X4*(9+LAWH!^4F7";W9<Z>@;&E35$9!IM\-]='>7+)?QO*OB
MC2;K+3&CPW5"DJR]QZH??UZW,-YE/_YRIDW\?$;DI9<BY4+.I)88D07DOQZI
M6Y5._9PS+@N/])Z\*5 :FVAZW*1R_W*JKE%\2__G@C!K2?/I*&,0,^ ]AM=\
M.^?KH/QXCRV;H5X>X%;W'&[UY %N]7?#K>X%H.ICQ$&_L.ZRH[]G;/,YE!0D
MP=V^HYIQ.:6"2PD&8"BA?209@W^$;;L_XY,202YX\<3;XR+R0!'%GW=]ATWO
MR20E]*#LFV%;U%UC6?:6RT3HS)!(.'N@_:VQBO9%PA$*O9$R.D,\[V",;IL-
M]7T,8,ZDRT8A0Q)Z#+]^5J]K; +1@KI>B]^1?KF>?''RS3?_KP=IXZGV=_6A
M['OCPQZ(W#$"%C^+M]=?09V)<_CD&XSLCE1$'*^^DCGS\0M]/<E37]5W>KO@
M'F5_>I:XBFGNW&BJ_IT*,>46BYS?D'IM?WN8F9>/CB]YMCKL&(,C/ ]Q@RSZ
M'TY??W?Z/Y-NNX0G76R^L^1UG+/E!FY!V_T'_+A-_2__ZW23=MWE1AJA/G]L
M$3Z?ZZT&&L='__KTBY,G%K=[JG\\KNCJ%9M-@]0B]6QM:M.>>[^ W0W5?;57
M]]V>EHU%Z45]7X5DSD[R:3TYU<0/S-%/M98JAV=>S$<-/BOS4,]2T -2OA?-
MYF_GP'S,)_]6K9([^:P]X2U>__EWDS_6$)E],V%B:N3* /GX99$[ALC8;<M0
M6%$1[FB#-S+(@B;52U>;1^E&VENMUY;K HDSEN526R[WMH3YK8,@5&U2G:>9
M.6>RR:Z?+<!.7LR(*JP%CS])+^#)].NO'D^_>/K-WKIN0,O&>?,G8;EMS']9
MB%:/% O$2J6+_^O7TR^^^6;ZS>/'?NE=6Q'V[^"JTYV!2 ]1NUZZ:(5:>VB/
M]'+0G0=I23L]]'F'"8KA4S"EDTEU2+=205@%-B@%I*"_9KJOT7)'("K0+%)(
MU_129=I<V&@&MSNXX/4>IL)SHLM)2^"J#T URGTR4X%!^0CI)$GR#25]\X)\
M9P?^Y/BH$!N"5Q8<.&[S7QT<V%/UR:7K%S=2\A=C 9<5Q@"A UIR#7ME4MTF
MG9F1'I)' P90D S+Y:CAR953X7>' ;G'"_:VKI>7Z7!:@ID(WM\K$L<D1_@A
MROJ(ZG_JZ KL0.E)0K#<Q#=R:6\D2'Y92=5HMV;PP^?2J2Y$*+3NL_3+M'JE
M"?S.BQJ)R2ZW$OJ*P9^1Q8D4W.Q8"ZD-&T0K<ZXYAVP>X:1/4<BRZCA0BG'-
M).H 5X1$:,. +,B CW"Z[4Y"4<3BH:9I"N'GJ)!)_SAR0?]WK7#F$?3M:&V&
M27%AKP*!VF0WO!Y;^W$5+E00;62U3@,I&\HSU8;]TYY)N+O_=TQ2<V3]L"+O
M,FSL9NGK^DW4@=1?)B^S!KL_>82DXSO%7XN&@EPRP)*/=.]0A:)FTI7&>61P
M@)Y />=1NB@(2@F3R;/%?C-.U\GD3R>O3VR:XI5/?SC]\_/__9_]]A)K[.LO
ML,;2OY\^^OIS6BJ!05JF8-[V"+D!(.'F[X35SURZ.57-TWN[Y:K2$SAOUVF1
M_*U99F8<5U8.22-U008D/LFIY8L823>:(K5,]\!.WCZJGDU>Z_.E2J,3TZW+
MYB_;]*1S33O=X\/]OIN)[Y/_B=<<B?,*99])5(.Y[&H'U&1%'L$"-PCWNLWX
M"GFENRVM+,#':L2=DQ]QAM56'CP^^M/K5S__. UB]<V:Q!%$"K>7MHFGR9QU
MS54E_TZ.YML*_'O*'DAN.XRV[EWXCS1BYYW(GN%/LI32-Q%<XF$T\D/LF\[#
M"Y#UK5V15-<N2R7.?C;XHY99V2;I&CR6I*H,(9MQP3YYTW!O7#L+>EH;'C&V
M=>$U3+6_(2V".47;=X8YA7?,YKGT]B:FECK*N[K'QHHK4:.X#(-C6CY;E6,!
M,:>IM#/TF&;-2L,NI"</G1M928B\@,4XL+][OVZS7B!-(-E+>$AA!<:''*BD
MJFN%LM1\<Z$-8>D]XM^+:'H4VNW])6:%R86Z>RX0CKFY0+]532(YY#.Z^5+I
M+A2+C14[S3"[.3?*O!Z2.+(<>=8J]D^G%/,C)T8]=8]M.$EI/5B_J3=H[[Z[
M@[.%#V7E>U=6?OI05OZ[R\KWE[SC8Q-W%8TP9D\U;IVUJ!M2#K"BU6O(:HR^
MC):-(E,YXZ83GFT&\UF3,D /DQR'JMWV^-$.[MQ;!))#;9"ME/,2/L>=KO[)
MY#6.:;]@/^CV$+7K!<I:?!SR!HBB7CU'[MT WK5ZK7I[);H^JYGXJKJNO<:!
MDH]RDLU=I#4YV:[]L9>UHKG;9;X>I!L#'@E2X",TZ_T&)PE=$SE_MKTZ&O%L
M85US+/3?D\206XW24^TZ^J5R3#RJ)K\G!+'$++)LH5RRPN#-^V12KK3*:ND@
M%(+WS+IISMTB\C848[>3WH:'Y^:+SKZ/(,'JMY?H$!,K1%?BHNW8C$'LW_!'
M%9HVBM-Z3EI 4RTO/#0T2"W22=5ZO&2]9EN-@D.^21U,DHV*%&9\FX.7F)PU
M.E*WI7$.SD&XAZE[0G\)I/4&-^E)5MN67]J:Q"Q(5\]CQ(\UO(Y_*!Q.L7"@
M=FC3BGCU[&>Y^J/P_61T8^9"^ [ "B"I"<;+<>&K8"]Z2L .)ZS2*?C!<M.(
M7WZ)SH^J2ZL[K<D4,JW2+OU!"7QM\ZQ1T!S+GZC>L/8!ODO62%GR,ZY4BE8[
MC)_.47*+(&CTVH9>W>X;?I;&U  W@ !1_V,Z^;Y=M[C.T*W;Z_Z)6%!G+D7V
MC-Y?O^C+=!\=<Z%7]%'W6/+,_IZAC[JT_]#G>7+RH9[EXX_U6<[.RT!%:EOS
M$$'7EWLKR.M*KRL,0BU]:_")3R;A>M)@ >]"$NRGZ^JJ?FMN5VT*E0)Q$'LD
M0]!]+/LPW&&98MRE;<?=6[$5.-Q/RR@A<M^8=(6'UH84D^J?>$HRB.PNL5VY
M$K]M @H&5%^0"YHUW6R[(J.EL%YY7W@UD00+S(H:)6M@3]]#);(GT$.08.2.
M#\WB,@#S48;.BQ[B$L/?3!V6L :'1 76$NA8!-9>I?[,DV6OUZ/]F' PN<81
M8[JK7O7W&YI/PKI\_(=X>D F1?GD?!7G-JQ5NZZ%0$;0'V4VE5EY\Z$ET,A5
MD5[<U72[ZCR7\7OV]S#KY9T4+J^D UB;HRZ-_DI5K>Z(:Q018;D!SWYHN,#N
M+#LLD@L ^U.0Y:7+4N[)&.%$_:*0PW3'Y6$'_;-VT.<'M(->:KK"MY#G+(;1
M620<O$1ONX7(?E@4JE#Y0@A(&>M;<F,#R'SC'6B7;=\WR8V5(2S:LHY/.D+<
M.S,1\LB=MXH7XI%;AX/EL_XW#XO_G[;XOSB@Q2]NHHRQZ5E(#\7Q0;4VQFE-
M"BT]6DVK]<RJ7 5;)NT^0%CI$%$&!N;J48X9WD('L9XHW;Q 4U4\RS2G9I-:
M].J8V6$JS,:ASO1%<[:;!:OF5Y*1W)$97)$$XTT]B3/!,Z[:;#I5?0"TP,\R
M9-X0]'^,'79@>^E##O?+#[9K/N2HOJL7TO8N W*+OJRN^RU2H&GI]./*D]IO
MG2;N1EV6M)0>S/(_S2Q_=4!F&<!$66\2",^3\9L;=@X]"A+=9W%)E%$DQ0?;
M.BBU;WO6#\1-\!ZM[&*XO)3E)J_KG)X0AH,6M?ZB%7Q>K2I<;4$C+-<ND>$/
M*_P?O,*_/J 5?BK#D^6]DA!.CNZMEC;2J4S-/X"^'1MCH#JFF,?#RXGVK(5B
ME/:K$0'4L\>04(L3&</IX&N:,_,25%K\@AW*/Y0DE?X7?N P_&FA/3BR;[KV
MIEH2C&/)'[GXC!TH>LG>(886CQLFS^XI79L:/VS7:!"X9"K\8?_]T_;?;P]H
M__U42TSIK@U7V[Z$3=_*T<.<S4[<:9A,RVI&)6:-;*7@'*6["_X2AKWND\.%
M&EW&BAZYGS7!ER)]R\3X=CU;UA7T<FO.#"97Z.U[".UN5*9[CJ[>C6H:;XCJ
M#?UOZ%C>[>$:XIR+RTY%*JM>72[;&]7SA9SD=KFI[,ULUTA)KZU5&5\!?X\@
M^$$TQ RY5.S(2V?$,B$G<3)Y[BG#*I0!CH^064=+=[-D 8'-;MJZ((T[!D#8
M&3JU2MV_=A3D%+]Q_]G7ASS62N3,U38J"(^O8;M6.2[:Q!(G:*"0[:9'6F<$
M!]))B6##-RX=T(V<0F'VB^$+5^TL%G@D'A7HO31J&+(/6^"J6N)!76\[E&C3
MX^#/CR[:ZT-@W3.>":[\?GL)>(,B2 WJ2&T2KRRK4K3@+X,";=N=5^OF;Y95
MN&A[TK:E?Z8U2Y%3/3?5W@ 7JY4?M!F(O+A(7/Q,;N]<R]:8/1R8:I2VZ_!F
MY23>]J.5_-QS((2PFN8@%AG%-.FYY7T#QG,,G?Z >+QWB,?/'Q"/?S?B\0Y%
M]@]AP3Z*Z+MV :I;H_TJ[OV/PU;<3P?F70'WU[6Z.&GI ,Q6JS:[*[-8VC)@
MV7)G]K4=^]5FD\[O34C[BUSLP,D"(@C@.0I/2N@$N!R,4"[!34,J0&,H"Z=*
M7X_@-77VY-$URNKKT/=@3QUH:FGTJ_2=7DGU!#>0_(C+[49ADZ(B7GG_\IA-
M)7IRK_^I3R2UR\*Z:DU=IZ932:SE4OZ.N5S/V?>1!CBE)&;GLN121Z3_<'SD
M>6ES&SZ\!OQ';&&%MH7Y:-:I,=!]<KI]Z\VV9G&G=_!X=G3)ZUO38RYTE?#5
MY4+N/@GCMB3#*Q5Z?, RAK:+^XD.Z6V#,G[DCBVD:3\I3T*\X0%04\D;-=-]
MWT<+MX]<]NS+$6!1]IML+56!>9:TO(MZ\GHFR^,G<\]>]EU5+R=_W,Q/ICMM
MH-;*Z$V5 Z.<>RJ'_9G272B-A9\_^OK)+B)88@<C7ZCUI]H$FQ4!W-IG;;H!
MP:2*:OS:I^:R[>O>QR.J-&)1M=5GY]H2E.A/4^1G>-$"*CU/9NQ<1(@C5K@R
MJ@<[5J*A2%9U*[U5<,"=J4F/JFFY3Q4O+<#^N5&5&TXJ2.? R9E=U/,=NR16
MB(CJD6=DD4[(=8TO8V)==761$LL_FK*KOJO/L"16[96G#U?-9J#V-PEB?WM;
MY(=-Q](9ZQ1J_=@8P*JQT$_STI78TL<_CY0 G(?E38#AN%DW!()Q!9"@*/0>
M3 O @)EC[9SS[K^@GLB5FWL5V$ =9:><V6OAX&"IQV;YM5UD>=Q,9QG#3^*=
MF0-YHO<SG/'* ,-[&H.YBSW^&VE<#"_&>RUE_Z _PKP7J$$I5@KKZ;QER_08
MJ^MDG-+59AN6+K>EVE$S'1,;QZ)4&3YNJ"!#64E)6W4*[J_%/Z!>YA'_4YHV
MAQWYV94HFIYSI:$:X3S< :'?GSD8?T>?%DC^P H/.O*G'WSDOWWZ]*M_R-"?
M'-ZD?\CADIP X[/V>XN%F"]T!LI17R2X6$2"I_!2V$V-M%S ^/VW'Z_>\6!@
M'@S,@X$Y" -CW,7&N;F/1RR$(NH\SD2Z,!9EQ]T<]7LM?C-Q*KF_4(NY'Y2_
M6'A"#[;JP58]V*H#FO2/XPQMS[)MR(#N[.^HDR3.D43-GKC_/^R]:5/;V-8H
M_)TJ_H-NWLZ]Z2I!>QZ2/EWE&)/0(4!C,GZA9'L;E-B2(\F ^?7O6FL/VK)E
M8XP'F>@YSSD!(VNOO=?::QYN(A7]46?P[\1>4I:1LHQ$'OHRP:4)40B?<D;'
M^'^G6T^W%-O!2@R>_R%;"?/96;'O?&.D/"3E(2D/>3X\1*D=>K,HKFR$+5BZ
MXJ]JXJ!,HQ-=>%!3D6E:Q@_7IK1K)H(.5"?!WQ%G-^%05YDG&P:_<)&AKS6D
MXGEF;_"3E 6E+"AE04\[]!AP])RWC=\=Q98>^C_JCRN&CBLF%9I-+-+3.G(7
MY1L2M.L)CI%X'C?9I7!Z&E0X/F)V0A0ZST(_W&1>%(7Z*2&+W9F\R;;,9:%X
MOB^SLBA*K<&CNC#[-"U<--+NHP"#=XW%$419-3;B$#-@Q8QA&D2,PV6BSU-L
M-%2PU2!<'B3E07#1K.!69'*T6,]FO)JI%>U#S#N&A>E\!$B/W5A3!R5@T5-X
M:J*/L6CS$;\>-0M2\705_(^W(-3J6MA6="_#KDF(8ME6>;Y(_\R8OFG,%=$W
M5&#:L+M:;!H_FG),D20:E?8$2+P1_7_YJ(3Q3!;5M#_44LASZWF6*,_T::I>
M9$Y06#O&J\I,+8<C'(L1&?0P/6.&KA:=(.O$N:XIT77:#-U%<.#/B81M"]DG
M![XT/SK-C]["_.BTV_B6U-X4TMJ;A.GW/!$]^2GH',Z+<#P$L&G>8'NJ&T=O
M52'Z#BB=BO>2FR]'5<BEM*I@E6.K*+^=)"BOHI6-SV,F5TV.-0FE8\Q8$=&B
M6$Z(FASCLKOS1;7Z#+2*5<K0H H'F3Z-4TQ]5;C,<_M%<T+'Q7[+0X]Z3XE^
M0%>BY;D5*%5%:%;L#J2O*I3?W6FIQM'"--549F>*JARQ!3!?FQ=:1TI7(T9"
M7"8S'1AE*^NCN/296T?=L2-69IG,'NFC:N%Q$QBOI,J2XX]%ZZTUG4U+E9-=
M766O:?H[S5!5M4:J;)YGXDOC>Q2#6]VJT5)<(OS $N.DJ/0!C7)B#>%H)#4.
M@.@GG% @)EU/;"..PKR8#'FMZB1::L+;S,L!,C1+C30#K6I!5V$91V\,WJ5&
M*HA0)\QP(A\G,#H?:>OQQL-JWZ2%3@[WTFLWQ( D*XA^2M-YM"XI;;F6:@\P
M;I9JK0_(+-TW#H<>'FN?CTRE['UX'W4<%_8I5X U@,-I.F/#<6]L/E^T)PCM
MALY.[ <K@>!5:D<*V+"<!=U)= %Q\#N_B=B10"@OOL@59YJ%P_%"$P?"[L.J
M\? TS;YE^?QL5%?W,9N EX1H]UZ,D^(*_L3HA#%BD4.&IZX?&CL1="(+X%8A
M-4BC\@]T* /?N[*P%!]1X%&W*949$KEJKC=C8)^\+/)=$;>:&6T=TG9]60F%
M#-,A[UUG;$23[,,ANE2']"WF?&CCOWB!SFB JK-HS($6D3Q01Q6DT<57LBHR
M]TLTHA!T([D-'_.D]XKKV1QO8C37F/?0H>D7;2:^"!L+L!P(!02YR\CWK%H<
M\&:XH=HB"&N:5SE10C_I'I S6>C*>U+)*2Z2/(?<C!?,PW9^#)VVXBB\4P5<
M(FX >NC;[$;['',1#E_ *KD>3C >$^5=SOAV=Z;[W69-C10#::<53>T;U.60
M!S]% PO:8,R@,QN @%5M;!(G>C134^E(BZNP>8OT(? \#LE%K6@C.=[:@SNN
M9>>:L+&TJ+G4*WEI7C5R-J&Y=^F-2F3Q=C1D >BR72'KP19=HK5=9 :%QQ![
MXB_<F0\:CNLY;.2+_GE&EXE^>**?3@0 DY91W;_P;(7[2K3:D:JIJJ\+Y1$V
MU$')[H9EH+YJ.!)AC9RLPG&Z6ONEF,9+8;-*;!9.G)<0!EH-UK2"9),EL#TY
MWY5<5C^I:U3\+="T Q^NG:4&,?E<OQ8!D<E&/WQ[^EV@-N&W4FFA/N>\ Q4B
M#CFOV@@\?$7C^;R0<*+Z@GJ!R'_63R&</83MCUSJV*GY-U&P.Z(-+LF *=7'
MVE90N'?ZMD/N-*Y;AQ+&Y)6LY!W4'(-<*Y"*M=/EY956+]*&26DB-.O5[8,2
MC):":MQ$:)N8Y@[\2,@LQ%],+@1 "DO1"IRUX/2)H:6'D[3=:;Y[J1 I=6BZ
M/>)9Y.4,JZJ[$<N!]/G'Q@-"SS_H0IKK/R9.D(8#5M%W(CHZ777&H@L?DK P
MDF)Z?@D[:L@F]94XK5L2!,WAXD$FSHLCK264H $5% S/+?#1)!WGU)..$+Y(
M4SIC.3WI>&^[QS>E,Y;3DPX+R!=O2F<LH2<=[ZX7$*H6:TIG)*XGW>_LZ\0.
M*G&CZR/27S>+-=HWPR&0K=$$LQWKGQ$F'%D^JIQ"(9;/P,66[7?4+37U.XI#
M.7$8(37@!Q9L\P8],L-$)D*&@4>ZC;P'GPX*3J\GG9>[O,2>^;V>LL]]X[U[
MRRAW@FN"HK&HS*0)/4W:0J1&M!AS#(I+\2BU*T*>O5Z8)2+U9BY$IB\0T[]3
M!9SGP1;W3X@W2W[649ZR2-M(]6BH%EU1/QKN$Y?>V @T?!!"S*V.ZLC:'=>!
M4\U-[%]#AN;5(8T;M%!1YPJD,@Q#&T V=!E/IB(_A-Y%= 8!2^LJKH^IWIB'
MG]N8TU%V3\46+\!5A>E%I"!:S0 -?F&B+:6Z9K +[R;LI')%27E"Z=7O$ TT
MG?<VXAV4;G6RX:Y'/G5&@?T,/4W]@?519Q>CQN53-(,)#0K/=>"&R2\I$"(R
M+U20_)$?,#336QC<H!F[RN"3[7I]%L+0![D-!H+FSY0]>7A#:V<49W]P"R>6
MJ)DGD[1ZUBT7UJ$[=PI)BN8L&LUKP]GD;#6/-_QQ972.W&SZ7#5]EBW?:B3$
M$:LD,&V ?20'R>M/#84D6-:E^0U;DM]03/,;DI;?D-A+S1786@\#UE?7RL2F
M&+1*2]8'^45=,UJ0DQL=VI-B9$W45E.SU<?&4LH&8K%)%%'^V6*A)62.F4&\
M/L;1XBW)U\JWRX:H3W8<GQ@'-Q98G\#GOB$)SG@TO=DT\0XU 6KS)AR)3*0Y
M1N)JPD]L10+U.-=<4* :KD0N6*2>QP8U=G<B33*N97B2YFL0L8K$4\TYH(T)
M4>O&MMU ]0I. H/^2-9_4?-P ;LTZ-58;,U;*AS@$6O>C *F0,)\43@YWJ1,
MY1=,KL:=JJ*^H.\Z Y#9 , [2H3%T("8YBM>$.8MJ"N+&22X%.;$AD'T/F.!
MU -]M+I0A06(A]054/C$>8M%37V7J:$.G%\/V /HK:T;;$7)G;2WH'SBM',P
M_=J>/9 .<L=U]AAYD6ALD 2>SWMS8G;K^RCQ=2>XW(10]#1?#\:%R6DOX[;H
M^04]6'JT-:SCGZ\93:90E0NA]JA<Y)^:9Q>G)D^PZ)"3VO9[S*(#P",209X.
M)1*3SBS7XP4:T@^D)IF+*Z*V)9+6=*Q/'L*$%RFYG"GI/LTC.7>;9G]2^I\'
MUK$<8JCX%M;JN#_'4XS$((*6AVPSP+\-?9Y#"!<Y; W*R48&QH @X4:@&47Y
M.[P-J CDQQ:(^1/=<,>X>MS@:,Q$&#I=Z\;U^)2#2#:"# .*I +*)" [BF?4
MJ!:Z$7L*>R*&:?>R+"K,4P?C4UT4--F H_ VIB1=3G7G?#OJG)?-3\-O(0]%
MR=!Q&1_$Y'8!2U1EJU9^*%>( G !,@?98-7B_&:B/['M\_<+7S"U*M =IF.N
M%PH=@H(?2:TZI8Q1%4*/Q@%MC<R,Z52&%$+=7@$*8*!4NF!WM;"V28_P@!<O
M&@L#F#RX*CPOO.AK;'YSZ*Y2'KXQ!S3O0*O%"7=W@#6Y;=M2/#0^!/A@N&XB
M!LC;)B.OCUP($744V9M "FC= 57BJX6W4?TYG.PAACV;"J/:.V=5YYE<^0VX
M4N1&<F=D&3=VHY$-C?F&66^ E-A:2#W1&]6J!,T$<_#MTH0YM'(8333+4RA7
M4@^2&<"17@+20R>8:[1OXZ3.O"T'LBWH^\*%\%AO\6F8Y(W104MC8S$++0(1
M6CU1L2TSJ(DS,S\0Y6>P_*UR7(:MYM4$OO&8YDR3"JNY: E.8#SFN2=_W3<B
M'O9;1F6QDULG2"-$JNK&>,T8L35TUL+W>&=SO8U[=THX1\$.ZL6UR\<F"!./
M4HS#^K@I#0CWC6,M;2=6MZ&LT#!_DXD<,!$RF;R.^BX5(8S3@TRTBK3\H ?G
MQ]R#MK#(;)B@19+.=#IB)'#885RFRVE3 T1>&3ZF<JM47IEPTE"(!+,?2'&9
M-M- 9*_S&)<^FDH_!5,56N+"8N#KU,)BM&3'YV3$8'EWIR'4D(F\V;&#$'B.
M',:$MO"0[D*9@5H%(CD4'M)AGMS*?7:!]Y2>[6DRT5)EU&E+!,YXV$^/I(4B
M69]&S^-*OK #P/:A"AM24N44#%*NP1JW0'/NN.TAD1 0'ICM/BF\788N@%&4
MM!#?H9-#S-88FU-',^"YV86-QVPYMB,>5&7O>#BNCG,IAI,H:/X#>3O0,@FW
M(:+QHK98@R95.9:=U@W_N!V[C1HCY1\1%749S\YUV"TF*3*.7F>()@QE^"*N
M)95Q?A2A#7H&K;M0D43OG6ZBJW*%SA#=;E3J-;#LCK0PN=- 7V<6]:FD(<$'
MHWE#R&Y#3]Z5;#O!V^UU*9N(XLRA1RP69 JE$T<546?*/T&W(]EU#.BY(WP*
MF.?,J5<>'A]I0TP;M2();]?V^KRXW,.,/L&0Y5_1+^JSWN0;Q:G1M?FTW]P?
M/P_N;YL\0_5\S&$"XY&G*1TDXXS%,IQAO\4;B<0Q%Y#P4YB*X<-U[UF>WO:%
M^PFU4P<(PN.6'9WIU,7!>0PT/](4>M8MG9UNI, 7NHPX&QC+>#K25.43P4R1
M!X3R= 0R7LP:PLHAE(HBOPTCL+)$K#T47BRY'4JS1^<0;1)]7R.Q=I]9O)&-
MU6Z[7B<\,DH-X;NBVH=A#[&C$GIX&C0I%G; LXUYC1L/+T79(L$5JA!6"S;D
MRKFA!@<]ZMB-=8^96OJSR* 2;65X8GJ @V)<7Z];$FXNX<=77N(?@$$?_;#D
MXI45@S@$BXH&(RD%X9PD+8^%.Q_PG:)DCZ<,8B_NMNT!4:&.U(ZD1LRMS6R=
M2I+F+20N;Z&4YBVD>0L+.=_&$O;TW-:9LR6#:PJG8*T^LL5;U^MM0_;^=FF]
MAQ1E,;40I<C3".UY%6!RIK@&2 +W>CQV[5'Y:@SJPD(,V8&)UW6%Z2)A\<9,
MND =5D2PQ'+3\^2%^D+Y\6&S!BHEXPVC(_'XW1W^M9A@".;+4!R<1VT]AK5Z
M(02B:8.D[=ETK06.Q(@/RP<UJH-J.3\#"B'S->,2!O:-NJPN#U";B\^,E;U,
MHOY.<A(.R*G2EB9U&&$DA2N*RZF'2UXFWIA =,GBG>A<+XA4+E*$/*RIT,*9
MMB,446GI1+ 0^N9TY8HV'RUA&(K<8A7AL3E-1KZ&5=\>4UWTPN9ERC>HV>GD
M;))9TU3HBOZUZ !(->0>"!AGW,<5;5+3+L]#4&GD8@2$B55YZJZ(\?=)";=Y
MT!/HP\=TX"OJ"T9.NUBRX$GVVLF/HMFNVOWUQ[P44URA$[Y'G=)4>28U#QAV
MNS85!D2)C_6E8YJPYEQMG38Z!I\-AJ+=-EHN<+/'P)K-P;,9(T]*R21\#F:9
M].83,?1MN_._%X#]?K85Z@*\&N^B\7%W)_MVW_AT<MYHGAY_;AP8S8O:X:%1
M/_WXL7%RT5R%8$J06U),AE\8HA/7>3"9)FEDD(NE@MR^<79^>M8XOSAJ_"98
M7WXD4C:[O.49CV"+Z"&B+RQLHB2=:R[R0N:K-K.\^(\^Q%24,O#BPYZ+U0[%
M++S #XQBSD$^[C&<JHO0?'.]G_#3-U"+/C5KE)HRY.V:Q(MXJDF/<G9$W,1C
M?%COG8V> 5"N_LAES$PF8PS0,0-[OB9P94M=<K )2'E$1_2EH(8&HJ*&9"$/
M=K!H9:WCWG)YQ$9J)O%0)"EIT@ M9R92.DASI&55](0@XN4BH'V&#;MXPJFJ
MD=FVZYB/O8[Y?>.X\:YVC)>RWF@<')V\>^ZW,O8ZOC%:5OOG%25YH@/%]5[C
M10G8D^XIUJ3RU-/0,S805LQ$"K*IT@$LZJ-E.]1KR$43B$53=MM4_:1&6VM1
M0GTVW^Y.G7ISC62T& .;=L>F0BF?$II%HW#%%<)J.MO3NA+Z,L=!-NKB6=B1
M%#'E& T+M;"9M,>H M,4]YKG/5CP<\]6.COG85>VSZLAJ8F7P_"Z4EC ;?^\
MAEL$1X/_\)BU)XRFXDL99/>O 2B?2I_#_G,R6P]>>8TY#R$:5'J%]%2*HYPX
M*A'5]]4W5J\N+I\8MXQ7%<9XU>X.<BNCL&]\/#II&,W:8>/BFW%PU*P?GS8_
MG?\NBL03U,<P@!.7EIVZMQ/GWBZG[NTX]_:C611>XRE7<*%W+<A_%7M#>11:
M1F>U\PM@;D<KY\_SVR +,^UB/-,N M.NG7]H7!B'I^?&>>/=4?/BO'9R(>1J
MDUP IR=&X[]/1Q??3'CBN'9!_H'3^H?WI\<'C7-XP<5%X[QIU$X.C*-F\Q-\
M=/;IO/Z^UFPTC=-#\5VCV:A_.C]:LF$9*Y\%X=,5(RD^=A/PX-6'R%*>1#QT
MG!\I"HO^4%7^LPJI1P3#P5]ZXV1>#<8U.M33?@W=@+</16OTI-8\J/T')B?^
ME>_6.#ZN&Z]HAE3F#?\[_9)]\Z<V5<4?]>%F&.*QVN>OQ_OBJ6>$_O>D ?N4
M#%/GY\A/:A5$L!+'18T#?\#:C!)5<A73R&5R&9EI0?T:HMZ"8M[@FC\Y+L"4
M  V ? $1$":5Y2]<62Z5S&HI9U:+97$XNSO<2@@;26@$><N[WE%+:^Z*#C#%
MH;,D#W%2".G 1K\(U6&ND'2>9#:K@ AEG8F4H&MLQ<DAEY&_"/H09;)!AVK7
MQ?-D1C(=.O(&8ATQY !$@B\4W:FDUP>TVC99PI1/1KXU9GD.-]QM:D]B4KKD
MD ?QHCXEF=\TUO!8+JSR8@SBD]TA-4"6T,K%55J>+,T3 V,P28XB._AOBX\(
M:+D67!7J&2DL\/VEF25)H>1SUJ:85-/J<1Q^<C0O0I/WE<$PU]:PR*9-&;9(
M)2VLLW;$\'(^9,S'9CPCH#H#N];@#@<!9Z7YC&2E>CC11W41R9[Z^XYDIQT>
M#Z>>ZJ*67CLUDJH< NT :VTBU6PUGQ_[*H;5,'V1JAPQ["A[G/\:@J++//4Y
MWKA#4%S@'/;^X[40V&9'7*_H,[L[E;T/SXGGGK/!T&M?6]08%PZRP1&BG3!<
M6V0WTF&'[*(FG60=XTQ\V_.3R+*W,3A5BO6&E\"$.&[4T?PX/#JIG=2/:L?&
M0>VB]HAC_RN;+;Y,D)/I<?"DGJ;?SM-423U-<9ZFI'&L<BS'*AL?:R>U=PU,
MHE >%72,?VHVCTY/R&,"#QQ_:QZ1IR1D:_73DX.C"_G,>:/YZ?B"'L'@? W_
M\,R=Z@N#<H$-,<)&*=A.<DBU#6!.A.54EFS.SN<MJ%F'V')@V*$L*2QZ11[&
M2ZU4?9_JUR+'-%%%/MK(.&R!#U4! .;2!\6@%VS@Z#.>[D5F"!@R-<?!;,#S
M"?7L6:E>A_)8=W?>P[(]RAE; 66+:[_D_*\#T:]'(%OI^)3"J,]JH483F ,A
MC$RK<X/5&=+(E/TJ (*A:D8ZHT&$WC])=K;H[.XPQP.RURW7,U1+C5SKK[Q1
MZ]U?,X#>4Q%3N!E\% PO"<$VHG=P#'*:!E%A$$9CY40MS" 5Y2[B29$FZ';W
MX/\!'IP(O+LCU@99YOVTX28Y$PMWZ !LBZ\2-NGHC)^/Q>=7[Z$E1-W_Q;MA
M6^KH1"^/\ 8&.--!ON&<!:"1C)P.6.0L>GSZ3A W$FZJ]IIZ-LRH?0;-\UP]
MCJ@;C9\43\_E'>W[?:9M"3]K?*TWCH\;)_6&MJ$!ZX!5X8%LB\#,W[]O4#-U
M0R,XX];R>0V0:AOD#@.2VS39H'[Z^>A@+UN5??>P$8_K69X-MI\//!*^UJ%,
M)<S,Y-:.K/028(:YO2J)@-?3\>8J?.81GVU#-7UF; \6X4 4R<:J'TL/!SWU
M9!-WSQL. CDW(UI!UW-QQT !PY[FM"'?BRJBO67QJU!.DL?:'MAU]*#?]K#!
MLP,7>P!OX\P<CE&4R8>-<%U)BK(=+K^@X]--;D,$<W1W;8_WAK@>PE'*RY -
MR943%ISPE&N>WRMG99U?!-MX%EVW/51.L@B='WJP95?@N&<<B!NVN_/J\.+@
M3ZWD3]T]V^EHE:78XM;IL\# KLBX*$XS6V9*Q6H8,3JO+5&<9^K./3@],46(
M,U7]*.7H>*J<_2.?W<\:?>R)3_7=Z+G[(U<-/T-DJF_C=:("2#%\'B]:U#=>
MVJ^^Y+6DZB%,?0D [RU1B8G$I;V#YF)/F<>E]@ H_B.W7]6!HKU@'? ?N>)^
M+MP"K\'50,KF]_,ODX_+:4)59/MUX "R^WEU C3A2J2FZU-<:/"A&(_X1[:R
M7U3?&+]5V:IP)J,76_9NQDB>3AY "NIL,25S4IOC+]&<RL2*N-Y(7(%J7'CK
M(-\?$E/!"A'EX];]Y;L[80 -(50^)J,FNZ6'4R*XAU7](?DH_L);+'()$%"#
M]?&K$.G3%7L=^)PIXMNW2J.B[\UJK16*)<'*=66 NQYDY0_A@NMC>%71H)"-
M[S38KRSBISW7N4)\,5#2P6*P3)$4J]XKYA:!]=#M\H9YLC\)%[+C*F#8094H
M 0SOL"&]OCZ(-6;3#+4!60JJE5YMB,U04(1J->O$!$5-.P[ATJ61#Y:1T"C%
MO%J4!X +]2:"@.(<.@0!BO! FP(9]E<3K="T,70ZHG9W!O: ]3!_4LV,7%X<
M9+4DC.U::\,K>$O(H7#\PY NNQ7I!]/OVUQ @W[6O+9^,N,H,#X-PG,%VP[V
MSM-'7S6//M4._R1$3:K.Y_)HD>$3WQL.\'2+F9>ANB:&I5F.3@,1 AMI,V!G
M7A>A32N5O>]VX-3$4#NN=I#+?*J2SV5@[&G<AB.:J%Z,\\<!=3AD7)7D#?6D
M<SXV+FP! +E,N/VN9:LQMF(X%->3Y&L,ZL=+ZJ*(V'%BOL*UA@-7CIS3[0(Y
MSV-,?0-YP  *!^,&U/M2S-,)Q(!H:O\2_8Y,T46M'4.A(*3" OR'/0X2'W%^
MA=T=*8JH@9CL=Z#(0AT\L0@BL^2+BA-,JJ&>"N/J&Y[@'[E2J J0RO-'9K]0
MI/H%$JPF'D5$%8C[1K$0?F-,STO^":4M$;;$DU]-/?E+R1E=S34ZYZW:2)J=
M*B5^OKCIYJ&G*/8- XV,.T\W#_4C(BEH#E@>B\O H:Y3>O)00'D]K".J4FC+
MON';4O>WR?M(775 5Q65>-@ML&UCX;+,"HI\'8TM,"[EM%@0Z7"=;/]:M(C7
MG%!R:!>F 0B[0$"+!N>>^EFTD03IT^;]H%RED^@UU7.&Y1.#J+];_WR# T1/
M<WQ$(R)J9\0^LM4Y_/M)NERGTIVTN],0OI@Y+MKF0;]P [1UIWC#IFF2(3[)
MAS'F&XNJ4[-<9-Q9#(H:^L%U;]E$V>E^1KV$M-/(:P!2<J<E_K2E=<;=_K$.
MO DME@XXZKF;4%ESFK]KA@\RXAHTJ1%NG >0+#+RN_N!:'XOJ(&&E(3>2M$J
M+S8L8QI:M"DN/L([X0.;51;AN+>!..K,*%=<X&3\+3-"9>A#YZ@@X#JZ,38F
M9,@GDWP"B_&-DD !VY7JR+G/*3([7%$>I[2BYCP>I[/2?F6ZMQN'4X3.;C":
M0DI#F[W/(TIJ H2KGN]P0WW/'8B6IGT$B#L[P"#WKH1;.QOR@.0C D6"'')%
M\S&V0QK@M72P6: :6B];N(CQ,G/)!#2\"QJM3/ KC<8B_ [,Z=V=@XF@%CG/
M>/D NO<+^P6=#*=Z@5'5<XC&.?BZ)W?, :J_8W<G_B5M'(P3J.M#^;:ZTUY[
MW85U9YQ2P;0ILD@<IB61Z+>3 >8HE*C[K#E3THXEZM'&,Y/%VM1P%3UIZ ^B
MK7E#:IZ$6% =B;2&H#)G%W%(C:DX:FQ?M*^<(J#&#W,<<<+=HH519FT<=Q2W
M\16EKFS.NZ33O67@U9+]/\<UG*EN)U'U,G%3Q%&%5O96Y_H<VV (=6@N+9)>
MW1J@>H_^;)!?;:H"V%P]8&:9._WBHBL<A+388]S&0B>9[A0;=YI%5T=/7!UV
MUO)LTWC/>C<,W5ZP,JA=>V+WPG%419]99$?YC(9.<0[\LZDNN!?_(*"SW&PO
MI,MGPG-5RKY<J9,SZ$PN/>:^;(V[+Z5#,8&083W<'O6]07/\UK,&(;B5:2[(
MA0D4^5N$*)=XFD^$;G5H3@Y@JT#HF#]%.H8?NL!QG4R\J]:K7*9@YO(5,U<L
M_AESR9<Z@E2H*S7?Q_DJ,T]XF>O^,0=&!2^6_#*;VZ^,EY0)C_R"0.0+9K&0
M,[/5\MS[?MJ"?ZQIG<<?;F6_6ESNX>:*9CY7-?/E_%+NA2A:7LME.+;YV#L:
MI$?K/87Q)$S:K?Q6E<U\IFB6<I6EG=K*+\-6 ;/RFULT,_FJ62H7ME&@"?5?
M6C@)N[^S!<#&KVZN#&@JF<52-2'7Y6GG]7M=VUS&S%7@WE:K<?=6Y"@DT2U:
MPRX%TZKU.V.YO^CVLGSNC:0?L'S_QNKQ:8'C 9ERZ-162>6Y2";QY-*8CWQ!
M&6382G) "94/!FG0]43@B'S0CHRC41(9!KS#^@Z*%%7V"[L[D9C;>&:R3+,3
MG1O=;A=4=,QAI'54.C8FZX9)S_1N+3\[^:Y\S#Z@CB2=\=1>V2B^+9Q5GG)6
M:74A>JW+'#$I'MBR^&)P;%UJJ' +0B,Z!'/@L8'R"HJ&(Y.=26+R9Q-_WFF^
MVG;DJQ4R:;Y:@O/5ZL"$=W<.>^[M1)+:BKW+G,17XC<NEE].*"K%_0(B6G[*
M_=GBPS6;MO( JHM#^305:U[OK;R06W&:E8V>YJ3K="M.<Y7F\(8VR3D:PM)%
MKH;JEZY=1G38Q[@6UT-,?W P7N6R8 65S4RA].<J@%S#O=SH\64K9C%7-K/9
M\I8<W](=R@FY?6)"!S45B+,BDT="N8J9+V;,0KZP'923C%/+ELUR)6=F,[-=
M;HDYM6<H^(Z$.T>P0)DX^:?T-26/:$3T=-K_@O@KY<U\978$)C$DE< S?54N
M%,U,IK)E0G"JDS=)M1Q<TG5Y.?\L%7,[,GH]X!N8K3C60($[:6?L3Q0,5*;V
MQ<AEI'-Y_-71*NCPE3B2U>?C?_B$K@[SVY[=PM*!EGLS;QO2S1]KE$H>5H6V
M@%+X?A[:2FP>K);4'Q-BF-+0)-J_9'=GLH')M/XE5  32T0M!NC8-Z9DD*OF
M\(9U!>^ZH@%T7:.J!SH$<+A+T Y\7\[(4D$1=1TFEZ&*IJG+E/;+QN0JNSLQ
MRV3+VC(/$$Y"O(U_MV2]PZ&D&G\K6O0!X)+R=G<4B<T%^GYQ?N W,5CV4>TT
MESPOQ-G=^7?H,*-LAA>#8@U,S&>V8CH6&:_PMHM!(%.Z&JD!(E10<(S%"#V'
MVHNHG/%#8"T@:?3A(_IS\@W$1JP^+V.!2_GO$"O@9&QW,/20907A2+[(6KQ;
MAF!ZJG,([[7R1Y&&9.)_J5I\O"4)C=L.V_?01G#C[(X&IH<=!*<< 6_J%>4V
M^5P!].G\K(D("%ID#]0$I,MX#-$.?+T%B+ZK&4,W'FQ"Q0MJX V]'@=5G%&V
MA&F-6?EN8'^&1UV1;J^9F.+=C4*KNKR8V%X+(<'.K1X+9ZIKYZZQWG!3^[L[
M%WJ?%[$V=<3'*=0MQGONZZB?M37].ZV1:/T4/>%Q0$%A\,9'/O#:<HWZ<ML^
MT7J#\&&P'O'"YV9$L*'H!A#&(L1#'1_YA$S2860S']?A;;E\,^:6YP2EC?=G
MD[?-Y<-]U73;#D#URI+<[9SZ5'J*K"13XID=8?F=98P_*<DN;#_'+Z& >G>G
M;7OM81]GWV F@@"V& %6:7E$^^/,D1?C*@;GMGIR="DRBG%X_/&=[N[@5OF5
MIWX,=ZC9@/(D+R=5G1'#HY'NM]J5I 9-H-3)$Z"F:JA(8JGRY%&(E:] V72B
MZXLVNR/>#RV&&B(8U?JO\86I:YS5;K,>S2GNJ&9MXBG%C$0FCGS1P+-Q LC4
MMGVZJLSW2ID;V*B+:O9$PZD6X57V[T2.B(,Z+)L*^T2?"%J*%O"Q*ZE8#]#)
MF]LB9\&_D>H,FPF59-%%8PI72WG/TM/$QBO]"M&."#/$J\?ZO'[30N13U!YO
M@B(WD#HZ3<_1%'+KT)OF_20N[R>;YOW$Y?ULU"!<U229I1O;8/H$V!<$^]&+
M.4JGW2XC3\J8GV?9PRN6;^)^M#2+<<+"=8R:L"Y1>SAGU*:QPZEM;*L1RW?L
M;U&+MPZ&B4MNEN#^"GMZ=(S_:_6!4]3=?5JG^?FM<<SP0'_R^9LQ;\9<Y- ,
MGC1UA>[D(F*X=@QL+Q14T5&@?&Y>:'!QAQ8J'A&OUH1M'#/]3F^GH,-*F]C=
MD2-"@SWX=4_,&)74HS3HI*L)28?OTP"-F [K@5;MC;@1$C9;!8T>],Y00^4]
MU?S &[;#KON:,44:+//Z_ ^A225]'!.^7?4ANN,(^4B*40*,:DF@!?59<.UV
M4,N%MY!VW:*.T8)BN%:L.JQ%*89:=#CL"C;&57//<GR+[V9WAWP#NL*M:>+B
MM;JN35W5U;.:MD]*^C0MGAH^M$9DS/"&*WQ#NSL#'!5)9AC\N6?=ZCU,IL!L
MZL?/N\G9V##$P_>05>NC(DC-HL480&'B<4C[V( 8(?$Y%N)<]N,=Q?%EKC=Y
M;PEU0Q\;?-#?:? E,@EJF!)[CWF+74%FV,68)E;0H6"[Z)$YVU07UY_,L@@H
M9%MA+UVT[/A'+LTPQ/Y1'O;1I?9$6$A!FA_K EO#?H] ZK9/QX9=7]!@%0X[
MVY.]\>#X>1]OI'U:=. A-I &R')4$]4,$@+T89=UJ"<38=4;PK<XZ/@W;8Q%
M.")$>P9P<F+Y'>O7UNGSR8%/C:JUD(RY(]<:3=(P>4)H0)1JB@>8]YEW(PWP
M_'[87GHLG*,B8)PY")XGO#!"[E*K][A;)4CYBQ@*2JX,#5CNQ)D$F.BS#:<#
MN_9PY$R']?FD(7+B"#[,!TV03Y+4<9Q9$C>V@&J60H?4'P6]QT^,@3J=222=
M()82\$E$,YV_,=X\YXRL;=H4R(B]MU;/HC&[S6L&8J/F@>B[XMW/5S'QCF*.
M?"LK83Z.B_K(7HOO"B0M;LK2-L5]M/0LZA8>"X44: 3V3_0I 3?@'$)U]PJK
MPD".L;"#?#><IZ9DIHEM]AQLLT=-_<)._.KOJH\NO%;V"S1%_WCNN=(&J_1D
M)R=3%<9%NI>YJF .F^*KBCG<)>X.W624-B*T%]+QQ!CY=!YI\KU#N=0[]'3O
MT"IR'<2[R%3 JM+7H&G#M6U;6)(%_+7&E52N$L"=KN-L:\QLJ;5IPALJN&=B
MG-I6I':<X@29J7,YK;;H/TNF% WI1/8CZFKY&/0VMIP,NWN++JK <#$T1(/H
MK/!L1#EVCZDICI\<G!,*D@I7!OWJC-[-<X9BH/(8]0+WQ=@?&8<G>XS!42!G
M%+#[_K _X'8T9YR<R9.5(.>XBT@6X=*B[DG(FU7C&,7597=>XNH4S_)GK8>'
MQ)?C1FD(K(H=6B$E\<EGVB$) B*+L<5Z-L# MT!Z(T8M57].;GC1#%6+1)E0
MGZ?#9CLW;N]&#";B 38YYQ4S#P< M JTQ*( #3U)]MR%%P5KQG>37UB-.D?+
M$C7K$90B :A#!:1=@Z7K>G0*2!B>32P\' X8$=JW&B)=,3Q7&M&:AP3,BW8P
M%$*?] 9T#MR@A4)&$@(5 B%;2X>*222L;1(A 9[@IZN>VT) 05]Q^_P3T>U8
MQ=XUMQ/EH_!==,%$=T&IH+EL^C16C<!(W8J$;'%FD"1MXY8T-<%1> /C+2 $
MD11,-WGR:DY@%9_3CT<-,&+H2%)G,?5BD"^F[_J!_A9B2WQF9AP,_-!]N9;V
M")K@#P]_\P5WX*VEN;=2[RR]NR,>VZ:4XVC[^ -MSRN:.?";>82FM^?G,]/P
M(@BR0;F#KE@TMSI*:"K*\WC'#<\F+_G8W#7\I3[6^QZG@0&;#9 =3F_"+'R2
MNA,8;N'X:$!SO-^(B4)ZB.R.9RP3)*;!^H.>.V+DF[)H?B^NUP+FV;4#P2F%
MAWWB_LB]\J',Z.P,/6(A<#@HT7/TB7]3+ZL\2^$_TBW@W1TASFVO0SY@!-47
MHWC5\FH)U[NR'/N>FZ,J [1^?JJ%O. LA!HD#P/;:%_CU'>!:B7K!/M7# /X
MV4<YU@T=AGWAZ.XP.5Y9X);S+AWF"/U0HB-Y!D$M0:883HL#8QYG+6(B9/L:
M67!G'V.-$RB<2I!QRJNFQ3=1G;$ L#I.ZY.:FCRI6K.N0HYE] ).93N40<MY
MN+3:?3F'!VPO,>GZ1J4Y\7XY@8]>2WX/;,_@K740\0\SXY1W3>]4[CH>PSPR
MU+L 4Z+[D")0JFAP,4;F:LYK+NI%UAD5 [E(\7@%1=:=0-W4"ZR5AEC4@ZC+
MD (YK8 ) I2/3:#P>G&M <!U1>(A^<L))OY5BCBRCBE#25+S4N"2@<9[(N%C
M6B (?=1@X_B^Z'Z$6F8;%^7VSH@K(?)FHDGEZRIO5UPH_0+Q@8U\@K!B9,A&
M>,)HR'7M0##WR")X E9O=$^GS/CX><9;OT^PYY!C]O!HZ2$Q=UP;HV*2?2,"
MBZ+"1CGS+;+'^"Z0M0"_$IJJL*: 0?T:6FTUM5VX]$/V(:-,XM#)$+8[W'24
M%K.'N>;2B(1#;6IJX8]AYTJ9U["\.MT^#D&58SSQ1;+JK,-X0%"!*!:0SE#-
M,"6.YHPBNB)14A2Q8-+:[%9 P%_G(\ZB2N%8?1H?>*J>4*%M:KJER,W@<;F>
M34FUKA,EG^#:]:6(#Z-]*K+#QY3QP+4V-M3B:Z-IQ'>.H(:L7:-OW!@/05E"
M]HE68HJNJ#>9?/D^,&WQ!:[G\T$J'4[+ZD2U"PF_\=P//B.U+1W/F%MKH!XC
M57$)"6"4YD#\=-Q;'*:&,@8 &<C(;#A'6=T/'MP/;02>%Q#: 3)2-+%[&>F6
MX:O0:E3B7[1FPY_WC3/)]4B9H!"RS]3??9E"/730 R)8&H]1.](J5 H&)TP2
MPVK$D(@Z4_ZRV!4\CMW9ND-4=@"9HHXBO,A8_#@Y.!9]-7HZQ!AI(J^V02^P
M/#W$323OTND@=F2O-[2=1NC"X%.?0?KKZA4?J!SK]5 4;Y&%'O+;")L1RJ=P
MYJ/66^.G9"J2HAN'5*E7!.I\$J,.DKH11. >]W3AM6P2>:_DD708TL7DY0DS
MR#$J0:B0NE28Y:R4J^A<[Q&)&$^$.3C5K,]L/W)4+CFOX4&I$\&5N$AD).-8
M0NEBP$0#AJDC,O'<<UN"&8M,<"1">K3'G"N<2-A5*59";//L+9[RH+OJ0AJ4
MO0+'\WCH-O7(81H/%/6;M''P#0X6IB4YA^>\W!G"LN[01W[R4R0VX#QLNDVD
M0K [VQ<)%AHOD2ZDWBB&!'1E!(X#X?7E$&6;9BBCJ\LC@1+9'5#"8[='FA)#
M5::EWW@.ESA2)&BL#94,TV=\N\;$;H$AW"K]G?-B6C:ZJI3I?-3Z/(.\;&>6
MDS+Y;HYFZ+/9W:EK1N=6U%'3L%*NI?#$2$Q<T[Q02B,G%-Z"&:8G5M%T<AI+
M+A[GB6"I8;0T?/ D'8OKD#*W+2RI<#6?N/+NHM8DG"78=DSJJR&R!)I0\_88
M)O)AKAG'+::PA5^6MI::9@8JEO8:4?+3T<0?P<JYO?Y@EQ/6',!;Z.M5:KXT
MQ&Q/23X4^3<H=95231:8,MGPNV1="%V8&Y9<;21OK-/CC@^AS!!P?//RJZ0(
MXQJF%,QMBW= 5DX/0>\"$),+ 4S/\U 2N#S^HKI,4(/=L!P+#)4]ZFE!>07I
M;5D8/DI-V]V935&BYA@5<]?9"XF;TC< /4./$W8P0;-$3CSKGR<-R[ ;OG#?
MJ,=YZ(G&YB'T:6#9?GC=%%$+'3>&IC%.:V.*O4A L3IB,B7 7VM^,D[<?:RN
MJNQERF8$XCT27)&/C%<7[@#D:CE;^?.U<=3'G#V9UN/"FQSE@Z6#WWM+=T"8
M+[L[FL\.WG4*A@EFYF5E37WL*6A*C;S4--F3;PY58,ISW5.(XO7'7#4:8N('
MI=GJ!\/[QPC5BW'W!UK;/#J'7_48VH^6KROUZJBCO$7Y'Y!#\$IOH:I;??01
M. ZZ?WVL_Q;]U?%V@]**G460:-!)2VKQB)=,HI+K":XL:(NS$HW"P%;I!@*<
MF?B\510LWK77[H'^2#:%&,07E>.2TT6(+Z0]P=")B1-;-['._9I H;F3?#7E
M 1$R0ZN#B.!!4W])1E@\']T&I9JP2@D$J;;PA"XX$0[$56_B/W$:'$\*045=
MR:UQRY92S%%%QYRF/6K%3FD-*8J>I- -A<%$V7M[S?:UBVDWXEZ'$?J^VV$]
MWI:HU\:$>A8CD^;2H0)=+^..'*&8G?)%L9"#ZCIP297+PYL?.8,A>8*N@0AZ
M(\FAT6;3LC#&I].&6A>6B!@W+GJCR>L*1E&8%B%<9UHV1QL.589C,%4I3 W2
M]JV<E\G/5CA$66Q1PX:A+P>(HV>*H@]:^I7KN$,Q"-R7[FP;_6+P+5'1H67"
MBBP4$S0!!C( $)M[Y?PILT[K<)*8#TI>K,,P:;89>LVZZ$4P -GLECL;'#Y\
MH^8X0YI<BNIP\H\W+;O>DL3:?)I8&Y=8*SQ7H@_: DFV^4%\3TY1VS67TXJ^
M;7?^]\(&[E"VPEH2*EO8W3FZ:'S<W2G7C/\^U4XNCBYJ%T>?&T;MY  _.):_
M'QPUZ\>GS4_GC:91>WOZZ<+X6#O_T+@PSH^:'U90W" .8/EUWL!.P7A18; Y
M<ZP2A,+*% Q6]HW#HY/:2?VH=FPT 6V-CXV3BR9ALOGI[.R8?J^=?S,.:A>U
M1]7@+%2>_Q0WJ[Q_DS[5E/DGCOD7?E_FO\3K(DX$*R+Q33E.#K,X:0VUZ*D#
M;Z98.$^?V,R'@^WN'!\=-HQF_:AQ4@>94#\]/]N?5P;,!WF\3OG$#=1/3YJG
MQT?  AL'NSMQ##/A&U!5L+L[L@PVX1#/;[2G0*;VT+,0B<7?5R0N68N,%XLK
M:T0U-WA3S)(WAIC805>*Y"5WMJ!CZ,CAJ5P4/SEG5]BS Z,<9\,6VAA:1.70
M]OI<F"[3-:.#-L6HHE"/J&@F/]5;U_(ZE.MS0(TJ7<]?DM]U#FAJCG7#[HQC
MN\N,9ILJO7RC[GJ#J;DBRX<!7_/-Q1:M\J>5^\O&:#[3[D^2E5PZ^OGIP'9X
MC:PCTOWC7(6&YBE</I4MM*&PX<FP8U-VGJBL4F6P;7TKD98$E!PVG51DUR??
M[MB\E$1O.Z85NV!5 0V!@-=-]AJAU_#8IIZ*' %+RUL<:SR@%0OJ30-$C8V(
MYYD\-YBBB7R0E4P*&3'+\\>R8GEE0GQ3E&BZ-*\@?H4"E_OV*1['D^$I6X%G
MDHH3T7<4GY09-@0^XOYJEY.=*2*UVHG$YG2*ZCSR^?=&E':!"2.JNX)(KY-9
MJ>$[!JYOZ_EU,K7:BFL.HR$L/!#5%0*KB+31SQ3KQ88ZD;/GZ_/##[ FALZ<
M (9=8N@3([H\&R2VV#JF*CM2?\UO(B?@/L.JUJ5PM@<NXWR\Y"V5.",%"JZ2
M$%9!]6S4(N0!,K-$C(OGZ/AVF(L:5^46UHKSHMNQ;_'4978W\'@2*[!8?BJ&
M8K71]ST,7R2SF/B>KSJ?6<: *P5Z=2DH!=A]2Z@-JO2,205"7@=-D3@%E=E'
M59(+<N-5A.[^5(559_7:Z5M56D5)%!0LYD%[43QMA_H+$3V52^N)L!* F!(O
MHOG]YKYJ+>:S]M#CQ3D]ZU8%Q?1^9-14S!CK.:8:5:GO\V3=QIU(^:BKGECJ
MG;2[]=^L+\0,.T,*E89(QI'ML>?CB]HWM4<.MW%!!1SA7\, +B^&'O0LOE>1
MC\'/$=>BD&&+"@+"RG>4<3+KV&JYPP!3 T7>QSSLFT:[B[1WQ;/QR.4CIGJA
M*)4'28.Y>!Y\#< 2LPX4L?C4YT^G-=0$3/20\_0@ZEYZ98D:$;%)WON+-BG8
M.5;K42%4F_=QY5D^X19X]PFX%0! S:?*1UF?P!&#"XV3O3B]N&X+<Z]GM(;4
MG%**<\IA&[@\R5"P%-ZBSQAC*CPLC"WD17E6'*>9?]_$&3R$'\2NS/ FAN:(
M+I!B_27?E3G4[-,0"SS7(,SI%!'T-NM@CR;*?>/U=)R[4P+[-%(,ZP8>H.H'
M:-;4[Q>U[ @AXO=09()R5NC*S/I]H\F;:ZJ'U>[8G<7KRTR>B0/\.. ).*;!
ML'L>WD_L6^NIO LU  #51$PZZ+F^>.E\N^2B39PS]>P+P1DKR8O59X:R&B_2
M+4$KIQ.EQJ$PI3K<6^R0"O^.K4$UD/"7\6X-<VXEX@68-"<B'5RT2RY[$UIZ
M,Y"64G8T?7;UB5#C$B/TLZQGO;_\OXRW!Z?&IV;--(Z/S]9^[67_2$QYY77B
M&H?[?S['&2KBP"#;-#D@ORS;/X'H6(VO 5UIA?WRG!ZK ];F=E2N(J(+BS7T
MBC_)506;E^DF3+WLV^%E%RO]QI[VAUKZ)?0J/;7G:0(CVAL#/QK/?EL[K@'P
M1O-]HS%?)'MC@-=X _L9?KM$@P]D(XE[DD+F8]F8T'77N;O,9PXNL]GLY?WI
MQ[NSXHE[5K0+P-"'?6R138^\#CWVQIZAH]R(8OS%XX]H/HGQ8O;8>L[9XB;7
M?[FV Z:-JQ^3#_JO$R/")V7.F'"1)UBH9B^1=#+5?.;R_EW^9_'#^^S[?R]R
M+^)>%</PYU]S60 7+Y'$.<"-[L%%8S"X/OW263; 8K;Y0YA[,;F7AY276T3L
M'M(SPV3&6\\:+/DR1??Y$#RDT=PRWO$;TS77!&)X<$#Q^/'_7N3&U;'''&+L
M3I;+N'C.T-:==-*(<_F87R*:(P(T@8?W!,ZT3/C&%%3!XY?VLIDDLFH26/'>
MTH.:]V4AJ2OYGVE<LJ&_=V59@[V]&G7 KK5\:GEP:;]],?M.Q.E9WE7K52Y3
M,'/YBIDK%O_45:Z%-70$:PTHGZK)+!.?,Q2K52^S_,VD6-@\%N)N=6[B5M?Y
MT)/P<F>RBUSO"3-J47<!!R<EI\214XJ%)& A[E(?:I>Z;OG7-:>#_^"$V!NK
MA['(6E"W/ _3%#]C!3M<\MS1Y6"0&60N^U;MWO_Q_?+>S=S7SMB/9JY77*YX
M'_-OES,O)[WU;PSAB!+#KJI/\.GBWOGBU*\4$^98>!13<"9=22]CS,<EXF_:
MH<2N&QO46 R2/Q[8=N[A]9]V8?ZV[UX[KG/H\4&;AF/UX?N";%_/1;4O*'\$
M(#IGW?^]J/FG7?03[&6J>_G,"X/ZO 3_>V'?!:^=8;_C!AW6MOM6[X4A?O!Y
M' K(F=%/0\?FK_K4/ ![M&KF"E4SDZW\_5<4UFDV_II0-Y/5*!C61*-K)<C$
M4U^VNC3JRYG92M$LY3,+4-^ZY4U=DS='#C8ROK#NF'].#6\QLA K7YRCCQ?-
MB_<EY_WU$O3+:;)VF8($]@:$8-^P4)H$UIUH[(O[G"9,UBI!-L9[-B@O8JEN
MM?*A8%9 /.0+<U_0M>,E5<^733U+Y.]FJ9 SRX7BO-2S;IY>U'CZ&9]>(.8B
M"8L\EJ=_8%_M[S?_?F;OK=78# ^% E;)_L4Q<)@B,Q ZC I]IK'_1\>G5BD>
M%@B6K>>V/Q&P53*(V NP8O%2R)N5?'5>]K"E6-TDH2=A_PDDX>7)N&(F8U:K
M<YO/F\07EX#C,K TX1Q';_B%DGJ!D'JM@O?I-O/+:N5[:Y1Z.>KMU7&'H*PL
M\70N7!HFCA#$QM,> =/FY=H#\*S!?_%TL%;)%3B&5RO)\@6S"+INMEI^$B=8
M'RH?S\]UV#9,XTD@Z,U3[Q(-M:*9SX&=7\XOD7K78\QM+&:;>B,2&BQ,L9 $
M+#SD0C\6(R%MYM><3E/KOM*@KBLKR[M:^N:UG9"?1-_+_^/+\BVE5)HX*DVQ
MD 0LQ/&*:CRO6%'BUM)W*> T--!3PDL<X:582 (6'DS$YDTO_#-KA#&KV-#,
M<?W^O'YT>3\X9/WR6[_=>KNBV,PJ8R]RHWS1 =_N<X^V3S/!-^DPBB6X%3N0
MS&JE:F:*A332O@)B2A[E+,]YDS>+N;R9S^>2&F4_C/)R'%L_J='%L_/F6?<T
MDQ]>W%2K2]3R-AE?%P? 8>I-U0[3J/HSB:I/)?A5BY-\MF06RW.+DRW%;1I;
M3R0A+T^Z9<TB$'*^,+=TVWR$?;HEHQT>RCLMR"X$'DB^6K-Q?_KIR^5]\6>O
M&WSP[!\_63+2S)81;9_N#TDEWC.1>!J*5ROCRF8^4S1+N:4EWR04FZF,2PCI
M+C%KS,SDJV9I>>I9&FQ/ID/BN?MN4RPD 0MQ>F=9KX_&YOL!-6C&DC^7.D@S
MI\WUT*Q40SN9R_N;LR^'W:MVT*PN4K"VSKB[MBF*NT>VQ9?=XV.ZBRG))HYD
M4RPD 0NI:$]I(\5"DK'PA!NZ5F%L#7 FNT%CU%(R2AP9I5A( A:6*&[E&Z*1
MR<Q^-E>TG<6CD\/@VO7L>]9YG9)/XL@GQ4(2L+!:B3Q^GY]TG?G7I$^@&HE%
MG<E9HY2O3A.&_?#Z7[95Y_:!;;\P CO I=67N* W#4M]8W*UTJ-6$VW7YU_M
MH4K@&>LM(2YQ='*H.77Y LL'ZI$>YWB@LADSDZ'_QGB;I[F?Z1^< <8AYG0J
MT#"P/ -GAC'CCW&<9Z?B_,SR3CT:F-"AUE)GS", YZ6T<-%7MF-T<!R"Y^/L
M-\/'U_PY27^UA6"9AP[G@.41A# -FJ53Z:?FP=DBE/H8 )]$L3J F?U,)OMX
M@I4X>#:"4]%S93H]R_Z6NB>W;S4;]V^_M[3[=3_*_3P<YH\_?,ZU%7%'+#=#
M4P"-D&^$?""&!1"BPH-77N..[0]ZU@A[@SM3ZF4?08./;(9XSSRW8_G74^-Q
M."KQ?R_VQ@-S>Y,$MF7JR?.@]8.%:5V.;RFV_[VM_O1.VN?7SX;6XYGK[TOK
M:["GEZI_OQV+R;G.8Y1O_@U.>?YLU3LW_T(Q^LZLA6;W%)V^U(94[D="M"1]
M>W&%NTWPSJMM'\2C^9&J]ABZ'Z]H%Q\/QL-4]U0=>PY -JA@+PA=JEVG;JEG
MJ/<]'RRL-UPW7ICT5/?_D>^KVB1,J7&'@1_ #[!"&@]('K&E6$@"%K;-")EI
M&W .,)^B:-.SDPOD9RUP&K*4^5;1>-"CE7V^FZ28'MK65P92*6=F"D4S&]N1
M]!&F![W.>(4:I[%GC&.X.A\)/:SD3R.A^B-(Z.%55D-"2[$5ETM"2P&IF#-+
MQ8Q9S#W:/OCSN?>J>,AKF8TGVPF799QO?IBO]LKOO_WJ9W[.Y:\,'9;M:8;S
MN+O2X,0\H=H9(=>(ODPQ@) F_GPQYT&O=';-V-FNMLZ,3F?NOJYI7XX%+DYC
M@8LC'?W9J\/FC^9%\>Q7<3LN3I)NR1)+VG"GDU7:<U:K%/0>(:#\XG>MWIEE
M=XX<@4QM.[$D<7_\ON\'IU;Q[:]%FH6L,ULVW*&!_>KW;*%VM?E.?T\QNGFQ
M\C#AK5;09"LELU+,FN68>Y1*F\1Y'%9!3$MLG%',FZ5\WJQDYE9=UEVBJ"<(
MGK/ LAW6:5B> Z+5K[7;P_ZPAU&1 ]:UVW80S_1+OYS <3^=5K[;&^P0]91V
M4'*;'(@.WVS:'.,)5WRCS3%>S68+#]/YLF7,E.R/;!$;$)1!WYE[N-\F$3[-
MMY"VSEA7ZXR5$/93Y-TTP@:AEZ^6S')I:82](BJ.DXFZ\WRR*_[8:"8A!/6N
M4;VOW_.=+R?O+MHK,H(VT34JTE(_OIM^*B&W1D+.YB.31+_B$>@H DMFL92.
M(4QEX3I)>(GCFS)FK@+:7'5I)+QN2[#PB,DPE[;>-U$)OM&/P_\^5PO=1BZ[
M:D-P]IRK92?EQ'=/G!PULX!<3"<9+N.8-M*?+O9JI#,.GR@LTAF'&YEQN A=
MI],/_PIPQ@ ?Z3MX[(O?&'W+N[(!.GPT$P6XS>"TO66!/%@IB.+U\C^_\4DL
M!F*3L=T=G%O1AZ^/0&VAGGF^$;C848_T0?3A&(>V8SEMV^H95*M ??<2O;'8
MLP<@_\_>'FR&]3JOC3/K"JYJD_T:,J?-7AL%@.!T@#???XTO;C)B V\,BI_#
MLL;>GF3F'?MF7FV:[W$O< >OC=(@4!_(+Y1HG@3=9MATKR?T1V)5^#OLH"U_
MCR[9QK*8@0^@R9_>&+=V)[BF1(>70KSZ]CWC9X;+3,U3!?AB^5;(]\2K\_F7
MX?%&.:-\HO R'I>'>_KYRY-_8UR,!@!BS0,YT'YCG(!TX-@Y<?'(L_J7_I+?
MPK],6S__,E9ZZ4 C%Y4\].^_ )TQF!T "'LMCUD_]UH,Y Q 9?5NK9$_+U+5
MC=#H/ 1C$%U8WR1NGE/;$N[5<^9??[?^J9W4/C>^[NX<'QTVC&;]J'%2;S2-
M^NGYV?[??[7^233X]=.3YNGQT4'MHG&PN].\@'\_-DXNFL;IH7%ZUCBO71S!
M$XG>PJ'K[>X$U\P8,2S18TX'Q$63#4!(M)AGY#.F@68(6:RHMTVRY-6J!LDZ
MK2EBB0#E(H#S=L7]9TD#Z4')9XJ7V6S^\O[X1V-P/_IR\_%]&63%L _[&-$C
MKT.Q;>P9.M49TXCNQ>./+2)[ILJH%[/K)?IVIX,J]*27YG;NL9T:HW\XM>F1
MC\<)R=@7*/]6]>TE$CX<2_;R,DSYK78O.H?NW=?CZ^M'9M6N!-Z9;WWTEANX
MY8K<LDS6O"]W;UGEYNZCEJ/WR/W-A.3A:AQ.70^[^EI+\IZ#?)+PM?YYC%.@
MM;K0U1PPP8W#C__W(C>N<\X/W[+E/-Z<[3K%C9/6 FA<(LXBTCX)!Q,;?-#[
M*IT.F&=A&_G&W8 Y/O/GF4,_76#]?_5ZHW%X.%<IKY"=I<++A?>MH.?+,;&'
MF2B0(GOQ51=([0PUA;4M2Y(E7+?X'/>;XG)K]QO+F?09'N^8 Y>[5W,ZM4[?
M=FQD2X%]PP2CPLP@E1Q[VKCOG9Y>WK/2]\^?#[R?%6?Z,(]E:-L+GH+8$AF&
M5F13CRM-V-8ZB#^>LO(JXS$/T%HT''/HN7T*QV0S>YELX"XSY%@T*\626<K,
M3FS8</'*"D9@K&E"]L-,-D$$5N$$MLS(7\FL%$IF\8&\F;46JCR4'7/.?&9Y
M[6LXN@-VPWKN %TZLX2 W_KW:W7XW]M,=Q$A,%V#?8P=\:13DEL.^])TPITG
MQ!9\?,S_L>;SJIC6DL!;);>82?/K$T:YHIG+9\U2;G:>P/-"_"9)+CFGD&1:
M7X%<S.7,7"ECY@N/%(P;1&BLX&S,\NR@L#RYD$V$[<M^("1FWS\Z/JR?WE^=
M_KR\__4N"$K_'=P-;J:GE6[0A*+D4,.5>YO/Y?-L#*BG+[_2DJ@)DEN?K (Y
ME:E40%[-KB1?*[;^W%JC:1'WU&:):A5"H6IF,R6S6I@];WUU6)A6/+<$F^8W
M=0:LE:X3LK$M!_^YX256;SO4]+83UU'JS9'3=OO22?2TR-S*-;/3X)K!G@AB
MXY74RU(9N$T;VW+PGQM>IMEX[:$/]B:QBM,HJT!MZ)UG.4'$,WIRU+BOO,M>
MWG_]TKO_6:I=O#UE*PWN+QXA0]@%$TE-NLT%QJR;N][K&>2U/L,N6ZB:E<HC
M5? T'I8,]KE$XEJ)@5<!Z^Z1SNUUL_MZR.[C7:5P>/"_]@WCIQC/^+]W.C?9
M=^\&W?]^)%%WE#L;#W;Q%6VYPU0P)$,PS$6(ZQ,1!3-?+IJ97#$5$L],2"Q.
M:*L0%V:A5#1+U;@V\0D2&/JXBR/,9F9^$/$CG+ IUL&0G?:^C X_-<I6,JT#
MN1TA!TS#8;/S(5)AL)88[C0R6Z.54*Z:U0?Z&20%8:D 6!UQK8+M9\IFKC*[
MM>+&F;[N0'YGV8Y_[/H^\T^=QAT:6$/;OT;)>=H]8"V=^W<B L"JY;/5FV^=
MD\%5$JT$W)B!(P=8$/18:!^X7<-JMP&4P#<&U@AK2E.IL'FI\" =+B8>'IS^
M'+V^__?_J^2RN3=3YC0D%X&IE%@#L:U 7&2S1;-<W%3*P )Y8G@XYXSZ%F.O
M?CO ,SMDU)D*_X:C8"RPN.JN'_ <,I5"!L+#5\+CXNI'\;SULY+M]Y)I/8B&
M/LZ5X?'M&NUKR[M*<\>2("P>184K$AQ3^FNG$N292) '$LV>3H*K$"?%K)G-
M;RI&\7#[]J(F20Y=#XC<J0\]CSGMT85G.3X'%Z4S"N>WU%/JPKJ+=T"]^X\%
MM]>'A6%I^FR3Q]L?:TO2%ON7M>@@79PK9ERAU?*J![O_\V&'55K \RP*>!YQ
M$];H(\L5S6+AD8Z,K::!I-3/;/HFK$V$/I7NER) IZAQA9R9KR2UOB=-]=YJ
MS3(A&]MR\)\;7A9/]::Q1VKF@]2/^Y96IS?\^>'+@?NIZ[06<;=L7%?6ACRX
M6N)XJB$G"+Q5:LA327^=:4.5?,8LY$JI1IQJQ(D@\Y4D+56J!3-;7++9M\F.
M,/P<T9C 8ZO#4K8SA/,5Z<2N(XP,_AR8&LQOW 6>!5NR'<L;'06L[P-B$ &>
MV^L1:GB.053NAM(6?53']Y__'5W>,SO_\:*4^_SS0T*3I$Y88*"WR> -W(V!
MY][8/AP+7Q(^DT5: 1Y-&OQ81_#C ;MYA22]2GDZQ=+.E<Q<L6Q6,H^4K*LD
M@+0.<1OI=)7^(*32;,XL5[>^O'_<F$L]"\_=LY#B)9D;B]5=*YKNRCWC@>*/
MPAIXRQS6M4']/-':,_E*Y_S\[]=^R^Y\^.E7MK.C(=\O7Q^T3MFUR33:_#Q2
MCT\RP%NI\C";]M?8UC!GEDJ%[7'ZQ*NNJ;\GD1'0!8A\!5Z?2L[,5AY9I[9]
ML<Y4[_W=]*L4+\G<6*S>JX^9.6%!Z#NXM/78IM!QN^>5T;N*&Q0_EE:OX^8&
M*QA<#'ODJY/W%3L9X(Q9CUV# ,#F!?CQXSFP#NKF-=V9T*QM4L1305NI!A A
M]0UY7RL9LU!>1LAG7?A>0,<-0=OH+4@*R2>(OE?MM:T6S&IY&9E\*\%CJMZF
M:E2*EV>%EUCUMJZIMPW+<VSGRC]C7O/:\MA;R[?;6#9D]X8!ZRQ[IN)34@.0
M:QL#!OP( 4VI;XLVMN7@/S>\Q'*%M_-S!5X#9Z^\U&TE6@[MA:]//?OXEE+S
M]MF;MP\0]9(-WJ.3PRFFP!FM[K_X)[-?>&3CO]3232W=59'ZHK;O7(1>7$;4
M,ME&;UJ_]OLI4BE>DKFQ!Z,Z#S!(F@AR8/OMGNL/@84M>8 )?(ZP_N]%;N$]
M?R$9SSJ&!7!85\P _MP"V]CM<O/8%Q5JP\ /0,V%O:9$EE[^WP(OL9<_HUU^
M>7=J_.J<T,TY[1(C. TOS#2C=P%M91JO&#^%F7I%@NS=!;2B#:K_FSS]=<%/
M%W85&YAM:"QVE59A:BO#0QH=Q8J9K1:PB'#)IL=S):?M@G;;3_MY7=XG.0\F
MKFZA8E8SI<<G@HR?-<?*$]$_7<'X*\"&S? 3_#QX[.O?&'W+N[(!2GPT$R4(
MG!+!/ #\K\%*7[^4:Y%$$)N,[>[4VIC&9CDC[)QZX@;PA< UZJY#><'41U5T
M5K5Z1C. #[!OHA^[/=C@_]G;@^=9K_/:.(/K\@;6^C5D3IN]-@K9-\9GJS>$
M'[/&WIZDS(Y],X5/O!W/4>9'L1>X@]=&:1"H#^07X#,X#"(X.)M>;V!U\&Y2
MP@G^#L"VY>_1)8&5]*R!#Z#)G]X8MW8GN,:3S+P4/F/?OF?\:'&9J>XO@"_6
M]Q;>0?'J?/YE2"AX9R:?*+R,1_GAGG[4\I#?&!>C 8!8\ZR6W7YCG  KXX@X
M<?'(<_J7_I+?PK],6S__,M8CJP.-%UU>\[__ G3&8'8 (.RU/&;]W.-UZZ\-
MJW=KC?QYD:HNCG8=0C &T87U3>+F.;4MX?H]9V[P=^N?VDGM<^/K[L[QT6'#
M:-:/&B?U1M.HGYZ?[?_]5^N?I(-?/SUIGAX?'=0N&@>[.\T+^/=CX^2B:9P>
M&O5:\[UQ>'SZI9GXG1RZWNY.<,V,$;,\WV!.!WAPDPV \Z+S*I\Q#=3^R5!%
M76*""3]E0_P>9O >3FYIXFYR3KBL4TS8[7H1.5+TE<PE6*0[)9^I7V:SN<M[
MY\C+7-]DSK]]Q_+.81\6&=$CKT-Y:NP9.O4:TXCWQ>/W-)^$>S$[HL,1'J=]
M?YE[+$B\H(O)"M >7*R)Q-A*RL%5K5SBA8']9B\O\0YEJOG,Y7WV\)M;=SN9
M_[1>:_/%X.?<TAPP;N(T#O T*O(TLE5^&K>%TMG=U?>Z4^Z^B$/FS*W/7OW!
MP*&T11ZR(-^NK QR[C5CTP@$7U#?R0Y6XQ]6L9'\N"+[&&B7*+/P,OT6Q[C4
M,]-D]V+78ZETOZ837IV-_8RV\5#NX0D+ZI9_?8;-OT ]?#OZY+/.43ARN=8.
M[!L[L)D?U\5'B]1>WO>N#D^^?SFSG4_9J6';Z>+?NVJ]RF4*9BY?,7/%XI^K
M;'V&.S8.>^ZM;PQANX8M>IZI71OAMM= %&L(TJTG[KBVS:18V#P6YN L>BEO
M!OL2U^^+/ZN7]U_JWTKWQ:-&Z6+ZE/''&PK"""F67BXQ84UV29QRP&+-RLLU
M9R5+@RMNW55E8,8LGWMX_:VNH7U2Y>SZT?5G2J73J#1!)/F4LM<G%;O&8V;E
MN;VA>#C0Q$.M\V/HT^@L:O0(&ADU?;QPSQF<6=ONL<A)7KASJJFA2IK)@E+Z
MO7=0*C?__9@]JR9<*=4.! -GGCP&OJ(CN_7"G_!G/#"IO!JN4LA?IXI2XA2E
M% M)P,)#,S9D8C(-]<->7'2A@(OD0KVU\K%58\ZGP+N:WM-[&0[N1</P@=O^
MN=?"/5!+&;F)*:>]5E5@E?)_)DVM5#V=K0K$D]3RU=2)<17E$F;TS*L+) <U
MSY( $TAM3]! H[16,@OY#-#;[+FCF\/"%"6T#8J6V\>1UEWF>7!@?+XS,?M.
M)N3WV4^'7SX5SN]+QTE7'N5. -M^,,U9\7O<MPTP?.OFKO=ZC)B6.GOZ:8.F
M$XF59TE[B2&TI7'X>>9*)XN_ES2E'J>)^N@^8/ZI<\[\P!NV@Z&',:PNCNI&
MCG]RV;&!Y_N"YS<J7VK_ONM>?_E63J*.CSLR@!Y\%@0]RO@1I8==PVJW 93
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MG*XT:3_ATJ"$!$.T!:P^ZBK&% Z-MQ]T?+S/@K7=6-X(#H8^AHT3T);A##'
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M),%%RQ'SZWFH0>JZ[_F@@#20GU0QDTZ,)#$13S-QZ.U0,\U-K]!D.3J-S.B
M[PI6A\2<:O3DF4T4[KTS#RWLT0S!0P-%F($'UXVEW.@7,+N,-J@_,TV!D)8
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M!U?U/#@T[>H=ZA?4>?CYSN172.&)R3SQ^IKL;X4UW+94-'Z;O_SYSH3H/?&
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MUO%_=Y<^URJ\+"C9\_S#_<^'GM=M).P0MC L;O$M;M82+.6.2_,Q53/LO]^
MD":-O'SKIVI5G\YNY-^-D&(R[%+)['%V/C9JN_9<57O1%!6PQH+G'!7]QN8<
M\\OEJT?J#4V4"Q,_?%O=,2H5-Q)K@PM*FLGCE:8+1R[@RALGD(ED]^]"(&L)
ML4C)(Z1"7[ /W82WF.!.-\??A]^_?/MYW?C^I15+@AN6&,@N)->H(J<DO=]Y
M,YHU]N5#VX0PN^0Q0N%IH C2GEX%";DWH#_I5;8)A4&V5#/(1[%PSU)9=?/A
M@6-.5BI+LPN5:7<CEG2C6;NHJX_#RT:BS)Q%W NHT!P3&?8\TJ].+VN+CZF*
MIQ=0ICFN?FW7NU6MU6GD@XOY4WH!Y9?I!91OCF^'#V?#Z_'HV\]4C+V RLUQ
MO5?)&^K;:5WS6N!$V@NHV!PW'FY;MUKC[<WQ[C^B7D SNEB<-,?6>4'[FJW<
M/38R:ZB.*'K]32X[&!V)/H=- =)W\IN7U!4STH*:38KFUJRO-<</#^<UY^IN
M7!R7UCI2[\KQ-!:3*C'4B>YGBZ;\SK1H"N30TT1V97.E;$G_;A9'V0__4&J2
M"#D)1:G^/\*QC^MH[!TTW@IS.G5&TA;$-8ONCQO':'6!]":OD0@?VQ(5YI)&
MK\2!*Y$ O6L3*XO\AMAB+54W7R,&)2VP\TW@>"@AGN 1>"*._$$6T2X;RBD]
MJ76!.Z5**'!GI;<WQSV[_-JX>CK_]6LF4$=D,A>ILPI.YT6SM1;&Q/ZF?P=X
M=F3@G=+JX)TU!U '(#Q!X$^I.>Y__5[2J^U&[CZW"/"'G3CC*._\$Q*_5&0_
M=JUA$B_F@GB^N6PIWPP+_Y]UVEFG,-*M'W.:AN]*A;^WH9-F6!BZ^_,NF^X_
MWK_E2FMN:!+!Y+[;US>)WOHED:P@G2JT QL1"'6W%4N WU6;$T=3X\44FP='
MW1L:>-=8.&?'6]S-PF>^-RX*])@S(7R-PX^AZ(@L_'\?CB;ZRA<3R5(^D5I@
MF-W, YT8__W'WM(ZU3O3[RB32B13\PO#%KFC,)E174]F,!VRALA8:B"Q4!GL
M:J\=*BAFQ,J6MDXU;O2DZRYJ0_*EF$CE4XE\;L59F3./?4+FO-_Z"K<>O;PB
M=UY,)0K%L*JFB.X\3(9EUY-A5YIA6L2KX%!*XO'XGU)['I)?7ZE.SR2_@:HR
M+#N(UTY:H#P7:]IVJZQ7++]=L\HV>F98]:(W)C/3>4(-A40QKD+PQ>3F.[%$
M3BS1BUH@E50Z42C%-(O:+VZ7*?L^:8Y?NUWKY]-+[;:EKI<5CRTPN7]15$AX
MFP;OJFJHY/(@-VUAFU<>,X42+]7!+JOD0[.2W1!:C:T7ZXY$5:OL@ @_E_%<
M" ]?:C+&$#5U[3+(*='4I=Y*>"532G]5B]GR76GY,*J4BJ=!:2GV!J6KQDR]
MN&BY.;ZN.G>5!\-Y_/*T2%S491B74Y ?=.]R9I8\;B 4R@.@W[4T#+=Z<H2-
M[4D ]%0(>PZ_-,JY]ITIUXHQACU3 AM.,!_3\$87U'9%MJP14;S8$<)M6+&-
M..<UH3V3+XTFP-KBXN(-JD51S;;$2<?;2B.=261*A41R ?#?UAN*[L#!1]=:
M*%5,% @/1'KP8?Q].HN_SXT;RVRKMAW>3&X=)E^_-2<JFC99KN90]I:"_+T>
M)'E5K.^RIQ@S R>2^=)"9!1OI=XV3S-"KDRD\ND(3G-I30N8 ?8SUN/,!R0W
ME!/54#N:8X<CS:$?4\PJ>7+#C2D=EG:,H"(XVGA9F!QY,?,[L7!,)QYE7[]<
M(1D3FU>]V;H3!W-O#&1-J5# _6:T*WTE!_EOAU!PPN_LPXB9P_:1O58\M0BY
M) J[(HQ%*K,TX9EI*J^:KF/(V)&-+D#5Z*\VKN&\!;"(1QO&X^R8M)UQ8/%R
M52H3A:FTK^<8'9]EXE)%F5E\=F]8*BWDK@PMJ-(:@0>\*;7$4NO>=#9P_DRG
MIUH[1A73CBEFKVZQD,R><-8R9QBA+Y>+B:V*L]C*Z]((N2$86=C4KGES7T5K
MCGL/O9=4ZWG@/*@;Q#[,3 ZX:Y9DONB0</]$6'6KN*'8<$(+W&B\O)_))$JE
MU$*TN^_@KUV[Q.B$3YJXF+G%]'JD:*Z9X=YKU0L2-95D<WSS931Z;=\^M<NM
M"+7]2I"):S$GOZ3,V1CF9BV4S9(42PYD<3DS5BU3D>W>@M2)U63ISQ.DZ2^2
MBP (LXO#,W;@$L/ES#Y<X@J0IDQS_'PY5FSMYX.^3F7Q]A%-Z?GHD%E=/=P>
M),?IG*_)^4XV#RD?'D!'$*.MZ1HU#LV.");B,^AE!QMTP-SJH6-"EDY5<-ZI
M\%EHKH,>GK] %7J.='3:0E&C?3[\P[ [FD%4M0;#:+RQV-!\>YG.)-K[W.S=
MF9O=Z<!D]Q</*PK-C6Y]=+8VLNPT?#3VTJ]NCKO/76,T&C]_*^=6@)>EM]I/
M?PLEN1Z\K- <CZHG:O=GS_I24A:!E[G7(QRF!#<D^:^(,<7ZCL0*Z*QB:+VM
M\71S]ZOVDO\VZNP;W*P46F];3=9TZUS]/OR:CA%XE@QK3.*_:_?'+(O(TH9E
MYY2JF ;7.3Z6WF8%[KFG\UITL: ?)W5C7#,+E@5++83\C^A>-E8(DDOD4HNE
MKK99F[LG%Q1]\06YGN1BH=E5RW)3\T4+RS_X]E_5.MBOSB$F50PUN=.3(()5
MK("\P#P(RHC8<XVKT=>\T]L8JQ?2JV;V(QI;L!,G&T,M:GK5Y,F"L<DIVZ\#
MY9<5<$HV4"4ZN7I\OS10R>%!M9"DL*-O;PLZ,X=<@N<5/>,%<A-1Y-3V\0S7
M8+% 5C(;5[:_X@'/INSTVH1@R9"\D+BYS#0(1]E6$';-S(:-Z,*I*'"& &?F
M]!:A6-$>:MR<FDJD\_L((MC444?&T*748E4<ZP'&IYP(MO2!$DF3L*-0?]T<
MIVY^J3_MEG';U3:'!^=A7ICAK=,H[VZ:6=/.;7/-"A*EU&(Y_KTQ79<ZTQC:
M/26RQ54%W@RCM3*?"6\LS;1^$2DD,N F=*9GM"#70>A=&@Y@J/4 EH09$HQ%
M#2P3>CYNNS1CB?.+W9 M[",D/*J#C,Z:+<6E_,1Y;S0W4._4&%@4G.*Z49'M
M'J)8GIW.,'/;N#7ZW4VI.KHBR%LP^"H.G.=1WHU$;F93R/0CBYVS\GO,6$L>
MVQP^F@+H6!_&L1YF%>5"#3O6:T:7R@JBM\E/-'N#VHN:BWW-T/K#/BHP%5>P
M&;MQ-AW,/Z*XV2B=3N3SV3UEHQ6/+S*U5$Q#+[T8M-("2<L*"HYS8Q%D^%AY
M.^L4[I\>KHW4KH#!*ZY">YF$A?\N&/"5S*LE;C9NZ5!(9+.+%5]MYI#?+SH6
M.99/Y!8LPESOB.<9X/P@IN25-]7 >!Y054!?,'3B'X<\GG)#.V*MO&/(X[G)
M31M.VX"1GS3';]G6^.N/5CW3RZV'(_^=8+MK#S"+%.J^\ZAV^_ @M+EG0AQ"
M*?5DA4Y:XH ]8T[+.0@%R8.!9;X1UG)4?23]RX^)+<VNQI[>ALP=$H"%6T:F
MJ?1AJBU'G_9^UN36**,_/'M#;9=:>80=TT+[I:]9'IF?,'WSQV%=>Y&<I;ZF
MZ["%CR *_YZ\@UJD=\ !L]\N6O?9ZZ^-2JFWRW>P<G7CQ!WDD]/OX/" 7<(G
MZ;6GM7L2]%206FH7*CQ,,,PTG%0F!>\FY^$7)K=WRK97@Z^C"0YQ[E38 '#W
M"NHA)W[$SRE!5T+]6TB4?%AU4*.0MUYXW8CV+DSH.T;%$ NS \G4" 10>C7B
M]^7UIHDA.9>\RYX\]YZ_Y-WSIP&^#=*^;Z7Q2J%4,G,<9B?YQ-#AP30Y5(CA
M*K@TNCSM)^_4X=C^];3#5Q&A,,H>A_G'OIN8)XO2R4R>F H!"V ./^6%2YS;
M*3?(,<W).&)YZ/2P:W[Y3;.%#S"17B%^LV.-KM!N:8[O3AYONNG4W>BZMYC$
MFW>[J[6@Y<MLAJUR_<O-'F?F*_NR[Y[*]]5_32B7XC;OJFE;SM$1[WU"O]%F
M_SHZ(NMMCMO60!\H5O4YG]_9VW37W"1+CH!O%V#;Z1*TO-*%,AFY-O,]J]_S
MVG6N<'%=W,9U<>$9,_-ECG/S!2N;IS#3-B$2MDQ,.V(*:\3EHZ*X)[^ ?2-!
M571'@PEUDJYUU(0DO\B:CB6?1$2;G0[.L!TZ0TL]/'#D-_P-JYC HF'35HE;
M:&FVHN$2[>.]\,!#@P6!H>?"F'28DO[9G4K_-UG39PG"T>2O*9B>'CH%_K0Y
MOE?[CY<G(SO?6WP:Z&*CX)<KRTUG\LUQQLA?%DH_OBMC.;B8.8.\/TMPLD>V
M-E;I\<("UI_KG<G\-2W R#^1_2N\NO'T2+P>?C&?I;O1@"RQ;,DMK?U9NB9<
M3B_OVH1K2A7$;_V'?PU^Y2[ .[)*<_S23SZ;WVXZ/[N/P<F-9/&A\<5@H(V'
MV?[['T(=X81"--#ICZ^/6N[N\N>UUY=J0-9]U+)4^>F(SL/]6Y+U5WED+THC
M ^$=Y>:XW[@Y5P=?OB1?O<VXK#80EC[P+U8\,CA+>EP"ITQPCOCB6G-<K=^\
MMF^S-=5Y7"-R&!VOSU[\LIQ%3C;U8WPW?DZ:9W4E;(-KSS0!'IQ33KXPTQ56
M'UY_;3HJI8F%_I<7AY%,*]0L959?C^]KN'>B6$WJZ/]-M"DY55V#4G<O-44>
MQU9U)'ULTV%:JO+)-S;%'QY?G-*)O+A6+JLUY3%CG>TJI>^D-MX+DP%'67$'
M5:7P#/)YS;'#L!J2190+\6]IUQ3:IAU^[YI7ZHNF@/(YEG[T5$-J:U9[V+<=
MQ'DP7&." HM[&EAT0UNU#P]D ?)(UDBD,;P 46R%SS;9H]*EB.26.:2M8:"-
M#!$6=$[0*'R6D$WC[QK9&\558C,8^B*3MH9QMTC6X.Y1"_20H2Z*PPS$8^E$
MQ74+*^4/Y^>HF&2WANGPKQ(/LJ7JFDJL4Z<GDR<Y\)(^#(/7M2?B8!(KE*P+
MOX(?$!^&\06R7U7#KZMN%P#Z4EMU=RN'7EE/)C>EDLM0;>!]S>[1BF!?ON+P
MP-?@9H_-W=U<ZCVY"<N1-4)HT(3DQK0U]"OV8O%[=,X^<=;1=!!E0L\HE;A\
MALT;0_GR*:*[AWSP(EN:.;0GHN;PMPZKLO?[B&*PCPLO]"_=%\.0/WO8>@2@
M-_%$*:I$[FL&G7DIM4;^17E1>Y1J+)Z@P89-:^*K?%6!SQX>$ ]>TYG<M >L
M)P[%EJL8Y=>UON90P4$#F+Z]@+":L^K *[&A%A%!\',F7VEK+7(51&""O0DB
M&#[4(9X/R)S,N\R)7.80(@+-HGK%.C9753A%U2 D=DNT$K$6R5TK*E68(:&7
MCT#.Z>3GZ_HE_BWU^5,@'!.@;(L8 F1=A'X/#P;D";3?O5=;!"03M@JR]!>M
MK4XG_&.)K(%:$(%13NY2^C*H6V1ZMB)R"";$A63#&)*7"=3.) &\'14J^1#8
M%5(N^1=1WOVA+B.O>.8)?-I\-53+[FG$3&:S:.&K4$.F=<A%&]"=QVP_]4R=
M7("-#P0;Q^E9JGJ$!53D=#5324 3.8Q4$8V,ACW9/Y4E4J:8QEUFBIDY5T:>
M\4K<./C3)AO394LX.>_BCXGF09O+'.H*/0)\JMR' !^\@QRL/6E^T,^WR!D9
M&)14X'J'1)YH8Y4=*#%O@F$U*1!5,RTJ"(71CE3$>*_'Q00O*"%I<"FCA/3*
MUZ&HY!CZ>&:N <IM.35HB6E$W"@:!O$)(6(%&T@PWR72RSV6&L.6C;$39^*7
ME*AD6J$#W_:3$-LSBC@?LTZ"$U\I.!%O0SSD_D!7P=Z4.0DP"I#UD:W!M9"G
M='OX[HX&P55:B3>S5:%G?;H&*3=#V4L.#^ M:&'*@P&]1X\TZ"V[C1H]*Q\H
MQ1/7?E$X V^5RC3'K;>2D1I:N@VXAAT4FHM=7T +[($R6&Q?4W:T6LQX"Y'A
M/S/^6YP?_XTXRAM=+'?-B"W]%?M &.,M!#BDRTP&>8Y>R\32DR(D<9+?B5[0
MM;;4(MJ?+ $!K NB'A$AF90RR_"^ ?DX?0D1 -*8\'J_Y'%[ZY__:O^<W]6N
M#@]*QU+E2_GZK-:0SJ^E\G55JIXWRF>WM=I5[?JN(?TXO_LBE2N5^OWU71E^
M4+_F_SR_/L,OG)Y?EZ\KY^5+Z:I\=U>[;1"50%[56DA.+HH/Q8."\XI62EZ;
MQ%8L$TU(.)\0_IP5+WO3$5^@''Z#97*%]>N[V_IE ^_CYK9>J57O;VN+7\0B
M1!MR[,'>L<D)UJ$WYFLZNWI<F.[::YH+CK_A6*9NH_6#(S\5\G,[0@+<_JY_
MD'WV9>)XD/\DQ>L8W!;W/G#W3@UZ\,X4%3P4:K^C6Z! .$"V34-FP\B&%@8,
M\1L ? &;A9BW-.4/1B"+_BKH3X$I3E]/PZ3FD/LUA"<L=6!:T%A;TUW?!DQ*
M7@0ME=L.#;2V05<35VA )[3"7VE79)CM0V/%]&'D.:^:TZ,^&%D!.17V/N+X
M#-0V\;V\GM^-6L4-'UM#" .QL$V?_FVA,["'[9YO_]#VN\W<0C@%-++-?G]H
M$'GAT*.%8_ BPPG\=[NGJ1U)?5/;0W0GB:M$G%R+#JB"8[.(FZ0-R&E[W<G9
M9Q+P3 SF2K!CL.7)5M&C@V;J7>+Q@I?.;T:@B(7B*7M![N#>P]U"\)\\0W6C
MW F!LNSA &('-@_? :W@+P8R&'+D=+D?$[PA<O:TJ#AP%^Y]T8N>>4G,[51Y
MQVF#D#+_(64\>MDTK.*M8SX#@X-_>,"C!)I!C:-;0M/T;ZG,1_G342KW4?TT
MA<^.I1//3R8D+)[?E!W[*-3]O=@\GW\ :APA#Z=0EEEL3]*K:@F'!:&+T **
M^22\3YKJ:B*S16P-&O"X10D'-^0&>9@NH^&H4_?<Z2>!6"/5YMRPRJ-AE8S6
MJJH/+=!9;K8,Y;X]("(,PX(0*W9S4[ S(!:NXO#?"I%N$-'2^.&TQ</QB-)R
M#T<(K!&- -QB<W:1@5DZGRA3IW(*_>=4WKF/7,+<>/Q4<QFN+C"<^P'AWNM<
MTKPB5T''.H@6B=)PJA""EX8>G<C0WMFY4;6VI:$1X,L<,@7;L8@7^FI:3ZY(
MFJ!<UH4$2;IKH7X\=;\%&,P,N02-J%R(Y(UXV*ZO.8Z*<;P&4(AIP9+J5E<V
M6"C*E:MW1',KQ-NDW[+Q7GB@NE)OU'FD.AHI$G#2(F81EE/&0C+(O6M&#]OS
M"H%&.[$$_4.X$N)] XN%MBV,FQ*C"T[*'7QR+)5UVT3CZY%%GG$) AB $9:?
MJ(A-PF*>W (+9K8@UZ393\S^=/6 $)LGJ^9\W6(9=;?W$5D%)-X)G6MLZSB@
MA86F%4).E$0P;JJAQ>9QHTF<,LA!F9:H<N#-&#K6 $NS@'6THFI9G02 [<CI
M3]'2@OP,T;E!RK"GD\9LW7MX$%2^7C1F0RHX&FU;$0AI8:4:MX>\\IZJ0Y"#
M-)E'>,:"I.FTV#]F\<@=XT4;IIO"8#[:XD($H#R.ZU9- G,.#P09,1A:]A!R
M7X3[4=]*1-42_?I1^02<2!0M_T=GTA/TN9PZS[2 _P<I8DMPTD8,,4-> S9%
MX!N))9EAGA38<H2G%1[A.9'J=U]JM]+Y]6G]]JI\=UZ_CL48C%C'1;LVB/]-
M1&S7C_\9DYKA/?NQF>S'*KF/;/X]]Q&6^U@]^["&WG6%%SA$&9?A;\JW=X<'
MY^?G$0O;L,1)M (XE0P5P*FD5#V_K57NZK>-A%3[6:O<WYU_KTGUT]/S2NV6
MAMTK]=N;^FWYKB:=U;_7;B$G4N-2&M+DOU%@HZI91/>:EDU]ZO^_O2]M3AQ9
M%OWN"/\'Q=PSYW7?IC$2^\P]$X$!VW@!#'C]<D)  ;*%A+6 \:]_F56EC<4&
M&]S"K3GWSMA&J+*R<J]<YIS:30;@MRO_::2BZVR'6AXLTDUX.C WMWF>RI 0
MRPE8$+DS$)RONL\KU%?"3" >,1-8+AY:^/ 83@8Q[0X&ON$WM/K9]Q@BP=!3
MJ?D5%P P8 S9Z-)49Q= =&H,,M0Q8@=/\*"<B6"B"X<1XTV$@3\7Z;1KYTP@
MDN5R*X!Y3" ?.>FS@$"57Q* E^<ZJQBXC]'3>V5*IZ=3_3IT5L<&=X.*NPC;
M;AO*TF2.@(Y=JHO?+GQ9/BA.RL&;.9 .HZ?C*3P7YZ]\H"/[XT:-N/8_J(,#
MW/Q*(4PR^TM!=?*L5P573/Q2< O]E1$KI7\II"79*9KJ*89I8?:8CFY7=Q9^
M7Q_ M4A]Y:V]>Q?%@:&8L/@ @QZX^H5BFBJ\/2;4!Z57SV#[P#DJ-<;6KAO$
MI-YX3"C2N\0Y'8O?[!C$DHWI9D#?+,FDTV&$ZM3&M%"$)1VC.>B?2KD;[D*&
M%42RJ>@F@ZCY*!LCHNIF&!'OD'<884NGP@C5J0P6I\&I-;_SU%I499L3ZAB^
MCU=LUV#*$6V#PO?W(=E4+HQ07> ,+0:,1 DVM\,$6\;6)!:#YD@>V_#)142G
MZ]+IZ\7SOXQ.N5C-4BI-[3"5-BV\V-,8.*T!/&)& O7KV "VQITND=FKZ1TF
MU3K>Q3-@2KHVP/M_<&)*\5H\C*@/-;&&TK<Z(FW#LUASE%ZS.TRO35GK&C*#
MYE GFF)BC+%8+\"_C@N_.%S@2RFC!LI\VA@F2V%*9B@I.)GGD(00MAJP?=N1
M5.)RL>OVG=_MNYQ#VU0PQ0MS$S&W"V]3=^;ZAG9_8/%^FK]B"K+0-C!>)G<Z
M_CICG/@KNYT>VGS/=,('VW+PFF7QE01>.=#;'TM0@;DL5I<PPI]Z^!PM!\:D
MO2Y6!^"3[ K#R[?6.QV;9XWR=]$$-J<XG+;)(;2K8S 1VX.8[T?WY4?N[[6G
MO!\B?#3E^5[#D:I/27>CMT%;*L):N0%6((*[*'H;%WR/N/%=VA&'9@19$Z)9
M4W90B,H!D55KT)%I ]\N=I><^FE"T82VTA=& ]D8RAUB4V45@[_I%D%/U_T.
M'I:BC8G3[$#6'C'92+C0@3:PE0\69<>$GJ$/!>HE@U1)9'U7@SR<[K1*P+L]
M7BH.)I(1][8"1M,8KR5-1GRP@>[<1F;A0((]-!3,&>L+_Y:'H[_AY7'<'1[)
MG6X\QMR?G 31Y8OR@+2K<O;WG%1F@*.(_5%B0D7KQ(5OU4*S5+C\J]BH-+]3
M%%6P<D8_QJ!/X(G*Q7'U>SRX)AP1)G,C<BZ:+$MZ4&(8I*U<-. XPU2L*<U?
MO<"*'#;W'4CIXK# GJSJAC68 #J(H?F^(IP1$!G]OM#L#'1,B(,7>-F6^)*;
MDRNA!C)7."28!:T,%S[ZI9C+'T^>C24#5;B?"M]:^O"[%VYF4M<D:N^G(W0X
M#>H&2]*EK"<E/+;SL1CFAM,D57B0-FP8.\UW1G9;I1WTD0UH^X@C>"'MH45[
M9XF2(W 'OIY7/;UC\VQVSJ::#D<]]=Z#P.GJF.4X=@V[CW?1)NTNQA@9_R9T
MO3GP3K(T0'"B!'0&KLH;9!A$I2C%'A(FV[;!I\H[]_,=N4N&L"-%@Q-EG7BP
M/539-O01VS(E5Z% &RG(P O #S-H[NFL; &06-#D,7G^4B3(@\3+ \0@W_&1
M12'D&"I^K6\&VK+0L[)P'F@@GS7FF =4?<QEC[)D#,QF]WT'CD+!,\<K)$0_
MF(6B2WJ>@(1]C6B^N>"(9I]D*?A6=5.4"S9VM,$5&[BB]SB 80E-@(A@GYBR
M*[F%LV.Y@,W?&(?0#%D3<T^.":@IK!'M8V:50!NA<+J?QO%*<8S]K52N4H(X
MG)'QCOM+A6O1W9-C+#IYU512]W16+E.U+8->OG-(3ZA.\DP7[ N-C%#4X8!H
M]SI@?K4[P9I,T\8:;$;8?55OX[ *YW6H8F =[/Q#NQ#25D%8_PFO![X>(%/)
M*G!GA6?2.]DB]'@FL"/X5!=D?_& 04;(GAI66HP9\\F ,)I6S4TL#@98>EW6
M&F9_SR+R$$0A[6!%N]=TGFR%K465']T8ZN_#0O/(77VV] F_Z4ON]TC1+8EU
MS3Q\CX?7_;T 8KL*JTV*.<+*R4R"UX"Y2ZM"P/X ^M!DRS; S3;!KJ!FC8=,
M!Z">KG?IE^=-(BI[@6)F&1,X6J95NJRSHX%D*E-=8"&Q4)FKF;9J(2?2!"6'
MU=BIHMQY]/*IYK_5P8YN!F#\!)N7 9M@GA0P\IE"6*>T)N^Z-.15P[1E(IXD
M+QB!9W$FHPX$8BXR'1#-[LNPQ!<.OXU%:'Q371UY@!6BN70<J&QS7PH&P\^W
M#08PT]$X1])!DARY+"E8L@T^GP=NE)2\2TG)*S3D_AV3DD-A?'PA^\BYDW3O
M(QTI(;!/V$4E6HI+DH90&K%G*MP(99*XP4U55,H^!>!8L%0,4PN!1EG\7T6!
MS&Q]D\IIUQ /O B;%5A3[WVLS1FM?[[!KI%@Y1 "THA:6. :9V),N7#G]5Q^
MP4S8HCRBALT%U1LF:S9HNDW<L"C($FJ=P<][I=?S/>U*WV-#MT=H"?&V<([S
M$02#F4<,3=1ZT"BV#)LF^J(A"<H3Q!T(<3B+"QIF MM05OPBWWG$YV13_,B6
MQ<JXYC71!7BP2A]6^W8(YIV8SV>^QQ8\!D?;D?LZ[L)Z><1(R()EOUV4,'*9
M$+^[4:7JW=7/0Y#59&P3X40W&79<,]3]:H-EGH'RK1MZWY"'6+J;2'VGX*-Y
M@UG)/[&[+4U5#M;;>0#0[S"+ G H^KR_-KB1'<'L,!]*E=M(ZGHP\N([F8&-
M1FV?:)AZ:[K.&)[UB6R, 1@X!%P6EF>8> UK#C:"G]85RS+;MM$??"E_RKT=
M]MT,QYV@.__0O35V@V1B>J&G3DT[YJS"ZB.PBJA9!R>G$1X!,WT="$=TV$N'
M<3!XN2-JGIY0%T4#+6*B8XSR9B@_Z*R$3\5<>$RS'^$B!AR-*D^8[ $:8TL'
M_9@!HQ1".[T(IS+LZR>K9F_)\%<9-NP/W;F=@AF%J'!.V,LS&-]S/"8Z<,8$
M#XHY!Z!'&2BNTT([<5*C]N= QVKF&9SX! V6.R*T^WL^<*M3+(ON<AACS)LP
M6&T\!Y].%1-%UETW,*#JJED2_@5<U68C=%CPC!TEK]8$XZA/<4G/ 9L((,'O
M[W4-N4<%*QRO S%K@,4KKV$9D^H-]$CF'Q"8H2&X9CP+?OH->_XM%C<W8[15
MN];EAO[^7F< PI9H?6\!5JLZ\APW6)!@J!7?K=DJ[?E.O2."K\'!B]BEI^-_
M P>+=H#7>A@+<(JG;8,V2Z>>$1G)K+ 6W2767, A9J>W/-N/[PV\ P(-)E$*
MZ:$-Q(K7P?G$"+ ?_Y236(L(&YNS!H(0YA 5S5 '4K=5O#T(T![7H;K:#40]
MF3M#D51T5ESFS[!(Z)<28SQS8''6@$ _]:<4X-0]+TPX%W=T3J(#+Z>GZ5HE
M;KM8G^P"!YKH0!^@/L#Q<[0;C>]Q?Y9WNAAR%4395*9]I 0GG.GR()T:J#$C
M"M5S@IXWEPF\V8'O.%TM[9XKU;:L)RQ1V<#./E9$@Y?>89$1C8"<'-HFD)=N
M/A*5X/>[L&<0BV:<&?9"R;E\PG(E.!0O4N*AQ>+=P-"Z [.$V3Z  W#-E1'X
M@2"V )%)[IF;_J8G_$^"R1IZ,)%V00QP.IM [R,>("KI UR:?A##._8!Y3D#
M338-?>@8$ ZP6(QUB6;-4L#<D36]IU#,N2X_;H09"NX9\1C /%:#UP4EZN/C
M'VO>4?OL&"2U[QZSL1C;3QZC!7P4:%B7]F+WWC"E=>RE0J$6FXLKN2JT <2
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MWP*^&BL= !_KJ'!),I#5'M\I)E;XGC! 0LF& G1KD"=;P;T";+*[RE>JGVO
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M ._O LUJ3#K3+WN;D9W-P)=4%< F8T6W31!S?3@J-,#:MH42=($YYAEB 1R
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M1G[I /D)C-KV]^;?F,@*<TP[\S)X)/"RB:*J/"SO;WV,=-8FH 64KF\/+BP
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MKGBTW(Z4\G]^M=@H_6>N8G@%=?#F+7%(N-*Y4,Z$ * 0XF@&)$E: M,Z#'F
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MY(++P@A,Q IX)"4"Q__S'W+FOCD+K(UX7\#H >;RB148I.'PXH2\4']KS;Z
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M0RY_.263>6L4_@::_ >WK35]Q-$.XNI#!YV#7G- $5,8Y9)IS 70NN0)$5*
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MY9A)\QSCFGN=ZJ+'W ?] 5!+ P04    " !OBYQ1@[U5]H0'  #]-   $
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MPC2/+TOKVXLZD)!LS\ZTROZ+,_,/6<@ZD]'?].]*X?^7Z-^<_@-02P,$%
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M[XF>+Y$WVP9S;3X)Y-\(S*>$OP%02P,$%     @ ;XN<40$#4$:DAP  2[P
M  T   !I;6%G95\P,#$N:G!G[+P'4%1KES:ZR8@$ U%"*T&0()(4$&A%R2)*
MSHAD$,E(;H* (AD!$001E"0Y2VARSE').2.YH>ET-^?,?(-GQO/-3-VI_[]U
MIZV-5?:[GY6?M5:[&]QWW QP3E%601; P\,#W, _ &X<N >0$A.3$!.1DI"0
MG#E#2D9.34%^]BPYPX6+5-3,ER LS)>8F"ZS7^>\S,K+QL3$=>L:[PT!86%A
M"*>8I*B@Q'4A8<$3$+PS9\Z0GR6GIZ"@%[S"=$7PO_S"U0'G2?'>$) 3X+$"
M^.?Q",[CX9H " #@$>']\0+^Y86'3T!(1$Q">H;L+'B@]!R CT= @$](0$1$
M2 B^ZPV^#Q">)[IP1> N\<7'QB2L#M2"?E&II&S2A?4TJOW;[$)/'?W/D-'2
MT3-<XKC*R76-6UCDYBU1,?%[]V5DY>05%-74-32UM'5T34S-S"TLK:R=G%U<
M7[BY>P2\# P*?O4Z)#KF;6Q<_+N$]Y_2TC]_R<C,RBXJ+BDM*Z^H_-;0V-3<
MTMK6WC$P.#0\,OK]Q]CLW/S"XM+RRNK:SN[>_@'B\ AY?&(7'D" ]Z^O_]"N
M\Z!=^(2$!(0D)W;AX;\X.7">D.B* /&%NX])C!TNL@KZD5)+1Z46UI]A$U+=
MIGGJV$]&RRX\R[%S8MH?EOWG#//_;UGV#\/^S:XQ (P>&#R"\P 4.#SF^N1+
MQB.Q5@'=F?7& 3ZPXWV8-0X8DD)AT3C@8(5 .J07.XP#,KT/,4@<L-Z/R<$!
MCU!;J#T<,/KQ[(M; KK29@EE'R_;GV&/\068HE6LLZ0J,_1X@SPC>#I?/ISM
M]U/G!*(B=',]'<L+2+N3TQAYOKY:)>TH$"-)Y@[XH=<M5O%^6C/:]8E!!_F-
M!G25ST^I1QZ/B#MM;IX5>]F[1^#O>K//\0Y1H:\""4M)?YY5LQFLQ/AI6+HY
M5QV-_G.V<(>H04D;6C[QL7,KD=93]\J67C6E,]T6#SVHXZO;QW]KA3A2]_36
M^73OK0KO=3%5=WJ)6&J\TJNE)HQ%Q6VNGQ1B ]NX6\_Z$U.J,&GL/UGYB@>$
M[MZ <2_I]GS_(9)9,H2@'Q"HO7RD[K@FMC[*A*#)HDTW>7UQ@Z[5VB_E,CD6
MZ"/^0)-RVB=I*"ULZN'TX3(.R+]SB5H3ALC'W-N";_7B ,.(3:/CX&G8= JV
M!K!\K(,#QN '5+4X  [%>$!+86N0?XD 7JJ,!0XX'8;3(>@C#OS_CDA-)BGN
MP:5HTH:N2Q:D'P.WRDD">J>9R*-Z[C3KGY8PC,?L&SY))U^C44[_YKR)';?3
M:)ZZTQW:S=)USZ:7XXT20<]B-<;D']WA]7E.PA9>.Q1]Y-]"6/9BSW7"EMO5
MGH )WYLD_[-J"(_E?2F#N*]?+DB?HY1.,A/?K:;D"C_+U?1D]=M;_QL:A"':
M1-@MPZ0^(I2WZ]A/LY"I:PM.G<#'9X92)C&#*?DD ^G%PYMVZ><;X1SICRL=
M#DD),90S<IDB,40? K-;RHY=<ZCB4O&4ZV+KZ#E?0)UAT58CB!':F%:^+_&9
M>F_KFN35;]0QA>[502(_4H;_7>E0D/% 3SE1[I0#?86YON* ?_,BY%3,@+Y/
MQ3C@5.#^"]7ZWQ;YM0KCT?OPVPU]=]^O/L9/\ #CB#R/*\OTAUFG4NA ]45I
MI7NR 3?RO673PRDMCKN<S&YKEOBP310!*ZM0&_/"G?Z\Q0[R9+D%217J,H_)
MTH.F&TWAE[3O-_(F76.G#.N=E!0*/_J*Y"M9-7=/E*O=TPD(/I^42B*FEA*?
MHNC]24]'GV&V<)@PE')72\J8/:E<(BGF#B/MH9437Y-U7BYALIX=?7N=&,MW
MD:>%FS]5QSQ?1W>J\=G/3@B:XA.+,LS[0KD+_Z\. 8\4#M N&\QC#7*X(NA_
M]Q$E\9V#7E5Q\U,%I?5^;LJ]:6#U1??EL#2*16?-%H?>4D!20B:CC4U ?H"G
MG<DX\CE0T=8C3FXBE?")PF=DR<8M+=Q@L/CEA+KW %[;9/)\>.VPM)+D=;N#
M]WSK88F   LQT+8<X"NV_C"(Q_)Z\YC.VI2/@L7EZ/EP*HF(MS[J>$7EF6,!
M.O0+.H0^3YX2C^C/AWNK>&F\;PYRFZE)WGQ6*L1^-,4@6.U<UPO!.*UKPO\O
M9[+'0R[RPJ6O>O+NA][Y3D+/P!D-O1*SJ7SZU)"00:-$7^?U!(]> MK0=SZK
M; SK=TBG. ;O"RH6";UJB">]1=-)LT")ON#MEW$3;EWL?I>=#Q%1'*YN5J#B
M2D_/?(SH?FRC+'C'7YEV9YC.4NL-MYRDK#NJ&SFH.=+-$:Y1-/RR<),4'9V-
MA^>QCXQ8OL.HDBG#DD$3P.->=,5%XHG?:"V,R60J=T2H]^*TG!OB4HP"_14\
ME5C'&_(,ZR'%_]TTYK;VG-3:N)43$UJB3;#>#1A]"N$"_O7*\X"<,YKDD2R+
M')"ES]NZA0-R#2B,C[2P=_EQ@$$BDFRNZ5MXR;4&_:R,TF]ZW[Q[WG.3)65P
M38UL+7^'EA[8'>/?PF! YSW&Y.? ^L[#M[9P@&XY5]K:,'QY#Y6&E48,X8#E
M,=0T\AUL[+@<@\>(Q8+AR<2.#L-72*</#T&!>K&:MK(]4]B1%IMW VL;8OZT
M=N_O^-+6;?G*0#1S<0 T91*R2V6K@O7.K\$!"8FG145L>NMA?<-P  QV/.PX
M;C"0-T93#O=7$QZX2Z_9L\K6<W <RH2YQB>RR8W:@)O!_>U*&0B)&*6,0V?K
MCEE*O'7+T5B8,ZQ-LA2*1-0>8LU43@$.P6S6IO<)[5 H'##RY598]<UB8>A8
MG]"GXAN/NJBO;T3?J4/E(E6M:T6W1]Z<B0,+N?PU7IBC(+IB N[,DI;R1?(_
M-( 340O^XQU9,(WA&.O37M1(-#JW2O<MQFID[.6%R6P[ 1[339#<J@7W5Z,T
MEG=@P9MVBX450[,A<WSC_?7ZMHR)T3?LB2V/2^V0:.P*#HCTM(;M;7IOH9M.
M^U?N%WG]@RZW^0R[G^^CWE;X%AJL?@_P)UTCE0S3^T?,[FYFX8#>TD/XW@V0
M\OYYC/_MO*#SI*%-YZKM==[NZJ@O:+K>C/(:&TWF?'38(?R@#K916JD1D+1(
M_.7GH#4VHDW[5;."8XX!YQ$1]6,#<SP9ZD<DM[./QF7Z2\_PVEV-M8A@] V-
M:B-TVA=1P=)J!8%YM&2'VK5YM1/V?@HM5QDNPT?&JL!%41*K/33/^<4-$N94
M/O94.SVERHK!#O\RN8];QT^""/UP&4_G FH.TG+/DH39D=8Y-C$.FZO]Z]#M
MHFHPVZ%"L.D8.31O/@5H0M?TX<)HO+ZVML0M>?_;"KEQ FPEX6W,[Q;EU.KJ
MCI<^P#*T=66XU)67EN1CO"*J@+R;?O5K'B"%6,PBAE(VR1\>LZ3@@+,\C;"]
MO5L8I#"LH6-[&HWN!CE*V?U#2^"SG8CBN+#YRO@>WA_X-(ZW?.@Q,D*J!8.Y
M3Q(^O;YKE<!Z01[EORDM$'X&&:&KA!?TO&-FCUQ1RU42>LI^2QP0&#L+1R(3
ML>CWNQC=7N7!A29[NBG3U_<=:<GNX<4DO_!+%G>\%F9L?ESZ,>3<,_,+-#QL
M9@A_^Q^+VD_PH=PV_(VEWC# />C*;:NCY(S?*FSJ2GM!CV,A4IG:[M+M^U^U
M,_>DHVO:V$2[Y1&T GKZ!A(WYX06WU%]N"*G"HGR2UKT8'DG#+.8!=D7P/8U
M(7TX0>A3>)!3#C?4=_9TX^5]?OV"(;/R5 OAAH\6X"@0[E-2]%VGWD*R*7(\
MM @)K8W,N2;M6,'0SI;FG(:"4@S@ %^8Y5./\1W)>[]SR/8QC\I&-@MLM*T3
MI0F/G\0!A(=41SJ&C#@@)0&^U9YV.I,:5])0W,$I![M4F[I8HQ?HBQ/063,W
M.ZR/.5@J5R-.W99/]2GB3UAHJ0W2>WI;Q?ZTU-.W54N%0(LRW7& T67L</[B
M(:Q>LO'WVG)A.U*7,5X!_ZOL_RK[GU-VW>9^05E%D-7U+L6BE.(&4]L*1Z$*
MCZA=K(M@YXT=K1?86ADYH2:%'WK'R.3<WQ:WIW:VU:Q%H7P_;U>84TG01>++
M%).4\BW<HL[?C>Z*[6(G61/?M6RE=*J%XJW(+J&)5! ^D-XM'M2]BXN'+%F_
MA9TXE@QKBJ>RNR1S[IO\ @,.4*46@!V=>41QY]CL\^)$5$-!*]-:_&,)V]C[
M:J\?L<PXPLAB_1K=W^X<I;"!Y?T[MPN[?8KCN68KW#9IX3UE]*.']'HC\8.=
M.NH=J;#TB5[J,M:E'S,0\T2\T("D0L[47@9F 1645/!][#YDC.:X]%!HX+<!
MY4IN@YF-);YB+79G=%1>+& QG+IU/BE.(B*C1NIRT$"_;L>/I=C.*^$3A;MO
MSU=D7BY[J((F3D&XLDSZX( C0AQ@.<<_^!,'^'MDG&HB_:<<)+(X>DFY^OU6
M7%$CM9B6VRLS,^74=U&A_#Y"S<H<T3R3^CK:=YV+29/I8Q^$I+ZF_!@A+?#>
MZ,>1'71] ;I)KO)'.NS#?Y<.G5HJI>'@7'CS"^.70/UZZWMB;9>=6A@))'L<
MM/*$JQZU<&T:AS-<B5JJ>.)@QT5PMDH"<&BMH<(+,@"GQDA>'PZ$Y,7?-A=O
MUX&QX6?*^;&+)?>?RY&;7GDUY0/'/!^.T)7C;6PW,#I&GN?M/4]G8;>^Y!G\
M._-G]]7^3.[7_[-%N_*!KLG#XM4%V<&?M][U,-/;&F\%C)7:+&URJE4/N-#G
M;;!?$T\6:#->D;.W6;$57)K;>U!>\:WLYF";7S*M&+=-5^L3;-[@FW[,<I9?
MB[>Q"$<VZHWS8QE[YEEP,#D93O"T?6C $4L)'+_-L=+E/%0-\-TSL..-Z38M
M9J/#;)]H'##^\!4,WR?GX!;7IY -L88*6\^&L:6,.:<\O4F]EA$^DN]/S'K?
M9;]0B%]++!=,LK@B\T)D6;PU3$3/[)N-1#'S0T^W?M[N1CGR\V;CEF;L"<!"
M$M#@RWW+%WW7A*.F)TKDJV.QH<1.R4O"]RH"; D/Q3<BGS,C^'2,"-:_/8QU
MLDF?'%.0+-DQM(H1!W>3[T]C&63M/XNUK6GWV^U<VN7Z^=.\6*F?)DF+CR(G
MF_V)= 0/B<F>V6<9C35[&T-^)@,#P]+<C."\+U&?XWB<EEL^&7'-:;9#N7/.
M54HJH"WQPU("#XRHUJ.5OHPEYL@4!Y'>A0NP"=[7.HS:O%+TT&GKP8 /PX^R
ML*NOYQB5;#JU\X@FJ_N*9<=_^+A<?A*H>J,:,YF6/1Q_%%EK?J7OYV*X*87E
M_<*@BJY.4J33[N*[2)5'Z4,V.^*DF\DV-9=^DF?\I):/=N^YNJL8EN%7Q2ZP
MAB=9"52,W2QVFG/<)'35]?Y*8?>EUU:P^$XZ18^)Z>7",6K*$$F%G%N7I'*N
M9DGNAY;+#C1NC%SYLOM> 9)@^C3GI4D@X-="E6NF[W7OW;B$39J!]F1-R@?(
M&,+?(/'IIO3=R.?C22:,\:+=%#LW29\Z2<4ZGWVB2V,&M>X*8YDA5@PH3$R9
M)>PC'O7?]]RDDZ\,0@6_W]5[J9G8XZ)9W]AV9^I'>V\J09*6G'YO$/KNBQSK
M>/M)/:5GN39V[A35[67R][8T90^0:;RW9W.^?,0/X?I(?ML(R;@%6_?% 3]L
M' LV80MVX':01X #S'([YNN]A'  -5PH[6*U-]T"]6,95Z:31"1)=LNHT\VK
MS#>8UIW2DR%?"WG\P^\R%[TH246W>?/V?%,?E[9+HML0 .BD,U&F-(Y]WB$)
M]9*QF<O9O/70+=0^*=/4D Z(5C@>43I"-??+240_4R^WCXXA0X=Z$""UJA1%
MX1;42;9FF&=N&F8O$=&VBH>PD45D[:6CZ$6RWIQQ^8Q,=_UE^*$5;%;/[6W+
M#@YXIK<1&;V^5$N?O+R(R'8\&F]YM+E':&+/*W"))<!AM6\^R>6CVWB+&8)(
M^LBDY'X"4EU@_OOY9H/"E&[(^H+,-JR3?WU)QRY(ZHKM>*F>6L6-9QWH(#'C
M0\]D92B6IORU5WD$ZNFT">9@S[31(=S'R!BIP;[3^V8AN%N-+KY U.02<+>=
MOM<P.+Q:-87)K?FI@DI\:8<?JJ1M\M!1/!313=L"$X;E1U86_"%(&Q9XC$Z8
MSAJ[:=2U) ?N=5.H&N_5K>W1IFA]CL8UQ*:@]P_RHN=&J>/J8#L2W?$5(MX=
M;><M>OY:=B"-755I'D[7*/%(ON^UV>W'7B7LR>]$5[S#_D6$$1&Z"%MKUK@]
MV&1N_G8-@34QX5]6B F(ZID:VME>;IJ=;"DF7@4HO5:EGCGW=JJ;[O2&LGKG
M+RX;V]^WK,L4%64+:#^9F:WFK[#)*E>8&71'T0,63$DS3#LAFG^*V K ZL",
M!)V/S.:XEMUC-,ITC!B3%&>2/#[4-J1#*"4>D+^TN6&N D>M2CT7Z.U<U8%O
MIQP5-%RE8 C[O'N/5-T?!TS20-%7DP7WF&_I^?O2LM\'VMGR'(98KE7,BW=
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M'K:$AB!)3ASRB#]@GZ@"%&_!IGAST\+5MDHQ4E:%A"L]:M2RQVK@2.GN>\+
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M*8@=T4K?3* C^^UMN[7_E':7G"6QAG*57)?'/LT&Y)\DGAPB$+((&^V"%N?
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M,H/8^'P,/Z@*H.)#8@+F8"6.X"$];!.%0 7\_!O^(RGC;PD:)=VXW^-&N_#
MPE,H#IK" U.<?W/[(U-DS6^9)CL2_ASJC_20SW[+&)J65!:Z.LJ,\T5BO/AP
MEW_Y_:/QWS)*+B[DFJ!=((/\J0 *R0():U;^YO9'9DOB?RNF>2LV.4YBCOF;
ME-%DWE?SW_L?ZU_36L\S!#NUUW$'!"S2WQG>CQ$.>A?97>86D+QW.O209!0/
MC N FY2>KZ9QKTK _6_&&(5+T1GT:XFI&NCC3=CC-GA@_3W4EFR-'>1T&"#0
M<U#?7\C:6C'>\PBT<J8P_J:U-7RDRLUI0C-\6#]XUM%W5U][]-+)00<D1\\6
M*&34SA=4R&GZ/+'>I:8SDF6E#G(MBAV1J#L[Y(=T?(@-6G"S?*\ZWQCG"6O"
MA)(O]<#FES"P;YN]WH9RM#?AT:T7FWQLH^D:93_ XB]Y&_"&SAK;*)&E69GJ
M D>8)@ 8R1[L%UBP2;%.V,+C:L@:/X3\IH7#!O!@!^+"%G-O.HB<18$?IE?*
MT=F6;>E4_B47ZSS2\BD'/_7S,B:8PU.>J/$$LC#D.H1^=H4_@ORJ\6L0"\/1
M>. ())3TR;CSGL=POBKKF!/,&)M0V]]0]E[:@<UO$3#N\3-4\2G5A;]N_404
M:R!UK5%H,>3*H\#[OE,J;Y(1RBGHK>/6[;LB*["-V 7F'4%C<((?\LL<P5K;
MCV!GBR=D<^H@CZMK-P /;"_B8#/,VI\@_1,]B3,+56"J.A;MS]<52,W*;:^F
MX>GP4DU^BK,G$S3WN6H8)#;&P8IU,(*<PE/5+_& /-L^[A@Y3DP)PWY(C"6-
M'D>1PE"C3&,(S"$8>D#<N_ [&8J[K(H?!)JO?R):NT3Q@J,O,JG?:# G1FKN
MI3^[8+8<ZPRNDK#0^6_0^]M&^K@)63M0A"-X]/TP.&._@P1N;"1A;7LP$GM(
M.#5&&W),9<5@^X1I;W>=7Y!B_I44N((WA.0BFWC@DJ<..2'A"-1YB!RFEK#M
M:0?(LH6BU'^&;=3[#[O,K%</_H[:_X70XE%B7W6J+R+&W2F+^R@HYJ1X^\ ]
M'1DL6J=B2-]@0%_!RNI< Y%*$842H,T;YFF5^W5K<6BWI]6/5%0QU>OC9RN5
M%1KF':H*/%#]B+"(J[U!.T-#.Z:HG"F*VD?2KI)QO:=*0?W/=4192-(NE=(O
M,#A_*0W\P^HO^-3O>?W\(/1G3?;Q=(\6\\\/DG]MZ.A_FOY/T_^P:16H)=B/
MIF^>H#RJ_'7)_7OG7[=D&8$3,J=O]3C2F55VK\Y'K_)6S%Q3Y1>'7\N%399@
M C7P0/](8HM5YKLX\_:&8:W#N*)'J48DMPYAG9#__5H3,AL?91*QAX0DUY#R
M9$+BL"0#2?E[O; /V+FQQL0M>&G3GY<+M=8\2!QC^O]+L2EA*2DK<G^WG*H4
MBCJ2P5R*$T!'W?TJNT,73*2,,:XR @\\SJTM:A"=I4;S-;>1A >%KT$!85(
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MX$SWDU.2RA!_ (%-7@0/L%\@Z^&:OB<"1F)K=@.,OU7O.+[3$?L%Q$^H,OW
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MA:M>\>O1(D4UP-9&!INI[&@@<34G!XCBS'DOK7A%3T_UY!*9FP!F63$ :+]
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ME(EHK*6;$137X5*A'E&5:Y[+4II<OKE[V@#^P2?/.5@W_':(XOPCM6_/3LC
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M_$[Y2(=+8Y:]^!- )_SRL,:/9+ :)5&ILV;R[8#Z4N4]GRL]I\)Z 8O7+ '
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MTZ4\S9Y+*29U51$/XY;28P5^SG7KC)A\_W5!82<!8T*ZA.Z$1&;Q$<J2>$\
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M%"542GVG3D]+2>#D67X"Y5S% &,M]!XW!"3B\'W#_'N4KI3W%?6SKF''-2<
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M!)E7\$270_-//YRGBTYI7ETL;Z7QBR-Q0B5NKB/3W(2D0"A:P4F\D?-J$:,
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M!,N^(/O^%/)3V@(M%[R#\Y%D%X9^I70:272=<4K157XW-?<ZVI"/[?)W@YA
M???=JO,2HA<"4?HC>ZPN$RY6WO!?/F=+WAL_N1[8R\'V;:=^3XD$&I%0Z%@4
MS)-6\/T0NMG@#DEZFHETP/Q)Z8(+._YV?9;WA\>SUUC26$Y?\F:+FT1_M<VM
MY\VHH-SGTX8B[[]=E (+EHEVPH&U8^+AMGDO;)];E&.;-8F7*JJFWMVX;F=9
M*A"^66=MIG5HA)!^?0%VU\INE]/AVHMQSW6>+>JK+'14O:P=.Y#CYMCRB_&T
MAF&%8!+V" 9AJ3;:P2N%;OQI($*&$C;MQ?PH=A/W=:]ZL[/!%Q!M6E2)U1,
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MW4M/%WGF<"OZN(4 BMKR1X8%Z%WC_2PP-()FI/*L8=I;9$:WWS!M[$J?\SS
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M-[?V#* ']1GWT^_)>1]/U+C 1 !827'*[_T[[==AM"P_0AJDD:1E/H5-^Q/
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MY]+ D@?8)4L!Q22Q#MX+\-<VYRM];YFS7/U:(?#7[L6'87:A@ RA'$:/&;3
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M9)P'\DE(*+M?+PZGQMZ1C2!1M\H,;[D45M:\V(O/M;N*X'YJ;5726&)P[NP
M6S_SPF)[1:B=(G"<Z+<%%P2LVT0X1B5#;"63*Q_()^%:+1,<CHNRF51=8H\5
M+N3I'IN$D:S+I"#,08Z ,L%L5#G8<[>%#F)NN)PWTU-BA<[(%LKVE+R;,=V5
M./WB3IOYN9-;VJ?OG]0"ZD+^^JJF&OQ/H@^=^2J3LR;^.! L![<8+5#40B"R
M*VMCCRJLRVU>T.-VB_[>NPHZ<<O]5Q_78;_(+0#^!Z840Y)T)$T<>-K="F'1
MN&Q/1' !@[V][E.2F/K0]BQ#?0OP,XEJ? N;_5F(9)<.,T3: H\Z!?. O(0+
MHEQ@\74\NU'K2F#&(#< 18@[TMTVN'3Q>]VMPCQKE\&BSQ@M)Y4US4P-MH&2
M3S.O>$+.A&B:4P\AC>/4^D0\T2<UI[-D BC1)6O&.Q*A["OFY[NXK68^^*7/
MOM,1Y=3= PMVX,Y)W/IRB6D=1P<Q?:?F2(\HE8B1](C1TRO/C!'V7(#GFH#_
M8=Q\+_?L>0L\_]>.9]:9&%@GGIER V@A==\D^>1[EP&&!&A8#8KY:IF1TTY<
MF7))]Y6>22TZ2.-)S2X7RPB)9I5]O_1&O">U_,]$Q W4\ZW9**'X@%=K37)!
MC@,:EEG^E39Z.VLB?0?6\E*HD7=M.];VGDB=9BH>!)$)4J9&(<]3[./AB!-!
M4/)ZI/%+!*P:[?VI_[=SL-K*$WCUU^(7I<UA[\B?/21"&,KIH%G(X=@V [I(
MN6U-9X8;KH)?K-=  /VV +.UL)I=O6L#^#O8.[Y@N7*/['FA*QVW5%ZC]#5/
MNZ4A*-S@G0\DZ5<-XD64&_T:T@3L)-R6[/2FS%6$KZZIFJSANYOFV.6:%]4\
M5)X5?4IX_9K>CK]A"2;I#"2C!@6<X\/A0^@@=(U5QH? //=]R,L&X;G.:/5I
M_O6:1HNVNA]I+Q)P2A(,RI7LA=;5D(3D(P:R6A!.0'U'$L"2F=M-?@5(XV""
MRVEM^TIV9PQE@T5\TP]4X-L6CC[SVE*ZG9? 7WP6'_=QD<$$;"22 VC=Q,W(
M]&\CV%?VD7UHU[H/N9.V4X@X!RWR);:\W!*0%N%YQ="YP]'&BFK1.0S?MAOX
M/E(,JN*)R;D$8Q$@<1^'VYTYD]ZZWV#X45OSY1,AIA_&#X=N.E9_CA.X1*GW
MR]^8<@>G'O;GE[18@0@*CS3Q:4O1],JQ%J\XE<!ZC'E=,G%*KQ*3WC?YG8EX
M[X.#;:=[2>Q[IQ!-P_]A1VG&$903(B2#"\ AB%<,.S*YE. 1 M(19S"=Z8Y2
MA<5N0WUBKRX]6LUU=*TE9.C]*!%X/I)JUEB[2SNN@.0%JCM&\3Q(&3][PLY+
M HJO9=::W=%KI>R6O+MIV@_;<QP=O/H><QB_O#2#8T##O+%\IHQ&WX[@B 8?
M <NQ7#=:2+:  Q?)?%<#K?]L5)8VT^'>H\+/J&:K\[AVH.N94)Q@B8Z$V[<3
M:I\%1U*6XR<%=VJIF720)S,9_@(-%YRAJ S*-8E-^(V".8T(_ODBYUV5 J_
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MW?$"]SH=<_S@Q-$D><PKZ*JR=4U5^$QOQ]DM_<7P8Y^BCY?_E)GQ:'WA_]X
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MQ.ME/%M;OS^,[/U:)JM;/'@A_&%G&N@[-4'SC%^N-5FU'7;,K\**#GI1L$O
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MF8AX_/7"S;BO77T6Q(KQ"H)T7(,RH4?0#/ FL$Y+MYYOK(UWVG^$U'D!C;_
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M8/[OII2GN.04/K(%M-D$9J\:%\@C&K2O\6F)OEV+!B;Q$6LKS' W-Z\5&6Y
M%I<W,%(PY%D3D!S#J\*US).:27<>QWCV!(MQV.V+U%V-G8!X7PR$N](U6("9
M()[<1D>;5NB6S]O2]*E)(5G*!6WXH3%Y:8 #WLZ9I_XY1X7G7(7C"9Q#+!1O
MA#@-D032L#MG+$/@?<I<]BR3B@8V6I^D R\.IQ4;E"?"FSQACA8I[(&RI@K/
M%<)JBT]<.TBX2/VQC8'(#^ACM]/QI</=!O?1>#_ZZN\L2M_D50=<]V%K>46#
MFC8O'_H,1>',(N0C>@^->A;CN2/$&PD.R6VL5>Z'UUU5WR_P3A0UDC'UL"\A
M15EZ'+GV\NI$L<2!])/;U$E)H4<<5&N++,<@%R-ZB"3A1T9G@;51:4<VU@9,
M.S.C(W/(_R;/0_+Y]81H]I8[T=Z2?J##Z8+1_SU\G//G#M$6(D8X09[3O%"'
M=WBF*3&_R;L8)Z68=WUA9^5&B(Y._=,W;Y83)$Z9CZWJG7)^T?^DXDQ(A^<'
MFHAHBS4=2N]Z:8(Q8>^\EA?IOTEAXYJ1M<U3WA'L9;!''1ZQ'3;Q;2L^:M?V
MS?55[LY?YXMM\<F.O (2#(@8(9^!OQ.D5A<L['%"!81JP]Q<I2S,TLS/>,98
M/,)\.7UPMN]PRGCD(/[D<J,Z#[ZL>Y%9>F=;70-;37T-<<]7:BLG",'T>OXM
M^=+IB]*/U9M#I]6(8LT4JY_R0:.799@_A^C;'8.B@]"X0RE8>6/S6"E1U2?R
MJO;-RW'GM>EG8"U7AT*9*&W@<";BDP-2I@<^L[.LD]CX _%.4SJGSR!_-5S&
MJ+;%$L)XH!K3E!^SO]DI?[ 3@*2UNC_#'I.@?5W8>)MJ_\AY0_"O\(.'Q(L0
M*X).4N#(,X$SA+RI]$H*VV:"7.-*.6S.<YHR=J\U*L,XW+CPM#AM(-7\6^_'
M<Y$/&65;7;^W_ZN_@&6^Z1=;2*66QL,?0D]4%C%@LI[HVE'$9^BZ)R=R&<%F
M*[KAQFO8K^CQ8L$N]MN6X[#Z.MTJ9VB=P--X/&(6W=<A-.[5F"?7]:AIO,S$
MU[^VPG'S\L^PA.?W:$$UPB("K2$42V-F;,42&I.AC)G*]D,-%]N'M=B69ZRL
M7N!!*D4L&=/=IQ0=N4BH5A^(]U67B2V[:IATK\RD)F@D4Q>\"ND7PS7F3 JO
MEZ4,,&3<'=KX*&?&9P+[@>JH#AIW_AH^/(N.X$?B>[.D"J2_9O4KC/&/S>E&
M?$\.JSL&@:Z .",JH:Y&QR!-9<&#L3^WC__*F!U\=^U^P:GJ/FHM OFR=JE_
MV!"7L?%[9$\1\3KT)^'M,:@C[1B44)DS21HJJR5RK*P9ZHL?]!'-"FF;.$V)
MUWW^*O/W&@4, 69&.'J*A=6[0C[\<Z/\M\P3J5$S<*/X,0C!!R>N@X'*OV5
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MS8@W0/0DDOV$?W:Q-)J@Z/A?4S:_IY_^RTA<W8H@3<0G@0N-M:-M*N)H2B,
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MS<+BT.4IN2U:9Y;(&EX_<?;1R3,?=SDQPP:!8([.!Z\1K!#7,77_)8=G N*
M5:6;/1>\:WE1>UQA8$#/4_CE"._CX(SQDQ?[0*6:]A>IAZ&N#L!%BR2PLYI,
M[&%L=4F(3Q\&W(.[/'T#G[>0> YEZA#2[=LQ-F6Y[>Q/$S/G5/]17[$%F:+7
M.0CG[>3I=(/"$ W'( I6KE8O/.IPVF&J$<PXZSI%'X+I2]Q^ ^G$J;T^-] \
MQ:#H5D(O9X#BL^+YDNB7LT%Z1!ER&_C.7B*1V)F 6F@AJ*[N=4LM 8;E&?MU
M;K4?9[=KI(J:DQ5C=X,M&0R?R(5GL J\XPL&8\& .',G5@9#;010ABW#[+)
M=<W,NFI$]*X[RAP&V;6<I=E[H"?2($.'R;N3R41_0R1:2?M#]Y, A^8#W*5E
MF:AC$*C)1Q"B09!!]U>I2YR+NQ=W=WQ;\5D@_><^_NJ\>LQ<3_.RU;PC5?_
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M599)4UW,P'A&YL",@\9DBX;#F.;C/PX4%O?_MW\:RW(\\R]02P$"% ,4
M" !OBYQ1C<:_@4T+   U;0  $0              @ $     879X;"TR,#(P
M,#DS,"YX<V102P$"% ,4    " !OBYQ1]\+: ;P)  "::@  %0
M    @ %\"P  879X;"TR,#(P,#DS,%]C86PN>&UL4$L! A0#%     @ ;XN<
M4;F?DNZZ%   M44! !4              ( !:Q4  &%V>&PM,C R,# Y,S!?
M9&5F+GAM;%!+ 0(4 Q0    ( &^+G%&4W2$E"3\  -"+ P 5
M  "  5@J  !A=GAL+3(P,C P.3,P7VQA8BYX;6Q02P$"% ,4    " !OBYQ1
M4?",?DHG  "YE0( %0              @ &4:0  879X;"TR,#(P,#DS,%]P
M<F4N>&UL4$L! A0#%     @ ;XN<4;M89&&>% ( 82D0  T
M ( !$9$  &4R,CDX7S$P:RYH=&U02P$"% ,4    " !OBYQ1H-$FC4H"  !'
M#0  $               @ ':I0( 93(R.3A?97@R,2TQ+FAT;5!+ 0(4 Q0
M   ( &^+G%'U7 MGTP(  !82   0              "  5*H @!E,C(Y.%]E
M>#(S+3$N:'1M4$L! A0#%     @ ;XN<48.]5?:$!P  _30  !
M     ( !4ZL" &4R,CDX7V5X,S$M,2YH=&U02P$"% ,4    " !OBYQ1:NWA
M%X$'  #M-   $               @ $%LP( 93(R.3A?97@S,2TR+FAT;5!+
M 0(4 Q0    ( &^+G%%HRCLR4@0  %$8   0              "  ;2Z @!E
M,C(Y.%]E>#,R+3$N:'1M4$L! A0#%     @ ;XN<40$#4$:DAP  2[P   T
M             ( !-+\" &EM86=E7S P,2YJ<&=02P$"% ,4    " !OBYQ1
M8YMW(3&H  !%P@  "P              @ $#1P, :6UG7S P,BYJ<&=02P4&
2      T #0 P P  7>\#

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
